-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
Q/ToXllJASkG8R5FT5wTcbBUC1JvvtQU/FSGcTYmu8zYDBvR16OCHTNI8Au+/s2D
ZyHlYCHi33W0wLBESLzz+Q==
0000950123-11-015948.txt : 20110222
0000950123-11-015948.hdr.sgml : 20110221
20110222060507
ACCESSION NUMBER: 0000950123-11-015948
CONFORMED SUBMISSION TYPE: 10-K
PUBLIC DOCUMENT COUNT: 15
CONFORMED PERIOD OF REPORT: 20101231
FILED AS OF DATE: 20110222
DATE AS OF CHANGE: 20110222
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: WATSON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000884629
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 953872914
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 10-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13305
FILM NUMBER: 11626316
BUSINESS ADDRESS:
STREET 1: 311 BONNIE CIRCLE
CITY: CORONA
STATE: CA
ZIP: 92880
BUSINESS PHONE: 9092701400
MAIL ADDRESS:
STREET 1: 311 BONNIE CIRCLE
CITY: CORONA
STATE: CA
ZIP: 92880
10-K
1
a58052e10vk.htm
FORM 10-K
e10vk
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
þ
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended
December 31,
2010
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period
from to
Commission file number
001-13305
WATSON PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
Nevada (State or other jurisdiction
of
incorporation or organization)
95-3872914 (I.R.S. Employer
Identification No.)
311
Bonnie Circle, Corona, CA 92880-2882 (Address
of principal executive offices, including ZIP
code)
(951) 493-5300
(Registrants telephone
number, including area code)
Securities registered pursuant to Section 12(b) of the
Act:
Title of Each Class
Name of Each Exchange on Which Registered
Common Stock, $0.0033 par value
New York Stock Exchange
Securities registered pursuant to Section 12(g) of the
Act:
None
Indicate by check mark if the registrant is a well known
seasoned issuer (as defined in Rule 405 of the Securities
Act). Yes þ No o
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the Registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the Registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days: Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the
past
90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein, and will not be contained, to the best
of Registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. þ
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
Large accelerated filer
þ
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
o
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the
Act). Yes o No þ
Aggregate market value of Common Stock held by non-affiliates of
the Registrant, as of June 30, 2010:
$5,065,021,000 based on the last reported sales price on the
New York Stock Exchange
Number of shares of Registrants Common Stock outstanding
on January 31, 2011: 125,827,379
DOCUMENTS
INCORPORATED BY REFERENCE
Part III incorporates certain information by reference from
the registrants proxy statement for the 2010 Annual
Meeting of Stockholders, to be held on May 13, 2011. Such
proxy statement will be filed no later than 120 days after
the close of the registrants fiscal year ended
December 31, 2010.
Watson Pharmaceuticals, Inc. (Watson, the
Company, we, us or
our) is a leading integrated global pharmaceutical
company engaged in the development, manufacturing, marketing,
sale and distribution of generic and brand pharmaceutical
products. We operate in key international markets including
Western Europe, Canada, Australasia, Asia, South America and
South Africa with our key commercial market being the United
States of America (U.S.). As of December 31,
2010, we marketed approximately 160 generic pharmaceutical
product families and approximately 30 brand pharmaceutical
product families in the U.S. and a significant number of
product families internationally through our Global Generics and
Global Brands Divisions, respectively, and distributed
approximately 8,500 stock-keeping units (SKUs)
through our Distribution Division.
Our principal executive offices are located at 311 Bonnie
Circle, Corona, California 92880. Our Internet website address
is www.watson.com. We do not intend this website address to be
an active link or to otherwise incorporate by reference the
contents of the website into this report. Our annual reports on
Form 10-K,
quarterly reports on
Form 10-Q
and current reports on
Form 8-K,
and all amendments thereto are available free of charge on our
Internet website. These reports are posted on our website as
soon as reasonably practicable after such reports are
electronically filed with the U.S. Securities and Exchange
Commission (SEC). The public may read and copy any
materials that we file with the SEC at the SECs Public
Reference Room or electronically through the SEC website
(www.sec.gov). Within the Investors section of our website, we
provide information concerning corporate governance, including
our Corporate Governance Guidelines, Board Committee Charters
and Composition, Code of Conduct and other information. See
ITEM 1A. RISK FACTORS-CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS in this Annual Report on
Form 10-K
(Annual Report).
Acquisition
of Arrow
On December 2, 2009, Watson completed its acquisition of
all the outstanding shares of common stock of Robin Hood
Holdings Limited, a Malta private limited liability company, and
Cobalt Laboratories, Inc., a Delaware corporation (together the
Arrow Group) for cash, stock and certain contingent
consideration (the Arrow Acquisition). In accordance
with the terms of the share purchase agreement dated
June 16, 2009, as amended on November 26, 2009
(together the Acquisition Agreement), the Company
acquired all the outstanding shares of common stock of the Arrow
Group for the following consideration:
The payment of cash and the assumption of certain liabilities
totaling $1.05 billion;
Approximately 16.9 million restricted shares of Common
Stock of Watson (the Restricted Common Stock);
200,000 shares of newly designated mandatorily redeemable,
non-voting Series A Preferred Stock of Watson (the
Mandatorily Redeemable Preferred Stock) placed in an
indemnity escrow account for the benefit of the former
shareholders of the Arrow Group (the Arrow Selling
Shareholders). The Arrow Selling Shareholders will be
entitled to the proceeds of the Mandatorily Redeemable Preferred
Stock in 2012, less the amount of any indemnity
payments; and
Certain contingent consideration based on the after-tax gross
profits on sales of the authorized generic version of
Lipitor®
(atorvastatin) in the U.S. calculated and payable as
described in the Acquisition Agreement.
Arrow Group operating results are included in the Global
Generics segment subsequent to the date of acquisition.
As part of the Arrow Acquisition, Watson acquired a 36%
ownership interest in Eden Biopharm Group Limited
(Eden), a company which provides development and
manufacturing services for early-stage biotech
companies, which will provide a long-term foundation for the
development of generic biologics. In January 2010, we purchased
the remaining 64% interest in Eden for $15.0 million.
Edens results are included in our Global Brands segment.
Eden will maintain its established contract services model,
while providing the Company with biopharmaceutical development
and manufacturing capabilities.
Business
Description
Prescription pharmaceutical products in the U.S. generally
are marketed as either generic or brand pharmaceuticals. Generic
pharmaceutical products are bioequivalents of their respective
brand products and provide a cost-efficient alternative to brand
products. Brand pharmaceutical products are marketed under brand
names through programs that are designed to generate physician
and consumer loyalty. Through our Distribution Segment, we
distribute pharmaceutical products, primarily generics, which
have been commercialized by us and others, to pharmacies and
physicians offices. As a result of the differences between
the types of products we market
and/or
distribute and the methods we distribute products, we operate
and manage our business as three operating segments: Global
Generics, Global Brands and Distribution. Outside the U.S., our
operations are primarily in Western Europe and Canada. In many
of these markets, there is limited generic substitution by
pharmacists and as a result, products are often promoted to
pharmacies. Therefore, physician and pharmacist loyalty to a
specific companys generic product can be a significant
factor in obtaining market share.
Business
Strategy
We apply three key strategies to grow our Global Generics and
Global Brands pharmaceutical businesses: (i) internal
development of differentiated and high demand products,
(ii) establishment of strategic alliances and
collaborations and (iii) acquisition of products and
companies that complement our current business. We believe our
three-pronged strategy will allow us to expand both our brand
and generic product offerings. Our Distribution business
distributes products for over 200 suppliers and is focused on
providing
next-day
delivery and responsive service to its customers. Our
Distribution business also distributes a number of Watson
generic and brand products. Growth in our Distribution business
will be largely dependent upon FDA approval of new generic
products in the U.S.
With the Arrow Acquisition in 2009, we now have commercial
operations in a number of established international markets with
the opportunity for rapid growth in many emerging markets around
the world. We believe a global presence will allow us to expand
our revenue base and manage risk through diversification. We
expect to capitalize on opportunities for growth within these
new markets. Additionally, we will continue to look for
opportunities to enhance these capabilities through further
strategic collaborations or acquisitions.
Based upon business conditions, our financial strength and other
factors, we regularly reexamine our business strategies and may
change them at anytime. See ITEM 1A. RISK
FACTORS Risks Related to Our Business in this
Annual Report.
Global
Generics Segment
Watson is a leader in the development, manufacturing and sale of
generic pharmaceutical products. When patents or other
regulatory exclusivity no longer protect a brand product,
opportunities exist to introduce generic counterparts to the
brand product. These generic products are bioequivalent to their
brand name counterparts and are generally sold at significantly
lower prices than the brand product. As such, generic
pharmaceuticals provide an effective and cost-efficient
alternative to brand products. Our portfolio of generic products
includes products we have developed internally, products we have
licensed from third parties and products we distribute for third
parties. Net revenues in our Global Generics segment accounted
for $2.3 billion or approximately 66% of our total net
revenues in 2010. At December 31, 2010, our global generics
business in the U.S. remains the dominant source of revenue
for the Company with approximately 80% of total generic net
revenues coming from our U.S. businesses.
Our Global Generics business is focused on maintaining a leading
position within the U.S. generics market and strengthening
our global position by offering a consistent and reliable supply
of quality generic products. We are leveraging our broad product
line by expanding commercial operations outside of the U.S.
Our strategy in the U.S. is to develop generic
pharmaceuticals that are difficult to formulate or manufacture
or will complement or broaden our existing product lines.
Internationally, our strategy is to grow our market share in key
markets while expanding our presence in new markets. We plan to
accomplish this through new product launches, filing existing
products overseas and in-licensing products through strategic
alliances. Since the sales and unit volumes of our brand
products will likely decrease upon the introduction of generic
alternatives, we also intend to market generic alternatives to
our brand products where market conditions and the competitive
environment justify such activities. Additionally, we distribute
generic versions of third parties brand products
(sometimes known as Authorized Generics) to the
extent such arrangements are complementary to our core business.
We have maintained an ongoing effort to enhance efficiencies and
reduce costs in our manufacturing operations. Execution of these
initiatives will allow us to maintain competitive pricing on our
products.
Global
Generics Business Development
In conjunction with our strategy to grow and expand
internationally and diversify our business, on October 4,
2010, we announced a partnership with Moksha8 Pharmaceuticals
Inc. (Moksha8) for Moksha8 to market a select number
of our products in Latin America, specifically in the two
largest Latin American markets of Brazil and Mexico. Watson
agreed to make an initial $30.0 million investment in
exchange for a significant minority ownership position in
Moksha8. We have also committed to invest an additional
$20.0 million, further increasing our equity position,
contingent upon successful execution by Moksha8 of additional
third-party product acquisitions. In conjunction with our
investment in Moksha8, we have also designated a representative
to serve as a member of the Moksha8 board of directors. Watson
will manufacture and supply select products to Moksha8, which
will have exclusive rights to market, sell and distribute these
products in Brazil and Mexico. Moksha8 and Watson have initially
identified approximately one dozen product candidates, with the
opportunity to expand the commercialization and marketing
agreement to include additional products in the future. The
products are expected to be launched beginning in the first half
of 2011.
In 2010, Watson entered into an exclusive agreement with
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI),
to market the Authorized Generic version of
Concerta®
(methylphenidate hydrochloride). Under the terms of the
agreement, OMJPI will supply Watson with the product. Watson
will launch its Authorized Generic of
Concerta®
on May 1, 2011, or earlier under certain circumstances.
Our portfolio of approximately 160 generic pharmaceutical
product families in the U.S. includes the following key
products which represented approximately 57% of total Global
Generics segment product revenues in 2010:
Watson Generic Product
Comparable Brand Name
Therapeutic Classification
Azurettetm
Mircette®
Oral contraceptive
Bupropion hydrochloride SR
Zyban®
Aid to smoking cessation
Bupropion hydrochloride SR
Wellbutrin
SR®
Anti-depressant
Bupropion hydrochloride XL
Wellbutrin
XL®
Anti-depressant
Desmopressin acetate
DDAVP®
Antidiuretic
Diclofenac sodium
Arthrotec®
Osteoarthritis and rheumatoid arthritis
Diltizem HCl ER
Cardizem®
LA
Calcium channel blocker
Dronabinol
Marinol®
Antiemetic
Fentanyl transdermal system
Duragesic®
Analgesic/narcotic combination
Glipizide ER
Glucotrol®
XL
Anti-diabetic
Hydrocodone bitartrate/
acetaminophen
Lorcet®,
Vicodin®,
Lortab®,
Norco®/Anexia
Analgesic
Levora®
Nordette®
Oral contraceptive
Low-Ogestrel®
Lo-Ovral®
Oral contraceptive
Lutera®
Alesse®
Oral contraceptive
Metoprolol succinate
Toprol
XL®
Anti-hypertensive
Microgestin®/Microgestin®
Fe
Loestrin®/Loestrin®
Fe
Oral contraceptive
Necon®
Ortho-Novum®,
Modicon®
Oral contraceptive
Next
Choicetm
Plan
B®
Emergency oral contraceptive
Nicotine polacrilex gum
Nicorette®
Aid to smoking cessation
Oxycodone/acetaminophen
Percocet®
Analgesic
Potassium chloride ER
Micro-K®
Hypokalemia
Potassium XR
Augmentin
XR®
Hypokalemia
Quasense
Seasonale®
Oral contraceptive
Reclipsen®
Ortho-Cept®
Oral contraceptive
Taztia
XT®
Tiazac®
Anti-hypertensive
TriNessatm
Ortho
Tri-Cyclen®
Oral contraceptive
Trivora®
Triphasil®
Oral contraceptive
Zarahtm
Yasmin®
Oral contraceptive
Zovia®
Demulen®
Oral contraceptive
In the U.S., we predominantly market our generic products to
various drug wholesalers, mail order, government and national
retail drug and food store chains utilizing 21 sales and
marketing professionals. We sell our generic prescription
products primarily under the Watson Laboratories and
Watson Pharma labels, with the exception of our
over-the-counter
generic products which we sell under our
Rugby®
label or under private label.
During 2010, we expanded our generic product line with the
launch of seven generic products. Key U.S. generic launches
in 2010 included diltiazem ER 180 mg and 240 mg,
metoprolol succinate ER 100 mg and 200 mg,
valacyclovir, tacrolimus 5 mg,
Zarahtm
(a generic version of
Yasmin®),
rivastigmine and amlodipine besylate/benazepril.
Watson currently has a leading U.S. market position in
generic oral contraceptives with over 30 product formulations
and a 36% market share. Our top five oral contraceptives,
NextChoicetm,
Microgestin®,
TriNessa®,
Necon®
and
Lutera®,
account for almost 50% of the total Watson oral contraceptives
portfolio. Key
oral contraceptive products in the pipeline include generic
versions of
Yaz®,
Seasonique®,
LoSeasonique®
and Tri-Cyclen
Lo®.
Operations
in Key International Markets
Outside the U.S., our operations are primarily in Western Europe
and Canada. In many of these markets, there is limited generic
substitution by pharmacists and as a result, products are often
promoted to pharmacies. Therefore, physician and pharmacist
loyalty to a specific companys generic product can be a
significant factor in obtaining market share.
In 2010, certain governments in Europe and Canada implemented
various healthcare reforms in an attempt to manage health care
budget expenditures. As a result of difficult economic
conditions in many of these regions, these healthcare reforms
had a greater than expected impact on our industry when compared
with previous years, as many governments mandated lower generic
pricing as a method of cost savings for their annual health care
expenditures. We expect pricing pressures to continue in many of
our key markets. However, the impact of government healthcare
reform in 2011 is expected to be less than in 2010.
Canada
Canadas generics market, with an estimated value of
approximately $5.6 billion, is one of the largest generic
markets in the world. Generic pharmaceuticals are substituted at
the pharmacy. The provincial governments have direct control
over pricing and reimbursement in Canada.
Watsons Global Generics division operates in Canada as
Cobalt Pharmaceuticals. We actively market 54 products in
Canada and have 40 sales representatives promoting our products
to pharmacies.
U.K.
The U.K. generics market has an estimated value of approximately
$3.6 billion and is one of the worlds largest in
terms of both size and generic penetration. The U.K. government
has direct control over pricing and reimbursement.
We now do business in the U.K. as Arrow Generics and currently
market 100 different products. We also have alliances to assist
in the distribution of these products.
France
France has an estimated generics market value of approximately
$3.5 billion. The French government regulates and promotes
generics and incentivizes pharmacists to dispense them. There
are approximately 23,000 pharmacies in France. It is a strong
branded generic market where substitution at the pharmacy level
is limited.
We now do business in France as Arrow Generiques and market 138
different molecules. We have over 65 sales representatives
calling on the individual pharmacies. The generic market is
expected to grow with doctors incentivized to prescribe
generics. There are also a number of brand products losing
exclusivity in 2011, which should create future opportunities
for growth in this market.
Global
Generics Research and Development
We devote significant resources to the research and development
(R&D) of generic products and proprietary drug
delivery technologies. Watson incurred Global Generics segment
R&D expenses of approximately $195.0 million in 2010,
$140.0 million in 2009 and $119.0 million in 2008. We
are presently developing a number of generic products through a
combination of internal and collaborative programs.
Our Global Generics R&D strategy focuses on the following
product development areas:
off-patent drugs that are difficult to develop or manufacture,
or that complement or broaden our existing product lines;
the development of sustained-release and other drug delivery
technologies and the application of these technologies to
proprietary drug forms; and
using in-house technologies to develop new products.
As of December 31, 2010, we conducted R&D in Corona,
California; Copiague, New York; Davie and Weston, Florida; Salt
Lake City, Utah; Ambernath and Mumbai, India; Mississauga,
Canada; and Melbourne, Australia. In 2010, we announced plans to
close R&D facilities in Melbourne, Australia and
Mississauga, Canada. The transfer of development activities from
our Melbourne, Australia facility to other existing research and
development sites will be completed in the first quarter of
2011. In January 2011, we announced plans to close R&D
facilities in Corona, California by the end of 2011.
In 2010, our product development efforts resulted in the
submission of over 30 Abbreviated New Drug Applications
(ANDAs) in the U.S. and more than 145
applications globally. At December 31, 2010, we had more
than 120 ANDAs on file in the U.S. and a significant number
of applications on file internationally. See the
Government Regulation and Regulatory Matters section
below for a description of our process for obtaining
U.S. Food and Drug Administration (FDA)
approval for our products. See also ITEM 1A. RISK
FACTORS Risks Related to our Business
Extensive industry regulation has had, and will continue to
have, a significant impact on our business, especially our
product development, manufacturing and distribution
capabilities. in this Annual Report.
Global
Brands Segment
Newly developed pharmaceutical products normally are patented
and, as a result, are generally offered by a single provider
when first introduced to the market. We currently market a
number of branded products to physicians, hospitals, and other
markets that we serve. We classify these patented and off-patent
trademarked products as our brand pharmaceutical products.
During 2010, we launched
Crinone®,
ella®,
and
Trelstar®
22.5 mg.
Crinone®
was acquired from Columbia Laboratories, Inc.
(Columbia) and is currently used for progesterone
supplementation or replacement as part of an Assisted
Reproductive Technology treatment for infertile women with a
progesterone deficiency.
Ella®
is an emergency contraceptive proven effective in helping
prevent pregnancies for up to five days after unprotected
intercourse or contraceptive failure.
Trelstar®
22.5 mg is a
6-month
intramuscular GnRH agonist for the palliative treatment of
advanced prostate cancer. Net revenues in our Global Brands
segment accounted for approximately $398.0 million or
approximately 11% of our total net revenues in 2010. Typically,
our brand products realize higher profit margins than our
generic products.
Our portfolio of over 30 brand pharmaceutical product families
includes the following products, which represented approximately
70% of total Global Brands segment product revenues in 2010:
Watson Brand Product
Active Ingredient
Therapeutic Classification
Androderm®
Testosterone (transdermal patch)
Male testosterone replacement
Gelnique®
Oxybutnin chloride (gel 10)%
Overactive bladder
INFeD®
Iron dextran
Hematinic
Oxytrol®
Oxybutnin (transdermal patch)
Overactive bladder
Rapaflo®
Silodosin
Benign prostatic hyperplasia
Trelstar®
Triptorelin pamoate injection
Prostate cancer
We market our brand products through approximately 350 sales
professionals. Our sales and marketing efforts focus on
physicians, specifically urologists, obstetricians and
gynecologists, who specialize in the diagnosis and treatment of
particular medical conditions and each group offers products to
satisfy the unique needs of these physicians. Approximately 60
of these sales professionals are strategic account specialists
who
focus on institutions and clinics. We believe this focused sales
and marketing approach enables us to foster close professional
relationships with specialty physicians, as well as cover the
primary care physicians who also prescribe in selected
therapeutic areas. We generally sell our brand products under
the Watson Pharma label. We believe that the current
structure of sales professionals is very adaptable to the
additional products we plan to add to our brand portfolio,
particularly in the therapeutic category of womens health.
We actively promote
Rapaflo®,
Gelnique®,
Trelstar®,
Crinone®,
ella®
and
INFeD®.
Our Global Brands segment also receives other revenues
consisting of co-promotion revenue and royalties. We promote
AndroGel®
on behalf of Abbott Laboratories (Abbott) and
Femring®
on behalf of Warner Chilcott Ltd. We expect to continue this
strategy of supplementing our existing brand revenues with
co-promoted products within our targeted therapeutic areas.
Other revenue totaled $81.5 million for 2010 or
approximately 20% of our total Global Brands segment net revenue.
Global
Brands Research and Development
We devote significant resources to the R&D of brand
products and proprietary drug delivery technologies. A number of
our brand products are protected by patents and have enjoyed
market exclusivity. We incurred Global Brands segment R&D
expenses of approximately $102.0 million in 2010,
$57.0 million in 2009 and $51.0 million in 2008.
Our Global Brands R&D strategy focuses on the following
product development areas:
the application of proprietary drug-delivery technology for new
product development in specialty areas; and
the acquisition of
mid-to-late
development-stage brand drugs.
We are presently developing a number of brand products, some of
which utilize novel drug-delivery systems, through a combination
of internal and collaborative programs. We also acquired Eden, a
company involved in biologics research and development.
Products in the brand pipeline include
Prochieve®
8% for the prevention of pre-term birth in women with a short
cervix, as well as two novel long-acting contraceptives in late
stage development, a progestin-only patch and a vaginal ring. We
received approval in December 2010 for a novel chewable oral
contraceptive licensed from Warner Chilcott Ltd., which we
expect to launch in the second quarter of 2011. We also have a
number of products in development as part of our life-cycle
management strategy on our existing product portfolio.
Biopharmaceuticals
or Biologics
Biopharmaceuticals will represent a significant opportunity in
the future, and we have taken strategic steps to enhance our
ability to offer products in this area. We believe biologics
will require selling and marketing resources for promotion.
Therefore, our biologics development efforts are managed by our
Global Brands division.
In January 2010, we acquired the remaining 64% of Eden for
approximately $15.0 million, making Eden a wholly-owned
subsidiary. Eden is a biopharmaceutical development and contract
manufacturing company located in Liverpool, UK. Eden will
maintain its established contract services model, while
providing the Company with proven biopharmaceutical development
and manufacturing capabilities.
In July 2010, we announced an exclusive, worldwide licensing
agreement with Itero Biopharmaceuticals, Inc.
(Itero), a venture-backed specialty
biopharmaceutical company, to develop and commercialize
Iteros recombinant follicle stimulating hormone
(rFSH) product. The product is currently in
preclinical development as a biosimilar molecule for the
treatment of female infertility. Under the terms of the
agreement, Watson paid Itero an undisclosed licensing fee and
will make additional payments based on the achievement of
certain development and regulatory performance milestones. Upon
successful commercialization, Watson will also pay
Itero a percentage of net sales or net profits in various
regions of the world. Watson will assume responsibility for all
future development, manufacturing, and commercial expenses
related to Iteros rFSH product.
The licensing of rFSH is an example of how we plan to enter
biologics, with products that are past the pre-clinical
development phase and complement our existing business.
Global
Brands Business Development
In 2010 we entered into a number of agreements as part of our
efforts to expand our brand product portfolio, specifically in
Womens Health.
In February 2010, we announced an exclusive licensing agreement
for Watson to become the U.S. commercial partner for
ella®
(ulipristal acetate), a selective progesterone receptor
modulator.
ella®
is a novel next-generation emergency contraceptive developed by
HRA Pharma specifically for emergency contraceptive use. Under
the terms of the agreement, Watson will be responsible for all
U.S. commercialization and marketing expenses and pay HRA
Pharma a royalty on U.S. sales of the product.
ella®
was approved by the FDA in August 2010 and launched in the
U.S. in December 2010. In September 2010, we expanded our
agreement with HRA Pharma to become the commercial partner for
ella®
in Canada.
In March 2010 we announced the acquisition of the exclusive
U.S. rights to Columbias bioadhesive progesterone gel
business. Products included in the acquisition were
Crinone®
for the treatment of infertility and
Prochieve®
under development for the prevention of pre-term birth in women
with a short cervix. Under the terms of the agreement, we paid
Columbia $62.0 million in cash and agreed to make certain
contingent payments in return for exclusive progesterone gel
product rights in the U.S. and 11.2 million newly
issued shares of Columbia common stock. We also obtained the
right to designate a member of Columbias board of
directors. Contingent payments will be made upon the successful
completion of clinical development milestones, receipt of
regulatory approvals and product launches and could total up to
$45.5 million. In addition, we will pay a royalty on our
sales of the progesterone gel product line and any subsequent
products. Pursuant to a supply agreement, Columbia will be
responsible for manufacturing the progesterone gel products.
Following the initial announcement in March 2010, we entered
into an agreement with Columbia to support Columbias
ongoing investment in the clinical development of the pre-term
birth indication for
Prochieve®,
as well as other Columbia capital requirements.
Following the close of the acquisition, Watson and Columbia
jointly announced top-line results from the PREGNANT Study, a
large, global Phase III clinical trial evaluating
Prochieve®
8% vaginal progesterone gel to reduce the risk of preterm birth
in women with a short cervical length as measured by
transvaginal ultrasound at mid-pregnancy. Columbia expects to
file a new drug application (NDA) in the first half
of 2011. We plan to collaborate with Columbia in the global
development of a second-generation vaginal progesterone product.
In March 2010, we announced an exclusive licensing agreement to
commercialize the Population Councils investigational
contraceptive vaginal ring in the United States, Canada, and
Mexico. The ring, which contains two hormonal
products ethinyl estradiol and
Nestorone®,
a novel, synthetic progestin, has concluded its Phase 3 clinical
development and is currently undergoing safety studies customary
with the introduction of a novel hormonal product.
In December 2010, we announced an exclusive licensing agreement
with PregLem, S.A., (PregLem) now a wholly-owned
subsidiary of Gedeon Richter Plc, to develop and market
Esmyatm
(ulipristal acetate), a product for the treatment of uterine
fibroids, in the U.S. and Canada. The product MMA has
recently been submitted for approval in Europe and Watson
expects to initiate U.S. Phase III clinical studies in
2011. Under terms of the agreement, Watson paid PregLem a
$17.0 million license fee and will pay royalties based on
sales in the U.S. and Canada. Watson will make additional
payments based on the achievement of certain regulatory
milestones. The companies will also collaborate on additional
Esmyatm
formulations, jointly sharing the development costs.
Additionally, we intend to market various products within our
Global Brands segment globally. As part of this strategy, we
have filed for regulatory approval of a number of our brand
products with various regulatory agencies internationally
including
Rapaflo®,
Gelnique®
and
ella®
in Canada and
Gelnique®
in Europe.
Distribution
Segment
Our Distribution business, which consists of our Anda, Anda
Pharmaceuticals and Valmed (also known as VIP)
subsidiaries (collectively Anda), primarily
distributes generic and selected brand pharmaceutical products
to independent pharmacies, alternate care providers (hospitals,
nursing homes and mail order pharmacies), pharmacy chains and
physicians offices. Additionally, we sell to members of
buying groups, which are independent pharmacies that join
together to enhance their buying power. We believe that we are
able to effectively compete in the distribution market, and
therefore optimize our market share, based on three critical
elements: (i) competitive pricing, (ii) high levels of
inventory for approximately 8,500 SKUs for responsive customer
service that includes, among other things, next day delivery to
the entire U.S., and (iii) well established telemarketing
relationships with our customers, supplemented by our electronic
ordering capabilities. While we purchase most of the approximate
8,500 SKUs in our Distribution operations from third party
manufacturers, we also utilize these operations for the sale and
marketing of our own products and our collaborative
partners products. We are the only
U.S. pharmaceutical company that has meaningful
distribution operations with direct access to independent
pharmacies and we believe that our Distribution operation is a
strategic asset in the national distribution of generic and
brand pharmaceuticals.
Revenue growth in our distribution operations will primarily be
dependent on the launch of new products, offset by the overall
level of net price and unit declines on existing distributed
products and will be subject to changes in market share.
We presently distribute products from our facilities in Weston,
Florida and Groveport, Ohio. For the year ended
December 31, 2010, approximately 67% of our Distribution
sales were shipped from our Groveport, Ohio facility and 33%
from our Weston, Florida facility, though this percentage can
vary. While our Weston, Florida facility is operating at 70%
capacity, our 355,000 square foot Ohio distribution center
currently operates at approximately 35% capacity, and provides
us with additional distribution capacity for the
U.S. market.
Strategic
Alliances and Collaborations
In 2004, we entered into an exclusive licensing agreement with
Kissei Pharmaceutical Co., Ltd. (Kissei) to develop
and market
Rapaflo®
for the North American market. The compound was originally
developed and launched by Kissei in Japan as
Urief®
and is marketed in Japan in cooperation with Daiichi Sankyo
Pharmaceutical Co., Ltd. for the treatment of the signs and
symptoms of benign prostatic hyperplasia.
In 2006, we entered into an agreement with Solvay
Pharmaceuticals, Inc. (Solvay) to utilize
Watsons Brands sales force to co-promote
AndroGel®
to urologists in the U.S. In February of 2010, Solvay was
acquired by Abbott.
We have an exclusive agreement with Pfizer, Inc. to market the
Authorized Generic version of
Lipitor®
(atorvastatin calcium). Under the terms of the agreement,
Pfizer, Inc. will supply Watson with the product for
distribution beginning in November 2011 or earlier under certain
circumstances.
Financial
Information About Segments
Watson evaluates the performance of its Global Generics, Global
Brands and Distribution business segments based on net revenues
and net contribution. Summarized net revenues and contribution
information for each of the last three fiscal years in the
U.S. and internationally, where applicable, is presented in
NOTE 13 Reportable Segments in the
accompanying Notes to Consolidated Financial
Statements in this Annual Report.
In our Global Generics and Global Brands operations, we sell our
generic and brand pharmaceutical products primarily to drug
wholesalers, retailers and distributors, including national
retail drug and food store chains, hospitals, clinics, mail
order, government agencies and managed healthcare providers such
as health maintenance organizations and other institutions. In
our Distribution business, we distribute generic and certain
select brand pharmaceutical products to independent pharmacies,
members of buying groups, alternate care providers (hospitals,
nursing homes and mail order pharmacies), pharmacy chains and
physicians offices.
Sales to certain of our customers accounted for 10% or more of
our annual net revenues during the past three years. The
following table illustrates any customer, on a global basis,
which accounted for 10% or more of our annual net revenues and
the respective percentage of our net revenues for which they
account for each of the last three years:
Customer
2010
2009
2008
Walgreen Co.
14
%
13
%
11
%
McKesson Corporation
11
%
11
%
11
%
McKesson and certain of our other customers comprise a
significant part of the distribution network for pharmaceutical
products in the U.S. As a result, a small number of large,
wholesale distributors and large chain drug stores control a
significant share of the market. This concentration may
adversely impact pricing and create other competitive pressures
on drug manufacturers. Our Distribution business competes
directly with our large wholesaler customers with respect to the
distribution of generic products.
The loss of any of these customers could have a material adverse
effect on our business, results of operations, financial
condition and cash flows. See ITEM 1A. RISK
FACTORS Risk Relating to Investing in the
Pharmaceutical Industry in this Annual Report.
Competition
The pharmaceutical industry is highly competitive. In our Global
Generics and Global Brands businesses, we compete with different
companies depending upon product categories, and within each
product category, upon dosage strengths and drug delivery
systems. Such competitors include the major brand name and
generic manufacturers of pharmaceutical products. In addition to
product development, other competitive factors in the
pharmaceutical industry include product quality and price,
reputation and service and access to proprietary and technical
information. It is possible that developments by others will
make our products or technologies noncompetitive or obsolete.
Competing in the brand product business requires us to identify
and bring to market new products embodying technological
innovations. Successful marketing of brand products depends
primarily on the ability to communicate their effectiveness,
safety and value to healthcare professionals in private
practice, group practices and receive formulary status from
managed care organizations. We anticipate that our brand product
offerings will support our existing areas of therapeutic focus.
Based upon business conditions and other factors, we regularly
reevaluate our business strategies and may from time to time
reallocate our resources from one therapeutic area to another,
withdraw from a therapeutic area or add an additional
therapeutic area in order to maximize our overall growth
opportunities. Our competitors in brand products include major
brand name manufacturers of pharmaceuticals. Based on total
assets, annual revenues and market capitalization, our Global
Brands segment is considerably smaller than many of these
competitors and other global competitors in the brand product
area. Many of our competitors have been in business for a longer
period of time, have a greater number of products on the market
and have greater financial and other resources than we do. If we
directly compete with them for certain contracted business, such
as the Pharmacy Benefit Manager business, and for the same
markets
and/or
products, their financial strength could prevent us from
capturing a meaningful share of those markets.
We actively compete in the generic pharmaceutical industry.
Revenues and gross profit derived from the sales of generic
pharmaceutical products tend to follow a pattern based on
certain regulatory and competitive factors. As patents and
regulatory exclusivity for brand name products expire or are
successfully challenged,
the first off-patent manufacturer to receive regulatory approval
for generic equivalents of such products is generally able to
achieve significant market penetration. As competing off-patent
manufacturers receive regulatory approvals on similar products,
market share, revenues and gross profit typically decline, in
some cases dramatically. Accordingly, the level of market share,
revenues and gross profit attributable to a particular generic
product normally is related to the number of competitors in that
products market and the timing of that products
regulatory approval and launch, in relation to competing
approvals and launches. Consequently, we must continue to
develop and introduce new products in a timely and
cost-effective manner to maintain our revenues and gross profit.
In addition to competition from other generic drug
manufacturers, we face competition from brand name companies in
the generic market. Many of these companies seek to participate
in sales of generic products by, among other things,
collaborating with other generic pharmaceutical companies or by
marketing their own generic equivalent to their brand products
as Authorized Generics. Our major competitors in generic
products include Teva Pharmaceutical Industries, Ltd., Mylan
Inc. and Sandoz (a division of Novartis AG). See
ITEM 1A. RISK FACTORS Risks Related to
Our Business The pharmaceutical industry is highly
competitive and our future revenue growth and profitability are
dependent on our timely development and launches of new products
ahead of our competitors. in this Annual Report.
In our Distribution business, we compete with a number of large
wholesalers and other distributors of pharmaceuticals, including
McKesson Corporation, AmerisourceBergen Corporation and Cardinal
Health, Inc., which distribute both brand and generic
pharmaceutical products to their customers. These same companies
are significant customers of our Global Generics and Global
Brands pharmaceutical businesses. As generic products generally
have higher gross margins than brand products for a
pharmaceutical distribution business, each of the large
wholesalers, on an increasing basis, are offering pricing
incentives on brand products if the customers purchase a
majority of their generic pharmaceutical products from the
primary wholesaler. As we do not offer a broad portfolio of
brand products to our customers, we are at times competitively
disadvantaged and must compete with these wholesalers based upon
our very competitive pricing for generic products, greater
service levels and our well-established telemarketing
relationships with our customers, supplemented by our electronic
ordering capabilities. Additionally, generic manufacturers are
increasingly marketing their products directly to drug store
chains with warehousing facilities and thus increasingly
bypassing wholesalers and distributors. Increased competition in
the generic industry as a whole may result in increased price
erosion in the pursuit of market share.
Manufacturing,
Suppliers and Materials
During 2010, we manufactured many of our own finished products
at our plants in Corona, California; Davie, Florida; Goa, India;
Birzebbugia, Malta; Mississauga, Canada; Rio de Janeiro, Brazil;
Carmel, New York; Copiague, New York and Salt Lake City,
Utah. As part of an ongoing effort to optimize our manufacturing
operations, we have implemented several cost reduction
initiatives, which included the transfer of several solid dosage
products from our Carmel, New York facility to our Goa, India
facility, and the ongoing implementation of our Global Supply
Chain Initiative at certain of our manufacturing facilities.
We have development and manufacturing capabilities for raw
material and active pharmaceutical ingredients (API)
and intermediate ingredients to support our internal product
development efforts in our Coleraine, Northern Ireland and
Ambernath, India facilities. Our Ambernath, India facility also
develops and manufactures API for third parties.
Our manufacturing operations are subject to extensive regulatory
oversight and could be interrupted at any time. Our Corona,
California facility is currently subject to a consent decree of
permanent injunction. See ITEM 1A. RISK
FACTORS Risks Related to Our Business
Extensive industry regulation has had, and will continue to
have, a significant impact on our business, especially our
product development, manufacturing and distribution
capabilities. Also refer to Legal Matters in
NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
We contract with third parties for the manufacture of certain of
our products, some of which are currently available only from
sole or limited suppliers. These third-party manufactured
products include products that have historically accounted for a
significant portion of our revenues, such as bupropion
hydrochloride
sustained-release tablets and a number of our oral contraceptive
products. Third-party manufactured product sales by our Global
Generics and Global Brands segments, accounted for approximately
33%, 38% and 44% of our product net revenues in 2010, 2009 and
2008, respectively.
We are dependent on third parties for the supply of the raw
materials necessary to develop and manufacture our products,
including the API and inactive pharmaceutical ingredients used
in our products. We are required to identify the supplier(s) of
all the raw materials for our products in the drug applications
that we file with the FDA. If raw materials for a particular
product become unavailable from an approved supplier specified
in a drug application, we would be required to qualify a
substitute supplier with the FDA, which would likely interrupt
manufacturing of the affected product. To the extent
practicable, we attempt to identify more than one supplier in
each drug application. However, some raw materials are available
only from a single source and, in many of our drug applications,
only one supplier of raw materials has been identified, even in
instances where multiple sources exist.
In addition, we obtain a significant portion of our raw
materials from foreign suppliers. Arrangements with
international raw material suppliers are subject to, among other
things, FDA regulation, customs clearance, various import
duties, foreign currency risk and other government clearances.
Acts of governments outside the U.S. may affect the price
or availability of raw materials needed for the development or
manufacture of our products. In addition, any changes in patent
laws in jurisdictions outside the U.S. may make it
increasingly difficult to obtain raw materials for R&D
prior to the expiration of the applicable U.S. or foreign
patents. See ITEM 1A. RISK FACTORS Risks
Related to Our Business If we are unable to obtain
sufficient supplies from key suppliers that in some cases may be
the only source of finished products or raw materials, our
ability to deliver our products to the market may be
impeded. in this Annual Report.
We continue to make substantial progress on our Global Supply
Chain Initiative and the transfer of product manufacturing from
our New York facility to our Florida, California, and Goa, India
sites. At the end of 2010, approximately 20% of our internally
sourced manufactured product was produced from our Goa, India
facility. At the end of 2010, we closed our Carmel, New York
solid dosage manufacturing facility. Additionally, during the
year we announced plans to close our manufacturing facility and
R&D facilities in Mississauga, Canada by late 2011 with
product being transferred to facilities with additional capacity
in the Watson global network, including Malta and India and the
transfer of development activities to other existing R&D
sites. In January 2011, the Company announced the closure of
R&D activities in Corona, California and the transfer of
development activities to existing R&D sites. We will
continue to implement operational efficiency programs at our
remaining sites.
Patents
and Proprietary Rights
We believe patent protection of our proprietary products is
important to our Global Brands business. Our success with our
brand products will depend, in part, on our ability to obtain,
and successfully defend if challenged, patent or other
proprietary protection for such products. We currently have a
number of U.S. and foreign patents issued or pending.
However, the issuance of a patent is not conclusive as to its
validity or as to the enforceable scope of the claims of the
patent. Accordingly, our patents may not prevent other companies
from developing similar or functionally equivalent products or
from successfully challenging the validity of our patents. If
our patent applications are not approved or, even if approved,
if such patents are circumvented or not upheld in a court of
law, our ability to competitively market our patented products
and technologies may be significantly reduced. Also, such
patents may or may not provide competitive advantages for their
respective products or they may be challenged or circumvented by
competitors, in which case our ability to commercially market
these products may be diminished. From time to time, we may need
to obtain licenses to patents and other proprietary rights held
by third parties to develop, manufacture and market our
products. If we are unable to timely obtain these licenses on
commercially reasonable terms, our ability to commercially
market such products may be inhibited or prevented. Patents
covering our
Androderm®
and
INFed®
products have expired and we have no further patent protection
on these products. Therefore, it is possible that a competitor
may launch a generic version of
Androderm®
and/or
INFed®
at any time, which would result in a significant decline in that
products revenue and profit. Both of these products were
significant contributors to our Global Brands business in 2010.
We also rely on trade secrets and proprietary know-how that we
seek to protect, in part, through confidentiality agreements
with our partners, customers, employees and consultants. It is
possible that these agreements will be breached or will not be
enforceable in every instance, and we will not have adequate
remedies for any such breach. It is also possible that our trade
secrets will otherwise become known or independently developed
by competitors.
We may find it necessary to initiate litigation to enforce our
patent rights, to protect our trade secrets or know-how or to
determine the scope and validity of the proprietary rights of
others. Litigation concerning patents, trademarks, copyrights
and proprietary technologies can often be protracted and
expensive and, as with litigation generally, the outcome is
inherently uncertain.
Pharmaceutical companies with brand products are suing companies
that produce off-patent forms of their brand name products for
alleged patent infringement or other violations of intellectual
property rights which may delay or prevent the entry of such a
generic product into the market. For instance, when we file an
ANDA in the U.S. seeking approval of a generic equivalent
to a brand drug, we may certify under the Drug Price Competition
and Patent Restoration Act of 1984 (the Hatch-Waxman
Act) to the FDA that we do not intend to market our
generic drug until any patent listed by the FDA as covering the
brand drug has expired, in which case, the ANDA will be approved
by the FDA no earlier than the expiration or final finding of
invalidity of such patent(s). On the other hand, we could
certify that we believe the patent or patents listed as covering
the brand drug are invalid
and/or will
not be infringed by the manufacture, sale or use of our generic
form of the brand drug. In that case, we are required to notify
the brand product holder or the patent holder that such patent
is invalid or is not infringed. If the patent holder sues us for
patent infringement within 45 days from receipt of the
notice, the FDA is then prevented from approving our ANDA for
30 months after receipt of the notice unless the lawsuit is
resolved in our favor in less time or a shorter period is deemed
appropriate by a court. In addition, increasingly aggressive
tactics employed by brand companies to delay generic
competition, including the use of Citizen Petitions and seeking
changes to U.S. Pharmacopeia, have increased the risks and
uncertainties regarding the timing of approval of generic
products.
Litigation alleging infringement of patents, copyrights or other
intellectual property rights may be costly and time consuming.
See ITEM 1A. RISK FACTORS Risks Related
to Our Business Third parties may claim that we
infringe their proprietary rights and may prevent us from
manufacturing and selling some of our products. in this
Annual Report.
Because a balanced and fair legislative and regulatory arena is
critical to the pharmaceutical industry, we will continue to
devote management time and financial resources on government
activities. We currently maintain an office and staff a
full-time government affairs function in Washington, D.C.
that maintains responsibility for keeping abreast of state and
federal legislative activities.
Government
Regulation and Regulatory Matters
All pharmaceutical manufacturers, including Watson, are subject
to extensive, complex and evolving regulation by the federal
government, principally the FDA, and to a lesser extent, by the
U.S. Drug Enforcement Administration (DEA),
Occupational Safety and Health Administration and state
government agencies, as well as by various regulatory agencies
in foreign countries where our products or product candidates
are being manufactured
and/or
marketed. The Federal Food, Drug and Cosmetic Act, the
Controlled Substances Act and other federal statutes and
regulations govern or influence the testing, manufacturing,
packing, labeling, storing, record keeping, safety, approval,
advertising, promotion, sale and distribution of our products.
In our international markets, the approval, manufacture and sale
of pharmaceutical products is similar to the United States with
some variations dependent upon local market dynamics.
FDA approval is required before any dosage form of any new drug,
including an off-patent equivalent of a previously approved
drug, can be marketed. The process for obtaining governmental
approval to manufacture and market pharmaceutical products is
rigorous, time-consuming and costly, and the extent to which it
may be affected by legislative and regulatory developments
cannot be predicted. We are dependent on receiving FDA and other
governmental approvals prior to manufacturing, marketing and
shipping new products. Consequently, there is always the risk
the FDA or another applicable agency will not approve our new
products, or the rate,
timing and cost of obtaining such approvals will adversely
affect our product introduction plans or results of operations.
See ITEM 1A. RISK FACTORS Risks Related
to Our Business If we are unable to successfully
develop or commercialize new products, our operating results
will suffer. and Extensive industry
regulation has had, and will continue to have, a significant
impact on our business, especially our product development,
manufacturing and distribution capabilities. in this
Annual Report.
All applications for FDA approval must contain information
relating to product formulation, raw material suppliers,
stability, manufacturing processes, packaging, labeling and
quality control. There are generally two types of applications
for FDA approval that would be applicable to our new products:
NDA. We file a NDA when we seek approval for
drugs with active ingredients
and/or with
dosage strengths, dosage forms, delivery systems or
pharmacokinetic profiles that have not been previously approved
by the FDA. Generally, NDAs are filed for newly developed brand
products or for a new dosage form of previously approved drugs.
ANDA. We file an ANDA when we seek approval
for off-patent, or generic equivalents of a previously approved
drug.
The process required by the FDA before a previously unapproved
pharmaceutical product may be marketed in the
U.S. generally involves the following:
preclinical laboratory and animal tests;
submission of an investigational new drug application
(IND), which must become effective before clinical
trials may begin;
adequate and well-controlled human clinical trials to establish
the safety and efficacy of the proposed product for its intended
use;
submission of a NDA containing the results of the preclinical
and clinical trials establishing the safety and efficacy of the
proposed product for its intended use; and
FDA approval of a NDA.
Preclinical tests include laboratory evaluation of the product,
its chemistry, formulation and stability, as well as animal
studies to assess the potential safety and efficacy of the
product. For products that require NDA approvals, these
preclinical studies and plans for initial human testing are
submitted to the FDA as part of an IND, which must become
effective before we may begin human clinical trials. The IND
automatically becomes effective 30 days after receipt by
the FDA unless the FDA, during that
30-day
period, raises concerns or questions about the conduct of the
trials as outlined in the IND. In such cases, the IND sponsor
and the FDA must resolve any outstanding concerns before
clinical trials can begin. In addition, an independent
Institutional Review Board must provide oversight to review and
approve any clinical study at the medical center proposing to
conduct the clinical trials.
Human clinical trials are typically conducted in the following
sequential phases:
Phase I. During this phase, the drug is
initially introduced into a relatively small number of healthy
human subjects or patients and is tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion.
Phase II. This phase involves studies in a
limited patient population to identify possible adverse effects
and safety risks, to determine the efficacy of the product for
specific targeted diseases or conditions, and to determine
dosage tolerance and optimal dosage.
Phase III. When Phase II evaluations
demonstrate that a dosage range of the product is effective and
has an acceptable safety profile, Phase III trials are
undertaken to further evaluate dosage, clinical efficacy and to
further test for safety in an expanded patient population at
geographically dispersed clinical study sites.
Phase IV. After a drug has been approved by
the FDA, Phase IV studies may be conducted to explore
additional patient populations, compare the drug to a
competitor, or to further study the risks, benefits and optimal
use of a drug. These studies may be a requirement as a condition
of the initial approval.
The results of product development, preclinical studies and
clinical studies are submitted to the FDA as part of a NDA, for
approval of the marketing and commercial shipment of the new
product. The NDA drug development and approval process currently
averages approximately five to ten years.
FDA approval of an ANDA is required before we may begin
marketing an off-patent or generic equivalent of a drug that has
been approved under an NDA, or a previously unapproved dosage
form of a drug that has been approved under an NDA. The ANDA
approval process generally differs from the NDA approval process
in that it does not typically require new preclinical and
clinical studies; instead, it relies on the clinical studies
establishing safety and efficacy conducted for the previously
approved NDA drug. The ANDA process, however, typically requires
data to show that the ANDA drug is bioequivalent (i.e.,
therapeutically equivalent) to the previously approved drug.
Bioequivalence compares the bioavailability of one
drug product with another and, when established, indicates
whether the rate and extent of absorption of a generic drug in
the body are substantially equivalent to the previously approved
drug. Bioavailability establishes the rate and
extent of absorption, as determined by the time dependent
concentrations of a drug product in the bloodstream needed to
produce a therapeutic effect. The ANDA drug development and
approval process generally takes three to four years which is
less time than the NDA drug development and approval process
since the ANDA process does not require new clinical trials
establishing the safety and efficacy of the drug product.
Supplemental NDAs or ANDAs are required for, among other things,
approval to transfer certain products from one manufacturing
site to another and may be under review for a year or more. In
addition, certain products may only be approved for transfer
once new bioequivalency studies are conducted or other
requirements are satisfied.
To obtain FDA approval of both NDAs and ANDAs, our manufacturing
procedures and operations must conform to FDA quality system and
control requirements generally referred to as current Good
Manufacturing Practices (cGMP), as defined in
Title 21 of the U.S. Code of Federal Regulations.
These regulations encompass all aspects of the production
process from receipt and qualification of components to
distribution procedures for finished products. They are evolving
standards; thus, we must continue to expend substantial time,
money and effort in all production and quality control areas to
maintain compliance. The evolving and complex nature of
regulatory requirements, the broad authority and discretion of
the FDA, and the generally high level of regulatory oversight
results in the continuing possibility that we may be adversely
affected by regulatory actions despite our efforts to maintain
compliance with regulatory requirements.
We are subject to the periodic inspection of our facilities,
procedures and operations
and/or the
testing of our products by the FDA, the DEA and other
authorities, which conduct periodic inspections to assess
compliance with applicable regulations. In addition, in
connection with its review of our applications for new products,
the FDA conducts pre-approval and post-approval reviews and
plant inspections to determine whether our systems and processes
comply with cGMP and other FDA regulations. Among other things,
the FDA may withhold approval of NDAs, ANDAs or other product
applications of a facility if deficiencies are found at that
facility. Vendors that supply finished products or components to
us that we use to manufacture, package and label products are
subject to similar regulation and periodic inspections.
Following such inspections, the FDA may issue notices on
Form 483 and Warning Letters that could cause us to modify
certain activities identified during the inspection. A
Form 483 notice is generally issued at the conclusion of an
FDA inspection and lists conditions the FDA investigators
believe may violate cGMP or other FDA regulations. FDA
guidelines specify that a Warning Letter be issued only for
violations of regulatory significance for which the
failure to adequately and promptly achieve correction may be
expected to result in an enforcement action.
Our Corona, California facility is currently subject to a
consent decree of permanent injunction. See also
Manufacturing, Suppliers and Materials discussion
above, ITEM 1A. RISK FACTORS Risks
Related to Our Business Extensive industry
regulation has had, and will continue to have, a significant
impact on our
business, especially our product development, manufacturing and
distribution capabilities. and Legal Matters in
NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
Failure to comply with FDA and other governmental regulations
can result in fines, unanticipated compliance expenditures,
recall or seizure of products, total or partial suspension of
production
and/or
distribution, suspension of the FDAs review of NDAs, ANDAs
or other product application enforcement actions, injunctions
and criminal prosecution. Under certain circumstances, the FDA
also has the authority to revoke previously granted drug
approvals. Although we have internal compliance programs, if
these programs do not meet regulatory agency standards or if our
compliance is deemed deficient in any significant way, it could
have a material adverse effect on us. See ITEM 1A.
RISK FACTORS Risks Related to Our
Business Extensive industry regulation has had, and
will continue to have, a significant impact on our business,
especially our product development, manufacturing and
distribution capabilities. in this Annual Report.
The Generic Drug Enforcement Act of 1992 established penalties
for wrongdoing in connection with the development or submission
of an ANDA. Under this Act, the FDA has the authority to
permanently or temporarily bar companies or individuals from
submitting or assisting in the submission of an ANDA, and to
temporarily deny approval and suspend applications to market
generic drugs. The FDA may also suspend the distribution of all
drugs approved or developed in connection with certain wrongful
conduct
and/or
withdraw approval of an ANDA and seek civil penalties. The FDA
can also significantly delay the approval of any pending NDA,
ANDA or other regulatory submissions under the Fraud, Untrue
Statements of Material Facts, Bribery and Illegal Gratuities
Policy Act.
U.S. Government reimbursement programs include Medicare,
Medicaid, TriCare, and State Pharmacy Assistance Programs
established according to statute, government regulations and
policy. Federal law requires that all pharmaceutical
manufacturers, as a condition of having their products receive
federal reimbursement under Medicaid, must pay rebates to state
Medicaid programs on units of their pharmaceuticals that are
dispensed to Medicaid beneficiaries. With enactment of The
Patient Protection and Affordable Care Act, (PPACA),
the required
per-unit
rebate for products marketed under ANDAs increased from 11% of
the average manufacturer price to approximately 13%.
Additionally, for products marketed under NDAs, the
manufacturers rebate will increase from 15.1% to 23.1% of the
average manufacturer price, or the difference between the
average manufacturer price and the lowest net sales price to a
non-government customer during a specified period. In some
states, supplemental rebates are additionally required as a
condition of including the manufacturers drug on the
states Preferred Drug List.
PPACA also made substantial changes to reimbursement when
seniors reach the Medicare Part D coverage gap donut
hole. By 2020, Medicare beneficiaries will pay just 25% of
drug costs when they reach the coverage threshold
the same percentage they were responsible for before they
reached that threshold.
The cost of closing the donut hole is being borne by generic and
brand drug companies. Brand drug manufacturers must provide a
50% discount on their drugs, beginning in 2011. Additionally,
beginning in 2013, the government will begin providing subsidies
for brand-name drugs bought by seniors who enter the coverage
gap. The governments share will start at 2.5%, but will
increase to 25% by 2020. At that point, the combined industry
discounts and government subsidies will add up to 75% of
brand-name drug costs. Generic drugs, which cost less than their
brand-name counterparts, are treated different from brand drugs.
Beginning in 2011, government subsidies will cover 7% of generic
drug costs. The government will then subsidize additional
portions each year until 2020, when federal subsidies will cover
75% of generic drug costs. By 2020, the donut hole will be
completely closed through these manufacturers subsidies.
The Medicare Prescription Drug, Improvement, and Modernization
Act of 2003 (the MMA) requires that manufacturers
report data to the Centers for Medicare and Medicaid Services
(CMS) on pricing of drugs and biologicals reimbursed
under Medicare Part B. These are generally drugs, such as
injectable products, that are administered incident
to a physician service, and in general are not
self-administered. Effective January 1, 2005, average
selling price (ASP) became the basis for
reimbursement to physicians and suppliers for drugs and
biologicals covered under Medicare Part B, replacing the
average wholesale price (AWP) provided and
published by pricing services. In general, we must comply with
all reporting requirements for any drug or biological that is
separately reimbursable under Medicare. Watsons
INFeD®
and
Trelstar®
products are reimbursed under Medicare Part B and, as a
result, we provide ASP data on these products to CMS on a
quarterly basis.
Under Part D of the MMA, some Medicare beneficiaries are
eligible to obtain subsidized prescription drug coverage from
private sector providers. Usage of pharmaceuticals has increased
as a result of the expanded access to medicines afforded by the
Medicare prescription drug benefit. However, such sales
increases have been offset by increased pricing pressures due to
the enhanced purchasing power of the private sector providers
who negotiate on behalf of Medicare beneficiaries. It is
anticipated that further pricing pressures will continue into
2011 and beyond.
The Deficit Reduction Act of 2005 (DRA) mandated a
number of changes in the Medicaid program, including the use of
Average Manufacturers Price (AMP) as the basis for
reimbursement to pharmaceutical companies that dispense generic
drugs under the Medicaid program. Three health care reform bills
passed in 2010 significantly changed the definition of AMP,
effective October 1, 2010. These legislative changes were
part of PPACA, the Health Care and Education Reconciliation Act,
and the FAA Air Transportation Modernization & Safety
Improvement Act (Transportation Bill). In PPACA,
Congress substantially revised the definition of AMP to, among
other things, narrow the scope of prices included in the
calculation of AMP to those paid to a manufacturer by
wholesalers for drugs distributed to retail community pharmacies
or by retail community pharmacies that purchase directly from
manufacturers. In August 2010, Congress further amended the
definition of AMP to specify that the exclusion of certain
classes of trade from AMP does not apply to inhalation,
infusion, instilled, implanted, or injected drugs that typically
are not dispensed to retail community pharmacies. PPACA also
requires disclosure of weighted average AMP instead of
manufacturer AMP, which was previously required. The impact of
this new legislation is that there will likely be increases in
Medicaid reimbursement to pharmacies for generics. These changes
became effective on October 1, 2010.
These new laws replaced the reimbursement guidelines that had
been established under the DRA. On November 9, 2010, CMS
issued a final rule withdrawing and amending regulations that
have governed the calculation of AMP and the establishment of
federal upper limits since October 2007. The regulations were
withdrawn to mandate AMP calculation under the recently revised
drug rebate statute, but no replacement regulations have yet
been proposed. The withdrawal required manufacturers to base
October 2010, and subsequent months AMPs on the statutory
language until official guidance is issued. CMS anticipates that
it will offer guidance by the second quarter of 2011.
In the absence of regulatory guidance governing the AMP
calculation, CMS has instructed pharmaceutical manufacturers to
base their AMP calculations on the definitions set forth in the
statute, as amended by the PPACA, the Health Care and Education
Reconciliation Act, and the Transportation Bill. Without the
benefit of interpretive guidance from CMS, Watson has adopted
mechanisms to ensure that we are calculating and reporting AMP
in a manner that is consistent with the statutes text and
intent.
As a result of these changes, in December of 2010, the National
Association of Chain Drugstores (NACDS) and the
National Community Pharmacists Association dropped their 2007
lawsuit that was previously blocking the implementation of the
AMP rule.
Twenty-six states are currently challenging the
constitutionality of PPACA. Ultimate resolution of this matter
remains uncertain.
There has been enhanced political attention, governmental
scrutiny and litigation at the federal and state levels of the
prices paid or reimbursed for pharmaceutical products under
Medicaid, Medicare and other government programs. See
ITEM 1A. RISK FACTORS Risks Related to
Our Business Investigations of the calculation of
average wholesale prices may adversely affect our
business. and Legal Matters in
NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
In order to assist us in commercializing products, we have
obtained from government authorities and private health insurers
and other organizations, such as Health Maintenance
Organizations (HMOs) and
Managed Care Organizations (MCOs), authorization to
receive reimbursement at varying levels for the cost of certain
products and related treatments. Third party payers increasingly
challenge pricing of pharmaceutical products. The trend toward
managed healthcare in the U.S., the growth of organizations such
as HMOs and MCOs and legislation to reform healthcare and
government insurance programs could significantly influence the
purchase of pharmaceutical products, resulting in lower prices
and a reduction in product demand. Such cost containment
measures and healthcare legislation could affect our ability to
sell our products and may have a material adverse effect on our
business, results of operations, financial condition and cash
flows. Due to the uncertainty surrounding reimbursement of newly
approved pharmaceutical products, reimbursement may not be
available for some of our products. Additionally, any
reimbursement granted may not be maintained or limits on
reimbursement available from third-party payers may reduce the
demand for, or negatively affect the price of, those products.
Federal, state, local and foreign laws of general applicability,
such as laws regulating working conditions, also govern us. In
addition, we are subject, as are all manufacturers generally, to
numerous and increasingly stringent federal, state and local
environmental laws and regulations concerning, among other
things, the generation, handling, storage, transportation,
treatment and disposal of toxic and hazardous substances and the
discharge of pollutants into the air and water. Environmental
permits and controls are required for some of our operations,
and these permits are subject to modification, renewal and
revocation by the issuing authorities. Our environmental capital
expenditures and costs for environmental compliance may increase
in the future as a result of changes in environmental laws and
regulations or increased manufacturing activities at any of our
facilities. We could be adversely affected by any failure to
comply with environmental laws, including the costs of
undertaking a
clean-up at
a site to which our wastes were transported.
As part of the MMA, companies are required to file with the
U.S. Federal Trade Commission (FTC) and the
Department of Justice certain types of agreements entered into
between brand and generic pharmaceutical companies related to
the manufacture, marketing and sale of generic versions of brand
drugs. This requirement could affect the manner in which generic
drug manufacturers resolve intellectual property litigation and
other disputes with brand pharmaceutical companies, and could
result generally in an increase in private-party litigation
against pharmaceutical companies. The impact of this
requirement, and the potential private-party lawsuits associated
with arrangements between brand name and generic drug
manufacturers, is uncertain and could adversely affect our
business. For example, in January 2009, the FTC and the State of
California filed a lawsuit against us alleging that our
settlement with Solvay related to our ANDA for a generic version
of
Androgel®
is unlawful. Beginning in February 2009, several private parties
purporting to represent various classes of plaintiffs filed
similar lawsuits. Additionally, we have received requests for
information, in the form of civil investigative demands or
subpoenas, from the FTC, and are subject to ongoing FTC
investigations, concerning our settlement with Cephalon related
to our ANDA for a generic version of
Provigil®.
Any adverse outcome of these or other FTC investigations or
actions could have a material adverse effect on our business,
results of operations, financial condition and cash flows. See
ITEM 1A. RISK FACTORS Risks Related to
Our Business Federal regulation of arrangements
between manufacturers of brand and generic products could
adversely affect our business. Also refer to Legal
Matters in NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
Continuing studies of the proper utilization, safety and
efficacy of pharmaceuticals and other health care products are
being conducted by industry, government agencies and others.
Such studies, which increasingly employ sophisticated methods
and techniques, can call into question the utilization, safety
and efficacy of previously marketed products and in some cases
have resulted, and may in the future result, in the
discontinuance of their marketing.
Our Distribution operations and our customers are subject to
various regulatory requirements, including requirements from the
DEA, FDA, and state boards of pharmacy and city and county
health regulators, among others. These include licensing,
registration, recordkeeping, security and reporting
requirements. In particular, several states and the federal
government have begun to enforce anti-counterfeit drug pedigree
laws which require the tracking of all transactions involving
prescription drugs beginning with the manufacturer, through the
supply chain, and down to the pharmacy or other health care
provider dispensing or administering
prescription drug products. For example, effective July 1,
2006, the Florida Department of Health began enforcement of the
drug pedigree requirements for distribution of prescription
drugs in the State of Florida. Pursuant to Florida law and
regulations, wholesalers and distributors, including our
subsidiary, Anda, are required to maintain records documenting
the chain of custody of prescription drug products they
distribute beginning with the purchase of such products from the
manufacturer. These entities are required to provide
documentation of the prior transaction(s) to their customers in
Florida, including pharmacies and other health care entities.
Several other states have proposed or enacted legislation to
implement similar or more stringent drug pedigree requirements.
In addition, federal law requires that a non-authorized
distributor of record must provide a drug pedigree
documenting the prior purchase of a prescription drug from the
manufacturer or from an authorized distributor of
record. In cases where the wholesaler or distributor
selling the drug product is not deemed an authorized
distributor of record, it would need to maintain such
records. The FDA had announced its intent to impose additional
drug pedigree requirements (e.g., tracking of lot numbers and
documentation of all transactions) through implementation of
drug pedigree regulations which were to have taken effect on
December 1, 2006. However, a federal appeals court has
issued a preliminary injunction to several wholesale
distributors granting an indefinite stay of these regulations
pending a challenge to the regulations by these wholesale
distributors.
Environmental
Matters
We are subject to federal, state, local and foreign
environmental laws and regulations. We believe that our
operations comply in all material respects with applicable
environmental laws and regulations in each jurisdiction where we
have a business presence. Although we continue to make capital
expenditures for environmental protection, we do not anticipate
any significant expenditure in order to comply with such laws
and regulations that would have a material impact on our
earnings or competitive position. We are not aware of any
pending litigation or significant financial obligations arising
from current or past environmental practices that are likely to
have a material adverse effect on our financial position. We
cannot assure you, however, that environmental problems relating
to facilities owned or operated by us will not develop in the
future, and we cannot predict whether any such problems, if they
were to develop, could require significant expenditures on our
part. In addition, we are unable to predict what legislation or
regulations may be adopted or enacted in the future with respect
to environmental protection and waste disposal.
Seasonality
There are no significant seasonal aspects to our business except
in Western Europe. During the months of July and August our
operations in Western Europe experience significantly lower
sales due to pharmacy closures and representatives on summer
vacations.
Backlog
Due to the relatively short lead-time required to fill orders
for our products, backlog of orders is not material to our
business.
Employees
As of December 31, 2010, we had approximately
6,030 employees. Of our employees, approximately 830 are
engaged in R&D, 1,850 in manufacturing, 1,070 in quality
assurance and quality control, 1,380 in sales, marketing and
distribution, and 900 in administration.
Any statements made in this report that are not statements of
historical fact or that refer to estimated or anticipated future
events are forward-looking statements. We have based our
forward-looking statements on managements beliefs and
assumptions based on information available to our management at
the time these statements are made. Such forward-looking
statements reflect our current perspective of our business,
future performance, existing trends and information as of the
date of this filing. These include, but are not limited to, our
beliefs about future revenue and expense levels and growth
rates, prospects related to our strategic initiatives and
business strategies, including the integration of, and synergies
associated with, strategic acquisitions, express or implied
assumptions about government regulatory action or inaction,
anticipated product approvals and launches, business initiatives
and product development activities, assessments related to
clinical trial results, product performance and competitive
environment, and anticipated financial performance. Without
limiting the generality of the foregoing, words such as
may, will, expect,
believe, anticipate, intend,
could, would, estimate,
continue, or pursue, or the negative
or other variations thereof or comparable terminology, are
intended to identify forward-looking statements. The statements
are not guarantees of future performance and involve certain
risks, uncertainties and assumptions that are difficult to
predict. We caution the reader that these statements are based
on certain assumptions, risks and uncertainties, many of which
are beyond our control. In addition, certain important factors
may affect our actual operating results and could cause such
results to differ materially from those expressed or implied by
forward-looking statements. We believe the risks and
uncertainties discussed under the section entitled Risks
Related to Our Business, and other risks and uncertainties
detailed herein and from time to time in our SEC filings, may
cause our actual results to vary materially than those
anticipated in any forward-looking statement.
We disclaim any obligation to publicly update any
forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. This discussion is provided as permitted by the Private
Securities Litigation Reform Act of 1995.
Risks
Related to Our Business
We operate in a rapidly changing environment that involves a
number of risks, some of which are beyond our control. The
following discussion highlights some of these risks and others
are discussed elsewhere in this annual report. These and other
risks could have a material adverse effect on our business,
results of operations, financial condition and cash flows.
Risks
Associated With Investing In the Business of Watson
Our
operating results and financial condition may
fluctuate.
Our operating results and financial condition may fluctuate from
quarter to quarter and year to year for a number of reasons. The
following events or occurrences, among others, could cause
fluctuations in our financial performance from period to period:
development of new competitive products or generics by others;
the timing and receipt of approvals by the FDA and other
regulatory authorities, including foreign regulatory authorities;
the failure to obtain, delay in obtaining or restrictions or
limitations on approvals from the FDA or other foreign
regulatory authorities;
difficulties or delays in resolving FDA-observed deficiencies at
our manufacturing facilities, which could delay our ability to
obtain approvals of pending FDA product applications;
delays or failures in clinical trials that affect our ability to
achieve FDA approvals or approvals from other foreign regulatory
authorities;
serious or unexpected health or safety concerns with our
products or product candidates;
changes in the amount we spend to develop, acquire or license
new products, technologies or businesses;
changes in the amount we spend to promote our products;
delays between our expenditures to acquire new products,
technologies or businesses and the generation of revenues from
those acquired products, technologies or businesses;
changes in treatment practices of physicians that currently
prescribe our products;
changes in coverage and reimbursement policies of health plans
and other health insurers, including changes that affect newly
developed or newly acquired products;
changes in laws and regulations concerning coverage and
reimbursement of pharmaceutical products, including changes to
Medicare, Medicaid, and similar state programs;
increases in the cost of raw materials used to manufacture our
products;
manufacturing and supply interruptions, including failure to
comply with manufacturing specifications;
the effect of economic changes in hurricane, monsoon, earthquake
and other natural disaster-affected areas;
the impact of third party patents and other intellectual
property rights which we may be found to infringe, or may be
required to license, and the potential damages or other costs we
may be required to pay as a result of a finding that we infringe
such intellectual property rights or a decision that we are
required to obtain a license to such intellectual property
rights;
the mix of products that we sell during any time period;
lower than expected demand for our products;
our responses to price competition;
our ability to successfully integrate and commercialize the
products, technologies and businesses we acquire or license, as
applicable;
expenditures as a result of legal actions;
market acceptance of our products;
the impairment and write-down of goodwill or other intangible
assets;
disposition of our primary products, technologies and other
rights;
termination or expiration of, or the outcome of disputes
relating to, trademarks, patents, license agreements and other
rights;
changes in insurance rates for existing products and the cost of
insurance for new products;
general economic and industry conditions, including changes in
interest rates affecting returns on cash balances and
investments that affect customer demand;
our level of R&D activities;
impairment or write-down of investments;
costs and outcomes of any tax audits;
fluctuations in foreign currency exchange rates;
costs and outcomes of any litigation involving intellectual
property, drug pricing or reimbursement, product liability,
customers or other issues;
timing of revenue recognition related to licensing agreements
and/or
strategic collaborations; and
risks related to the growth of our business across numerous
countries world-wide and the inherent international business
risks.
As a result, we believe that
period-to-period
comparisons of our results of operations are not necessarily
meaningful, and these comparisons should not be relied upon as
an indication of future performance. The above factors may cause
our operating results to fluctuate and adversely affect our
financial condition and results of operations.
If we
are unable to successfully develop or commercialize new
products, our operating results will suffer.
Our future results of operations will depend to a significant
extent upon our ability to successfully develop and
commercialize new brand and generic products in a timely manner.
There are numerous difficulties in developing and
commercializing new products, including:
developing, testing and manufacturing products in compliance
with regulatory standards in a timely manner;
receiving requisite regulatory approvals for such products in a
timely manner or at all;
the availability, on commercially reasonable terms, of raw
materials, including API and other key ingredients;
developing and commercializing a new product is time consuming,
costly and subject to numerous factors, including legal actions
brought by our competitors, that may delay or prevent the
development and commercialization of new products;
experiencing delays or unanticipated costs;
experiencing delays as a result of limited resources at FDA or
other regulatory agencies;
changing review and approval policies and standards at FDA and
other regulatory agencies; and
commercializing generic products may be substantially delayed by
the listing with the FDA of patents that have the effect of
potentially delaying approval of the generic product by up to
30 months.
As a result of these and other difficulties, products currently
in development by us may or may not receive timely regulatory
approvals, or approvals at all, necessary for marketing by us or
other third-party partners. This risk particularly exists with
respect to the development of proprietary products because of
the uncertainties, higher costs and lengthy time frames
associated with research and development of such products and
the inherent unproven market acceptance of such products.
Additionally, we face heightened risks in connection with our
development of extended release or controlled release generic
products because of the technical difficulties and regulatory
requirements related to such products. Additionally, with
respect to generic products for which we are the first applicant
to request approval on the basis that an innovator patent is
invalid or not infringed (a paragraph IV filing), our
ability to obtain 180 days of generic market exclusivity
may be contingent on our ability to obtain FDA approval or
tentative approval within 30 months of FDAs
acceptance of our application for filing. We therefore risk
forfeiting such market exclusivity if we are unable to obtain
such approval or tentative approval on a timely basis. If any of
our products are not timely approved or, when acquired or
developed and approved, cannot be successfully manufactured or
timely commercialized, our operating results could be adversely
affected. We cannot guarantee that any investment we make in
developing products will be recouped, even if we are successful
in commercializing those products.
Our
brand pharmaceutical expenditures may not result in commercially
successful products.
Developing and commercializing brand pharmaceutical products is
generally more costly than generic products. In the future, we
anticipate continuing our product development expenditures for
our Global Brands business segment. For example in 2010, we
acquired rights to
Prochieve®
8% vaginal progesterone gel to reduce the risk of preterm birth
in women with a short cervix. We plan to submit an NDA for FDA
approval
of this product in 2011. We cannot be sure this or other
business expenditures will result in the successful discovery,
development or launch of brand products that will prove to be
commercially successful or will improve the long-term
profitability of our business. If such business expenditures do
not result in successful discovery, development or launch of
commercially successful brand products our results of operations
and financial condition could be materially adversely affected.
Any
acquisitions of technologies, products and businesses, may be
difficult to integrate, could adversely affect our relationships
with key customers, and/or could result in significant charges
to earnings.
We regularly review potential acquisitions of technologies,
products and businesses complementary to our business.
Acquisitions typically entail many risks and could result in
difficulties in integrating operations, personnel, technologies
and products. If we are not able to successfully integrate our
acquisitions, we may not obtain the advantages and synergies
that the acquisitions were intended to create, which may have a
material adverse effect on our business, results of operations,
financial condition and cash flows, our ability to develop and
introduce new products and the market price of our stock. In
addition, in connection with acquisitions, we could experience
disruption in our business, technology and information systems,
customer or employee base, including diversion of
managements attention from our continuing operations.
There is also a risk that key employees of companies that we
acquire or key employees necessary to successfully commercialize
technologies and products that we acquire may seek employment
elsewhere, including with our competitors. Furthermore, there
may be overlap between our products or customers and the
companies that we acquire that may create conflicts in
relationships or other commitments detrimental to the integrated
businesses. If we are unable to successfully integrate products,
technologies, businesses or personnel that we acquire, we could
incur significant impairment charges or other adverse financial
consequences.
In addition, as a result of acquiring businesses or products, or
entering into other significant transactions, we have
experienced, and will likely continue to experience, significant
charges to earnings for merger and related expenses. These costs
may include substantial fees for investment bankers, attorneys,
accountants and financial printing costs and severance and other
closure costs associated with the elimination of duplicate or
discontinued products, operations and facilities. Charges that
we may incur in connection with acquisitions could adversely
affect our results of operations for particular quarterly or
annual periods.
If we
are unsuccessful in our joint ventures and other collaborations,
our operating results could suffer.
We have made substantial investments in joint ventures and other
collaborations and may use these and other methods to develop or
commercialize products in the future. These arrangements
typically involve other pharmaceutical companies as partners
that may be competitors of ours in certain markets. In many
instances, we will not control these joint ventures or
collaborations or the commercial exploitation of the licensed
products, and cannot assure you that these ventures will be
profitable. Although restrictions contained in certain of these
programs have not had a material adverse impact on the marketing
of our own products to date, any such marketing restrictions
could affect future revenues and have a material adverse effect
on our operations. Our results of operations may suffer if
existing joint venture or collaboration partners withdraw, or if
these products are not timely developed, approved or
successfully commercialized.
If we
are unable to adequately protect our technology or enforce our
patents, our business could suffer.
Our success with the brand products that we develop will depend,
in part, on our ability to obtain patent protection for these
products. We currently have a number of U.S. and foreign
patents issued and pending. However, issuance of a patent is not
conclusive evidence of its validity or enforceability. We cannot
be sure that we will receive patents for any of our pending
patent applications or any patent applications we may file in
the future, or that our issued patents will be upheld if
challenged. If our current and future patent applications are
not approved or, if approved, our patents are not upheld in a
court of law if challenged, it may reduce our ability to
competitively exploit our patented products. Also, such patents
may or may not provide competitive advantages for their
respective products or they may be challenged or circumvented by
our competitors, in which case our ability to commercially
market these products may be diminished. Patents covering our
Androderm®
and
INFed®
products have expired and we have no further patent protection
on
these products. Therefore, it is possible that a competitor may
launch a generic version of
Androderm®
and/or
INFed®
at any time, which would result in a significant decline in that
products revenue and profit. Both of these products were
significant contributors to our Global Brands business in 2010.
We also rely on trade secrets and proprietary know-how that we
seek to protect, in part, through confidentiality agreements
with our partners, customers, employees and consultants. It is
possible that these agreements will be breached or that they
will not be enforceable in every instance, and that we will not
have adequate remedies for any such breach. It is also possible
that our trade secrets will become known or independently
developed by our competitors.
If we are unable to adequately protect our technology, trade
secrets or propriety know-how, or enforce our intellectual
property rights, our results of operations, financial condition
and cash flows could suffer.
If
pharmaceutical companies are successful in limiting the use of
generics through their legislative, regulatory and other
efforts, our sales of generic products may suffer.
Many pharmaceutical companies increasingly have used state and
federal legislative and regulatory means to delay generic
competition. These efforts have included:
pursuing new patents for existing products which may be granted
just before the expiration of earlier patents, which could
extend patent protection for additional years or otherwise delay
the launch of generics;
selling the brand product as an Authorized Generic, either by
the brand company directly, through an affiliate or by a
marketing partner;
using the Citizen Petition process to request amendments to FDA
standards or otherwise delay generic drug approvals;
seeking changes to U.S. Pharmacopeia, an organization which
publishes industry recognized compendia of drug standards;
attaching patent extension amendments to non-related federal
legislation;
engaging in
state-by-state
initiatives to enact legislation that restricts the substitution
of some generic drugs, which could have an impact on products
that we are developing; and
seeking patents on methods of manufacturing certain API.
If pharmaceutical companies or other third parties are
successful in limiting the use of generic products through these
or other means, our sales of generic products may decline. If we
experience a material decline in generic product sales, our
results of operations, financial condition and cash flows will
suffer.
If
competitors are successful in limiting competition for certain
generic products through their legislative, regulatory and
litigation efforts, our sales of certain generic products may
suffer.
Certain of our competitors have recently challenged our ability
to distribute Authorized Generics during the competitors
180-day
period of ANDA exclusivity under the Hatch-Waxman Act. Under the
challenged arrangements, we have obtained rights to market and
distribute under a brand manufacturers NDA a generic
alternative of the brand product. Some of our competitors have
challenged the propriety of these arrangements by filing Citizen
Petitions with the FDA, initiating lawsuits alleging violation
of the antitrust and consumer protection laws, and seeking
legislative intervention. For example, in February 2011,
legislation was introduced in the U.S. Senate that would
prohibit the marketing of Authorized Generics during the
180-day
period of ANDA exclusivity under the Hatch-Waxman Act. If
distribution of Authorized Generic versions of brand products is
otherwise restricted or found unlawful, our results of
operations, financial condition and cash flows could be
materially adversely affected.
From
time to time we may need to rely on licenses to proprietary
technologies, which may be difficult or expensive to
obtain.
We may need to obtain licenses to patents and other proprietary
rights held by third parties to develop, manufacture and market
products. If we are unable to timely obtain these licenses on
commercially reasonable terms, our ability to commercially
market our products may be inhibited or prevented, which could
have a material adverse effect on our business, results of
operations, financial condition and cash flows.
Third
parties may claim that we infringe their proprietary rights and
may prevent us from manufacturing and selling some of our
products.
The manufacture, use and sale of new products that are the
subject of conflicting patent rights have been the subject of
substantial litigation in the pharmaceutical industry. These
lawsuits relate to the validity and infringement of patents or
proprietary rights of third parties. We may have to defend
against charges that we violated patents or proprietary rights
of third parties. This is especially true in the case of generic
products on which the patent covering the brand product is
expiring, an area where infringement litigation is prevalent,
and in the case of new brand products where a competitor has
obtained patents for similar products. Litigation may be costly
and time-consuming, and could divert the attention of our
management and technical personnel. In addition, if we infringe
the rights of others, we could lose our right to develop,
manufacture or market products or could be required to pay
monetary damages or royalties to license proprietary rights from
third parties. For example, we are engaged in litigation with
Bayer Pharmaceuticals concerning whether our
Zarahtm
product infringes Bayers U.S. Patent Number
5,569,652, and we continue to manufacture and market our
Zarahtm
product during the pendency of the litigation. Although the
parties to patent and intellectual property disputes in the
pharmaceutical industry have often settled their disputes
through licensing or similar arrangements, the costs associated
with these arrangements may be substantial and could include
ongoing royalties. Furthermore, we cannot be certain that the
necessary licenses would be available to us on commercially
reasonable terms, or at all. As a result, an adverse
determination in a judicial or administrative proceeding or
failure to obtain necessary licenses could result in substantial
monetary damage awards and could prevent us from manufacturing
and selling a number of our products, which could have a
material adverse effect on our business, results of operations,
financial condition and cash flows.
Our
distribution operations are highly dependent upon a primary
courier service.
Product deliveries within our Distribution business are highly
dependent on overnight delivery services to deliver our products
in a timely and reliable manner, typically by overnight service.
Our Distribution business ships a substantial portion of
products via one couriers air and ground delivery service.
If the courier terminates our contract or if we cannot renew the
contract on favorable terms or enter into a contract with an
equally reliable overnight courier to perform and offer the same
service level at similar or more favorable rates, our business,
results of operations, financial condition and cash flows could
be materially adversely affected.
Our
distribution operations concentrate on generic products and
therefore are subject to the risks of the generic
industry.
The ability of our Distribution business to provide consistent,
sequential quarterly growth is affected, in large part, by our
participation in the launch of new products by generic
manufacturers and the subsequent advent and extent of
competition encountered by these products. This competition can
result in significant and rapid declines in pricing with a
corresponding decrease in net sales of our Distribution
business. Our margins can also be affected by the risks inherent
to the generic industry, which is discussed below under
Risks Relating to Investing in the Pharmaceutical
Industry.
Our
distribution operations compete directly with significant
customers of our generic and brand businesses.
In our Distribution business, our main competitors are McKesson
Corporation, AmerisourceBergen Corporation and Cardinal Health,
Inc. These companies are significant customers of our Global
Generics and Global Brands operations and collectively accounted
for approximately 23% of our annual net revenues in 2010. Our
activities related to our Distribution business, as well as the
acquisition of other businesses that compete with our customers,
may result in the disruption of our business, which could harm
relationships with our current customers, employees or
suppliers, and could adversely affect our expenses, pricing,
third-party relationships and revenues. Further, a loss of a
significant customer of our Global Generics or Global Brands
operations could have a material adverse effect on our business,
results of operations, financial condition and cash flows.
If we
are unable to obtain sufficient supplies from key manufacturing
sites or suppliers that in some cases may be the only source of
finished products or raw materials, our ability to deliver our
products to the market may be impeded.
We are required to identify the supplier(s) of all the raw
materials for our products in our applications with the FDA and
other regulatory agencies. To the extent practicable, we attempt
to identify more than one supplier in each drug application.
However, some products and raw materials are available only from
a single source and, in many of our drug applications, only one
supplier of products and raw materials or site of manufacture
has been identified, even in instances where multiple sources
exist. Some of these products have historically accounted for a
significant portion of our revenues, such as
INFed®,
metoprolol succinate extended release, bupropion sustained
release tablets and a significant number of our oral
contraceptive and controlled substance products. From time to
time, certain of our manufacturing sites or outside suppliers
have experienced regulatory or supply-related difficulties that
have inhibited their ability to deliver products and raw
materials to us, causing supply delays or interruptions. To the
extent any difficulties experienced by our manufacturing sites
or suppliers cannot be resolved or extensions of our key supply
agreements cannot be negotiated within a reasonable time and on
commercially reasonable terms, or if raw materials for a
particular product become unavailable from an approved supplier
and we are required to qualify a new supplier with the FDA, or
if we are unable to do so, our profit margins and market share
for the affected product could decrease or be eliminated, as
well as delay our development and sales and marketing efforts.
Such outcomes could have a material adverse effect on our
business, results of operations, financial condition and cash
flows.
Our manufacturing sites in India, Canada and Malta, and our
arrangements with foreign suppliers, are subject to certain
additional risks, including the availability of government
clearances, export duties, political instability, war, acts of
terrorism, currency fluctuations and restrictions on the
transfer of funds. For example, we obtain a significant portion
of our raw materials from foreign suppliers. Arrangements with
international raw material suppliers are subject to, among other
things, FDA and foreign regulatory body regulation, customs
clearances, various import duties and other government
clearances, as well as potential shipping delays due to
inclement weather, strikes or other matters outside of our
control. Acts of governments outside the U.S. may affect
the price or availability of raw materials needed for the
development or manufacture of our products. In addition, recent
changes in patent laws in jurisdictions outside the
U.S. may make it increasingly difficult to obtain raw
materials for R&D prior to the expiration of the applicable
U.S. or foreign patents.
Our
policies regarding returns, allowances and chargebacks, and
marketing programs adopted by wholesalers, may reduce our
revenues in future fiscal periods.
Consistent with industry practice we, like many generic product
manufacturers, have liberal return policies and have been
willing to give customers post-sale inventory allowances. Under
these arrangements, from time to time, we may give our customers
credits on our generic products that our customers hold in
inventory after we have decreased the market prices of the same
generic products. Therefore, if new competitors enter the
marketplace and significantly lower the prices of any of their
competing products, we may reduce the price of our product. As a
result, we may be obligated to provide significant credits to
our
customers who are then holding inventories of such products,
which could reduce sales revenue and gross margin for the period
the credit is provided. Like our competitors, we also give
credits for chargebacks to wholesale customers that have
contracts with us for their sales to hospitals, group purchasing
organizations, pharmacies or other retail customers. A
chargeback represents an amount payable in the future to a
wholesaler for the difference between the invoice price paid to
us by our wholesale customer for a particular product and the
negotiated price that the wholesalers customer pays for
that product. Although we establish reserves based on our prior
experience and our best estimates of the impact that these
policies may have in subsequent periods, we cannot ensure that
our reserves are adequate or that actual product returns,
allowances and chargebacks will not exceed our estimates, which
could have a material adverse effect on our results of
operations, financial condition, cash flows and the market price
of our stock.
Investigations
of the calculation of average wholesale prices may adversely
affect our business.
Many government and third-party payers, including Medicare,
Medicaid, HMOs and MCOs, have historically reimbursed doctors,
pharmacies and others for the purchase of certain prescription
drugs based on a drugs AWP or wholesale average cost
(WAC). In the past several years, state and federal
government agencies have conducted ongoing investigations of
manufacturers reporting practices with respect to AWP and
WAC, in which they have suggested that reporting of inflated
AWPs or WACs have led to excessive payments for
prescription drugs. For example, beginning in July 2002, we and
certain of our subsidiaries, as well as numerous other
pharmaceutical companies, were named as defendants in various
state and federal court actions alleging improper or fraudulent
practices related to the reporting of AWP
and/or WAC
of certain products, and other improper acts, in order to
increase prices and market shares. Additional actions are
anticipated. These actions, if successful, could adversely
affect us and may have a material adverse effect on our
business, results of operations, financial condition and cash
flows. See Legal Matters in
NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
The
design, development, manufacture and sale of our products
involves the risk of product liability claims by consumers and
other third parties, and insurance against such potential claims
is expensive and may be difficult to obtain.
The design, development, manufacture and sale of our products
involve an inherent risk of product liability claims and the
associated adverse publicity. Insurance coverage is expensive
and may be difficult to obtain, and may not be available in the
future on acceptable terms, or at all. We regularly monitor the
use of our products for trends or increases in reports of
adverse events or product complaints, and regularly report such
matters to the FDA. In some, but not all, cases an increase in
adverse event reports may be an indication that there has been a
change in a products specifications or efficacy. Such
changes could lead to a recall of the product in question or, in
some cases, increases in product liability claims related to the
product in question. If the coverage limits for product
liability insurance policies are not adequate or if certain of
our products are excluded from coverage, a claim brought against
us, whether covered by insurance or not, could have a material
adverse effect on our business, results of operations, financial
condition and cash flows. See Legal Matters in
NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
The
loss of our key personnel could cause our business to
suffer.
The success of our present and future operations will depend, to
a significant extent, upon the experience, abilities and
continued services of key personnel. For example, although we
have other senior management personnel, a significant loss of
the services of Paul Bisaro, our Chief Executive Officer, or
other senior executive officers without having or hiring a
suitable successor, could cause our business to suffer. We
cannot assure you that we will be able to attract and retain key
personnel. We have entered into employment agreements with many
of our senior executive officers but such agreements do not
guarantee that our senior executive officers will remain
employed by us for a significant period of time, or at all. We
do not carry key-employee life insurance on any of our officers.
Significant
balances of intangible assets, including product rights and
goodwill acquired, are subject to impairment testing and may
result in impairment charges, which will adversely affect our
results of operations and financial condition.
A significant amount of our total assets is related to acquired
intangibles and goodwill. As of December 31, 2010, the
carrying value of our product rights and other intangible assets
was approximately $1.63 billion and the carrying value of
our goodwill was approximately $1.53 billion.
Our product rights are stated at cost, less accumulated
amortization. We determine original fair value and amortization
periods for product rights based on our assessment of various
factors impacting estimated useful lives and cash flows of the
acquired products. Such factors include the products
position in its life cycle, the existence or absence of like
products in the market, various other competitive and regulatory
issues and contractual terms. Significant adverse changes to any
of these factors would require us to perform an impairment test
on the affected asset and, if evidence of impairment exists, we
would be required to take an impairment charge with respect to
the asset. Such a charge could have a material adverse effect on
our results of operations and financial condition.
Our other significant intangible assets include acquired core
technology and customer relationships, which are intangible
assets with definite lives, our Anda trade name and acquired
in-process research and development (IPR&D)
intangibles, acquired in recent business acquisitions, which are
intangible assets with indefinite lives.
Our acquired core technology and customer relationship
intangible assets are stated at cost, less accumulated
amortization. We determined the original fair value of our other
intangible assets by performing a discounted cash flow analysis,
which is based on our assessment of various factors. Such
factors include existing operating margins, the number of
existing and potential competitors, product pricing patterns,
product market share analysis, product approval and launch
dates, the effects of competition, customer attrition rates,
consolidation within the industry and generic product lifecycle
estimates. Our other intangible assets with definite lives are
tested for impairment when there are significant changes to any
of these factors. If evidence of impairment exists, we would be
required to take an impairment charge with respect to the
impaired asset. Such a charge could have a material adverse
effect on our results of operations and financial condition.
Goodwill, our Anda trade name intangible asset and our
IPR&D intangible assets are tested for impairment annually
and when events occur or circumstances change that could
potentially reduce the fair value of the reporting unit or
intangible asset. Impairment testing compares the fair value of
the reporting unit or intangible asset to its carrying amount. A
goodwill, trade name or IPR&D impairment, if any, would be
recorded in operating income and could have a material adverse
effect on our results of operations and financial condition.
During the fourth quarter of 2010, the Company recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition.
We may
need to raise additional funds in the future which may not be
available on acceptable terms or at all.
We may consider issuing additional debt or equity securities in
the future to fund potential acquisitions or investments, to
refinance existing debt, or for general corporate purposes. If
we issue equity or convertible debt securities to raise
additional funds, our existing stockholders may experience
dilution, and the new equity or debt securities may have rights,
preferences and privileges senior to those of our existing
stockholders. If we incur additional debt, it may increase our
leverage relative to our earnings or to our equity
capitalization, requiring us to pay additional interest expenses
and potentially lower our credit ratings. We may not be able to
market such issuances on favorable terms, or at all, in which
case, we may not be able to develop or enhance our products,
execute our business plan, take advantage of future
opportunities, or respond to competitive pressures or
unanticipated customer requirements.
Our
business could suffer as a result of manufacturing difficulties
or delays.
The manufacture of certain of our products and product
candidates, particularly our controlled-release products,
transdermal products, and our oral contraceptive products, is
more difficult than the manufacture of immediate-release
products. Successful manufacturing of these types of products
requires precise
manufacturing process controls, API that conforms to very tight
tolerances for specific characteristics and equipment that
operates consistently within narrow performance ranges.
Manufacturing complexity, testing requirements, and safety and
security processes combine to increase the overall difficulty of
manufacturing these products and resolving manufacturing
problems that we may encounter.
Our manufacturing and other processes utilize sophisticated
equipment, which sometimes require a significant amount of time
to obtain and install. Our business could suffer if certain
manufacturing or other equipment, or a portion or all of our
facilities were to become inoperable for a period of time. This
could occur for various reasons, including catastrophic events
such as earthquake, monsoon, hurricane or explosion, unexpected
equipment failures or delays in obtaining components or
replacements thereof, as well as construction delays or defects
and other events, both within and outside of our control. Our
inability to timely manufacture any of our significant products
could have a material adverse effect on our results of
operations, financial condition and cash flows.
Our
substantial debt and other financial obligations could impair
our financial condition and our ability to fulfill our debt
obligations. Any refinancing of this substantial debt could be
at significantly higher interest rates.
As of December 31, 2010, we had total debt of approximately
$1.0 billion. Our substantial indebtedness and other
financial obligations could:
impair our ability to obtain financing in the future for working
capital, capital expenditures, acquisitions or general corporate
purposes;
have a material adverse effect on us if we fail to comply with
financial and affirmative and restrictive covenants in our debt
agreements and an event of default occurs as a result of a
failure that is not cured or waived;
require us to dedicate a substantial portion of our cash flow
for interest payments on our indebtedness and other financial
obligations, thereby reducing the availability of our cash flow
to fund working capital and capital expenditures;
limit our flexibility in planning for, or reacting to, changes
in our business and the industry in which we operate; and
place us at a competitive disadvantage compared to our
competitors that have proportionally less debt.
If we are unable to meet our debt service obligations and other
financial obligations, we could be forced to restructure or
refinance our indebtedness and other financial transactions,
seek additional equity capital or sell our assets. We might then
be unable to obtain such financing or capital or sell our assets
on satisfactory terms, if at all. Any refinancing of our
indebtedness could be at significantly higher interest rates,
and/or incur
significant transaction fees.
Our
business will continue to expose us to risks of environmental
liabilities.
Our product and API development programs, manufacturing
processes and distribution logistics involve the controlled use
of hazardous materials, chemicals and toxic compounds in our
owned and leased facilities. As a result, we are subject to
numerous and increasingly stringent federal, state and local
environmental laws and regulations concerning, among other
things, the generation, handling, storage, transportation,
treatment and disposal of toxic and hazardous materials and the
discharge of pollutants into the air and water. Our programs and
processes expose us to risks that an accidental contamination
could result in (i) our noncompliance with such
environmental laws and regulations and (ii) regulatory
enforcement actions or claims for personal injury and property
damage against us. If an accident or environmental discharge
occurs, or if we discover contamination caused by prior
operations, including by prior owners and operators of
properties we acquire, we could be liable for cleanup
obligations, damages and fines. The substantial unexpected costs
we may incur could have a material and adverse effect on our
business, results of operations, financial condition, and cash
flows. In addition, environmental permits and controls are
required for some of our operations, and these permits are
subject to modification, renewal and
revocation by the issuing authorities. Any modification,
revocation or non-renewal of our environmental permits could
have a material adverse effect on our ongoing operations,
business and financial condition. Our environmental capital
expenditures and costs for environmental compliance may increase
in the future as a result of changes in environmental laws and
regulations or increased development or manufacturing activities
at any of our facilities.
Global
economic conditions could harm us.
Recent global market and economic conditions have been
unprecedented and challenging with tighter credit conditions and
recession in most major economies during 2009, 2010 and
continuing in 2011. Continued concerns about the systemic impact
of potential long-term and wide-spread recession, energy costs,
geopolitical issues, the availability and cost of credit, and
the global real estate markets have contributed to increased
market volatility and diminished expectations for western and
emerging economies. These conditions, combined with volatile oil
prices, declining business and consumer confidence and increased
unemployment, have contributed to volatility of unprecedented
levels.
As a result of these market conditions, the cost and
availability of credit has been and may continue to be adversely
affected by illiquid credit markets and wider credit spreads.
Concern about the stability of the markets generally and the
strength of counterparties specifically has led many lenders and
institutional investors to reduce, and in some cases, cease to
provide credit to businesses and consumers. These factors have
resulted in a decrease in spending by businesses and consumers
alike, and a corresponding decrease in global infrastructure
spending. Continued turbulence in the U.S. and
international markets and economies and prolonged declines in
business consumer spending may adversely affect our liquidity
and financial condition, and the liquidity and financial
condition of our customers, including our ability to refinance
maturing liabilities and access the capital markets to meet
liquidity needs.
Our
foreign operations may become less attractive if political and
diplomatic relations between the United States and any
country where we conduct business operations
deteriorates.
The relationship between the United States and the foreign
countries where we conduct business operations may weaken over
time. Changes in the state of the relations between any such
country and the United States are difficult to predict and could
adversely affect our future operations. This could lead to a
decline in our profitability. Any meaningful deterioration of
the political and diplomatic relations between the United States
and the relevant country could have a material adverse effect on
our operations.
Our
global operations expose us to risks and challenges associated
with conducting business internationally.
We operate on a global basis with offices or activities in
Europe, Africa, Asia, South America, Australasia and North
America. We face several risks inherent in conducting business
internationally, including compliance with international and
U.S. laws and regulations that apply to our international
operations. These laws and regulations include data privacy
requirements, labor relations laws, tax laws, anti-competition
regulations, import and trade restrictions, export requirements,
U.S. laws such as the Foreign Corrupt Practices Act, and
local laws which also prohibit corrupt payments to governmental
officials or certain payments or remunerations to customers.
Given the high level of complexity of these laws, however, there
is a risk that some provisions may be inadvertently breached,
for example through fraudulent or negligent behavior of
individual employees, our failure to comply with certain formal
documentation requirements or otherwise. Violations of these
laws and regulations could result in fines, criminal sanctions
against us, our officers or our employees, and prohibitions on
the conduct of our business. Any such violations could include
prohibitions on our ability to offer our products in one or more
countries and could materially damage our reputation, our brand,
our international expansion efforts, our ability to attract and
retain employees, our business and our operating results. Our
success depends, in part, on our ability to anticipate these
risks and manage these difficulties.
In addition to the foregoing, engaging in international business
inherently involves a number of other difficulties and risks,
including:
longer payment cycles and difficulties in enforcing agreements
and collecting receivables through certain foreign legal systems;
political and economic instability;
potentially adverse tax consequences, tariffs, customs charges,
bureaucratic requirements and other trade barriers;
difficulties and costs of staffing and managing foreign
operations;
difficulties protecting or procuring intellectual property
rights; and
fluctuations in foreign currency exchange rates.
These factors or any combination of these factors may adversely
affect our revenue or our overall financial performance.
We
have exposure to foreign tax liabilities.
As a multinational corporation, we are subject to income taxes
as well as non-income based taxes, in both the United States and
various foreign jurisdictions. Significant judgment is required
in determining our worldwide provision for income taxes and
other tax liabilities. Changes in tax laws or tax rulings may
have a significantly adverse impact on our effective tax rate.
Recent proposals by the current U.S. administration for
fundamental U.S. international tax reform, including
without limitation provisions that would limit the ability of
U.S. multinationals to defer U.S. taxes on foreign
income, if enacted, could have a significant adverse impact on
our effective tax rate following the Arrow Acquisition.
Foreign
currency fluctuations could adversely affect our business and
financial results.
We do business and generate sales in numerous countries outside
the United States. As such, foreign currency fluctuations may
affect the costs that we incur in such international operations.
Some of our operating expenses are incurred in
non-U.S. dollar
currencies. The appreciation of
non-U.S. dollar
currencies in those countries where we have operations against
the U.S. dollar could increase our costs and could harm our
results of operations and financial condition.
Risks
Relating To Investing In the Pharmaceutical Industry
Extensive
industry regulation has had, and will continue to have, a
significant impact on our business, especially our product
development, manufacturing and distribution
capabilities.
All pharmaceutical companies, including Watson, are subject to
extensive, complex, costly and evolving government regulation.
For the U.S., this is principally administered by the FDA and to
a lesser extent by the DEA and state government agencies, as
well as by varying regulatory agencies in foreign countries
where products or product candidates are being manufactured
and/or
marketed. The Federal Food, Drug and Cosmetic Act, the
Controlled Substances Act and other federal statutes and
regulations, and similar foreign statutes and regulations,
govern or influence the testing, manufacturing, packing,
labeling, storing, record keeping, safety, approval,
advertising, promotion, sale and distribution of our products.
Under these regulations, we are subject to periodic inspection
of our facilities, procedures and operations
and/or the
testing of our products by the FDA, the DEA and other
authorities, which conduct periodic inspections to confirm that
we are in compliance with all applicable regulations. In
addition, the FDA and foreign regulatory agencies conduct
pre-approval and post-approval reviews and plant inspections to
determine whether our systems and processes are in compliance
with cGMP and other regulations. Following such inspections, the
FDA or other agency may issue observations, notices, citations
and/or
Warning Letters that could cause us to modify certain activities
identified during the inspection. FDA guidelines specify that a
Warning Letter is issued only for violations of regulatory
significance for which the failure to adequately
and promptly achieve correction may be expected to result in an
enforcement action. We are also required to report adverse
events associated with our products to FDA and other regulatory
authorities. Unexpected or serious health or safety concerns
would result in product liability claims, labeling changes,
recalls, market withdrawals or other regulatory actions.
Our manufacturing facility in Corona, California is currently
subject to a consent decree of permanent injunction. We cannot
assure that the FDA will determine we have adequately corrected
deficiencies at our Corona manufacturing site, that subsequent
FDA inspections at any of our manufacturing sites will not
result in additional inspectional observations at such sites,
that approval of any of the pending or subsequently submitted
NDAs, ANDAs or supplements to such applications by Watson or our
subsidiaries will be granted or that the FDA will not seek to
impose additional sanctions against Watson or any of its
subsidiaries. The range of possible sanctions includes, among
others, FDA issuance of adverse publicity, product recalls or
seizures, fines, total or partial suspension of production
and/or
distribution, suspension of the FDAs review of product
applications, enforcement actions, injunctions, and civil or
criminal prosecution. Any such sanctions, if imposed, could have
a material adverse effect on our business, operating results,
financial condition and cash flows. Under certain circumstances,
the FDA also has the authority to revoke previously granted drug
approvals. Similar sanctions as detailed above may be available
to the FDA under a consent decree, depending upon the actual
terms of such decree. Although we have instituted internal
compliance programs, if these programs do not meet regulatory
agency standards or if compliance is deemed deficient in any
significant way, it could materially harm our business. Certain
of our vendors are subject to similar regulation and periodic
inspections.
The process for obtaining governmental approval to manufacture
and market pharmaceutical products is rigorous, time-consuming
and costly, and we cannot predict the extent to which we may be
affected by legislative and regulatory developments. We are
dependent on receiving FDA and other governmental or third-party
approvals prior to manufacturing, marketing and shipping our
products. Consequently, there is always the chance that we will
not obtain FDA or other necessary approvals, or that the rate,
timing and cost of obtaining such approvals, will adversely
affect our product introduction plans or results of operations.
We carry inventories of certain product(s) in anticipation of
launch, and if such product(s) are not subsequently launched, we
may be required to write-off the related inventory.
Our Distribution operations and our customers are subject to
various regulatory requirements, including requirements from the
DEA, FDA, state boards of pharmacy and city and county health
regulators, among others. These include licensing, registration,
recordkeeping, security and reporting requirements. Although
physicians may prescribe FDA approved products for an off
label indication, we are permitted to market our products
only for the indications for which they have been approved. Some
of our products are prescribed off label and FDA or other
regulatory authorities could take enforcement actions if they
conclude that we or our distributors have engaged in off label
marketing. In addition, several states and the federal
government have begun to enforce anti-counterfeit drug pedigree
laws which require the tracking of all transactions involving
prescription drugs beginning with the manufacturer, through the
supply chain, and down to the pharmacy or other health care
provider dispensing or administering prescription drug products.
For example, effective July 1, 2006, the Florida Department
of Health began enforcement of the drug pedigree requirements
for distribution of prescription drugs in the State of Florida.
Pursuant to Florida law and regulations, wholesalers and
distributors, including our subsidiary, Anda Pharmaceuticals,
are required to maintain records documenting the chain of
custody of prescription drug products they distribute beginning
with the purchase of products from the manufacturer. These
entities are required to provide documentation of the prior
transaction(s) to their customers in Florida, including
pharmacies and other health care entities. Several other states
have proposed or enacted legislation to implement similar or
more stringent drug pedigree requirements. In addition, federal
law requires that a non-authorized distributor of
record must provide a drug pedigree documenting the prior
purchase of a prescription drug from the manufacturer or from an
authorized distributor of record. In cases where the
wholesaler or distributor selling the drug product is not deemed
an authorized distributor of record it would need to
maintain such records. FDA had announced its intent to impose
additional drug pedigree requirements (e.g., tracking of lot
numbers and documentation of all transactions) through
implementation of drug pedigree regulations which were to have
taken effect on December 1, 2006. However, a federal
appeals court has issued a preliminary injunction to several
wholesale distributors granting an indefinite stay of these
regulations pending a challenge to the regulations by these
wholesale distributors.
Federal
regulation of arrangements between manufacturers of brand and
generic products could adversely affect our
business.
As part of the MMA, companies are required to file with the FTC
and the Department of Justice certain types of agreements
entered into between brand and generic pharmaceutical companies
related to the manufacture, marketing and sale of generic
versions of brand drugs. This requirement, as well as new
legislation pending in U.S. Congress related to settlement
between brand and generic drug manufacturers, could affect the
manner in which generic drug manufacturers resolve intellectual
property litigation and other disputes with brand pharmaceutical
companies and could result generally in an increase in
private-party litigation against pharmaceutical companies or
additional investigations or proceedings by the FTC or other
governmental authorities. The impact of this requirement, the
pending legislation and the potential private-party lawsuits
associated with arrangements between brand name and generic drug
manufacturers, is uncertain and could adversely affect our
business. For example, in January 2009, the FTC and the State of
California filed a lawsuit against us alleging that our
settlement with Solvay related to our ANDA for a generic version
of
Androgel®
is unlawful. From February 2009 through September 2010, numerous
private parties purporting to represent various classes of
plaintiffs filed similar lawsuits. Additionally, we have
received requests for information, in the form of civil
investigative demands or subpoenas, from the FTC, and are
subject to ongoing FTC investigations, concerning our settlement
with Cephalon related to our ANDA for a generic version of
Provigil®.
We have also received requests for information in connection
with similar investigations into settlements and other
arrangements between competing pharmaceutical companies by the
European Competition Commission. Any adverse outcome of these
actions or investigations, or actions or investigations related
to other settlements we have entered into, could have a material
adverse effect on our business, results of operations, financial
condition and cash flows. See Legal Matters in
NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
We are
subject to federal and state healthcare fraud and abuse laws
which may adversely affect our business.
In the United States, most of our products are reimbursed under
federal and state health care programs such as Medicaid,
Medicare, TriCare, and or state pharmaceutical assistance
programs. Many foreign countries have similar laws. Federal and
state laws designed to prevent fraud and abuse under these
programs prohibit pharmaceutical companies from offering
valuable items or services to customers or potential customers
to induce them to buy, prescribe, or recommend Watsons
product (the so-called antikickback laws).
Exceptions are provided for discounts and certain other
arrangements if specified requirements are met. Other federal
and state laws, and similar foreign laws, not only prohibit us
from submitting any false information to government
reimbursement programs but also prohibit us and our employees
from doing anything to cause, assist, or encourage our customers
to submit false claims for payment to these programs. Violations
of the fraud and abuse laws may result in severe penalties
against the responsible employees and Watson, including jail
sentences, large fines, and the exclusion of Watson products
from reimbursement under federal and state programs. Watson is
committed to conducting the sales and marketing of its products
in compliance with the healthcare fraud and abuse laws, but
certain applicable laws may impose liability even in the absence
of specific intent to defraud. Furthermore, should there be
ambiguity, a governmental authority may take a position contrary
to a position we have taken, or should an employee violate these
laws without our knowledge, a governmental authority may impose
civil and/or
criminal sanctions. For example, in December 2009, we learned
that numerous pharmaceutical companies, including certain
subsidiaries of the Company, have been named as defendants in a
qui tam action pending in the United States District Court for
the District of Massachusetts alleging that the defendants
falsely reported to the United States that certain
pharmaceutical products were eligible for Medicaid reimbursement
and thereby allegedly caused false claims for payment to be made
through the Medicaid program. Any adverse outcome of this
action, or the imposition of penalties or sanctions for failing
to comply with the fraud and abuse laws, could adversely affect
us and may have a material adverse effect on our business,
results of operations, financial condition and cash flows. See
Legal Matters in NOTE 16
Commitments and Contingencies in the accompanying
Notes to Consolidated Financial Statements in this
Annual Report.
Healthcare
reform and a reduction in the coverage and reimbursement levels
by governmental authorities, HMOs, MCOs or other third-party
payers may adversely affect our business.
Demand for our products depends in part on the extent to which
coverage and reimbursement is available from third-party payers,
such as the Medicare and Medicaid programs and private payors.
In order to commercialize our products, we have obtained from
government authorities and private health insurers and other
organizations, such as HMOs and MCOs, recognition for coverage
and reimbursement at varying levels for the cost of certain of
our products and related treatments. Third-party payers
increasingly challenge pricing of pharmaceutical products.
Further, the trend toward managed healthcare in the U.S., the
growth of organizations such as HMOs and MCOs and legislative
proposals to reform healthcare and government insurance programs
create uncertainties regarding the future levels of coverage and
reimbursement for pharmaceutical products. Such cost containment
measures and healthcare reform could reduce reimbursement of our
pharmaceutical products, resulting in lower prices and a
reduction in the product demand. This could affect our ability
to sell our products and could have a material adverse effect on
our business, results of operations, financial condition and
cash flows.
There is uncertainty surrounding implementation of legislation
involving payments for pharmaceuticals under government programs
such as Medicare, Medicaid and Tricare. Depending on how
existing provisions are implemented, the methodology for certain
payment rates and other computations under the Medicaid Drug
Rebate program reimbursements may be reduced or not be available
for some of Watsons products. Additionally, any
reimbursement granted may not be maintained or limits on
reimbursement available from third-party payers may reduce
demand for, or negatively affect the price of those products.
Ongoing uncertainty and legal challenges to the PPACA, including
but not limited to, modification in calculation of rebates,
mandated financial or other contributions to close the Medicare
Part D coverage gap donut hole, calculation of
AMP, and other provisions could have a material adverse effect
on our business. In addition, various legislative and regulatory
initiatives in states, including proposed modifications to
reimbursements and rebates, product pedigree and tracking,
pharmaceutical waste take-back initiatives, and
therapeutic category generic substitution carve-out legislation
may also have a negative impact on the Company. Watson maintains
a full-time government affairs department in Washington, DC,
which is responsible for coordinating state and federal
legislative activities, and place a major emphasis in terms of
management time and resources to ensure a fair and balance
legislative and regulatory arena.
PPACA also extended Medicaid rebates to Medicaid MCOs. MCO
rebates may have a significant impact on our brand portfolio.
Medicaid Managed care enrollment is over 70% of total Medicaid
enrollment. This provision is likely to increase
manufacturers Medicaid Rebate liability substantially,
particularly in states with large Medicaid managed care
enrollment (e.g., Michigan, Kentucky, Colorado, Arizona). The
effective date of this was January 1, 2010.
The
pharmaceutical industry is highly competitive and our future
revenue growth and profitability are dependent on our timely
development and launches of new products ahead of our
competitors.
We face strong competition in our Global Generics, Global Brands
and Distribution businesses. The intensely competitive
environment requires an ongoing, extensive search for
technological innovations and the ability to market products
effectively, including the ability to communicate the
effectiveness, safety and value of brand products to healthcare
professionals in private practice, group practices and MCOs. Our
competitors vary depending upon product categories, and within
each product category, upon dosage strengths and drug-delivery
systems. Based on total assets, annual revenues, and market
capitalization, we are smaller than certain of our national and
international competitors in the brand and distribution product
arenas. Most of our competitors have been in business for a
longer period of time than us, have a greater number of products
on the market and have greater financial and other resources
than we do. Furthermore, recent trends in this industry are
toward further market consolidation of large drug companies into
a smaller number of very large entities, further concentrating
financial, technical and market strength and increasing
competitive pressure in the industry. If we directly compete
with them for the same markets
and/or
products, their financial strength could prevent us from
capturing a profitable share of those markets. It is possible
that developments by our competitors will make our products or
technologies noncompetitive or obsolete.
Revenues and gross profit derived from the sales of generic
pharmaceutical products tend to follow a pattern based on
certain regulatory and competitive factors. As patents for brand
name products and related exclusivity periods expire, the first
generic manufacturer to receive regulatory approval for generic
equivalents of such products is generally able to achieve
significant market penetration. Therefore, our ability to
increase or maintain revenues and profitability in our generics
business is largely dependent on our success in challenging
patents and developing non-infringing formulations of
proprietary products. As competing manufacturers receive
regulatory approvals on similar products or as brand
manufacturers launch generic versions of such products (for
which no separate regulatory approval is required), market
share, revenues and gross profit typically decline, in some
cases dramatically. Accordingly, the level of market share,
revenue and gross profit attributable to a particular generic
product normally is related to the number of competitors in that
products market and the timing of that products
regulatory approval and launch, in relation to competing
approvals and launches. Consequently, we must continue to
develop and introduce new products in a timely and
cost-effective manner to maintain our revenues and gross
margins. We may have fewer opportunities to launch significant
generic products in the future, as the number and size of
proprietary products that are subject to patent challenges is
expected to decrease in the next several years compared to
historical levels. Additionally, as new competitors enter the
market, there may be increased pricing pressure on certain
products, which would result in lower gross margins. This is
particularly true in the case of certain Asian and other
overseas generic competitors, who may be able to produce
products at costs lower than the costs of domestic
manufacturers. If we experience substantial competition from
Asian or other overseas generic competitors with lower
production costs, our profit margins will suffer.
We also face strong competition in our Distribution business,
where we compete with a number of large wholesalers and other
distributors of pharmaceuticals, including McKesson Corporation,
AmerisourceBergen Corporation and Cardinal Health, Inc., which
market both brand and generic pharmaceutical products to their
customers. These companies are significant customers of our
Global Brands and Global Generics businesses. As generic
products generally have higher gross margins for distributors,
each of the large wholesalers, on an increasing basis, are
offering pricing incentives on brand products if the customers
purchase a large portion of their generic pharmaceutical
products from the primary wholesaler. As we do not offer a full
line of brand products to our customers, we are at times
competitively disadvantaged and must compete with these
wholesalers based upon our very competitive pricing for generic
products, greater service levels and our well-established
telemarketing relationships with our customers, supplemented by
our electronic ordering capabilities. The large wholesalers have
historically not used telemarketers to sell to their customers,
but recently have begun to do so. Additionally, generic
manufacturers are increasingly marketing their products directly
to smaller chains and thus increasingly bypassing wholesalers
and distributors. Increased competition in the generic industry
as a whole may result in increased price erosion in the pursuit
of market share.
Sales
of our products may continue to be adversely affected by the
continuing consolidation of our distribution network and the
concentration of our customer base.
Our principal customers in our brand and generic pharmaceutical
operations are wholesale drug distributors and major retail drug
store chains. These customers comprise a significant part of the
distribution network for pharmaceutical products in the
U.S. This distribution network is continuing to undergo
significant consolidation marked by mergers and acquisitions
among wholesale distributors and the growth of large retail drug
store chains. As a result, a small number of large wholesale
distributors and large chain drug stores control a significant
share of the market. We expect that consolidation of drug
wholesalers and retailers will increase pricing and other
competitive pressures on drug manufacturers, including Watson.
For the year ended December 31, 2010, our three largest
customers accounted for 14%, 11% and 6% respectively, of our net
revenues. The loss of any of these customers could have a
material adverse effect on our business, results of operations,
financial condition and cash flows. In addition, none of our
customers are party to any long-term supply agreements with us,
and thus are able to change suppliers freely should they wish to
do so.
We conduct our operations using a combination of owned and
leased properties.
Our owned properties consist of facilities used for R&D,
manufacturing, distribution (including warehousing and storage),
sales and marketing and administrative functions. The following
table provides a summary of locations of our significant owned
properties:
Location
Primary Use
Segment
Ambernath, India
Manufacturing, R&D
Global Generics
Carmel, New York
Manufacturing
Global Generics
Changzhou City, Peoples Republic of China
Manufacturing
Global Generics
Coleraine, United Kingdom
Manufacturing
Global Generics
Copiague, New York
Manufacturing, R&D
Global Generics
Corona, California
Manufacturing, R&D, Administration
Global Generics/Global Brands
Davie, Florida
Manufacturing, R&D, Administration
Global Generics/Global Brands
Grand Island, New York
Sales and Marketing, Administration
Distribution
Goa, India
Manufacturing
Global Generics
Gurnee, Illinois
Distribution
Global Generics/Global Brands
Melbourne, Australia
R&D, Administration
Global Generics
Mississauga, Canada
Manufacturing, R&D, Administration
Global Generics
Rio de Janeiro, Brazil
Manufacturing, Distribution, Sales and Marketing, Administration
Properties that we lease include R&D, manufacturing,
distribution (including warehousing and storage), sales and
marketing, and administrative facilities. The following table
provides a summary of locations of our significant leased
properties:
Location
Primary Use
Segment
Birzebbuga, Malta
Manufacturing, Sales and Marketing Distribution, Administration
Global Generics
Davie, Florida
Manufacturing, Administration
Global Generics/Global Brands
Groveport, Ohio
Distribution, Administration
Distribution
Liverpool, United Kingdom
Administration, R&D
Global Brands
London, United Kingdom
Sales and Marketing, Administration
Global Generics
Lyon, France
Sales and Marketing, Administration
Global Generics
Mississauga, Canada
Distribution, Administration
Global Generics
Morristown, New Jersey
Sales and Marketing, Administration
Global Generics/Global Brands
Mumbai, India
Administration, R&D
Global Generics
Parsippany, New Jersey
Sales and Marketing, Administration
Global Generics/Global Brands
Stevenage, United Kingdom
Sales and Marketing, Administration
Global Generics
Sunrise, Florida
Distribution, Administration
Global Generics
Sydney, Australia
Sales and Marketing, Administration
Global Generics
Weston, Florida
R&D, Administration
Global Generics
Weston, Florida
Distribution, Sales and Marketing, Administration
Distribution
Our leased properties are subject to various lease terms and
expirations.
We believe that we have sufficient facilities to conduct our
operations during 2011. However, we continue to evaluate the
purchase or lease of additional properties, or the consolidation
of existing properties as our business requires.
ITEM 3.
LEGAL
PROCEEDINGS
For information regarding legal proceedings, refer to Legal
Matters in NOTE 16 Commitments and
Contingencies in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
MARKET
FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES
Market
for Registrants Common Equity
Our common stock is traded on the New York Stock Exchange under
the symbol WPI. The following table sets forth the
quarterly high and low share trading price information for the
periods indicated:
High
Low
Year ended December 31, 2010:
First
$
42.50
$
37.26
Second
$
44.97
$
40.50
Third
$
45.15
$
39.34
Fourth
$
52.20
$
42.17
Year ended December 31, 2009:
First
$
32.95
$
23.05
Second
$
33.97
$
28.06
Third
$
37.20
$
32.61
Fourth
$
40.25
$
33.88
As of February 8, 2011, there were approximately 2,700
registered holders of our common stock.
We have not paid any cash dividends since our initial public
offering in February 1993, and do not anticipate paying any cash
dividends in the foreseeable future.
Issuer
Purchases of Equity Securities
During the quarter ended December 31, 2010, we repurchased
11,441 shares of our common stock surrendered to the
Company to satisfy tax withholding obligations in connection
with the vesting of restricted stock issued to employees as
follows:
Total Number of
Approximate Dollar
Total Number
Average
Shares Purchased as
Value of Shares that
of Shares
Price Paid
Part of Publicaly
May Yet Be Purchased
Period
Purchased
per Share
Announced Program
Under the Program
October 1 - 31, 2010
$
November 1 - 30, 2010
4,948
$
49.10
December 1 - 31, 2010
6,493
$
51.31
Recent
Sale of Unregistered Securities; Uses of Proceeds from
Registered Securities
None.
Securities
Authorized for Issuance Under Equity Compensation
Plans
For information regarding securities authorized for issuance
under equity compensation plans, refer to ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS and
NOTE 12 Stockholders Equity
in the accompanying Notes to Consolidated Financial
Statements in this Annual Report.
The information in this section of the Annual Report
pertaining to our performance relative to our peers is being
furnished but not filed with the SEC, and as such, the
information is neither subject to Regulation 14A or 14C or
to the liabilities of Section 18 of the Securities Exchange
Act of 1934.
The following graph compares the cumulative
5-year total
return of holders of Watsons common stock with the
cumulative total returns of the S&P 500 index and the Dow
Jones US Pharmaceuticals index. The graph tracks the performance
of a $100 investment in our common stock and in each of the
indexes (with reinvestment of all dividends, if any) on
December 31, 2005 with relative performance tracked through
December 31, 2010.
Notwithstanding anything to the contrary set forth in our
previous filings under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, which might
incorporate future filings made by us under those statutes, the
following graph will not be deemed incorporated by reference
into any future filings made by us under those statutes.
COMPARISON
OF 5 YEAR CUMULATIVE TOTAL RETURN*
Among Watson Pharmaceuticals, The S&P 500 Index
And The Dow Jones US Pharmaceuticals Index
* $100 invested on
December 31, 2005 in stock or index, including reinvestment
of dividends.
Fiscal year ending December 31.
WATSON
PHARMACEUTICALS, INC.
FINANCIAL HIGHLIGHTS(1)
(In millions, except per share amounts)
Years Ended December 31,
2010
2009(2)
2008
2007
2006(3)
Operating Highlights:
Net revenues
$
3,566.9
$
2,793.0
$
2,535.5
$
2,496.7
$
1,979.2
Operating income (loss)(1)
$
305.4
$
383.9
$
358.2
$
255.7
$
(422.1
)
Net income (loss)(1)
attributable to common shareholders
$
184.4
$
222.0
$
238.4
$
141.0
$
(445.0
)
Basic earnings (loss) per share
$
1.51
$
2.11
$
2.32
$
1.38
$
(4.37
)
Diluted earnings (loss) per share
$
1.48
$
1.96
$
2.09
$
1.27
$
(4.37
)
Weighted average shares outstanding:
Basic
122.4
105.0
102.8
102.3
101.8
Diluted
124.2
116.4
117.7
117.0
101.8
At December 31,
2010
2009(2)
2008
2007
2006(3)
Balance Sheet Highlights:
Current assets
$
1,799.4
$
1,769.5
$
1,458.4
$
1,173.8
$
1,261.7
Working capital
$
978.7
$
721.6
$
976.4
$
728.8
$
571.7
Total assets
$
5,827.3
$
5,903.5
$
3,677.9
$
3,472.0
$
3,760.6
Total debt
$
1,016.1
$
1,457.8
$
877.9
$
905.6
$
1,231.2
Total equity
$
3,282.6
$
3,023.1
$
2,108.6
$
1,849.5
$
1,680.4
(1)
For discussion on comparability of operating income and net
income, please refer to financial line item discussion in our
Managements Discussion and Analysis of Financial
Condition and Results of Operations in this Annual Report.
(2)
On December 2, 2009, the Company acquired all the
outstanding equity of the Arrow Group in exchange for cash
consideration of $1.05 billion, approximately
16.9 million shares of Restricted Common Stock of Watson,
200,000 shares of Mandatorily Redeemable Preferred Stock of
Watson and certain contingent consideration. The fair value of
the total consideration was approximately $1.95 billion.
Certain balance sheet amounts were revised in accordance with
the completion of our purchase accounting. Refer to
NOTE 4 Acquisitions and Divestitures in
the accompanying Notes to Consolidated Financial
Statements in this Annual Report.
(3)
On November 3, 2006, the Company acquired all the
outstanding shares of common stock of Andrx Corporation in an
all-cash transaction for $25 per share, or total consideration
of approximately $1.9 billion.
MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Except for the historical information contained herein, the
following discussion contains forward-looking statements that
are subject to known and unknown risks, uncertainties and other
factors that may cause actual results to differ materially from
those expressed or implied by such forward-looking statements.
We discuss such risks, uncertainties and other factors
throughout this report and specifically under the caption
Cautionary Note Regarding Forward-Looking Statements
under ITEM 1A. RISK FACTORS in this annual
report on
Form 10-K
(Annual Report). In addition, the following
discussion of financial condition and results of operations
should be read in conjunction with the Consolidated Financial
Statements and Notes thereto included elsewhere in this Annual
Report.
EXECUTIVE
SUMMARY
Overview
of Watson
Watson Pharmaceuticals, Inc. (Watson, the
Company, we, us or
our) was incorporated in 1985 and is engaged in the
development, manufacturing, marketing, sale and distribution of
brand and generic pharmaceutical products. Watson operates
manufacturing, distribution, research and development
(R&D), and administrative facilities in the
United States of America (U.S.) and, beginning in
2009, in key international markets including Western Europe,
Canada, Australasia, South America and South Africa.
As of December 31, 2010, we marketed approximately 160
generic pharmaceutical product families and approximately 30
brand pharmaceutical product families in the U.S. and a
significant number of product families internationally through
our Global Generics and Global Brands Divisions and distributed
approximately 8,500 stock-keeping units (SKUs)
through our Distribution business (also known as
Anda) in the U.S. Prescription pharmaceutical
products in the U.S. are generally marketed as either
generic or brand pharmaceuticals. Generic pharmaceutical
products are bioequivalents of their respective brand products
and provide a cost-efficient alternative to brand products.
Brand pharmaceutical products are marketed under brand names
through programs that are designed to generate physician and
consumer loyalty. Our Distribution business primarily
distributes generic pharmaceutical products to independent
pharmacies, alternate care providers (hospitals, nursing homes
and mail order pharmacies) and pharmacy chains, and generic
products and certain selective brand products to
physicians offices.
Acquisition
of Arrow Group
On December 2, 2009, Watson completed its acquisition of
all the outstanding equity of Robin Hood Holdings Limited, a
Malta private limited liability company, and Cobalt
Laboratories, Inc., a Delaware corporation (together the
Arrow Group) for cash, stock and certain contingent
consideration (the Arrow Acquisition). In accordance
with the terms of the share purchase agreement dated
June 16, 2009, as amended on November 26, 2009
(together the Acquisition Agreement), the Company
acquired all the outstanding equity of the Arrow Group for the
following consideration:
The payment of cash and the assumption of certain liabilities
totaling $1.05 billion;
Approximately 16.9 million restricted shares of Common
Stock of Watson (the Restricted Common Stock);
200,000 shares of newly designated mandatorily redeemable,
non-voting Series A Preferred Stock of Watson (the
Mandatorily Redeemable Preferred Stock) placed in an
indemnity escrow account for the benefit of the former
shareholders of the Arrow Group (the Arrow Selling
Shareholders);
The Arrow Selling Shareholders will be entitled to the proceeds
of the Mandatorily Redeemable Preferred Stock in 2012, less the
amount of any indemnity payments; and
Certain contingent consideration based on the after-tax gross
profits on sales of the authorized generic version of
Lipitor®
(atorvastatin) in the U.S. calculated and payable as
described in the Acquisition Agreement.
As a result of the Arrow Acquisition, Watson also acquired a 36%
ownership interest in Eden Biopharm Group Limited
(Eden), a company which provides development and
manufacturing services for early-stage biotech companies, which
will provide a long-term foundation for generic biologics. In
January 2010, we purchased the remaining interest in Eden for
$15.0 million. Eden results are included in our Global
Brands division and will maintain its established contract
services model, while providing the Company with
biopharmaceutical development and manufacturing capabilities.
2010
Financial Highlights
Among the significant consolidated financial highlights for 2010
were the following:
Net revenues grew to $3,566.9 million from
$2,793.0 million in 2009, an increase of
$773.9 million or 28%;
R&D investment increased $98.8 million or 50% to
$296.1 million from $197.3 million in 2009;
Operating income decreased by $78.5 million or 20% to
$305.4 million from $383.9 million in 2009; and
Net income for 2010 was $184.4 million ($1.48 per diluted
share) compared to $222.0 million ($1.96 per diluted
share) in 2009.
Segments
Watson has three reportable segments: Global Generics, Global
Brands and Distribution. The Global Generics segment includes
off-patent pharmaceutical products that are therapeutically
equivalent to proprietary products. The Global Brands segment
includes patent-protected products and certain trademarked
off-patent products that Watson sells and markets as brand
pharmaceutical products. The Distribution segment mainly
distributes generic pharmaceutical products manufactured by
third parties, as well as by Watson, primarily to independent
pharmacies, pharmacy chains, pharmacy buying groups and
physicians offices under the Anda trade name. Sales are
principally generated through an in-house telemarketing staff
and through internally developed ordering systems. The
Distribution segment operating results exclude sales of products
developed, acquired, or licensed by Watsons Global
Generics and Global Brands segments. Our international operating
results are included in the Global Generics segment subsequent
to the Arrow Acquisition except for operating results from Eden
which are included in the Global Brands segment.
The Company evaluates segment performance based on segment net
revenues, gross profit and contribution. Segment contribution
represents segment net revenues less cost of sales (excludes
amortization), direct R&D expenses and selling and
marketing expenses. The Company does not report total assets,
capital expenditures, corporate general and administrative
expenses, amortization, gains on disposal or impairment losses
by segment as such information has not been used by management,
or has not been accounted for at the segment level.
Global
Supply Chain Initiative
During the first quarter of 2008, we announced steps to improve
our operating cost structure and achieve operating efficiencies
through our Global Supply Chain Initiative (GSCI).
These 2008 GSCIs included the planned closure of
manufacturing facilities in Carmel, New York, our distribution
center in Brewster, New York and the transition of
manufacturing to our other manufacturing locations within the
U.S. and India. Distribution activities at our distribution
center in Brewster, New York ceased in July 2009. Product
manufacturing ceased in Carmel, New York by December 31,
2010 and we expect a closure of the facility by early 2011.
During the second quarter of 2010, the Company announced
additional measures to reduce its cost structure involving a
manufacturing facility in Canada, certain R&D activities in
Canada and certain R&D activities in Australia. In
January 2011, the Company announced the closure of R&D
activities in Corona, California. These additional restructuring
activities, and the transfer of development activities to
existing R&D sites, are expected to be completed in
Australia by early 2011, in Corona by the end of 2011 and in
Canada by late 2012. The Company expects to incur additional
pre-tax costs associated with the
planned closures during 2011 and 2012 of approximately $20.0 to
$25.0 million which includes accelerated depreciation
expense of $7.0 to $8.5 million, severance, retention,
relocation and other employee related costs of approximately
$5.0 to $8.0 million and product transfer costs of
approximately $8.0 to $8.5 million.
YEAR
ENDED DECEMBER 31, 2010 COMPARED TO 2009
Results of operations, including segment net revenues, segment
operating expenses and segment contribution information for the
Companys Global Generics, Global Brands and Distribution
segments, consisted of the following (in millions):
Years Ended December 31,
2010
2009
Global
Global
Global
Global
Generics
Brands
Distribution
Total
Generics
Brands
Distribution
Total
Product sales
$
2,268.9
$
316.3
$
830.7
$
3,415.9
$
1,641.8
$
393.7
$
663.8
$
2,699.3
Other revenue
69.5
81.5
151.0
26.4
67.3
93.7
Net revenues
2,338.4
397.8
830.7
3,566.9
1,668.2
461.0
663.8
2,793.0
Operating expenses:
Cost of sales(1)
1,198.9
88.4
711.2
1,998.5
947.1
89.3
560.4
1,596.8
Research and development
194.6
101.5
296.1
140.4
56.9
197.3
Selling and marketing
111.9
137.8
70.3
320.0
53.8
144.5
64.8
263.1
Contribution
$
833.0
$
70.1
$
49.2
952.3
$
526.9
$
170.3
$
38.6
735.8
Contibution margin
35.6
%
17.6
%
5.9
%
26.7
%
31.6
%
36.9
%
5.8
%
26.3
%
General and administrative
436.1
257.1
Amortization
180.0
92.6
Loss on asset sales and impairments
30.8
2.2
Operating income
$
305.4
$
383.9
Operating margin
8.6
%
13.7
%
(1)
Excludes amortization of acquired intangibles including product
rights.
Global
Generics Segment
Net
Revenues
Our Global Generics segment develops, manufactures, markets,
sells and distributes generic products that are the therapeutic
equivalent to their brand name counterparts and are generally
sold at prices significantly less than the brand product. As
such, generic products provide an effective and cost-efficient
alternative to brand products. When patents or other regulatory
exclusivity no longer protect a brand product, or if we are
successful in developing a bioequivalent, non-infringing version
of a brand product, opportunities exist to introduce off-patent
or generic counterparts to the brand product. Additionally, we
distribute generic versions of third parties brand
products (sometimes known as Authorized Generics) to
the extent such arrangements are complementary to our core
business. Our portfolio of generic products includes products we
have internally developed, products we have licensed from third
parties, and products we distribute for third parties.
Net revenues in our Global Generics segment include product
sales and other revenue. Our Global Generics segment product
line includes a variety of products and dosage forms.
Indications for this line include pregnancy prevention, pain
management, depression, hypertension and smoking cessation.
Dosage forms include oral solids, transdermals, injectables,
inhalation products and transmucosals.
Other revenues consist primarily of royalties, milestone
receipts and commission revenue.
Net revenues from our Global Generics segment during the year
ended December 31, 2010 increased 40.2% or
$670.2 million to $2,338.4 million compared to net
revenues of $1,668.2 million from the prior year. The
increase in net revenues was mainly attributable to increased
international revenues due to the Arrow
Acquisition in 2009 ($367.8 million), higher sales of
extended release products ($225.3 million) and an increase
in other revenue ($43.1 million).
The 2010 increase in other revenue ($43.1 million)
primarily related to milestone receipts ($27.5 million) and
other revenues from the Arrow Group.
Cost of
Sales
Cost of sales includes production and packaging costs for the
products we manufacture, third party acquisition costs for
products manufactured by others, profit-sharing or royalty
payments for products sold pursuant to licensing agreements,
inventory reserve charges and excess capacity utilization
charges, where applicable. Cost of sales does not include
amortization costs for acquired product rights or other acquired
intangibles.
Cost of sales for our Global Generics segment increased 26.6% or
$251.8 million to $1,198.9 million in the year ended
December 31, 2010 compared to $947.1 million in the
prior year. This increase in cost of sales was mainly
attributable to the inclusion of Arrow Group during the period
($242.5 million) and higher sales of extended release
products ($13.5 million). The increase in cost of sales was
partially offset by cost savings from the implementation of our
GSCI.
Research
and Development Expenses
R&D expenses consist mainly of personnel-related costs,
active pharmaceutical ingredient (API) costs,
contract research, biostudy and facilities costs associated with
the development of our products.
R&D expenses within our Global Generics segment increased
38.6% or $54.2 million to $194.6 million for the year
ended December 31, 2010 compared to $140.4 million
from the prior year. This increase in R&D expenses was
due primarily to the inclusion of Arrow Group
($51.2 million).
Selling
and Marketing Expenses
Selling and marketing expenses consist mainly of
personnel-related costs, distribution costs, professional
services costs, insurance, depreciation and travel costs.
Selling and marketing expenses increased 108.1% or
$58.1 million to $111.9 million for the year ended
December 31, 2010 compared to $53.8 million from the
prior year due primarily to the inclusion of Arrow Group selling
and marketing expenses in the current period
($61.1 million) which was partially offset by cost savings
as a result of the implementation of our Global Supply Chain
Initiative.
Global
Brands Segment
Net
Revenues
Our Global Brands segment includes our promoted products such as
Rapaflo®,
Gelnique®,
Crinone®,
Trelstar®,
ella®
and
INFeD®
and a number of non-promoted products.
Other revenues in the Global Brands segment consist primarily of
co-promotion revenue, royalties and the recognition of deferred
revenue relating to our obligation to manufacture and supply
brand products to third parties. Other revenues also include
revenue recognized from R&D and licensing agreements.
Net revenues from our Global Brands segment for the year ended
December 31, 2010 decreased 13.7% or $63.2 million to
$397.8 million compared to net revenues of
$461.0 million from the prior year. The decrease in net
revenues was primarily attributable to the loss of
Ferrlecit®
($113.8 million), as our distribution rights for
Ferrlecit®
terminated on December 31, 2009. The decline in revenues
from the loss of
Ferrlecit®
was partially offset by sales of new products, including
Rapaflo®,
Gelnique®
and
Crinone®,
higher sales of
INFeD®
(as sales during 2009 were negatively impacted by a supply
interruption) and higher sales of
Androderm®.
Combined these products resulted in an increase in product sales
of $55.2 million. Other revenues also increased by
$14.2 million.
The increase in other revenue was primarily due to the
out-licensing of a number of legacy brand products including
Monodox®
and certain forms of
Cordran®
($8.0 million), higher co-promotion revenues
($2.8 million) and an increase in international other
revenues related to our acquisition of Eden.
Cost of
Sales
Cost of sales includes production and packaging costs for the
products we manufacture, third party acquisition costs for
products manufactured by others, profit-sharing or royalty
payments for products sold pursuant to licensing agreements,
inventory reserve charges and excess capacity utilization
charges, where applicable. Cost of sales does not include
amortization costs for acquired product rights or other acquired
intangibles.
Cost of sales for our Global Brands segment decreased 0.9% or
$0.9 million to $88.4 million in the year ended
December 31, 2010 compared to $89.3 million in the
prior year. This decrease in cost of sales was attributable to
the loss in sales of
Ferrlecit®
offset by increases in cost of sales due to new products and
overall product mix.
Research
and Development Expenses
R&D expenses consist mainly of personnel-related costs,
contract research costs, clinical costs and facilities costs
associated with the development of our products.
R&D expenses within our Global Brands segment increased
78.3% or $44.6 million to $101.5 million compared to
$56.9 million from the prior year primarily due to an
increase in milestone payments in the current year
($22.8 million), a fair value adjustment related to a
product in development acquired from Columbia Laboratories, Inc.
(Columbia) ($7.7 million), the inclusion of
R&D expenditures from recently acquired Eden
($6.8 million) and higher clinical spending.
Selling
and Marketing Expenses
Selling and marketing expenses consist mainly of
personnel-related costs, product promotion costs, distribution
costs, professional services costs, insurance and depreciation.
Selling and marketing expenses within our Global Brands segment
decreased 4.6% or $6.7 million to $137.8 million
compared to $144.5 million from the prior year primarily
due to lower field force, marketing and support costs
($5.4 million) and lower promotional costs
($2.0 million) due mainly to the loss of
Ferrlecit®.
Distribution
Segment
Net
Revenues
Our Distribution business distributes generic and certain select
brand pharmaceutical products manufactured by third parties, as
well as by Watson, primarily to independent pharmacies, pharmacy
chains, pharmacy buying groups and physicians offices.
Sales are principally generated through an in-house
telemarketing staff and through internally developed ordering
systems. The Distribution segment operating results exclude
sales by Anda of products developed, acquired, or licensed by
Watsons Global Generics and Global Brands segments.
Net revenues from our Distribution segment for the year ended
December 31, 2010 increased 25.1% or $166.9 million to
$830.7 million compared to net revenues of
$663.8 million in the prior year primarily due to an
increase in net revenues from new product launches
($175.9 million) and higher third party brand product sales
($14.1 million) which were partially offset by a decline in
the base business ($23.1 million).
Cost of
Sales
Cost of sales for our Distribution segment includes third party
acquisition costs for products manufactured by others,
profit-sharing or royalty payments for products sold pursuant to
licensing agreements and inventory
reserve charges, where applicable. Cost of sales does not
include amortization costs for acquired product rights or other
acquired intangibles.
Cost of sales for our Distribution segment increased 26.9% or
$150.8 million to $711.2 million in the year ended
December 31, 2010 compared to $560.4 million in the
prior year due to higher product sales.
Selling
and Marketing Expenses
Selling and marketing expenses consist mainly of personnel
costs, facilities costs, insurance and freight costs which
support the Distribution segment sales and marketing functions.
Distribution segment selling and marketing expenses increased
8.3% or $5.5 million to $70.3 million in the year
ended December 31, 2010 as compared to $64.8 million
in the prior year primarily due to higher variable costs related
to increased sales.
Corporate
General and Administrative Expenses
Years Ended December 31,
Change
2010
2009
Dollars
%
($ in millions):
Corporate general and administrative expenses
$
436.1
$
257.1
$
179.0
69.6
%
as % of net revenues
12.2
%
9.2
%
Corporate general and administrative expenses consist mainly of
personnel-related costs, facilities costs, insurance,
depreciation, litigation and settlement costs and professional
services costs which are general in nature and not directly
related to specific segment operations.
Corporate general and administrative expenses increased 69.6% or
$179.0 million to $436.1 million compared to
$257.1 million from the prior year due to an increase in
accrued legal contingencies and legal costs over the prior year
period ($123.0 million), inclusion of Arrow administrative
expenses for the period ($50.9 million) and higher Anda bad
debt expense ($4.3 million).
Amortization
Years Ended December 31,
Change
2010
2009
Dollars
%
($ in millions):
Amortization
$
180.0
$
92.6
$
87.4
94.4
%
as % of net revenues
5.0
%
3.3
%
The Companys amortizable assets consist primarily of
acquired product rights. Amortization in 2010 increased
primarily as a result of the amortization of product rights the
Company acquired in the Arrow Acquisition.
Loss
on Asset Sales and Impairments
Years Ended December 31,
Change
2010
2009
Dollars
%
($ in millions):
Loss on asset sales and impairments
$
30.8
$
2.2
$
28.6
1300.0
%
Due to changes in market conditions in certain international
locations, the Company performed an off-cycle impairment review
in the fourth quarter of 2010. As a result of this review, the
Company recorded an impairment charge for certain acquired
in-process research and development (IPR&D)
intangibles acquired in the Arrow Acquisition of
$28.6 million. Additionally, we recognized a loss on the
sale of stock in our Sweden subsidiary during the year ended
December 31, 2010.
In January 2009, we recognized a $1.5 million gain on the
sale of certain property and equipment in Dombivli, India for
cash consideration of $3.0 million. In September 2009, we
recognized a $3.5 million impairment on an API
manufacturing facility in China.
Interest
Income
Years Ended December 31,
Change
2010
2009
Dollars
%
($ in millions):
Interest income
$
1.6
$
5.0
$
(3.4
)
(68.0
)%
Interest income decreased during the year ended
December 31, 2010 primarily due to the decrease in interest
rates and invested balances over the prior year period.
Interest
Expense
Years Ended December 31,
Change
2010
2009
Dollars
%
($ in millions):
Interest expense $850.0 million Senior Notes
due 2014 (the 2014 Notes) and due 2019 (the
2019 Notes), together the Senior Notes
$
48.8
$
17.5
$
31.3
Interest expense Preferred accretion
15.2
1.2
14.0
Interest expense Atorvastatin accretion
12.1
1.0
11.1
Interest expense Columbia accretion
3.3
3.3
Interest expense Senior Credit Facility with
Canadian Imperial Bank of Commerce, Wachovia Capital Markets,
LLC and a syndicate of banks (2006 Credit Facility),
due 2011
Interest expense increased for the year ended December 31,
2010 over the prior year primarily due to interest on the Senior
Notes issued in 2009, interest accretion charges on the
Mandatorily Redeemable Preferred Stock issued in the Arrow
Acquisition, accretion of interest on the atorvastatin
contingent consideration obligation and accretion of interest on
the Columbia contingent consideration obligation, which was
partially offset by interest on the CODES which were redeemed
during 2009.
During 2010, we completed the sale of our outstanding shares of
Scinopharm Taiwan Ltd. (Scinopharm) for net proceeds
of approximately $94.0 million and recorded a gain of
$23.3 million.
In the year ended December 31, 2009, the Company recorded
an
other-than-temporary
impairment charge of $2.2 million related to our investment
in common shares of inVentiv Health, Inc. as the fair value of
our investment fell below our carrying value. This loss was
partially offset by the receipt of cash proceeds of
$1.1 million as additional consideration on the sale of our
investment in Adheris, Inc.
Earnings
on Equity Method Investments
The Companys equity investments are accounted for under
the equity method when the Companys ownership does not
exceed 50% and when the Company can exert significant influence
over the management of the investee.
The earnings on equity investments for the year ended
December 31, 2009 were higher than the current year due to
the sale of our outstanding shares of Scinopharm during the
first quarter of 2010.
Loss on
Early Extinguishment of Debt
In November 2006, we entered into the 2006 Credit Facility in
connection with the acquisition of Andrx Corporation
(Andrx) on November 3, 2006 (the Andrx
Acquisition). The 2006 Credit Facility provides an
aggregate of $1.15 billion of senior financing to Watson,
consisting of a $500.0 million revolving credit facility
(Revolving Facility) and a $650.0 million
senior term loan facility (Term Facility) and is due
to expire in November 2011.
For the year ended December 31, 2010, we recognized a
$0.5 million loss on early extinguishment of debt due to
the early repayment of the remaining amount owing under the Term
Facility of the 2006 Credit Facility.
On July 1, 2009, the Company entered into an amendment to
the 2006 Credit Facility. The terms of the amendment included
the repayment of $100.0 million on the Term Facility under
the 2006 Credit Agreement not later than December 16, 2009.
As a result of the $100.0 million repayment in 2009 under
the Term Facility, the Companys 2009 results reflect a
$0.8 million charge for a loss on the early extinguishment
of debt in respect of the 2006 Credit Facility.
On September 14, 2009, the CODES were redeemed in
accordance with the terms of the CODES. As a result of the
redemption of the CODES, the Companys results for 2009
reflect a $1.2 million loss on the early extinguishment of
the CODES.
Provision
for Income Taxes
Years Ended December 31,
Change
2010
2009
Dollars
%
($ in millions):
Provision for income taxes
$
67.3
$
140.6
$
(73.3
)
(52.1
)%
Effective tax rate
26.9
%
38.8
%
The lower effective tax rate for the year ended
December 31, 2010 compared to the prior year, is primarily
due to non-recurring tax benefits associated with the closure of
the IRS audit for the
2004-2006
tax years, reduction in the statutory tax rates in foreign
jurisdictions, tax benefits associated with the Arrow
Acquisition and the disposition and write-off of foreign
subsidiaries.
Results of operations, including segment net revenues, segment
operating expenses and segment contribution information for the
Companys Global Generics, Global Brands and Distribution
segments, consisted of the following (in millions):
Years Ended December 31,
2009
2008
Global
Global
Global
Global
Generics
Brands
Distribution
Total
Generics
Brands
Distribution
Total
Product sales
$
1,641.8
$
393.7
$
663.8
$
2,699.3
$
1,404.0
$
397.0
$
606.2
$
2,407.2
Other revenue
26.4
67.3
93.7
70.3
58.0
128.3
Net revenues
1,668.2
461.0
663.8
2,793.0
1,474.3
455.0
606.2
2,535.5
Operating expenses:
Cost of sales(1)
947.1
89.3
560.4
1,596.8
883.8
107.1
511.9
1,502.8
Research and development
140.4
56.9
197.3
119.2
50.9
170.1
Selling and marketing
53.8
144.5
64.8
263.1
55.2
118.2
59.5
232.9
Contribution
$
526.9
$
170.3
$
38.6
735.8
$
416.1
$
178.8
$
34.8
629.7
Contribution margin
31.6
%
36.9
%
5.8
%
26.3
%
28.2
%
39.3
%
5.7
%
24.8
%
General and administrative
257.1
190.5
Amortization
92.6
80.7
Loss on asset sales and impairments
2.2
0.3
Operating income
$
383.9
$
358.2
Operating margin
13.7
%
14.1
%
(1)
Excludes amortization of acquired intangibles including product
rights.
Global
Generics Segment
Net
Revenues
Net revenues from our Global Generics segment during the year
ended December 31, 2009 increased 13.2% or
$193.9 million to $1,668.2 million compared to net
revenues of $1,474.3 million from the prior year.
The increase in net revenues was mainly attributable to new
product launches in 2009 and in late 2008 ($244.9 million)
as well as revenue from the inclusion of Arrow Group results for
the month of December ($46.4 million) offset in part by a
decrease in other revenue ($43.9 million) and a decrease in
sales of alendronate sodium tablets and omeprazole due to
increased competition ($66.9 million).
Of the $43.9 million decrease in other revenue, there was a
$20.2 million decline in royalties on sales by Sandoz, Inc.
of metoprolol succinate 50 mg extended release tablets and
reduced royalties on sales by GlaxoSmithKline of Wellbutrin
XL®
150 mg. Sales of metoprolol succinate 50 mg declined
as Sandoz, Inc. ceased shipping the product in the fourth
quarter of 2008. Sales of Wellbutrin
XL®
150 mg declined due to increased competition. Other revenue
also declined as the prior year period included a
$15.0 million milestone payment.
Cost of
Sales
Cost of sales for our Global Generics segment increased 7.2% or
$63.3 million to $947.1 million in the year ended
December 31, 2009 compared to $883.8 million in the
prior year. This increase in cost of sales was mainly
attributable to the inclusion of Arrow Group results for the
month of December ($43.5 million) and higher product sales
in the current year partially offset by manufacturing
efficiencies as a result of the implementation of our Global
Supply Chain Initiative. Arrow Groups cost of sales for
the month of December include $14.2 million of additional
inventory costs associated with the fair value
step-up in
acquired inventory.
R&D expenses within our Global Generics segment increased
17.8% or $21.2 million to $140.4 million for the year
ended December 31, 2009 compared to $119.2 million
from the prior year. This increase in R&D expenses was
mainly due to higher test chemical and biostudy costs
($14.8 million) and increased international R&D
expenditures ($11.4 million), (including those of the
recently acquired Arrow Group), partially offset by lower
consulting costs ($3.5 million).
Selling
and Marketing Expenses
Global Generics selling and marketing expenses decreased 2.5% or
$1.4 million to $53.8 million for the year ended
December 31, 2009 compared to $55.2 million from the
prior year due primarily to cost savings as a result of the
implementation of our GSCI.
Global
Brands Segment
Net
Revenues
Net revenues from our Global Brands segment for the year ended
December 31, 2009 increased 1.3% or $6.0 million to
$461.0 million compared to net revenues of
$455.0 million from the prior year. The increase in net
revenues was primarily attributable to higher other revenues
($9.3 million) which was partially offset by lower net
product sales ($3.3 million).
The increase in other revenue was primarily due to increased
revenues from the Companys promotion of
AndroGel®
and
Femring®
which was partially offset by a decrease in the amount of
deferred revenues recognized in 2009.
During 2009, the Global Brands segment launched
Rapaflo®
and
Gelnique®
and experienced higher sales of certain non-promoted products in
the year. The increase in sales from product launches and sales
of certain non-promoted products was offset by declines in sales
of both
INFeD®
and
Ferrlecit®
during 2009. Lower sales of
INFeD®
resulted from a supply interruption of
INFeD®s
API which is available from only one source. We resumed
shipments of
INFeD®
in July 2009. Lower sales of
Ferrlecit®
primarily resulted from a customer transitioning to a competing
product during the current year period. Our distribution rights
for
Ferrlecit®
terminated on December 31, 2009.
Cost of
Sales
Cost of sales for our Global Brands segment decreased 16.6% or
$17.8 million to $89.3 million in the year ended
December 31, 2009 compared to $107.1 million in the
prior year. This decrease in cost of sales was attributable to a
$7.7 million inventory reserve charge to cost of sales in
2008 related to our
INFeD®
product, lower product sales in 2009 and lower unit
manufacturing costs for products we manufacture due to higher
manufacturing volumes at certain manufacturing sites.
Research
and Development Expenses
R&D expenses within our Global Brands segment increased
11.8% or $6.0 million to $56.9 million in the year
ended December 31, 2009 compared to $50.9 million from
the prior year primarily due to a higher clinical spending
($4.4 million) and higher labor costs ($2.7 million)
which were partially offset by lower milestone payments in 2009.
Selling
and Marketing Expenses
Selling and marketing expenses within our Global Brands segment
increased 22.3% or $26.3 million to $144.5 million in
the year ended December 31, 2009 compared to
$118.2 million from the prior year primarily due to higher
expenditures in 2009 to support launch activities related to
Rapaflo®
and
Gelnique®.
Net revenues from our Distribution segment for the year ended
December 31, 2009 increased 9.5% or $57.6 million to
$663.8 million compared to net revenues of
$606.2 million in the prior year primarily due to an
increase in net revenues from new products launched in late 2008
and in 2009 ($166.6 million) which was partially offset by
lower levels of sales in the current year from prior period
product launches and declines in the base business
($108.9 million).
Cost of
Sales
Cost of sales for our Distribution segment increased 9.5% or
$48.5 million to $560.4 million in the year ended
December 31, 2009 compared to $511.9 million in the
prior year due to higher product sales.
Selling
and Marketing Expenses
Distribution segment selling and marketing expenses increased
8.9% or $5.3 million to $64.8 million in the year
ended December 31, 2009 as compared to $59.5 million
in the prior year primarily due to an increase in payroll costs
($5.0 million).
Corporate
General and Administrative Expenses
Years Ended December 31,
Change
2009
2008
Dollars
%
($ in millions):
Corporate general and administrative expenses
$
257.1
$
190.5
$
66.6
35.0
%
as % of net revenues
9.2
%
7.5
%
Corporate general and administrative expenses increased 35.0% or
$66.6 million to $257.1 million in the year ended
December 31, 2009 compared to $190.5 million from the
prior year due to an increase in legal settlements
($24.7 million), acquisition and integration costs
($16.6 million), higher litigation and legal costs
($13.5 million) and as well as general and administrative
costs from the inclusion of Arrow Group results for the month of
December ($6.2 million). In addition, 2008 was favorably
impacted by the settlement of a tax-related liability
($5.9 million) as a result of the resolution of the
Internal Revenue Service (IRS) federal income tax
return examination.
Amortization
Years Ended December 31,
Change
2009
2008
Dollars
%
($ in millions):
Amortization
$
92.6
$
80.7
$
11.9
14.7
%
as % of net revenues
3.3
%
3.2
%
The Companys amortizable assets consist primarily of
acquired product rights. Amortization in 2009 increased
primarily as a result of the amortization of product rights the
Company acquired in the fourth quarter of 2008 as a result of
the merger between Teva Pharmaceutical Industries, Ltd.
(Teva) and Barr Pharmaceuticals, Inc.
(Barr) and from one month of amortization expense
related to currently marketed product intangibles acquired in
the Arrow Acquisition.
Interest income decreased during the year ended
December 31, 2009 primarily due to the decrease in interest
rates over the prior year period.
Interest
Expense
Years Ended December 31,
Change
2009
2008
Dollars
%
($ in millions):
Interest expense Senior Notes
$
17.5
$
$
17.5
Interest expense CODES
8.9
12.6
(3.7
)
Interest expense 2006 Credit Facility due 2011
4.9
15.4
(10.5
)
Interest expense Preferred accretion
1.2
1.2
Interest expense Atorvastatin accretion
1.0
1.0
Interest expense other
0.7
0.2
0.5
Interest expense
$
34.2
$
28.2
$
6.0
21.1
%
Interest expense increased for the year ended December 31,
2009 over the prior year primarily due to interest on the Senior
Notes issued during the year and interest accretion charges on
the Preferred Shares issued in the Arrow Acquisition and
accretion of interest on the atorvastatin obligation which was
partially offset by reduced interest on the CODES which were
redeemed during the year and due to reduced LIBOR rates of
interest on the 2006 Credit Facility.
Other
Income
Years Ended December 31,
Change
2009
2008
Dollars
%
($ in millions):
Earnings on equity method investments
$
10.8
$
10.6
$
0.2
(Loss) gain on sale of securities
(1.1
)
9.6
(10.7
)
Loss on early extinguishment of debt
(2.0
)
(1.1
)
(0.9
)
Other income
0.2
0.2
$
7.9
$
19.3
$
(11.4
)
(59.1
)%
Earnings
on Equity Method Investments
The earnings on equity investments for the year ended
December 31, 2009 and 2008 primarily represent our share of
equity earnings in Scinopharm. As discussed in
NOTE 4 Acquisitions and
Divestitures in the accompanying Notes to
Consolidated Financial Statements in this Annual Report,
the Company sold its shares in Scinopharm in 2010.
(Loss)
Gain on Sale of Securities
The 2008 gain on sale of securities primarily related to the
Companys sale of our fifty percent interest in Somerset
Pharmaceuticals, Inc. (Somerset), our joint venture
with Mylan Inc.
Loss on
Early Extinguishment of Debt
On July 1, 2009, the Company entered into an amendment to
the 2006 Credit Facility. The terms of the amendment included
the repayment of $100.0 million on the term facility under
the 2006 Credit Agreement not later than December 16, 2009.
As a result of the $100.0 million repayment in 2009 under
the term facility, the Companys results reflect a
$0.8 million charge for losses on the early extinguishment
of debt in respect of the 2006 Credit Facility.
As a result of the redemption of the CODES on September 14,
2009, the Companys results for 2009 reflect a
$1.2 million loss on the early extinguishment of the CODES.
For the year ended December 31, 2008, the Company prepaid
$75.0 million of outstanding debt on the 2006 Credit
Facility. As a result of this prepayment, our results for the
year ended December 31, 2008 reflect debt repurchase
charges of $1.1 million which consist of unamortized debt
issue costs associated with the repurchased amount.
Provision
for Income Taxes
Years Ended December 31,
Change
2009
2008
Dollars
%
($ in millions):
Provision for income taxes
$
140.6
$
119.9
$
20.7
17.2
%
Effective tax rate
38.8
%
33.5
%
The higher effective tax rate for the year ended
December 31, 2009, compared to the prior year, primarily
reflects the impact of non-recurring tax benefits which occurred
in 2008 related to the resolution of the Companys IRS exam
for the years ended December 31, 2000 to 2003 (2.2%) and
the sale of Somerset (1.2%). The 2009 effective tax rate is also
higher than the 2008 effective tax rate due to the 2009 impact
of non-deductible items, including transaction costs related to
the Arrow Acquisition (1.6%) and certain permanent differences.
LIQUIDITY
AND CAPITAL RESOURCES
Working
Capital Position
Working capital at December 31, 2010 and 2009 is summarized
as follows:
Increase
2010
2009
(Decrease)
Revised
($ in millions):
Current Assets:
Cash and cash equivalents
$
282.8
$
201.4
$
81.4
Marketable securities
11.1
13.6
(2.5
)
Accounts receivable, net of allowances
560.9
517.4
43.5
Inventories, net
631.0
692.3
(61.3
)
Prepaid expenses and other current assets
134.2
213.9
(79.7
)
Deferred tax assets
179.4
130.9
48.5
Total current assets
1,799.4
1,769.5
29.9
Current liabilities:
Accounts payable and accrued expenses
741.1
614.3
126.8
Short-term debt and current portion of long-term debt
307.6
(307.6
)
Income taxes payable
39.9
78.4
(38.5
)
Other
39.7
47.6
(7.9
)
Total current liabilities
820.7
1,047.9
(227.2
)
Working Capital
$
978.7
$
721.6
$
257.1
Current Ratio
2.19
1.69
In 2010, our working capital increased by $257.1 million to
$978.7 million from $721.6 million in 2009 primarily
related to cash provided by operating activities and cash
received from the sale of Scinopharm, partially offset by
expenditures on business acquisitions, investments, property and
equipment and debt repayments.
Summarized cash flow from operations is as follows:
Years Ended December 31,
2010
2009
2008
($ in millions):
Net cash provided by operating activities
$
571.0
$
376.8
$
416.6
Cash flows from operations represents net income adjusted for
certain non-cash items and changes in assets and liabilities.
The Company has generated cash flows from operating activities
primarily driven by net income adjusted for amortization of our
acquired product rights and depreciation. Cash provided by
operating activities was $571.0 million in 2010, compared
to $376.8 million in 2009 and $416.6 million in 2008.
Net cash provided by operations was higher in 2010 compared to
2009, as accounts payable and accrued expenses increased in
2010, inventory decreased in 2010, $55.0 million was
collected on an acquisition-related receivable during 2010 and
net income adjusted for amortization charges was higher in 2010.
Net cash provided by operations was lower in 2009 compared to
2008 primarily due to comparatively higher levels of inventory
and accounts receivables partially offset by decreased levels of
accounts payable and accrued expenses.
Management expects that available cash balances and 2011 cash
flows from operating activities will provide sufficient
resources to fund our operating liquidity needs and expected
2011 capital expenditure funding requirements.
Investing
Cash Flows
Our cash flows from investing activities are summarized as
follows:
Years Ended December 31,
2010
2009
2008
($ in millions):
Net cash used in investing activities
$
74.1
$
1,036.1
$
93.4
Investing cash flows consist primarily of expenditures related
to acquisitions, capital expenditures, investment and marketable
security additions, as well as proceeds from investment and
marketable security sales. We used $74.1 million in net
cash for investing activities during 2010 compared to
$1,036.1 million in 2009 and $93.4 million in 2008.
Net cash used in investing activities was lower in 2010 compared
to 2009 due primarily to the Arrow Acquisition in 2009. Net cash
used in investing activities was higher in 2009 compared to 2008
primarily due to the Arrow Acquisition.
Financing
Cash Flows
Our cash flows from financing activities are summarized as
follows:
Years Ended December 31,
2010
2009
2008
($ in millions):
Net cash (used in) provided by financing activities
$
(411.3
)
$
353.1
$
(20.2
)
Financing cash flows consist primarily of borrowings and
repayments of debt, repurchases of common stock and proceeds
from exercising of stock options. For 2010, net cash used in
financing activities was $411.3 million compared to
$353.1 million provided by financing activities during 2009
and $20.2 million used in financing activities during 2008.
Cash used in financing activities in 2010 primarily related to
the repayment of $400.0 million on the 2006 Credit
Facility. Cash provided by financing activities in 2009
primarily related to net proceeds received from the issue of
$850.0 million under the Senior Notes and net borrowings of
$100.0 million under the 2006 Credit Facility which was
partially offset by the redemption of the CODES. During 2008, we
prepaid $75.0 million and borrowed $50.0 million under
our 2006 Credit Facility.
Our outstanding debt obligations are summarized as follows:
Increase
2010
2009
(Decrease)
($ in millions):
Short-term debt and current portion of long-term debt
$
$
307.6
$
(307.6
)
Long-term debt
1,016.2
1,150.2
(134.0
)
Total debt outstanding
$
1,016.2
$
1,457.8
$
(441.6
)
Debt to capital ratio
23.5
%
32.5
%
On August 24, 2009, the Company gave notice to Wells Fargo
Bank, National Association, as trustee of the CODES (the
Trustee), and the Trustee delivered an irrevocable
notice of redemption to the holders of the CODES that the
Company elected to redeem the CODES for cash at a price equal to
100% of the principal amount of the CODES, plus interest accrued
and unpaid to, but excluding, the redemption date. On
September 14, 2009 the CODES were redeemed in accordance
with the terms of the CODES. As a result of the redemption of
the CODES, the Companys results for the year ended
December 31, 2009 reflect a $1.2 million charge for
losses on the early extinguishment of debt in respect of the
CODES.
In November 2006, we entered into the 2006 Credit Facility. The
2006 Credit Facility provides an aggregate of $1.15 billion
of senior financing to Watson, consisting of a
$500.0 million Revolving Facility and a $650.0 million
Term Facility and an initial interest rate equal to LIBOR plus
0.75% (subject to certain adjustments). In July 2010, the
interest rate on the 2006 Credit Facility was reduced to LIBOR
plus 0.625%.
The 2006 Credit Facility has a five-year term and matures in
November 2011. Indebtedness under the 2006 Credit Facility is
guaranteed by Watsons material domestic subsidiaries. The
Revolving Facility is available for working capital and other
general corporate requirements subject to the satisfaction of
certain conditions.
On July 1, 2009, the Company entered into an amendment to
the 2006 Credit Facility which, among other things, provided
certain modifications and clarifications with respect to
refinancing of the Companys outstanding indebtedness,
allowed an increase in the Companys ability to incur
general unsecured indebtedness from $100.0 million to
$500.0 million and provides an exclusion from certain
restrictions under the 2006 Credit Facility on up to
$151.4 million of certain anticipated acquired indebtedness
under the Arrow Acquisition. The terms of the amendment also
required the repayment of $100.0 million on the Term
Facility under the 2006 Credit Agreement. As a result of this
$100.0 million repayment, the Companys results for
the year ended December 31, 2009 reflect a
$0.8 million charge for losses on the early extinguishment
of debt in respect of the 2006 Credit Facility. In addition to
the above repayment on the Term Facility of the 2006 Credit
Facility, the Company also made a $75.0 million repayment
on the Revolving Facility of the 2006 Credit Facility in the
year ended December 31, 2009. The Company borrowed
$275.0 million under the Revolving Facility in 2009 to fund
a portion of the cash consideration for the Arrow Acquisition.
During the year ended December 31, 2010, we incurred
$0.5 million charge for losses on the early extinguishment
of debt in respect of the 2006 Credit Facility matures in
November 2011. As of December 31, 2010, no amounts were
outstanding on either the Revolving Facility or the Term
Facility of the 2006 Credit Facility.
Under the terms of the 2006 Credit Facility, each of our
subsidiaries, other than minor subsidiaries, entered into a full
and unconditional guarantee on a joint and several basis. We are
subject to, and, as of December 31, 2010, were in
compliance with financial and operation covenants under the
terms of the 2006 Credit Facility. The agreement currently
contains the following financial covenants:
maintenance of a minimum net worth of at least $1.7 billion;
maintenance of a maximum leverage ratio not greater than 2.50 to
1.0; and
maintenance of a minimum interest coverage ratio of at least 5.0
to 1.0.
At December 31, 2010, our net worth was $3.3 billion,
and our leverage ratio was 1.01 to 1.0. Our interest coverage
ratio for the period ended December 31, 2010 was 15.7 to
1.0.
Under the 2006 Credit Facility, interest coverage ratio, with
respect to any financial covenant period, is defined as the
ratio of EBITDA for such period to interest expense for such
period. The leverage ratio, for any financial covenant period,
is defined as the ratio of the outstanding principal amount of
funded debt for the borrower and its subsidiaries at the end of
such period, to EBITDA for such period. EBITDA under the Credit
Facility, for any covenant period, is defined as net income plus
(1) depreciation and amortization, (2) interest
expense, (3) provision for income taxes,
(4) extraordinary or unusual losses, (5) non-cash
portion of nonrecurring losses and charges, (6) other
non-operating, non-cash losses, (7) minority interest
expense in respect of equity holdings in affiliates,
(8) non-cash expenses relating to stock-based compensation
expense and (9) any one-time charges related to the Andrx
Acquisition; minus (1) extraordinary gains,
(2) interest income and (3) other non-operating,
non-cash income.
Long-term
Obligations
The following table lists our enforceable and legally binding
obligations as of December 31, 2010. Some of the amounts
included herein are based on managements estimates and
assumptions about these obligations, including their duration,
the possibility of renewal, anticipated actions by third
parties, and other factors. Because these estimates and
assumptions are necessarily subjective, the enforceable and
legally binding obligation we will actually pay in future
periods may vary from those reflected in the table:
Payments Due by Period (Including Interest on Debt)
Less than
1-3
4-5
After 5
Total
1 Year
Years
Years
Years
(In millions):
Long-term debt and other debt(1)
$
1,345.2
$
47.2
$
783.2
$
50.5
$
464.3
Contingent consideration liabilities(2)
264.6
46.5
211.3
6.0
0.8
Operating lease obligations
135.9
24.4
45.7
22.8
43.0
Milestone obligations(3)
48.2
11.0
26.0
11.2
Other obligations and commitments(4)
99.8
19.0
14.8
5.4
60.6
Total(5)
$
1,893.7
$
148.1
$
1,081.0
$
95.9
$
568.7
(1)
Amounts represent total anticipated cash payments and
anticipated interest payments, as applicable, on the Senior
Notes, the Mandatorily Redeemable Preferred Stock and amounts
outstanding on our long term-debt obligations assuming existing
debt maturity or redemption schedules. The maturity schedule in
the above table in respect of the Mandatorily Redeemable
Preferred Stock assumes redemption in cash on December 2,
2012, the third anniversary of issuance, in accordance with the
terms of the Share Purchase Agreement. Amounts exclude fair
value adjustments, discounts or premiums on outstanding debt
obligations.
(2)
Amount represents contingent payment obligations resulting from
the Arrow Acquisition and the Columbia acquisition. Arrow
Acquisition contingent obligations include amounts due to Arrow
Selling Shareholders on the after-tax gross profits on sales of
atorvastatin in the U.S. as described in the Acquisition
Agreement. Columbia acquisition contingent obligations include
amounts due to Columbia primarily related to anticipated future
milestone payments and royalty payments. For a more detailed
description of the terms of the contingent consideration
liabilities, refer to NOTE 10 Other
Long-Term Liabilities in the accompanying Notes to
Consolidated Financial Statements in this Annual Report.
(3)
We have future potential milestone payments payable to third
parties as part of our licensing and development programs.
Payments under these agreements generally become due and payable
upon the satisfaction or achievement of certain developmental,
regulatory or commercial milestones. Amounts represent
contractual payment obligations due on achievement of
developmental, regulatory or commercial milestones based on
anticipated approval dates assuming all milestone approval
events are met. Milestone payment obligations are uncertain,
including the prediction of timing and the occurrence of events
triggering a future
obligation and are not reflected as liabilities in our
consolidated balance sheet. Amounts in the table above do not
include royalty obligations on future sales of product as the
timing and amount of future sales levels and costs to produce
products subject to milestone obligations is not reasonably
estimable.
(4)
Other obligations and commitments include agreements to purchase
third-party manufactured products, capital purchase obligations
for the construction or purchase of property, plant and
equipment and the liability for income tax associated with
uncertain tax positions.
(5)
Total does not include contractual obligations already included
in current liabilities on our Consolidated Balance Sheet (except
for short-term debt and the current portion of long-term debt)
or certain purchase obligations, which are discussed below.
For purposes of the table above, obligations for the purchase of
goods or services are included only for purchase orders that are
enforceable, legally binding and specify all significant terms
including fixed or minimum quantities to be purchased; fixed,
minimum or variable price provisions; and the timing of the
obligation. Our purchase orders are based on our current
manufacturing needs and are typically fulfilled by our suppliers
within a relatively short period. At December 31, 2010, we
have open purchase orders that represent authorizations to
purchase rather than binding agreements that are not included in
the table above.
We are involved in certain joint venture arrangements that are
intended to complement our core business and markets. We have
the discretion to provide funding on occasion for working
capital or capital expenditures. We make an evaluation of
additional funding based on an assessment of the ventures
business opportunities. We believe that any possible commitments
arising from the current arrangements will not be significant to
our financial condition, results of operations or liquidity.
Off-Balance
Sheet Arrangements
We do not have any material off-balance sheet arrangements that
have, or are reasonably likely to have, a current or future
effect on our financial condition, changes in financial
condition, net revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources.
CRITICAL
ACCOUNTING ESTIMATES
Our consolidated financial statements are prepared in accordance
with accounting principles generally accepted in the United
States (GAAP). These accounting principles require
us to make certain estimates, judgments and assumptions. We
believe that the estimates, judgments and assumptions are
reasonable based upon information available to us at the time
that these estimates, judgments and assumptions are made. These
estimates, judgments and assumptions can affect the reported
amounts of assets and liabilities as of the date of the
financial statements, as well as the reported amounts of
revenues and expenses during the periods presented. To the
extent there are material differences between these estimates,
judgments or assumptions and actual results, our financial
statements will be affected. The significant accounting
estimates that we believe are important to aid in fully
understanding and evaluating our reported financial results
include the following:
Revenue and Provision for Sales Returns and Allowances
Revenue Recognition
Inventory Valuation
Investments
Product Rights and other Definite-Lived Intangible Assets
Goodwill and Intangible Assets with Indefinite-Lives
Allocation of Acquisition Fair Values to Assets Acquired and
Liabilities Assumed
In many cases, the accounting treatment of a particular
transaction is specifically dictated by GAAP and does not
require managements judgment in its application. There are
also areas in which managements judgment in selecting
among available GAAP alternatives would not produce a materially
different result.
Revenue
and Provision for Sales Returns and Allowances
As is customary in the pharmaceutical industry, our gross
product sales are subject to a variety of deductions in arriving
at reported net product sales. When we recognize revenue from
the sale of our products, an estimate of sales returns and
allowances (SRA) is recorded which reduces product
sales. Accounts receivable
and/or
accrued liabilities are also reduced
and/or
increased by the SRA amount. These adjustments include estimates
for chargebacks, rebates, cash discounts and returns and other
allowances. These provisions are estimated based on historical
payment experience, historical relationship to revenues,
estimated customer inventory levels and current contract sales
terms with direct and indirect customers. The estimation process
used to determine our SRA provision has been applied on a
consistent basis and no material adjustments have been necessary
to increase or decrease our reserves for SRA as a result of a
significant change in underlying estimates. We use a variety of
methods to assess the adequacy of our SRA reserves to ensure
that our financial statements are fairly stated. This includes
periodic reviews of customer inventory data, customer contract
programs and product pricing trends to analyze and validate the
SRA reserves.
Chargebacks The provision for chargebacks is
our most significant sales allowance. A chargeback represents an
amount payable in the future to a wholesaler for the difference
between the invoice price paid to the Company by our wholesale
customer for a particular product and the negotiated contract
price that the wholesalers customer pays for that product.
Our chargeback provision and related reserve varies with changes
in product mix, changes in customer pricing and changes to
estimated wholesaler inventories. The provision for chargebacks
also takes into account an estimate of the expected wholesaler
sell-through levels to indirect customers at contract prices. We
validate the chargeback accrual quarterly through a review of
the inventory reports obtained from our largest wholesale
customers. This customer inventory information is used to verify
the estimated liability for future chargeback claims based on
historical chargeback and contract rates. These large
wholesalers represent 85% 90% of our chargeback
payments. We continually monitor current pricing trends and
wholesaler inventory levels to ensure the liability for future
chargebacks is fairly stated.
Rebates Rebates include volume related
incentives to direct and indirect customers and Medicaid rebates
based on claims from Medicaid benefit providers.
Volume rebates are generally offered to customers as an
incentive to continue to carry our products and to encourage
greater product sales. These rebate programs include contracted
rebates based on customers purchases made during an
applicable monthly, quarterly or annual period. The provision
for rebates is estimated based on our customers contracted
rebate programs and our historical experience of rebates paid.
Any significant changes to our customer rebate programs are
considered in establishing our provision for rebates. We
continually monitor our customer rebate programs to ensure that
the liability for accrued rebates is fairly stated.
The provision for Medicaid rebates is based upon historical
experience of claims submitted by the various states. We monitor
Medicaid legislative changes to determine what impact such
legislation may have on our provision for Medicaid rebates. Our
accrual of Medicaid rebates is based on historical payment rates
and is reviewed on a quarterly basis against actual claim data
to ensure the liability is fairly stated.
Returns and Other Allowances Our provision
for returns and other allowances include returns, pricing
adjustments, promotional allowances and billback adjustments.
Consistent with industry practice, we maintain a return policy
that allows our customers to return product for credit. In
accordance with our return goods policy, credit for customer
returns of product is applied against outstanding account
activity or by check. Product exchanges are not permitted.
Customer returns of product are not resalable unless the return
is due to a shipping error. Our estimate of the provision for
returns is based upon historical experience and current trends
of actual customer returns. Additionally, we consider other
factors when estimating our current period return provision,
including levels of inventory in our distribution channel as
well as significant market changes which may impact future
expected returns, and make adjustments to our current period
provision for returns when it appears product returns may differ
from our original estimates.
Pricing adjustments, which include shelf stock adjustments, are
credits issued to reflect price decreases in selling prices
charged to our direct customers. Shelf stock adjustments are
based upon the amount of product our customers have in their
inventory at the time of an
agreed-upon
price reduction. The provision for shelf stock adjustments is
based upon specific terms with our direct customers and includes
estimates of existing customer inventory levels based upon their
historical purchasing patterns. We regularly monitor all price
changes to help evaluate our reserve balances. The adequacy of
these reserves is readily determinable as pricing adjustments
and shelf stock adjustments are negotiated and settled on a
customer-by-customer
basis.
Promotional allowances are credits that are issued in connection
with a product launch or as an incentive for customers to begin
carrying our product. We establish a reserve for promotional
allowances based upon these contractual terms.
Billback adjustments are credits that are issued to certain
customers who purchase directly from us as well as indirectly
through a wholesaler. These credits are issued in the event
there is a difference between the customers direct and
indirect contract price. The provision for billbacks is
estimated based upon historical purchasing patterns of qualified
customers who purchase product directly from us and supplement
their purchases indirectly through our wholesale customers.
Cash Discounts Cash discounts are provided to
customers that pay within a specific period. The provision for
cash discounts are estimated based upon invoice billings,
utilizing historical customer payment experience. Our
customers payment experience is fairly consistent and most
customer payments qualify for the cash discount. Accordingly,
our reserve for cash discounts is readily determinable.
The estimation process used to determine our SRA provision has
been applied on a consistent basis and there have been no
significant changes in underlying estimates that have resulted
in a material adjustment to our SRA reserves. The Company does
not expect future payments of SRA to materially exceed our
current estimates. However, if future SRA payments were to
materially exceed our estimates, such adjustments may have a
material adverse impact on our financial position, results of
operations and cash flows. For additional information on our
reserves for SRA refer to NOTE 2 Summary
of Significant Accounting Policies in the accompanying
Notes to Consolidated Financial Statements in this
Annual Report.
Revenue
Recognition
Revenue is generally realized or realizable and earned when
persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the sellers price
to the buyer is fixed or determinable, and collectability is
reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to
the customer, which is typically upon delivery to the customer.
Revenues recognized from research, development and licensing
agreements (including milestone payments) are recorded on the
contingency-adjusted performance model which
requires deferral of revenue until such time as contract
milestone requirements, as specified in the individual
agreements, have been met. Under this model, revenue related to
each payment is recognized over the entire contract performance
period, starting with the contracts commencement, but not
prior to earning
and/or
receiving the milestone payment (i.e., removal of any
contingency). The amount of revenue recognized is based on the
ratio of costs incurred to date to total estimated cost to be
incurred. Royalty and commission revenue is recognized in
accordance with the terms of their respective contractual
agreements when collectability is reasonably assured and revenue
can be reasonably measured.
Inventory
Valuation
Inventories consist of finished goods held for distribution, raw
materials and work in process. Included in inventory are generic
pharmaceutical products that are capitalized only when the
bioequivalence of the product is demonstrated or the product is
already U.S. Food and Drug Administration approved and is
awaiting a contractual triggering event to enter the
marketplace. Inventory valuation reserves are established based
on a number of factors/situations including, but not limited to,
raw materials, work in process, or finished goods not meeting
product specifications, product obsolescence, or lower of cost
(first-in,
first-out method) or market (net realizable value). The
determination of events requiring the establishment of inventory
valuation reserves,
together with the calculation of the amount of such reserves may
require judgment. Assumptions utilized in our quantification of
inventory reserves include, but are not limited to, estimates of
future product demand, consideration of current and future
market conditions, product net selling price, anticipated
product launch dates, potential product obsolescence and other
events relating to special circumstances surrounding certain
products. No material adjustments have been required to our
inventory reserve estimates for the periods presented. Adverse
changes in assumptions utilized in our inventory reserve
calculations could result in an increase to our inventory
valuation reserves and higher cost of sales.
Investments
We employ a systematic methodology that considers all available
evidence in evaluating potential impairment of our investments.
In the event that the cost of an investment exceeds its fair
value, we evaluate, among other factors, general market
conditions, the duration and extent to which the fair value is
less than cost, as well as our intent and ability to hold the
investment. We also consider specific adverse conditions related
to the financial health of and business outlook for the
investee, including industry and sector performance, changes in
technology, operational and financing cash flow factors, and
rating agency actions. However, when a decline in the fair value
of an investment falls below the carrying value for a six-month
period, unless sufficient positive, objective evidence exists to
support such an extended period, the decline will be considered
other-than-temporary.
Any decline in the market prices of our equity investments that
are deemed to be
other-than-temporary
may require us to incur additional impairment charges.
Our equity investments are accounted for under the equity method
when the Company can exert significant influence and ownership
does not exceed 50%. We account for joint ventures using the
equity method. We record equity method investments at cost and
adjust for the appropriate share of investee net earnings or
losses. Investments in which the Company owns less than a 20%
interest and cannot exert significant influence are accounted
for using the cost method if the fair value of such investments
is not readily determinable.
All of our marketable securities are classified as
available-for-sale
and are reported at fair value, based on quoted market prices.
Unrealized temporary adjustments to fair value are included on
the balance sheet in a separate component of stockholders
equity as unrealized gains and losses and reported as a
component of other comprehensive income. No gains or losses on
marketable securities are realized until shares are sold or a
decline in fair value is determined to be
other-than-temporary.
If a decline in fair value is determined to be
other-than-temporary,
an impairment charge is recorded and a new cost basis in the
investment is established.
Product
Rights and Other Definite-Lived Intangible Assets
Our product rights and other definite-lived intangible assets
are stated at cost, less accumulated amortization, and are
amortized using the straight-line method over their estimated
useful lives. We determine amortization periods for product
rights and other definite-lived intangible assets based on our
assessment of various factors impacting estimated useful lives
and cash flows. Such factors include the products position
in its life cycle, the existence or absence of like products in
the market, various other competitive and regulatory issues, and
contractual terms. Significant changes to any of these factors
may result in a reduction in the intangibles useful life and an
acceleration of related amortization expense, which could cause
our operating income, net income and earnings per share to
decline.
Product rights and other definite-lived intangible assets are
tested periodically for impairment when events or changes in
circumstances indicate that an assets carrying value may
not be recoverable. The impairment testing involves comparing
the carrying amount of the asset to the forecasted undiscounted
future cash flows. In the event the carrying value of the asset
exceeds the undiscounted future cash flows, the carrying value
is considered not recoverable and impairment exists. An
impairment loss is measured as the excess of the assets
carrying value over its fair value, calculated using a
discounted future cash flow method. The computed impairment loss
is recognized in net income in the period that the impairment
occurs. Our projections of discounted cash flows using a
discount rate determined by our management to be commensurate
with the risk inherent in our business model. Our estimates of
future cash flows attributable to our other definite-lived
intangible assets require significant judgment based on our
historical and anticipated results and are subject to many
factors. Different assumptions and judgments could materially
affect the calculation of the fair value of the other
definite-lived intangible assets which could trigger impairment.
Goodwill
and Intangible Assets with Indefinite-Lives
We test goodwill and intangible assets with indefinite-lives for
impairment annually at the end of the second quarter by
comparing the fair value of each of the Companys reporting
units to the respective carrying value of the reporting units.
Additionally, we may perform tests between annual tests if an
event occurs or circumstances change that could potentially
reduce the fair value of a reporting unit below its carrying
amount. The Companys reporting units have been identified
by Watson as Global Generics, Global Brands and Distribution.
The carrying value of each reporting unit is determined by
assigning the assets and liabilities, including the existing
goodwill and intangible assets, to those reporting units.
Goodwill is considered impaired if the carrying amount of the
net assets exceeds the fair value of the reporting unit.
Impairment, if any, would be recorded in operating income and
this could result in a material reduction in net income and
earnings per share. During the second quarter of 2010, the
Company performed its annual impairment assessment of goodwill,
IPR&D and trade name intangible assets with
indefinite-lives and determined there was no impairment. Due to
changes in market conditions in certain international locations,
the Company performed an off-cycle impairment review in the
fourth quarter of 2010 and recorded a $28.6 million
impairment charge related to certain IPR&D assets acquired
in the Arrow Acquisition.
Included in intangible assets with indefinite-lives are trade
name intangible assets acquired prior to January 1, 2009
and IPR&D intangibles acquired after January 1, 2009.
Upon adoption of FASB issued authoritative guidance on
January 1, 2009, using the purchase method of accounting,
IPR&D intangible assets are recognized at their fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. Prior to January 1,
2009, amounts allocated to IPR&D intangible assets were
expensed at the date of acquisition.
IPR&D intangible assets represent the value assigned to
acquired research and development projects that, as of the date
acquired, represent the right to develop, use, sell
and/or offer
for sale a product or other intellectual property that we have
acquired with respect to products
and/or
processes that have not been completed or approved. The
IPR&D intangible assets will be subject to impairment
testing until completion or abandonment of each project.
Impairment testing will require the development of significant
estimates and assumptions involving the determination of
estimated net cash flows for each year for each project or
product (including net revenues, cost of sales, research and
development costs, selling and marketing costs), the appropriate
discount rate to select in order to measure the risk inherent in
each future cash flow stream, the assessment of each
assets life cycle, competitive trends impacting the asset
and each cash flow stream as well as other factors. The major
risks and uncertainties associated with the timely and
successful completion of the IPR&D projects include legal
risk and regulatory risk. Changes in these assumptions or
uncertainties could result in future impairment charges. No
assurances can be given that the underlying assumptions used to
prepare the discounted cash flow analysis will not change or the
timely completion of each project to commercial success will
occur. For these and other reasons, actual results may vary
significantly from estimated results.
Upon successful completion of each project and launch of the
product, Watson will make a separate determination of useful
life of the intangible, transfer the amount to currently
marketed products and amortization expense will be recorded over
the estimated useful life.
Allocation
of Acquisition Fair Values to Assets Acquired and Liabilities
Assumed
We account for acquired businesses using the purchase method of
accounting, which requires that assets acquired and liabilities
assumed be recorded at date of acquisition at their respective
fair values. The consolidated financial statements and results
of operations reflect an acquired business after the completion
of the acquisition. The fair value of the consideration paid,
including contingent consideration, is allocated to the
underlying net assets of the acquired business based on their
respective fair values. Any excess of the purchase price over
the estimated fair values of the net assets acquired is recorded
as goodwill. Beginning in 2009,
amounts allocated to IPR&D are included on the balance
sheet (refer to discussion above in Goodwill and
Intangible Assets with Indefinite Lives). Intangible
assets, including IPR&D assets upon successful completion
of the project and launch of the product, are amortized on a
straight-line basis to amortization expense over the expected
life of the asset. Significant judgments are used in determining
the estimated fair values assigned to the assets acquired and
liabilities assumed and in determining estimates of useful lives
of long-lived assets. Fair value determinations and useful life
estimates are based on, among other factors, estimates of
expected future net cash flows, estimates of appropriate
discount rates used to present value expected future net cash
flow streams, the timing of approvals for IPR&D projects
and the timing of related product launch dates, the assessment
of each assets life cycle, the impact of competitive
trends on each assets life cycle and other factors. These
judgments can materially impact the estimates used to allocate
acquisition date fair values to assets acquired and liabilities
assumed and the resulting timing and amount of amounts charged
to, or recognized in current and future operating results. For
these and other reasons, actual results may vary significantly
from estimated results.
The Company determines the acquisition date fair value of
contingent consideration obligations based on a
probability-weighted income approach derived from revenue
estimates, post-tax gross profit levels and a probability
assessment with respect to the likelihood of achieving
contingent obligations including contingent payments such as
milestone obligations, royalty obligations and contract earn-out
criteria, where applicable. The fair value measurement is based
on significant inputs not observable in the market and thus
represents a Level 3 measurement as defined in fair value
measurement accounting. The resultant probability-weighted cash
flows are discounted using an appropriate effective annual
interest rate. At each reporting date, the contingent
consideration obligation will be revalued to estimated fair
value and changes in fair value will be reflected as income or
expense in our consolidated statement of operations. Changes in
the fair value of the contingent consideration obligations may
result from changes in discount periods and rates, changes in
the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of
achieving the various contingent payment obligations. Adverse
changes in assumptions utilized in our contingent consideration
fair value estimates could result in an increase in our
contingent consideration obligation and a corresponding charge
to operating income.
RECENT
ACCOUNTING PRONOUNCEMENTS
In October 2009, the FASB issued an amendment to its accounting
guidance on revenue arrangements with multiple deliverables,
which addresses the unit of accounting for arrangements
involving multiple deliverables and how consideration should be
allocated to separate units of accounting, when applicable. The
amendment requires that arrangement considerations be allocated
at the inception of the arrangement to all deliverables using
the relative selling price method and provides for expanded
disclosures related to such arrangements. The amendment is
effective for revenue arrangements entered into or materially
modified in fiscal years beginning on or after June 15,
2010. Early adoption is allowed. The adoption of the statement
will not have a material impact on the Companys
consolidated financial statements.
In January 2010, the FASB issued an amendment to the disclosure
requirements for fair value measurements. The amendment requires
an entity to: (i) disclose separately the amounts of
significant transfers in and out of Level 1 and
Level 2 fair value measurements and describe the reasons
for the transfers, and (ii) present separate information
for Level 3 activity pertaining to gross purchases, sales,
issuances and settlements. The new disclosures are effective for
interim and annual reporting periods beginning after
December 15, 2009, except for the Level 3 disclosures,
which are effective for fiscal years beginning after
December 15, 2010. The adoption of the statement will not
have a material impact on the Companys consolidated
financial statements.
In March 2010, the FASB ratified accounting guidance on defining
a milestone and determining when it may be appropriate to apply
the milestone method of revenue recognition for research or
development transactions. This guidance provides criteria that
must be met to recognize consideration that is contingent upon
achievement of a substantive milestone in its entirety in the
period in which the milestone is achieved. The amendment is
effective for milestones achieved in fiscal years beginning on
or after June 15, 2010. Early adoption is allowed. The
adoption of the statement will not have a material impact on the
Companys consolidated financial statements.
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk for changes in the market values
of our investments (Investment Risk) and the impact of interest
rate changes (Interest Rate Risk). We have not used derivative
financial instruments in our investment portfolio.
We maintain our portfolio of cash equivalents and short-term
investments in a variety of securities, including both
government and government agency obligations with ratings of AA
or better, money market funds with ratings of AAm or better, and
time deposits with financial institutions with short-term
ratings of
A-1/P-1 or
higher by S&P and Moodys, respectively. Our
investments in marketable securities are governed by our
investment policy which seeks to preserve the value of our
principal, provide liquidity and maximize return on the
Companys investments. Additionally, our investment policy
limits the amount invested with any one counterparty and places
limits on an investments maximum maturity. Consequently, our
interest rate and principal risk are minimal on our non-equity
investment portfolio. The quantitative and qualitative
disclosures about market risk are set forth below.
Investment
Risk
As of December 31, 2010, our total holdings in equity
securities of other companies, including equity method
investments and
available-for-sale
securities, were $64.3 million. Of this amount, we had
equity method investments of $40.2 million and publicly
traded equity securities
(available-for-sale
securities) at fair value totaling $23.9 million (included
in marketable securities and investments and other assets). The
fair values of these investments are subject to significant
fluctuations due to volatility of the stock market and changes
in general economic conditions.
We regularly review the carrying value of our investments and
identify and recognize losses, for income statement purposes,
when events and circumstances indicate that any declines in the
fair values of such investments below our accounting basis are
other than temporary.
Interest
Rate Risk
Our exposure to interest rate risk relates primarily to our
non-equity investment. Our cash is invested in bank deposits and
AAm-rated money market mutual funds.
Our portfolio of marketable securities includes
U.S. Treasury and agency securities classified as
available-for-sale
securities, with no security having a maturity in excess of two
years. These securities are exposed to interest rate
fluctuations. Because of the short-term nature of these
investments, we are subject to minimal interest rate risk and do
not believe that an increase in market rates would have a
significant negative impact on the realized value of our
portfolio.
Based on the quoted market value of our Senior Notes as of
December 31, 2010, the fair value was $71.0 million
greater than the carrying value. While changes in market
interest rates may affect the fair value of our fixed-rate debt,
we believe the effect, if any, of reasonably possible near-term
changes in the fair value of such debt on our financial
condition, results of operations or cash flows will not be
material.
We operate and transact business in various foreign countries
and are, therefore, subject to the risk of foreign currency
exchange rate fluctuations. Net foreign currency gains and
losses did not have a material effect on the Companys
results of operations for 2010, 2009 or 2008.
At this time, we have no material commodity price risks.
We do not believe that inflation has had a significant impact on
our revenues or operations.
The information required by this Item is contained in the
financial statements set forth in Item 15 (a) under
the caption Consolidated Financial Statements and
Supplementary Data as a part of this Annual Report on
Form 10-K.
ITEM 9.
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
There have been no changes in or disagreements with accountants
on accounting or financial disclosure matters.
ITEM 9A.
CONTROLS
AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
The Company maintains disclosure controls and
procedures, as such term is defined under
Rule 13a-15(e)
of the Exchange Act, that are designed to ensure that
information required to be disclosed in the Companys
Exchange Act reports is recorded, processed, summarized and
reported within the time periods specified in the
U.S. Securities and Exchange Commissions
(SECs) rules and forms, and that such
information is accumulated and communicated to the
Companys management, including its Principal Executive
Officer and Principal Financial Officer, as appropriate, to
allow timely decisions regarding required disclosure. In
designing and evaluating the disclosure controls and procedures,
management recognized that any controls and procedures, no
matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control
objectives, and management necessarily was required to apply its
judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Also, the Company has investments in
certain unconsolidated entities. However, our assessment of the
disclosure controls and procedures with respect to the
Companys equity method investees did include an assessment
of the controls over the recording of amounts related to our
investments that are recorded in our consolidated financial
statements, including controls over the selection of accounting
methods for our investments, the recognition of equity method
earnings and losses and the determination, valuation and
recording of our investment account balances.
As required by SEC
Rule 13a-15(b),
the Company carried out an evaluation, under the supervision and
with the participation of the Companys management,
including the Companys Principal Executive Officer and
Principal Financial Officer, of the effectiveness of the design
and operation of the Companys disclosure controls and
procedures as of December 31, 2010. Based on this
evaluation, the Companys Principal Executive Officer and
Principal Financial Officer concluded that the Companys
disclosure controls and procedures were effective at a
reasonable assurance level as of December 31, 2010.
Managements
Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining
adequate internal control over financial reporting,
as such term is defined under
Rule 13a-15(f)
of the Exchange Act. We maintain internal control over financial
reporting designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
Therefore, internal control over financial reporting determined
to be effective provides only reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles.
Under the supervision and with the participation of management,
including the Companys Principal Executive Officer and
Principal Financial Officer, the Company conducted an evaluation
of the effectiveness
of its internal control over financial reporting based on the
framework in Internal Control Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission. This evaluation included an assessment of
the design of the Companys internal control over financial
reporting and testing of the operational effectiveness of its
internal control over financial reporting. Based on this
evaluation, management has concluded that the Companys
internal control over financial reporting was effective as of
December 31, 2010.
The effectiveness of the Companys internal control over
financial reporting as of December 31, 2010 has been
audited by PricewaterhouseCoopers LLP, an independent registered
public accounting firm, as stated in their report which appears
under Item 15(a)(1) of this
Form 10-K.
Changes
in Internal Control Over Financial Reporting
There have been no changes in the Companys internal
control over financial reporting, during the fiscal quarter
ended December 31, 2010, that has materially affected, or
are reasonably likely to materially affect, the Companys
internal control over financial reporting.
ITEM 9B.
OTHER
INFORMATION
We have filed with the New York Stock Exchange the most recent
annual Chief Executive Officer Certification as required by
Section 303A.12(a) of the New York Stock Exchange Listed
Company Manual.
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Directors
The information concerning directors of Watson required under
this Item is incorporated herein by reference from our
definitive proxy statement, to be filed pursuant to
Regulation 14A, related to our 2011 Annual Meeting of
Stockholders to be held on May 13, 2011 (our 2011
Proxy Statement).
Information concerning our Audit Committee and the independence
of its members, along with information about the financial
expert(s) serving on the Audit Committee, is set forth in the
Audit Committee section of our 2011 Proxy Statement and is
incorporated herein by reference.
Executive
Officers of the Registrant
Below are our executive officers as of February 21, 2011:
Name
Age
Principal Position with Registrant
Paul M. Bisaro
50
President and Chief Executive Officer
Sigurdur O. Olafsson
42
Executive Vice President, Global Generics
G. Frederick Wilkinson
54
Executive Vice President, Global Brands
Albert Paonessa, III
50
Executive Vice President, Chief Operating Officer, Distribution
Division
Robert A. Stewart
43
Executive Vice President, Global Operations
R. Todd Joyce
53
Senior Vice President, Chief Financial Officer
David A. Buchen
46
Senior Vice President, General Counsel, and Secretary
Paul M. Bisaro, age 50, has served as President and Chief
Executive Officer since September 2007. Prior to joining Watson,
Mr. Bisaro was President and Chief Operating Officer of
Barr Pharmaceuticals, Inc. (Barr) from 1999 to 2007.
Between 1992 and 1999, Mr. Bisaro served as General Counsel
and from 1997 to 1999 served in various additional capacities
including Senior Vice President Strategic Business
Development. Prior to joining Barr, he was associated with the
law firm Winston & Strawn and a predecessor firm,
Bishop, Cook, Purcell and Reynolds from 1989 to 1992.
Mr. Bisaro also served as a Senior Consultant with Arthur
Andersen & Co. Mr. Bisaro received his
undergraduate degree in General Studies from the University of
Michigan in 1983 and a Juris Doctor from Catholic University of
America in Washington, D.C. in 1989.
Sigurdur
O. Olafsson
Sigurdur O. Olafsson, age 42, was appointed Executive Vice
President, Global Generics Division on September 1, 2010.
Prior to joining Watson, Mr. Olafsson served as Chief
Executive Officer of the Actavis Group from 2008 to 2010. From
2006 until 2008 Mr. Olafsson served as Deputy CEO of the
Actavis Group and was CEO, Actavis Inc. U.S. and Chief
Executive Corporate Development from 2003 to 2006, where he led
Actavis sales and marketing organization. Prior to joining
Actavis, he held a number of senior positions with Pfizers
Global Research and Development organization in both the
U.S. and the U.K. from 1998 to 2003. Prior to joining
Pfizer, he served as Head of Drug Development for Omega Farma in
Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy
(Cand Pharm) from the University of Reykjavik.
G.
Frederick Wilkinson
G. Frederick Wilkinson, age 54, was appointed Executive
Vice President, Global Brands on September 21, 2009. Prior
to joining Watson, Mr. Wilkinson was President and Chief
Operating Officer of Duramed Pharmaceuticals, Inc. the
proprietary products subsidiary of Barr from 2006 to 2009. Prior
to joining Duramed Pharmaceuticals, Inc., he was President
and Chief Executive Officer of Columbia Laboratories, Inc. from
2001 to 2006. From 1996 to 2001, Mr. Wilkinson was Senior
Vice President and Chief Operating Officer of
Watson Pharmaceuticals, Inc. Prior to joining Watson, he
spent sixteen years at Sandoz in numerous senior management
positions of increasing responsibility. Mr. Wilkinson
received his M.B.A. from Capital University in 1984 and his B.S.
in Pharmacy from Ohio Northern University in 1979.
Albert
Paonessa III
Albert Paonessa, age 50, has served as our Executive Vice
President, Chief Operating Officer of Anda, our Distribution
company following our acquisition of Andrx. Mr. Paonessa
was appointed Anda Executive Vice President and Chief Operating
Officer in August 2005 and had been with Anda since Andrx
acquired VIP in March 2000. From March 2000 through January
2002, Mr. Paonessa was Vice President, Operations of VIP.
In January 2002, he became Vice President, Information Systems
at Anda and in January 2004 was appointed Senior Vice President,
Sales at Anda. Mr. Paonessa received a B.A. and a B.S. from
Bowling Green State University in 1983.
Robert A.
Stewart
Robert A. Stewart, age 43, was appointed Executive Vice
President, Global Operations on August 3, 2010.
Mr. Stewart joined Watson in November 2009 as Senior Vice
President, Global Operations. Prior to joining Watson,
Mr. Stewart held various positions with Abbott
Laboratories, Inc. from 2002 until 2009 where he most recently
served as Vice President, Global Supply Chain. From 2005 until
2008, he served as Divisional Vice President, Quality Assurance
and prior to this position served as Divisional Vice President
for U.S./Puerto Rico and Latin America Plant Operations as well
as Director of Operations for Abbotts Whippany plant.
Prior to joining Abbott Laboratories, Inc., he worked for Knoll
Pharmaceutical Company from 1995 to 2001 and Hoffman La-Roche
Inc. Mr. Stewart received B.S. degrees in Business
Management / Finance in 1994 from Fairleigh Dickinson
University.
R. Todd Joyce, age 53, was appointed Senior Vice
President, Chief Financial Officer of Watson on October 30,
2009. Mr. Joyce joined Watson in 1997 as Corporate
Controller, and was named Vice President, Corporate Controller
and Treasurer in 2001. During the periods October 2006 to
November 2007 and from July 2009 until his appointment as Chief
Financial Officer, Mr. Joyce served as interim Principal
Financial Officer. Prior to joining Watson, Mr. Joyce
served as Vice President of Tax from 1992 to 1996 and as Vice
President of Tax and Finance from 1996 until 1997 at ICN
Pharmaceuticals. Prior to ICN Pharmaceuticals, Mr. Joyce
served as a Certified Public Accountant with Coopers &
Lybrand and Price Waterhouse. Mr. Joyce received a B.S. in
Business Administration from the University of North Carolina at
Chapel Hill in 1983 and a M.S. in Taxation from Golden State
University in 1992.
David A.
Buchen
David A. Buchen, age 46, has served as Senior Vice
President, General Counsel and Secretary since November 2002.
From November 2000 to November 2002, Mr. Buchen served as
Vice President and Associate General Counsel. From February 2000
to November 2000, he served as Vice President and Senior
Corporate Counsel. From November 1998 to February 2000, he
served as Senior Corporate Counsel and as Corporate Counsel. He
also served as Assistant Secretary from February 1999 to
November 2002. Prior to joining Watson, Mr. Buchen was
Corporate Counsel at Bausch & Lomb Surgical (formerly
Chiron Vision Corporation) from November 1995 until November
1998 and was an attorney with the law firm of
Fulbright & Jaworski, LLP. Mr. Buchen received a
B.A. in Philosophy from the University of California, Berkeley
in 1985, and a Juris Doctor with honors from George Washington
University Law School in 1989.
Clare
Carmichael
Clare Carmichael, age 51, was appointed Senior Vice
President, Human Resources of Watson effective August 12,
2008. Prior to joining Watson, Ms. Carmichael was Vice
President, Human Resources for Schering-Plough Research
Institute. Ms Carmichael was Vice President, Human Resources for
Eyetech Pharmaceuticals Inc. from 2003 to 2005. She also held
positions of increasing responsibility at Pharmacia Corporation
until 2003. Ms. Carmichael received a B.A. in Psychology
from Rider University in 1981.
Charles
M. Mayr
Charles M. Mayr, age 54, was appointed Senior Vice
President, Corporate Affairs of Watson effective September 2009.
Prior to joining Watson, Mr. Mayr operated an advertising
and public relations consulting company, serving such clients as
Watson, the Generic Pharmaceuticals Association, Barr and a
variety of professional associations and consumer products and
service companies. Prior to starting his consultancy business,
he served as director of corporate communications for Barr.
Prior to joining Barr, he served as director of global
communications for Sterling Drug Inc., the global brand and
consumer health products pharmaceutical subsidiary of Kodak.
Mr. Mayr began his career as a broadcast and print
journalist and has a B.A. in journalism from New York University.
Our executive officers are appointed annually by the Board of
Directors, hold office until their successors are chosen and
qualified, and may be removed at any time by the affirmative
vote of a majority of the Board of Directors. We have employment
agreements with most of our executive officers. There are no
family relationships between any director and executive officer
of Watson.
Section 16(a)
Compliance
Information concerning compliance with Section 16(a) of the
Securities Exchange Act of 1934 will be set forth in the
Section 16(a) Beneficial Ownership Reporting Compliance
section of our 2011 Proxy Statement and is incorporated herein
by reference.
Watson has adopted a Code of Conduct that applies to our
employees, including our principal executive officer, principal
financial officer and principal accounting officer. The Code of
Conduct is posted on our Internet website at www.watson.com. Any
person may request a copy of our Code of Conduct by contacting
us at 311 Bonnie Circle, Corona, California, 92880, Attn:
Secretary. Any amendments to or waivers from the Code of Conduct
will be posted on our website at www.watson.com under the
caption Corporate Governance within the Investors
section of our website.
ITEM 11.
EXECUTIVE
COMPENSATION
The information concerning executive and director compensation,
and concerning our compensation committee and the compensation
committee report for Watson required under this Item is
incorporated herein by reference to the Compensation
Discussion and Analysis section of our 2011 Proxy
Statement.
ITEM 12.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information concerning security ownership of certain
beneficial owners and management and related stockholder matters
and the equity compensation plan information required under this
Item is incorporated herein by reference to the Beneficial
Ownership of Stockholders, Directors and Executive
Officers and Equity Compensation Plan Information as
of December 31, 2010 sections of our 2011 Proxy
Statement.
ITEM 13.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The information concerning certain relationships and related
transactions, and director independence required under this Item
is incorporated herein by reference to the Certain
Relationships and Related Transactions and Director
Independence sections of our 2011 Proxy Statement.
ITEM 14.
PRINCIPAL
ACCOUNTING FEES AND SERVICES
The information concerning principal accountant fees and
services required under this Item is incorporated herein by
reference to the Audit Fees section of our 2011
Proxy Statement.
All other financial statement schedules have been omitted
because they are not applicable or the required information is
included in the Consolidated Financial Statements or notes
thereto.
3. Exhibits
Reference is hereby made to the Exhibit Index immediately
following
page F-49
Supplementary Data (Unaudited) of this Annual Report on
Form 10-K.
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Watson Pharmaceuticals,
Inc.
(Registrant)
By:
/s/ PAUL
M. BISARO
Paul M. Bisaro
President and Chief Executive Officer
(Principal Executive Officer)
Date: February 21, 2011
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the
dates indicated.
Signature
Title
Date
/s/ Paul
M. Bisaro
Paul
M. Bisaro
President, Chief Executive Officer and Director
February 21, 2011
/s/ R.
Todd Joyce
R.
Todd Joyce
Senior Vice President Chief Financial Officer
(Principal Financial Officer)
All other financial statement schedules have been omitted
because they are not applicable or the required information is
included in the Consolidated Financial Statements or notes
thereto.
In our opinion, the accompanying consolidated balance sheets and
the related consolidated statements of operations, of cash
flows, of stockholders equity and of comprehensive income
present fairly, in all material respects, the financial position
of Watson Pharmaceuticals, Inc. and its subsidiaries at
December 31, 2010 and December 31, 2009, and the
results of their operations and their cash flows for each of the
three years in the period ended December 31, 2010 in
conformity with accounting principles generally accepted in the
United States of America. In addition, in our opinion, the
financial statement schedule listed in the accompanying index
presents fairly, in all material respects, the information set
forth therein when read in conjunction with the related
consolidated financial statements. Also in our opinion, the
Company maintained, in all material respects, effective internal
control over financial reporting as of December 31, 2010,
based on criteria established in Internal Control
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The
Companys management is responsible for these financial
statements and financial statement schedules, for maintaining
effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over
financial reporting, included in Managements Annual Report
on Internal Control over Financial Reporting under Item 9A.
Our responsibility is to express opinions on these financial
statements, on the financial statement schedule, and on the
Companys internal control over financial reporting based
on our integrated audits. We conducted our audits in accordance
with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement and
whether effective internal control over financial reporting was
maintained in all material respects. Our audits of the financial
statements included examining, on a test basis, evidence
supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, and evaluating the
overall financial statement presentation. Our audit of internal
control over financial reporting included obtaining an
understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, and testing
and evaluating the design and operating effectiveness of
internal control based on the assessed risk. Our audits also
included performing such other procedures as we considered
necessary in the circumstances. We believe that our audits
provide a reasonable basis for our opinions.
A companys internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (i) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (ii) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of
management and directors of the company; and (iii) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
Watson Pharmaceuticals, Inc. (Watson or the
Company) is primarily engaged in the development,
manufacturing, marketing, sale and distribution of brand and
generic pharmaceutical products. Watson was incorporated in 1985
and began operations as a manufacturer and marketer of
off-patent pharmaceuticals. Through internal product development
and synergistic acquisitions of products and businesses, the
Company has grown into a diversified specialty pharmaceutical
company. Watson operates manufacturing, distribution, research
and development (R&D) and administrative
facilities in the United States of America (U.S.)
and, beginning in 2009, in key international markets including
Western Europe, Canada, Australasia, South America and South
Africa.
Acquisition
of Arrow Group
On December 2, 2009 (the Acquisition Date),
Watson completed its acquisition of all the outstanding equity
of Robin Hood Holdings Limited, a Malta private limited
liability company, and Cobalt Laboratories, Inc., a Delaware
corporation (together the Arrow Group). The Arrow
Group is principally engaged in the manufacture and distribution
of generic pharmaceuticals and operates in the U.S. and
international markets including Western Europe, Canada,
Australasia, South America and South Africa.
As a result of the acquisition of the Arrow Group, Watson also
acquired a 36% ownership interest in Eden Biopharm Group Limited
(Eden), a company which provides development and
manufacturing services for early-stage biotech companies. In
January 2010, we repurchased the remaining interest in Eden for
$15.0 million. Edens results are included in the
Global Brands segment. For additional information on the
acquisition of the Arrow Group, refer to
NOTE 4 Acquisitions and
Divestitures.
NOTE 2
Summary of Significant Accounting Policies
Basis
of Presentation
The Companys consolidated financial statements are
prepared in accordance with accounting principles generally
accepted in the U.S. (GAAP). The consolidated
financial statements include the accounts of wholly-owned
subsidiaries, after elimination of intercompany accounts and
transactions. Certain prior year amounts have been reclassified
to conform to the current-year presentation.
Our consolidated financial statements include the financial
results of the Arrow Group subsequent to the Acquisition Date.
Use of
Estimates
Management is required to make certain estimates and assumptions
in order to prepare consolidated financial statements in
conformity with GAAP. Such estimates and assumptions affect the
reported amounts of assets, liabilities, revenues and expenses
and disclosure of contingent assets and liabilities in the
consolidated financial statements and accompanying notes. The
Companys most significant estimates relate to the
determination of sales returns and allowances (SRA)
for accounts receivable and accrued liabilities, valuation of
inventory balances, the determination of useful lives for
intangible assets and the assessment of expected cash flows used
in evaluating goodwill and other long-lived assets for
impairment. The estimation process required to prepare the
Companys consolidated financial statements requires
assumptions to be made about future events and conditions, and
as such, is inherently subjective and uncertain. Watsons
actual results could differ materially from those estimates.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Foreign
Currency Translation
For most of the Companys international operations, the
local currency has been determined to be the functional
currency. We translate functional currency assets and
liabilities to their U.S. dollar equivalents at rates in
effect at the balance sheet date and record these translation
adjustments as a component of accumulated other comprehensive
income (loss) within stockholders equity in the
consolidated balance sheets. We translate functional currency
statement of income amounts to their U.S. dollar
equivalents at the average rates for the period. The effects of
converting non-functional currency assets and liabilities into
the functional currency are recorded as general and
administrative expenses in the consolidated statements of
operations.
Cash
and Cash Equivalents
The Company considers cash and cash equivalents to include cash
in banks, commercial paper and deposits with financial
institutions that can be liquidated without prior notice or
penalty. The Company considers all highly liquid investments
with an original maturity of three months or less to be cash
equivalents.
Fair
Value of Other Financial Instruments
The Companys financial instruments consist primarily of
cash and cash equivalents, marketable securities, accounts and
other receivables, investments, trade accounts payable, our
$450.0 million aggregate principal amount of
5.000% notes due August 14, 2014 (the 2014
Notes) and $400.0 million aggregate principal amount
of 6.125% notes due August 14, 2019 (the 2019
Notes) (together the Senior Notes) and our
Senior Credit Facility with Canadian Imperial Bank of Commerce,
acting through its New York agency, as administrative agent (the
2006 Credit Facility). The carrying amounts of cash
and cash equivalents, marketable securities, accounts and other
receivables and trade accounts payable are representative of
their respective fair values due to their relatively short
maturities. The fair values of investments in companies that are
publicly traded are based on quoted market prices. The Company
estimates the fair value of its fixed rate long-term obligations
based on quoted market rates of interest and maturity schedules
for similar issues. At December 31, 2010, the fair value of
our Senior Notes was approximately $71.0 million greater
than the carrying value.
Inventories
Inventories consist of finished goods held for sale and
distribution, raw materials and work in process. Included in
inventory at December 31, 2010 and 2009 is approximately
$4.6 million and $14.1 million, respectively, of
inventory that is pending approval by the U.S. Food and
Drug Administration (FDA), by other regulatory
agencies or has not been launched due to contractual
restrictions. This inventory consists of generic pharmaceutical
products that are capitalized only when the bioequivalence of
the product is demonstrated or the product has already received
regulatory approval and is awaiting a contractual triggering
event to enter the marketplace. Inventories are stated at the
lower of cost
(first-in,
first-out method) or market (net realizable value). The Company
writes down inventories to net realizable value based on
forecasted demand and market conditions, which may differ from
actual results.
Property
and Equipment
Property and equipment are stated at cost, less accumulated
depreciation. Major renewals and improvements are capitalized,
while routine maintenance and repairs are expensed as incurred.
Costs associated with internally developed software are
accounted for in accordance with the guidance for the treatment
of costs associated with computer software development that
defines those costs to be capitalized and those to be expensed.
The Company capitalizes interest on qualified construction
projects. At the time property and equipment are retired from
service, the cost and accumulated depreciation is removed from
the respective accounts and the related gains or losses are
reflected in income.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Depreciation expense is computed principally on the
straight-line method, over estimated useful lives of the related
assets. The following table provides the range of estimated
useful lives used for each asset type:
Computer software / hardware
3-7 years
Machinery and equipment
5-18 years
Research and laboratory equipment
5-10 years
Furniture and fixtures
5-10 years
Buildings, improvements, leasehold improvements and other
5-40 years
The Company assesses property and equipment for impairment
whenever events or changes in circumstances indicate that an
assets carrying amount may not be recoverable.
Investments
The Companys equity investments are accounted for under
the equity method when the Company can exert significant
influence and ownership does not exceed 50%. Watson accounts for
its joint ventures using the equity method. The Company records
equity method investments at cost and adjust for the appropriate
share of investee net earnings or losses. Investments in which
the Company owns less than a 20% interest and cannot exert
significant influence are accounted for using the cost method if
the fair value of such investments is not readily determinable.
Marketable
Securities
The Companys marketable securities consist of
U.S. Treasury and agency securities and equity securities
of publicly-held companies. The Companys marketable
securities are classified as
available-for-sale
and are recorded at fair value, based upon quoted market prices.
Unrealized temporary adjustments to fair value are included on
the balance sheet in a separate component of stockholders
equity as unrealized gains and losses and reported as a
component of accumulated other comprehensive income. No gains or
losses on marketable securities are realized until shares are
sold or a decline in fair value is determined to be
other-than-temporary.
If a decline in fair value is determined to be
other-than-temporary,
an impairment charge is recorded and a new cost basis in the
investment is established.
Goodwill
and Intangible Assets with Indefinite-Lives
We test goodwill and intangible assets with indefinite-lives for
impairment annually at the end of the second quarter by
comparing the fair value of each of the Companys reporting
units to the respective carrying value of the reporting units.
Additionally, we may perform tests between annual tests if an
event occurs or circumstances change that could potentially
reduce the fair value of a reporting unit below its carrying
amount. The Companys reporting units have been identified
by Watson as Global Generics, Global Brands and Distribution.
The carrying value of each reporting unit is determined by
assigning the assets and liabilities, including the existing
goodwill and intangible assets, to those reporting units.
Goodwill is considered impaired if the carrying amount of the
net assets exceeds the fair value of the reporting unit.
Impairment, if any, would be recorded in operating income and
this could result in a material reduction in net income and
earnings per share. During the second quarter of 2010, the
Company performed its annual impairment assessment of goodwill,
acquired in-process research and development
(IPR&D) intangibles and trade name intangible
assets with indefinite-lives and determined there was no
impairment. Due to changes in market conditions in certain
international locations, the Company performed an off-cycle
impairment review in the fourth quarter of 2010 and recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. (Refer to
Note 8 Goodwill, Product Rights and Other
Intangibles for additional details.)
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Included in intangible assets with indefinite-lives are trade
name intangible assets acquired prior to January 1, 2009
and IPR&D intangibles acquired after January 1, 2009.
Upon adoption of Financial Accounting Standards Board
(FASB) issued authoritative guidance on
January 1, 2009, using the purchase method of accounting,
IPR&D intangible assets are recognized at their fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. Prior to January 1,
2009, amounts allocated to IPR&D intangible assets were
expensed at the date of acquisition.
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the date acquired,
represent the right to develop, use, sell
and/or offer
for sale a product or other intellectual property that we have
acquired with respect to products
and/or
processes that have not been completed or approved. The
IPR&D intangible assets are subject to impairment testing
until completion or abandonment of each project. Impairment
testing requires the development of significant estimates and
assumptions involving the determination of estimated net cash
flows for each year for each project or product (including net
revenues, cost of sales, R&D costs, selling and marketing
costs), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each assets life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The major risks and uncertainties associated with the
timely and successful completion of the IPR&D projects
include legal risk and regulatory risk. Changes in these
assumptions or uncertainties could result in future impairment
charges. No assurances can be given that the underlying
assumptions used to prepare the discounted cash flow analysis
will not change or the timely completion of each project to
commercial success will occur. For these and other reasons,
actual results may vary significantly from estimated results.
Upon successful completion of each project and launch of the
product, Watson will make a separate determination of the useful
life of the intangible, transfer the amount to currently
marketed products (CMP) and amortization expense
will be recorded over the estimated useful life.
Contingent
Consideration
Subsequent to January 1, 2009, contingent consideration is
recorded at the acquisition date estimated fair value of the
contingent payment for all acquisitions. The fair value of the
contingent consideration is remeasured at each reporting period
with any adjustments in fair value included in our consolidated
statement of operations.
Revenue
Recognition
Revenue is generally realized or realizable and earned when
persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the sellers price
to the buyer is fixed or determinable, and collectability is
reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to
the customer, which is typically upon delivery to the customer.
Revenues recognized from research, development and licensing
agreements (including milestone receipts) are recorded on the
contingency-adjusted performance model which
requires deferral of revenue until such time as contract
milestone requirements, as specified in the individual
agreements, have been met. Under this model, revenue related to
each payment is recognized over the entire contract performance
period, starting with the contracts commencement, but not
prior to earning
and/or
receiving the milestone amount (i.e., removal of any
contingency). The amount of revenue recognized is based on the
ratio of costs incurred to date to total estimated cost to be
incurred. Royalty and commission revenue is recognized in
accordance with the terms of their respective contractual
agreements when collectability is reasonably assured and revenue
can be reasonably measured.
Provisions
for Sales Returns and Allowances
As is customary in the pharmaceutical industry, the
Companys gross product sales are subject to a variety of
deductions in arriving at reported net product sales. When the
Company recognizes revenue from the sale of its products, an
estimate of SRA is recorded which reduces product sales.
Accounts receivable
and/or
accrued liabilities are also reduced
and/or
increased by the SRA amount. These adjustments include estimates
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
for chargebacks, rebates, cash discounts and returns and other
allowances. These provisions are estimated based on historical
payment experience, historical relationship to revenues,
estimated customer inventory levels and current contract sales
terms with direct and indirect customers. The estimation process
used to determine our SRA provision has been applied on a
consistent basis and no material adjustments have been necessary
to increase or decrease our reserves for SRA as a result of a
significant change in underlying estimates. The Company uses a
variety of methods to assess the adequacy of our SRA reserves to
ensure that our consolidated financial statements are fairly
stated. This includes periodic reviews of customer inventory
data, customer contract programs and product pricing trends to
analyze and validate the SRA reserves.
Chargebacks The provision for chargebacks is
our most significant sales allowance. A chargeback represents an
amount payable in the future to a wholesaler for the difference
between the invoice price paid to the Company by our wholesale
customer for a particular product and the negotiated contract
price that the wholesalers customer pays for that product.
The Companys chargeback provision and related reserve vary
with changes in product mix, changes in customer pricing and
changes to estimated wholesaler inventories. The provision for
chargebacks also takes into account an estimate of the expected
wholesaler sell-through levels to indirect customers at contract
prices. The Company validates the chargeback accrual quarterly
through a review of the inventory reports obtained from our
largest wholesale customers. This customer inventory information
is used to verify the estimated liability for future chargeback
claims based on historical chargeback and contract rates. These
large wholesalers represent 85% 90% of the
Companys chargeback payments. The Company continually
monitors current pricing trends and wholesaler inventory levels
to ensure the liability for future chargebacks is fairly stated.
Rebates Rebates include volume related
incentives to direct and indirect customers and Medicaid rebates
based on claims from Medicaid benefit providers.
Volume rebates are generally offered to customers as an
incentive to continue to carry our products and to encourage
greater product sales. These rebate programs include contracted
rebates based on customers purchases made during an
applicable monthly, quarterly or annual period. The provision
for rebates is estimated based on our customers contracted
rebate programs and our historical experience of rebates paid.
Any significant changes to our customer rebate programs are
considered in establishing our provision for rebates. The
Company continually monitors its customer rebate programs to
ensure that the liability for accrued rebates is fairly stated.
The provision for Medicaid rebates is based upon historical
experience of claims submitted by the various states. The
Company monitors Medicaid legislative changes to determine what
impact such legislation may have on our provision for Medicaid
rebates. Our accrual of Medicaid rebates is based on historical
payment rates and is reviewed on a quarterly basis against
actual claim data to ensure the liability is fairly stated.
Returns and Other Allowances Our provision
for returns and other allowances include returns, pricing
adjustments, promotional allowances and billback adjustments.
Consistent with industry practice, the company maintains a
return policy that allows our customers to return product for
credit. In accordance with our return goods policy, credit for
customer returns of product is applied against outstanding
account activity or by check. Product exchanges are not
permitted. Customer returns of product are not resalable unless
the return is due to a shipping error. Our estimate of the
provision for returns is based upon historical experience and
current trends of actual customer returns. Additionally, we
consider other factors when estimating our current period return
provision, including levels of inventory in our distribution
channel as well as significant market changes which may impact
future expected returns, and make adjustments to our current
period provision for returns when it appears product returns may
differ from our original estimates.
Pricing adjustments, which include shelf stock adjustments, are
credits issued to reflect price decreases in selling prices
charged to our direct customers. Shelf stock adjustments are
based upon the amount of product
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
our customers have in their inventory at the time of an
agreed-upon
price reduction. The provision for shelf stock adjustments is
based upon specific terms with our direct customers and includes
estimates of existing customer inventory levels based upon their
historical purchasing patterns. The Company regularly monitors
all price changes to help evaluate our reserve balances. The
adequacy of these reserves is readily determinable as pricing
adjustments and shelf stock adjustments are negotiated and
settled on a
customer-by-customer
basis.
Promotional allowances are credits, which are issued in
connection with a product launch or as an incentive for
customers to begin carrying our product. The Company establishes
a reserve for promotional allowances based upon these
contractual terms.
Billback adjustments are credits that are issued to certain
customers who purchase directly from the Company as well as
indirectly through a wholesaler. These credits are issued in the
event there is a difference between the customers direct
and indirect contract price. The provision for billbacks is
estimated based upon historical purchasing patterns of qualified
customers who purchase product directly from the Company and
supplement their purchases indirectly through the Companys
wholesale customers.
Cash Discounts Cash discounts are provided to
customers that pay within a specific period. The provision for
cash discounts are estimated based upon invoice billings,
utilizing historical customer payment experience. Our
customers payment experience is fairly consistent and most
customer payments qualify for the cash discount. Accordingly,
our reserve for cash discounts is readily determinable.
Net revenues and accounts receivable balances in the
Companys consolidated financial statements are presented
net of SRA estimates. In addition, certain SRA balances are
included in accounts payable and accrued liabilities. Accounts
receivable are presented net of SRA balances of
$320.5 million and $335.0 million at December 31,
2010 and 2009, respectively. Accounts payable and accrued
liabilities include $106.5 million and $83.6 million
at December 31, 2010 and 2009, respectively, for certain
rebates and other amounts due to indirect customers.
The
following table summarizes the activity in the Companys
major categories of SRA (in millions):
Returns and Other
Chargebacks
Rebates
Allowances
Cash Discounts
Total
Balance at December 31, 2007
$
164.4
$
154.3
$
56.1
$
12.9
$
387.7
Provision related to sales in 2008
1,224.0
309.1
179.8
67.2
1,780.1
Credits and payments
(1,267.8
)
(337.6
)
(166.4
)
(67.8
)
(1,839.6
)
Balance at December 31, 2008
120.6
125.8
69.5
12.3
328.2
Add: Arrow Acquisition
5.3
37.0
11.3
1.5
55.1
Provision related to sales in 2009
1,169.0
415.1
183.8
72.8
1,840.7
Credits and payments
(1,177.5
)
(389.5
)
(167.1
)
(71.3
)
(1,805.4
)
Balance at December 31, 2009 (Revised)
117.4
188.4
97.5
15.3
418.6
Provision related to sales in 2010
1,175.5
755.0
206.5
90.5
2,227.5
Credits and payments
(1,192.1
)
(723.5
)
(214.7
)
(88.8
)
(2,219.1
)
Balance at December 31, 2010
$
100.8
$
219.9
$
89.3
$
17.0
$
427.0
The Company does not expect future payments of SRA to materially
exceed our current estimates. However, if future SRA payments
were to materially exceed our estimates, such adjustments may
have a material adverse impact on our financial position,
results of operations and cash flows.
Shipping
and Handling Costs
The Company records shipping and handling costs in selling and
marketing expenses. These expenses were $66.5 million,
$51.9 million and $50.8 million in 2010, 2009 and
2008, respectively.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Concentration
of Major Customers and Suppliers
For the year ended December 31, 2010, the Companys
three largest customers accounted for 14%, 11%, and 6%,
individually, of the Companys net revenues. For the year
ended December 31, 2009, the Companys three largest
customers accounted for 13%, 11%, and 9%, individually, of the
Companys net revenues. For the year ended
December 31, 2008, the Companys three largest
customers accounted for 11%, 11%, and 9%, individually, of the
Companys net revenues. No other individual customers
accounted for more than 10% of net revenues.
The Company is subject to a concentration of credit risk with
respect to its accounts receivable balance, all of which is due
from wholesalers, distributors, chain drug stores and service
providers in the health care and pharmaceutical industries
throughout the U.S. and international markets in which we
operate. Approximately 52% and 53% of the gross accounts
receivable balance consists of amounts due from the four largest
customers at December 31, 2010 and 2009, respectively. The
Company performs ongoing credit evaluations of its customers and
maintains an allowance for potential uncollectible accounts.
Actual losses from uncollectible accounts have been minimal.
Certain of the Companys finished products and raw
materials are obtained from single source suppliers. Although
the Company seeks to identify more than one source for its
various finished products and raw materials, loss of a single
source supplier could have an adverse effect on the
Companys results of operations, financial condition and
cash flows. Third-party manufactured products accounted for
approximately 33%, 38% and 44% of our Global Generics and Global
Brands product net revenues in 2010, 2009 and 2008, respectively.
Research
and Development Activities
R&D activities are expensed as incurred and consist of
self-funded R&D costs and the costs associated with work
performed under collaborative R&D agreements. R&D
expenses include direct and allocated expenses. R&D
expenses incurred under collaborative agreements were
approximately $11.1 million, $6.8 million, and
$5.9 million for the years ended December 31, 2010,
2009 and 2008, respectively.
Income
Taxes
Income taxes are accounted for using an asset and liability
approach that requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of
temporary differences between the financial statement and tax
bases of assets and liabilities at the applicable tax rates. A
valuation allowance is provided when it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The Company evaluates the realizability of its
deferred tax assets by assessing its valuation allowance and by
adjusting the amount of such allowance, if necessary. The
factors used to assess the likelihood of realization include the
Companys forecast of future taxable income and available
tax planning strategies that could be implemented to realize the
net deferred tax assets. Failure to achieve forecasted taxable
income in applicable tax jurisdictions could affect the ultimate
realization of deferred tax assets and could result in an
increase in the Companys effective tax rate on future
earnings.
Income tax positions must meet a more-likely-than-not
recognition threshold to be recognized. Income tax positions
that previously failed to meet the more-likely-than-not
threshold are recognized in the first subsequent financial
reporting period in which that threshold is met. Previously
recognized tax positions that no longer meet the
more-likely-than-not threshold are derecognized in the first
subsequent financial reporting period in which that threshold is
no longer met. We recognize potential accrued interest and
penalties related to unrecognized tax benefits within the
consolidated statements of income as income tax expense.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Comprehensive
Income
Comprehensive income includes all changes in equity during a
period except those that resulted from investments by or
distributions to the Companys stockholders. Other
comprehensive income refers to revenues, expenses, gains and
losses that, under GAAP, are included in comprehensive income,
but excluded from net income as these amounts are recorded
directly as an adjustment to stockholders equity.
Watsons other comprehensive income (loss) is composed of
unrealized gains (losses) on its holdings of publicly traded
equity securities, net of realized gains (losses) included in
net income and foreign currency translation adjustments.
Earnings
Per Share (EPS)
Basic EPS is computed by dividing net income attributable to
common shareholders by the weighted average common shares
outstanding during a period. Diluted EPS is based on the
treasury stock method and includes the effect from potential
issuance of common stock, such as shares issuable upon
conversion of our convertible contingent senior debentures
(CODES), and shares issuable pursuant to the
exercise of stock options, assuming the exercise of all
in-the-money
stock options. Common share equivalents have been excluded where
their inclusion would be anti-dilutive. The Company is required
to add the weighted average potential common shares outstanding
associated with the conversion of the CODES to the number of
shares outstanding for the calculation of diluted EPS for all
periods in which the securities were outstanding. On
September 14, 2009 the CODES were redeemed in accordance
with the terms of the CODES.
A reconciliation of the
numerators and denominators of basic and diluted EPS consisted
of the following (in millions, except per share amounts):
Years Ended December 31,
2010
2009
2008
EPS basic
Net income attributable to common shareholders
$
184.4
$
222.0
$
238.4
Basic weighted average common shares outstanding
122.4
105.0
102.8
EPS basic
$
1.51
$
2.11
$
2.32
EPS assuming dilution
Net income attributable to common shareholders
$
184.4
$
222.0
$
238.4
Add: Interest expense on CODES, net of tax
5.5
7.9
Net income, adjusted
$
184.4
$
227.5
$
246.3
Basic weighted average common shares outstanding
122.4
105.0
102.8
Effect of dilutive securities:
Conversion of CODES
10.1
14.4
Dilutive stock awards
1.8
1.3
0.5
Diluted weighted average common shares outstanding
124.2
116.4
117.7
EPS diluted
$
1.48
$
1.96
$
2.09
Stock awards to purchase 1.1 million, 3.5 million and
8.1 million common shares in 2010, 2009 and 2008,
respectively, were outstanding but not included in the
computation of diluted EPS as the awards were anti-dilutive.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Share-based
Compensation
The Company recognizes compensation expense for all share-based
compensation awards made to employees and directors based on
estimated fair values. The Company estimates the fair value of
its stock option plans using the Black-Scholes option pricing
model (the Option Model). The Option Model requires
the use of subjective and complex assumptions, including the
options expected term and the estimated future price
volatility of the underlying stock, which determine the fair
value of the share-based awards. The Companys estimate of
expected term was determined based on the weighted average
period of time that options granted are expected to be
outstanding considering current vesting schedules and the
historical exercise patterns of existing option plans. The
expected volatility assumption used in the Option Model is based
on implied volatility based on traded options on the
Companys stock. The risk-free interest rate used in the
Option Model is based on the yield of U.S. Treasuries with
a maturity closest to the expected term of the Companys
stock options. No stock options were granted during the years
ended December 31, 2010, 2009 or 2008.
Share-based compensation expense recognized during a period is
based on the value of the portion of share-based awards that are
expected to vest with employees. Accordingly, the recognition of
share-based compensation expense has been reduced for estimated
future forfeitures. These estimates will be revised in future
periods if actual forfeitures differ from the estimates. Changes
in forfeiture estimates impact compensation expense in the
period in which the change in estimate occurs.
Recent
Accounting Pronouncements
In October 2009, the FASB issued an amendment to its accounting
guidance on revenue arrangements with multiple deliverables,
which addresses the unit of accounting for arrangements
involving multiple deliverables and how consideration should be
allocated to separate units of accounting, when applicable. The
amendment requires that arrangement considerations be allocated
at the inception of the arrangement to all deliverables using
the relative selling price method and provides for expanded
disclosures related to such arrangements. The amendment is
effective for revenue arrangements entered into or materially
modified in fiscal years beginning on or after June 15,
2010. Early adoption is allowed. The adoption of this guidance
will not have a material impact on the Companys
consolidated financial statements.
In January 2010, the FASB issued an amendment to the disclosure
requirements for fair value measurements. The amendment requires
an entity to: (i) disclose separately the amounts of
significant transfers in and out of Level 1 and
Level 2 fair value measurements and describe the reasons
for the transfers, and (ii) present separate information
for Level 3 activity pertaining to gross purchases, sales,
issuances and settlements. The new disclosures are effective for
interim and annual reporting periods beginning after
December 15, 2009, except for the Level 3 disclosures,
which are effective for fiscal years beginning after
December 15, 2010. The adoption of this guidance will not
have a material impact on the Companys consolidated
financial statements.
In March 2010, the FASB ratified accounting guidance on defining
a milestone and determining when it may be appropriate to apply
the milestone method of revenue recognition for research or
development transactions. This guidance provides criteria that
must be met to recognize consideration that is contingent upon
achievement of a substantive milestone in its entirety in the
period in which the milestone is achieved. The amendment is
effective for milestones achieved in fiscal years beginning on
or after June 15, 2010. Early adoption is allowed. The
adoption of this guidance will not have a material impact on the
Companys consolidated financial statements.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
NOTE 3
Share-Based Compensation
As indicated above, the Company recognizes compensation expense
for all share-based compensation awards made to employees and
directors based on estimated fair values. A summary of the
Companys share-based compensation plans is presented below.
Equity
Award Plans
The Company has adopted several equity award plans, all of which
have been approved by the Companys shareholders that
authorize the granting of options, restricted stock and other
forms of equity awards of the Companys common shares
subject to certain conditions. At December 31, 2010, the
Company had reserved 5.2 million of its common shares for
issuance of share-based compensation awards under the
Companys equity award plans.
Option award plans require options to be granted at the fair
value of the shares underlying the options at the date of the
grant and generally become exercisable over periods ranging from
three to five years and expire in ten years. In conjunction with
certain of the Companys acquisitions, Watson assumed stock
option and warrant plans from the acquired companies. The
options and warrants in these plans were adjusted by the
individual exchange ratios specified in each transaction. No
additional options or warrants have been granted under any of
the assumed plans.
Beginning in 2005, the Compensation Committee of the board of
directors of the Company (the Board) authorized and
issued restricted stock to the Companys employees,
including its executive officers and certain non-employee
directors (the Participants) under the
Companys equity compensation plans. The restricted stock
award program offers Participants the opportunity to earn shares
of our common stock over time, rather than options that give
Participants the right to purchase stock at a set price.
Restricted stock awards are grants that entitle the holder to
shares of common stock subject to certain terms. Restricted
stock awards generally have restrictions eliminated over a one
to four year period. Restrictions generally lapse for
non-employee directors after one year. Restrictions generally
lapse for employees over a two to four year period. The fair
value of restricted stock grants is based on the fair market
value of our common stock on the respective grant dates.
Restricted stock compensation is being amortized and charged to
operations over the same period as the restrictions are
eliminated for the Participants.
Share-Based
Compensation
Share-based compensation expense recognized in the
Companys results of operations for the years ended
December 31, 2010, 2009 and 2008 was $23.5 million,
$19.1 million and $18.5 million, respectively.
Share-based compensation capitalized to inventory was
$3.6 million, $2.7 million and $3.3 million for
the years ended December 31, 2010, 2009 and 2008,
respectively.
NOTE 4
Acquisitions and Divestitures
Acquisition
of Arrow Group
On the Acquisition Date, Watson acquired all the outstanding
equity of privately held Arrow Group for cash, stock and certain
contingent consideration (the Arrow Acquisition). In
accordance with the terms of the share purchase agreement dated
June 16, 2009, as amended on November 26, 2009
(together the Acquisition Agreement), the Company
acquired all the outstanding equity of the Arrow Group for the
following consideration:
The payment of cash and the assumption of certain liabilities
totaling $1.05 billion;
Approximately 16.9 million restricted shares of Common
Stock of Watson (the Restricted Common Stock);
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
200,000 shares of newly designated mandatorily redeemable,
non-voting Series A Preferred Stock of Watson (the
Mandatorily Redeemable Preferred Stock) placed in
escrow for the benefit of the former shareholders of the Arrow
Group (the Arrow Selling Shareholders); and
Certain contingent consideration based on the after-tax gross
profits on sales of the authorized generic version of
Lipitor®
(atorvastatin) in the U.S. calculated and payable as
described in the Acquisition Agreement. For additional
information on the contingent payment, refer to
NOTE 10 Other Long-Term Liabilities.
The following table presents a summary of the purchase price
consideration for the Arrow Acquisition (in millions):
Amount
Cash consideration
$
1,050.0
Fair value of Restricted Common Stock
636.2
Fair value of Mandatorily Redeemable Preferred Stock
150.0
Fair value estimate of atorvastatin contingent payment
consideration (refer to NOTE 10 Other
Long-Term Liabilities.)
110.0
$
1,946.2
Fair
Value of Consideration Transferred
In accordance with existing U.S. GAAP, the fair value of
Restricted Common Stock issued as part of the consideration
transferred was measured on the Acquisition Date at the
then-current market price of $37.55 per share for
approximately $636.2 million.
Mandatorily Redeemable Preferred Stock was issued in the form of
zero-coupon, non-convertible preferred stock which will be
redeemable in the amount of $200.0 million, less the amount
of any indemnity payments, three years after the Acquisition
Date. The fair value of the Mandatorily Redeemable Preferred
Stock at Acquisition Date was estimated by the Company to be
$150.0 million, based on the terms they were issued under
and the cost of the Companys other fixed rate borrowings
and is presented within long-term debt at its current fair value
at December 31, 2010 of $166.4 million. For additional
information on the Mandatorily Redeemable Preferred Stock, refer
to NOTE 9 Long-Term Debt.
The Company determined the acquisition date fair value of the
contingent consideration obligation based on a
probability-weighted income approach derived from atorvastatin
revenue estimates and post-tax gross profit levels and a
probability assessment with respect to the likelihood of
achieving the various earn-out criteria. The fair value
measurement is based on significant inputs not observable in the
market and thus represents a Level 3 measurement as defined
in fair value measurement accounting. The resultant
probability-weighted cash flows were discounted using an
effective annual interest rate of 10.4%. At each reporting date,
the Company adjusts the contingent consideration obligation to
estimated fair value and records changes in fair value as
expense in our consolidated statement of operations. Changes in
the fair value of the contingent consideration obligations may
result from changes in discount periods and rates, changes in
the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of
achieving the various earn-out criteria. As of December 31,
2010 the range of outcomes and the assumptions used to develop
the estimates have not changed significantly from those used at
Acquisition Date. Accretion expense related to the increase in
the net present value of the contingent liability is included in
interest expense for the period.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Divestiture
of Certain Assets
In order to obtain regulatory approval under the
Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the HSR
Act), in connection with the Arrow Acquisition, Watson and
the Arrow Group were required to divest certain assets. In
conjunction with the closing, Watson sold its Abbreviated New
Drug Application (ANDA) for Cabergoline, the generic
equivalent to Dostinex, to Impax Laboratories, Inc. The Arrow
Group sold its pending ANDA for Dronabinol, a generic equivalent
to Marinol, to Impax Laboratories, Inc.
Resolution Chemicals Ltd., the subsidiary of the Arrow Group
that manufactures the Dronabinol active pharmaceutical
ingredient, was divested in accordance with the terms of the
consent order under the HSR Act immediately prior to the closing.
Allocation
of Consideration Transferred
The transaction has been accounted for using the purchase method
of accounting under existing U.S. GAAP. The purchase method
under existing U.S. GAAP requires, among other things, that
assets acquired and liabilities assumed in a business purchase
combination be recognized at their fair values as of the
acquisition date and that IPR&D be recorded at fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. In addition, any common stock
consideration transferred is measured at acquisition date at the
then current market price.
The following table summarizes the fair values of the
tangible & identifiable intangible assets acquired and
liabilities assumed at Acquisition Date, with the excess being
allocated to goodwill. During the quarter ended June 30,
2010, management completed its allocation of intellectual
properties by tax jurisdiction and the resulting deferred tax
liabilities by legal entity, its evaluation of uncertain tax
positions and related deferred tax assets and liabilities.
These
adjustments are reflected in the values presented below and in
our revised December 31, 2009 balance sheet (in millions):
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Inventories
The fair value of inventories acquired included a
step-up in
the value of inventories of approximately $26.0 million.
Approximately $14.2 million was amortized to cost of sales
during 2009 and the remaining $11.8 million was amortized
to cost of sales in the first quarter of 2010.
Other
Current Assets
At Acquisition Date, included in other current assets was
$90.0 million related to the fair value of amounts due from
Sepracor, Inc. (Sepracor) prior to the end of 2010
(the Sepracor Receivable) for the transfer of
certain product rights and technology from the Arrow Group. The
entire amount due under the Sepracor Receivable was received by
December 31, 2010.
IPR&D
and Intangible Assets
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the Acquisition Date, had
not established technological feasibility and had no alternative
future use. The IPR&D intangible assets are capitalized and
accounted for as indefinite-lived intangible assets and will be
subject to impairment testing until completion or abandonment of
the projects. Upon successful completion of each project and
launch of the product, Watson will make a separate determination
of useful life of the IPR&D intangible and amortization
will be recorded as an expense over the estimated useful life.
The fair value of the IPR&D and identifiable intangible
assets was determined primarily using the income
approach, which is a valuation technique that provides an
estimate of the fair value of an asset based on market
participant expectations of the cash flows an asset would
generate over its remaining useful life. Some of the more
significant assumptions inherent in the development of the
identifiable intangible assets valuations, from the perspective
of a market participant, include the estimated net cash flows
for each year for each project or product (including net
revenues, cost of sales, research and development costs, selling
and marketing costs and working capital/asset contributory asset
charges), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each assets life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The discount rate used to arrive at the present value
of IPR&D projects as of the Acquisition Date was
approximately 10.4% to reflect the internal rate of return and
incremental commercial uncertainty in the projections as the
products have not yet received regulatory approval. The major
risks and uncertainties associated with the timely and
successful completion of the IPR&D projects include legal
risk and regulatory risk. No assurances can be given that the
underlying assumptions used to prepare the discounted cash flow
analysis will not change or the timely completion of each
project to commercial success will occur. For these and other
reasons, actual results may vary significantly from estimated
results.
Intangible assets represent the Arrow Groups CMP and have
an estimated weighted average useful life of five years.
Goodwill
Allocation
Among the primary reasons the Company entered into the Arrow
Acquisition and factors that contributed to a purchase price
allocation resulting in the recognition of goodwill were a
history of operating margins and profitability, a strong
R&D department and several first-to file opportunities,
expanded commercial footprint on a global basis and key pipeline
additions, including atorvastatin and budesonide which will
enable Watson to expand its product offerings and offer its
customers a greater breadth of product offerings. The goodwill
recognized from the Arrow Acquisition is not deductible for tax
purposes. All goodwill from the Arrow Acquisition was assigned
to the Global Generics segment.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Long-Term
Deferred Tax Liabilities and Other Tax Liabilities
Long-term deferred tax liabilities and other tax liabilities
reflects a deferred income tax liability representing the impact
of purchase accounting adjustments for the inventory fair value
step-up,
property, plant and equipment fair value adjustment,
contingencies adjustment and identifiable IPR&D and
intangible assets fair value adjustment. This determination of
deferred tax liabilities was based on the excess book basis over
the tax basis resulting from the above fair value adjustments
using the statutory tax rate for each country these fair value
adjustments were assigned.
Acquisition-Related
Expenses
Included in general and administrative expenses in the
consolidated statement of operations for the year ended
December 31, 2009 were pretax charges totaling
$16.6 million for advisory, legal and regulatory costs in
connection with the Arrow Acquisition.
Unaudited
Pro Forma Results of Operations
The following table presents the unaudited pro forma operating
results for the Company, assuming the Arrow Acquisition had
occurred as of the beginning of each period presented. The
unaudited pro forma results reflect certain adjustments related
to the acquisition, such as increased depreciation and
amortization expense on the fair valuation of assets acquired,
the impact of acquisition financing in place at
December 31, 2009 and the related tax effects. The pro
forma results do not include any anticipated synergies which may
be achievable subsequent to the Acquisition Date. Accordingly,
such pro forma amounts are not necessarily indicative of the
results that actually would have occurred had the acquisition
been completed on the dates indicated, nor are they indicative
of the future operating results of the combined company.
Year Ended December 31,
2009
2008
(In millions, except
per share amounts)
Net revenues
$
3,261.9
$
3,170.6
Net income
119.3
281.5
Earnings per share:
Basic
0.99
2.35
Diluted
0.98
2.34
Acquisition
of
Crinone®
and
Prochieve®
Assets from Columbia Laboratories, Inc.
(Columbia)
On July 2, 2010, the Company completed the acquisition of
the U.S. rights to Columbia products
Crinone®
and
Prochieve®
and acquired 11.2 million shares of Columbias common
stock, representing approximately a 13% ownership share, for
initial cash consideration of $62.0 million and certain
contingent consideration of up to an additional
$45.5 million based upon the successful completion of
certain milestones and regulatory approvals.
The transaction was accounted for using the purchase method of
accounting under existing U.S. GAAP with assets acquired
and liabilities assumed recorded at their fair values as of the
acquisition date. The purchase price for the Columbia
acquisition was allocated to tangible and identifiable
intangible assets
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
acquired and liabilities assumed based on their estimated fair
values at the acquisition date as follows (in millions):
Amount
Investments
$
11.5
IPR&D intangible assets
75.8
Intangible assets
39.5
Long-term deferred tax assets
24.3
Contingent consideration obligations
(64.8
)
Long-term deferred tax liabilities
(24.3
)
Net assets acquired
$
62.0
Pro forma results of operations have not been presented because
the effect of the acquisition was not material.
Acquisition
of Equity Interest in Moksha8 Pharmaceuticals, Inc.
(Moksha8)
On October 4, 2010, the Company entered into an agreement
with Moksha8 to expand into markets in Brazil and Mexico. The
Company made an initial investment of $30.0 million in cash
in Moksha8 in exchange for an approximate 22% ownership share in
Moksha8. The Company is also committed to invest an additional
$20.0 million in Moksha8 contingent upon the successful
execution by Moksha8 of additional third-party product
acquisitions over the next year which will increase our
ownership share to approximately 31%.
Sale
of Scinopharm Taiwan Ltd. (Scinopharm)
On March 24, 2010, all closing conditions were satisfied in
our agreement with Uni-President Enterprises Corporation to sell
our outstanding shares of Scinopharm. Under the terms of the
stock purchase agreement, we sold our entire holdings of common
shares for net proceeds of approximately $94.0 million
resulting in a gain on sale of securities in the amount of
$23.4 million.
NOTE 5
Other Income
Other income consisted of the following (in millions):
Years Ended December 31,
2010
2009
2008
Gain (loss) on sale of securities
$
25.6
$
(1.1
)
$
9.6
Earnings on equity method investments
1.6
10.8
10.6
Loss on early extinguishment of debt
(0.5
)
(2.0
)
(1.1
)
Other income
1.0
0.2
0.2
$
27.7
$
7.9
$
19.3
In March 2010, we completed the sale of our outstanding shares
of Scinopharm for net proceeds of approximately
$94.0 million. The earnings on equity investments for the
year ended December 31, 2009 were higher than the current
year due to the sale of our outstanding shares of Scinopharm
during the first quarter of 2010.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
NOTE 7
Investments in Marketable Securities and Other
Investments
December 31,
2010
2009
(In millions)
Marketable securities:
U.S. Treasury and agency securities maturing within
one year
$
4.8
$
6.0
U.S. Treasury and agency securities maturing within
two years
5.5
6.3
Equity securities
0.8
1.3
Total marketable securities
$
11.1
$
13.6
Investments and other assets:
Equity method investments
$
63.2
$
75.4
Cost method and other long-term investments
0.3
9.4
Other assets
21.0
29.7
Total investments and other assets
$
84.5
$
114.5
Watsons marketable securities and other long-term
investments are classified as
available-for-sale
and are recorded at fair value based on quoted market prices
using the specific identification method. These investments are
classified as either current or non-current, as appropriate, in
the Companys Consolidated Balance Sheets.
The following table provides a summary of the fair value and
unrealized gains (losses) related to Watsons
available-for-sale
securities (in millions):
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Current
Investments
The Company invests in U.S. Treasury and agency securities.
These investments are included in marketable securities on the
Companys Consolidated Balance Sheets at December 31,
2010 and 2009. Current investments are classified as
available-for-sale
and are recorded at fair value based on quoted market prices.
Investment
in Equity Method Investments
The Companys investments in equity method investments at
December 31, 2010 consist of its investments in Columbia
and Moksha8 and certain equity method investments in privately
held companies acquired as part of Arrow Acquisition. (Refer to
NOTE 4 Acquisition and Divestitures
for additional information on Columbia and Moksha8.)
On March 24, 2010, the Company sold its entire holdings of
common shares in the equity of Scinopharm to Uni-President
Enterprises Corporation. (Refer to NOTE 4
Acquisition and Divestitures for additional information on
Scinopharm).
The Company recorded net earnings from equity method investments
of $1.6 million in 2010, $10.8 million in 2009 and
$10.6 million in 2008, respectively.
The Company is not required to provide ongoing investments or
additional funding to its joint ventures with the exception of a
commitment to invest an additional $20.0 million in Moksha8
upon Moksha8 meeting certain conditions. (Refer to
NOTE 4 Acquisition and Divestitures
for additional information on Moksha8.)
Cost
Method Investments
The Companys cost method investments consist primarily of
investments in common shares of a number of private and public
companies where our ownership interest is under 20% or where we
do not have the ability to exercise significant influence.
Other
Assets
Other assets include security and equipment deposits and
deferred financing fees, net of amortization.
NOTE 8
Goodwill, Product Rights and Other Intangibles
Goodwill for the Companys reporting units consisted of the
following:
December 31,
2010
2009
(Revised)
(In millions)
Global Brands segment
$
371.6
$
348.2
Global Generics segment
1,070.2
1,066.5
Distribution segment
86.3
86.3
Total goodwill
$
1,528.1
$
1,501.0
The increase in goodwill in 2010 primarily relates to the
acquisition of the remaining 64% of Eden as discussed in
NOTE 1 Description of Business.
Goodwill for the Companys Global Generics segment as of
December 31, 2009 has been revised from the amount
presented in our Annual report on
Form 10-K
for the year ended December 31, 2009. (Refer to
NOTE 4 Acquisitions and
Divestitures for additional details.)
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Other intangible assets consist primarily of product rights. The
original cost and accumulated amortization of these intangible
assets, where applicable, consisted of the following:
December 31,
2010
2009
(Revised)
(In millions)
Intangibles with definite lives
Product rights and other related intangibles
$
2,049.7
$
1,855.8
Core technology
52.5
52.5
Customer relationships
49.1
49.1
2,151.3
1,957.4
Less accumulated amortization
(1,211.1
)
(1,031.1
)
940.2
926.3
Intangibles with indefinite lives
IPR&D
615.6
711.0
Trade Name
76.2
76.2
691.8
787.2
Total product rights and related intangibles, net
$
1,632.0
$
1,713.5
Intangible assets acquired with the Arrow Acquisition amounted
to $1,119.6 million, including $518.6 million relating
to CMP and $711.0 relating to IPR&D intangibles. CMP
intangibles have been included in product rights and other
related intangibles and will be amortized over a weighted
average useful life of approximately five years.
In July 2010, the Company acquired intangible assets in
connection with the acquisition of the U.S rights to certain
Columbia products amounting to $115.3 million, including
$39.5 million relating to CMP and $75.8 million
relating to IPR&D intangibles. CMP intangibles have been
included in product rights and other related intangibles and
will be amortized using a weighted average useful life of
approximately five years.
During 2010 approximately $142.3 million of IPR&D
intangibles were transferred to product rights and other related
intangibles as products received regulatory approval.
Amortization of these intangibles commenced upon product launch
using a weighted average useful life of approximately five years.
Watson re-evaluates the carrying value of identifiable
intangible and long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying value may
not be recoverable. The Company continually evaluates the
appropriateness of useful lives assigned to long-lived assets,
including product rights.
During the fourth quarter of 2010, the Company recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. The
impairment charge results from the Companys current
estimate of the fair value of these IPR&D assets, based on
updated forecasts, compared to their assigned fair values on
Acquisition Date. The fair value of acquired identifiable
intangible assets generally is determined using an income
approach, based on a forecast of all expected future net cash
flows related to the asset which are adjusted to present value
using appropriate discount rates. Forecasts used to determine
fair values of IPR&D assets are based on appropriate
assumptions which include, among other factors, the impact of
changes to the development programs, the current competitive
environment, the regulatory timeframes impacting future product
launch dates and the risk associated with these assets.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Assuming no additions, disposals or adjustments are made to the
carrying values
and/or
useful lives of the assets, annual amortization expense on
product rights and related over the next five years is estimated
to be as follows (in millions):
Amount
2011
$
270.0
2012
417.5
2013
311.5
2014
299.3
2015
138.6
The above amortization expense is an estimate. Actual amounts
may change from such estimated amounts due to fluctuations in
foreign currency exchange rates, additional intangible asset
acquisitions, potential impairments, accelerated amortization or
other events. The Companys current product rights and
related intangibles have a weighted average remaining useful
life of approximately five years.
NOTE 9
Long-Term Debt
Long-term debt consisted of the following:
December 31,
2010
2009
(In millions)
Senior Notes,
2014 Notes
$
450.0
$
450.0
2019 Notes
400.0
400.0
850.0
850.0
Less: Unamortized discount
(2.1
)
(2.5
)
Senior Notes, net
847.9
847.5
2006 Credit Facility
400.0
Mandatorily Redeemable Preferred Stock
166.4
151.2
Loan with Lombard Odier Darier Hentsch & Cie.
(Lombard Loan)
55.0
Other notes payable
1.8
4.1
1,016.1
1,457.8
Less: Current portion
307.6
Total long-term debt
$
1,016.1
$
1,150.2
Senior
Notes
The offering of $450.0 million of 2014 Notes and
$400.0 million of 2019 Notes was registered under an
automatic shelf registration statement filed with
the Securities and Exchange Commission (SEC). The
Senior Notes were issued pursuant to a senior note indenture
dated as of August 24, 2009 between the Company and Wells
Fargo Bank, National Association, as trustee, as supplemented by
a first supplemental indenture dated August 24, 2009
(together the Senior Note Indentures).
Interest payments are due on the Senior Notes semi-annually in
arrears on February 15 and August 15, respectively,
beginning February 15, 2010 at an effective annual interest
rate of 5.43% on the 2014 Notes and 6.35% on the 2019 Notes.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company may redeem the Senior Notes on at least 15 days
but no more than 60 days prior written notice for cash for
a redemption price equal to the greater of 100% of the principal
amount of the Senior Notes to be redeemed and the sum of the
present values of the remaining scheduled payments, as defined
by the Senior Note Indentures, of the Senior Notes to be
redeemed, discounted to the date of redemption at the applicable
treasury rate, as defined by the Senior Note Indentures, plus
40 basis points. As of December 31, 2010, the fair
value of our Senior Notes was approximately $71.0 million
greater than the carrying value.
Upon a change of control triggering event, as defined by the
Senior Note Indentures, the Company is required to make an offer
to repurchase the Senior Notes for cash at a repurchase price
equal to 101% of the principal amount of the Senior Notes to be
repurchased plus accrued and unpaid interest to the date of
purchase.
Net proceeds from the offering of Senior Notes in 2009 were used
to repay certain amounts under the 2006 Credit Facility and to
redeem other debt with the remaining net proceeds being used to
fund a portion of the cash consideration for the Arrow
Acquisition.
2006
Credit Facility
In November 2006, the Company entered into the 2006 Credit
Facility with Canadian Imperial Bank of Commerce, acting through
its New York agency, as Administrative Agent, Wachovia Capital
Markets, LLC, as Syndication Agent, and a syndicate of banks.
The 2006 Credit Facility provides an aggregate of
$1.15 billion of senior financing to Watson, consisting of
a $500.0 million revolving credit facility (Revolving
Facility) and a $650.0 million senior term loan
facility (Term Facility) and an initial interest
rate equal to LIBOR plus 0.75% (subject to certain adjustments).
In July 2010, the interest rate on the 2006 Credit Facility was
reduced to LIBOR plus 0.625%.
The 2006 Credit Facility has a five-year term and matures in
November 2011. The indebtedness under the 2006 Credit Facility
is guaranteed by Watsons material domestic subsidiaries,
other than minor subsidiaries, on a joint and several basis. The
Revolving Facility is available for working capital and other
general corporate requirements subject to the satisfaction of
certain conditions. During 2010, the Company repaid
$400.0 million on the 2006 Credit Facility. As of
December 31, 2010, no amounts were outstanding on either
the Revolving Facility or the Term Facility of the 2006 Credit
Facility.
The Company is subject to, and, as of December 31, 2010,
was in compliance with, all financial and operation covenants
under the terms of the 2006 Credit Facility.
Mandatorily
Redeemable Preferred Stock
In connection with the Arrow Acquisition, on December 2,
2009, pursuant to the Purchase Agreement, Watson issued
0.2 million shares of newly designed non-voting
Series A Preferred Stock of Watson, having a stated value
of $1,000 per share (the Stated Value), or an
aggregate stated value of $200.0 million, which have been
placed in an indemnity escrow account for a period of three
years.
The provisions for the Mandatorily Redeemable Preferred Stock
are as follows:
Dividends
The holders of Mandatorily Redeemable Preferred Stock shall be
entitled to receive dividends, when and of declared by the board
of directors.
Liquidation
Preference
In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, the holders of the
Mandatorily Redeemable Preferred Stock will be paid out of the
assets of Watson available for
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
distribution to Watsons shareholders before any payment
shall be paid to the holders of Watsons common stock, an
amount equal to the Stated Value of the Mandatorily Redeemable
Preferred Stock.
Mandatory
Redemption
Each share of Mandatorily Redeemable Preferred Stock is
mandatorily redeemable by Watson in cash on December 2,
2012, the third anniversary of its issuance at the Stated Value.
Change
in Control Redemption
Upon occurrence of a Change in Control event (as defined in the
Certificate of Designations of the Mandatorily Redeemable
Preferred Stock that was previously filed with the SEC on
December 2, 2009), Watson shall have the right to redeem
all of the outstanding Mandatorily Redeemable Preferred Stock in
cash for a price per share equal to the Stated Value.
Voting
Rights
The holders of the Mandatorily Redeemable Preferred Stock are
not entitled to vote on any matters presented to the
shareholders of Watson for their actions or consideration at any
meetings of the shareholders of Watson (or by written consent of
shareholders in lieu of the meetings), except that the written
consent or affirmative vote of at least two thirds of the then
outstanding shares of Mandatorily Redeemable Preferred Stock
consenting or voting separately as a class is required on any
matters that would amend, alter or repeal any terms,
preferences, special rights or powers of the Mandatorily
Redeemable Preferred Stock. The holders of the Mandatorily
Redeemable Preferred Stock may also vote on any matters required
by law.
In accordance with the existing U.S. GAAP, the Mandatorily
Redeemable Preferred Stock has been reported as long-term debt
and accretion expense has been classified as interest expense.
The fair value of the Mandatorily Redeemable Preferred Stock was
estimated to be $150.0 million at Acquisition Date based on
the mandatory redemption value of $200.0 million on
December 2, 2012 using a discount rate of 9.63% per annum.
At December 31, 2010, the fair value of the Mandatorily
Redeemable Preferred Stock was $166.4 million and the
unamortized accretion expense was $33.6 million.
Lombard
Loan
On November 25, 2009, prior to closing the Arrow
Acquisition, the Arrow Group received loan proceeds from Lombard
Odier Darier Hentsch & Cie. in the amount of
$90.0 million.
In accordance with the terms of the Lombard Loan,
$35.0 million was paid in December 2009 and the remaining
balance of $55.0 million was paid in 2010.
Fair
Value of Outstanding Debt
Based on quoted market rates of interest and maturity schedules
for similar debt issues, we estimate that the fair values of our
2006 Credit Facility and our other notes payable approximated
their carrying values on December 31, 2010. As of
December 31, 2010, the fair value of our Senior Notes was
$71.0 million greater than the carrying value. While
changes in market interest rates may affect the fair value of
our fixed-rate debt, we believe the effect, if any, of
reasonably possible near-term changes in the fair value of such
debt on our financial condition, results of operations or cash
flows will not be material.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Annual
Debt Maturities
At December 31, 2010, annual maturities of long-term debt
were as follows (in millions):
Amount
2011
$
0.1
2012
200.1
2013
0.1
2014
450.1
2015
1.4
Thereafter
400.0
Amounts represent total anticipated cash payments on our Senior
Notes, Mandatorily Redeemable Preferred Stock and other current
and long-term debt assuming existing debt maturity schedules.
Any early settlement of our Senior Notes through redemption or
repurchase privileges, as defined under the terms of the Senior
Notes, would change the timing of principal amounts due under
the Companys long-term debt obligations.
NOTE 10
Other Long-Term Liabilities
Other long-term liabilities consisted of the following:
December 31,
2010
2009
(In millions)
Atorvastatin contingent consideration liability
$
123.1
$
111.0
Columbia contingent consideration liability
75.4
Other long-term liabilities
13.5
7.7
212.0
118.7
Less: Current portion included in accounts payable and accrued
expenses
28.9
Total other long-term liabilities
$
183.1
$
118.7
The Company determines the acquisition date fair value of
contingent consideration obligations based on a
probability-weighted income approach derived from revenue
estimates and a probability assessment with respect to the
likelihood of achieving contingent obligations including
contingent payments such as milestone obligations, royalty
obligations and contract earn-out criteria, where applicable.
The fair value measurement is based on significant inputs not
observable in the market and thus represents a Level 3
measurement as defined in fair value measurement accounting. The
resultant probability-weighted cash flows are discounted using
an appropriate effective annual interest rate to reflect the
internal rate of return and incremental commercial uncertainty,
major risks and uncertainties associated with the successful
completion of the projects triggering the contingent obligation.
At each reporting date, the Company will revalue the contingent
consideration obligation to estimated fair value and record
changes in fair value as income or expense in our consolidated
statement of operations. Changes in the fair value of the
contingent consideration obligations may result from changes in
discount periods and rates, changes in the timing and amount of
revenue estimates and changes in probability assumptions with
respect to the likelihood of achieving the various contingent
consideration obligations. Accretion expense related to the
increase in the net present value of the contingent liability is
included in interest expense for the period.
Atorvastatin
Contingent Consideration Liability
In accordance with the Acquisition Agreement, the Arrow Selling
Shareholders will have the right to receive certain contingent
payments based on the after-tax gross profits on sales of
atorvastatin within the
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
U.S. (the Territory) from product launch date
up to and including May 31, 2013 (the Contingent
Payment Period). The determination of contingent payment
amounts is dependent upon the existence of generic competition
within the Territory and post-tax gross profits earned, as
defined in the Acquisition Agreement. Should there be no
competing generic product launched in the Territory during the
Contingent Payment Period, payment of contingent consideration
will be calculated as 50% of the post-tax gross profits, as
defined in the Acquisition Agreement. Should there be a
competing product to atorvastatin launched in the Territory
during the Contingent Payment Period, the contingent
consideration will be calculated as either 85% of the post-tax
gross profits or 15% of the post-tax gross profits, as defined
in the Acquisition Agreement, with total contingent payments
being limited to $250.0 million during the Contingent
Payment Period.
As of December 31, 2010 the range of outcomes and the
assumptions used to develop the estimates have not changed
significantly from those used at Acquisition Date. Other
long-term liabilities at December 31, 2010 and 2009
includes the fair value of the atorvastatin contingent liability
of $123.1 million and $111.0 million, respectively.
Columbia
Contingent Consideration Liability
On July 2, 2010, the Company completed the acquisition of
the U.S. rights to Columbia products
Crinone®
and
Prochieve®
for initial cash consideration of $62.0 million and
acquired certain assets and assumed certain contingent
consideration obligations. The transaction was accounted for
using the purchase method of accounting under existing
U.S. GAAP with assets acquired and liabilities assumed
recorded at their fair values as of the acquisition date. The
purchase price for the Columbia acquisition was allocated to
tangible and identifiable intangible assets acquired and
liabilities assumed based on their estimated fair values at the
acquisition date. Fair value determinations of Columbias
contingent payment obligations on acquisition date were based
on, among other factors, estimates of expected future cash
flows, estimates of appropriate discount rates used to present
value expected future cash flow streams, the timing of approvals
for IPR&D projects and the timing of related product launch
dates and other factors. Contingent consideration obligations
primarily relate to anticipated future milestone payments and
royalty payments due to Columbia in accordance with the terms of
the Columbia acquisition agreement.
Other long-term liabilities at December 31, 2010 include
the fair value of the Columbia contingent consideration
liability of $46.5 million (which excludes the current
amount of $28.9 million presented within accounts payable
and current liabilities).
NOTE 11
Income Taxes
The Companys income before provision for income taxes was
generated from the United States and international operations as
follows:
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Companys provision for income taxes consisted of the
following:
Years Ended December 31,
2010
2009
2008
(In millions)
Current provision:
Federal
$
161.4
$
133.0
$
101.3
State
14.9
20.2
14.3
Foreign
9.3
6.4
0.8
Total current provision
185.6
159.6
116.4
Deferred (benefit) provision:
Federal
(54.1
)
(7.8
)
3.1
State
(10.2
)
(5.5
)
0.4
Foreign
(54.0
)
(5.7
)
Total deferred (benefit) provision
(118.3
)
(19.0
)
3.5
Total provision for income taxes
$
67.3
$
140.6
$
119.9
The exercise of certain stock options resulted in a tax benefit
and has been reflected as a reduction of income taxes payable
and an increase to additional paid-in capital. Such benefits
recorded were $6.7 million, $2.3 million, and
$0.2 million for the years ended December 31, 2010,
2009, and 2008, respectively.
Reconciliations between the statutory federal income tax rate
and the Companys effective income tax rate were as follows:
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Deferred tax assets and liabilities are measured based on the
difference between the financial statement and tax basis of
assets and liabilities at the applicable tax rates.
The
significant components of the Companys net deferred tax
assets (liabilities) consisted of the following:
December 31,
2010
2009
(In millions)
Benefits from net operating loss and tax credit carryforwards
$
94.2
$
86.9
Differences in financial statement and tax accounting for:
Inventories, receivables and accruals
145.6
101.6
Property, equipment and intangible assets
(305.7
)
(366.1
)
Deferred revenue
12.9
12.1
Deferred interest expense
(76.3
)
(76.3
)
Share-based compensation
12.8
10.5
Other
4.3
14.4
Total deferred tax liability, gross
(112.2
)
(216.9
)
Less: Valuation allowance
(29.7
)
(28.4
)
Total deferred tax liability, net
$
(141.9
)
$
(245.3
)
The Company had the following carryforward tax attributes at
December 31, 2010:
$197.0 million state tax net operating losses
(NOLs) which begin to expire in 2011;
$96.0 million foreign tax NOLs which begin to expire in
2011; and
Tax credits of $36.0 million in foreign jurisdictions which
are not subject to expiration.
A valuation allowance has been established due to the
uncertainty of realizing certain net operating losses, tax
credits and deferred tax assets relating to some impaired
investments.
Deferred income taxes have not been provided on the
undistributed earnings of certain of the Companys foreign
subsidiaries of approximately $89.3 million and
$36.1 million as of December 31, 2010 and 2009,
respectively. These amounts have been indefinitely reinvested.
It is not practicable to calculate the deferred taxes associated
with these earnings; however, foreign tax credits would likely
be available to reduce federal income taxes in the event of
distribution.
Accounting
for Uncertainty in Income Taxes
At December 31, 2010, 2009 and 2008, the liability for
income tax associated with uncertain tax positions was
$68.0 million, $72.2 million and $61.3 million,
respectively. As of December 31, 2010, the net amount of
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
$60.2 million, if recognized, would favorably affect the
Companys effective tax rate. A reconciliation of the
beginning and ending amount of unrecognized tax benefits is as
follows:
December 31,
2010
2009
2008
(In millions)
Balance at the beginning of the year
$
72.2
$
61.3
$
71.2
Increases for current year tax positions
5.9
6.9
5.0
Increases for prior year tax positions
20.1
12.7
7.8
Decreases for prior year tax positions
(27.5
)
(3.9
)
(11.9
)
Settlements
(2.3
)
(4.4
)
(10.8
)
Lapse of applicable statue of limitations
(0.4
)
(0.4
)
Balance at the end of the year
$
68.0
$
72.2
$
61.3
The Companys continuing practice is to recognize interest
and penalties related to uncertain tax positions in tax expense.
During the years ended December 31, 2010, 2009 and 2008,
the company recognized approximately ($2.3) million,
$1.4 million and ($0.8) million in interest and
penalties, respectively. At December 31, 2010, 2009 and
2008 the Company had accrued $2.4 million (net of tax
benefit of $1.8 million), $5.1 million (net of tax
benefit of $3.1 million), and $3.9 million (net of tax
benefit of $2.3 million) of interest and penalties related
to uncertain tax positions, respectively.
The Company conducts business globally and, as a result, it
files federal, state and foreign tax returns. The Company
strives to resolve open matters with each tax authority at the
examination level and could reach agreement with a tax authority
at any time. While the Company has accrued for amounts it
believes are the probable outcomes, the final outcome with a tax
authority may result in a tax liability that is more or less
than that reflected in the consolidated financial statements.
Furthermore, the Company may later decide to challenge any
assessments, if made, and may exercise its right to appeal. The
uncertain tax positions are reviewed quarterly and adjusted as
events occur that affect potential liabilities for additional
taxes, such as lapsing of applicable statutes of limitations,
proposed assessments by tax authorities, negotiations with or
between tax authorities and issuance of new legislation,
regulations, rulings or case law. Management believes that
adequate amounts of tax and related penalty and interest have
been provided for any adjustments that may result from these
uncertain tax positions.
With few exceptions, the Company is no longer subject to
U.S. federal, state and local, or
non-U.S. income
tax examinations for years before 2003. During the third quarter
of 2010, the Internal Revenue Service (IRS)
completed its examination of the Andrx Corporations tax
returns for the pre-acquisition period and the Joint Committee
of Taxation completed its review of the Companys tax
returns for the
2004-2006
periods. As a result, the Company recorded a reduction to its
income tax expense of $4.7 million relating to the
completion of the Andrx examination and $13.9 million
relating to the Companys examination.
In the fourth quarter of 2010, the IRS began examining the
Companys 2007, 2008, and 2009 tax years. While it is often
difficult to predict the final outcome or the timing of
resolution of any particular uncertain tax position, the Company
has accrued for amounts it believes are the probable outcomes.
As a result of the ongoing IRS exam, the potential completion
and/or
settlement of other examinations in state and foreign
jurisdictions, and the future completion of the Companys
assessment of the uncertain tax positions of the Arrow Group,
the quantification of all those potential changes cannot be
estimated at this time.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
NOTE 12
Stockholders Equity
Preferred
stock
In 1992, the Company authorized 2.5 million shares of no
par preferred stock. The Board has the authority to fix the
rights, preferences, privileges and restrictions, including but
not limited to, dividend rates, conversion and voting rights,
terms and prices of redemptions and liquidation preferences
without vote or action by the stockholders. On December 2,
2009 the Company issued 0.2 million shares of
Mandatorily Redeemable Preferred Stock. The Mandatorily
Redeemable Preferred Stock is redeemable in cash on
December 2, 2012 and is accordingly, included within
long-term debt in the consolidated balance sheet at
December 31, 2010 (for additional information on the
Mandatorily Redeemable Preferred Stock refer to
NOTE 9 Long-Term Debt).
Stock
option plans
The Company has adopted several stock option plans, all of which
have been approved by the Companys shareholders that
authorize the granting of options to purchase the Companys
common shares subject to certain conditions. At
December 31, 2010, the Company had reserved
5.2 million of its common shares for issuance upon exercise
of options granted or to be granted under these plans and for
restricted stock grants (see discussion below). The option award
plans require options to be granted at the fair value of the
shares underlying the options at the date of the grant and
generally become exercisable over periods ranging from three to
five years and expire in ten years. In conjunction with certain
of the Companys acquisitions, Watson assumed stock option
and warrant plans from the acquired companies. The options and
warrants in these plans were adjusted by the individual exchange
ratios specified in each transaction. No additional options or
warrants will be granted under any of the assumed plans.
A summary of the Companys stock option plans consisted of
the following (options and aggregate intrinsic value in
millions):
Weighted
Weighted Average
Average
Remaining
Aggregate
Exercise
Contractual
Intrinsic
Options
Price
Term (Years)
Value
Outstanding, December 31, 2009
5.3
$
36.91
Granted
Exercised
(1.7
)
33.30
Cancelled
(0.5
)
49.49
Outstanding, December 31, 2010
3.1
$
36.63
3.2
$
48.6
Vested and expected to vest at December 31, 2010
3.0
$
36.71
3.1
$
47.6
Options exercisable at December 31, 2010
2.8
$
37.30
2.8
$
42.0
As of December 31, 2010, the Company had $0.5 million
of total unrecognized compensation expense, net of estimated
forfeitures, related to stock option grants, which will be
recognized over the remaining weighted average period of
1.1 years. Total intrinsic value of options exercised for
the year ended December 31, 2010 and 2009 was
$18.4 million and $7.4 million, respectively.
Restricted
Stock Plan
Beginning in 2005, the Compensation Committee of the Board
authorized and issued restricted stock to the Companys
Participants under the Companys equity compensation plans.
The restricted stock award program offers Participants the
opportunity to earn shares of our common stock over time, rather
than options that give Participants the right to purchase stock
at a set price. Restricted stock awards are grants that entitle
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the holder to shares of common stock subject to certain terms.
Watsons restricted stock awards generally have
restrictions eliminated over a one- to four-year period.
Restrictions generally lapse for non-employee directors after
one year. Restrictions generally lapse for employees over a two-
to four-year period. The fair value of restricted stock grants
is based on the fair market value of our common stock on the
respective grant dates. Restricted stock compensation is being
amortized and charged to operations over the same period as the
restrictions are eliminated for the Participants.
A summary of the changes in restricted stock grants during the
year ended December 31, 2010 is presented below (shares and
aggregate intrinsic value in millions):
Weighted
Weighted
Average
Average
Remaining
Aggregate
Grant Date
Contractual
Intrinsic
Shares
Fair Value
Term (Years)
Value
Restricted shares outstanding at December 31, 2009
1.9
$
28.79
1.7
$
55.7
Granted
1.0
41.03
43.7
Vested
(0.4
)
27.74
(12.9
)
Cancelled
(0.2
)
31.55
(6.9
)
Restricted shares outstanding at December 31, 2010
2.3
$
34.33
1.6
$
79.6
As of December 31, 2010, the Company had $28.6 million
of total unrecognized compensation expense, net of estimated
forfeitures, related to restricted stock grants, which will be
recognized over the remaining weighted average period of
1.6 years.
Stock
Repurchases
During the years ended December 31, 2010 and 2009, the
Company repurchased approximately 0.1 million and
0.1 million shares, respectively, of its common stock
surrendered to the Company to satisfy tax withholding
obligations in connection with the vesting of restricted stock
issued to employees for total consideration of $6.3 million
and $3.6 million, respectively.
Accumulated
Other Comprehensive Income (Loss)
Accumulated other comprehensive income (loss) at
December 31, 2010 consists of unrealized gains on
securities of $9.2 million and foreign currency translation
adjustments of ($11.7) million.
NOTE 13
Reportable Segments
Watson has three reportable segments: Global Generics, Global
Brands and Distribution. The Global Generics segment includes
off-patent pharmaceutical products that are therapeutically
equivalent to proprietary products. The Global Brands segment
includes patent-protected products and certain trademarked
off-patent products that Watson sells and markets as brand
pharmaceutical products. The Distribution segment mainly
distributes generic pharmaceutical products manufactured by
third parties, as well as by Watson, primarily to independent
pharmacies, pharmacy chains, pharmacy buying groups and
physicians offices under the Anda trade name. Sales are
principally generated through an in-house telemarketing staff
and through internally developed ordering systems. The
Distribution segment operating results exclude sales by Anda of
products developed, acquired, or licensed by Watsons
Global Generics and Global Brands segments. Arrow operating
results are included in the Global Generics segment subsequent
to the date of acquisition except for operating results from
Eden which are included in our Global Brands segment.
The accounting policies of the operating segments are the same
as those described in NOTE 2 Summary of
Significant Accounting Policies. The other revenue
classification consists primarily of milestone payments,
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
commission revenue, royalties and revenues from research,
development and licensing fees and also includes co-promotion
revenue and revenue (including the amortization of deferred
revenue) relating to our obligation to manufacture and supply
products to third parties. The Company evaluates segment
performance based on segment contribution. Segment contribution
represents segment net revenues less cost of sales (excludes
amortization), direct R&D expenses and selling and
marketing expenses. The Company does not report total assets,
capital expenditures, corporate general and administrative
expenses, amortization, gains on disposal or impairment losses
by segment as such information has not been used by management,
or has not been accounted for at the segment level.
Segment net revenues, segment operating expenses and segment
contribution information for the Companys Global Generics,
Global Brands and Distribution segments consisted of the
following:
Years Ended December 31,
2010
2009
2008
(In millions)
Global Generics Segment
Product sales
$
2,268.9
$
1,641.8
$
1,404.0
Other revenue
69.5
26.4
70.3
Net revenues
2,338.4
1,668.2
1,474.3
Operating expenses:
Cost of sales(1)
1,198.9
947.1
883.8
Research and development
194.6
140.4
119.2
Selling and marketing
111.9
53.8
55.2
Global Generics Contribution
$
833.0
$
526.9
$
416.1
Contibution margin
35.6
%
31.6
%
28.2
%
Global Brands Segment
Product sales
$
316.3
$
393.7
$
397.0
Other revenue
81.5
67.3
58.0
Net revenues
397.8
461.0
455.0
Operating expenses:
Cost of sales(1)
88.4
89.3
107.1
Research and development
101.5
56.9
50.9
Selling and marketing
137.8
144.5
118.2
Global Brands Contribution
$
70.1
$
170.3
$
178.8
Contibution margin
17.6
%
36.9
%
39.3
%
Distribution Segment
Product sales
$
830.7
$
663.8
$
606.2
Other revenue
Net revenues
830.7
663.8
606.2
Operating expenses:
Cost of sales(1)
711.2
560.4
511.9
Research and development
Selling and marketing
70.3
64.8
59.5
Distribution Contribution
$
49.2
$
38.6
$
34.8
Contibution margin
5.9
%
5.8
%
5.7
%
Total Segment Contribution
$
952.3
$
735.8
$
629.7
Corporate general and administrative
436.1
257.1
190.5
Amortization
180.0
92.6
80.7
Loss on asset sales and impairments
30.8
2.2
0.3
Operating income
$
305.4
$
383.9
$
358.2
(1)
Excludes amortization of acquired intangibles including product
rights.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Companys net product sales are represented by the sale
of products in the following geographic areas for the years
ended December 31:
2010
2009
2008
(In millions)
United States
$
2,990.1
$
2,642.2
$
2,384.7
International
425.8
57.1
22.5
$
3,415.9
$
2,699.3
$
2,407.2
The Companys net product sales are represented by the sale
of products in the following therapeutic categories for the
years ended December 31:
2010
2009
2008
(In millions)
Central nervous system
$
907.6
$
836.7
$
795.7
Hormones and synthetic substitutes
682.3
609.8
525.7
Cardiovascular
594.6
269.4
245.5
Anti-infective agents
161.5
133.7
116.8
Urology
127.3
111.4
88.7
Other
942.6
738.3
634.8
$
3,415.9
$
2,699.3
$
2,407.2
NOTE 14
Business Restructuring Charges
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities involving facilities at Carmel, New York;
Mississauga, Canada; and Melbourne, Australia for the year ended
December 31, 2010 as follows:
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities at Carmel, New York and Brewster, New York for the
year ended December 31, 2009 as follows:
Accrual
Accrual
Balance at
Balance at
December 31,
Charged
Cash
Non-Cash
December 31,
2008
to Expense
Payments
Adjustments
2009
(In millions)
Cost of sales
$
14.6
$
29.3
$
(22.4
)
$
(7.2
)
$
14.3
Operating expenses
R&D
0.7
2.3
(1.8
)
(0.4
)
0.8
Selling, general and administrative
0.8
1.0
(1.0
)
0.8
Total restructuring activity
$
16.1
$
32.6
$
(25.2
)
$
(7.6
)
$
15.9
Product transfer costs consist of documentation, testing and
shipping costs to transfer product to other facilities.
Operating expenses include severance, retention and accelerated
depreciation. Retention is expensed only to the extent earned by
employees. Activity related to our business restructuring and
facility rationalization activities is primarily attributable to
our Global Generics segment.
During the first quarter of 2008, we announced steps to improve
our operating cost structure and achieve operating efficiencies
through our Global Supply Chain Initiative (GSCI).
These 2008 GSCIs include the planned closure of
manufacturing facilities in Carmel, New York, our distribution
center in Brewster, New York and the transition of
manufacturing to our other manufacturing locations within the
U.S. and India. Distribution activities at our distribution
center in Brewster, New York ceased in July 2009. Product
manufacturing ceased in Carmel, New York by December 31,
2010 and we expect a closure of the facility by early 2011.
During the second quarter of 2010, the Company announced
additional measures to reduce its cost structure involving a
manufacturing facility and certain R&D activities in Canada
and certain R&D activities in Australia. In January 2011,
the Company announced the closure of R&D activities in
Corona, California. These additional restructuring activities,
and the transfer of development activities to existing R&D
sites, are expected to be completed in Australia by early 2011,
in Corona by the end of 2011 and in Canada by late 2012.
NOTE 15
Fair Value Measurement
In September 2006, the FASB issued authoritative guidance for
fair value measurements, which defines fair value, establishes a
framework for measuring fair value in U.S. GAAP and expands
disclosures about fair value measurements. The Company adopted
the provisions of the guidance effective January 1, 2008
for all financial assets and liabilities and any other assets
and liabilities that are recognized or disclosed at fair value
on a recurring basis. The Company adopted the provisions of the
guidance for nonfinancial assets and liabilities measured at
fair value on a non-recurring basis effective January 1,
2009. Although the adoption of the guidance did not materially
impact the Companys financial condition, results of
operations or cash flows, we are required to provide additional
disclosures within our consolidated financial statements.
The guidance defines fair value as the price that would be
received to sell an asset or paid to transfer the liability (an
exit price) in an orderly transaction between market
participants and also establishes a fair value hierarchy which
requires an entity to maximize the use of observable inputs and
minimize the use of unobservable inputs when measuring fair
value. The fair value hierarchy within the guidance
distinguishes three levels of inputs that may be utilized when
measuring fair value, including level 1 inputs (using
quoted prices in active markets for identical assets or
liabilities), level 2 inputs (using inputs other than
level 1 prices such as quoted prices for similar assets and
liabilities in active markets or inputs that are observable for
the asset or liability) and level 3 inputs (using
unobservable inputs supported by little or no market activity
based
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
on our own assumptions used to measure assets and liabilities).
A financial asset or liabilitys classification within the
above hierarchy is determined based on the lowest level input
that is significant to the fair value measurement.
Financial assets and liabilities measured at fair value or
disclosed at fair value on a recurring basis as at
December 31, 2010 and 2009 consisted of the following (in
millions):
Fair Value Measurements as at December 31, 2010
Using:
Total
Level 1
Level 2
Level 3
Assets:
Marketable securities
$
11.1
$
11.1
$
$
Investments
23.1
23.1
Liabilities:
Contingent consideration
198.5
198.5
Fair Value Measurements as at December 31, 2009
Using:
Total
Level 1
Level 2
Level 3
Assets:
Marketable securities
$
13.6
$
13.6
$
$
Investments
3.0
3.0
Liabilities:
Contingent consideration
111.0
111.0
Marketable securities and investments consist of
available-for-sale
investments in U.S. Treasury and agency securities and
publicly traded equity securities for which market prices are
readily available. Unrealized gains or losses on marketable
securities and investments are recorded in accumulated other
comprehensive (loss) income.
The fair value measurement of the contingent consideration
obligations is determined using Level 3 inputs. The fair
value of contingent consideration obligations is based on a
probability-weighted income approach. The measurement is based
upon unobservable inputs supported by little or no market
activity based on our own assumptions. Changes in the fair value
of the contingent consideration obligations are recorded as a
component of operating income in our consolidated statement of
operations.
The tables below provide a summary of the changes in fair value,
including net transfers in
and/or out,
of all financial assets and liabilities measured at fair value
on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December 31, 2010
and 2009 (in millions):
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
NOTE 16
Commitments and Contingencies
Facility
and Equipment Leases
The Company has operating leases for certain facilities and
equipment. The terms of the operating leases for the
Companys facilities require the Company to pay property
taxes, normal maintenance expenses and maintain minimum
insurance coverage. Total rental expense for operating leases in
2010, 2009 and 2008 was $26.0 million, $20.0 million
and $19.0 million, respectively.
At December 31, 2010, future minimum lease payments under
all non-cancelable operating leases are approximately,
$24.4 million in 2011, $18.6 million in 2012,
$14.6 million in 2013, $12.5 million in 2014,
$12.8 million in 2015 and $53.0 million thereafter.
Employee
Retirement Plans
The Company maintains certain defined contribution retirement
plans covering substantially all
U.S.-based
employees. The Company contributes to the plans based upon the
employee contributions. Watsons contributions to these
retirement plans were $9.5 million, $11.0 million and
$10.6 million in the years ended December 31, 2010,
2009 and 2008, respectively. The Company does not sponsor any
defined benefit retirement plans or postretirement benefit plans.
Legal
Matters
Watson and its affiliates are involved in various disputes,
governmental
and/or
regulatory inspections, inquires, investigations and
proceedings, and litigation matters that arise from time to time
in the ordinary course of business. The process of resolving
matters through litigation or other means is inherently
uncertain and it is possible that an unfavorable resolution of
these matters will adversely affect the Company, its results of
operations, financial condition and cash flows. The
Companys regular practice is to expense legal fees as
services are rendered in connection with legal matters, and to
accrue for liabilities when losses are probable and reasonably
estimable.
Cipro®Litigation. Beginning in July 2000, a number
of suits were filed against Watson, The Rugby Group, Inc.
(Rugby) and other company affiliates in various
state and federal courts alleging claims under various federal
and state competition and consumer protection laws. Several
plaintiffs have filed amended complaints and motions seeking
class certification. Approximately 42 cases have been filed
against Watson, Rugby and other Watson entities. Twenty-two of
these actions have been consolidated in the U.S. District
Court for the Eastern District of New York (In re:
Ciprofloxacin Hydrochloride Antitrust Litigation, MDL Docket
No. 001383). On May 20, 2003, the court hearing
the consolidated action granted Watsons motion to dismiss
and made rulings limiting the theories under which plaintiffs
can seek recovery against Rugby and the other defendants. On
March 31, 2005, the court hearing the consolidated action
granted summary judgment in favor of the defendants on all of
plaintiffs claims and denied the plaintiffs motions
for class certification. On May 7, 2005, three groups of
plaintiffs from the consolidated action (the direct purchaser
plaintiffs, the indirect purchaser plaintiffs and plaintiffs
Rite Aid and CVS) filed notices of appeal in the United States
Court of Appeals for the Second Circuit, appealing, among other
things, the May 20, 2003 order dismissing Watson and the
March 31, 2005 order granting summary judgment in favor of
the defendants. On November 7, 2007, the U.S. Court of
Appeals for the Second Circuit ordered the appeal by the
indirect purchaser plaintiffs transferred to the United States
Court of Appeals for the Federal Circuit. On October 15,
2008, the United States Court of Appeals for the Federal
Circuit affirmed the dismissal of the indirect purchasers
claims, and on December 22, 2008, denied the indirect
purchaser plaintiffs petition for rehearing and rehearing
en banc. On June 22, 2009, the Supreme Court denied the
indirect purchaser plaintiffs petition for writ of
certiorari. In the appeal in the United States Court of Appeals
for the Second Circuit by the direct purchaser plaintiffs and
plaintiffs CVS and Rite Aid, on April 29, 2010, the United
States Court of Appeals
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
for the Second Circuit affirmed the ruling of the District Court
granting summary judgment in favor of the defendants, and on
September 7, 2010, denied the appellants petition for
rehearing en banc. On December 6, 2010, the appellants
filed a petition for writ of certiorari with the United States
Supreme Court seeking review of the Second Circuits
decision. The defendants filed their opposition to the petition
on February 7, 2011. Other actions are pending in various
state courts, including California, Kansas, Tennessee, and
Florida. The actions generally allege that the defendants
engaged in unlawful, anticompetitive conduct in connection with
alleged agreements, entered into prior to Watsons
acquisition of Rugby from Sanofi Aventis (Sanofi),
related to the development, manufacture and sale of the drug
substance ciprofloxacin hydrochloride, the generic version of
Bayers brand drug,
Cipro®.
The actions generally seek declaratory judgment, damages,
injunctive relief, restitution and other relief on behalf of
certain purported classes of individuals and other entities. In
the action pending in Kansas, the court has administratively
terminated the matter pending the outcome of the appeals in the
consolidated case. In the action pending in the California
Superior Court for the County of San Diego (In re: Cipro
Cases I & II, JCCP Proceeding Nos. 4154 &
4220), on July 21, 2004, the California Court of Appeal
ruled that the majority of the plaintiffs would be permitted to
pursue their claims as a class. On August 31, 2009, the
California Superior Court granted defendants motion for
summary judgment, and final judgment was entered on
September 24, 2009. On November 19, 2009, the
plaintiffs filed a notice of appeal. The appeal remains pending.
In addition to the pending actions, Watson understands that
various state and federal agencies are investigating the
allegations made in these actions. Sanofi has agreed to defend
and indemnify Watson and its affiliates in connection with the
claims and investigations arising from the conduct and
agreements allegedly undertaken by Rugby and its affiliates
prior to Watsons acquisition of Rugby, and is currently
controlling the defense of these actions.
Governmental Reimbursement Investigations and Drug Pricing
Litigation. In November 1999,
Schein Pharmaceutical, Inc., now known as Watson Pharma,
Inc. (Watson Pharma) was informed by the
U.S. Department of Justice that it, along with numerous
other pharmaceutical companies, is a defendant in a qui tam
action brought in 1995 under the U.S. False Claims Act
currently pending in the U.S. District Court for the
Southern District of Florida. Watson Pharma has not been served
in the qui tam action. A qui tam action is a civil
lawsuit brought by an individual or a company (the qui tam
relator) for an alleged violation of a federal statute, in
which the U.S. Department of Justice has the right to
intervene and take over the prosecution of the lawsuit at its
option. Pursuant to applicable federal law, the qui tam
action is under seal as to Watson Pharma. The Company
believes that the qui tam action relates to whether
allegedly improper price reporting by pharmaceutical
manufacturers led to increased payments by Medicare
and/or
Medicaid. The qui tam action may seek to recover damages
from Watson Pharma based on its price reporting practices.
Watson Pharma subsequently also received and responded to
notices or subpoenas from the Attorneys General of various
states, including Florida, Nevada, New York, California and
Texas, relating to pharmaceutical pricing issues and whether
allegedly improper actions by pharmaceutical manufacturers led
to excessive payments by Medicare
and/or
Medicaid. On June 26, 2003, the Company received a request
for records and information from the U.S. House Committee
on Energy and Commerce in connection with that committees
investigation into pharmaceutical reimbursements and rebates
under Medicaid. The Company produced documents in response to
the request. Other state and federal inquiries regarding pricing
and reimbursement issues are anticipated.
Beginning in July 2002, the Company and certain of its
subsidiaries, as well as numerous other pharmaceutical
companies, were named as defendants in various state and federal
court actions alleging improper or fraudulent reporting
practices related to the reporting of average wholesale prices
and wholesale acquisition costs of certain products, and that
the defendants committed other improper acts in order to
increase prices and market shares. Some of these actions have
been consolidated in the U.S. District Court for the
District of Massachusetts (In re: Pharmaceutical Industry
Average Wholesale Price Litigation, MDL Docket
No. 145). The consolidated amended Class Action
complaint in that case alleges that the defendants acts
improperly inflated the reimbursement amounts of certain drugs
paid by various public and private plans and programs. Certain
defendants, including the Company, have entered into a
settlement agreement resolving
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
all claims against them in the Consolidated Class Action.
The total amount of the settlement for all of the settling
defendants is $125 million. The amount to be paid by each
settling defendant is confidential. On July 2, 2008, the
United States District Court for the District of Massachusetts
preliminarily approved the Track Two settlement. On
April 27, 2009, the Court held a hearing to further
consider the fairness of the proposed settlement. The Court
adjourned the hearing without ruling on the fairness of the
proposed settlement until additional notices are provided to
certain of the class members in the action. The settlement is
not expected to materially adversely affect the Companys
business, results of operations, financial condition and cash
flows.
The Company and certain of its subsidiaries also are named as
defendants in various lawsuits filed by numerous states and qui
tam relators, including Texas, Kansas, Nevada, Montana,
Massachusetts, Wisconsin, Kentucky, Alabama, Illinois,
Mississippi, Florida, Arizona, Missouri, Alaska, Idaho, South
Carolina, Hawaii, Utah, Iowa, Oklahoma and Louisiana captioned
as follows: State of Nevada v. American Home Products,
et al., Civil Action
No. 02-CV-12086-PBS,
United States District Court for the District of Massachusetts;
State of Montana v. Abbott Laboratories, et al., Civil
Action
No. 02-CV-12084-PBS,
United States District Court for the District of Massachusetts;
Commonwealth of Massachusetts v. Mylan Laboratories, et
al., Civil Action
No. 03-CV-11865-PBS,
United States District Court for the District of Massachusetts;
State of Wisconsin v. Abbott Laboratories, et al., Case
No. 04-cv-1709,
Wisconsin Circuit Court for Dane County; Commonwealth of
Kentucky v. Alpharma, Inc., et al., Case Number 04-CI-1487,
Kentucky Circuit Court for Franklin County; State of
Alabama v. Abbott Laboratories, Inc. et al., Civil Action
No. CV05-219,
Alabama Circuit Court for Montgomery County; State of
Illinois v. Abbott Laboratories, Inc. et al., Civil Action
No. 05-CH-02474,
Illinois Circuit Court for Cook County; State of
Mississippi v. Abbott Laboratories, Inc. et al., Civil
Action
No. G2005-2021
S/2, Mississippi Chancery Court of Hinds County; State of
Florida ex rel.
Ven-A-Care,
Civil Action No
98-3032G,
Florida Circuit Court in Leon County (the Florida
Ven-A-Care
Action); State of Arizona ex rel. Terry Goddard,
No. CV
2005-18711,
Arizona Superior Court for Maricopa County; State of Missouri ex
rel. Jeremiah W. (Jay) Nixon v. Mylan Laboratories, et al,
Case
No. 054-2486,
Missouri Circuit Court of St. Louis; State of
Alaska v. Alpharma Branded Products Division Inc., et
al., In the Superior Court for the State of Alaska Third
Judicial District at Anchorage, C.A.
No. 3AN-06-12026
CI; State of Idaho v. Alpharma USPD Inc. et al., In the
District Court of the Fourth Judicial District of the State of
Idaho, in and for the County of Ada, C.A.
No. CV0C-0701847;
State of South Carolina and Henry D. McMaster v. Watson
Pharmaceuticals (New Jersey), Inc., In the Court of Common Pleas
for the Fifth Judicial Circuit, State of South Carolina, County
of Richland, C.A.
No. 2006-CP-40-7152;
State of South Carolina and Henry D. McMaster v. Watson
Pharmaceuticals (New Jersey), Inc., In the Court of Common Pleas
for the Fifth Judicial Circuit, State of South Carolina, County
of Richland, C.A.
No. 2006-CP-40-7155;
State of Hawaii v. Abbott Laboratories, Inc. et al., In the
Circuit Court of the First Circuit, State of Hawaii, C.A.
No. 06-1-0720-04
EEH; State of Utah v. Actavis U.S., Inc., et al., In the
Third Judicial District Court of Salt Lake County, Civil
No. 07-0913719;
State of Iowa v. Abbott Laboratories, Inc., et al., In the
U.S. District Court for the Southern District of Iowa,
Central Division, Case
No. 07-CV-00461
(the Iowa AG Action); State of Texas ex rel.
Ven-A-Care
of the Florida Keys, Inc. v. Alpharma Inc., et al, Case
No. 08-001565,
in the District Court of Travis County, Texas (the Texas
Ven-A-Care
Action); United States of America ex rel.
Ven-A-Care
of the Florida Keys, Inc.,v. Actavis Mid-Atlantic LLC, Civil
Action
No. 08-10852,
in the U.S. District Court for the District of
Massachussetts (the Federal
Ven-A-Care
Action); State of Kansas ex rel. Steve Six v.
Watson Pharmaceuticals, Inc. and Watson Pharma, Inc., Case
Number: 08CV2228, District Court of Wyandotte County, Kansas,
Civil Court Department; State of Oklahoma, ex rel., W.A. Drew
Edmondson, Attorney General of Oklahoma v. Abbott
Laboratories, Inc., et al., Case
No. CJ-2010-474,
District Court of Pottawatomie County, Oklahoma, and State of
Louisiana V. Abbott Laboratories, Inc., et al., Case
No. 596144, Parish of East Baton Rouge,
19thJudicial District. In December of 2010, the State of Utah
served the Company with a Civil Investigative Demand seeking
additional information relating to the Companys pricing
practices.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
On August 4, 2004, the City of New York filed an action
against the Company and numerous other pharmaceutical defendants
alleging similar claims. The case has been consolidated with
similar cases filed by forty one individual New York counties.
(City of New York v. Abbott Laboratories, Inc., et al.,
Civil Action
No. 01-CV-12257-PBS,
United States District Court for the District of
Massachusetts) (hereinafter the Consolidated NY
Counties Actions), as well as by four additional New York
counties, with three of these cases pending in New York state
courts. On January 27, 2010, the U.S. District Court
granted Plaintiffs motion in the Consolidated NY Counties
Actions for partial summary judgment as to each of the generic
defendants, including Watson, with respect to some of
Watsons drugs reimbursed at the Federal Upper Limit, and
found violations of New Yorks state false claims act
statute.
In August 2010, the Company reached an agreement in principle to
settle each of the following pending actions: the Texas
Ven-a-Care
Action, the Florida
Ven-a-Care
Action, the Federal
Ven-A-Care
Action, the Iowa AG Action, and the Consolidated New York
Counties Action (collectively the
Ven-A-Care
Settlement). The
Ven-A-Care
Settlement was contingent upon approval of the United States
Department of Justice and the execution of definitive settlement
documents. In December of 2010, after the parties failed to
finalize the
Ven-A-Care
Settlement, the Company reached an agreement in principle to
settle the following pending actions: the Texas
Ven-a-Care
Action, the Florida
Ven-a-Care
Action, the Iowa AG Action, and the Consolidated New York
Counties Action (the State
Ven-A-Care
Settlement). In addition, at the same time the Company
reached an agreement in principle to settle claims pending in
the Federal
Ven-A-Care
Action relative to the Texas, Florida, Iowa and New York
Medicaid programs (the Federal
Ven-A-Care
Settlement, and collectively with the State
Ven-A-Care
Settlement, the December 2010
Ven-A-Care
Settlement). The total amount to be paid by the Company
under the terms of the proposed December 2010
Ven-A-Care
Settlement is $79 million. The December 2010
Ven-A-Care
Settlement is contingent upon obtaining final approval by the
U.S. Department of Justice and the execution of definitive
settlement documents.
The cases against the Company on behalf of Arizona, Hawaii and
Massachusetts have been settled. The case against the Company on
behalf of Alabama was tried in 2009. The jury was unable to
reach a verdict, and the court declared a mistrial and ordered
the case to be retried. New trials against the Company and
Andrx Corporation, a Company subsidiary, are scheduled for
May and August of 2011, respectively. The case against the
Company on behalf of Kentucky is scheduled for trial in November
of 2011. The case against the Company on behalf of Mississippi
is scheduled for trial in June 2011. The case against the
Company on behalf of Alaska is scheduled for trial in January of
2012. The case against the Company on behalf of Idaho is
scheduled for trial in March 2012. The case against the Company
on behalf of Missouri is scheduled for trial in June of 2012.
The Company has accrued a $129.9 million liability reserve
on its balance sheet in connection with the December 2010
Ven-A-Care
Settlement and the remaining drug pricing actions. The December
2010
Ven-A-Care
Settlement will resolve a considerable portion of the damages
claims asserted against the Company and its affiliates in the
various pending pricing litigations. With regard to the
remaining drug pricing actions, the Company believes that it has
meritorious defenses and intends to vigorously defend itself in
those actions. The Company continually monitors the status of
these actions and may settle or otherwise resolve some or all of
these matters on terms that the Company deems to be in its best
interests. However, the
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Company can give no assurance that it will be able to settle the
remaining actions on terms it deems reasonable, or that such
settlements or adverse judgments in the remaining actions, if
entered, will not exceed the amounts of the liability reserves.
Additional actions by other states, cities
and/or
counties are anticipated. These actions
and/or the
actions described above, if successful, could adversely affect
the Company and could have a material adverse effect on the
Companys business, results of operations, financial
condition and cash flows.
Medicaid Drug Reimbursement Litigation. In
December 2009, the Company learned that numerous pharmaceutical
companies, including certain subsidiaries of the Company, have
been named as defendants in a qui tam action pending in the
United States District Court for the District of Massachusetts
(United States of America ex rel. Constance A. Conrad v.
Actavis Mid-Atlantic, LLC, f/k/a Biovail Pharmaceuticals, LLC,
et. al.,USDC Case
No. 02-CV-11738-NG).
The seventh amended complaint, which was served on certain
of the Companys subsidiaries in December 2009, alleges
that the defendants falsely reported to the United States that
certain pharmaceutical products were eligible for Medicaid
reimbursement and thereby allegedly caused false claims for
payment to be made through the Medicaid program. In December
2010 the plaintiff served a ninth amended complaint that unseals
the action in its entirety and continues to allege the
previously asserted claims against certain subsidiaries of the
Company. The Company believes that it has meritorious defenses
to the claims and intends to vigorously defend itself in the
action. However, this action, if successful, could adversely
affect the Company and could have a material adverse effect on
the Companys business, results of operations, financial
condition and cash flows.
FDA Matters. In May 2002, Watson reached an
agreement with the FDA on the terms of a consent decree with
respect to its Corona, California manufacturing facility. The
court approved the consent decree on May 13, 2002
(United States of America v. Watson Laboratories, Inc.,
and Allen Y. Chao, United States District Court for the
Central District of California, EDCV-02-412-VAP). The consent
decree with the FDA does not require any fine, a facility
shutdown, product recalls or any reduction in production or
service at the Companys Corona facility. The consent
decree applies only to the Corona facility and not other
manufacturing sites. On July 9, 2008, the court entered an
order dismissing Allen Y. Chao, the Companys former
President and Chief Executive Officer, from the action and from
the consent decree. The decree requires Watson to ensure that
its Corona, California facility complies with the FDAs
current Good Manufacturing Practices (cGMP)
regulations.
Pursuant to the agreement, Watson hired an independent expert to
conduct inspections of the Corona facility at least once each
year. In each year since 2002, the independent expert has
reported its opinion to the FDA that, based on the findings of
the audit of the facility, the FDAs applicable cGMP
requirements, applicable FDA regulatory guidance, and the
collective knowledge, education, qualifications and experience
of the experts auditors and reviewers, the systems at
Watsons Corona facility audited and evaluated by the
expert are in compliance with the FDAs cGMP regulations.
However, the FDA is not required to accept or agree with the
independent experts opinion. The FDA has conducted
periodic inspections of the Corona facility since the entry of
the consent decree. The FDAs most recent inspection was
conducted from August 2, 2010 through August 13, 2010.
At the conclusion of the inspection no formal observations were
made and no FDA Form 483 was issued. However, if in the
future, the FDA determines that, with respect to its Corona
facility, Watson has failed to comply with the consent decree or
FDA regulations, including cGMPs, or has failed to adequately
address the FDAs inspectional observations, the consent
decree allows the FDA to order Watson to take a variety of
actions to remedy the deficiencies. These actions could include
ceasing manufacturing and related operations at the Corona
facility, and recalling affected products. Such actions, if
taken by the FDA, could have a material adverse effect on the
Company, its results of operations, financial position and cash
flows.
Federal Trade Commission Investigations. The
Company has received Civil Investigative Demands or requests for
information from the Federal Trade Commission seeking
information and documents related to the terms on which the
Company has settled lawsuits initiated by patentees under the
Hatch-Waxman Act, and
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
other commercial arrangements between the Company and third
parties. These investigations include the Companys August
2006 settlement with Cephalon, Inc. related to the
Companys generic version of
Provigil®
(modafinil). The Company believes these agreements comply with
applicable laws and rules. However, if the Federal Trade
Commission concludes that any of these agreements violate
applicable antitrust laws or rules, it could initiate legal
action against the Company. These actions, if successful, could
have a material adverse effect on the Companys business,
results of operations, financial condition and cash flows.
Androgel®Antitrust Litigation. On January 29,
2009, the U.S. Federal Trade Commission and the State of
California filed a lawsuit in the United States District Court
for the Central District of California (Federal Trade
Commission, et. al. v. Watson Pharmaceuticals, Inc., et.
al., USDC Case No. CV
09-00598)
alleging that the Companys September 2006 patent
lawsuit settlement with Solvay Pharmaceuticals, Inc., related to
AndroGel®
1% (testosterone gel) CIII is unlawful. The complaint generally
alleged that the Company improperly delayed its launch of a
generic version of
Androgel®
in exchange for Solvays agreement to permit the Company to
co-promote
Androgel®
for consideration in excess of the fair value of the services
provided by the Company, in violation of federal and state
antitrust and consumer protection laws. The complaint sought
equitable relief and civil penalties. On February 2 and 3, 2009,
three separate lawsuits alleging similar claims were filed in
the United States District Court for the Central District of
California by various private plaintiffs purporting to represent
certain classes of similarly situated claimants (Meijer,
Inc., et. al., v. Unimed Pharmaceuticals, Inc., et. al.,
USDC Case No. EDCV
09-0215);
(Rochester Drug Co-Operative, Inc. v. Unimed
Pharmaceuticals Inc., et. al., Case No. EDCV
09-0226);
(Louisiana Wholesale Drug Co. Inc. v. Unimed
Pharmaceuticals Inc., et. al, Case No. EDCV
09-0228).
On April 8, 2009, the Court transferred the government and
private cases to the United States District Court for the
Northern District of Georgia. On April 21, 2009 the State
of California voluntarily dismissed its lawsuit against the
Company without prejudice. The Federal Trade Commission and the
private plaintiffs in the Northern District of Georgia filed
amended complaints on May 28, 2009. The private plaintiffs
amended their complaints to include allegations concerning
conduct before the U.S. Patent and Trademark Office,
conduct in connection with the listing of Solvays patent
in the Food and Drug Administrations Orange
Book, and sham litigation. Additional actions alleging
similar claims have been filed in various courts by other
private plaintiffs purporting to represent certain classes of
similarly situated direct or indirect purchasers of
Androgel®
(Stephen L. LaFrance Pharm., Inc. d/b/a SAJ Dist. v.
Unimed Pharms., Inc., et al.,D. NJ Civ.
No. 09-1507);
( Fraternal Order of Police, Fort Lauderdale Lodge 31,
Insurance Trust Fund v. Unimed Pharms. Inc., et al.,D.
NJ Civ.
No. 09-1856
); (Scurto v. Unimed Pharms., Inc., et al., D. NJ
Civ.
No. 09-1900);
(United Food and Commercial Workers Unions and Employers
Midwest Health Benefits Fund v. Unimed Pharms., Inc., et
al., D. MN Civ.
No. 09-1168);
( Rite Aid Corp. et al. v. Unimed Pharms., Inc. et
al., M.D. PA Civ.
No. 09-1153);
(Walgreen Co., et al. v. Unimed Pharms.,LLC, et al., MD. PA
Civ.
No. 09-1240);
(Supervalu, Inc. v. Unimed Pharms., LLC, et al, ND.
GA Civ.
No. 10-1024);
(LeGrand v. Unimed Pharms., Inc., et al., ND. GA
Civ.
No. 10-2883);
(Jabos Pharmacy Inc. v. Solvay Pharmaceuticals,
Inc., et al ., Cocke County, TN Circuit Court Case
No. 31,837). On April 20, 2009, the Company was
dismissed without prejudice from the Stephen L. LaFrance
action pending in the District of New Jersey. On
October 5, 2009, the Judicial Panel on Multidistrict
Litigation transferred all actions then pending outside of the
United States District Court for the Northern District of
Georgia to that district for consolidated pre-trial proceedings
(In re: AndroGel
®Antitrust Litigation (No. II), MDL Docket
No. 2084), and all currently-pending related actions
are presently before that court. On February 22, 2010, the
judge presiding over all the consolidated litigations related to
Androgel®
then pending in the United States District Court for the
Northern District of Georgia granted the Companys motions
to dismiss the complaints, except the portion of the private
plaintiffs complaints that include allegations concerning
sham litigation. On July 20, 2010, the plaintiff in the
Fraternal Order of Police action filed an amended
complaint adding allegations concerning conduct before the
U.S. Patent and Trademark Office, conduct in connection
with the listing of Solvays patent in the Food and Drug
Administrations Orange Book, and sham
litigation similar to the claims raised in the direct purchaser
actions. On October 28, 2010, the judge presiding over MDL
2084 entered an order pursuant to which the LeGrand
action, filed on September 10, 2010, was consolidated
for pretrial purposes with the
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
other indirect purchaser class action as part of MDL 2084 and
made subject to the Courts February 22, 2010 order on
the motion to dismiss. Discovery in the private actions is
ongoing. Final judgment in favor of the defendants was entered
in the Federal Trade Commissions action on April 21,
2010. On June 10, 2010, the Federal Trade Commission filed
a notice of appeal to the Eleventh Circuit Court of Appeals,
appealing the district courts dismissal of its complaint.
The appeal is pending.
The Company believes that these actions are without merit and
intends to defend itself vigorously. However, these actions, if
successful, could have a material adverse effect on the
Companys business, results of operations, financial
condition and cash flows.
Hormone Replacement Therapy
Litigation. Beginning in early 2004 a number of
product liability suits were filed against the Company and
certain Company affiliates for personal injuries allegedly
arising out of the use of hormone replacement therapy products,
including but not limited to estropipate and estradiol. These
complaints also name numerous other pharmaceutical companies as
defendants, and allege various injuries, including ovarian
cancer, breast cancer and blood clots. Approximately 100 cases
are pending against Watson
and/or its
affiliates in state and federal courts representing claims by
approximately 100 plaintiffs. Many of the cases involve multiple
plaintiffs. The majority of the cases have been transferred to
and consolidated in the United States District Court for the
Eastern District of Arkansas (In re: Prempro Products
Liability Litigation, MDL Docket No. 1507). Discovery
in these cases is ongoing. The Company believes it has
substantial meritorious defenses to these cases and maintains
product liability insurance against such cases. However,
litigation is inherently uncertain and the Company cannot
predict the outcome of this litigation. These actions, if
successful, or if insurance does not provide sufficient coverage
against such claims, could adversely affect the Company and
could have a material adverse effect on the Companys
business, results of operations, financial condition and cash
flows.
Fentanyl Transdermal System
Litigation. Beginning in 2009, a number of
product liability suits were filed against the Company and
certain Company affiliates, as well as other manufacturers and
distributors of fentanyl transdermal system products, for
personal injuries or deaths allegedly arising out of the use of
the fentanyl transdermal system products. Approximately 38 cases
are pending against the Company
and/or its
affiliates in state and federal courts, representing claims by
approximately 110 plaintiffs. Discovery is ongoing. The Company
believes it has substantial meritorious defenses to these cases
and maintains product liability insurance against such cases.
However, litigation is inherently uncertain and the Company
cannot predict the outcome of this litigation. These actions, if
successful, or if insurance does not provide sufficient coverage
against such claims, could adversely affect the Company and
could have a material adverse effect on the Companys
business, results of operations, financial condition and cash
flows.
Metoclopramide Litigation. Beginning in 2009,
a number of product liability suits were filed against the
Company and certain Company affiliates, as well as other
manufacturers and distributors of metoclopramide, for personal
injuries allegedly arising out of the use of metoclopramide.
Approximately 300 cases are pending against the Company
and/or its
affiliates in state and federal courts, representing claims by
approximately 800 plaintiffs. These cases are generally at
their preliminary stages and discovery is ongoing. The Company
believes that it will be indemnified for the majority of these
claims by Pliva, Inc., an affiliate of Teva Pharmaceutical
Industries, Ltd., from whom the Company purchased its
metoclopramide product in late 2008. Further, the Company
believes that it has substantial meritorious defenses to these
cases and maintains product liability insurance against such
cases. However, litigation is inherently uncertain and the
Company cannot predict the outcome of this litigation. These
actions, if successful, or if our indemnification arrangements
or insurance do not provide sufficient coverage against such
claims, could adversely affect the Company and could have a
material adverse effect on the Companys business, results
of operations, financial condition and cash flows.
Medical West Ballas Pharmacy, LTD, et al. v. Anda, Inc.,
(Circuit Court of the County of St. Louis, State of
Missouri, Case
No. 08SL-CC00257).
In January 2008, Medical West Ballas Pharmacy, LTD, filed a
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
purported class action complaint against the Company alleging
conversion and alleged violations of the Telephone Consumer
Protection Act (TCPA) and Missouri Consumer Fraud
and Deceptive Business Practices Act. In April 2008, plaintiff
filed an amended complaint substituting Anda, Inc., a subsidiary
of the Company, as the defendant. The amended complaint alleges
that by sending unsolicited facsimile advertisements, Anda
misappropriated the class members paper, toner, ink and
employee time when they received the alleged unsolicited faxes,
and that the alleged unsolicited facsimile advertisements were
sent to the plaintiff in violation of the TCPA and Missouri
Consumer Fraud and Deceptive Business Practices Act. The
complaint seeks to assert class action claims on behalf of the
plaintiff and other similarly situated third parties. In April
2008, Anda filed an answer to the amended complaint, denying the
allegations. In November 2009, the court granted
plaintiffs motion to expand the class of plaintiffs from
individuals for which Anda lacked evidence of express permission
or an established business relationship to All persons who
on or after four years prior to the filing of this action, were
sent telephone facsimile messages advertising pharmaceutical
drugs and products by or on behalf of Defendant. In
November 2010, the plaintiff filed a second amended complaint
further expanding the definition and scope of the proposed class
of plaintiffs. On November 30, 2010, Anda filed a petition
with the Federal Communications Commission (FCC),
asking the FCC to clarify the statutory basis for its regulation
requiring opt-out language on faxes sent with
express permission of the recipient. The FCCs ruling on
Andas petition may determine whether fax recipients who
expressly agree to receive faxes may assert claims for receipt
of such faxes pursuant to the TCPA. On December 2, 2010,
Anda filed a motion to dismiss claims the plaintiff is seeking
to assert on behalf of putative class members who expressly
consented or agreed to receive faxes from Defendant, or in the
alternative, to stay the court proceedings pending resolution of
Andas petition to the FCC. The motion remains pending. No
trial date has been set. Anda intends to defend the action
vigorously. However, this action, if successful, could have an
adverse effect on the Companys business, results of
operations, financial condition and cash flows.
Drospirenone/Ethinyl Estradiol Tablets (Generic version of
Yasmin®). On
April 7, 2008, Bayer Schering Pharma AG sued the Company in
the United States District Court for the Southern District of
New York, alleging that sales of the Companys
drospirenone/ethinyl estradiol tablets, a generic version of
Bayers
Yasmin®
tablets, infringes Bayers U.S. Patent
No. 5,569,652 (Bayer Schering Pharma AG v. Watson
Pharmaceuticals, Inc., et. al., Case No. 08cv3710). The
complaint sought damages and injunctive relief. On
September 28, 2010, the district court granted the
Companys motion for judgment on the pleadings and
dismissed the case with prejudice. Final judgment was entered on
January 7, 2011. On January 21, 2011, Bayer filed a
Notice of Appeal with the United States Court of Appeals for the
Second Circuit. The Company believes it has substantial
meritorious defenses to the case. However, the Company has sold
and is continuing to sell its generic version of
Yasmin®.
Therefore, an adverse ruling on the appeal or a subsequent final
determination that the Company has infringed the patent in suit
could have a material adverse effect on the Companys
business, results of operations, financial condition and cash
flows.
Watson and its affiliates are involved in various other
disputes, governmental
and/or
regulatory inspections, inquires, investigations and proceedings
that could result in litigation, and other litigation matters
that arise from time to time. The process of resolving matters
through litigation or other means is inherently uncertain and it
is possible that an unfavorable resolution of these matters will
adversely affect the Company, its results of operations,
financial condition and cash flows.
Agreement and Plan of Merger by and among Watson
Pharmaceuticals, Inc., Water Delaware, Inc. and Andrx
Corporation dated March 12, 2006, is incorporated by reference
to Exhibit 2.1 to the Companys March 13, 2006 Form 8-K.
2
.2
Share Purchase Agreement dated as of June 16, 2009, by and among
Robin Hood Holdings Limited, Watson Pharmaceuticals, Inc.,
certain shareholders of Robin Hood Holdings Limited, and Anthony
Selwyn Tabatznik, solely in his capacity as the
Shareholders Representative, is incorporated by reference
to Exhibit 2.1 to the Companys June 16, 2009 Form 8-K.
2
.3
First Amendment to Share Purchase Agreement, dated as of
November 26, 2009, by and among Robin Hood Holdings Limited,
Arrow Pharmaceutical Holdings Ltd., Cobalt Laboratories, Inc.,
Arrow International Ltd., Arrow Supplies Ltd., Watson
Pharmaceuticals, Inc., Watson Pharma S.À.R.L., Watson
Cobalt Holdings, LLC, the shareholders of Robin Hood Holdings
Limited, and Anthony Selwyn Tabatznik, solely in his capacity as
Shareholders Representative, is incorporated by reference
to Exhibit 2.2 to the Companys November 26, 2009 Form 8-K.
3
.1
Articles of Incorporation of the Company and all amendments
thereto are incorporated by reference to Exhibit 3.1 to the
Companys June 30, 1995 Form 10-Q and to Exhibit 3.1(A) to
the Companys June 30, 1996 Form 10-Q.
3
.2
Second Amended and Restated Bylaws of Watson Pharmaceuticals,
Inc. are incorporated by reference to Exhibit 3.1 to the
Companys March 5, 2009 Form 8-K.
3
.3
Certificate of Designations for Series A Preferred Stock is
incorporated by reference to Exhibit 3.1 to the Companys
November 26, 2009 Form 8-K.
4
.1
Indenture between the Company and Wells Fargo Bank, N.A., as
trustee, dated as of August 24, 2009, is incorporated by
reference to Exhibit 4.1 to the Companys August 18, 2009
Form 8-K.
4
.2
First Supplemental Indenture between the Company and Wells Fargo
Bank, N.A., as trustee, dated as of August 24, 2009, including
the forms of the Companys 5.000% Senior Notes due
2014 and 6.125% Senior Notes due 2019, is incorporated by
reference to Exhibit 4.2 to the Companys August 18,
2009 Form 8-K.
4
.3
Second Supplemental Indenture between the Company and Wells
Fargo Bank, N.A., as trustee, dated as of May 7, 2010, is
incorporated by reference to Exhibit 10. to the Companys
March 31, 2010
10-Q.
4
.4
Shareholders Agreement, dated as of December 2, 2009, by and
among Watson Pharmaceuticals, Inc., Quiver Inc. and Friar Tuck
Limited, is incorporated by reference to Exhibit 4.1 to the
Companys November 26, 2009 Form 8-K.
*10
.1
1991 Stock Option Plan of the Company, as revised, is
incorporated by reference to Exhibit 10.1 to the Companys
June 30, 1995 Form 10-Q.
Plan amendments are incorporated by reference to Exhibit 10.6(a)
to the Companys June 30, 1996 Form 10-Q and by reference
to Exhibit 10.6(a) to the Companys March 31, 1997 Form
10-Q.
*10
.2
Amendment and Restatement of the 2001 Incentive Award Plan of
Watson Pharmaceuticals, Inc. is incorporated by reference to
Exhibit 10.1 to the Companys June 30, 2005 Form 10-Q.
Second Amendment and Restatement of the 2001 Incentive Award
Plan of Watson Pharmaceuticals, Inc. is incorporated by
reference to Exhibit 10.1 to the Companys March 31, 2007
Form 10-Q.
Third Amendment and Restatement of the 2001 Incentive Award Plan
of Watson Pharmaceuticals, Inc.
*10
.3
Key Employee Agreement entered into as of February 28, 2000,
between David A. Buchen and the Company is incorporated by
reference to Exhibit 10.4 to the Companys 2000 Form 10-K.
*10
.4
Amendment to Key Employment Agreement entered into as of
December 31, 2008, between David A. Buchen and the Company,
is incorporated by reference to Exhibit 10.9 to the
Companys 2008 Form 10-K.
*10
.5
Key Employment Agreement entered into as of September 5, 2006 by
and between Thomas R. Russillo and the Company is incorporated
by reference to Exhibit 10.1 to the Companys Form 8-K
filed on September 7, 2006.
Amendment to Watson Pharmaceuticals, Inc. Key Employment
Agreement entered into as of December 29, 2008 by and between
Thomas R. Russillo and the Company is incorporated by reference
to Exhibit 10.6 to the Companys 2008 Form
10-K.
*10
.7
Amendment to Key Employment Agreement entered into as of
December 31, 2008, between AI Paonessa III and the Company,
is incorporated by reference to Exhibit 10.8 to the
Companys 2008 Form 10-K.
10
.8
Credit Agreement by and among Watson Pharmaceuticals, Inc.,
Canadian Imperial Bank of Commerce, Wachovia Capital Markets,
LLC, Wells Fargo Bank, National Association, Union Bank of
California, N.A. and Sumitomo Mitsui Banking Corporation dated
November 3, 2006 is incorporated by reference to Exhibit 10.1 to
the Companys Form 8-K filed on November 6, 2006.
*10
.9
2001 Incentive Award Plan Form of Notice of Grant and Signature
Page for an Employee or a Consultant is incorporated by
reference to Exhibit 10.15 to the Companys 2004 Form 10-K.
*10
.10
2001 Incentive Award Plan Form of Notice of Grant and Signature
Page for a Director is incorporated by reference to Exhibit
10.16 to Exhibit 10.16 to the Companys 2004 Form 10-K.
*10
.11
Form of Amendment and Restatement of the 2001 Incentive Award
Plan Notice of Grant and Signature Page for a Non-Employee
Director Restricted Stock Award is incorporated by reference to
Exhibit 10.2 to the Companys June 30, 2005 Form 10-Q.
*10
.12
Form of Amendment and Restatement of the 2001 Incentive Award
Plan Notice of Grant and Signature Page for a Non-Employee
Director Option Grant is incorporated by reference to
Exhibit 10.3 to the Companys June 30, 2005 Form 10-Q.
*10
.13
Form of Amendment and Restatement of the 2001 Incentive Award
Plan Notice of Grant and Signature Page for an Employee
Restricted Stock Award is incorporated by reference to Exhibit
10.4 to the Companys June 30, 2005 Form 10-Q.
*10
.14
Form of Amendment and Restatement of the 2001 Incentive Award
Plan Notice of Grant and Signature Page for an Employee Stock
Option Award is incorporated by reference to Exhibit 10.5 to the
Companys June 30, 2005 Form 10-Q.
*10
.15
Form of Amendment and Restatement of the 2001 Incentive Award
Plan Notice of Grant and Signature Page for a Vice-President and
Above Stock Option Award is incorporated by reference to Exhibit
10.6 to the Companys June 30, 2005 Form 10-Q.
*10
.16
Form of Amendment and Restatement of the 2001 Incentive Award
Plan Notice of Grant and Signature Page for a Vice-President and
Above Restricted Stock Award is incorporated by reference to
Exhibit 10.22 to the Companys 2006 Form 10-K.
*10
.17
Key Employee Agreement between Watson Pharmaceuticals, Inc. and
Paul M. Bisaro, dated as of August 1, 2007, is incorporated by
reference to Exhibit 10.2 to the Companys August 1, 2007
Form 8-K.
*10
.18
Amendment to Watson Pharmaceuticals, Inc. Key Employee Agreement
entered into as of December 22, 2008 by and between Paul M.
Bisaro and the Company is incorporated by reference to Exhibit
10.27 to the Companys 2008 Form 10-K.
*10
.19
Key Employee Agreement between Anda, Inc. and Al Paonessa III,
dated as of August 2, 2007 is incorporated by reference to
Exhibit 10.28 to the Companys 2007 Form 10-K.
10
.20
Amendment No. 1, dated July 1, 2009, to the Credit Agreement
dated November 3, 2006, by and among Watson Pharmaceuticals,
Inc., Canadian Imperial Bank of Commerce, acting through its
New York agency, as administrative agent, Wachovia Capital
Markets, LLC, as syndication agent, a syndicate of lenders, and
Wells Fargo Bank, National Association, Union Bank of
California, N.A., Sumitomo Mitsui Banking Corporation, as
documentation agents and the financial institutions from time to
time party thereto, is incorporated by reference to Exhibit 10.1
to the Companys June 30, 2009 Form 10-Q.
*10
.21
Second Amendment to Key Employee Agreement between Watson
Pharmaceuticals, Inc. and Thomas R. Russillo, dated as of August
13, 2009, is incorporated by reference to Exhibit 10.1 to the
Companys August 13, 2009 Form 8-K
*10
.22
Key Employee Agreement entered into as of October 30, 2009 by
and between R. Todd Joyce and the Company is incorporated by
reference to Exhibit 10.1 to the Companys October 30, 2009
Form 8-K.
Purchase and Collaboration Agreement, dated as of March 3, 2010,
by and among Columbia Laboratories, Inc., Coventry Acquisition,
Inc. and Watson Pharmaceuticals, Inc., is incorporated by
reference to Exhibit 2.1 to the Companys March 5, 2010
Form 8-K.
10
.24
Consulting agreement between Arrow No. 7 Ltd., and Anthony
Selwyn Tabatznik as of May 10, 2010, is incorporated by
reference to Exhibit 10.1 to the Companys March 31, 2010
Form 10-Q.
12
.1
Statement regarding the computation of ratio of earnings to
fixed charges is incorporated by reference to Exhibit 12.1 to
the Companys August 17, 2009 Form S-3.
21
.1
Subsidiaries of the Company.
23
.1
Consent of PricewaterhouseCoopers LLP.
31
.1**
Certification of Chief Executive Officer pursuant to Rule
13a-14(a) of the Securities Exchange Act of 1934.
31
.2**
Certification of Chief Financial Officer pursuant to Rule
13a-14(a) of the Securities Exchange Act of 1934.
32
.1**
Certification of Chief Executive Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
32
.2**
Certification of Chief Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
Furnished herewith and not filed for purposes of
Section 18 of the Exchange Act.
***
XBRL information is furnished and not filed for purposes of
Sections 11 and 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), and is not to be
incorporated by reference into any filing of the Company,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
+
Confidential treatment has been requested with respect to
certain portions of this exhibit. Omitted portions have been
filed separately with the SEC.
EX-10.2
2
a58052exv10w2.htm
EX-10.2
exv10w2
Exhibit 10.2
THIRD AMENDMENT AND RESTATEMENT OF
THE 2001 INCENTIVE AWARD PLAN OF
WATSON PHARMACEUTICALS, INC.
Watson Pharmaceuticals, Inc., a Nevada corporation, adopted the 2001 Incentive Award Plan of
Watson Pharmaceuticals, Inc. (the Plan), effective as of February 12, 2001 (the Effective
Date), for the benefit of its eligible Employees, Consultants and Directors. The Plan was
subsequently amended effective as of May 16, 2001, May 19, 2003, and August 4, 2003, May 13, 2005,
and November 3, 2006. The Plan was amended and restated in its entirety to provide for certain
additional types of awards to eligible Employees, Consultants and Directors, effective as of May 4,
2007.
The Plan is hereby amended and restated to add Section 3.6, titled Foreign Holders, which
sets forth certain provisions related to for awards that may be made to eligible Employees,
Consultants and Directors outside of the United States. This amendment and restatement of the Plan
is effective as of May 7, 2010.
The purposes of the Plan are as follows:
(1) To provide an additional incentive for Directors, key Employees and Consultants (as
such terms are defined below) to further the growth, development and financial success of the
Company by personally benefiting through the ownership of Company stock and/or rights which
recognize such growth, development and financial success.
(2) To enable the Company to obtain and retain the services of Directors, key Employees
and Consultants considered essential to the long range success of the Company by offering them an
opportunity to own stock in the Company and/or rights which will reflect the growth, development
and financial success of the Company.
ARTICLE I.
DEFINITIONS
Wherever the following terms are used in the Plan they shall have the meanings specified
below, unless the context clearly indicates otherwise. The singular pronoun shall include the
plural where the context so indicates.
1.1. Administrator shall mean the entity that conducts the general administration of the
Plan as provided herein. With reference to the administration of the Plan with respect to Awards
granted to Independent Directors, the term Administrator shall refer to the Board. With reference
to the administration of the Plan with respect to any other Award, the term Administrator shall
refer to the Committee unless the Board has assumed the authority for administration of the Plan
generally as provided in Section 11.1. With reference to the duties of the Committee under the Plan
which have been delegated to one or more persons pursuant to Section 11.5, the term Administrator
shall refer to such person(s) unless the Committee or the Board has revoked such delegation.
1.2. Award shall mean an Option, a Restricted Stock award, a Restricted Stock Unit
award, a Dividend Equivalents award, a Deferred Stock award, a Stock Payment award or a Stock
Appreciation Right, which may be awarded or granted under the Plan (collectively, Awards).
B-1
1.3. Award Agreement shall mean a written agreement executed by an authorized officer of
the Company and the Holder which shall contain such terms and conditions with respect to an Award
as the Administrator shall determine, consistent with the Plan.
1.4. Award Limit shall mean five hundred thousand (500,000) shares of Common Stock, as
adjusted pursuant to Section 12.3; provided, however, that each share of Common Stock subject to an
Award shall be counted as one share against the Award Limit.
1.5. Board shall mean the Board of Directors of the Company.
1.6. Change in Control shall mean the occurrence of any of the following:
(a) a sale of assets representing fifty percent (50%) or more of the net book value and
of the fair market value of the Companys consolidated assets (in a single transaction or in a
series of related transactions);
(b) a liquidation or dissolution of the Company;
(c) a merger or consolidation involving the Company or any subsidiary of the Company
after the completion of which: (i) in the case of a merger (other than a triangular merger) or
a consolidation involving the Company, the stockholders of the Company immediately prior to the
completion of such merger or consolidation beneficially own (within the meaning of Rule 13d-3
promulgated under the Exchange Act, or comparable successor rules), directly or indirectly,
outstanding voting securities representing less than sixty percent (60%) of the combined voting
power of the surviving entity in such merger or consolidation, and (ii) in the case of a
triangular merger involving the Company or a subsidiary of the Company, the stockholders of the
Company immediately prior to the completion of such merger beneficially own (within the meaning
of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rules), directly or
indirectly, outstanding voting securities representing less than sixty percent (60%) of the
combined voting power of the surviving entity in such merger and less than sixty percent (60%)
of the combined voting power of the parent of the surviving entity in such merger;
(d) an acquisition by any person, entity or group (within the meaning of Section 13(d)
or 14(d) of the Exchange Act or any comparable successor provisions), other than any employee
benefit plan, or related trust, sponsored or maintained by the Company or an affiliate of the
Company and other than in a merger or consolidation of the type referred to in subsection (c),
of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act,
or comparable successor rules) of outstanding voting securities of the Company representing
more than thirty percent (30%) of the combined voting power of the Company (in a single
transaction or series of related transactions); or
(e) in the event that the individuals who, as of the Effective Date, are members of the
Board (the Incumbent Board), cease for any reason to constitute at least fifty percent (50%)
of the Board; provided, that if the election, or nomination for election by the Companys
stockholders, of any new member of the Board is approved by a vote of at least fifty percent
(50%) of the Incumbent Board, such new member of the Board shall be considered as a member of
the Incumbent Board.
1.7. Code shall mean the Internal Revenue Code of 1986, as amended.
1.8. Committee shall mean the Compensation Committee of the Board, or another committee
or subcommittee of the Board, appointed as provided in Section 11.1.
1.9. Common Stock shall mean the common stock of the Company, par value $0.0033 per
share.
1.10. Company shall mean Watson Pharmaceuticals, Inc., a Nevada corporation.
B-2
1.11. Consultant shall mean any consultant or adviser if: (a) the consultant or adviser
renders bona fide services to the Company; (b) the services rendered by the consultant or adviser
are not in connection with the offer or sale of securities in a capital-raising transaction and do
not directly or indirectly promote or maintain a market for the Companys securities; and (c) the
consultant or adviser is a natural person who has contracted directly with the Company to render
such services.
1.12. Deferred Stock shall mean rights to receive Common Stock awarded under Section 8.4 of
the Plan.
1.13. Director shall mean a member of the Board.
1.14. Dividend Equivalent shall mean a right to receive the equivalent value (in cash or
Common Stock) of dividends paid on Common Stock, awarded under Section 8.2 of the Plan.
1.15. DRO shall mean a domestic relations order as defined by the Code or Title I of the
Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder.
1.16. Employee shall mean any officer or other employee (as defined in accordance with
Section 3401(c) of the Code) of the Company, or of any corporation which is a Subsidiary.
1.17. Exchange Act shall mean the Securities Exchange Act of 1934, as amended.
1.18. Fair Market Value means, as of any date, the value of a share of Common Stock
determined as follows:
(a) If the Common Stock is listed on any established stock exchange (such as the New
York Stock Exchange, the NASDAQ Global Market and the NASDAQ Global Select Market) or any
national market system, including without limitation any market system of The NASDAQ Stock
Market, the value of a share of Common Stock shall be the closing sales price for a share of
Common Stock as quoted on such exchange or system for such date, or if there is no closing
sales price for a share of Common Stock on the date in question, the closing sales price for a
share of Common Stock on the last preceding date for which such quotation exists, as reported
in The Wall Street Journal or such other source as the Administrator deems reliable;
(b) If the Common Stock is regularly quoted by a recognized securities dealer but
closing sales prices are not reported, the value of a share of Common Stock shall be the mean
of the high bid and low asked prices for such date or, if there are no high bid and low asked
prices for a share of Common Stock on the date in question, the high bid and low asked prices
for a share of Common Stock on the last preceding date for which such information exists, as
reported in The Wall Street Journal or such other source as the Administrator deems reliable;
or
(c) If the Common Stock is neither listed on an established stock exchange or a
national market system nor regularly quoted by a recognized securities dealer, the value of a
share of Common Stock shall be established by the Administrator in good faith.
1.19. Holder shall mean a person who has been granted or awarded an Award.
1.20. Incentive Stock Option shall mean an option which conforms to the applicable
provisions of Section 422 of the Code and which is designated as an Incentive Stock Option by the
Administrator.
1.21. Independent Director shall mean a member of the Board who is not an Employee.
1.22. Full Value Award shall mean any Award other than an Option or Stock Appreciation
Right.
1.23. Non-Qualified Stock Option shall mean an Option which is not designated as an
Incentive Stock Option by the Administrator.
B-3
1.24. Option shall mean a stock option granted under Article IV of the Plan. An Option
granted under the Plan shall, as determined by the Administrator, be either a Non-Qualified Stock
Option or an Incentive Stock Option; provided, however, that Options granted to Independent
Directors and Consultants shall be Non-Qualified Stock Options.
1.25. Performance Criteria shall mean any one or more of the following business criteria
with respect to the Company, any Subsidiary or any division or operating unit thereof: (a) revenue
or sales, (b) net income, (c) pre-tax income, (d) operating income, (e) cash flow, (f) earnings per
share, (g) return on equity, (h) return on invested capital or assets, (i) cost reductions or
savings, (j) funds from operations, (k) appreciation in the Fair Market Value of Common Stock, or
(l) earnings before any one or more of the following: (i) interest, (ii) taxes, (iii) depreciation
or (iv) amortization, each as determined in accordance with generally accepted accounting
principles.
1.26. Plan shall mean the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc., as
amended.
1.27. Restricted Stock shall mean Common Stock awarded under Article VII of the Plan.
1.28. Restricted Stock Units shall mean rights to receive Common Stock awarded under
Section 8.5 of the Plan.
1.29. Rule 16b-3 shall mean Rule 16b-3 promulgated under the Exchange Act, as such Rule may
be amended from time to time.
1.30. Section 162(m) Participant shall mean any key Employee designated by the
Administrator as a key Employee whose compensation for the fiscal year in which the key Employee is
so designated or a future fiscal year may be subject to the limit on deductible compensation
imposed by Section 162(m) of the Code.
1.31. Securities Act shall mean the Securities Act of 1933, as amended.
1.32. Stock Appreciation Right shall mean a stock appreciation right granted under Article
IX of the Plan.
1.33. Stock Payment shall mean: (a) a payment in the form of shares of Common Stock, or (b)
an option or other right to purchase shares of Common Stock, as part of a deferred compensation
arrangement, made in lieu of all or any portion of the compensation, including without limitation,
salary, bonuses and commissions, that otherwise would become payable to a key Employee, Independent
Director or Consultant in cash, awarded under Section 8.3 of the Plan.
1.34. Subsidiary shall mean any corporation in an unbroken chain of corporations beginning
with the Company if each of the corporations other than the last corporation in the unbroken chain
then owns stock possessing fifty percent (50%) or more of the total combined voting power of all
classes of stock in one of the other corporations in such chain.
1.35. Substitute Award shall mean an Option granted under this Plan upon the assumption of,
or in substitution for, outstanding equity awards previously granted by a company or other entity
in connection with a corporate transaction, such as a merger, combination, consolidation or
acquisition of property or stock; provided, however, that in no event shall the term Substitute
Award be construed to refer to an award made in connection with the cancellation and repricing of
an Option.
1.36. Termination of Consultancy shall mean the time when the engagement of a Holder as a
Consultant to the Company or a Subsidiary is terminated for any reason, with or without cause,
including, but not by way of limitation, by resignation, discharge, death or retirement, but
excluding terminations where there is a simultaneous commencement of employment with the Company or
any Subsidiary, or any parent thereof. The Administrator, in its absolute discretion, shall
determine the effect of all matters and questions relating to Termination of Consultancy,
including, but not by way of limitation, the question of
B-4
whether a Termination of Consultancy resulted from a discharge for good cause, and all questions of
whether a particular leave of absence constitutes a Termination of Consultancy. Notwithstanding any
other provision of the Plan, the Company or any Subsidiary has an absolute and unrestricted right
to terminate a Consultants service at any time for any reason whatsoever, with or without cause,
except to the extent expressly provided otherwise in writing.
1.37. Termination of Directorship shall mean the time when a Holder who is an Independent
Director ceases to be a Director for any reason, including, but not by way of limitation, a
termination by resignation, removal, failure to be elected, death or retirement. The Board, in its
sole and absolute discretion, shall determine the effect of all matters and questions relating to
Termination of Directorship with respect to Independent Directors.
1.38. Termination of Employment shall mean the time when the employee-employer relationship
between a Holder and the Company or any Subsidiary is terminated for any reason, with or without
cause, including, but not by way of limitation, a termination by resignation, discharge, death,
disability or retirement; but excluding: (a) terminations where there is a simultaneous
reemployment or continuing employment of a Holder by the Company or any Subsidiary, or any parent
thereof, (b) at the discretion of the Administrator, terminations which result in a temporary
severance of the employee-employer relationship, and (c) at the discretion of the Administrator,
terminations which are followed by the simultaneous establishment of a consulting relationship by
the Company or a Subsidiary, or any parent thereof, with the former employee. The Administrator, in
its absolute discretion, shall determine the effect of all matters and questions relating to
Termination of Employment, including, but not by way of limitation, the question of whether a
Termination of Employment resulted from a discharge for good cause, and all questions of whether a
particular leave of absence constitutes a Termination of Employment; provided, however, that, with
respect to Incentive Stock Options, unless otherwise determined by the Administrator in its
discretion, a leave of absence, change in status from an employee to an independent contractor or
other change in the employee-employer relationship shall constitute a Termination of Employment if,
and to the extent that, such leave of absence, change in status or other change interrupts
employment for the purposes of Section 422(a)(2) of the Code and the then applicable regulations
and revenue rulings under said Section.
ARTICLE II.
SHARES SUBJECT TO PLAN
2.1. Shares Subject to Plan.
(a) The shares of stock subject to Awards shall be Common Stock. Subject to adjustment
as provided in Section 12.3, the aggregate number of such shares of Common Stock which may be
issued pursuant to Awards under the Plan shall not exceed 19,728,333 shares. The shares of
Common Stock issuable upon exercise of such Options or rights or upon any such Awards may be
either previously authorized but unissued shares or treasury shares. The aggregate number of
shares of Common Stock available for issuance under the Plan pursuant to this Section 2.1 shall
be reduced by two shares for each share of Common Stock delivered in settlement of any Full
Value Award.
(b) The maximum number of shares which may be subject to Awards granted under the Plan
to any individual in any fiscal year of the Company shall not exceed the Award Limit. To the
extent required by Section 162(m) of the Code, shares subject to Awards which are canceled
continue to be counted against the Award Limit.
2.2. Add-Back of Options and Other Rights. If any Option, or other right to acquire
shares of Common Stock under any other Award under the Plan, expires or is canceled without having
been fully exercised, the number of shares subject to such Option or other right but as to which
such Option or other right was not exercised prior to its expiration, cancellation or exercise may
again be optioned, granted or
B-5
awarded hereunder, subject to the limitations of Section 2.1; provided, however, that the number of
shares that shall again be available for the grant of an Award pursuant to the Plan shall be
increased by two shares for each share of Common Stock subject to a Full Value Award at the time
such Full Value Award terminates, expires, lapses or is forfeited for any reason. Furthermore, any
shares subject to Awards which are adjusted pursuant to Section 12.3 and become exercisable with
respect to shares of stock of another corporation shall be considered cancelled and may again be
optioned, granted or awarded hereunder, subject to the limitations of Section 2.1. If any shares of
Restricted Stock are surrendered by the Holder or repurchased by the Company pursuant to Section
7.4 or 7.5 hereof, such shares may again be optioned, granted or awarded hereunder, subject to the
limitations of Section 2.1. To the extent exercised, the full number of shares subject to an Option
or Stock Appreciation Right shall be counted for purposes of calculating the aggregate number of
shares of Common Stock available for issuance under the Plan as set forth in Section 2.1(a) and for
purposes of calculating the share limitation set forth in Section 2.1(b), regardless of the actual
number of shares issued or transferred upon any net exercise of an Option (in which Common Stock is
withheld to satisfy the exercise price or taxes) or upon exercise of any Stock Appreciation Right
for Common Stock or cash. Notwithstanding the provisions of this Section 2.2, no shares of Common
Stock may again be optioned, granted or awarded if such action would cause an Incentive Stock
Option to fail to qualify as an incentive stock option under Section 422 of the Code.
ARTICLE III.
GRANTING OF AWARDS
3.1. Award Agreement. Each Award shall be evidenced by an Award Agreement. Award
Agreements evidencing Awards intended to qualify as performance-based compensation as described in
Section 162(m)(4)(C) of the Code shall contain such terms and conditions as may be necessary to
meet the applicable provisions of Section 162(m) of the Code. Award Agreements evidencing Incentive
Stock Options shall contain such terms and conditions as may be necessary to meet the applicable
provisions of Section 422 of the Code.
3.2. Provisions Applicable to Section 162(m) Participants.
(a) The Committee, in its discretion, may determine whether an Award is to qualify as
performance-based compensation as described in Section 162(m)(4)(C) of the Code.
(b) Notwithstanding anything in the Plan to the contrary, the Committee may grant any
Award to a Section 162(m) Participant, including a Restricted Stock award, a Restricted Stock
Unit award, a Dividend Equivalent award, a Deferred Stock award or a Stock Payment award, the
restrictions with respect to which lapse upon the attainment of performance goals which are
related to one or more of the Performance Criteria and any Award described in Article VIII that
vests or becomes exercisable or payable upon the attainment of performance goals which are
related to one or more of the Performance Criteria.
(c) To the extent necessary to comply with the performance-based compensation
requirements of Section 162(m)(4)(C) of the Code, with respect to any Award granted under
Articles VII and VIII which may be granted to one or more Section 162(m) Participants, no later
than ninety (90) days following the commencement of any fiscal year in question or any other
designated fiscal period or period of service (or such other time as may be required or
permitted by Section 162(m) of the Code), the Committee shall, in writing, (i) designate one or
more Section 162(m) Participants, (ii) select the Performance Criteria applicable to the fiscal
year or other designated fiscal period or period of service, (iii) establish the various
performance targets, in terms of an objective formula or standard, and amounts of such Awards,
as applicable, which may be earned for such fiscal year or other designated fiscal period or
period of service, and (iv) specify the relationship between Performance Criteria and the
performance targets and the amounts of such Awards, as applicable, to be earned by
B-6
each Section 162(m) Participant for such fiscal year or other designated fiscal period or
period of service. Following the completion of each fiscal year or other designated fiscal
period or period of service, the Committee shall certify in writing whether the applicable
performance targets have been achieved for such fiscal year or other designated fiscal period
or period of service. In determining the amount earned by a Section 162(m) Participant, the
Committee shall have the right to reduce (but not to increase) the amount payable at a given
level of performance to take into account additional factors that the Committee may deem
relevant to the assessment of individual or corporate performance for the fiscal year or other
designated fiscal period or period of service.
(d) Furthermore, notwithstanding any other provision of the Plan, any Award which is
granted to a Section 162(m) Participant and is intended to qualify as performance-based
compensation as described in Section 162(m)(4)(C) of the Code shall be subject to any
additional limitations set forth in Section 162(m) of the Code (including any amendment to
Section 162(m) of the Code) or any regulations or rulings issued thereunder that are
requirements for qualification as performance-based compensation as described in Section
162(m)(4)(C) of the Code, and the Plan shall be deemed amended to the extent necessary to
conform to such requirements.
3.3. Limitations Applicable to Section 16 Persons. Notwithstanding any other provision
of the Plan, the Plan, and any Award granted or awarded to any individual who is then subject to
Section 16 of the Exchange Act, shall be subject to any additional limitations set forth in any
applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule
16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the
extent permitted by applicable law, the Plan and Awards granted or awarded hereunder shall be
deemed amended to the extent necessary to conform to such applicable exemptive rule.
3.4. Consideration. In consideration of the granting of an Award under the Plan, the
Holder shall agree, in the Award Agreement, to remain in the employ of (or to consult for or to
serve as an Independent Director of, as applicable) the Company or any Subsidiary for a period of
at least one year (or such shorter period as may be fixed in the Award Agreement or by action of
the Administrator following grant of the Award) after the Award is granted (or, in the case of an
Independent Director, until the next annual meeting of stockholders of the Company).
3.5. At-Will Employment. Nothing in the Plan or in any Award Agreement hereunder shall
confer upon any Holder any right to continue in the employ of, or as a Consultant for, the Company
or any Subsidiary, or as a Director of the Company, or shall interfere with or restrict in any way
the rights of the Company and any Subsidiary, which are hereby expressly reserved, to discharge any
Holder at any time for any reason whatsoever, with or without cause, except to the extent expressly
provided otherwise in a written employment agreement between the Holder and the Company and any
Subsidiary.
3.6. Foreign Holders. Notwithstanding any provision of the Plan to the contrary, in order to
comply with the laws in other countries in which the Company and any Subsidiary of the Company
operate or have Employees, Independent Directors or Consultants, or in order to comply with the
requirements of any foreign stock exchange or applicable laws, the Administrator, in its sole
discretion, shall have the power and authority to: (a) determine which Subsidiaries shall be
covered by the Plan; (b) determine which Employees, Independent Directors or Consultants outside
the United States are eligible to participate in the Plan; (c) modify the terms and conditions of
any Award granted to Employees, Independent Directors or Consultants outside the United States to
comply with applicable foreign laws or listing requirements of any such foreign stock exchange; (d)
establish subplans and modify exercise procedures and other terms and procedures, to the extent
such actions may be necessary or advisable (any such subplans and/or modifications shall be
attached to the Plan as appendices); provided, however, that no such subplans and/or modifications
shall increase the share limitations contained in Article II or expand the classes of persons to
whom Awards may be granted under the Plan; and (e) take any action, before or after an Award is
made, that it deems advisable to obtain approval or comply with any necessary local governmental
regulatory exemptions or approvals or listing requirements of any such foreign stock exchange.
Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards
shall be granted, that would violate the Code, the Exchange Act, the Securities Act or any other
securities law or governing statute or any other applicable law.
B-7
ARTICLE IV.
GRANTING OF OPTIONS TO EMPLOYEES,
CONSULTANTS AND INDEPENDENT DIRECTORS
4.1. Eligibility. Any Employee or Consultant selected by the Administrator pursuant to
Section 4.4(a)(i) shall be eligible to be granted an Option. Each Independent Director of the
Company shall be eligible to be granted Options at the times and in the manner set forth in Section
4.5.
4.2. Disqualification for Stock Ownership. No person may be granted an Incentive Stock
Option under the Plan if such person, at the time the Incentive Stock Option is granted, owns stock
possessing more than 10% of the total combined voting power of all classes of stock of the Company
or any then existing Subsidiary or parent corporation (within the meaning of Section 422 of the
Code) unless such Incentive Stock Option conforms to the applicable provisions of Section 422 of
the Code.
B-8
4.3. Qualification of Incentive Stock Options. No Incentive Stock Option shall be
granted to any person who is not an Employee.
4.4. Granting of Options to Employees and Consultants.
(a) The Administrator shall from time to time, in its absolute discretion, and, subject
to applicable limitations of the Plan:
(i) Determine which Employees are key Employees and select from among the key
Employees or Consultants (including Employees or Consultants who have previously received
Awards under the Plan) such of them as in its opinion should be granted Options;
(ii) Subject to the Award Limit, determine the number of shares to be subject to
such Options granted to the selected key Employees or Consultants;
(iii) Subject to Section 4.3, determine whether such Options are to be Incentive
Stock Options or Non-Qualified Stock Options and whether such Options are to qualify as
performance-based compensation as described in Section 162(m)(4)(C) of the Code; and
(iv) Determine the terms and conditions of such Options, consistent with the Plan;
provided, however, that the terms and conditions of Options intended to qualify as
performance-based compensation as described in Section 162(m)(4)(C) of the Code shall
include, but not be limited to, such terms and conditions as may be necessary to meet the
applicable provisions of Section 162(m) of the Code.
(b) Upon the selection of a key Employee or Consultant to be granted an Option, the
Administrator shall instruct the Secretary of the Company to issue the Option and may impose
such conditions on the grant of the Option as it deems appropriate.
(c) Any Incentive Stock Option granted under the Plan may be modified by the
Administrator, with the consent of the Holder, to disqualify such Option from treatment as an
incentive stock option under Section 422 of the Code.
4.5. Granting of Options to Independent Directors. The Board shall from time to time, in
its absolute discretion, and subject to applicable limitations of the Plan:
(a) Select from among the Independent Directors (including Independent Directors who
have previously received Options under the Plan) such of them as in its opinion should be
granted Options;
(b) Subject to the Award Limit, determine the number of shares to be subject to such
Options granted to the selected Independent Directors; and
(c) Determine the terms and conditions of such Options, consistent with the Plan.
All the foregoing Option grants authorized by this Section 4.5 are subject to stockholder approval
of the Plan.
4.6. Options in Lieu of Cash Compensation. Options may be granted under the Plan to
Employees and Consultants in lieu of cash bonuses which would otherwise be payable to such
Employees and Consultants, and to Independent Directors in lieu of directors fees which would
otherwise be payable to such Independent Directors, pursuant to such policies which may be adopted
by the Administrator from time to time.
B-9
ARTICLE V.
TERMS OF OPTIONS
5.1. Option Price. The price per share of the shares subject to each Option granted to
Employees, Independent Directors and Consultants shall be set by the Administrator; provided,
however, that:
(a) In the case of Options intended to qualify as performance-based compensation as
described in Section 162(m)(4)(C) of the Code, such price shall not be less than 100% of the
Fair Market Value of a share of Common Stock on the date the Option is granted;
(b) In the case of Incentive Stock Options such price shall not be less than 100% of the
Fair Market Value of a share of Common Stock on the date the Option is granted (or the date the
Option is modified, extended or renewed for purposes of Section 424(h) of the Code);
(c) In the case of Incentive Stock Options granted to an individual then owning (within
the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of
all classes of stock of the Company or any Subsidiary or parent corporation thereof (within the
meaning of Section 422 of the Code), such price shall not be less than 110% of the Fair Market
Value of a share of Common Stock on the date the Option is granted (or the date the Option is
modified, extended or renewed for purposes of Section 424(h) of the Code); and
(d) In the case of Non-Qualified Stock Options, such price shall not be less than 100%
of the Fair Market Value of a share of Common Stock on the date the Option is granted.
5.2. Option Term. The term of an Option granted to an Employee, Independent Director or
Consultant shall be set by the Administrator in its discretion; provided, however, that the term
shall not be more than ten (10) years from the date the Option is granted, or five (5) years from
the date the Option is granted if the Option is an Incentive Stock Option granted to an individual
then owning (within the meaning of Section 424(d) of the Code) more than 10% of the total combined
voting power of all classes of stock of the Company or any Subsidiary Corporation or parent
corporation thereof (as defined in Section 424(e) of the Code). Except as limited by requirements
of Section 422 of the Code and regulations and rulings thereunder applicable to Incentive Stock
Options, the Administrator may extend the term of any outstanding Option in connection with any
Termination of Employment, Termination of Directorship or Termination of Consultancy of the Holder,
or amend any other term or condition of such Option relating to such a Termination of Employment,
Termination of Directorship or Termination of Consultancy.
5.3. Option Vesting.
(a) The period during which the right to exercise, in whole or in part, an Option
granted to an Employee, Independent Director or a Consultant vests in the Holder shall be set
by the Administrator and the Administrator may determine that an Option may not be exercised in
whole or in part for a specified period after it is granted; provided, however, that, unless
the Administrator otherwise provides in the terms of the Award Agreement or otherwise, no
Option shall be exercisable by any Holder who is then subject to Section 16 of the Exchange Act
within the period ending six months and one day after the date the Option is granted. At any
time after grant of an Option, the Administrator may, in its sole and absolute discretion and
subject to whatever terms and conditions it selects, accelerate the period during which an
Option granted to an Employee, Independent Director or Consultant vests.
(b) No portion of an Option granted to an Employee, Independent Director or Consultant
which is unexercisable at Termination of Employment, Termination of Directorship or Termination
of Consultancy, as applicable, shall thereafter become exercisable, except as may be otherwise
provided
B-10
by the Administrator either in the Award Agreement or by action of the Administrator following
the grant of the Option.
(c) To the extent that the aggregate fair market value of stock with respect to which
incentive stock options (within the meaning of Section 422 of the Code, but without regard to
Section 422(d) of the Code) are exercisable for the first time by a Holder during any calendar
year under the Plan, and all other plans of the Company and any Subsidiary or parent
corporation thereof, within the meaning of Section 424 of the Code, exceeds $100,000, the
Options shall be treated as Non-Qualified Stock Options to the extent required by Section 422
of the Code. The rule set forth in the preceding sentence shall be applied by taking Options
and other incentive stock options into account in the order in which they were granted. For
purposes of this Section 5.3(c), the fair market value of stock shall be determined as of the
time the Option or other incentive stock options with respect to such stock is granted.
5.4. Substitute Awards. Notwithstanding the foregoing provisions of this Article V to
the contrary, in the case of an Option that is a Substitute Award, the price per share of the
shares subject to such Option may be less than the Fair Market Value per share on the date of
grant, provided, that the excess of: (a) the aggregate Fair Market Value (as of the date such
Substitute Award is granted) of the shares subject to the Substitute Award, over (b) the aggregate
exercise price thereof, does not exceed the excess of: (c) the aggregate fair market value (as of
the time immediately preceding the transaction giving rise to the Substitute Award, such fair
market value to be determined by the Committee) of the shares of the predecessor entity that were
subject to the grant assumed or substituted for by the Company, over (d) the aggregate exercise
price of such shares.
5.5. Substitution of Stock Appreciation Rights. The Administrator may provide in the
Award Agreement evidencing the grant of an Option that the Administrator, in its sole discretion,
shall have the right to substitute a Stock Appreciation Right for such Option at any time prior to
or upon exercise of such Option, subject to the provisions of Section 9.2; provided, that such
Stock Appreciation Right shall be exercisable with respect to the same number of shares of Common
Stock for which such substituted Option would have been exercisable and at the Option exercise
price per share.
ARTICLE VI.
EXERCISE OF OPTIONS
6.1. Partial Exercise. An exercisable Option may be exercised in whole or in part.
However, an Option shall not be exercisable with respect to fractional shares and the Administrator
may require that, by the terms of the Option, a partial exercise be with respect to a minimum
number of shares.
6.2. Manner of Exercise. All or a portion of an exercisable Option shall be deemed
exercised upon delivery of all of the following to the Secretary of the Company, or such other
person or entity designated by the Board, or his, her or its office, as applicable:
(a) A written notice complying with the applicable rules established by the
Administrator stating that the Option, or a portion thereof, is exercised. The notice shall be
signed by the Holder or other person then entitled to exercise the Option or such portion of
the Option;
(b) Such representations and documents as the Administrator, in its absolute discretion,
deems necessary or advisable to effect compliance with all applicable provisions of the
Securities Act and any other federal or state securities laws or regulations. The Administrator
may, in its absolute discretion, also take whatever additional actions it deems appropriate to
effect such compliance including, without limitation, placing legends on share certificates and
issuing stop-transfer notices to agents and registrars;
B-11
(c) In the event that the Option shall be exercised pursuant to Section 12.1 by any
person or persons other than the Holder, appropriate proof of the right of such person or
persons to exercise the Option; and
(d) Full cash payment to the Secretary of the Company for the shares with respect to
which the Option, or portion thereof, is exercised. However, the Administrator may, in its
discretion, (i) allow payment, in whole or in part, through the delivery of shares of Common
Stock which have been owned by the Holder for at least six months, duly endorsed for transfer
to the Company with a Fair Market Value on the date of delivery equal to the aggregate exercise
price of the Option or exercised portion thereof; (ii) allow payment, in whole or in part,
through the surrender of shares of Common Stock then issuable upon exercise of the Option
having a Fair Market Value on the date of Option exercise equal to the aggregate exercise price
of the Option or exercised portion thereof; (iii) allow payment, in whole or in part, through
the delivery of property of any kind which constitutes good and valuable consideration; (iv)
allow payment, in whole or in part, through the delivery of a notice that the Holder has placed
a market sell order with a broker with respect to shares of Common Stock then issuable upon
exercise of the Option, and that the broker has been directed to pay a sufficient portion of
the net proceeds of the sale to the Company in satisfaction of the Option exercise price,
provided, that payment of such proceeds is then made to the Company upon settlement of such
sale; or (v) allow payment through any combination of the consideration provided in the
foregoing paragraphs (i), (ii), (iii) and (iv); provided, however, that the payment in the
manner prescribed in the preceding paragraphs shall not be permitted to the extent that the
Administrator determines that payment in such manner shall result in an extension or
maintenance of credit, an arrangement for the extension of credit, or a renewal or an extension
of credit in the form of a personal loan to or for any Director or executive officer of the
Company that is prohibited by Section 13(k) of the Exchange Act or other applicable law.
6.3. Conditions to Issuance of Stock Certificates. The Company shall not be required to
issue or deliver any certificate or certificates for shares of stock purchased upon the exercise of
any Option or portion thereof prior to fulfillment of all of the following conditions:
(a) The admission of such shares to listing on all stock exchanges on which such class
of stock is then listed;
(b) The completion of any registration or other qualification of such shares under any
state or federal law, or under the rulings or regulations of the Securities and Exchange
Commission or any other governmental regulatory body which the Administrator shall, in its
absolute discretion, deem necessary or advisable;
(c) The obtaining of any approval or other clearance from any state or federal
governmental agency which the Administrator shall, in its absolute discretion, determine to be
necessary or advisable;
(d) The lapse of such reasonable period of time following the exercise of the Option as
the Administrator may establish from time to time for reasons of administrative convenience;
and
(e) The receipt by the Company of full payment for such shares, including payment of
any applicable withholding tax, which in the discretion of the Administrator may be in the form
of consideration used by the Holder to pay for such shares under Section 6.2(d).
6.4. Rights as Stockholders. Holders shall not be, nor have any of the rights or
privileges of, stockholders of the Company in respect of any shares purchasable upon the exercise
of any part of an Option unless and until certificates representing such shares have been issued by
the Company to such Holders.
B-12
6.5. Ownership and Transfer Restrictions. The Administrator, in its absolute discretion,
may impose such restrictions on the ownership and transferability of the shares purchasable upon
the exercise of an Option as it deems appropriate. Any such restriction shall be set forth in the
respective Award Agreement and may be referred to on the certificates evidencing such shares. The
Holder shall give the Company prompt notice of any disposition of shares of Common Stock acquired
by exercise of an Incentive Stock Option within (a) two years from the date of granting (including
the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code)
such Option to such Holder, or (b) one year after the transfer of such shares to such Holder.
6.6. Additional Limitations on Exercise of Options. Holders may be required to comply
with any timing or other restrictions with respect to the settlement or exercise of an Option,
including a window-period limitation, as may be imposed in the discretion of the Administrator.
ARTICLE VII.
AWARD OF RESTRICTED STOCK
7.1. Eligibility. Subject to the Award Limit, Restricted Stock may be awarded to any
Employee whom the Administrator determines is a key Employee, or any Independent Director or any
Consultant, whom the Administrator determines should receive such an Award.
7.2. Award of Restricted Stock.
(a) The Administrator may from time to time, in its absolute discretion:
(i) Determine which Employees are key Employees, and select from among the key
Employees, Independent Directors or Consultants (including Employees, Independent
Directors or Consultants who have previously received other Awards under the Plan) such of
them as in its opinion should be awarded Restricted Stock; and
(ii) Determine the purchase price, if any, and other terms and conditions
applicable to such Restricted Stock, consistent with the Plan.
(b) The Administrator shall establish the purchase price, if any, and form of payment
for Restricted Stock; provided, however, that such purchase price shall be no less than the par
value of the Common Stock to be purchased, unless otherwise permitted by applicable state law.
In all cases, legal consideration shall be required for each issuance of Restricted Stock.
(c) Upon the selection of an Employee, Independent Director or Consultant to be awarded
Restricted Stock, the Administrator shall instruct the Secretary of the Company to issue such
Restricted Stock and may impose such conditions on the issuance of such Restricted Stock as it
deems appropriate.
7.3. Rights as Stockholders. Subject to Section 7.4, upon delivery of the shares of
Restricted Stock to the escrow holder pursuant to Section 7.7, the Holder shall have, unless
otherwise provided by the Administrator, all the rights of a stockholder with respect to said
shares, subject to the restrictions in his or her Award Agreement, including the right to receive
all dividends and other distributions paid or made with respect to the shares; provided, however,
that, in the discretion of the Administrator, any dividends or distributions with respect to the
Common Stock shall be subject to the restrictions set forth in Section 7.4.
7.4. Restriction. All shares of Restricted Stock issued under the Plan (including any
shares received by Holders thereof with respect to shares of Restricted Stock as a result of stock
dividends, stock splits or any other form of recapitalization) shall, in the terms of each
individual Award Agreement, be subject to such restrictions as the Administrator shall provide,
which restrictions may include, without limitation, restrictions concerning voting rights and
transferability and restrictions based on duration of employment, directorship or consultancy with
the Company, or any Subsidiary, or any parent thereof, Company
B-13
performance and individual performance, or any one or more of the Performance Criteria or other
specific performance criteria determined appropriate by the Administrator; provided, however, that,
unless the Administrator otherwise provides in the terms of the Award Agreement or otherwise, no
share of Restricted Stock granted to a person subject to Section 16 of the Exchange Act shall be
sold, assigned or otherwise transferred until at least six months and one day have elapsed from the
date on which the Restricted Stock was issued; and, provided, further, that, except with respect to
shares of Restricted Stock granted to Section 162(m) Participants, by action taken after the
Restricted Stock is issued, the Administrator may, on such terms and conditions as it may determine
to be appropriate, remove any or all of the restrictions imposed by the terms of the Award
Agreement. Restricted Stock may not be sold or encumbered until all restrictions are terminated or
expire. If no consideration was paid by the Holder upon issuance, a Holders rights in unvested
Restricted Stock shall lapse, and such Restricted Stock shall be surrendered to the Company without
consideration, upon Termination of Employment, Termination of Directorship, or Termination of
Consultancy, as applicable; provided, however, that the Administrator in its sole and absolute
discretion may provide that such rights shall not lapse in the event of a Termination of
Employment, Termination of Directorship or Termination of Consultancy, as applicable, following a
change of ownership or control (within the meaning of Treasury Regulation Section
1.162-27(e)(2)(v) or any successor regulation thereto) of the Company or because of the Holders
death or disability; and, provided, further, except with respect to shares of Restricted Stock
granted to Section 162(m) Participants that is intended to qualify as performance-based
compensation as described in Section 162(m)(4)(C) of the Code, the Administrator in its sole and
absolute discretion may provide that no such lapse or surrender shall occur in the event of a
Termination of Employment, Termination of Directorship, or Termination of Consultancy, as
applicable, without cause or following any Change in Control or because of the Holders retirement,
or otherwise.
7.5. Repurchase of Restricted Stock. The Administrator shall provide in the terms of
each individual Award Agreement that the Company shall have the right to repurchase from the Holder
the Restricted Stock then subject to restrictions under the Award Agreement immediately upon a
Termination of Employment, Termination of Directorship, or Termination of Consultancy, as
applicable, at a cash price per share equal to the price paid by the Holder for such Restricted
Stock; provided, however, that the Administrator in its sole and absolute discretion may provide
that no such right of repurchase shall exist in the event of a Termination of Employment,
Termination of Directorship or Termination of Consultancy, as applicable, following a change of
ownership or control (within the meaning of Treasury Regulation Section 1.162-27(e)(2)(v) or any
successor regulation thereto) of the Company or because of the Holders death or disability; and,
provided, further, that, except with respect to shares of Restricted Stock granted to Section
162(m) Participants that is intended to qualify as performance-based compensation as described in
Section 162(m)(4)(C) of the Code, the Administrator in its sole and absolute discretion may provide
that no such right of repurchase shall exist in the event of a Termination of Employment,
Termination of Directorship, or Termination of Consultancy, as applicable, without cause or
following any Change in Control or because of the Holders retirement, or otherwise.
7.6. Escrow. The Secretary of the Company or such other escrow holder as the
Administrator may appoint shall retain physical custody of each certificate representing Restricted
Stock until all of the restrictions imposed under the Award Agreement with respect to the shares
evidenced by such certificate expire or shall have been removed.
7.7. Legend. In order to enforce the restrictions imposed upon shares of Restricted
Stock hereunder, the Administrator shall cause a legend or legends to be placed on certificates
representing all shares of Restricted Stock that are still subject to restrictions under Award
Agreements, which legend or legends shall make appropriate reference to the conditions imposed
thereby.
7.8. Section 83(b) Election. If a Holder makes an election under Section 83(b) of the
Code, or any successor section thereto, to be taxed with respect to the Restricted Stock as of the
date of transfer of the
B-14
Restricted Stock rather than as of the date or dates upon which the Holder would otherwise be
taxable under Section 83(a) of the Code, the Holder shall deliver a copy of such election to the
Company immediately after filing such election with the Internal Revenue Service.
ARTICLE VIII.
DIVIDEND EQUIVALENTS, DEFERRED STOCK, STOCK PAYMENTS,
RESTRICTED STOCK UNITS
8.1. Eligibility. Subject to the Award Limit, one or more Dividend Equivalent awards,
Deferred Stock awards, Stock Payment awards, and/or Restricted Stock Unit awards may be granted to
any Employee whom the Administrator determines is a key Employee, or any Independent Director or
any Consultant, whom the Administrator determines should receive such an Award.
8.2. Dividend Equivalents.
(a) Any key Employee, Independent Director or Consultant selected by the Administrator
may be granted Dividend Equivalents based on the dividends declared on the Common Stock, to be
credited as of dividend payment dates, during the period between the date a Stock Appreciation
Right, Deferred Stock award, or Restricted Stock Unit award is granted, and the date such Stock
Appreciation Right, Deferred Stock award, or Restricted Stock Unit award vests, is exercised,
is distributed, terminates or expires, as determined by the Administrator. Such Dividend
Equivalents shall be converted to cash or additional shares of Common Stock by such formula and
at such time and subject to such limitations as may be determined by the Administrator.
(b) Any Holder of an Option who is an Employee, Independent Director or Consultant
selected by the Administrator may be granted Dividend Equivalents based on the dividends
declared on the Common Stock, to be credited as of dividend payment dates, during the period
between the date an Option is granted, and the date such Option vests, is exercised, terminates
or expires, as determined by the Administrator. Such Dividend Equivalents shall be converted to
cash or additional shares of Common Stock by such formula and at such time and subject to such
limitations as may be determined by the Administrator.
(c) Dividend Equivalents granted with respect to Options intended to be qualified
performance-based compensation for purposes of Section 162(m) of the Code shall be payable,
with respect to pre-exercise periods, regardless of whether such Option is subsequently
exercised.
8.3. Stock Payments. Any key Employee, Independent Director or Consultant selected by
the Administrator may receive Stock Payments in the manner determined from time to time by the
Administrator. The number of shares shall be determined by the Administrator and may be based upon
the Performance Criteria or other specific performance criteria determined appropriate by the
Administrator, determined on the date such Stock Payment is made or on any date thereafter.
8.4. Deferred Stock. Any key Employee, Independent Director or Consultant selected by
the Administrator may be granted an award of Deferred Stock in the manner determined from time to
time by the Administrator. The number of shares of Deferred Stock shall be determined by the
Administrator and may be based upon the Performance Criteria or other specific performance criteria
determined to be appropriate by the Administrator, in each case on a specified date or dates or
over any period or periods determined by the Administrator. Common Stock underlying a Deferred
Stock award shall not be issued until the Deferred Stock award shall have vested, pursuant to a
vesting schedule or performance criteria set by the Administrator. The Administrator shall specify
the distribution dates applicable to each Deferred Stock award which shall be no earlier than the
vesting dates or events of the award and may be determined at the election of the Employee,
Independent Director or Consultant. Unless otherwise provided by the Administrator, a Holder of
Deferred Stock shall have no rights as a Company stockholder
B-15
with respect to such Deferred Stock until such time as the Award has vested and the Common Stock
underlying the Award has been issued.
8.5. Restricted Stock Units. Any key Employee, Independent Director or Consultant
selected by the Administrator may be granted an award of Restricted Stock Units in the manner
determined from time to time by the Administrator. The Administrator is authorized to make awards
of Restricted Stock Units in such amounts and subject to such terms and conditions as determined by
the Administrator. The Administrator shall specify the date or dates on which the Restricted Stock
Units shall become fully vested and nonforfeitable, and may specify such conditions to vesting as
it deems appropriate, and may specify that such Restricted Stock Units become fully vested and
nonforfeitable pursuant to the satisfaction of one or more Performance Goals or other specific
performance goals as the Administrator determines to be appropriate at the time of the grant of the
Restricted Stock Units or thereafter, in each case on a specified date or dates or over any period
or periods determined by the Administrator. The Administrator shall specify the distribution dates
applicable to each award of Restricted Stock Units which shall be no earlier than the vesting dates
or events of the award and may be determined at the election of the Employee, Independent Director
or Consultant. On the distribution dates, the Company shall issue to the Participant one
unrestricted, fully transferable share of Common Stock for each Restricted Stock Unit distributed.
The Administrator shall specify the purchase price, if any, to be paid by the Employee, Independent
Director or Consultant to the Company for such shares of Common Stock to be distributed pursuant to
the Restricted Stock Unit award.
8.6. Term. The term of a Dividend Equivalent award, Deferred Stock award, Stock Payment
award and/or Restricted Stock Unit award shall be set by the Administrator in its discretion.
8.7. Exercise or Purchase Price. The Administrator may establish the exercise or
purchase price of shares of Deferred Stock, shares distributed as a Stock Payment award or shares
distributed pursuant to a Restricted Stock Unit award; provided, however, that such price shall not
be less than the par value of a share of Common Stock, unless otherwise permitted by applicable
state law.
8.8. Exercise upon Termination of Employment, Termination of Consultancy or Termination of
Directorship. A Dividend Equivalent award, Deferred Stock award, Stock Payment award and/or
Restricted Stock Unit award is exercisable or distributable only while the Holder is an Employee,
Consultant or Independent Director, as applicable; provided, however, that the Administrator in its
sole and absolute discretion may provide that the Dividend Equivalent award, Deferred Stock award,
Stock Payment award and/or Restricted Stock Unit award may be exercised or distributed subsequent
to a Termination of Employment, Termination of Directorship or Termination of Consultancy following
a change of control or ownership (within the meaning of Section 1.162-27(e)(2)(v) or any
successor regulation thereto) of the Company.
8.9. Form of Payment. Payment of the amount determined under Section 8.2 above shall be
in cash, in Common Stock or a combination of both, as determined by the Administrator. To the
extent any payment under this Article VIII is effected in Common Stock, it shall be made subject to
satisfaction of all provisions of Section 6.3.
ARTICLE IX.
STOCK APPRECIATION RIGHTS
9.1. Grant of Stock Appreciation Rights. A Stock Appreciation Right may be granted to
any key Employee, Independent Director or Consultant selected by the Administrator. A Stock
Appreciation Right may be granted: (a) in connection and simultaneously with the grant of an
Option, (b) with respect to a previously granted Option, or (c) independent of an Option. A Stock
Appreciation Right shall be subject to such terms and conditions not inconsistent with the Plan as
the Administrator shall impose and shall be evidenced by an Award Agreement.
B-16
9.2. Coupled Stock Appreciation Rights.
(a) A Coupled Stock Appreciation Right (CSAR) shall be related to a particular Option
and shall be exercisable only when and to the extent the related Option is exercisable.
(b) A CSAR may be granted to the Holder for no more than the number of shares subject to
the simultaneously or previously granted Option to which it is coupled.
(c) A CSAR shall entitle the Holder (or other person entitled to exercise the Option
pursuant to the Plan) to surrender to the Company unexercised a portion of the Option to which
the CSAR relates (to the extent then exercisable pursuant to its terms) and to receive from the
Company in exchange therefor an amount determined by multiplying the difference obtained by
subtracting the Option exercise price from the Fair Market Value of a share of Common Stock on
the date of exercise of the CSAR by the number of shares of Common Stock with respect to which
the CSAR shall have been exercised, subject to any limitations the Administrator may impose.
9.3. Independent Stock Appreciation Rights.
(a) An Independent Stock Appreciation Right (ISAR) shall be unrelated to any Option
and shall have a term set by the Administrator provided, however, that the term shall not be
more than ten (10) years from the date the ISAR is granted. An ISAR shall be exercisable in
such installments as the Administrator may determine. An ISAR shall cover such number of shares
of Common Stock as the Administrator may determine; provided, however, that unless the
Administrator otherwise provides in the terms of the ISAR or otherwise, no ISAR granted to a
person subject to Section 16 of the Exchange Act shall be exercisable until at least six months
have elapsed from (but excluding) the date on which the Option was granted. The exercise price
per share of Common Stock subject to each ISAR shall be set by the Administrator; provided,
that such exercise price per share shall not be less than 100% of the Fair Market Value of a
share of Common Stock on the date the ISAR is granted. An ISAR is exercisable only while the
Holder is an Employee, Independent Director or Consultant; provided, that the Administrator may
determine that the ISAR may be exercised subsequent to Termination of Employment, Termination
of Directorship or Termination of Consultancy without cause, or following a Change in Control
of the Company, or because of the Holders retirement, death or disability, or otherwise.
(b) An ISAR shall entitle the Holder (or other person entitled to exercise the ISAR
pursuant to the Plan) to exercise all or a specified portion of the ISAR (to the extent then
exercisable pursuant to its terms) and to receive from the Company an amount determined by
multiplying the difference obtained by subtracting the exercise price per share of the ISAR
from the Fair Market Value of a share of Common Stock on the date of exercise of the ISAR by
the number of shares of Common Stock with respect to which the ISAR shall have been exercised,
subject to any limitations the Administrator may impose.
9.4. Payment and Limitations on Exercise.
(a) Payment of the amounts determined under Section 9.2(c) and 9.3(b) above shall be in
cash, in Common Stock (based on its Fair Market Value as of the date the Stock Appreciation
Right is exercised) or a combination of both, as determined by the Administrator. To the extent
such payment is effected in Common Stock it shall be made subject to satisfaction of all
provisions of Section 6.3 above pertaining to Options.
(b) Holders of Stock Appreciation Rights may be required to comply with any timing or
other restrictions with respect to the settlement or exercise of a Stock Appreciation Right,
including a window-period limitation, as may be imposed in the discretion of the Administrator.
B-17
ARTICLE X.
COMPLIANCE WITH SECTION 409A OF THE CODE
10.1. Awards subject to Code Section 409A. Any Award that constitutes, or provides for, a
deferral of compensation subject to Section 409A of the Code (a Section 409A Award) shall satisfy
the requirements of Section 409A of the Code and this Article X, to the extent applicable. The
Award Agreement with respect to a Section 409A Award shall incorporate the terms and conditions
required by Section 409A of the Code and this Article X.
10.2. Distributions under a Section 409A Award.
(a) Subject to subsection (b), any shares of Common Stock, cash or other property or
amounts to be paid or distributed upon the grant, issuance, vesting, exercise or payment of a
Section 409A Award shall be distributed in accordance with the requirements of Section
409A(a)(2) of the Code, and shall not be distributed earlier than:
(i) the Holders separation from service, as determined by the Secretary of the
Treasury,
(ii) the date the Holder becomes disabled,
(iii) the Holders death,
(iv) a specified time (or pursuant to a fixed schedule) specified under the Award
Agreement at the date of the deferral of such compensation,
(v) to the extent provided by the Secretary of the Treasury, a change in the
ownership or effective control of the Company or a Subsidiary, or in the ownership of a
substantial portion of the assets of the Company or a Subsidiary, or
(vi) the occurrence of an unforeseeable emergency with respect to the Holder.
(b) In the case of a Holder who is a specified employee, the requirement of paragraph
(a)(i) shall be met only if the distributions with respect to the Section 409A Award may not be
made before the date which is six months after the Holders separation from service (or, if
earlier, the date of the Holders death). For purposes of this subsection (b), a Holder shall
be a specified employee if such Holder is a key employee (as defined in Section 416(i) of the
Code without regard to paragraph (5) thereof) of a corporation any stock of which is publicly
traded on an established securities market or otherwise, as determined under Section
409A(a)(2)(B)(i) of the Code and the Treasury Regulations thereunder.
(c) The requirement of paragraph (a)(vi) shall be met only if, as determined under
Treasury Regulations under Section 409A(a)(2)(B)(ii) of the Code, the amounts distributed with
respect to the unforeseeable emergency do not exceed the amounts necessary to satisfy such
unforeseeable emergency plus amounts necessary to pay taxes reasonably anticipated as a result
of the distribution, after taking into account the extent to which such unforeseeable emergency
is or may be relieved through reimbursement or compensation by insurance or otherwise or by
liquidation of the Holders assets (to the extent the liquidation of such assets would not
itself cause severe financial hardship).
(d) For purposes of this Section, the terms specified therein shall have the respective
meanings ascribed thereto under Section 409A of the Code and the Treasury Regulations
thereunder.
10.3. Prohibition on Acceleration of Benefits. The time or schedule of any distribution or
payment of any shares of Common Stock, cash or other property or amounts under a Section 409A Award
shall not be accelerated, except as otherwise permitted under Section 409A(a)(3) of the Code and
the Treasury Regulations thereunder.
B-18
10.4. Elections under Section 409A Awards.
(a) Any deferral election provided under or with respect to an Award to any Employee,
Independent Director or Consultant, or to the Holder of a Section 409A Award, shall satisfy the
requirements of Section 409A(a)(4)(B) of the Code, to the extent applicable, and, except as
otherwise permitted under paragraph (i) or (ii), any such deferral election with respect to
compensation for services performed during a taxable year shall be made not later than the
close of the preceding taxable year, or at such other time as provided in Treasury Regulations.
(i) In the case of the first year in which an Employee, Independent Director or
Consultant, or the Holder, becomes eligible to participate in the Plan, any such deferral
election may be made with respect to services to be performed subsequent to the election
with thirty (30) days after the date the Employee, Independent Director or Consultant, or
the Holder, becomes eligible to participate in the Plan, as provided under Section
409A(a)(4)(B)(ii) of the Code.
(ii) In the case of any performance-based compensation based on services performed
by an Employee, Independent Director or Consultant, or the Holder, over a period of at
least twelve (12) months, any such deferral election may be made no later than six months
before the end of the period, as provided under Section 409A(a)(4)(B)(iii) of the Code.
(b) In the event that a Section 409A Award permits, under a subsequent election by the
Holder of such Section 409A Award, a delay in a distribution or payment of any shares of Common
Stock, cash or other property or amounts under such Section 409A Award, or a change in the form
of distribution or payment, such subsequent election shall satisfy the requirements of Section
409A(a)(4)(C) of the Code, and:
(i) such subsequent election may not take effect until at least twelve (12) months
after the date on which the election is made,
(ii) in the case such subsequent election relates to a distribution or payment not
described in Section 10.2(a)(ii), (iii) or (vi), the first payment with respect to such
election may be deferred for a period of not less than five years from the date such
distribution or payment otherwise would have been made, and
(iii) in the case such subsequent election relates to a distribution or payment
described in Section 10.2(a)(iv), such election may not be made less than twelve (12)
months prior to the date of the first scheduled distribution or payment under Section
10.2(a)(iv).
10.5. Compliance in Form and Operation. A Section 409A Award, and any election under or
with respect to such Section 409A Award, shall comply in form and operation with the requirements
of Section 409A of the Code and the Treasury Regulations thereunder.
ARTICLE XI.
ADMINISTRATION
11.1. Compensation Committee. The Compensation Committee (or another committee or a
subcommittee of the Board assuming the functions of the Committee under the Plan) shall consist
solely of two or more Independent Directors appointed by and holding office at the pleasure of the
Board, each of whom is both a non-employee director as defined by Rule 16b-3 and an outside
director for purposes of Section 162(m) of the Code. Appointment of Committee members shall be
effective upon acceptance of appointment. Committee members may resign at any time by delivering
written notice to the Board. Vacancies in the Committee may be filled by the Board.
B-19
11.2. Duties and Powers of Committee. It shall be the duty of the Committee to conduct the
general administration of the Plan in accordance with its provisions. The Committee shall have the
power to interpret the Plan and the Award Agreements, and to adopt such rules for the
administration, interpretation and application of the Plan as are consistent therewith, to
interpret, amend or revoke any such rules and to amend any Award Agreement provided that the rights
or obligations of the Holder of the Award that is the subject of any such Award Agreement are not
affected adversely. Any such grant or award under the Plan need not be the same with respect to
each Holder. Any such interpretations and rules with respect to Incentive Stock Options shall be
consistent with the provisions of Section 422 of the Code. In its absolute discretion, the Board
may at any time and from time to time exercise any and all rights and duties of the Committee under
the Plan except with respect to matters which under Rule 16b-3 or Section 162(m) of the Code, or
any regulations or rules issued thereunder, are required to be determined in the sole discretion of
the Committee. Notwithstanding the foregoing, the full Board, acting by a majority of its members
in office, shall conduct the general administration of the Plan with respect to Awards granted to
Independent Directors.
11.3. Majority Rule; Unanimous Written Consent. The Committee shall act by a majority of
its members in attendance at a meeting at which a quorum is present or by a memorandum or other
written instrument signed by all members of the Committee.
11.4. Compensation; Professional Assistance; Good Faith Actions. Members of the Committee
shall receive such compensation, if any, for their services as members as may be determined by the
Board. All expenses and liabilities which members of the Committee incur in connection with the
administration of the Plan shall be borne by the Company. The Committee may, with the approval of
the Board, employ attorneys, consultants, accountants, appraisers, brokers or other persons. The
Committee, the Company and the Companys officers and Directors shall be entitled to rely upon the
advice, opinions or valuations of any such persons. All actions taken and all interpretations and
determinations made by the Committee or the Board in good faith shall be final and binding upon all
Holders, the Company and all other interested persons. No members of the Committee or Board shall
be personally liable for any action, determination or interpretation made in good faith with
respect to the Plan or Awards, and all members of the Committee and the Board shall be fully
protected by the Company in respect of any such action, determination or interpretation.
11.5. Delegation of Authority to Grant Awards. The Committee may, but need not, delegate
from time to time some or all of its authority to grant Awards under the Plan to a committee
consisting of one or more members of the Committee or of one or more officers of the Company, to
the extent permitted by applicable state law; provided, however, that the Committee may not
delegate its authority to grant Awards to individuals: (a) who are subject on the date of the
grant to the reporting rules under Section 16(a) of the Exchange Act, (b) who are Section 162(m)
Participants, or (c) who are officers of the Company who are delegated authority by the Committee
hereunder. Any delegation hereunder shall be subject to the restrictions and limits that the
Committee specifies at the time of such delegation of authority and may be rescinded at any time by
the Committee. At all times, any committee appointed under this Section 11.5 shall serve in such
capacity at the pleasure of the Committee.
ARTICLE XII.
MISCELLANEOUS PROVISIONS
12.1. Transferability of Awards.
(a) Except as otherwise provided in Section 12.1(b):
(i) No Award under the Plan may be sold, pledged, assigned or transferred in any
manner other than by will or the laws of descent and distribution or, subject to the
consent of the Administrator, pursuant to a DRO, unless and until such Award has been
exercised, or the shares
B-20
underlying such Award have been issued, and all restrictions applicable to such shares
have lapsed;
(ii) No Option, Restricted Stock award, Deferred Stock award, Stock Appreciation
Right, Dividend Equivalent award, Stock Payment award, or Restricted Stock Unit award, or
any interest or right therein, shall be liable for the debts, contracts or engagements of
the Holder or his successors in interest or shall be subject to disposition by transfer,
alienation, anticipation, pledge, encumbrance, assignment or any other means whether such
disposition be voluntary or involuntary or by operation of law by judgment, levy,
attachment, garnishment or any other legal or equitable proceedings (including
bankruptcy), and any attempted disposition thereof shall be null and void and of no
effect, except to the extent that such disposition is permitted by the preceding sentence;
and
(iii) During the lifetime of the Holder, only the Holder may exercise an Option or
other Award (or any portion thereof) granted to him under the Plan, unless it has been
disposed of pursuant to a DRO; after the death of the Holder, any exercisable portion of
an Option or other Award may, prior to the time when such portion becomes unexercisable
under the Plan or the applicable Award Agreement, be exercised by his personal
representative or by any person empowered to do so under the deceased Holders will or
under the then applicable laws of descent and distribution.
(b) Notwithstanding Section 12.1(a), the Administrator, in its sole discretion, may
determine to permit a Holder to transfer a Non-Qualified Stock Option to any one or more
Permitted Transferees (as defined below), subject to the following terms and conditions: (i) a
Non-Qualified Stock Option transferred to a Permitted Transferee shall not be assignable or
transferable by the Permitted Transferee other than by will or the laws of descent and
distribution; (ii) any Non-Qualified Stock Option which is transferred to a Permitted
Transferee shall continue to be subject to all the terms and conditions of the Non-Qualified
Stock Option as applicable to the original Holder (other than the ability to further transfer
the Non-Qualified Stock Option); and (iii) the Holder and the Permitted Transferee shall
execute any and all documents requested by the Administrator, including, without limitation
documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy
any requirements for an exemption for the transfer under applicable federal and state
securities laws and (C) evidence the transfer. For purposes of this Section 12.1(b), Permitted
Transferee shall mean, with respect to a Holder, any child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including
adoptive relationships, any person sharing the Holders household (other than a tenant or
employee), a trust in which these persons (or the Holder) control the management of assets, and
any other entity in which these persons (or the Holder) own more than fifty percent of the
voting interests, or any other transferee specifically approved by the Administrator after
taking into account any state or federal tax or securities laws applicable to transferable
Non-Qualified Stock Options.
12.2. Amendment, Suspension or Termination of the Plan. Except as otherwise provided in
this Section 12.2, the Plan may be wholly or partially amended or otherwise modified, suspended or
terminated at any time or from time to time by the Board. However, without approval of the
Companys stockholders given within twelve (12) months before or after the action by the Board, no
action of the Board may, except as provided in Section 12.3, (i) increase the limits imposed in
Section 2.1 on the maximum number of shares which may be issued under the Plan, or the maximum
number of shares which may be granted or issued as Restricted Stock awards, Restricted Stock Unit
awards, Dividend Equivalent awards, Deferred Stock awards, or Stock Payment awards, (ii) expand the
classes of persons to whom Awards may be granted under the Plan, or (iii) decrease the exercise
price of any outstanding Option or Stock Appreciation Right granted under the Plan. No amendment,
suspension or termination of the Plan shall,
B-21
without the consent of the Holder, alter or impair any rights or obligations under any Award
theretofore granted or awarded, unless the Award itself otherwise expressly so provides. No Awards
may be granted or awarded during any period of suspension or after termination of the Plan, and in
no event may any Award be granted under the Plan after the first to occur of the following events:
(a) The expiration of ten (10) years from the date this second amendment and
restatement of the Plan is adopted by the Board; or
(b) The expiration of ten (10) years from the date this second amendment and restatement
of the Plan is approved by the Companys stockholders under Section 12.4.
12.3. Changes in Common Stock or Assets of the Company, Acquisition or Liquidation of the
Company and Other Corporate Events.
(a) Subject to Section 12.3(e), in the event that the Administrator determines that any
dividend or other distribution (whether in the form of cash, Common Stock, other securities or
other property), recapitalization, reclassification, stock split, reverse stock split,
reorganization, merger, consolidation, split-up, spin-off, combination, repurchase,
liquidation, dissolution, or sale, transfer, exchange or other disposition of all or
substantially all of the assets of the Company, or exchange of Common Stock or other securities
of the Company, issuance of warrants or other rights to purchase Common Stock or other
securities of the Company, or other similar corporate transaction or event affects the Common
Stock, then the Administrator shall equitably adjust any or all of the following in order to
prevent dilution or enlargement of the benefits or potential benefits intended to be made
available under the Plan or with respect to an Award:
(i) The number and kind of shares of Common Stock (or other securities or
property) with respect to which Awards may be granted or awarded (including, but not
limited to, adjustments of the limitations in Section 2.1 on the maximum number and kind
of shares which may be issued under the Plan, and the maximum number and kind of shares
which may be granted or issued as Restricted Stock awards, Restricted Stock Unit awards,
Dividend Equivalent awards, Deferred Stock awards or Stock Payment awards, adjustments of
the Award Limit, and adjustments of the manner in which shares subject to Full Value
Awards will be counted);
(ii) The number and kind of shares of Common Stock (or other securities or
property) subject to outstanding Awards; and
(iii) The grant or exercise price with respect to any Award.
(b) Subject to Sections 12.3(c) and 12.3(e), in the event of any transaction or event
described in Section 12.3(a) or any unusual or nonrecurring transactions or events affecting
the Company, any affiliate of the Company, or the financial statements of the Company or any
affiliate, or of changes in applicable laws, regulations or accounting principles, the
Administrator, in its sole and absolute discretion, and on such terms and conditions as it
deems appropriate, either by the terms of the Award or by action taken prior to the occurrence
of such transaction or event and either automatically or upon the Holders request, is hereby
authorized to take any one or more of the following actions whenever the Administrator
determines that such action is appropriate in order to prevent dilution or enlargement of the
benefits or potential benefits intended to be made available under the Plan or with respect to
any Award under the Plan, to facilitate such transactions or events or to give effect to such
changes in laws, regulations or principles:
(i) To provide for either the purchase of any such Award for an amount of cash
equal to the amount that could have been attained upon the exercise of such Award or
realization of the Holders rights had such Award been currently exercisable or payable or
fully vested or the
B-22
replacement of such Award with other rights or property selected by the Administrator in
its sole discretion;
(ii) To provide that the Award cannot vest, be exercised or become payable after
such event;
(iii) To provide that such Award shall be exercisable as to all shares covered
thereby, notwithstanding anything to the contrary in Section 5.3 or the provisions of such
Award;
(iv) To provide that such Award be assumed by the successor or survivor corporation,
or a parent or subsidiary thereof, or shall be substituted for by similar options, rights
or awards covering the stock of the successor or survivor corporation, or a parent or
subsidiary thereof, with appropriate adjustments as to the number and kind of shares and
prices; and
(v) To make adjustments in the number and type of shares of Common Stock (or other
securities or property) subject to outstanding Awards, and/or in the terms and conditions
of (including the grant, exercise or purchase price), and the criteria included in,
outstanding options, rights and awards and options, rights and awards which may be granted
in the future.
(vi) To provide that, for a specified period of time prior to such event, the
restrictions imposed under an Award Agreement upon some or all shares of Restricted Stock,
Restricted Stock Units or Deferred Stock may be terminated, and, in the case of Restricted
Stock, some or all shares of such Restricted Stock may cease to be subject to repurchase
under Section 7.5 or forfeiture under Section 7.4 after such event.
(c) Notwithstanding any other provision of the Plan, in the event of a Change in
Control, each outstanding Award shall remain outstanding, or shall be assumed or an equivalent
award substituted by the successor corporation, or a parent or subsidiary of the successor
corporation. In the event that the successor corporation, or a parent or subsidiary of the
successor corporation, with respect to the Change in Control transaction refuses to assume or
substitute for the Award, the Holder shall have the right to exercise the Award as to all of
the shares subject thereto, including shares as to which such Award otherwise would not be
exercisable, and the Holder shall have the right to vest in, and received a distribution of,
such Award, with respect to all of the shares subject thereto. If an Award becomes exercisable
in lieu of assumption or substitution by the successor corporation, or a parent or subsidiary
corporation, with respect to a Change in Control transaction, the Administrator shall notify
the Holder that the Award shall be fully exercisable for a period of not less than fifteen (15)
days from the date of such notice prior to the Change in Control transaction, and the Award
shall terminate upon the expiration of such period. For purposes of this Section 12.3(c), the
Award shall be assumed, or an equivalent award shall be substituted for such Award, if,
following the Change in Control transaction, the Award or substituted award confers on the
Holder the right to purchase or receive, for each share subject to the Award immediately prior
to the Change in Control transaction, the consideration (whether in stock, cash, or other
securities or property, or a combination thereof) received or to be received for each share of
Common Stock in the Change in Control transaction on the effective date of the Change in
Control transaction (and if holders of shares of Common Stock were offered a choice of
consideration, the type of consideration chosen by the holders of a majority of the outstanding
shares of Common Stock); provided, however, that, if such consideration received in the Change
in Control transaction was not solely common stock of the successor corporation or its parent,
the Administrator may, with the consent of the successor corporation or its parent, provide for
the consideration to be received upon the exercise, vesting or distribution of the assumed
Award or substituted award, for each share subject to the Award, to be solely common stock of
the successor corporation or its parent equal in fair market value to the per share
consideration received by the holders of Common Stock in the Change in Control transaction.
B-23
(d) Subject to Sections 12.3(e), 3.2 and 3.3, the Administrator may, in its discretion,
include such further provisions and limitations in any Award or Award Agreement as it may deem
equitable and in the best interests of the Company.
(e) With respect to Awards which are granted to Section 162(m) Participants and are
intended to qualify as performance-based compensation under Section 162(m)(4)(C), no adjustment
or action described in this Section 12.3 or in any other provision of the Plan shall be
authorized to the extent that such adjustment or action would cause such Award to fail to so
qualify under Section 162(m)(4)(C), or any successor provisions thereto. No adjustment or
action described in this Section 12.3 or in any other provision of the Plan shall be authorized
to the extent that such adjustment or action would cause the Plan to violate Section 422(b)(1)
of the Code. Furthermore, no such adjustment or action shall be authorized to the extent such
adjustment or action would result in short-swing profits liability under Section 16 or violate
the exemptive conditions of Rule 16b-3 unless the Administrator determines that the Award is
not to comply with such exemptive conditions. The number of shares of Common Stock subject to
any Award shall always be rounded to the next whole number.
(f) Notwithstanding the foregoing, in the event that the Company becomes a party to a
transaction that is intended to qualify for pooling of interests accounting treatment and,
but for one or more of the provisions of this Plan or any Award Agreement would so qualify,
then this Plan and any Award Agreement shall be interpreted so as to preserve such accounting
treatment, and to the extent that any provision of the Plan or any Award Agreement would
disqualify the transaction from pooling of interests accounting treatment (including, if
applicable, an entire Award Agreement), then such provision shall be null and void. All
determinations to be made in connection with the preceding sentence shall be made by the
independent accounting firm whose opinion with respect to pooling of interests treatment is
required as a condition to the Companys consummation of such transaction.
(g) The existence of the Plan, the Award Agreement and the Awards granted hereunder
shall not affect or restrict in any way the right or power of the Company or the shareholders
of the Company to make or authorize any adjustment, recapitalization, reorganization or other
change in the Companys capital structure or its business, any merger or consolidation of the
Company, any issue of stock or of options, warrants or rights to purchase stock or of bonds,
debentures, preferred or prior preference stocks whose rights are superior to or affect the
Common Stock or the rights thereof or which are convertible into or exchangeable for Common
Stock, or the dissolution or liquidation of the company, or any sale or transfer of all or any
part of its assets or business, or any other corporate act or proceeding, whether of a similar
character or otherwise.
(h) No action shall be taken under this Section 12.3 which shall cause an Award to fail
to comply with Section 409A of the Code or the Treasury Regulations thereunder, to the extent
applicable to such Award.
12.4. Approval of Plan by Stockholders. The Plan will be submitted for the approval of the
Companys stockholders within twelve (12) months after the date of the Boards initial adoption of
the Plan. Awards may be granted or awarded prior to such stockholder approval, provided, that such
Awards shall not be exercisable nor shall such Awards vest prior to the time when the Plan is
approved by the stockholders, and provided further, that if such approval has not been obtained at
the end of said twelve-month period, all Awards previously granted or awarded under the Plan shall
thereupon be canceled and become null and void. In addition, if the Board determines that Awards
other than Options or Stock Appreciation Rights which may be granted to Section 162(m) Participants
should continue to be eligible to qualify as performance-based compensation under Section
162(m)(4)(C) of the Code, the Performance Criteria must be disclosed to and approved by the
Companys stockholders no later than the first
B-24
stockholder meeting that occurs in the fifth year following the year in which the Companys
stockholders previously approved the Plan, as amended and restated to include the Performance
Criteria.
12.5. Tax Withholding. The Company shall be entitled to require payment in cash or
deduction from other compensation payable to each Holder of any sums required by federal, state or
local tax law to be withheld with respect to the grant, issuance, vesting, exercise or payment of
any Award. The Administrator may in its discretion and in satisfaction of the foregoing requirement
allow such Holder to elect to have the Company withhold shares of Common Stock otherwise issuable
under such Award (or allow the return of shares of Common Stock) having a Fair Market Value equal
to the sums required to be withheld. Notwithstanding any other provision of the Plan, the number of
shares of Common Stock which may be withheld with respect to the issuance, vesting, exercise or
payment of any Award (or which may be repurchased from the Holder of such Award within six months
after such shares of Common Stock were acquired by the Holder from the Company) in order to satisfy
the Holders federal and state income and payroll tax liabilities with respect to the issuance,
vesting, exercise or payment of the Award shall be limited to the number of shares which have a
Fair Market Value on the date of withholding or repurchase equal to the aggregate amount of such
liabilities based on the minimum statutory withholding rates for federal and state tax income and
payroll tax purposes that are applicable to such supplemental taxable income.
12.6. Prohibition on Repricing. Subject to Section 12.3, the Administrator shall not,
without the approval of the stockholders of the Company, authorize the amendment of any outstanding
Award to reduce its price per share. Furthermore, no Award shall be canceled and replaced with the
grant of an Award having a lesser price per share without the further approval of stockholders of
the Company.
12.7. Forfeiture Provisions. Pursuant to its general authority to determine the terms and
conditions applicable to Awards and the Award Agreements under the Plan, the Administrator shall
have the right to provide, in the terms of Awards made under the Plan, or to require a Holder to
agree by separate written instrument, that: (a)(i) any proceeds, gains or other economic benefit
actually or constructively received by the Holder upon any receipt or exercise of the Award, or
upon the receipt or resale of any Common Stock underlying the Award, must be paid to the Company,
and (ii) the Award shall terminate and any unexercised portion of the Award (whether or not vested)
shall be forfeited, if (b)(i) a Termination of Employment, Termination of Directorship or
Termination of Consultancy occurs prior to a specified date, or within a specified time period
following receipt or exercise of the Award, or (ii) the Holder at any time, or during a specified
time period, engages in any activity in competition with the Company, or which is inimical,
contrary or harmful to the interests of the Company, as further defined by the Administrator or
(iii) the Holder incurs a Termination of Employment, Termination of Directorship or Termination of
Consultancy for cause (as such term is defined in the sole and absolute discretion of the
Committee, or as set forth in a written agreement relating to such Award between the Company and
the Holder).
12.8. Effect of Plan upon Options and Compensation Plans. The adoption of the Plan shall
not affect any other compensation or incentive plans in effect for the Company or any Subsidiary.
Nothing in the Plan shall be construed to limit the right of the Company: (a) to establish any
other forms of incentives or compensation for Employees, Directors or Consultants of the Company or
any Subsidiary, or (b) to grant or assume options or other rights or awards otherwise than under
the Plan in connection with any proper corporate purpose including but not by way of limitation,
the grant or assumption of options in connection with the acquisition by purchase, lease, merger,
consolidation or otherwise, of the business, stock or assets of any corporation, partnership,
limited liability company, firm or association.
12.9. Compliance with Laws. The Plan, the granting and vesting of Awards under the Plan and
the issuance and delivery of shares of Common Stock and the payment of money under the Plan or
under Awards granted or awarded hereunder are subject to compliance with all applicable federal and
state laws, rules and regulations (including but not limited to state and federal securities law
and federal margin
B-25
requirements) and to such approvals by any listing, regulatory or governmental authority as may, in
the opinion of counsel for the Company, be necessary or advisable in connection therewith. Any
securities delivered under the Plan shall be subject to such restrictions, and the person acquiring
such securities shall, if requested by the Company, provide such assurances and representations to
the Company as the Company may deem necessary or desirable to assure compliance with all applicable
legal requirements. To the extent permitted by applicable law, the Plan and Awards granted or
awarded hereunder shall be deemed amended to the extent necessary to conform to such laws, rules
and regulations.
12.10. Titles. Titles are provided herein for convenience only and are not to
serve as a basis for interpretation or construction of the Plan.
12.11. Governing Law. The Plan and any agreements hereunder shall be
administered, interpreted and enforced under the internal laws of the State of California without
regard to conflicts of laws thereof.
* * *
I hereby certify that the foregoing amendment and restatement of the Plan was duly adopted by
the Board of Directors of Watson Pharmaceuticals, Inc. on May 7, 2010.
Executed on this 7th day of May 2010.
By:
/s/ DAVID A. BUCHEN
David A. Buchen
Secretary
* * *
I hereby certify that the Plan was previously approved by the stockholders of Watson
Pharmaceuticals, Inc. on May 4, 2007.
Executed on this 7th day of May 2010.
By:
/s/ DAVID A. BUCHEN
David A. Buchen
Secretary
B-26
EX-21.1
3
a58052exv21w1.htm
EX-21.1
exv21w1
Exhibit 21.1
Watson Pharmaceuticals, Inc.
Subsidiaries of the Company
As of February 18, 2011
Name
Jurisdiction of Incorporation
Watson Laboratories, Inc.
Nevada
Watson Laboratories, Inc.
New York
Watson Laboratories, Inc.
Delaware
Watson Laboratories, Inc
Connecticut
Watson Pharma, Inc.
Delaware
Watson Pharmaceuticals (New Jersey), Inc.
Delaware
Andrx Corporation
Delaware
Watson Manufacturing Services, Inc.
Delaware
Watson Cobalt Holdings, LLC
Delaware
Cobalt Laboratories, Inc.
Delaware
Watson Pharma Private Limited
India
Nicobrand Limited
United Kingdom
The Rugby Group, Inc.
New York
Valmed Pharmaceutical, Inc.
New York
Watson Laboratories, Inc.
Florida
Anda, Inc.
Florida
Anda Pharmaceuticals, Inc.
Florida
Watson Management Corporation
Florida
Watson Therapeutics, Inc.
Florida
Makoff R&D Laboratories, Inc.
California
R&D Ferrlecit Capital Resources, Inc.
California
Watson Pharma Holding S.a.r.l.
Luxembourg
Watson Pharma S.a.r.l.
Luxembourg
Robin Hood Holdings, Ltd.
Malta
Arrow Pharmaceutical Holdings, Ltd.
Malta
Arrow Supplies, Ltd.
Malta
Arrow International, Ltd.
Malta
Arrow Group ApS
Denmark
Arrow Scandinavia AB
Sweden
Seeker Investments, Ltd.
British Virgin Islands
Gaja Investments BV
Holland
Arrow Generiques SAS
France
Selamine, Ltd.
Ireland
Arrow Poland SA
Poland
Eden Biopharma Group, Ltd.
United Kingdom
Breath, Ltd.
United Kingdom
Arrow Generics, Ltd.
United Kingdom
Arrow No 7, Ltd.
United Kingdom
Arrow Pharmaceuticals, Inc.
Canada
Cobalt Pharmaceuticals, Inc.
Canada
Arrow Farmaceutica, Ltda.
Brazil
Spirit Pharmaceuticals (Proprietary), Ltd.
Australia
Juta Pharma GmbH
Germany
Scriptpharm Holdings (Proprietary), Ltd.
South Africa
EX-23.1
4
a58052exv23w1.htm
EX-23.1
exv23w1
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3
(Nos. 333-70943, 333-53312, 333-105816, 333-161404) and Form S-8 (Nos. 333-05737, 333-24577,
333-37733, 333-70933, 333-38596, 333-45650, 333-53334, 333-61844, 333-61842, 333-102285,
333-111032, 33-144039) of Watson Pharmaceuticals, Inc. of our report dated February 21, 2011
relating to the financial statements, financial statement schedule and the effectiveness of
internal control over financial reporting, which appears in this Form 10-K.
PricewaterhouseCoopers LLP
Orange County, CA
February 21, 2011
EX-31.1
5
a58052exv31w1.htm
EX-31.1
exv31w1
Exhibit 31.1
Certification of Chief Executive Officer
Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934
I, Paul M. Bisaro, President and Chief Executive Officer, certify that:
1. I have reviewed this annual report on Form 10-K of Watson Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this
report;
4. The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter (the
registrants fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrants internal control over financial
reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrants auditors and
the audit committee of the registrants board of directors (or persons performing the equivalent
function):
a) all significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the
registrants ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrants internal control over financial reporting.
Date: February 21, 2011
By:
/s/ PAUL M. BISARO
Paul M. Bisaro
President and Chief Executive Officer
(Principal Executive Officer)
EX-31.2
6
a58052exv31w2.htm
EX-31.2
exv31w2
Exhibit 31.2
Certification of Chief Financial Officer
Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934
I, R. Todd Joyce, Senior Vice President Chief Financial Officer, certify that:
1. I have reviewed this annual report on Form 10-K of Watson Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this
report;
4. The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter (the
registrants fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrants internal control over financial
reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrants auditors and
the audit committee of the registrants board of directors (or persons performing the equivalent
function):
a) all significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the
registrants ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrants internal control over financial reporting.
Date: February 21, 2011
By:
/s/ R. TODD JOYCE
R. Todd Joyce
Senior Vice President Chief Financial Officer
(Principal Financial Officer)
EX-32.1
7
a58052exv32w1.htm
EX-32.1
exv32w1
Exhibit 32.1
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. of Section 1350, as Created by Section 906 of the Sarbanes-Oxley Act of 2002
The undersigned officer of Watson Pharmaceuticals, Inc. (the Company), hereby
certifies, to such officers knowledge, that:
(i) the Annual Report on Form 10-K of the Company for the year ended December 31, 2010
(the Report) fully complies with the requirements of Section 13(a) or Section 15(d), as
applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
Date: February 21, 2011
By:
/s/ PAUL M. BISARO
Paul M. Bisaro
President and Chief Executive Officer
(Principal Executive Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to
18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, and is not to be incorporated by reference into any filing of the Company,
whether made before or after the date hereof, regardless of any general incorporation language in
such filing.
EX-32.2
8
a58052exv32w2.htm
EX-32.2
exv32w2
Exhibit 32.2
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. of Section 1350, as Created by Section 906 of the Sarbanes-Oxley Act of 2002
The undersigned officer of Watson Pharmaceuticals, Inc. (the Company), hereby
certifies, to such officers knowledge, that:
(i) the Annual Report on Form 10-K of the Company for the year ended December 31, 2010
(the Report) fully complies with the requirements of Section 13(a) or Section 15(d), as
applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
Date: February 21, 2011
By:
/s/ R. TODD JOYCE
R. Todd Joyce
Senior Vice President Chief Financial Officer
(Principal Financial Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to
18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, and is not to be incorporated by reference into any filing of the Company,
whether made before or after the date hereof, regardless of any general incorporation language in
such filing.
EX-101.INS
9
wpi-20101231.xml
EX-101 INSTANCE DOCUMENT
0000884629wpi:VenaCareMember2010-01-012010-12-310000884629wpi:EmployeesMember2010-01-012010-12-310000884629us-gaap:DirectorMember2010-01-012010-12-310000884629us-gaap:MandatorilyRedeemablePreferredStockMember2012-12-020000884629wpi:ContingentConsiderationObligationMember2010-12-310000884629wpi:ContingentConsiderationObligationMember2009-12-310000884629wpi:ContingentConsiderationObligationMember2008-12-3100008846292012-12-0200008846292010-01-012010-03-310000884629us-gaap:ReserveForCashDiscountMember2010-01-012010-12-310000884629wpi:ReturnsAndOtherAllowancesMember2010-01-012010-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2010-01-012010-12-310000884629wpi:RebatesMember2010-01-012010-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2010-01-012010-12-310000884629wpi:ChargebacksMember2010-01-012010-12-310000884629us-gaap:InventoryValuationReserveMember2010-01-012010-12-310000884629us-gaap:InventoryValuationReserveMember2009-01-012009-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2009-01-012009-12-310000884629wpi:RebatesMember2009-01-012009-12-310000884629wpi:ChargebacksMember2009-01-012009-12-310000884629wpi:ReturnsAndOtherAllowancesMember2009-01-012009-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2009-01-012009-12-310000884629us-gaap:ReserveForCashDiscountMember2009-01-012009-12-310000884629us-gaap:InventoryValuationReserveMember2008-01-012008-12-310000884629wpi:ChargebacksMember2008-01-012008-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2008-01-012008-12-310000884629us-gaap:ReserveForCashDiscountMember2008-01-012008-12-310000884629wpi:RebatesMember2008-01-012008-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2008-01-012008-12-310000884629wpi:ReturnsAndOtherAllowancesMember2008-01-012008-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2010-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2010-12-310000884629wpi:RebatesMember2010-12-310000884629wpi:ChargebacksMember2010-12-310000884629wpi:ReturnsAndOtherAllowancesMember2010-12-310000884629us-gaap:InventoryValuationReserveMember2010-12-310000884629us-gaap:ReserveForCashDiscountMember2010-12-310000884629wpi:ReturnsAndOtherAllowancesMember2009-12-310000884629wpi:RebatesMember2009-12-310000884629us-gaap:InventoryValuationReserveMember2009-12-310000884629wpi:ChargebacksMember2009-12-310000884629us-gaap:ReserveForCashDiscountMember2009-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2009-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2009-12-310000884629wpi:ReturnsAndOtherAllowancesMember2008-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2008-12-310000884629wpi:ChargebacksMember2008-12-310000884629us-gaap:InventoryValuationReserveMember2008-12-310000884629us-gaap:ReserveForCashDiscountMember2008-12-310000884629wpi:RebatesMember2008-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2008-12-310000884629us-gaap:ReserveForCashDiscountMember2007-12-310000884629us-gaap:AllowanceForDoubtfulAccountsMember2007-12-310000884629us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2007-12-310000884629us-gaap:InventoryValuationReserveMember2007-12-310000884629wpi:ChargebacksMember2007-12-310000884629wpi:RebatesMember2007-12-310000884629wpi:ReturnsAndOtherAllowancesMember2007-12-310000884629us-gaap:TreasuryStockMember2008-01-012008-12-310000884629us-gaap:TreasuryStockMember2010-01-012010-12-310000884629us-gaap:TreasuryStockMember2009-01-012009-12-310000884629us-gaap:ForeignCountryMember2010-12-310000884629us-gaap:CommonStockMember2010-01-012010-12-310000884629us-gaap:CommonStockMember2008-01-012008-12-310000884629us-gaap:CommonStockMember2009-01-012009-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2010-12-310000884629us-gaap:RetainedEarningsMember2010-12-310000884629us-gaap:AdditionalPaidInCapitalMember2010-12-310000884629us-gaap:AdditionalPaidInCapitalMember2009-12-310000884629us-gaap:RetainedEarningsMember2009-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2009-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2008-12-310000884629us-gaap:AdditionalPaidInCapitalMember2008-12-310000884629us-gaap:RetainedEarningsMember2008-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2007-12-310000884629us-gaap:RetainedEarningsMember2007-12-310000884629us-gaap:AdditionalPaidInCapitalMember2007-12-310000884629us-gaap:TreasuryStockMember2010-12-310000884629us-gaap:CommonStockMember2010-12-310000884629us-gaap:TreasuryStockMember2009-12-310000884629us-gaap:CommonStockMember2009-12-310000884629us-gaap:TreasuryStockMember2008-12-310000884629us-gaap:CommonStockMember2008-12-310000884629us-gaap:TreasuryStockMember2007-12-310000884629us-gaap:CommonStockMember2007-12-310000884629us-gaap:RestrictedStockMember2009-12-310000884629wpi:UrologyMember2010-01-012010-12-310000884629wpi:OthersMember2010-01-012010-12-310000884629wpi:HormonesAndSyntheticSubstitutesMember2010-01-012010-12-310000884629wpi:AntiInfectiveAgentsMember2010-01-012010-12-310000884629wpi:CardiovascularMember2010-01-012010-12-310000884629wpi:CentralNervousSystemMember2010-01-012010-12-310000884629wpi:AntiInfectiveAgentsMember2009-01-012009-12-310000884629wpi:UrologyMember2009-01-012009-12-310000884629wpi:OthersMember2009-01-012009-12-310000884629wpi:HormonesAndSyntheticSubstitutesMember2009-01-012009-12-310000884629wpi:CentralNervousSystemMember2009-01-012009-12-310000884629wpi:CardiovascularMember2009-01-012009-12-310000884629wpi:CentralNervousSystemMember2008-01-012008-12-310000884629wpi:AntiInfectiveAgentsMember2008-01-012008-12-310000884629wpi:HormonesAndSyntheticSubstitutesMember2008-01-012008-12-310000884629wpi:UrologyMember2008-01-012008-12-310000884629wpi:OthersMember2008-01-012008-12-310000884629wpi:CardiovascularMember2008-01-012008-12-310000884629wpi:SeveranceAndRetentionMember2010-01-012010-12-310000884629us-gaap:ResearchAndDevelopmentArrangementMember2010-01-012010-12-310000884629wpi:ProductTransferCostsMember2010-01-012010-12-310000884629us-gaap:FacilityClosingMember2010-01-012010-12-310000884629wpi:SellingGeneralAndAdministrativeMember2010-01-012010-12-310000884629wpi:SellingGeneralAndAdministrativeMember2009-01-012009-12-310000884629wpi:AcceleratedDepreciationResearchAndDevelopmentMember2010-01-012010-12-310000884629wpi:AcceleratedDepreciationMember2010-01-012010-12-310000884629wpi:OperatingExpensesMember2010-01-012010-12-310000884629us-gaap:CostOfSalesMember2010-01-012010-12-310000884629us-gaap:CostOfSalesMember2009-01-012009-12-310000884629us-gaap:ResearchAndDevelopmentArrangementMember2009-01-012009-12-310000884629wpi:SellingGeneralAndAdministrativeMember2010-12-310000884629us-gaap:ResearchAndDevelopmentArrangementMember2010-12-310000884629wpi:ProductTransferCostsMember2010-12-310000884629wpi:AcceleratedDepreciationMember2010-12-310000884629us-gaap:CostOfSalesMember2010-12-310000884629us-gaap:FacilityClosingMember2010-12-310000884629wpi:SeveranceAndRetentionMember2010-12-310000884629wpi:OperatingExpensesMember2010-12-310000884629wpi:AcceleratedDepreciationResearchAndDevelopmentMember2010-12-310000884629wpi:SellingGeneralAndAdministrativeMember2009-12-310000884629wpi:SeveranceAndRetentionMember2009-12-310000884629wpi:OperatingExpensesMember2009-12-310000884629us-gaap:ResearchAndDevelopmentArrangementMember2009-12-310000884629wpi:ProductTransferCostsMember2009-12-310000884629us-gaap:FacilityClosingMember2009-12-310000884629us-gaap:CostOfSalesMember2009-12-310000884629us-gaap:CostOfSalesMember2008-12-310000884629us-gaap:ResearchAndDevelopmentArrangementMember2008-12-310000884629wpi:SellingGeneralAndAdministrativeMember2008-12-310000884629wpi:LombardLoanMember2010-01-012010-12-310000884629wpi:LombardLoanMember2009-01-012009-12-310000884629us-gaap:LandBuildingsAndImprovementsMember2010-01-012010-12-310000884629us-gaap:FurnitureAndFixturesMember2010-01-012010-12-310000884629us-gaap:MachineryAndEquipmentMember2010-01-012010-12-310000884629us-gaap:ComputerEquipmentMember2010-01-012010-12-310000884629wpi:ResearchAndLaboratoryEquipmentMember2010-01-012010-12-3100008846291992-12-310000884629wpi:MokshaEightMember2010-01-012010-12-310000884629wpi:EdenBiopharmGroupLimitedMember2010-01-012010-01-310000884629wpi:AtorvastatinContingentConsiderationLiabilityMember2010-12-310000884629wpi:AtorvastatinContingentConsiderationLiabilityMember2009-12-310000884629wpi:ColumbiaContingentConsiderationLiabilityMember2009-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2010-01-012010-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2009-01-012009-12-310000884629us-gaap:AccumulatedOtherComprehensiveIncomeMember2008-01-012008-12-310000884629us-gaap:ForeignCountryMember2010-12-310000884629us-gaap:StateAndLocalJurisdictionMember2010-12-310000884629us-gaap:RetainedEarningsMember2010-01-012010-12-310000884629us-gaap:RetainedEarningsMember2009-01-012009-12-310000884629us-gaap:RetainedEarningsMember2008-01-012008-12-310000884629us-gaap:LineOfCreditMember2010-12-310000884629wpi:LombardLoanMember2010-12-310000884629us-gaap:NotesPayableOtherPayablesMember2010-12-310000884629us-gaap:MandatorilyRedeemablePreferredStockMember2010-12-310000884629us-gaap:LineOfCreditMember2009-12-310000884629us-gaap:MandatorilyRedeemablePreferredStockMember2009-12-310000884629us-gaap:NotesPayableOtherPayablesMember2009-12-310000884629wpi:LombardLoanMember2009-12-310000884629wpi:VenaCareMember2010-12-310000884629wpi:RevolvingCreditFacilityMember2010-12-310000884629us-gaap:LineOfCreditMember2010-12-310000884629wpi:TermFacilityMember2010-12-310000884629wpi:TermFacilityMember2010-07-012010-07-310000884629wpi:TermFacilityMember2010-01-012010-12-310000884629wpi:IPRAndDMember2010-12-310000884629us-gaap:TradeNamesMember2010-12-310000884629us-gaap:TradeNamesMember2009-12-310000884629wpi:IPRAndDMember2009-12-310000884629wpi:ArrowBusinessAcquisitionMember2010-10-012010-12-310000884629wpi:DistributionSegmentMember2010-12-310000884629wpi:GlobalGenericsSegmentMember2010-12-310000884629wpi:GlobalBrandsContributionMember2010-12-310000884629wpi:GlobalGenericsSegmentMember2009-12-310000884629wpi:DistributionSegmentMember2009-12-310000884629wpi:GlobalBrandsContributionMember2009-12-310000884629wpi:ScinopharmMember2010-01-012010-03-310000884629wpi:ProductRightsAndOtherRelatedIntangiblesMember2010-01-012010-12-310000884629us-gaap:CustomerRelationshipsMember2010-12-310000884629wpi:CoreTechnologyMember2010-12-310000884629wpi:CoreTechnologyMember2009-12-310000884629us-gaap:CustomerRelationshipsMember2009-12-310000884629wpi:ProductRightsAndOtherRelatedIntangiblesMember2009-12-310000884629wpi:ContingentConsiderationObligationMember2010-01-012010-12-310000884629wpi:ContingentConsiderationObligationMember2009-01-012009-12-310000884629us-gaap:FairValueInputsLevel2Member2010-12-310000884629us-gaap:FairValueInputsLevel3Member2010-12-310000884629us-gaap:FairValueInputsLevel1Member2010-12-310000884629us-gaap:FairValueInputsLevel3Member2009-12-310000884629us-gaap:FairValueInputsLevel1Member2009-12-310000884629us-gaap:FairValueInputsLevel2Member2009-12-310000884629wpi:MokshaEightMember2010-10-040000884629us-gaap:RestrictedStockMember2010-01-012010-12-310000884629us-gaap:RestrictedStockMember2010-12-310000884629wpi:Notes6Point125PercentDueAugust142019Member2010-01-012010-12-310000884629wpi:Notes5PercentDueAugust142014Member2010-01-012010-12-310000884629wpi:SeniorNotesDueTwoThousandNineteenMember2010-08-150000884629wpi:SeniorNotesDueTwoThousandFourteenMember2010-02-150000884629wpi:Notes5PercentDueAugust142014Member2010-12-310000884629wpi:Notes6Point125PercentDueAugust142019Member2010-12-310000884629wpi:LombardLoanMember2009-11-250000884629us-gaap:SeniorNotesMember2010-12-310000884629wpi:SeniorNotesDueTwoThousandFourteenMember2010-12-310000884629wpi:SeniorNotesDueTwoThousandNineteenMember2010-12-310000884629us-gaap:SeniorNotesMember2009-12-310000884629wpi:SeniorNotesDueTwoThousandFourteenMember2009-12-310000884629wpi:SeniorNotesDueTwoThousandNineteenMember2009-12-310000884629wpi:DistributionSegmentMember2010-01-012010-12-310000884629wpi:GlobalGenericsSegmentMember2010-01-012010-12-310000884629wpi:GlobalBrandsContributionMember2010-01-012010-12-310000884629wpi:GlobalBrandsContributionMember2009-01-012009-12-310000884629wpi:GlobalGenericsSegmentMember2009-01-012009-12-310000884629wpi:DistributionSegmentMember2009-01-012009-12-310000884629wpi:DistributionSegmentMember2008-01-012008-12-310000884629wpi:GlobalGenericsSegmentMember2008-01-012008-12-310000884629wpi:GlobalBrandsContributionMember2008-01-012008-12-3100008846292008-12-3100008846292007-12-310000884629wpi:IPRAndDMember2010-12-310000884629wpi:IPRAndDMember2010-07-020000884629wpi:ProductRightsAndOtherRelatedIntangiblesMember2010-12-310000884629wpi:ProductRightsAndOtherRelatedIntangiblesMember2010-07-020000884629wpi:EdenBiopharmGroupLimitedMember2009-12-020000884629us-gaap:MandatorilyRedeemablePreferredStockMember2009-12-020000884629us-gaap:MandatorilyRedeemablePreferredStockMember2009-01-012009-12-310000884629wpi:UnitedStatesRightsColumbiaProductsMember2010-07-0200008846292009-12-020000884629wpi:ColumbiaLaboratoriesMember2010-07-020000884629us-gaap:FairValueInputsLevel2Member2010-12-310000884629us-gaap:FairValueInputsLevel3Member2010-12-310000884629wpi:ColumbiaContingentConsiderationLiabilityMember2010-12-310000884629wpi:ArrowBusinessAcquisitionMember2010-12-310000884629us-gaap:FairValueInputsLevel1Member2010-12-3100008846292010-07-020000884629us-gaap:FairValueInputsLevel3Member2009-12-310000884629us-gaap:FairValueInputsLevel2Member2009-12-310000884629us-gaap:FairValueInputsLevel1Member2009-12-310000884629wpi:ArrowBusinessAcquisitionMember2009-12-310000884629wpi:USTreasuryAndAgencySecuritiesMaturingWithinOneYearMember2010-12-310000884629wpi:USTreasuryAndAgencySecuritiesMaturingWithinTwoYearsMember2010-12-310000884629wpi:USTreasuryAndAgencySecuritiesMaturingWithinTwoYearsMember2009-12-310000884629wpi:USTreasuryAndAgencySecuritiesMaturingWithinOneYearMember2009-12-310000884629us-gaap:AdditionalPaidInCapitalMember2010-01-012010-12-310000884629us-gaap:AdditionalPaidInCapitalMember2009-01-012009-12-310000884629us-gaap:AdditionalPaidInCapitalMember2008-01-012008-12-3100008846292008-01-012008-12-310000884629wpi:ArrowBusinessAcquisitionMember2010-07-012010-07-310000884629wpi:UnitedStatesRightsColumbiaProductsMember2010-01-012010-12-310000884629wpi:IPRAndDMember2010-01-012010-12-3100008846292009-01-012009-12-3100008846292010-12-3100008846292009-12-3100008846292010-06-3000008846292011-01-3100008846292010-01-012010-12-31iso4217:USDxbrli:sharesxbrli:purexbrli:sharesiso4217:USD<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-->
<div align="left" style="margin-left: 0%"><!-- XBRL,ns -->
<!-- xbrl,nx -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">
</font></b>
</div>
<div style="margin-top: 0pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">
</font></b>
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 1 —
Description of Business</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson Pharmaceuticals, Inc. (“Watson” or the
“Company”) is primarily engaged in the development,
manufacturing, marketing, sale and distribution of brand and
generic pharmaceutical products. Watson was incorporated in 1985
and began operations as a manufacturer and marketer of
off-patent pharmaceuticals. Through internal product development
and synergistic acquisitions of products and businesses, the
Company has grown into a diversified specialty pharmaceutical
company. Watson operates manufacturing, distribution, research
and development (“R&D”) and administrative
facilities in the United States of America (“U.S.”)
and, beginning in 2009, in key international markets including
Western Europe, Canada, Australasia, South America and South
Africa.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of Arrow Group</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On December 2, 2009 (the “Acquisition Date”),
Watson completed its acquisition of all the outstanding equity
of Robin Hood Holdings Limited, a Malta private limited
liability company, and Cobalt Laboratories, Inc., a Delaware
corporation (together the “Arrow Group”). The Arrow
Group is principally engaged in the manufacture and distribution
of generic pharmaceuticals and operates in the U.S. and
international markets including Western Europe, Canada,
Australasia, South America and South Africa.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As a result of the acquisition of the Arrow Group, Watson also
acquired a 36% ownership interest in Eden Biopharm Group Limited
(“Eden”), a company which provides development and
manufacturing services for early-stage biotech companies. In
January 2010, we repurchased the remaining interest in Eden for
$15.0 million. Eden’s results are included in the
Global Brands segment. For additional information on the
acquisition of the Arrow Group, refer to
“NOTE 4 — Acquisitions and
Divestitures.”
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock-->
<div align="left" style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 2 —
Summary of Significant Accounting Policies</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Basis
of Presentation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s consolidated financial statements are
prepared in accordance with accounting principles generally
accepted in the U.S. (“GAAP”). The consolidated
financial statements include the accounts of wholly-owned
subsidiaries, after elimination of intercompany accounts and
transactions. Certain prior year amounts have been reclassified
to conform to the current-year presentation.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Our consolidated financial statements include the financial
results of the Arrow Group subsequent to the Acquisition Date.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Use of
Estimates</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Management is required to make certain estimates and assumptions
in order to prepare consolidated financial statements in
conformity with GAAP. Such estimates and assumptions affect the
reported amounts of assets, liabilities, revenues and expenses
and disclosure of contingent assets and liabilities in the
consolidated financial statements and accompanying notes. The
Company’s most significant estimates relate to the
determination of sales returns and allowances (“SRA”)
for accounts receivable and accrued liabilities, valuation of
inventory balances, the determination of useful lives for
intangible assets and the assessment of expected cash flows used
in evaluating goodwill and other long-lived assets for
impairment. The estimation process required to prepare the
Company’s consolidated financial statements requires
assumptions to be made about future events and conditions, and
as such, is inherently subjective and uncertain. Watson’s
actual results could differ materially from those estimates.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Foreign
Currency Translation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For most of the Company’s international operations, the
local currency has been determined to be the functional
currency. We translate functional currency assets and
liabilities to their U.S. dollar equivalents at rates in
effect at the balance sheet date and record these translation
adjustments as a component of accumulated other comprehensive
income (loss) within stockholders’ equity in the
consolidated balance sheets. We translate functional currency
statement of income amounts to their U.S. dollar
equivalents at the average rates for the period. The effects of
converting non-functional currency assets and liabilities into
the functional currency are recorded as general and
administrative expenses in the consolidated statements of
operations.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Cash
and Cash Equivalents</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company considers cash and cash equivalents to include cash
in banks, commercial paper and deposits with financial
institutions that can be liquidated without prior notice or
penalty. The Company considers all highly liquid investments
with an original maturity of three months or less to be cash
equivalents.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Fair
Value of Other Financial Instruments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s financial instruments consist primarily of
cash and cash equivalents, marketable securities, accounts and
other receivables, investments, trade accounts payable, our
$450.0 million aggregate principal amount of
5.000% notes due August 14, 2014 (the “2014
Notes”) and $400.0 million aggregate principal amount
of 6.125% notes due August 14, 2019 (the “2019
Notes”) (together the “Senior Notes”) and our
Senior Credit Facility with Canadian Imperial Bank of Commerce,
acting through its New York agency, as administrative agent (the
“2006 Credit Facility”). The carrying amounts of cash
and cash equivalents, marketable securities, accounts and other
receivables and trade accounts payable are representative of
their respective fair values due to their relatively short
maturities. The fair values of investments in companies that are
publicly traded are based on quoted market prices. The Company
estimates the fair value of its fixed rate long-term obligations
based on quoted market rates of interest and maturity schedules
for similar issues. At December 31, 2010, the fair value of
our Senior Notes was approximately $71.0 million greater
than the carrying value.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Inventories</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Inventories consist of finished goods held for sale and
distribution, raw materials and work in process. Included in
inventory at December 31, 2010 and 2009 is approximately
$4.6 million and $14.1 million, respectively, of
inventory that is pending approval by the U.S. Food and
Drug Administration (“FDA”), by other regulatory
agencies or has not been launched due to contractual
restrictions. This inventory consists of generic pharmaceutical
products that are capitalized only when the bioequivalence of
the product is demonstrated or the product has already received
regulatory approval and is awaiting a contractual triggering
event to enter the marketplace. Inventories are stated at the
lower of cost
<font style="white-space: nowrap">(first-in,</font>
first-out method) or market (net realizable value). The Company
writes down inventories to net realizable value based on
forecasted demand and market conditions, which may differ from
actual results.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Property
and Equipment</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Property and equipment are stated at cost, less accumulated
depreciation. Major renewals and improvements are capitalized,
while routine maintenance and repairs are expensed as incurred.
Costs associated with internally developed software are
accounted for in accordance with the guidance for the treatment
of costs associated with computer software development that
defines those costs to be capitalized and those to be expensed.
The Company capitalizes interest on qualified construction
projects. At the time property and equipment are retired from
service, the cost and accumulated depreciation is removed from
the respective accounts and the related gains or losses are
reflected in income.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Depreciation expense is computed principally on the
straight-line method, over estimated useful lives of the related
assets. The following table provides the range of estimated
useful lives used for each asset type:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="88%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="10%"> </td><!-- colindex=02 type=maindata -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Computer software / hardware
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
3-7 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-18 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Buildings, improvements, leasehold improvements and other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-40 years
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company assesses property and equipment for impairment
whenever events or changes in circumstances indicate that an
asset’s carrying amount may not be recoverable.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s equity investments are accounted for under
the equity method when the Company can exert significant
influence and ownership does not exceed 50%. Watson accounts for
its joint ventures using the equity method. The Company records
equity method investments at cost and adjust for the appropriate
share of investee net earnings or losses. Investments in which
the Company owns less than a 20% interest and cannot exert
significant influence are accounted for using the cost method if
the fair value of such investments is not readily determinable.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Marketable
Securities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s marketable securities consist of
U.S. Treasury and agency securities and equity securities
of publicly-held companies. The Company’s marketable
securities are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value, based upon quoted market prices.
Unrealized temporary adjustments to fair value are included on
the balance sheet in a separate component of stockholders’
equity as unrealized gains and losses and reported as a
component of accumulated other comprehensive income. No gains or
losses on marketable securities are realized until shares are
sold or a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary.</font>
If a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary,</font>
an impairment charge is recorded and a new cost basis in the
investment is established.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Goodwill
and Intangible Assets with Indefinite-Lives</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
We test goodwill and intangible assets with indefinite-lives for
impairment annually at the end of the second quarter by
comparing the fair value of each of the Company’s reporting
units to the respective carrying value of the reporting units.
Additionally, we may perform tests between annual tests if an
event occurs or circumstances change that could potentially
reduce the fair value of a reporting unit below its carrying
amount. The Company’s reporting units have been identified
by Watson as Global Generics, Global Brands and Distribution.
The carrying value of each reporting unit is determined by
assigning the assets and liabilities, including the existing
goodwill and intangible assets, to those reporting units.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill is considered impaired if the carrying amount of the
net assets exceeds the fair value of the reporting unit.
Impairment, if any, would be recorded in operating income and
this could result in a material reduction in net income and
earnings per share. During the second quarter of 2010, the
Company performed its annual impairment assessment of goodwill,
acquired in-process research and development
(“IPR&D”) intangibles and trade name intangible
assets with indefinite-lives and determined there was no
impairment. Due to changes in market conditions in certain
international locations, the Company performed an off-cycle
impairment review in the fourth quarter of 2010 and recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. (Refer to
“Note 8 — Goodwill, Product Rights and Other
Intangibles” for additional details.)
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Included in intangible assets with indefinite-lives are trade
name intangible assets acquired prior to January 1, 2009
and IPR&D intangibles acquired after January 1, 2009.
Upon adoption of Financial Accounting Standards Board
(“FASB”) issued authoritative guidance on
January 1, 2009, using the purchase method of accounting,
IPR&D intangible assets are recognized at their fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. Prior to January 1,
2009, amounts allocated to IPR&D intangible assets were
expensed at the date of acquisition.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the date acquired,
represent the right to develop, use, sell
<font style="white-space: nowrap">and/or</font> offer
for sale a product or other intellectual property that we have
acquired with respect to products
<font style="white-space: nowrap">and/or</font>
processes that have not been completed or approved. The
IPR&D intangible assets are subject to impairment testing
until completion or abandonment of each project. Impairment
testing requires the development of significant estimates and
assumptions involving the determination of estimated net cash
flows for each year for each project or product (including net
revenues, cost of sales, R&D costs, selling and marketing
costs), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each asset’s life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The major risks and uncertainties associated with the
timely and successful completion of the IPR&D projects
include legal risk and regulatory risk. Changes in these
assumptions or uncertainties could result in future impairment
charges. No assurances can be given that the underlying
assumptions used to prepare the discounted cash flow analysis
will not change or the timely completion of each project to
commercial success will occur. For these and other reasons,
actual results may vary significantly from estimated results.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon successful completion of each project and launch of the
product, Watson will make a separate determination of the useful
life of the intangible, transfer the amount to currently
marketed products (“CMP”) and amortization expense
will be recorded over the estimated useful life.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Contingent
Consideration</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Subsequent to January 1, 2009, contingent consideration is
recorded at the acquisition date estimated fair value of the
contingent payment for all acquisitions. The fair value of the
contingent consideration is remeasured at each reporting period
with any adjustments in fair value included in our consolidated
statement of operations.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Revenue
Recognition</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Revenue is generally realized or realizable and earned when
persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the seller’s price
to the buyer is fixed or determinable, and collectability is
reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to
the customer, which is typically upon delivery to the customer.
Revenues recognized from research, development and licensing
agreements (including milestone receipts) are recorded on the
“contingency-adjusted performance model” which
requires deferral of revenue until such time as contract
milestone requirements, as specified in the individual
agreements, have been met. Under this model, revenue related to
each payment is recognized over the entire contract performance
period, starting with the contract’s commencement, but not
prior to earning
<font style="white-space: nowrap">and/or</font>
receiving the milestone amount (i.e., removal of any
contingency). The amount of revenue recognized is based on the
ratio of costs incurred to date to total estimated cost to be
incurred. Royalty and commission revenue is recognized in
accordance with the terms of their respective contractual
agreements when collectability is reasonably assured and revenue
can be reasonably measured.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Provisions
for Sales Returns and Allowances</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As is customary in the pharmaceutical industry, the
Company’s gross product sales are subject to a variety of
deductions in arriving at reported net product sales. When the
Company recognizes revenue from the sale of its products, an
estimate of SRA is recorded which reduces product sales.
Accounts receivable
<font style="white-space: nowrap">and/or</font>
accrued liabilities are also reduced
<font style="white-space: nowrap">and/or</font>
increased by the SRA amount. These adjustments include estimates
for chargebacks, rebates, cash discounts and returns and other
allowances. These provisions are estimated based on historical
payment experience, historical relationship to revenues,
estimated customer inventory levels and current contract sales
terms with direct and indirect customers. The estimation process
used to determine our SRA provision has been applied on a
consistent basis and no material adjustments have been necessary
to increase or decrease our reserves for SRA as a result of a
significant change in underlying estimates. The Company uses a
variety of methods to assess the adequacy of our SRA reserves to
ensure that our consolidated financial statements are fairly
stated. This includes periodic reviews of customer inventory
data, customer contract programs and product pricing trends to
analyze and validate the SRA reserves.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Chargebacks — </i>The provision for chargebacks is
our most significant sales allowance. A chargeback represents an
amount payable in the future to a wholesaler for the difference
between the invoice price paid to the Company by our wholesale
customer for a particular product and the negotiated contract
price that the wholesaler’s customer pays for that product.
The Company’s chargeback provision and related reserve vary
with changes in product mix, changes in customer pricing and
changes to estimated wholesaler inventories. The provision for
chargebacks also takes into account an estimate of the expected
wholesaler sell-through levels to indirect customers at contract
prices. The Company validates the chargeback accrual quarterly
through a review of the inventory reports obtained from our
largest wholesale customers. This customer inventory information
is used to verify the estimated liability for future chargeback
claims based on historical chargeback and contract rates. These
large wholesalers represent 85% — 90% of the
Company’s chargeback payments. The Company continually
monitors current pricing trends and wholesaler inventory levels
to ensure the liability for future chargebacks is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Rebates — </i>Rebates include volume related
incentives to direct and indirect customers and Medicaid rebates
based on claims from Medicaid benefit providers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Volume rebates are generally offered to customers as an
incentive to continue to carry our products and to encourage
greater product sales. These rebate programs include contracted
rebates based on customer’s purchases made during an
applicable monthly, quarterly or annual period. The provision
for rebates is estimated based on our customers’ contracted
rebate programs and our historical experience of rebates paid.
Any significant changes to our customer rebate programs are
considered in establishing our provision for rebates. The
Company continually monitors its customer rebate programs to
ensure that the liability for accrued rebates is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The provision for Medicaid rebates is based upon historical
experience of claims submitted by the various states. The
Company monitors Medicaid legislative changes to determine what
impact such legislation may have on our provision for Medicaid
rebates. Our accrual of Medicaid rebates is based on historical
payment rates and is reviewed on a quarterly basis against
actual claim data to ensure the liability is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Returns and Other Allowances — </i>Our provision
for returns and other allowances include returns, pricing
adjustments, promotional allowances and billback adjustments.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Consistent with industry practice, the company maintains a
return policy that allows our customers to return product for
credit. In accordance with our return goods policy, credit for
customer returns of product is applied against outstanding
account activity or by check. Product exchanges are not
permitted. Customer returns of product are not resalable unless
the return is due to a shipping error. Our estimate of the
provision for returns is based upon historical experience and
current trends of actual customer returns. Additionally, we
consider other factors when estimating our current period return
provision, including levels of inventory in our distribution
channel as well as significant market changes which may impact
future expected returns, and make adjustments to our current
period provision for returns when it appears product returns may
differ from our original estimates.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pricing adjustments, which include shelf stock adjustments, are
credits issued to reflect price decreases in selling prices
charged to our direct customers. Shelf stock adjustments are
based upon the amount of product
our customers have in their inventory at the time of an
<font style="white-space: nowrap">agreed-upon</font>
price reduction. The provision for shelf stock adjustments is
based upon specific terms with our direct customers and includes
estimates of existing customer inventory levels based upon their
historical purchasing patterns. The Company regularly monitors
all price changes to help evaluate our reserve balances. The
adequacy of these reserves is readily determinable as pricing
adjustments and shelf stock adjustments are negotiated and
settled on a
<font style="white-space: nowrap">customer-by-customer</font>
basis.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Promotional allowances are credits, which are issued in
connection with a product launch or as an incentive for
customers to begin carrying our product. The Company establishes
a reserve for promotional allowances based upon these
contractual terms.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Billback adjustments are credits that are issued to certain
customers who purchase directly from the Company as well as
indirectly through a wholesaler. These credits are issued in the
event there is a difference between the customer’s direct
and indirect contract price. The provision for billbacks is
estimated based upon historical purchasing patterns of qualified
customers who purchase product directly from the Company and
supplement their purchases indirectly through the Company’s
wholesale customers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Cash Discounts — </i>Cash discounts are provided to
customers that pay within a specific period. The provision for
cash discounts are estimated based upon invoice billings,
utilizing historical customer payment experience. Our
customer’s payment experience is fairly consistent and most
customer payments qualify for the cash discount. Accordingly,
our reserve for cash discounts is readily determinable.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Net revenues and accounts receivable balances in the
Company’s consolidated financial statements are presented
net of SRA estimates. In addition, certain SRA balances are
included in accounts payable and accrued liabilities. Accounts
receivable are presented net of SRA balances of
$320.5 million and $335.0 million at December 31,
2010 and 2009, respectively. Accounts payable and accrued
liabilities include $106.5 million and $83.6 million
at December 31, 2010 and 2009, respectively, for certain
rebates and other amounts due to indirect customers.
The
following table summarizes the activity in the Company’s
major categories of SRA (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="42%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Returns and Other<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Chargebacks</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Rebates</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Allowances</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Cash Discounts</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2007
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
164.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
154.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
387.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,224.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
309.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
179.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,780.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,267.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(337.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(67.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,839.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
125.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
328.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Arrow Acquisition
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,169.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
415.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,840.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,177.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(389.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(167.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(71.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,805.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2009 (Revised)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
188.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
97.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
418.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,175.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
755.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
206.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,192.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(723.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(214.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(88.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2,219.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
100.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
219.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
427.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company does not expect future payments of SRA to materially
exceed our current estimates. However, if future SRA payments
were to materially exceed our estimates, such adjustments may
have a material adverse impact on our financial position,
results of operations and cash flows.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Shipping
and Handling Costs</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company records shipping and handling costs in selling and
marketing expenses. These expenses were $66.5 million,
$51.9 million and $50.8 million in 2010, 2009 and
2008, respectively.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Concentration
of Major Customers and Suppliers</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For the year ended December 31, 2010, the Company’s
three largest customers accounted for 14%, 11%, and 6%,
individually, of the Company’s net revenues. For the year
ended December 31, 2009, the Company’s three largest
customers accounted for 13%, 11%, and 9%, individually, of the
Company’s net revenues. For the year ended
December 31, 2008, the Company’s three largest
customers accounted for 11%, 11%, and 9%, individually, of the
Company’s net revenues. No other individual customers
accounted for more than 10% of net revenues.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is subject to a concentration of credit risk with
respect to its accounts receivable balance, all of which is due
from wholesalers, distributors, chain drug stores and service
providers in the health care and pharmaceutical industries
throughout the U.S. and international markets in which we
operate. Approximately 52% and 53% of the gross accounts
receivable balance consists of amounts due from the four largest
customers at December 31, 2010 and 2009, respectively. The
Company performs ongoing credit evaluations of its customers and
maintains an allowance for potential uncollectible accounts.
Actual losses from uncollectible accounts have been minimal.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Certain of the Company’s finished products and raw
materials are obtained from single source suppliers. Although
the Company seeks to identify more than one source for its
various finished products and raw materials, loss of a single
source supplier could have an adverse effect on the
Company’s results of operations, financial condition and
cash flows. Third-party manufactured products accounted for
approximately 33%, 38% and 44% of our Global Generics and Global
Brands product net revenues in 2010, 2009 and 2008, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Research
and Development Activities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
R&D activities are expensed as incurred and consist of
self-funded R&D costs and the costs associated with work
performed under collaborative R&D agreements. R&D
expenses include direct and allocated expenses. R&D
expenses incurred under collaborative agreements were
approximately $11.1 million, $6.8 million, and
$5.9 million for the years ended December 31, 2010,
2009 and 2008, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Income
Taxes</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income taxes are accounted for using an asset and liability
approach that requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of
temporary differences between the financial statement and tax
bases of assets and liabilities at the applicable tax rates. A
valuation allowance is provided when it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The Company evaluates the realizability of its
deferred tax assets by assessing its valuation allowance and by
adjusting the amount of such allowance, if necessary. The
factors used to assess the likelihood of realization include the
Company’s forecast of future taxable income and available
tax planning strategies that could be implemented to realize the
net deferred tax assets. Failure to achieve forecasted taxable
income in applicable tax jurisdictions could affect the ultimate
realization of deferred tax assets and could result in an
increase in the Company’s effective tax rate on future
earnings.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income tax positions must meet a more-likely-than-not
recognition threshold to be recognized. Income tax positions
that previously failed to meet the more-likely-than-not
threshold are recognized in the first subsequent financial
reporting period in which that threshold is met. Previously
recognized tax positions that no longer meet the
more-likely-than-not threshold are derecognized in the first
subsequent financial reporting period in which that threshold is
no longer met. We recognize potential accrued interest and
penalties related to unrecognized tax benefits within the
consolidated statements of income as income tax expense.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Comprehensive
Income</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Comprehensive income includes all changes in equity during a
period except those that resulted from investments by or
distributions to the Company’s stockholders. Other
comprehensive income refers to revenues, expenses, gains and
losses that, under GAAP, are included in comprehensive income,
but excluded from net income as these amounts are recorded
directly as an adjustment to stockholders’ equity.
Watson’s other comprehensive income (loss) is composed of
unrealized gains (losses) on its holdings of publicly traded
equity securities, net of realized gains (losses) included in
net income and foreign currency translation adjustments.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Earnings
Per Share (“EPS”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Basic EPS is computed by dividing net income attributable to
common shareholders by the weighted average common shares
outstanding during a period. Diluted EPS is based on the
treasury stock method and includes the effect from potential
issuance of common stock, such as shares issuable upon
conversion of our convertible contingent senior debentures
(“CODES”), and shares issuable pursuant to the
exercise of stock options, assuming the exercise of all
<font style="white-space: nowrap">in-the-money</font>
stock options. Common share equivalents have been excluded where
their inclusion would be anti-dilutive. The Company is required
to add the weighted average potential common shares outstanding
associated with the conversion of the CODES to the number of
shares outstanding for the calculation of diluted EPS for all
periods in which the securities were outstanding. On
September 14, 2009 the CODES were redeemed in accordance
with the terms of the CODES.
A reconciliation of the
numerators and denominators of basic and diluted EPS consisted
of the following (in millions, except per share amounts):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="74%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — basic</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.51
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.32
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — assuming dilution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Interest expense on CODES, net of tax
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income, adjusted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
246.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effect of dilutive securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Conversion of CODES
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Dilutive stock awards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
124.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.48
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.96
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.09
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Stock awards to purchase 1.1 million, 3.5 million and
8.1 million common shares in 2010, 2009 and 2008,
respectively, were outstanding but not included in the
computation of diluted EPS as the awards were anti-dilutive.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Share-based
Compensation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company recognizes compensation expense for all share-based
compensation awards made to employees and directors based on
estimated fair values. The Company estimates the fair value of
its stock option plans using the Black-Scholes option pricing
model (the “Option Model”). The Option Model requires
the use of subjective and complex assumptions, including the
option’s expected term and the estimated future price
volatility of the underlying stock, which determine the fair
value of the share-based awards. The Company’s estimate of
expected term was determined based on the weighted average
period of time that options granted are expected to be
outstanding considering current vesting schedules and the
historical exercise patterns of existing option plans. The
expected volatility assumption used in the Option Model is based
on implied volatility based on traded options on the
Company’s stock. The risk-free interest rate used in the
Option Model is based on the yield of U.S. Treasuries with
a maturity closest to the expected term of the Company’s
stock options. No stock options were granted during the years
ended December 31, 2010, 2009 or 2008.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Share-based compensation expense recognized during a period is
based on the value of the portion of share-based awards that are
expected to vest with employees. Accordingly, the recognition of
share-based compensation expense has been reduced for estimated
future forfeitures. These estimates will be revised in future
periods if actual forfeitures differ from the estimates. Changes
in forfeiture estimates impact compensation expense in the
period in which the change in estimate occurs.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Recent
Accounting Pronouncements</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In October 2009, the FASB issued an amendment to its accounting
guidance on revenue arrangements with multiple deliverables,
which addresses the unit of accounting for arrangements
involving multiple deliverables and how consideration should be
allocated to separate units of accounting, when applicable. The
amendment requires that arrangement considerations be allocated
at the inception of the arrangement to all deliverables using
the relative selling price method and provides for expanded
disclosures related to such arrangements. The amendment is
effective for revenue arrangements entered into or materially
modified in fiscal years beginning on or after June 15,
2010. Early adoption is allowed. The adoption of this guidance
will not have a material impact on the Company’s
consolidated financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In January 2010, the FASB issued an amendment to the disclosure
requirements for fair value measurements. The amendment requires
an entity to: (i) disclose separately the amounts of
significant transfers in and out of Level 1 and
Level 2 fair value measurements and describe the reasons
for the transfers, and (ii) present separate information
for Level 3 activity pertaining to gross purchases, sales,
issuances and settlements. The new disclosures are effective for
interim and annual reporting periods beginning after
December 15, 2009, except for the Level 3 disclosures,
which are effective for fiscal years beginning after
December 15, 2010. The adoption of this guidance will not
have a material impact on the Company’s consolidated
financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In March 2010, the FASB ratified accounting guidance on defining
a milestone and determining when it may be appropriate to apply
the milestone method of revenue recognition for research or
development transactions. This guidance provides criteria that
must be met to recognize consideration that is contingent upon
achievement of a substantive milestone in its entirety in the
period in which the milestone is achieved. The amendment is
effective for milestones achieved in fiscal years beginning on
or after June 15, 2010. Early adoption is allowed. The
adoption of this guidance will not have a material impact on the
Company’s consolidated financial statements.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 3 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 3 —
Share-Based Compensation</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As indicated above, the Company recognizes compensation expense
for all share-based compensation awards made to employees and
directors based on estimated fair values. A summary of the
Company’s share-based compensation plans is presented below.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Equity
Award Plans</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has adopted several equity award plans, all of which
have been approved by the Company’s shareholders that
authorize the granting of options, restricted stock and other
forms of equity awards of the Company’s common shares
subject to certain conditions. At December 31, 2010, the
Company had reserved 5.2 million of its common shares for
issuance of share-based compensation awards under the
Company’s equity award plans.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Option award plans require options to be granted at the fair
value of the shares underlying the options at the date of the
grant and generally become exercisable over periods ranging from
three to five years and expire in ten years. In conjunction with
certain of the Company’s acquisitions, Watson assumed stock
option and warrant plans from the acquired companies. The
options and warrants in these plans were adjusted by the
individual exchange ratios specified in each transaction. No
additional options or warrants have been granted under any of
the assumed plans.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Beginning in 2005, the Compensation Committee of the board of
directors of the Company (the “Board”) authorized and
issued restricted stock to the Company’s employees,
including its executive officers and certain non-employee
directors (the “Participants”) under the
Company’s equity compensation plans. The restricted stock
award program offers Participants the opportunity to earn shares
of our common stock over time, rather than options that give
Participants the right to purchase stock at a set price.
Restricted stock awards are grants that entitle the holder to
shares of common stock subject to certain terms. Restricted
stock awards generally have restrictions eliminated over a one
to four year period. Restrictions generally lapse for
non-employee directors after one year. Restrictions generally
lapse for employees over a two to four year period. The fair
value of restricted stock grants is based on the fair market
value of our common stock on the respective grant dates.
Restricted stock compensation is being amortized and charged to
operations over the same period as the restrictions are
eliminated for the Participants.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Share-Based
Compensation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Share-based compensation expense recognized in the
Company’s results of operations for the years ended
December 31, 2010, 2009 and 2008 was $23.5 million,
$19.1 million and $18.5 million, respectively.
Share-based compensation capitalized to inventory was
$3.6 million, $2.7 million and $3.3 million for
the years ended December 31, 2010, 2009 and 2008,
respectively.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 4 - wpi:AcquisitionsAndDivestituresTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 4 —
Acquisitions and Divestitures</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of Arrow Group</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On the Acquisition Date, Watson acquired all the outstanding
equity of privately held Arrow Group for cash, stock and certain
contingent consideration (the “Arrow Acquisition”). In
accordance with the terms of the share purchase agreement dated
June 16, 2009, as amended on November 26, 2009
(together the “Acquisition Agreement”), the Company
acquired all the outstanding equity of the Arrow Group for the
following consideration:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
The payment of cash and the assumption of certain liabilities
totaling $1.05 billion;
</td>
</tr>
<tr style="line-height: 6pt; font-size: 1pt">
<td> </td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
Approximately 16.9 million restricted shares of Common
Stock of Watson (the “Restricted Common Stock”);
</td>
</tr>
</table>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
200,000 shares of newly designated mandatorily redeemable,
non-voting Series A Preferred Stock of Watson (the
“Mandatorily Redeemable Preferred Stock”) placed in
escrow for the benefit of the former shareholders of the Arrow
Group (the “Arrow Selling Shareholders”); and
</td>
</tr>
<tr style="line-height: 6pt; font-size: 1pt">
<td> </td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
Certain contingent consideration based on the after-tax gross
profits on sales of the authorized generic version of
Lipitor<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(atorvastatin) in the U.S. calculated and payable as
described in the Acquisition Agreement. For additional
information on the contingent payment, refer to
“NOTE 10 — Other Long-Term Liabilities.”
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table presents a summary of the purchase price
consideration for the Arrow Acquisition (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,050.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Restricted Common Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
636.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
150.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value estimate of atorvastatin contingent payment
consideration (refer to “NOTE 10 — Other
Long-Term Liabilities.”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Fair
Value of Consideration Transferred</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with existing U.S. GAAP, the fair value of
Restricted Common Stock issued as part of the consideration
transferred was measured on the Acquisition Date at the
then-current market price of $37.55 per share for
approximately $636.2 million.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Mandatorily Redeemable Preferred Stock was issued in the form of
zero-coupon, non-convertible preferred stock which will be
redeemable in the amount of $200.0 million, less the amount
of any indemnity payments, three years after the Acquisition
Date. The fair value of the Mandatorily Redeemable Preferred
Stock at Acquisition Date was estimated by the Company to be
$150.0 million, based on the terms they were issued under
and the cost of the Company’s other fixed rate borrowings
and is presented within long-term debt at its current fair value
at December 31, 2010 of $166.4 million. For additional
information on the Mandatorily Redeemable Preferred Stock, refer
to “NOTE 9 — Long-Term Debt.”
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company determined the acquisition date fair value of the
contingent consideration obligation based on a
probability-weighted income approach derived from atorvastatin
revenue estimates and post-tax gross profit levels and a
probability assessment with respect to the likelihood of
achieving the various earn-out criteria. The fair value
measurement is based on significant inputs not observable in the
market and thus represents a Level 3 measurement as defined
in fair value measurement accounting. The resultant
probability-weighted cash flows were discounted using an
effective annual interest rate of 10.4%. At each reporting date,
the Company adjusts the contingent consideration obligation to
estimated fair value and records changes in fair value as
expense in our consolidated statement of operations. Changes in
the fair value of the contingent consideration obligations may
result from changes in discount periods and rates, changes in
the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of
achieving the various earn-out criteria. As of December 31,
2010 the range of outcomes and the assumptions used to develop
the estimates have not changed significantly from those used at
Acquisition Date. Accretion expense related to the increase in
the net present value of the contingent liability is included in
interest expense for the period.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Divestiture
of Certain Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In order to obtain regulatory approval under the
<font style="white-space: nowrap">Hart-Scott-Rodino</font>
Antitrust Improvements Act of 1976, as amended (the “HSR
Act”), in connection with the Arrow Acquisition, Watson and
the Arrow Group were required to divest certain assets. In
conjunction with the closing, Watson sold its Abbreviated New
Drug Application (“ANDA”) for Cabergoline, the generic
equivalent to Dostinex, to Impax Laboratories, Inc. The Arrow
Group sold its pending ANDA for Dronabinol, a generic equivalent
to Marinol, to Impax Laboratories, Inc.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Resolution Chemicals Ltd., the subsidiary of the Arrow Group
that manufactures the Dronabinol active pharmaceutical
ingredient, was divested in accordance with the terms of the
consent order under the HSR Act immediately prior to the closing.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Allocation
of Consideration Transferred</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The transaction has been accounted for using the purchase method
of accounting under existing U.S. GAAP. The purchase method
under existing U.S. GAAP requires, among other things, that
assets acquired and liabilities assumed in a business purchase
combination be recognized at their fair values as of the
acquisition date and that IPR&D be recorded at fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. In addition, any common stock
consideration transferred is measured at acquisition date at the
then current market price.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table summarizes the fair values of the
tangible & identifiable intangible assets acquired and
liabilities assumed at Acquisition Date, with the excess being
allocated to goodwill. During the quarter ended June 30,
2010, management completed its allocation of intellectual
properties by tax jurisdiction and the resulting deferred tax
liabilities by legal entity, its evaluation of uncertain tax
positions and related deferred tax assets and liabilities.
These
adjustments are reflected in the values presented below and in
our revised December 31, 2009 balance sheet (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash and cash equivalents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Accounts receivable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Inventories
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
187.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other current assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
174.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Property, plant & equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
518.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
632.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current liabilties
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(306.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax and other tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(303.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Inventories</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The fair value of inventories acquired included a
<font style="white-space: nowrap">step-up</font> in
the value of inventories of approximately $26.0 million.
Approximately $14.2 million was amortized to cost of sales
during 2009 and the remaining $11.8 million was amortized
to cost of sales in the first quarter of 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Other
Current Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At Acquisition Date, included in other current assets was
$90.0 million related to the fair value of amounts due from
Sepracor, Inc. (“Sepracor”) prior to the end of 2010
(the “Sepracor Receivable”) for the transfer of
certain product rights and technology from the Arrow Group. The
entire amount due under the Sepracor Receivable was received by
December 31, 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">IPR&D
and Intangible Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the Acquisition Date, had
not established technological feasibility and had no alternative
future use. The IPR&D intangible assets are capitalized and
accounted for as indefinite-lived intangible assets and will be
subject to impairment testing until completion or abandonment of
the projects. Upon successful completion of each project and
launch of the product, Watson will make a separate determination
of useful life of the IPR&D intangible and amortization
will be recorded as an expense over the estimated useful life.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The fair value of the IPR&D and identifiable intangible
assets was determined primarily using the “income
approach,” which is a valuation technique that provides an
estimate of the fair value of an asset based on market
participant expectations of the cash flows an asset would
generate over its remaining useful life. Some of the more
significant assumptions inherent in the development of the
identifiable intangible assets valuations, from the perspective
of a market participant, include the estimated net cash flows
for each year for each project or product (including net
revenues, cost of sales, research and development costs, selling
and marketing costs and working capital/asset contributory asset
charges), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each asset’s life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The discount rate used to arrive at the present value
of IPR&D projects as of the Acquisition Date was
approximately 10.4% to reflect the internal rate of return and
incremental commercial uncertainty in the projections as the
products have not yet received regulatory approval. The major
risks and uncertainties associated with the timely and
successful completion of the IPR&D projects include legal
risk and regulatory risk. No assurances can be given that the
underlying assumptions used to prepare the discounted cash flow
analysis will not change or the timely completion of each
project to commercial success will occur. For these and other
reasons, actual results may vary significantly from estimated
results.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Intangible assets represent the Arrow Group’s CMP and have
an estimated weighted average useful life of five years.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Goodwill
Allocation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Among the primary reasons the Company entered into the Arrow
Acquisition and factors that contributed to a purchase price
allocation resulting in the recognition of goodwill were a
history of operating margins and profitability, a strong
R&D department and several first-to file opportunities,
expanded commercial footprint on a global basis and key pipeline
additions, including atorvastatin and budesonide which will
enable Watson to expand its product offerings and offer its
customers a greater breadth of product offerings. The goodwill
recognized from the Arrow Acquisition is not deductible for tax
purposes. All goodwill from the Arrow Acquisition was assigned
to the Global Generics segment.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Long-Term
Deferred Tax Liabilities and Other Tax Liabilities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Long-term deferred tax liabilities and other tax liabilities
reflects a deferred income tax liability representing the impact
of purchase accounting adjustments for the inventory fair value
<font style="white-space: nowrap">step-up,</font>
property, plant and equipment fair value adjustment,
contingencies adjustment and identifiable IPR&D and
intangible assets fair value adjustment. This determination of
deferred tax liabilities was based on the excess book basis over
the tax basis resulting from the above fair value adjustments
using the statutory tax rate for each country these fair value
adjustments were assigned.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition-Related
Expenses</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Included in general and administrative expenses in the
consolidated statement of operations for the year ended
December 31, 2009 were pretax charges totaling
$16.6 million for advisory, legal and regulatory costs in
connection with the Arrow Acquisition.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Unaudited
Pro Forma Results of Operations</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table presents the unaudited pro forma operating
results for the Company, assuming the Arrow Acquisition had
occurred as of the beginning of each period presented. The
unaudited pro forma results reflect certain adjustments related
to the acquisition, such as increased depreciation and
amortization expense on the fair valuation of assets acquired,
the impact of acquisition financing in place at
December 31, 2009 and the related tax effects. The pro
forma results do not include any anticipated synergies which may
be achievable subsequent to the Acquisition Date. Accordingly,
such pro forma amounts are not necessarily indicative of the
results that actually would have occurred had the acquisition
been completed on the dates indicated, nor are they indicative
of the future operating results of the combined company.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="3%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="3%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Year Ended December 31,</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>(In millions, except<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>per share amounts)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,261.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,170.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
281.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings per share:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.99
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.35
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.98
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.34
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of
Crinone<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and
Prochieve<sup style="font-size: 85%; vertical-align: text-top">®</sup>
Assets from Columbia Laboratories, Inc.
(“Columbia”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On July 2, 2010, the Company completed the acquisition of
the U.S. rights to Columbia products
Crinone<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and
Prochieve<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and acquired 11.2 million shares of Columbia’s common
stock, representing approximately a 13% ownership share, for
initial cash consideration of $62.0 million and certain
contingent consideration of up to an additional
$45.5 million based upon the successful completion of
certain milestones and regulatory approvals.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The transaction was accounted for using the purchase method of
accounting under existing U.S. GAAP with assets acquired
and liabilities assumed recorded at their fair values as of the
acquisition date. The purchase price for the Columbia
acquisition was allocated to tangible and identifiable
intangible assets
acquired and liabilities assumed based on their estimated fair
values at the acquisition date as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="92%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
62.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pro forma results of operations have not been presented because
the effect of the acquisition was not material.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of Equity Interest in Moksha8 Pharmaceuticals, Inc.
(“Moksha8”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On October 4, 2010, the Company entered into an agreement
with Moksha8 to expand into markets in Brazil and Mexico. The
Company made an initial investment of $30.0 million in cash
in Moksha8 in exchange for an approximate 22% ownership share in
Moksha8. The Company is also committed to invest an additional
$20.0 million in Moksha8 contingent upon the successful
execution by Moksha8 of additional third-party product
acquisitions over the next year which will increase our
ownership share to approximately 31%.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Sale
of Scinopharm Taiwan Ltd. (“Scinopharm”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On March 24, 2010, all closing conditions were satisfied in
our agreement with Uni-President Enterprises Corporation to sell
our outstanding shares of Scinopharm. Under the terms of the
stock purchase agreement, we sold our entire holdings of common
shares for net proceeds of approximately $94.0 million
resulting in a gain on sale of securities in the amount of
$23.4 million.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 5 - us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 5 —
Other Income</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other income consisted of the following (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Gain (loss) on sale of securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings on equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loss on early extinguishment of debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
19.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In March 2010, we completed the sale of our outstanding shares
of Scinopharm for net proceeds of approximately
$94.0 million. The earnings on equity investments for the
year ended December 31, 2009 were higher than the current
year due to the sale of our outstanding shares of Scinopharm
during the first quarter of 2010.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 6 - wpi:BalanceSheetComponentsTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 6 —
Balance Sheet Components</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Selected balance sheet components consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Inventories:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Raw materials
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
178.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
196.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
<font style="white-space: nowrap">Work-in-process</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Finished goods
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
465.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
509.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
770.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Inventory reserves
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Inventories, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
631.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
692.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Property and equipment:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
570.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Buildings and improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
385.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
382.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
106.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Leasehold improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
78.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
46.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
45.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Land and land improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Construction in progress
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, at cost
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,265.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,197.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Less accumulated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(623.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(503.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
642.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
694.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Accounts payable and accrued expenses:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade accounts payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
215.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
263.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Proposed legal settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
129.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued payroll and related benefits
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued third-party rebates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
83.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
60.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Royalties and sales agent payables
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current portion of contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued indirect returns
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Interest payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued severence, retention and other shutdown costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
98.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
95.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total accounts payable and accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
741.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
614.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 7 - us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 7 —
Investments in Marketable Securities and Other
Investments</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="84%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
one year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
two years
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments and other assets:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
63.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cost method and other long-term investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
21.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total investments and other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
84.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
114.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson’s marketable securities and other long-term
investments are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value based on quoted market prices
using the specific identification method. These investments are
classified as either current or non-current, as appropriate, in
the Company’s Consolidated Balance Sheets.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table provides a summary of the fair value and
unrealized gains (losses) related to Watson’s
<font style="white-space: nowrap">available-for-sale</font>
securities (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2010</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2009</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Current
Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company invests in U.S. Treasury and agency securities.
These investments are included in marketable securities on the
Company’s Consolidated Balance Sheets at December 31,
2010 and 2009. Current investments are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value based on quoted market prices.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Investment
in Equity Method Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s investments in equity method investments at
December 31, 2010 consist of its investments in Columbia
and Moksha8 and certain equity method investments in privately
held companies acquired as part of Arrow Acquisition. (Refer to
“NOTE 4 — Acquisition and Divestitures”
for additional information on Columbia and Moksha8.)
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On March 24, 2010, the Company sold its entire holdings of
common shares in the equity of Scinopharm to Uni-President
Enterprises Corporation. (Refer to “NOTE 4 —
Acquisition and Divestitures” for additional information on
Scinopharm).
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company recorded net earnings from equity method investments
of $1.6 million in 2010, $10.8 million in 2009 and
$10.6 million in 2008, respectively.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is not required to provide ongoing investments or
additional funding to its joint ventures with the exception of a
commitment to invest an additional $20.0 million in Moksha8
upon Moksha8 meeting certain conditions. (Refer to
“NOTE 4 — Acquisition and Divestitures”
for additional information on Moksha8.)
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Cost
Method Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s cost method investments consist primarily of
investments in common shares of a number of private and public
companies where our ownership interest is under 20% or where we
do not have the ability to exercise significant influence.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Other
Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other assets include security and equipment deposits and
deferred financing fees, net of amortization.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 8 - us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 8 —
Goodwill, Product Rights and Other Intangibles</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill for the Company’s reporting units consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Brands segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
371.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
348.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Generics segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,070.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,066.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Distribution segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,528.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,501.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The increase in goodwill in 2010 primarily relates to the
acquisition of the remaining 64% of Eden as discussed in
“NOTE 1 — Description of Business”.
Goodwill for the Company’s Global Generics segment as of
December 31, 2009 has been revised from the amount
presented in our Annual report on
<font style="white-space: nowrap">Form 10-K</font>
for the year ended December 31, 2009. (Refer to
“NOTE 4 — Acquisitions and
Divestitures” for additional details.)
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other intangible assets consist primarily of product rights. The
original cost and accumulated amortization of these intangible
assets, where applicable, consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with definite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product rights and other related intangibles
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,049.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,855.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Core technology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Customer relationships
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,151.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,957.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less accumulated amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,211.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,031.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
940.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
926.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with indefinite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
IPR&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
615.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade Name
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
691.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
787.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total product rights and related intangibles, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,632.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,713.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Intangible assets acquired with the Arrow Acquisition amounted
to $1,119.6 million, including $518.6 million relating
to CMP and $711.0 relating to IPR&D intangibles. CMP
intangibles have been included in product rights and other
related intangibles and will be amortized over a weighted
average useful life of approximately five years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In July 2010, the Company acquired intangible assets in
connection with the acquisition of the U.S rights to certain
Columbia products amounting to $115.3 million, including
$39.5 million relating to CMP and $75.8 million
relating to IPR&D intangibles. CMP intangibles have been
included in product rights and other related intangibles and
will be amortized using a weighted average useful life of
approximately five years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During 2010 approximately $142.3 million of IPR&D
intangibles were transferred to product rights and other related
intangibles as products received regulatory approval.
Amortization of these intangibles commenced upon product launch
using a weighted average useful life of approximately five years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson re-evaluates the carrying value of identifiable
intangible and long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying value may
not be recoverable. The Company continually evaluates the
appropriateness of useful lives assigned to long-lived assets,
including product rights.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During the fourth quarter of 2010, the Company recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. The
impairment charge results from the Company’s current
estimate of the fair value of these IPR&D assets, based on
updated forecasts, compared to their assigned fair values on
Acquisition Date. The fair value of acquired identifiable
intangible assets generally is determined using an income
approach, based on a forecast of all expected future net cash
flows related to the asset which are adjusted to present value
using appropriate discount rates. Forecasts used to determine
fair values of IPR&D assets are based on appropriate
assumptions which include, among other factors, the impact of
changes to the development programs, the current competitive
environment, the regulatory timeframes impacting future product
launch dates and the risk associated with these assets.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Assuming no additions, disposals or adjustments are made to the
carrying values
<font style="white-space: nowrap">and/or</font>
useful lives of the assets, annual amortization expense on
product rights and related over the next five years is estimated
to be as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="93%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2011
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
270.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2012
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
417.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2013
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
311.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2014
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
299.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2015
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
138.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The above amortization expense is an estimate. Actual amounts
may change from such estimated amounts due to fluctuations in
foreign currency exchange rates, additional intangible asset
acquisitions, potential impairments, accelerated amortization or
other events. The Company’s current product rights and
related intangibles have a weighted average remaining useful
life of approximately five years.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 9 - us-gaap:DebtDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 9 —
Long-Term Debt</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Long-term debt consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes,
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2014 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2019 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Unamortized discount
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2006 Credit Facility
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
151.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loan with Lombard Odier Darier Hentsch & Cie.
(“Lombard Loan”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other notes payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,457.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
307.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total long-term debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,150.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Senior
Notes</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The offering of $450.0 million of 2014 Notes and
$400.0 million of 2019 Notes was registered under an
“automatic shelf” registration statement filed with
the Securities and Exchange Commission (“SEC”). The
Senior Notes were issued pursuant to a senior note indenture
dated as of August 24, 2009 between the Company and Wells
Fargo Bank, National Association, as trustee, as supplemented by
a first supplemental indenture dated August 24, 2009
(together the “Senior Note Indentures”).
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Interest payments are due on the Senior Notes semi-annually in
arrears on February 15 and August 15, respectively,
beginning February 15, 2010 at an effective annual interest
rate of 5.43% on the 2014 Notes and 6.35% on the 2019 Notes.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company may redeem the Senior Notes on at least 15 days
but no more than 60 days prior written notice for cash for
a redemption price equal to the greater of 100% of the principal
amount of the Senior Notes to be redeemed and the sum of the
present values of the remaining scheduled payments, as defined
by the Senior Note Indentures, of the Senior Notes to be
redeemed, discounted to the date of redemption at the applicable
treasury rate, as defined by the Senior Note Indentures, plus
40 basis points. As of December 31, 2010, the fair
value of our Senior Notes was approximately $71.0 million
greater than the carrying value.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon a change of control triggering event, as defined by the
Senior Note Indentures, the Company is required to make an offer
to repurchase the Senior Notes for cash at a repurchase price
equal to 101% of the principal amount of the Senior Notes to be
repurchased plus accrued and unpaid interest to the date of
purchase.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Net proceeds from the offering of Senior Notes in 2009 were used
to repay certain amounts under the 2006 Credit Facility and to
redeem other debt with the remaining net proceeds being used to
fund a portion of the cash consideration for the Arrow
Acquisition.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">2006
Credit Facility</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In November 2006, the Company entered into the 2006 Credit
Facility with Canadian Imperial Bank of Commerce, acting through
its New York agency, as Administrative Agent, Wachovia Capital
Markets, LLC, as Syndication Agent, and a syndicate of banks.
The 2006 Credit Facility provides an aggregate of
$1.15 billion of senior financing to Watson, consisting of
a $500.0 million revolving credit facility (“Revolving
Facility”) and a $650.0 million senior term loan
facility (“Term Facility”) and an initial interest
rate equal to LIBOR plus 0.75% (subject to certain adjustments).
In July 2010, the interest rate on the 2006 Credit Facility was
reduced to LIBOR plus 0.625%.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The 2006 Credit Facility has a five-year term and matures in
November 2011. The indebtedness under the 2006 Credit Facility
is guaranteed by Watson’s material domestic subsidiaries,
other than minor subsidiaries, on a joint and several basis. The
Revolving Facility is available for working capital and other
general corporate requirements subject to the satisfaction of
certain conditions. During 2010, the Company repaid
$400.0 million on the 2006 Credit Facility. As of
December 31, 2010, no amounts were outstanding on either
the Revolving Facility or the Term Facility of the 2006 Credit
Facility.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is subject to, and, as of December 31, 2010,
was in compliance with, all financial and operation covenants
under the terms of the 2006 Credit Facility.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Mandatorily
Redeemable Preferred Stock</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In connection with the Arrow Acquisition, on December 2,
2009, pursuant to the Purchase Agreement, Watson issued
0.2 million shares of newly designed non-voting
Series A Preferred Stock of Watson, having a stated value
of $1,000 per share (the “Stated Value”), or an
aggregate stated value of $200.0 million, which have been
placed in an indemnity escrow account for a period of three
years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The provisions for the Mandatorily Redeemable Preferred Stock
are as follows:
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Dividends</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The holders of Mandatorily Redeemable Preferred Stock shall be
entitled to receive dividends, when and of declared by the board
of directors.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Liquidation
Preference</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, the holders of the
Mandatorily Redeemable Preferred Stock will be paid out of the
assets of Watson available for
distribution to Watson’s shareholders before any payment
shall be paid to the holders of Watson’s common stock, an
amount equal to the Stated Value of the Mandatorily Redeemable
Preferred Stock.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Mandatory
Redemption</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Each share of Mandatorily Redeemable Preferred Stock is
mandatorily redeemable by Watson in cash on December 2,
2012, the third anniversary of its issuance at the Stated Value.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Change
in Control Redemption</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon occurrence of a Change in Control event (as defined in the
Certificate of Designations of the Mandatorily Redeemable
Preferred Stock that was previously filed with the SEC on
December 2, 2009), Watson shall have the right to redeem
all of the outstanding Mandatorily Redeemable Preferred Stock in
cash for a price per share equal to the Stated Value.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Voting
Rights</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The holders of the Mandatorily Redeemable Preferred Stock are
not entitled to vote on any matters presented to the
shareholders of Watson for their actions or consideration at any
meetings of the shareholders of Watson (or by written consent of
shareholders in lieu of the meetings), except that the written
consent or affirmative vote of at least two thirds of the then
outstanding shares of Mandatorily Redeemable Preferred Stock
consenting or voting separately as a class is required on any
matters that would amend, alter or repeal any terms,
preferences, special rights or powers of the Mandatorily
Redeemable Preferred Stock. The holders of the Mandatorily
Redeemable Preferred Stock may also vote on any matters required
by law.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with the existing U.S. GAAP, the Mandatorily
Redeemable Preferred Stock has been reported as long-term debt
and accretion expense has been classified as interest expense.
The fair value of the Mandatorily Redeemable Preferred Stock was
estimated to be $150.0 million at Acquisition Date based on
the mandatory redemption value of $200.0 million on
December 2, 2012 using a discount rate of 9.63% per annum.
At December 31, 2010, the fair value of the Mandatorily
Redeemable Preferred Stock was $166.4 million and the
unamortized accretion expense was $33.6 million.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Lombard
Loan</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On November 25, 2009, prior to closing the Arrow
Acquisition, the Arrow Group received loan proceeds from Lombard
Odier Darier Hentsch & Cie. in the amount of
$90.0 million.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with the terms of the Lombard Loan,
$35.0 million was paid in December 2009 and the remaining
balance of $55.0 million was paid in 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<i><font style="font-family: 'Times New Roman', Times">Fair
Value of Outstanding Debt</font></i>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Based on quoted market rates of interest and maturity schedules
for similar debt issues, we estimate that the fair values of our
2006 Credit Facility and our other notes payable approximated
their carrying values on December 31, 2010. As of
December 31, 2010, the fair value of our Senior Notes was
$71.0 million greater than the carrying value. While
changes in market interest rates may affect the fair value of
our fixed-rate debt, we believe the effect, if any, of
reasonably possible near-term changes in the fair value of such
debt on our financial condition, results of operations or cash
flows will not be material.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Annual
Debt Maturities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At December 31, 2010, annual maturities of long-term debt
were as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="93%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2011
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2012
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
200.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2013
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2014
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2015
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
Thereafter
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Amounts represent total anticipated cash payments on our Senior
Notes, Mandatorily Redeemable Preferred Stock and other current
and long-term debt assuming existing debt maturity schedules.
Any early settlement of our Senior Notes through redemption or
repurchase privileges, as defined under the terms of the Senior
Notes, would change the timing of principal amounts due under
the Company’s long-term debt obligations.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 10 - us-gaap:OtherLiabilitiesDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 10 —
Other Long-Term Liabilities</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other long-term liabilities consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="83%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Atorvastatin contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
123.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Columbia contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
212.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion included in accounts payable and accrued
expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company determines the acquisition date fair value of
contingent consideration obligations based on a
probability-weighted income approach derived from revenue
estimates and a probability assessment with respect to the
likelihood of achieving contingent obligations including
contingent payments such as milestone obligations, royalty
obligations and contract earn-out criteria, where applicable.
The fair value measurement is based on significant inputs not
observable in the market and thus represents a Level 3
measurement as defined in fair value measurement accounting. The
resultant probability-weighted cash flows are discounted using
an appropriate effective annual interest rate to reflect the
internal rate of return and incremental commercial uncertainty,
major risks and uncertainties associated with the successful
completion of the projects triggering the contingent obligation.
At each reporting date, the Company will revalue the contingent
consideration obligation to estimated fair value and record
changes in fair value as income or expense in our consolidated
statement of operations. Changes in the fair value of the
contingent consideration obligations may result from changes in
discount periods and rates, changes in the timing and amount of
revenue estimates and changes in probability assumptions with
respect to the likelihood of achieving the various contingent
consideration obligations. Accretion expense related to the
increase in the net present value of the contingent liability is
included in interest expense for the period.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Atorvastatin
Contingent Consideration Liability</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with the Acquisition Agreement, the Arrow Selling
Shareholders will have the right to receive certain contingent
payments based on the after-tax gross profits on sales of
atorvastatin within the
U.S. (the “Territory”) from product launch date
up to and including May 31, 2013 (the “Contingent
Payment Period”). The determination of contingent payment
amounts is dependent upon the existence of generic competition
within the Territory and post-tax gross profits earned, as
defined in the Acquisition Agreement. Should there be no
competing generic product launched in the Territory during the
Contingent Payment Period, payment of contingent consideration
will be calculated as 50% of the post-tax gross profits, as
defined in the Acquisition Agreement. Should there be a
competing product to atorvastatin launched in the Territory
during the Contingent Payment Period, the contingent
consideration will be calculated as either 85% of the post-tax
gross profits or 15% of the post-tax gross profits, as defined
in the Acquisition Agreement, with total contingent payments
being limited to $250.0 million during the Contingent
Payment Period.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As of December 31, 2010 the range of outcomes and the
assumptions used to develop the estimates have not changed
significantly from those used at Acquisition Date. Other
long-term liabilities at December 31, 2010 and 2009
includes the fair value of the atorvastatin contingent liability
of $123.1 million and $111.0 million, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Columbia
Contingent Consideration Liability</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On July 2, 2010, the Company completed the acquisition of
the U.S. rights to Columbia products
Crinone<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and
Prochieve<sup style="font-size: 85%; vertical-align: text-top">®</sup>
for initial cash consideration of $62.0 million and
acquired certain assets and assumed certain contingent
consideration obligations. The transaction was accounted for
using the purchase method of accounting under existing
U.S. GAAP with assets acquired and liabilities assumed
recorded at their fair values as of the acquisition date. The
purchase price for the Columbia acquisition was allocated to
tangible and identifiable intangible assets acquired and
liabilities assumed based on their estimated fair values at the
acquisition date. Fair value determinations of Columbia’s
contingent payment obligations on acquisition date were based
on, among other factors, estimates of expected future cash
flows, estimates of appropriate discount rates used to present
value expected future cash flow streams, the timing of approvals
for IPR&D projects and the timing of related product launch
dates and other factors. Contingent consideration obligations
primarily relate to anticipated future milestone payments and
royalty payments due to Columbia in accordance with the terms of
the Columbia acquisition agreement.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other long-term liabilities at December 31, 2010 include
the fair value of the Columbia contingent consideration
liability of $46.5 million (which excludes the current
amount of $28.9 million presented within accounts payable
and current liabilities).
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 11 - us-gaap:IncomeTaxDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 11 —
Income Taxes</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s income before provision for income taxes was
generated from the United States and international operations as
follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="73%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Income before income taxes:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. 
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
391.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
366.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
353.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(141.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Income before income taxes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
250.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
362.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s provision for income taxes consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="73%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current provision:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Federal
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
State
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total current provision
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
185.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
159.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Deferred (benefit) provision:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Federal
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(54.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
State
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(54.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total deferred (benefit) provision
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(118.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(19.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total provision for income taxes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The exercise of certain stock options resulted in a tax benefit
and has been reflected as a reduction of income taxes payable
and an increase to additional paid-in capital. Such benefits
recorded were $6.7 million, $2.3 million, and
$0.2 million for the years ended December 31, 2010,
2009, and 2008, respectively.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Reconciliations between the statutory federal income tax rate
and the Company’s effective income tax rate were as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="78%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="4%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="4%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Federal income tax at statutory rates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
State income taxes, net of federal benefit
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Foreign rate differential
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Non-deductible expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
R&D credit and U.S. manufacturing deduction
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Charitable contributions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Favorable tax audit outcomes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Valuation allowance
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Transaction costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Sale of subsidiary
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effective income tax rate
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Deferred tax assets and liabilities are measured based on the
difference between the financial statement and tax basis of
assets and liabilities at the applicable tax rates.
The
significant components of the Company’s net deferred tax
assets (liabilities) consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Benefits from net operating loss and tax credit carryforwards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Differences in financial statement and tax accounting for:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Inventories, receivables and accruals
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
145.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Property, equipment and intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(305.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(366.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Deferred revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Deferred interest expense
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Share-based compensation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total deferred tax liability, gross
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(112.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(216.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Valuation allowance
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total deferred tax liability, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(141.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(245.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company had the following carryforward tax attributes at
December 31, 2010:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
$197.0 million state tax net operating losses
(“NOLs”) which begin to expire in 2011;
</td>
</tr>
<tr style="line-height: 6pt; font-size: 1pt">
<td> </td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
$96.0 million foreign tax NOLs which begin to expire in
2011; and
</td>
</tr>
<tr style="line-height: 6pt; font-size: 1pt">
<td> </td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
Tax credits of $36.0 million in foreign jurisdictions which
are not subject to expiration.
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A valuation allowance has been established due to the
uncertainty of realizing certain net operating losses, tax
credits and deferred tax assets relating to some impaired
investments.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Deferred income taxes have not been provided on the
undistributed earnings of certain of the Company’s foreign
subsidiaries of approximately $89.3 million and
$36.1 million as of December 31, 2010 and 2009,
respectively. These amounts have been indefinitely reinvested.
It is not practicable to calculate the deferred taxes associated
with these earnings; however, foreign tax credits would likely
be available to reduce federal income taxes in the event of
distribution.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">Accounting
for Uncertainty in Income Taxes</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At December 31, 2010, 2009 and 2008, the liability for
income tax associated with uncertain tax positions was
$68.0 million, $72.2 million and $61.3 million,
respectively. As of December 31, 2010, the net amount of
$60.2 million, if recognized, would favorably affect the
Company’s effective tax rate. A reconciliation of the
beginning and ending amount of unrecognized tax benefits is as
follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="75%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at the beginning of the year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
61.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
71.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Increases for current year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Increases for prior year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Decreases for prior year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(27.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(4.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Lapse of applicable statue of limitations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at the end of the year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
68.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
61.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s continuing practice is to recognize interest
and penalties related to uncertain tax positions in tax expense.
During the years ended December 31, 2010, 2009 and 2008,
the company recognized approximately ($2.3) million,
$1.4 million and ($0.8) million in interest and
penalties, respectively. At December 31, 2010, 2009 and
2008 the Company had accrued $2.4 million (net of tax
benefit of $1.8 million), $5.1 million (net of tax
benefit of $3.1 million), and $3.9 million (net of tax
benefit of $2.3 million) of interest and penalties related
to uncertain tax positions, respectively.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company conducts business globally and, as a result, it
files federal, state and foreign tax returns. The Company
strives to resolve open matters with each tax authority at the
examination level and could reach agreement with a tax authority
at any time. While the Company has accrued for amounts it
believes are the probable outcomes, the final outcome with a tax
authority may result in a tax liability that is more or less
than that reflected in the consolidated financial statements.
Furthermore, the Company may later decide to challenge any
assessments, if made, and may exercise its right to appeal. The
uncertain tax positions are reviewed quarterly and adjusted as
events occur that affect potential liabilities for additional
taxes, such as lapsing of applicable statutes of limitations,
proposed assessments by tax authorities, negotiations with or
between tax authorities and issuance of new legislation,
regulations, rulings or case law. Management believes that
adequate amounts of tax and related penalty and interest have
been provided for any adjustments that may result from these
uncertain tax positions.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
With few exceptions, the Company is no longer subject to
U.S. federal, state and local, or
<font style="white-space: nowrap">non-U.S. income</font>
tax examinations for years before 2003. During the third quarter
of 2010, the Internal Revenue Service (“IRS”)
completed its examination of the Andrx Corporation’s tax
returns for the pre-acquisition period and the Joint Committee
of Taxation completed its review of the Company’s tax
returns for the
<font style="white-space: nowrap">2004-2006</font>
periods. As a result, the Company recorded a reduction to its
income tax expense of $4.7 million relating to the
completion of the Andrx examination and $13.9 million
relating to the Company’s examination.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In the fourth quarter of 2010, the IRS began examining the
Company’s 2007, 2008, and 2009 tax years. While it is often
difficult to predict the final outcome or the timing of
resolution of any particular uncertain tax position, the Company
has accrued for amounts it believes are the probable outcomes.
As a result of the ongoing IRS exam, the potential completion
<font style="white-space: nowrap">and/or</font>
settlement of other examinations in state and foreign
jurisdictions, and the future completion of the Company’s
assessment of the uncertain tax positions of the Arrow Group,
the quantification of all those potential changes cannot be
estimated at this time.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 12 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 12 —
Stockholders’ Equity</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Preferred
stock</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In 1992, the Company authorized 2.5 million shares of no
par preferred stock. The Board has the authority to fix the
rights, preferences, privileges and restrictions, including but
not limited to, dividend rates, conversion and voting rights,
terms and prices of redemptions and liquidation preferences
without vote or action by the stockholders. On December 2,
2009 the Company issued 0.2 million shares of
Mandatorily Redeemable Preferred Stock. The Mandatorily
Redeemable Preferred Stock is redeemable in cash on
December 2, 2012 and is accordingly, included within
long-term debt in the consolidated balance sheet at
December 31, 2010 (for additional information on the
Mandatorily Redeemable Preferred Stock refer to
“NOTE 9 — Long-Term Debt”).
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Stock
option plans</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has adopted several stock option plans, all of which
have been approved by the Company’s shareholders that
authorize the granting of options to purchase the Company’s
common shares subject to certain conditions. At
December 31, 2010, the Company had reserved
5.2 million of its common shares for issuance upon exercise
of options granted or to be granted under these plans and for
restricted stock grants (see discussion below). The option award
plans require options to be granted at the fair value of the
shares underlying the options at the date of the grant and
generally become exercisable over periods ranging from three to
five years and expire in ten years. In conjunction with certain
of the Company’s acquisitions, Watson assumed stock option
and warrant plans from the acquired companies. The options and
warrants in these plans were adjusted by the individual exchange
ratios specified in each transaction. No additional options or
warrants will be granted under any of the assumed plans.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the Company’s stock option plans consisted of
the following (options and aggregate intrinsic value in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="57%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Exercise<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Options</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Price</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.91
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Exercised
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.49
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.63
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
48.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Vested and expected to vest at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.71
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
47.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Options exercisable at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
42.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As of December 31, 2010, the Company had $0.5 million
of total unrecognized compensation expense, net of estimated
forfeitures, related to stock option grants, which will be
recognized over the remaining weighted average period of
1.1 years. Total intrinsic value of options exercised for
the year ended December 31, 2010 and 2009 was
$18.4 million and $7.4 million, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Restricted
Stock Plan</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Beginning in 2005, the Compensation Committee of the Board
authorized and issued restricted stock to the Company’s
Participants under the Company’s equity compensation plans.
The restricted stock award program offers Participants the
opportunity to earn shares of our common stock over time, rather
than options that give Participants the right to purchase stock
at a set price. Restricted stock awards are grants that entitle
the holder to shares of common stock subject to certain terms.
Watson’s restricted stock awards generally have
restrictions eliminated over a one- to four-year period.
Restrictions generally lapse for non-employee directors after
one year. Restrictions generally lapse for employees over a two-
to four-year period. The fair value of restricted stock grants
is based on the fair market value of our common stock on the
respective grant dates. Restricted stock compensation is being
amortized and charged to operations over the same period as the
restrictions are eliminated for the Participants.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the changes in restricted stock grants during the
year ended December 31, 2010 is presented below (shares and
aggregate intrinsic value in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="60%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Grant Date<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Shares</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.79
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.03
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
43.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Vested
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.74
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.55
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.33
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
79.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As of December 31, 2010, the Company had $28.6 million
of total unrecognized compensation expense, net of estimated
forfeitures, related to restricted stock grants, which will be
recognized over the remaining weighted average period of
1.6 years.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Stock
Repurchases</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During the years ended December 31, 2010 and 2009, the
Company repurchased approximately 0.1 million and
0.1 million shares, respectively, of its common stock
surrendered to the Company to satisfy tax withholding
obligations in connection with the vesting of restricted stock
issued to employees for total consideration of $6.3 million
and $3.6 million, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Accumulated
Other Comprehensive Income (Loss)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Accumulated other comprehensive income (loss) at
December 31, 2010 consists of unrealized gains on
securities of $9.2 million and foreign currency translation
adjustments of ($11.7) million.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 13 - us-gaap:SegmentReportingDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 13 —
Reportable Segments</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson has three reportable segments: Global Generics, Global
Brands and Distribution. The Global Generics segment includes
off-patent pharmaceutical products that are therapeutically
equivalent to proprietary products. The Global Brands segment
includes patent-protected products and certain trademarked
off-patent products that Watson sells and markets as brand
pharmaceutical products. The Distribution segment mainly
distributes generic pharmaceutical products manufactured by
third parties, as well as by Watson, primarily to independent
pharmacies, pharmacy chains, pharmacy buying groups and
physicians’ offices under the Anda trade name. Sales are
principally generated through an in-house telemarketing staff
and through internally developed ordering systems. The
Distribution segment operating results exclude sales by Anda of
products developed, acquired, or licensed by Watson’s
Global Generics and Global Brands segments. Arrow operating
results are included in the Global Generics segment subsequent
to the date of acquisition except for operating results from
Eden which are included in our Global Brands segment.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The accounting policies of the operating segments are the same
as those described in “NOTE 2 — Summary of
Significant Accounting Policies.” The other revenue
classification consists primarily of milestone payments,
commission revenue, royalties and revenues from research,
development and licensing fees and also includes co-promotion
revenue and revenue (including the amortization of deferred
revenue) relating to our obligation to manufacture and supply
products to third parties. The Company evaluates segment
performance based on segment contribution. Segment contribution
represents segment net revenues less cost of sales (excludes
amortization), direct R&D expenses and selling and
marketing expenses. The Company does not report total assets,
capital expenditures, corporate general and administrative
expenses, amortization, gains on disposal or impairment losses
by segment as such information has not been used by management,
or has not been accounted for at the segment level.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Segment net revenues, segment operating expenses and segment
contribution information for the Company’s Global Generics,
Global Brands and Distribution segments consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="71%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Generics Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,268.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,641.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,404.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,338.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,668.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,474.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,198.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
947.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
883.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
194.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
53.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
<b>Global Generics Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>833.0</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>526.9</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>416.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Brands Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
316.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
393.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
81.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
58.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
461.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
455.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
50.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
137.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
144.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Global Brands Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>70.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>170.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>178.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Distribution Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
560.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
511.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
59.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Distribution Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>49.2</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>38.6</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>34.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Total Segment Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>952.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>735.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>629.7</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Corporate general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
436.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
257.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
190.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
180.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
92.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
80.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Loss on asset sales and impairments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Operating income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
305.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
383.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000">
</div>
<div style="margin-top: 3pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<tr>
<td width="2%"></td>
<td width="1%"></td>
<td width="97%"></td>
</tr>
<tr>
<td align="right" valign="top">
(1) </td>
<td></td>
<td valign="bottom">
Excludes amortization of acquired intangibles including product
rights.</td>
</tr>
</table>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following geographic areas for the years
ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
United States
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,990.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,642.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,384.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
International
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
425.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
57.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following therapeutic categories for the
years ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Central nervous system
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
907.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
836.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
795.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Hormones and synthetic substitutes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
609.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cardiovascular
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
594.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
269.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
245.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Anti-infective agents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Urology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
127.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
942.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
738.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
634.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 14 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 14 —
Business Restructuring Charges</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities involving facilities at Carmel, New York;
Mississauga, Canada; and Melbourne, Australia for the year ended
December 31, 2010 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Severance and retention
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product transfer costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Facility decommission costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(18.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation — R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities at Carmel, New York and Brewster, New York for the
year ended December 31, 2009 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(22.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Product transfer costs consist of documentation, testing and
shipping costs to transfer product to other facilities.
Operating expenses include severance, retention and accelerated
depreciation. Retention is expensed only to the extent earned by
employees. Activity related to our business restructuring and
facility rationalization activities is primarily attributable to
our Global Generics segment.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During the first quarter of 2008, we announced steps to improve
our operating cost structure and achieve operating efficiencies
through our Global Supply Chain Initiative (“GSCI”).
These 2008 GSCI’s include the planned closure of
manufacturing facilities in Carmel, New York, our distribution
center in Brewster, New York and the transition of
manufacturing to our other manufacturing locations within the
U.S. and India. Distribution activities at our distribution
center in Brewster, New York ceased in July 2009. Product
manufacturing ceased in Carmel, New York by December 31,
2010 and we expect a closure of the facility by early 2011.
During the second quarter of 2010, the Company announced
additional measures to reduce its cost structure involving a
manufacturing facility and certain R&D activities in Canada
and certain R&D activities in Australia. In January 2011,
the Company announced the closure of R&D activities in
Corona, California. These additional restructuring activities,
and the transfer of development activities to existing R&D
sites, are expected to be completed in Australia by early 2011,
in Corona by the end of 2011 and in Canada by late 2012.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 15 - us-gaap:FairValueDisclosuresTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 15 —
Fair Value Measurement</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In September 2006, the FASB issued authoritative guidance for
fair value measurements, which defines fair value, establishes a
framework for measuring fair value in U.S. GAAP and expands
disclosures about fair value measurements. The Company adopted
the provisions of the guidance effective January 1, 2008
for all financial assets and liabilities and any other assets
and liabilities that are recognized or disclosed at fair value
on a recurring basis. The Company adopted the provisions of the
guidance for nonfinancial assets and liabilities measured at
fair value on a non-recurring basis effective January 1,
2009. Although the adoption of the guidance did not materially
impact the Company’s financial condition, results of
operations or cash flows, we are required to provide additional
disclosures within our consolidated financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The guidance defines fair value as the price that would be
received to sell an asset or paid to transfer the liability (an
exit price) in an orderly transaction between market
participants and also establishes a fair value hierarchy which
requires an entity to maximize the use of observable inputs and
minimize the use of unobservable inputs when measuring fair
value. The fair value hierarchy within the guidance
distinguishes three levels of inputs that may be utilized when
measuring fair value, including level 1 inputs (using
quoted prices in active markets for identical assets or
liabilities), level 2 inputs (using inputs other than
level 1 prices such as quoted prices for similar assets and
liabilities in active markets or inputs that are observable for
the asset or liability) and level 3 inputs (using
unobservable inputs supported by little or no market activity
based
on our own assumptions used to measure assets and liabilities).
A financial asset or liability’s classification within the
above hierarchy is determined based on the lowest level input
that is significant to the fair value measurement.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Financial assets and liabilities measured at fair value or
disclosed at fair value on a recurring basis as at
December 31, 2010 and 2009 consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2010
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2009
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Marketable securities and investments consist of
<font style="white-space: nowrap">available-for-sale</font>
investments in U.S. Treasury and agency securities and
publicly traded equity securities for which market prices are
readily available. Unrealized gains or losses on marketable
securities and investments are recorded in accumulated other
comprehensive (loss) income.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The fair value measurement of the contingent consideration
obligations is determined using Level 3 inputs. The fair
value of contingent consideration obligations is based on a
probability-weighted income approach. The measurement is based
upon unobservable inputs supported by little or no market
activity based on our own assumptions. Changes in the fair value
of the contingent consideration obligations are recorded as a
component of operating income in our consolidated statement of
operations.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The tables below provide a summary of the changes in fair value,
including net transfers in
<font style="white-space: nowrap">and/or</font> out,
of all financial assets and liabilities measured at fair value
on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December 31, 2010
and 2009 (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 16 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 16 —
Commitments and Contingencies</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Facility
and Equipment Leases</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has operating leases for certain facilities and
equipment. The terms of the operating leases for the
Company’s facilities require the Company to pay property
taxes, normal maintenance expenses and maintain minimum
insurance coverage. Total rental expense for operating leases in
2010, 2009 and 2008 was $26.0 million, $20.0 million
and $19.0 million, respectively.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At December 31, 2010, future minimum lease payments under
all non-cancelable operating leases are approximately,
$24.4 million in 2011, $18.6 million in 2012,
$14.6 million in 2013, $12.5 million in 2014,
$12.8 million in 2015 and $53.0 million thereafter.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Employee
Retirement Plans</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company maintains certain defined contribution retirement
plans covering substantially all
<font style="white-space: nowrap">U.S.-based</font>
employees. The Company contributes to the plans based upon the
employee contributions. Watson’s contributions to these
retirement plans were $9.5 million, $11.0 million and
$10.6 million in the years ended December 31, 2010,
2009 and 2008, respectively. The Company does not sponsor any
defined benefit retirement plans or postretirement benefit plans.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Legal
Matters</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson and its affiliates are involved in various disputes,
governmental
<font style="white-space: nowrap">and/or</font>
regulatory inspections, inquires, investigations and
proceedings, and litigation matters that arise from time to time
in the ordinary course of business. The process of resolving
matters through litigation or other means is inherently
uncertain and it is possible that an unfavorable resolution of
these matters will adversely affect the Company, its results of
operations, financial condition and cash flows. The
Company’s regular practice is to expense legal fees as
services are rendered in connection with legal matters, and to
accrue for liabilities when losses are probable and reasonably
estimable.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Cipro</i><sup style="font-size: 85%; vertical-align: text-top">®</sup>
<i>Litigation.</i>  Beginning in July 2000, a number
of suits were filed against Watson, The Rugby Group, Inc.
(“Rugby”) and other company affiliates in various
state and federal courts alleging claims under various federal
and state competition and consumer protection laws. Several
plaintiffs have filed amended complaints and motions seeking
class certification. Approximately 42 cases have been filed
against Watson, Rugby and other Watson entities. Twenty-two of
these actions have been consolidated in the U.S. District
Court for the Eastern District of New York (<i>In re:
Ciprofloxacin Hydrochloride Antitrust Litigation, MDL Docket
No. 001383</i>). On May 20, 2003, the court hearing
the consolidated action granted Watson’s motion to dismiss
and made rulings limiting the theories under which plaintiffs
can seek recovery against Rugby and the other defendants. On
March 31, 2005, the court hearing the consolidated action
granted summary judgment in favor of the defendants on all of
plaintiffs’ claims and denied the plaintiffs’ motions
for class certification. On May 7, 2005, three groups of
plaintiffs from the consolidated action (the direct purchaser
plaintiffs, the indirect purchaser plaintiffs and plaintiffs
Rite Aid and CVS) filed notices of appeal in the United States
Court of Appeals for the Second Circuit, appealing, among other
things, the May 20, 2003 order dismissing Watson and the
March 31, 2005 order granting summary judgment in favor of
the defendants. On November 7, 2007, the U.S. Court of
Appeals for the Second Circuit ordered the appeal by the
indirect purchaser plaintiffs transferred to the United States
Court of Appeals for the Federal Circuit. On October 15,
2008, the United States Court of Appeals for the Federal
Circuit affirmed the dismissal of the indirect purchasers’
claims, and on December 22, 2008, denied the indirect
purchaser plaintiffs’ petition for rehearing and rehearing
en banc. On June 22, 2009, the Supreme Court denied the
indirect purchaser plaintiffs’ petition for writ of
certiorari. In the appeal in the United States Court of Appeals
for the Second Circuit by the direct purchaser plaintiffs and
plaintiffs CVS and Rite Aid, on April 29, 2010, the United
States Court of Appeals
for the Second Circuit affirmed the ruling of the District Court
granting summary judgment in favor of the defendants, and on
September 7, 2010, denied the appellants’ petition for
rehearing en banc. On December 6, 2010, the appellants
filed a petition for writ of certiorari with the United States
Supreme Court seeking review of the Second Circuit’s
decision. The defendants filed their opposition to the petition
on February 7, 2011. Other actions are pending in various
state courts, including California, Kansas, Tennessee, and
Florida. The actions generally allege that the defendants
engaged in unlawful, anticompetitive conduct in connection with
alleged agreements, entered into prior to Watson’s
acquisition of Rugby from Sanofi Aventis (“Sanofi”),
related to the development, manufacture and sale of the drug
substance ciprofloxacin hydrochloride, the generic version of
Bayer’s brand drug,
Cipro<sup style="font-size: 85%; vertical-align: text-top">®</sup>.
The actions generally seek declaratory judgment, damages,
injunctive relief, restitution and other relief on behalf of
certain purported classes of individuals and other entities. In
the action pending in Kansas, the court has administratively
terminated the matter pending the outcome of the appeals in the
consolidated case. In the action pending in the California
Superior Court for the County of San Diego (<i>In re: Cipro
Cases I & II, JCCP Proceeding Nos. 4154 &
4220</i>), on July 21, 2004, the California Court of Appeal
ruled that the majority of the plaintiffs would be permitted to
pursue their claims as a class. On August 31, 2009, the
California Superior Court granted defendants’ motion for
summary judgment, and final judgment was entered on
September 24, 2009. On November 19, 2009, the
plaintiffs filed a notice of appeal. The appeal remains pending.
In addition to the pending actions, Watson understands that
various state and federal agencies are investigating the
allegations made in these actions. Sanofi has agreed to defend
and indemnify Watson and its affiliates in connection with the
claims and investigations arising from the conduct and
agreements allegedly undertaken by Rugby and its affiliates
prior to Watson’s acquisition of Rugby, and is currently
controlling the defense of these actions.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Governmental Reimbursement Investigations and Drug Pricing
Litigation.</i>  In November 1999,
Schein Pharmaceutical, Inc., now known as Watson Pharma,
Inc. (“Watson Pharma”) was informed by the
U.S. Department of Justice that it, along with numerous
other pharmaceutical companies, is a defendant in a <i>qui tam
</i>action brought in 1995 under the U.S. False Claims Act
currently pending in the U.S. District Court for the
Southern District of Florida. Watson Pharma has not been served
in the <i>qui tam </i>action. A <i>qui tam </i>action is a civil
lawsuit brought by an individual or a company (the “qui tam
relator”) for an alleged violation of a federal statute, in
which the U.S. Department of Justice has the right to
intervene and take over the prosecution of the lawsuit at its
option. Pursuant to applicable federal law, the <i>qui tam
</i>action is under seal as to Watson Pharma. The Company
believes that the <i>qui tam </i>action relates to whether
allegedly improper price reporting by pharmaceutical
manufacturers led to increased payments by Medicare
<font style="white-space: nowrap">and/or</font>
Medicaid. The <i>qui tam</i> action may seek to recover damages
from Watson Pharma based on its price reporting practices.
Watson Pharma subsequently also received and responded to
notices or subpoenas from the Attorneys General of various
states, including Florida, Nevada, New York, California and
Texas, relating to pharmaceutical pricing issues and whether
allegedly improper actions by pharmaceutical manufacturers led
to excessive payments by Medicare
<font style="white-space: nowrap">and/or</font>
Medicaid. On June 26, 2003, the Company received a request
for records and information from the U.S. House Committee
on Energy and Commerce in connection with that committee’s
investigation into pharmaceutical reimbursements and rebates
under Medicaid. The Company produced documents in response to
the request. Other state and federal inquiries regarding pricing
and reimbursement issues are anticipated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Beginning in July 2002, the Company and certain of its
subsidiaries, as well as numerous other pharmaceutical
companies, were named as defendants in various state and federal
court actions alleging improper or fraudulent reporting
practices related to the reporting of average wholesale prices
and wholesale acquisition costs of certain products, and that
the defendants committed other improper acts in order to
increase prices and market shares. Some of these actions have
been consolidated in the U.S. District Court for the
District of Massachusetts (<i>In re: Pharmaceutical Industry
Average Wholesale Price Litigation, MDL Docket
No. 145</i>). The consolidated amended Class Action
complaint in that case alleges that the defendants’ acts
improperly inflated the reimbursement amounts of certain drugs
paid by various public and private plans and programs. Certain
defendants, including the Company, have entered into a
settlement agreement resolving
all claims against them in the Consolidated Class Action.
The total amount of the settlement for all of the settling
defendants is $125 million. The amount to be paid by each
settling defendant is confidential. On July 2, 2008, the
United States District Court for the District of Massachusetts
preliminarily approved the Track Two settlement. On
April 27, 2009, the Court held a hearing to further
consider the fairness of the proposed settlement. The Court
adjourned the hearing without ruling on the fairness of the
proposed settlement until additional notices are provided to
certain of the class members in the action. The settlement is
not expected to materially adversely affect the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company and certain of its subsidiaries also are named as
defendants in various lawsuits filed by numerous states and qui
tam relators, including Texas, Kansas, Nevada, Montana,
Massachusetts, Wisconsin, Kentucky, Alabama, Illinois,
Mississippi, Florida, Arizona, Missouri, Alaska, Idaho, South
Carolina, Hawaii, Utah, Iowa, Oklahoma and Louisiana captioned
as follows: <i>State of Nevada v. American Home Products,
et al., Civil Action
<font style="white-space: nowrap">No. 02-CV-12086-PBS,</font>
United States District Court for the District of Massachusetts;
State of Montana v. Abbott Laboratories, et al., Civil
Action
<font style="white-space: nowrap">No. 02-CV-12084-PBS,</font>
United States District Court for the District of Massachusetts;
Commonwealth of Massachusetts v. Mylan Laboratories, et
al., Civil Action
<font style="white-space: nowrap">No. 03-CV-11865-PBS,</font>
United States District Court for the District of Massachusetts;
State of Wisconsin v. Abbott Laboratories, et al., Case
<font style="white-space: nowrap">No. 04-cv-1709,</font>
Wisconsin Circuit Court for Dane County; Commonwealth of
Kentucky v. Alpharma, Inc., et al., Case Number 04-CI-1487,
Kentucky Circuit Court for Franklin County; State of
Alabama v. Abbott Laboratories, Inc. et al., Civil Action
<font style="white-space: nowrap">No. CV05-219,</font>
Alabama Circuit Court for Montgomery County; State of
Illinois v. Abbott Laboratories, Inc. et al., Civil Action
<font style="white-space: nowrap">No. 05-CH-02474,</font>
Illinois Circuit Court for Cook County; State of
Mississippi v. Abbott Laboratories, Inc. et al., Civil
Action
<font style="white-space: nowrap">No. G2005-2021</font>
S/2, Mississippi Chancery Court of Hinds County; State of
Florida ex rel.
<font style="white-space: nowrap">Ven-A-Care,</font>
Civil Action No
<font style="white-space: nowrap">98-3032G,</font>
Florida Circuit Court in Leon County (the “Florida
<font style="white-space: nowrap">Ven-A-Care</font>
Action”); State of Arizona ex rel. Terry Goddard,
No. CV
<font style="white-space: nowrap">2005-18711,</font>
Arizona Superior Court for Maricopa County; State of Missouri ex
rel. Jeremiah W. (Jay) Nixon v. Mylan Laboratories, et al,
Case
<font style="white-space: nowrap">No. 054-2486,</font>
Missouri Circuit Court of St. Louis; State of
Alaska v. Alpharma Branded Products Division Inc., et
al., In the Superior Court for the State of Alaska Third
Judicial District at Anchorage, C.A.
<font style="white-space: nowrap">No. 3AN-06-12026</font>
CI; State of Idaho v. Alpharma USPD Inc. et al., In the
District Court of the Fourth Judicial District of the State of
Idaho, in and for the County of Ada, C.A.
<font style="white-space: nowrap">No. CV0C-0701847;</font>
State of South Carolina and Henry D. McMaster v. Watson
Pharmaceuticals (New Jersey), Inc., In the Court of Common Pleas
for the Fifth Judicial Circuit, State of South Carolina, County
of Richland, C.A.
<font style="white-space: nowrap">No. 2006-CP-40-7152;</font>
State of South Carolina and Henry D. McMaster v. Watson
Pharmaceuticals (New Jersey), Inc., In the Court of Common Pleas
for the Fifth Judicial Circuit, State of South Carolina, County
of Richland, C.A.
<font style="white-space: nowrap">No. 2006-CP-40-7155;</font>
State of Hawaii v. Abbott Laboratories, Inc. et al., In the
Circuit Court of the First Circuit, State of Hawaii, C.A.
<font style="white-space: nowrap">No. 06-1-0720-04</font>
EEH; State of Utah v. Actavis U.S., Inc., et al., In the
Third Judicial District Court of Salt Lake County, Civil
<font style="white-space: nowrap">No. 07-0913719;</font>
State of Iowa v. Abbott Laboratories, Inc., et al., In the
U.S. District Court for the Southern District of Iowa,
Central Division, Case
<font style="white-space: nowrap">No. 07-CV-00461</font>
(the “Iowa AG Action”); State of Texas ex rel.
<font style="white-space: nowrap">Ven-A-Care</font>
of the Florida Keys, Inc. v. Alpharma Inc., et al, Case
<font style="white-space: nowrap">No. 08-001565,</font>
in the District Court of Travis County, Texas (the “Texas
<font style="white-space: nowrap">Ven-A-Care</font>
Action”); United States of America ex rel.
<font style="white-space: nowrap">Ven-A-Care</font>
of the Florida Keys, Inc.,v. Actavis Mid-Atlantic LLC, Civil
Action
<font style="white-space: nowrap">No. 08-10852,</font>
in the U.S. District Court for the District of
Massachussetts (the “Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Action”); State of Kansas ex rel. Steve Six v.
Watson Pharmaceuticals, Inc. and Watson Pharma, Inc., Case
Number: 08CV2228, District Court of Wyandotte County, Kansas,
Civil Court Department; State of Oklahoma, ex rel., W.A. Drew
Edmondson, Attorney General of Oklahoma v. Abbott
Laboratories, Inc., et al., Case
<font style="white-space: nowrap">No. CJ-2010-474,</font>
District Court of Pottawatomie County, Oklahoma, and State of
Louisiana V. Abbott Laboratories, Inc., et al., Case
No. 596144, Parish of East Baton Rouge,
19<sup style="font-size: 85%; vertical-align: top">th</sup></i>
<i>Judicial District. </i>In December of 2010, the State of Utah
served the Company with a Civil Investigative Demand seeking
additional information relating to the Company’s pricing
practices.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On August 4, 2004, the City of New York filed an action
against the Company and numerous other pharmaceutical defendants
alleging similar claims. The case has been consolidated with
similar cases filed by forty one individual New York counties.
(<i>City of New York v. Abbott Laboratories, Inc., et al.,
Civil Action
<font style="white-space: nowrap">No. 01-CV-12257-PBS,</font>
United States District Court for the District of
Massachusetts</i>) (hereinafter the “Consolidated NY
Counties Actions”), as well as by four additional New York
counties, with three of these cases pending in New York state
courts. On January 27, 2010, the U.S. District Court
granted Plaintiffs’ motion in the Consolidated NY Counties
Actions for partial summary judgment as to each of the generic
defendants, including Watson, with respect to some of
Watson’s drugs reimbursed at the Federal Upper Limit, and
found violations of New York’s state false claims act
statute.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In August 2010, the Company reached an agreement in principle to
settle each of the following pending actions: the Texas
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Florida
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Action, the Iowa AG Action, and the Consolidated New York
Counties Action (collectively the
<font style="white-space: nowrap">“Ven-A-Care</font>
Settlement”). The
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement was contingent upon approval of the United States
Department of Justice and the execution of definitive settlement
documents. In December of 2010, after the parties failed to
finalize the
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement, the Company reached an agreement in principle to
settle the following pending actions: the Texas
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Florida
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Iowa AG Action, and the Consolidated New York
Counties Action (the “State
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement”). In addition, at the same time the Company
reached an agreement in principle to settle claims pending in
the Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Action relative to the Texas, Florida, Iowa and New York
Medicaid programs (the “Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement,” and collectively with the State
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement, the “December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement”). The total amount to be paid by the Company
under the terms of the proposed December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement is $79 million. The December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement is contingent upon obtaining final approval by the
U.S. Department of Justice and the execution of definitive
settlement documents.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The cases against the Company on behalf of Arizona, Hawaii and
Massachusetts have been settled. The case against the Company on
behalf of Alabama was tried in 2009. The jury was unable to
reach a verdict, and the court declared a mistrial and ordered
the case to be retried. New trials against the Company and
Andrx Corporation, a Company subsidiary, are scheduled for
May and August of 2011, respectively. The case against the
Company on behalf of Kentucky is scheduled for trial in November
of 2011. The case against the Company on behalf of Mississippi
is scheduled for trial in June 2011. The case against the
Company on behalf of Alaska is scheduled for trial in January of
2012. The case against the Company on behalf of Idaho is
scheduled for trial in March 2012. The case against the Company
on behalf of Missouri is scheduled for trial in June of 2012.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has accrued a $129.9 million liability reserve
on its balance sheet in connection with the December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement and the remaining drug pricing actions. The December
2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement will resolve a considerable portion of the damages
claims asserted against the Company and its affiliates in the
various pending pricing litigations. With regard to the
remaining drug pricing actions, the Company believes that it has
meritorious defenses and intends to vigorously defend itself in
those actions. The Company continually monitors the status of
these actions and may settle or otherwise resolve some or all of
these matters on terms that the Company deems to be in its best
interests. However, the
Company can give no assurance that it will be able to settle the
remaining actions on terms it deems reasonable, or that such
settlements or adverse judgments in the remaining actions, if
entered, will not exceed the amounts of the liability reserves.
Additional actions by other states, cities
<font style="white-space: nowrap">and/or</font>
counties are anticipated. These actions
<font style="white-space: nowrap">and/or</font> the
actions described above, if successful, could adversely affect
the Company and could have a material adverse effect on the
Company’s business, results of operations, financial
condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Medicaid Drug Reimbursement Litigation.</i>  In
December 2009, the Company learned that numerous pharmaceutical
companies, including certain subsidiaries of the Company, have
been named as defendants in a qui tam action pending in the
United States District Court for the District of Massachusetts
(<i>United States of America ex rel. Constance A. Conrad v.
Actavis Mid-Atlantic, LLC, f/k/a Biovail Pharmaceuticals, LLC,
et. al.,USDC Case
<font style="white-space: nowrap">No. 02-CV-11738-NG).</font>
</i>The seventh amended complaint, which was served on certain
of the Company’s subsidiaries in December 2009, alleges
that the defendants falsely reported to the United States that
certain pharmaceutical products were eligible for Medicaid
reimbursement and thereby allegedly caused false claims for
payment to be made through the Medicaid program. In December
2010 the plaintiff served a ninth amended complaint that unseals
the action in its entirety and continues to allege the
previously asserted claims against certain subsidiaries of the
Company. The Company believes that it has meritorious defenses
to the claims and intends to vigorously defend itself in the
action. However, this action, if successful, could adversely
affect the Company and could have a material adverse effect on
the Company’s business, results of operations, financial
condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>FDA Matters.</i>  In May 2002, Watson reached an
agreement with the FDA on the terms of a consent decree with
respect to its Corona, California manufacturing facility. The
court approved the consent decree on May 13, 2002
(<i>United States of America v. Watson Laboratories, Inc.,
and Allen Y. Chao</i>, United States District Court for the
Central District of California, EDCV-02-412-VAP). The consent
decree with the FDA does not require any fine, a facility
shutdown, product recalls or any reduction in production or
service at the Company’s Corona facility. The consent
decree applies only to the Corona facility and not other
manufacturing sites. On July 9, 2008, the court entered an
order dismissing Allen Y. Chao, the Company’s former
President and Chief Executive Officer, from the action and from
the consent decree. The decree requires Watson to ensure that
its Corona, California facility complies with the FDA’s
current Good Manufacturing Practices (“cGMP”)
regulations.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pursuant to the agreement, Watson hired an independent expert to
conduct inspections of the Corona facility at least once each
year. In each year since 2002, the independent expert has
reported its opinion to the FDA that, based on the findings of
the audit of the facility, the FDA’s applicable cGMP
requirements, applicable FDA regulatory guidance, and the
collective knowledge, education, qualifications and experience
of the expert’s auditors and reviewers, the systems at
Watson’s Corona facility audited and evaluated by the
expert are in compliance with the FDA’s cGMP regulations.
However, the FDA is not required to accept or agree with the
independent expert’s opinion. The FDA has conducted
periodic inspections of the Corona facility since the entry of
the consent decree. The FDA’s most recent inspection was
conducted from August 2, 2010 through August 13, 2010.
At the conclusion of the inspection no formal observations were
made and no FDA Form 483 was issued. However, if in the
future, the FDA determines that, with respect to its Corona
facility, Watson has failed to comply with the consent decree or
FDA regulations, including cGMPs, or has failed to adequately
address the FDA’s inspectional observations, the consent
decree allows the FDA to order Watson to take a variety of
actions to remedy the deficiencies. These actions could include
ceasing manufacturing and related operations at the Corona
facility, and recalling affected products. Such actions, if
taken by the FDA, could have a material adverse effect on the
Company, its results of operations, financial position and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Federal Trade Commission Investigations.</i>  The
Company has received Civil Investigative Demands or requests for
information from the Federal Trade Commission seeking
information and documents related to the terms on which the
Company has settled lawsuits initiated by patentees under the
Hatch-Waxman Act, and
other commercial arrangements between the Company and third
parties. These investigations include the Company’s August
2006 settlement with Cephalon, Inc. related to the
Company’s generic version of
Provigil<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(modafinil). The Company believes these agreements comply with
applicable laws and rules. However, if the Federal Trade
Commission concludes that any of these agreements violate
applicable antitrust laws or rules, it could initiate legal
action against the Company. These actions, if successful, could
have a material adverse effect on the Company’s business,
results of operations, financial condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Androgel</i><sup style="font-size: 85%; vertical-align: text-top">®</sup>
<i>Antitrust Litigation.</i>  On January 29,
2009, the U.S. Federal Trade Commission and the State of
California filed a lawsuit in the United States District Court
for the Central District of California <i>(Federal Trade
Commission, et. al. v. Watson Pharmaceuticals, Inc., et.
al., USDC Case No. CV
<font style="white-space: nowrap">09-00598)</font>
</i>alleging that the Company’s September 2006 patent
lawsuit settlement with Solvay Pharmaceuticals, Inc., related to
AndroGel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
1% (testosterone gel) CIII is unlawful. The complaint generally
alleged that the Company improperly delayed its launch of a
generic version of
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
in exchange for Solvay’s agreement to permit the Company to
co-promote
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
for consideration in excess of the fair value of the services
provided by the Company, in violation of federal and state
antitrust and consumer protection laws. The complaint sought
equitable relief and civil penalties. On February 2 and 3, 2009,
three separate lawsuits alleging similar claims were filed in
the United States District Court for the Central District of
California by various private plaintiffs purporting to represent
certain classes of similarly situated claimants <i>(Meijer,
Inc., et. al., v. Unimed Pharmaceuticals, Inc., et. al.,
USDC Case No. EDCV
<font style="white-space: nowrap">09-0215);</font>
(Rochester Drug Co-Operative, Inc. v. Unimed
Pharmaceuticals Inc., et. al., Case No. EDCV
<font style="white-space: nowrap">09-0226);</font>
(Louisiana Wholesale Drug Co. Inc. v. Unimed
Pharmaceuticals Inc., et. al, Case No. EDCV
<font style="white-space: nowrap">09-0228)</font></i>.
On April 8, 2009, the Court transferred the government and
private cases to the United States District Court for the
Northern District of Georgia. On April 21, 2009 the State
of California voluntarily dismissed its lawsuit against the
Company without prejudice. The Federal Trade Commission and the
private plaintiffs in the Northern District of Georgia filed
amended complaints on May 28, 2009. The private plaintiffs
amended their complaints to include allegations concerning
conduct before the U.S. Patent and Trademark Office,
conduct in connection with the listing of Solvay’s patent
in the Food and Drug Administration’s “Orange
Book,” and sham litigation. Additional actions alleging
similar claims have been filed in various courts by other
private plaintiffs purporting to represent certain classes of
similarly situated direct or indirect purchasers of
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(<i>Stephen L. LaFrance Pharm., Inc. d/b/a SAJ Dist. v.
Unimed Pharms., Inc., et al.,D. NJ Civ.
<font style="white-space: nowrap">No. 09-1507</font></i>);
( <i>Fraternal Order of Police, Fort Lauderdale Lodge 31,
Insurance Trust Fund v. Unimed Pharms. Inc., et al.,D.
NJ Civ.
<font style="white-space: nowrap">No. 09-1856</font>
</i>); (<i>Scurto v. Unimed Pharms., Inc., et al., D. NJ
Civ.
<font style="white-space: nowrap">No. 09-1900</font></i>);
(<i>United Food and Commercial Workers Unions and Employers
Midwest Health Benefits Fund v. Unimed Pharms., Inc., et
al., D. MN Civ.
<font style="white-space: nowrap">No. 09-1168</font></i>);
( <i>Rite Aid Corp. et al. v. Unimed Pharms., Inc. et
al., M.D. PA Civ.
<font style="white-space: nowrap">No. 09-1153);</font>
(Walgreen Co., et al. v. Unimed Pharms.,LLC, et al., MD. PA
Civ.
<font style="white-space: nowrap">No. 09-1240</font></i>);
(<i>Supervalu, Inc. v. Unimed Pharms., LLC, et al, </i>ND.
GA Civ.
<font style="white-space: nowrap">No. 10-1024);</font>
(<i>LeGrand v. Unimed Pharms., Inc., et al</i>., ND. GA
Civ.
<font style="white-space: nowrap">No. 10-2883);</font>
(<i>Jabo’s Pharmacy Inc. v. Solvay Pharmaceuticals,
Inc., et al </i>., Cocke County, TN Circuit Court Case
No. 31,837). On April 20, 2009, the Company was
dismissed without prejudice from the <i>Stephen L. LaFrance
</i>action pending in the District of New Jersey. On
October 5, 2009, the Judicial Panel on Multidistrict
Litigation transferred all actions then pending outside of the
United States District Court for the Northern District of
Georgia to that district for consolidated pre-trial proceedings
(<i>In re: AndroGel
</i><sup style="font-size: 85%; vertical-align: text-top">®</sup>
<i>Antitrust Litigation (No. II), MDL Docket
No. 2084</i>), and all currently-pending related actions
are presently before that court. On February 22, 2010, the
judge presiding over all the consolidated litigations related to
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
then pending in the United States District Court for the
Northern District of Georgia granted the Company’s motions
to dismiss the complaints, except the portion of the private
plaintiffs’ complaints that include allegations concerning
sham litigation. On July 20, 2010, the plaintiff in the
<i>Fraternal Order of Police </i>action filed an amended
complaint adding allegations concerning conduct before the
U.S. Patent and Trademark Office, conduct in connection
with the listing of Solvay’s patent in the Food and Drug
Administration’s “Orange Book,” and sham
litigation similar to the claims raised in the direct purchaser
actions. On October 28, 2010, the judge presiding over MDL
2084 entered an order pursuant to which the <i>LeGrand
</i>action, filed on September 10, 2010, was consolidated
for pretrial purposes with the
other indirect purchaser class action as part of MDL 2084 and
made subject to the Court’s February 22, 2010 order on
the motion to dismiss. Discovery in the private actions is
ongoing. Final judgment in favor of the defendants was entered
in the Federal Trade Commission’s action on April 21,
2010. On June 10, 2010, the Federal Trade Commission filed
a notice of appeal to the Eleventh Circuit Court of Appeals,
appealing the district court’s dismissal of its complaint.
The appeal is pending.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company believes that these actions are without merit and
intends to defend itself vigorously. However, these actions, if
successful, could have a material adverse effect on the
Company’s business, results of operations, financial
condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Hormone Replacement Therapy
Litigation.</i>  Beginning in early 2004 a number of
product liability suits were filed against the Company and
certain Company affiliates for personal injuries allegedly
arising out of the use of hormone replacement therapy products,
including but not limited to estropipate and estradiol. These
complaints also name numerous other pharmaceutical companies as
defendants, and allege various injuries, including ovarian
cancer, breast cancer and blood clots. Approximately 100 cases
are pending against Watson
<font style="white-space: nowrap">and/or</font> its
affiliates in state and federal courts representing claims by
approximately 100 plaintiffs. Many of the cases involve multiple
plaintiffs. The majority of the cases have been transferred to
and consolidated in the United States District Court for the
Eastern District of Arkansas (<i>In re: Prempro Products
Liability Litigation, MDL Docket No. 1507</i>). Discovery
in these cases is ongoing. The Company believes it has
substantial meritorious defenses to these cases and maintains
product liability insurance against such cases. However,
litigation is inherently uncertain and the Company cannot
predict the outcome of this litigation. These actions, if
successful, or if insurance does not provide sufficient coverage
against such claims, could adversely affect the Company and
could have a material adverse effect on the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Fentanyl Transdermal System
Litigation.</i>  Beginning in 2009, a number of
product liability suits were filed against the Company and
certain Company affiliates, as well as other manufacturers and
distributors of fentanyl transdermal system products, for
personal injuries or deaths allegedly arising out of the use of
the fentanyl transdermal system products. Approximately 38 cases
are pending against the Company
<font style="white-space: nowrap">and/or</font> its
affiliates in state and federal courts, representing claims by
approximately 110 plaintiffs. Discovery is ongoing. The Company
believes it has substantial meritorious defenses to these cases
and maintains product liability insurance against such cases.
However, litigation is inherently uncertain and the Company
cannot predict the outcome of this litigation. These actions, if
successful, or if insurance does not provide sufficient coverage
against such claims, could adversely affect the Company and
could have a material adverse effect on the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Metoclopramide Litigation.</i>  Beginning in 2009,
a number of product liability suits were filed against the
Company and certain Company affiliates, as well as other
manufacturers and distributors of metoclopramide, for personal
injuries allegedly arising out of the use of metoclopramide.
Approximately 300 cases are pending against the Company
<font style="white-space: nowrap">and/or</font> its
affiliates in state and federal courts, representing claims by
approximately 800 plaintiffs. These cases are generally at
their preliminary stages and discovery is ongoing. The Company
believes that it will be indemnified for the majority of these
claims by Pliva, Inc., an affiliate of Teva Pharmaceutical
Industries, Ltd., from whom the Company purchased its
metoclopramide product in late 2008. Further, the Company
believes that it has substantial meritorious defenses to these
cases and maintains product liability insurance against such
cases. However, litigation is inherently uncertain and the
Company cannot predict the outcome of this litigation. These
actions, if successful, or if our indemnification arrangements
or insurance do not provide sufficient coverage against such
claims, could adversely affect the Company and could have a
material adverse effect on the Company’s business, results
of operations, financial condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Medical West Ballas Pharmacy, LTD, et al. v. Anda, Inc.,
</i>(Circuit Court of the County of St. Louis, State of
Missouri, Case
<font style="white-space: nowrap">No. 08SL-CC00257).</font>
In January 2008, Medical West Ballas Pharmacy, LTD, filed a
purported class action complaint against the Company alleging
conversion and alleged violations of the Telephone Consumer
Protection Act (“TCPA”) and Missouri Consumer Fraud
and Deceptive Business Practices Act. In April 2008, plaintiff
filed an amended complaint substituting Anda, Inc., a subsidiary
of the Company, as the defendant. The amended complaint alleges
that by sending unsolicited facsimile advertisements, Anda
misappropriated the class members’ paper, toner, ink and
employee time when they received the alleged unsolicited faxes,
and that the alleged unsolicited facsimile advertisements were
sent to the plaintiff in violation of the TCPA and Missouri
Consumer Fraud and Deceptive Business Practices Act. The
complaint seeks to assert class action claims on behalf of the
plaintiff and other similarly situated third parties. In April
2008, Anda filed an answer to the amended complaint, denying the
allegations. In November 2009, the court granted
plaintiff’s motion to expand the class of plaintiffs from
individuals for which Anda lacked evidence of express permission
or an established business relationship to “All persons who
on or after four years prior to the filing of this action, were
sent telephone facsimile messages advertising pharmaceutical
drugs and products by or on behalf of Defendant.” In
November 2010, the plaintiff filed a second amended complaint
further expanding the definition and scope of the proposed class
of plaintiffs. On November 30, 2010, Anda filed a petition
with the Federal Communications Commission (“FCC”),
asking the FCC to clarify the statutory basis for its regulation
requiring “opt-out” language on faxes sent with
express permission of the recipient. The FCC’s ruling on
Anda’s petition may determine whether fax recipients who
expressly agree to receive faxes may assert claims for receipt
of such faxes pursuant to the TCPA. On December 2, 2010,
Anda filed a motion to dismiss claims the plaintiff is seeking
to assert on behalf of putative class members who expressly
consented or agreed to receive faxes from Defendant, or in the
alternative, to stay the court proceedings pending resolution of
Anda’s petition to the FCC. The motion remains pending. No
trial date has been set. Anda intends to defend the action
vigorously. However, this action, if successful, could have an
adverse effect on the Company’s business, results of
operations, financial condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Drospirenone/Ethinyl Estradiol Tablets (Generic version of
Yasmin</i><sup style="font-size: 85%; vertical-align: text-top">®</sup><i>).</i>  On
April 7, 2008, Bayer Schering Pharma AG sued the Company in
the United States District Court for the Southern District of
New York, alleging that sales of the Company’s
drospirenone/ethinyl estradiol tablets, a generic version of
Bayer’s
Yasmin<sup style="font-size: 85%; vertical-align: text-top">®</sup>
tablets, infringes Bayer’s U.S. Patent
No. 5,569,652 (<i>Bayer Schering Pharma AG v. Watson
Pharmaceuticals, Inc., et. al., Case No. 08cv3710</i>). The
complaint sought damages and injunctive relief. On
September 28, 2010, the district court granted the
Company’s motion for judgment on the pleadings and
dismissed the case with prejudice. Final judgment was entered on
January 7, 2011. On January 21, 2011, Bayer filed a
Notice of Appeal with the United States Court of Appeals for the
Second Circuit. The Company believes it has substantial
meritorious defenses to the case. However, the Company has sold
and is continuing to sell its generic version of
Yasmin<sup style="font-size: 85%; vertical-align: text-top">®</sup>.
Therefore, an adverse ruling on the appeal or a subsequent final
determination that the Company has infringed the patent in suit
could have a material adverse effect on the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson and its affiliates are involved in various other
disputes, governmental
<font style="white-space: nowrap">and/or</font>
regulatory inspections, inquires, investigations and proceedings
that could result in litigation, and other litigation matters
that arise from time to time. The process of resolving matters
through litigation or other means is inherently uncertain and it
is possible that an unfavorable resolution of these matters will
adversely affect the Company, its results of operations,
financial condition and cash flows.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table1 - us-gaap:ConsolidationPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s consolidated financial statements are
prepared in accordance with accounting principles generally
accepted in the U.S. (“GAAP”). The consolidated
financial statements include the accounts of wholly-owned
subsidiaries, after elimination of intercompany accounts and
transactions. Certain prior year amounts have been reclassified
to conform to the current-year presentation.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Our consolidated financial statements include the financial
results of the Arrow Group subsequent to the Acquisition Date.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table2 - wpi:UseOfEstimatesPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Management is required to make certain estimates and assumptions
in order to prepare consolidated financial statements in
conformity with GAAP. Such estimates and assumptions affect the
reported amounts of assets, liabilities, revenues and expenses
and disclosure of contingent assets and liabilities in the
consolidated financial statements and accompanying notes. The
Company’s most significant estimates relate to the
determination of sales returns and allowances (“SRA”)
for accounts receivable and accrued liabilities, valuation of
inventory balances, the determination of useful lives for
intangible assets and the assessment of expected cash flows used
in evaluating goodwill and other long-lived assets for
impairment. The estimation process required to prepare the
Company’s consolidated financial statements requires
assumptions to be made about future events and conditions, and
as such, is inherently subjective and uncertain. Watson’s
actual results could differ materially from those estimates.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table3 - us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For most of the Company’s international operations, the
local currency has been determined to be the functional
currency. We translate functional currency assets and
liabilities to their U.S. dollar equivalents at rates in
effect at the balance sheet date and record these translation
adjustments as a component of accumulated other comprehensive
income (loss) within stockholders’ equity in the
consolidated balance sheets. We translate functional currency
statement of income amounts to their U.S. dollar
equivalents at the average rates for the period. The effects of
converting non-functional currency assets and liabilities into
the functional currency are recorded as general and
administrative expenses in the consolidated statements of
operations.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table4 - us-gaap:CashAndCashEquivalentsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company considers cash and cash equivalents to include cash
in banks, commercial paper and deposits with financial
institutions that can be liquidated without prior notice or
penalty. The Company considers all highly liquid investments
with an original maturity of three months or less to be cash
equivalents.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table5 - wpi:FairValueOfOtherFinancialInstrumentsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s financial instruments consist primarily of
cash and cash equivalents, marketable securities, accounts and
other receivables, investments, trade accounts payable, our
$450.0 million aggregate principal amount of
5.000% notes due August 14, 2014 (the “2014
Notes”) and $400.0 million aggregate principal amount
of 6.125% notes due August 14, 2019 (the “2019
Notes”) (together the “Senior Notes”) and our
Senior Credit Facility with Canadian Imperial Bank of Commerce,
acting through its New York agency, as administrative agent (the
“2006 Credit Facility”). The carrying amounts of cash
and cash equivalents, marketable securities, accounts and other
receivables and trade accounts payable are representative of
their respective fair values due to their relatively short
maturities. The fair values of investments in companies that are
publicly traded are based on quoted market prices. The Company
estimates the fair value of its fixed rate long-term obligations
based on quoted market rates of interest and maturity schedules
for similar issues. At December 31, 2010, the fair value of
our Senior Notes was approximately $71.0 million greater
than the carrying value.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table6 - us-gaap:InventoryPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Inventories consist of finished goods held for sale and
distribution, raw materials and work in process. Included in
inventory at December 31, 2010 and 2009 is approximately
$4.6 million and $14.1 million, respectively, of
inventory that is pending approval by the U.S. Food and
Drug Administration (“FDA”), by other regulatory
agencies or has not been launched due to contractual
restrictions. This inventory consists of generic pharmaceutical
products that are capitalized only when the bioequivalence of
the product is demonstrated or the product has already received
regulatory approval and is awaiting a contractual triggering
event to enter the marketplace. Inventories are stated at the
lower of cost
<font style="white-space: nowrap">(first-in,</font>
first-out method) or market (net realizable value). The Company
writes down inventories to net realizable value based on
forecasted demand and market conditions, which may differ from
actual results.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table7 - us-gaap:PropertyPlantAndEquipmentPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Property and equipment are stated at cost, less accumulated
depreciation. Major renewals and improvements are capitalized,
while routine maintenance and repairs are expensed as incurred.
Costs associated with internally developed software are
accounted for in accordance with the guidance for the treatment
of costs associated with computer software development that
defines those costs to be capitalized and those to be expensed.
The Company capitalizes interest on qualified construction
projects. At the time property and equipment are retired from
service, the cost and accumulated depreciation is removed from
the respective accounts and the related gains or losses are
reflected in income.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Depreciation expense is computed principally on the
straight-line method, over estimated useful lives of the related
assets. The following table provides the range of estimated
useful lives used for each asset type:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="88%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="10%"> </td><!-- colindex=02 type=maindata -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Computer software / hardware
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
3-7 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-18 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Buildings, improvements, leasehold improvements and other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-40 years
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company assesses property and equipment for impairment
whenever events or changes in circumstances indicate that an
asset’s carrying amount may not be recoverable.
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table8 - us-gaap:InvestmentPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s equity investments are accounted for under
the equity method when the Company can exert significant
influence and ownership does not exceed 50%. Watson accounts for
its joint ventures using the equity method. The Company records
equity method investments at cost and adjust for the appropriate
share of investee net earnings or losses. Investments in which
the Company owns less than a 20% interest and cannot exert
significant influence are accounted for using the cost method if
the fair value of such investments is not readily determinable.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table9 - wpi:MarketableSecuritiesPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s marketable securities consist of
U.S. Treasury and agency securities and equity securities
of publicly-held companies. The Company’s marketable
securities are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value, based upon quoted market prices.
Unrealized temporary adjustments to fair value are included on
the balance sheet in a separate component of stockholders’
equity as unrealized gains and losses and reported as a
component of accumulated other comprehensive income. No gains or
losses on marketable securities are realized until shares are
sold or a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary.</font>
If a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary,</font>
an impairment charge is recorded and a new cost basis in the
investment is established.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table10 - us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
We test goodwill and intangible assets with indefinite-lives for
impairment annually at the end of the second quarter by
comparing the fair value of each of the Company’s reporting
units to the respective carrying value of the reporting units.
Additionally, we may perform tests between annual tests if an
event occurs or circumstances change that could potentially
reduce the fair value of a reporting unit below its carrying
amount. The Company’s reporting units have been identified
by Watson as Global Generics, Global Brands and Distribution.
The carrying value of each reporting unit is determined by
assigning the assets and liabilities, including the existing
goodwill and intangible assets, to those reporting units.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill is considered impaired if the carrying amount of the
net assets exceeds the fair value of the reporting unit.
Impairment, if any, would be recorded in operating income and
this could result in a material reduction in net income and
earnings per share. During the second quarter of 2010, the
Company performed its annual impairment assessment of goodwill,
acquired in-process research and development
(“IPR&D”) intangibles and trade name intangible
assets with indefinite-lives and determined there was no
impairment. Due to changes in market conditions in certain
international locations, the Company performed an off-cycle
impairment review in the fourth quarter of 2010 and recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. (Refer to
“Note 8 — Goodwill, Product Rights and Other
Intangibles” for additional details.)
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Included in intangible assets with indefinite-lives are trade
name intangible assets acquired prior to January 1, 2009
and IPR&D intangibles acquired after January 1, 2009.
Upon adoption of Financial Accounting Standards Board
(“FASB”) issued authoritative guidance on
January 1, 2009, using the purchase method of accounting,
IPR&D intangible assets are recognized at their fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. Prior to January 1,
2009, amounts allocated to IPR&D intangible assets were
expensed at the date of acquisition.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the date acquired,
represent the right to develop, use, sell
<font style="white-space: nowrap">and/or</font> offer
for sale a product or other intellectual property that we have
acquired with respect to products
<font style="white-space: nowrap">and/or</font>
processes that have not been completed or approved. The
IPR&D intangible assets are subject to impairment testing
until completion or abandonment of each project. Impairment
testing requires the development of significant estimates and
assumptions involving the determination of estimated net cash
flows for each year for each project or product (including net
revenues, cost of sales, R&D costs, selling and marketing
costs), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each asset’s life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The major risks and uncertainties associated with the
timely and successful completion of the IPR&D projects
include legal risk and regulatory risk. Changes in these
assumptions or uncertainties could result in future impairment
charges. No assurances can be given that the underlying
assumptions used to prepare the discounted cash flow analysis
will not change or the timely completion of each project to
commercial success will occur. For these and other reasons,
actual results may vary significantly from estimated results.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon successful completion of each project and launch of the
product, Watson will make a separate determination of the useful
life of the intangible, transfer the amount to currently
marketed products (“CMP”) and amortization expense
will be recorded over the estimated useful life.
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table11 - us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Subsequent to January 1, 2009, contingent consideration is
recorded at the acquisition date estimated fair value of the
contingent payment for all acquisitions. The fair value of the
contingent consideration is remeasured at each reporting period
with any adjustments in fair value included in our consolidated
statement of operations.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table12 - us-gaap:RevenueRecognitionPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Revenue is generally realized or realizable and earned when
persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the seller’s price
to the buyer is fixed or determinable, and collectability is
reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to
the customer, which is typically upon delivery to the customer.
Revenues recognized from research, development and licensing
agreements (including milestone receipts) are recorded on the
“contingency-adjusted performance model” which
requires deferral of revenue until such time as contract
milestone requirements, as specified in the individual
agreements, have been met. Under this model, revenue related to
each payment is recognized over the entire contract performance
period, starting with the contract’s commencement, but not
prior to earning
<font style="white-space: nowrap">and/or</font>
receiving the milestone amount (i.e., removal of any
contingency). The amount of revenue recognized is based on the
ratio of costs incurred to date to total estimated cost to be
incurred. Royalty and commission revenue is recognized in
accordance with the terms of their respective contractual
agreements when collectability is reasonably assured and revenue
can be reasonably measured.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table13 - wpi:ProvisionsForSalesReturnsAndAllowancesPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As is customary in the pharmaceutical industry, the
Company’s gross product sales are subject to a variety of
deductions in arriving at reported net product sales. When the
Company recognizes revenue from the sale of its products, an
estimate of SRA is recorded which reduces product sales.
Accounts receivable
<font style="white-space: nowrap">and/or</font>
accrued liabilities are also reduced
<font style="white-space: nowrap">and/or</font>
increased by the SRA amount. These adjustments include estimates
for chargebacks, rebates, cash discounts and returns and other
allowances. These provisions are estimated based on historical
payment experience, historical relationship to revenues,
estimated customer inventory levels and current contract sales
terms with direct and indirect customers. The estimation process
used to determine our SRA provision has been applied on a
consistent basis and no material adjustments have been necessary
to increase or decrease our reserves for SRA as a result of a
significant change in underlying estimates. The Company uses a
variety of methods to assess the adequacy of our SRA reserves to
ensure that our consolidated financial statements are fairly
stated. This includes periodic reviews of customer inventory
data, customer contract programs and product pricing trends to
analyze and validate the SRA reserves.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Chargebacks — </i>The provision for chargebacks is
our most significant sales allowance. A chargeback represents an
amount payable in the future to a wholesaler for the difference
between the invoice price paid to the Company by our wholesale
customer for a particular product and the negotiated contract
price that the wholesaler’s customer pays for that product.
The Company’s chargeback provision and related reserve vary
with changes in product mix, changes in customer pricing and
changes to estimated wholesaler inventories. The provision for
chargebacks also takes into account an estimate of the expected
wholesaler sell-through levels to indirect customers at contract
prices. The Company validates the chargeback accrual quarterly
through a review of the inventory reports obtained from our
largest wholesale customers. This customer inventory information
is used to verify the estimated liability for future chargeback
claims based on historical chargeback and contract rates. These
large wholesalers represent 85% — 90% of the
Company’s chargeback payments. The Company continually
monitors current pricing trends and wholesaler inventory levels
to ensure the liability for future chargebacks is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Rebates — </i>Rebates include volume related
incentives to direct and indirect customers and Medicaid rebates
based on claims from Medicaid benefit providers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Volume rebates are generally offered to customers as an
incentive to continue to carry our products and to encourage
greater product sales. These rebate programs include contracted
rebates based on customer’s purchases made during an
applicable monthly, quarterly or annual period. The provision
for rebates is estimated based on our customers’ contracted
rebate programs and our historical experience of rebates paid.
Any significant changes to our customer rebate programs are
considered in establishing our provision for rebates. The
Company continually monitors its customer rebate programs to
ensure that the liability for accrued rebates is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The provision for Medicaid rebates is based upon historical
experience of claims submitted by the various states. The
Company monitors Medicaid legislative changes to determine what
impact such legislation may have on our provision for Medicaid
rebates. Our accrual of Medicaid rebates is based on historical
payment rates and is reviewed on a quarterly basis against
actual claim data to ensure the liability is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Returns and Other Allowances — </i>Our provision
for returns and other allowances include returns, pricing
adjustments, promotional allowances and billback adjustments.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Consistent with industry practice, the company maintains a
return policy that allows our customers to return product for
credit. In accordance with our return goods policy, credit for
customer returns of product is applied against outstanding
account activity or by check. Product exchanges are not
permitted. Customer returns of product are not resalable unless
the return is due to a shipping error. Our estimate of the
provision for returns is based upon historical experience and
current trends of actual customer returns. Additionally, we
consider other factors when estimating our current period return
provision, including levels of inventory in our distribution
channel as well as significant market changes which may impact
future expected returns, and make adjustments to our current
period provision for returns when it appears product returns may
differ from our original estimates.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pricing adjustments, which include shelf stock adjustments, are
credits issued to reflect price decreases in selling prices
charged to our direct customers. Shelf stock adjustments are
based upon the amount of product
our customers have in their inventory at the time of an
<font style="white-space: nowrap">agreed-upon</font>
price reduction. The provision for shelf stock adjustments is
based upon specific terms with our direct customers and includes
estimates of existing customer inventory levels based upon their
historical purchasing patterns. The Company regularly monitors
all price changes to help evaluate our reserve balances. The
adequacy of these reserves is readily determinable as pricing
adjustments and shelf stock adjustments are negotiated and
settled on a
<font style="white-space: nowrap">customer-by-customer</font>
basis.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Promotional allowances are credits, which are issued in
connection with a product launch or as an incentive for
customers to begin carrying our product. The Company establishes
a reserve for promotional allowances based upon these
contractual terms.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Billback adjustments are credits that are issued to certain
customers who purchase directly from the Company as well as
indirectly through a wholesaler. These credits are issued in the
event there is a difference between the customer’s direct
and indirect contract price. The provision for billbacks is
estimated based upon historical purchasing patterns of qualified
customers who purchase product directly from the Company and
supplement their purchases indirectly through the Company’s
wholesale customers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Cash Discounts — </i>Cash discounts are provided to
customers that pay within a specific period. The provision for
cash discounts are estimated based upon invoice billings,
utilizing historical customer payment experience. Our
customer’s payment experience is fairly consistent and most
customer payments qualify for the cash discount. Accordingly,
our reserve for cash discounts is readily determinable.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Net revenues and accounts receivable balances in the
Company’s consolidated financial statements are presented
net of SRA estimates. In addition, certain SRA balances are
included in accounts payable and accrued liabilities. Accounts
receivable are presented net of SRA balances of
$320.5 million and $335.0 million at December 31,
2010 and 2009, respectively. Accounts payable and accrued
liabilities include $106.5 million and $83.6 million
at December 31, 2010 and 2009, respectively, for certain
rebates and other amounts due to indirect customers.
The
following table summarizes the activity in the Company’s
major categories of SRA (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="42%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Returns and Other<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Chargebacks</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Rebates</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Allowances</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Cash Discounts</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2007
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
164.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
154.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
387.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,224.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
309.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
179.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,780.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,267.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(337.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(67.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,839.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
125.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
328.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Arrow Acquisition
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,169.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
415.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,840.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,177.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(389.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(167.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(71.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,805.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2009 (Revised)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
188.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
97.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
418.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,175.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
755.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
206.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,192.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(723.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(214.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(88.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2,219.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
100.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
219.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
427.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company does not expect future payments of SRA to materially
exceed our current estimates. However, if future SRA payments
were to materially exceed our estimates, such adjustments may
have a material adverse impact on our financial position,
results of operations and cash flows.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table14 - us-gaap:ShippingAndHandlingCostPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company records shipping and handling costs in selling and
marketing expenses. These expenses were $66.5 million,
$51.9 million and $50.8 million in 2010, 2009 and
2008, respectively.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table15 - wpi:ConcentrationOfMajorCustomersAndSuppliersPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For the year ended December 31, 2010, the Company’s
three largest customers accounted for 14%, 11%, and 6%,
individually, of the Company’s net revenues. For the year
ended December 31, 2009, the Company’s three largest
customers accounted for 13%, 11%, and 9%, individually, of the
Company’s net revenues. For the year ended
December 31, 2008, the Company’s three largest
customers accounted for 11%, 11%, and 9%, individually, of the
Company’s net revenues. No other individual customers
accounted for more than 10% of net revenues.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is subject to a concentration of credit risk with
respect to its accounts receivable balance, all of which is due
from wholesalers, distributors, chain drug stores and service
providers in the health care and pharmaceutical industries
throughout the U.S. and international markets in which we
operate. Approximately 52% and 53% of the gross accounts
receivable balance consists of amounts due from the four largest
customers at December 31, 2010 and 2009, respectively. The
Company performs ongoing credit evaluations of its customers and
maintains an allowance for potential uncollectible accounts.
Actual losses from uncollectible accounts have been minimal.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Certain of the Company’s finished products and raw
materials are obtained from single source suppliers. Although
the Company seeks to identify more than one source for its
various finished products and raw materials, loss of a single
source supplier could have an adverse effect on the
Company’s results of operations, financial condition and
cash flows. Third-party manufactured products accounted for
approximately 33%, 38% and 44% of our Global Generics and Global
Brands product net revenues in 2010, 2009 and 2008, respectively.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table16 - us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
R&D activities are expensed as incurred and consist of
self-funded R&D costs and the costs associated with work
performed under collaborative R&D agreements. R&D
expenses include direct and allocated expenses. R&D
expenses incurred under collaborative agreements were
approximately $11.1 million, $6.8 million, and
$5.9 million for the years ended December 31, 2010,
2009 and 2008, respectively.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table17 - us-gaap:IncomeTaxPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income taxes are accounted for using an asset and liability
approach that requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of
temporary differences between the financial statement and tax
bases of assets and liabilities at the applicable tax rates. A
valuation allowance is provided when it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The Company evaluates the realizability of its
deferred tax assets by assessing its valuation allowance and by
adjusting the amount of such allowance, if necessary. The
factors used to assess the likelihood of realization include the
Company’s forecast of future taxable income and available
tax planning strategies that could be implemented to realize the
net deferred tax assets. Failure to achieve forecasted taxable
income in applicable tax jurisdictions could affect the ultimate
realization of deferred tax assets and could result in an
increase in the Company’s effective tax rate on future
earnings.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income tax positions must meet a more-likely-than-not
recognition threshold to be recognized. Income tax positions
that previously failed to meet the more-likely-than-not
threshold are recognized in the first subsequent financial
reporting period in which that threshold is met. Previously
recognized tax positions that no longer meet the
more-likely-than-not threshold are derecognized in the first
subsequent financial reporting period in which that threshold is
no longer met. We recognize potential accrued interest and
penalties related to unrecognized tax benefits within the
consolidated statements of income as income tax expense.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table18 - wpi:ComprehensiveIncomePolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Comprehensive income includes all changes in equity during a
period except those that resulted from investments by or
distributions to the Company’s stockholders. Other
comprehensive income refers to revenues, expenses, gains and
losses that, under GAAP, are included in comprehensive income,
but excluded from net income as these amounts are recorded
directly as an adjustment to stockholders’ equity.
Watson’s other comprehensive income (loss) is composed of
unrealized gains (losses) on its holdings of publicly traded
equity securities, net of realized gains (losses) included in
net income and foreign currency translation adjustments.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table19 - us-gaap:EarningsPerSharePolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Basic EPS is computed by dividing net income attributable to
common shareholders by the weighted average common shares
outstanding during a period. Diluted EPS is based on the
treasury stock method and includes the effect from potential
issuance of common stock, such as shares issuable upon
conversion of our convertible contingent senior debentures
(“CODES”), and shares issuable pursuant to the
exercise of stock options, assuming the exercise of all
<font style="white-space: nowrap">in-the-money</font>
stock options. Common share equivalents have been excluded where
their inclusion would be anti-dilutive. The Company is required
to add the weighted average potential common shares outstanding
associated with the conversion of the CODES to the number of
shares outstanding for the calculation of diluted EPS for all
periods in which the securities were outstanding. On
September 14, 2009 the CODES were redeemed in accordance
with the terms of the CODES.
A reconciliation of the
numerators and denominators of basic and diluted EPS consisted
of the following (in millions, except per share amounts):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="74%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — basic</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.51
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.32
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — assuming dilution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Interest expense on CODES, net of tax
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income, adjusted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
246.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effect of dilutive securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Conversion of CODES
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Dilutive stock awards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
124.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.48
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.96
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.09
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Stock awards to purchase 1.1 million, 3.5 million and
8.1 million common shares in 2010, 2009 and 2008,
respectively, were outstanding but not included in the
computation of diluted EPS as the awards were anti-dilutive.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table20 - us-gaap:CompensationRelatedCostsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company recognizes compensation expense for all share-based
compensation awards made to employees and directors based on
estimated fair values. The Company estimates the fair value of
its stock option plans using the Black-Scholes option pricing
model (the “Option Model”). The Option Model requires
the use of subjective and complex assumptions, including the
option’s expected term and the estimated future price
volatility of the underlying stock, which determine the fair
value of the share-based awards. The Company’s estimate of
expected term was determined based on the weighted average
period of time that options granted are expected to be
outstanding considering current vesting schedules and the
historical exercise patterns of existing option plans. The
expected volatility assumption used in the Option Model is based
on implied volatility based on traded options on the
Company’s stock. The risk-free interest rate used in the
Option Model is based on the yield of U.S. Treasuries with
a maturity closest to the expected term of the Company’s
stock options. No stock options were granted during the years
ended December 31, 2010, 2009 or 2008.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Share-based compensation expense recognized during a period is
based on the value of the portion of share-based awards that are
expected to vest with employees. Accordingly, the recognition of
share-based compensation expense has been reduced for estimated
future forfeitures. These estimates will be revised in future
periods if actual forfeitures differ from the estimates. Changes
in forfeiture estimates impact compensation expense in the
period in which the change in estimate occurs.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table21 - wpi:RecentAccountingPronouncementsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In October 2009, the FASB issued an amendment to its accounting
guidance on revenue arrangements with multiple deliverables,
which addresses the unit of accounting for arrangements
involving multiple deliverables and how consideration should be
allocated to separate units of accounting, when applicable. The
amendment requires that arrangement considerations be allocated
at the inception of the arrangement to all deliverables using
the relative selling price method and provides for expanded
disclosures related to such arrangements. The amendment is
effective for revenue arrangements entered into or materially
modified in fiscal years beginning on or after June 15,
2010. Early adoption is allowed. The adoption of this guidance
will not have a material impact on the Company’s
consolidated financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In January 2010, the FASB issued an amendment to the disclosure
requirements for fair value measurements. The amendment requires
an entity to: (i) disclose separately the amounts of
significant transfers in and out of Level 1 and
Level 2 fair value measurements and describe the reasons
for the transfers, and (ii) present separate information
for Level 3 activity pertaining to gross purchases, sales,
issuances and settlements. The new disclosures are effective for
interim and annual reporting periods beginning after
December 15, 2009, except for the Level 3 disclosures,
which are effective for fiscal years beginning after
December 15, 2010. The adoption of this guidance will not
have a material impact on the Company’s consolidated
financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In March 2010, the FASB ratified accounting guidance on defining
a milestone and determining when it may be appropriate to apply
the milestone method of revenue recognition for research or
development transactions. This guidance provides criteria that
must be met to recognize consideration that is contingent upon
achievement of a substantive milestone in its entirety in the
period in which the milestone is achieved. The amendment is
effective for milestones achieved in fiscal years beginning on
or after June 15, 2010. Early adoption is allowed. The
adoption of this guidance will not have a material impact on the
Company’s consolidated financial statements.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note2_table1 - us-gaap:PropertyPlantAndEquipmentTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="88%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="10%"> </td><!-- colindex=02 type=maindata -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Computer software / hardware
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
3-7 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-18 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Buildings, improvements, leasehold improvements and other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-40 years
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note2_table2 - wpi:ProvisionsForSalesReturnsAndAllowancesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
The
following table summarizes the activity in the Company’s
major categories of SRA (in millions):
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="42%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Returns and Other<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Chargebacks</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Rebates</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Allowances</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Cash Discounts</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2007
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
164.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
154.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
387.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,224.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
309.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
179.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,780.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,267.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(337.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(67.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,839.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
125.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
328.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Arrow Acquisition
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,169.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
415.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,840.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,177.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(389.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(167.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(71.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,805.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2009 (Revised)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
188.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
97.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
418.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,175.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
755.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
206.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,192.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(723.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(214.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(88.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2,219.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
100.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
219.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
427.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note2_table3 - us-gaap:EarningsPerShareTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
A reconciliation of the
numerators and denominators of basic and diluted EPS consisted
of the following (in millions, except per share amounts):
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="74%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — basic</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.51
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.32
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — assuming dilution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Interest expense on CODES, net of tax
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income, adjusted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
246.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effect of dilutive securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Conversion of CODES
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Dilutive stock awards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
124.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.48
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.96
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.09
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table1 - us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock-->
<div align="left" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table presents a summary of the purchase price
consideration for the Arrow Acquisition (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,050.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Restricted Common Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
636.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
150.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value estimate of atorvastatin contingent payment
consideration (refer to “NOTE 10 — Other
Long-Term Liabilities.”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table2 - wpi:AllocationOfConsiderationTransferredTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
These
adjustments are reflected in the values presented below and in
our revised December 31, 2009 balance sheet (in millions):
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash and cash equivalents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Accounts receivable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Inventories
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
187.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other current assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
174.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Property, plant & equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
518.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
632.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current liabilties
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(306.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax and other tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(303.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table3 - wpi:UnauditedProFormaResultsOfOperationsTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="3%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="3%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Year Ended December 31,</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>(In millions, except<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>per share amounts)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,261.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,170.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
281.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings per share:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.99
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.35
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.98
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.34
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table4 - wpi:TangibleAndIdentifiableIntangibleAssetsAcquiredAndLiabilitiesAssumedBasedOnEstimatedFairValuesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The transaction was accounted for using the purchase method of
accounting under existing U.S. GAAP with assets acquired
and liabilities assumed recorded at their fair values as of the
acquisition date. The purchase price for the Columbia
acquisition was allocated to tangible and identifiable
intangible assets
acquired and liabilities assumed based on their estimated fair
values at the acquisition date as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="92%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
62.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note5_table1 - wpi:ComponentOfOtherIncomeTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other income consisted of the following (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Gain (loss) on sale of securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings on equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loss on early extinguishment of debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
19.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note6_table1 - us-gaap:FairValueByBalanceSheetGroupingTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Selected balance sheet components consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Inventories:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Raw materials
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
178.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
196.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
<font style="white-space: nowrap">Work-in-process</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Finished goods
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
465.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
509.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
770.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Inventory reserves
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Inventories, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
631.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
692.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Property and equipment:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
570.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Buildings and improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
385.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
382.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
106.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Leasehold improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
78.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
46.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
45.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Land and land improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Construction in progress
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, at cost
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,265.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,197.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Less accumulated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(623.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(503.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
642.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
694.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Accounts payable and accrued expenses:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade accounts payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
215.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
263.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Proposed legal settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
129.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued payroll and related benefits
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued third-party rebates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
83.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
60.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Royalties and sales agent payables
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current portion of contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued indirect returns
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Interest payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued severence, retention and other shutdown costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
98.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
95.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total accounts payable and accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
741.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
614.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note7_table1 - wpi:MarketableSecuritiesAndOtherInvestmentsTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="84%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
one year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
two years
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments and other assets:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
63.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cost method and other long-term investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
21.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total investments and other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
84.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
114.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note7_table2 - wpi:AvailableForSaleSecuritiesAmortizedCostFairValueAndUnrealizedGainsLossesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table provides a summary of the fair value and
unrealized gains (losses) related to Watson’s
<font style="white-space: nowrap">available-for-sale</font>
securities (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2010</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2009</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table1 - us-gaap:ScheduleOfGoodwillTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill for the Company’s reporting units consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Brands segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
371.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
348.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Generics segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,070.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,066.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Distribution segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,528.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,501.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table2 - us-gaap:ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with definite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product rights and other related intangibles
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,049.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,855.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Core technology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Customer relationships
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,151.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,957.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less accumulated amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,211.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,031.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table3 - us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsByMajorClassTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
940.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
926.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with indefinite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
IPR&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
615.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade Name
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
691.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
787.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total product rights and related intangibles, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,632.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,713.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table4 - wpi:FiniteLivedIntangibleAssetsFutureAmortizationExpenseTextBlock-->
<div align="center" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Assuming no additions, disposals or adjustments are made to the
carrying values
<font style="white-space: nowrap">and/or</font>
useful lives of the assets, annual amortization expense on
product rights and related over the next five years is estimated
to be as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="93%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2011
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
270.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2012
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
417.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2013
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
311.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2014
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
299.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2015
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
138.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note9_table1 - us-gaap:LongTermDebtTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Long-term debt consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes,
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2014 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2019 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Unamortized discount
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2006 Credit Facility
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
151.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loan with Lombard Odier Darier Hentsch & Cie.
(“Lombard Loan”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other notes payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,457.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
307.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total long-term debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,150.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note10_table1 - wpi:OtherLongTermLiabilitiesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other long-term liabilities consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="83%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Atorvastatin contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
123.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Columbia contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
212.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion included in accounts payable and accrued
expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table1 - wpi:IncomeBeforeProvisionOfIncomeTaxesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s income before provision for income taxes was
generated from the United States and international operations as
follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="73%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Income before income taxes:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. 
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
391.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
366.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
353.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(141.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Income before income taxes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
250.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
362.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table2 - wpi:ProvisionForIncomeTaxesTextBlock-->
<div align="center" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s provision for income taxes consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="73%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current provision:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Federal
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
State
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total current provision
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
185.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
159.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Deferred (benefit) provision:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Federal
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(54.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
State
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(54.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total deferred (benefit) provision
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(118.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(19.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total provision for income taxes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table3 - wpi:ReconciliationsBetweenStatutoryFederalIncomeTaxRateAndCompanysEffectiveIncomeTaxRateTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Reconciliations between the statutory federal income tax rate
and the Company’s effective income tax rate were as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="78%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="4%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="4%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Federal income tax at statutory rates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
State income taxes, net of federal benefit
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Foreign rate differential
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Non-deductible expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
R&D credit and U.S. manufacturing deduction
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Charitable contributions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Favorable tax audit outcomes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Valuation allowance
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Transaction costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Sale of subsidiary
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effective income tax rate
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table4 - wpi:ComponentsOfCompanysNetDeferredTaxAssetsLiabilitiesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
The
significant components of the Company’s net deferred tax
assets (liabilities) consisted of the following:
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Benefits from net operating loss and tax credit carryforwards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Differences in financial statement and tax accounting for:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Inventories, receivables and accruals
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
145.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Property, equipment and intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(305.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(366.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Deferred revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Deferred interest expense
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Share-based compensation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total deferred tax liability, gross
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(112.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(216.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Valuation allowance
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total deferred tax liability, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(141.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(245.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table5 - us-gaap:SummaryOfIncomeTaxContingenciesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="75%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at the beginning of the year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
61.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
71.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Increases for current year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Increases for prior year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Decreases for prior year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(27.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(4.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Lapse of applicable statue of limitations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at the end of the year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
68.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
61.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note12_table1 - wpi:SummaryOfCompanyStockOptionPlansTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the Company’s stock option plans consisted of
the following (options and aggregate intrinsic value in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="57%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Exercise<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Options</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Price</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.91
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Exercised
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.49
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.63
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
48.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Vested and expected to vest at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.71
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
47.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Options exercisable at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
42.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note12_table2 - wpi:SummaryOfChangesInRestrictedStockGrantsTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the changes in restricted stock grants during the
year ended December 31, 2010 is presented below (shares and
aggregate intrinsic value in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="60%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Grant Date<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Shares</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.79
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.03
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
43.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Vested
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.74
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.55
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.33
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
79.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note13_table1 - us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Segment net revenues, segment operating expenses and segment
contribution information for the Company’s Global Generics,
Global Brands and Distribution segments consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="71%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Generics Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,268.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,641.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,404.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,338.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,668.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,474.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,198.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
947.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
883.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
194.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
53.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
<b>Global Generics Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>833.0</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>526.9</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>416.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Brands Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
316.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
393.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
81.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
58.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
461.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
455.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
50.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
137.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
144.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Global Brands Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>70.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>170.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>178.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Distribution Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
560.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
511.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
59.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Distribution Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>49.2</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>38.6</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>34.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Total Segment Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>952.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>735.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>629.7</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Corporate general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
436.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
257.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
190.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
180.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
92.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
80.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Loss on asset sales and impairments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Operating income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
305.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
383.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000">
</div>
<div style="margin-top: 3pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<tr>
<td width="2%"></td>
<td width="1%"></td>
<td width="97%"></td>
</tr>
<tr>
<td align="right" valign="top">
(1) </td>
<td></td>
<td valign="bottom">
Excludes amortization of acquired intangibles including product
rights.</td>
</tr>
</table>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note13_table2 - us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock-->
<div align="center" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following geographic areas for the years
ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
United States
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,990.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,642.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,384.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
International
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
425.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
57.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note13_table3 - wpi:NetProductSalesInTherapeuticCategoriesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following therapeutic categories for the
years ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Central nervous system
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
907.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
836.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
795.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Hormones and synthetic substitutes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
609.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cardiovascular
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
594.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
269.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
245.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Anti-infective agents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Urology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
127.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
942.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
738.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
634.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note14_table1 - us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities involving facilities at Carmel, New York;
Mississauga, Canada; and Melbourne, Australia for the year ended
December 31, 2010 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Severance and retention
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product transfer costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Facility decommission costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(18.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation — R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities at Carmel, New York and Brewster, New York for the
year ended December 31, 2009 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(22.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note15_table1 - wpi:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Financial assets and liabilities measured at fair value or
disclosed at fair value on a recurring basis as at
December 31, 2010 and 2009 consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2010
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2009
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note15_table2 - us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The tables below provide a summary of the changes in fair value,
including net transfers in
<font style="white-space: nowrap">and/or</font> out,
of all financial assets and liabilities measured at fair value
on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December 31, 2010
and 2009 (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 69 - us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-->
<!-- xbrl,nx -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times"></font></b>
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<b></b>
</div>
<div style="margin-top: 0pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<b>
Valuation and Qualifying Accounts</b>
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<b>
Years Ended December 31, 2010,
2009 and 2008</b>
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="51%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="3%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="3%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="3%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Charged to<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Beginning of<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Costs and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Deductions/<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>End of<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Period</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Expenses</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Write-offs</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Other*</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Period</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="19" align="center" valign="bottom">
<b>(In millions)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Allowance for doubtful accounts:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Inventory reserves:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
50.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(22.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
47.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
45.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(58.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Tax valuation allowance:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000">
</div>
<div style="margin-top: 3pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<tr>
<td width="1%"></td>
<td width="1%"></td>
<td width="98%"></td>
</tr>
<tr>
<td valign="top">
* </td>
<td></td>
<td valign="bottom">
Represents opening balances of businesses acquired in the period.</td>
</tr>
</table>
false--12-31FY20102010-12-3110-K0000884629125827379YesLarge Accelerated Filer5065021000WATSON PHARMACEUTICALS INCNoYes614300000741100000263100000215200000517400000560900000760000006510000078400000399000005032000006233000009200000-117000001900000-250000055555168690000017718000008070000092600000180000000-13900000-760000011300000185000001850000019100000191000002350000023500000178200000154800000387700000540000012500000810000035000001100000590350000058273000001769500000179940000016600000112000001310000010300000123000006000000630000010300000550000048000001300000800000300000010000038240000038570000011100000011100000000111000000648000001985000000123100000465000001985000000455000002500000001050000000620000006200000063620000011000000019462000002000002000002000000002000000000.360.132.350.992.340.982815000001193000003170600000326190000051860000039500000395000005186000001946200000620000006490000018790000010760000030630000063290000071100000075800000758000007110000001664000001060000039000008240000016600000204600000507600000201400000282800000303000000-306200000814000000.00330.00335000000005000000001330000001355000001234000001258000004000004000002328000002271000001800000003960000032500000150280000010710000088380000051190000015968000005604000009471000008930000019985000008840000011989000007112000001420000021773000002409100000326150000010130000013300000016140000080000064000009300000116400000159600000185600000143000002020000014900000307600000040000000045000000085000000040000000045000000085000000090000000400000000450000000710000000.05430.06350.061250.050002014-08-142019-08-14250000021000003100000-7800000-54100000-5700000-540000003500000-19000000-11830000016300000189000003190000018200000400000-5500000-10200000-245300000-141900000130900000179400000110800000141000000869000009420000010500000128000003130000020800000455700000441500000-14400000-4300000-12100000-129000001060000011000000950000090000000964000001019000002.322.111.512.091.961.480.3350.3880.2690.350.350.350-0.007-0.005-0.0140-0.001-0.008-0.005-0.001-0.0100.0030.0080.0570.0050.0090.0140.0260.0290.016-0.0160-0.078-42000008210000088700000286000001.623847000002642200000299010000022500000571000004258000000.22754000003000000063200000300000003000000023100000231000000010000002270000011000000064800000001031100000121110000019574000001855800000491000005250000021513000002049700000525000004910000092630000094020000045100000462000001386000002993000002700000003115000004175000009600000-1100000256000009600000-11000002340000027300000-1100000-2000000-50000019050000025710000043610000015010000003482000008630000010665000001528100000371600000107020000086300000286000003532000003665000003916000005100000-3900000-141000000358300000362600000250600000106000001080000016000009180000014270000019390000023000003100000180000011990000014060000067300000-17600000720000009650000039100000108200000571000002460000016900000-20800000-145000002000000-106000002820000082200000-10500000-3300000-3400000-15000000-33300000-9100000-5540000014400000101000005000001300000180000078720000071100000076200000691800000762000006156000001713500000115300000163200000011196000002820000034200000841000007900000550000024400000173000004940000016900000176000007770000051400000509100000465600000770000000682400000692300000631000000196800000178400000641000003840000026000000900000050000001600000190000002000000026000000785000009000000028804000002544700000590350000058273000001047900000820700000The Company is subject to, and, as of December 31, 2010, was in compliance with, financial and operation covenants under the terms of the 2006 Credit Facility400000000LIBOR plus 0.75% (subject to certain
adjustments)LIBOR plus 0.625%6500000001150000000500000000129900000145780000055000000410000015120000084750000040000000010161000001664000001800000008479000004000000001000001400000450100000100000200100000115020000010161000005250000005704000001500000001500000001360000000136000001110000011100000000900000-20200000353100000-411300000-93400000-1036100000-74100000416600000376800000571000000238400000238400000222000000222000000184400000184400000-1100000100000-21300000-548000003582000003839000003054000002440000012800000125000001460000018600000530000001970000009600000095200000988000002970000021000000-5500000-550000018000001800000-11500000-11500000900000900000-1000000-1000000330000033000007100000710000011870000018310000077000000111000000135000007540000012310000019300000790000027700000220000038400000-400000-250000090000036000006300000150000009682000006750000043700000-20000000370000001650000010900000820000080000005500000635000005540000056600000002500000250000025000000011099000006790000067000009000000950000082000009400000095400000300000027000008400000334000005470000023840000022200000018330000011974000001265600000694200000642300000107181040535551200000340000095000002000003500000055000000170100000509000001192000001973000005690000014040000029610000010150000019460000001610000080000070000014600000159000001430000020000010000008000001600000131000008000002000000004100000129000001600000159000000140000031000001000000-7600000-400000-7200000-11800000-10400000-1400000-10400000-1400000326000002300000293000001000000415000001700000112000003030000014000001070000033000008100000590000010400000-25200000-22400000-1800000-1000000-25600000-6100000-2900000-1500000-7300000-18300000-5800000-93000001640100000182450000025355000004550000006062000001474300000279300000016682000004610000006638000003566900000233840000039780000083070000062970000041610000034800000178800000735800000526900000170300000386000009523000007010000083300000049200000240720000024550000063480000088700000397000000525700000140400000060620000011680000079570000026993000002694000008367000001641800000663800000609800000393700000738300000111400000133700000341590000090760000059460000031630000022689000001615000008307000006823000009426000001273000002329000005950000011820000055200000263100000648000005380000014450000032000000011190000013780000070300000185000001910000023500000ten yearsOver three to five years200000690000031.5510000004370000041.0355700000796000001900000230000028.7934.334000001290000027.74520000042000000280000037.302.8170000074000001840000033.3050000049.4900486000005300000310000036.9136.633.247600000300000036.713.1113100000-9500000114100000-9500000133000000-9600000135500000-97000002012-12-025080000051900000665000001849600000-3017000009688000001179700000400000240000021086000001418100000400000995900000-3200000-3026000003023100000400000190000016401000001686900000-3062000003281700000-31250000017718000004000001824500000-25000003023100000328260000016900000169000001000000200000025000006362000006362000008400000840000033400000334000005470000054700000-200000-200000-2300000-2300000-6700000-67000003600000096000009700000100000100000100000100000306200000312500000900000900000360000036000006300000630000071200000613000007220000068000000119000003900000275000001080000044000002300000390000051000002400000-8000001400000-2300000500000069000005900000780000012700000201000004000004000006020000028400000297000003877000005610000015430000016440000047700000125000003800000129000003282000003300000125800000123000003470000012060000081000006950000041860000054000002840000015300000117400000777000001884000009750000042700000017000000514000008930000010080000021990000012500000297000001780100000179800000-60000030910000067200000120000012240000004570000018407000007280000034000001838000001169000000415100000200000510000002227500000500000001175500000730000075500000095000002065000009050000020100000144000001800000183960000058700000678000001664000001267800000170000038000003376000001805400000310000038950000022400000167100000117750000071300000221910000021470000011921000006000000240000088800000763000007235000005510000053000001130000015000003700000011770000011640000012420000010280000010500000012240000023500000235000001590000020000000602000008300000024630000022750000018440000011800000Annual Debt Maturities13000000103000006000008000000012300000103000000000700000060000080000000100000029000001000000035000009000000015000000010001150000024300000174500000112000002000000050% of the post-tax gross profitsEither 85% of the post-tax gross profits or 15% of the
post-tax gross profits0.0570.3930.2820.3690.0580.3160.3560.0590.1769400000300000537.55028900000028900000101600000145600000-216900000-112200000-366100000-3057000007630000076300000Equal to the greater of 100% of the principal amount of the Senior Notes to be redeemed and the sum of the present values of the remaining scheduled payments plus 40 basis points101% of the principal amount of the Senior Notes to be repurchased plus accrued and unpaid interest to the date of purchase710000000.0963over
a one to four year period0.104-0.01-0.017-0.037-0.0110-0.02100.0160.000011100000019850000090000000289000000.530.520.64142300000141000004600000114500000845000003190000033900000two to four year periodafter one year0.850.9030360000069600000243000003000002200000308000003000002600000298000002000000000.20.5601533303three to five years10 years2000002000001000000118700000212000000under 20%0.312139000001342000009560000078660000045970000020600000129900000457000005100000050000000470000013900000590000068000001110000094900000106900000one- to four-yearAfter one yeartwo- to four-year36800000355000008360000010650000033500000032050000070300000580000002640000067300000081500000695000001.71.65000001.13300000270000036000000.440.380.3312500000079000000336000003610000089300000EX-101.SCH
10
wpi-20101231.xsd
EX-101 SCHEMA DOCUMENT
06023 - Disclosure - Summary of Significant Accounting Policies (Details Textual)link:presentationLinklink:calculationLinklink:definitionLink0512 - Disclosure - Stockholders' Equity (Tables)link:presentationLinklink:calculationLinklink:definitionLink06041 - Disclosure - Acquisitions and Divestitures (Details) (Textual)link:presentationLinklink:calculationLinklink:definitionLink0604 - Disclosure - Acquisitions and Divestitures (Details)link:presentationLinklink:calculationLinklink:definitionLink0504 - Disclosure - Acquisitions and Divestitures (Tables)link:presentationLinklink:calculationLinklink:definitionLink0204 - Disclosure - Acquisitions and Divestitureslink:presentationLinklink:calculationLinklink:definitionLink06151 - Disclosure - Fair Value Measurement (Details 1)link:presentationLinklink:calculationLinklink:definitionLink0506 - Disclosure - Balance Sheet Components (Tables)link:presentationLinklink:calculationLinklink:definitionLink0606 - Disclosure - Balance Sheet Components (Details)link:presentationLinklink:calculationLinklink:definitionLink0505 - Disclosure - Other Income (Tables)link:presentationLinklink:calculationLinklink:definitionLink0605 - Disclosure - Other Income (Details)link:presentationLinklink:calculationLinklink:definitionLink0701 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)link:presentationLinklink:calculationLinklink:definitionLink06082 - Disclosure - Goodwill Product Rights and Other Intangibles (Details 2)link:presentationLinklink:calculationLinklink:definitionLink0510 - Disclosure - Other Long-Term Liabilities (Tables)link:presentationLinklink:calculationLinklink:definitionLink0616 - Disclosure - Commitments and Contingencies (Details)link:presentationLinklink:calculationLinklink:definitionLink0615 - Disclosure - Fair Value Measurement (Details)link:presentationLinklink:calculationLinklink:definitionLink0515 - Disclosure - Fair Value Measurement (Tables)link:presentationLinklink:calculationLinklink:definitionLink0514 - Disclosure - Business Restructuring Charges (Tables)link:presentationLinklink:calculationLinklink:definitionLink0614 - Disclosure - Business Restructuring Charges (Details)link:presentationLinklink:calculationLinklink:definitionLink0601 - Disclosure - Description of Business (Details)link:presentationLinklink:calculationLinklink:definitionLink06132 - Disclosure - Reportable Segments (Therapeutic Categories) (Details 2)link:presentationLinklink:calculationLinklink:definitionLink06122 - Disclosure - Stockholders' Equity (Details Textual)link:presentationLinklink:calculationLinklink:definitionLink06121 - Disclosure - Stockholders' Equity (Details 1)link:presentationLinklink:calculationLinklink:definitionLink06112 - Disclosure - Income Taxes (Details Textual)link:presentationLinklink:calculationLinklink:definitionLink06111 - Disclosure - Income Taxes (Details 1)link:presentationLinklink:calculationLinklink:definitionLink0612 - Disclosure - Stockholders' Equity (Details)link:presentationLinklink:calculationLinklink:definitionLink0511 - Disclosure - Income Taxes (Tables)link:presentationLinklink:calculationLinklink:definitionLink0611 - Disclosure - Income Taxes (Details)link:presentationLinklink:calculationLinklink:definitionLink0607 - Disclosure - Investments in Marketable Securities and Other Investments (Details)link:presentationLinklink:calculationLinklink:definitionLink0507 - Disclosure - Investments in Marketable Securities and Other Investments (Tables)link:presentationLinklink:calculationLinklink:definitionLink0603 - Disclosure - Share-Based Compensation (Details)link:presentationLinklink:calculationLinklink:definitionLink0610 - Disclosure - Other Long-Term Liabilities (Details)link:presentationLinklink:calculationLinklink:definitionLink06091 - Disclosure - Long-Term Debt (Details Textual)link:presentationLinklink:calculationLinklink:definitionLink0509 - Disclosure - Long Term Debt (Tables)link:presentationLinklink:calculationLinklink:definitionLink0609 - Disclosure - Long-Term Debt (Details)link:presentationLinklink:calculationLinklink:definitionLink06081 - Disclosure - Goodwill Product Rights and Other Intangibles (Details 1)link:presentationLinklink:calculationLinklink:definitionLink0508 - Disclosure - Goodwill Product Rights and Other Intangibles (Tables)link:presentationLinklink:calculationLinklink:definitionLink0608 - Disclosure - Goodwill, Product Rights and Other Intangibles (Details)link:presentationLinklink:calculationLinklink:definitionLink0111 - Statement - Consolidated Balance Sheets (Parenthetical)link:presentationLinklink:calculationLinklink:definitionLink0216 - Disclosure - Commitments and Contingencieslink:presentationLinklink:calculationLinklink:definitionLink0210 - Disclosure - Other Long-Term Liabilitieslink:presentationLinklink:calculationLinklink:definitionLink0209 - Disclosure - Long Term Debtlink:presentationLinklink:calculationLinklink:definitionLink0208 - Disclosure - Goodwill, Product Rights and Other Intangibleslink:presentationLinklink:calculationLinklink:definitionLink0207 - Disclosure - Investments in Marketable Securities and Other Investmentslink:presentationLinklink:calculationLinklink:definitionLink0206 - Disclosure - Balance Sheet Componentslink:presentationLinklink:calculationLinklink:definitionLink0203 - Disclosure - Share Based Compensationlink:presentationLinklink:calculationLinklink:definitionLink0201 - Disclosure - Description of Businesslink:presentationLinklink:calculationLinklink:definitionLink0301 - Schedule - Valuation and Qualifying Accountslink:presentationLinklink:calculationLinklink:definitionLink06131 - Disclosure - Reportable Segments (Geographic Area) (Details 1)link:presentationLinklink:calculationLinklink:definitionLink0613 - Disclosure - Reportable Segments (Details)link:presentationLinklink:calculationLinklink:definitionLink0513 - Disclosure - Reportable Segments (Tables)link:presentationLinklink:calculationLinklink:definitionLink06022 - Disclosure - Summary of Significant Accounting Policies (Details 2)link:presentationLinklink:calculationLinklink:definitionLink06021 - Disclosure - Summary of Significant Accounting Policies (Details 1)link:presentationLinklink:calculationLinklink:definitionLink0602 - Disclosure - Summary of Significant Accounting Policies (Details)link:presentationLinklink:calculationLinklink:definitionLink0502 - Disclosure - Summary of Significant Accounting Policies (Tables)link:presentationLinklink:calculationLinklink:definitionLink0402 - Disclosure - Summary of Significant Accounting Policies (Policies)link:presentationLinklink:calculationLinklink:definitionLink0202 - Disclosure - Summary of Significant Accounting Policieslink:presentationLinklink:calculationLinklink:definitionLink0140 - Statement - Consolidated Statements of Stockholders' Equity and Comprehensive Incomelink:presentationLinklink:calculationLinklink:definitionLink0213 - Disclosure - Reportable Segmentslink:presentationLinklink:calculationLinklink:definitionLink00 - Document - Document and Entity Informationlink:presentationLinklink:calculationLinklink:definitionLink0215 - Disclosure - Fair Value Measurementlink:presentationLinklink:calculationLinklink:definitionLink0212 - Disclosure - Stockholders' Equitylink:presentationLinklink:calculationLinklink:definitionLink0211 - Disclosure - Income Taxeslink:presentationLinklink:calculationLinklink:definitionLink0214 - Disclosure - Business Restructuring Chargeslink:presentationLinklink:calculationLinklink:definitionLink0205 - Disclosure - Other Incomelink:presentationLinklink:calculationLinklink:definitionLink0130 - Statement - Consolidated Statements of Cash Flowslink:presentationLinklink:calculationLinklink:definitionLink0120 - Statement - Consolidated Statements of Operationslink:presentationLinklink:calculationLinklink:definitionLink0110 - Statement - Consolidated Balance Sheetslink:presentationLinklink:calculationLinklink:definitionLinkEX-101.CAL
11
wpi-20101231_cal.xml
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101.LAB
12
wpi-20101231_lab.xml
EX-101 LABELS LINKBASE DOCUMENT
EX-101.PRE
13
wpi-20101231_pre.xml
EX-101 PRESENTATION LINKBASE DOCUMENT
EX-101.DEF
14
wpi-20101231_def.xml
EX-101 DEFINITION LINKBASE DOCUMENT
GRAPHIC
15
a58052a5805203.gif
GRAPHIC
begin 644 a58052a5805203.gif
M1TE&.#EA50+_`-4@`("`@$!`0+^_OS\_/_#P\']_?Z"@H+"PL.#@X&!@8)"0
MD%!04._O[R`@(!`0$-#0T'!P<#`P,)^?G\_/S]_?WX^/CV]O;R\O+P\/#U]?
M7Z^OKT]/3Q\?'\#`P````/_______P``````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"``+`````!5`O\```;_
M0)!P2"P:C\BD$PNF\_HM'K-;KO?\+A\
M3J_;[_B\?L\W&@()!$,`A!U"!P<*@GV,C8Z/D)&2C`8&'0L!0AT0A((=`"`$
M"Y.DI::GJ*FI!D($'D()#T0+AB`!LJJYNKN\O;Y<#2`(#1X-N`Z#"K_+S,W.
MSY*50P@+#@@@KT*$1P`>WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[
M^FX$H$4"*,L&8IL1`!<$*%S(L*'#AQ`C2IQ(L:+%BQ@S:MS(L:/'A1X4=!A)
MLJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FRT5$%P#L,BV_PB+(!S@-N"#T:-(DRI=
MRK2ITZ=0HTJ=2K6JU:M8LVH]ZJ$6M*_+.NQ,H^@0$0BR``RUMNW;M0NX+=ZTLLFP3@$"B`0*##6@*!I!'%R[BQX\>0(S_5R[=R+K]Q"GL=
MTN$:$@!O)8L>3;JTZ:24+:LVA5D2Z-.P8\N>G37UZMN16D=Z3;NW[]^S;>,>
MSD@W)-[`DRM?CE=YC#]"SKRZ]>M3G4/?3D>Z(^K8PXL/KYV[^3?>&X$?
M7Y?![PE3W;._6OZ\?37I&:V72BXT50H;;#`!!18,H(%1%6Q`07L%#""`!@4(
MP,``!?@V`091:8"!`//1M__9?2#B-]9T_E'E@5("E#B5!!ZX)X`'"WX@@`1+
M<:C5BT:].$$!%3+PI0P`:WILI`!@Q44*$$&&C`@0`;
M9)#@`+YBL&`&%$SPE@44"/NEE0E^T&"APU)P0044L&B4!C1>L&JS;PE9@)T]
M'MK_5)&+MHM%DGPL:=0&YJ!83JI/O4A!!;5J<*"_UE;(HXRI`OD6`RT^^0&A
M93Z8P8&P&G4B!14JW*)1`Y^)<86G:ER!E!7Z.J,'D9;+(:%-7I`CAQTW*>0`
M\-VI[E+LNFOS%/#N(>]D*#XZ%96G%OMICAK@&K!1%UP`G\(+*V0RFY,>K?$'
MW5X[M=1-#LR`!!J[,-"=Z\]M4Y*S'SDY%3;96
ML5;P0=<=:Z#WP%I;ZX$`$W0Z:,EH0YU4QA.?:O%1C&^,JGM>2_GE!D,7JO#+
M-IXH@.%O;D!YXC]>X#/;-<.MNA)RYT'WN@Y5<'I4$US\_\&&@QYH@F[+-5.JKMU]$ZWB\SM0`]-=/?^98I9MY!1@44(&E')#`!/IDI4+U
M28`?2)"=-J`WHS"@0160#P,L`*WE*00#%I@>UPQ$-0I&RT`$LD#A-B"!"WS*
M`AZ`F:<\,*Q!;8M5"4S(\@Y4N/Y]B0,D-.$$A!"?A0?6USGQ"=`+\[R`^(
M2$QB=MPVQ"9RIE'JF9T2ITC%=3'1B4TLHAV.6,4N3I%]6(2;%NO`12^:47U@
M#./-QDB',I[QC4-*HQK=Q<8YN/\1CG@4CQSGN*@ZRN&.>0QD=?;(QR/Y,0Z`
M%*0B@4/(0H;HD'!(Y"(G&9PK.O)MD'R#)"G)2=,T\I+VR:0;-MG)4DKFDZ`T
MCRC;0$I3NK(QJ$SE=E;)AE:^\I9UB:4LGT-+GD@Q*F3"I3"QHLM=#J>7:B!E
MX8(YS&;RQY+&-"04]?/+IUS``_C*RJ[`Q;`)"@!_$A@`^0I@N:,4B$*J^N&T
MOLE,9\JFF-%<#3+3L,D">*`"'BBG57Q%M*/P,T)(&=R7,-#`.$4H2Q3H&+,^
ML-"$NO,W\(RG9>:)!DG6KD*QPE15_B>?`R%(=-F4F(WHAY0,G`MR#>0GAHRR
MTH?2)J+_$N4+1<^PLW/:SWX<.!@'&)JIU+H,O2JA$I?(!`@6(`@`&.(3H1@%8:G"@)PN
MQ717R5,&BL+/WP4PH))U4JK(J:4*@0YTF;4K-#G+'<\F@16A>,4#1'N)T=;B
M%JN="@I-UU,.W-,JHO/4J2K``1=AX`(46)-`G<(UJBET60MR_VAPISI(2F_C$*$XQ/?P!D`V_@B`;
M!K%^14QCFHD$)SC.L8YWS.,>^_C'-M')*`,+@59$``1`$8)0HEOC)C.IO18^
MYC3),-@#$$"T!P"%6H00@+;(V,E@?G*4C81A(P#F&]>H!&($L6;%Y#?,<+;B
MF!\Y934@X$.=24*(XSS,SU*1S_Z%)'NPJ0I74I+7[H4F>;"IO\YS4E/?WH2H=["J$D]25.?.C>)GMNB
M6>U.5[_Z$:G6PB9WY#^-#K.=L)'94X`M&EO?NA&YSH(D49A3#$0)*PDFGP0@
M"VW9+5@NRQ/0MS@XP,<"]P/A'">-SN:;ZT'%K#_5+)2/W=E8NV[6D,OG43(P
M7OK8J'#ZK$J]Y8).R,W+1FI"#8[F2:W3LD8>]DM95(`DN!)&4!(]9TG
M8,G'4/S)DZ$8P'&9`4I/PE[8VGI4K#@)>[PD/=&`PF2\'[E'3%>ZD_:<'&/1M!:)HX`I"921:J%%)O@J=X>]Z,]=E?J#OIMAGZ%G36H
MIP.XIE*ZAOE^U\UX:*J`1RDX)0Z17@,A%ZCH/?4I(3UI`QKX)H94*&S/6^LH
M&@J64NXI`+>>R3V`6]#+/%J\NQ5`^!Q2F8P()RH!P#5KO$L0?S7^%
MBKSD54-Y*SQFETWU/+
M&+B$ZM2G*6S_3H,4"B[)"0CFB*QX0>PR4;^O'@00#-D^B>U\27F95(D;C3SER%%0B<*@A.2($
M-OV7.$]2@P[R.3GW/X&2?]$'-C#B0+\#'^92(1RW`;+B@.L&@;P@@5202!."
M3:[B`?A#)'/20A+0,>HT6^"VA&QR)@NRA:IB@D61`7'7*PDT4$E10F$B):&1
M=[@U@T=S,?QG(\7W)';((3$X/A0@;PYV,:3'(^XA)!D@.@_T>]S#(0/30$K#
MA$Y8&5`X!9NTA0J&<,`4;C,20>9$/@4U(YZ2%`2G/YY(-0RT+PHRA0.P(!FD
M3@*(*Q504!E@`3-RA>%T;62C`2%4?R\$>_\\U"L"LD/USL!)(P<-P`>(%6`&'^$W0LB40HGV1:%7N%C_P1FM]UH3=J`J3*`6K
M)HZ!](#E&`>Z00@`@%R(X0`.T%=$\`#(Q4KAJ(ZWQ([MB!X[`0$>``!L%@'@
M<&1$@%JCM(_\6&GD^(^LL1,+D(_=X`$.8`D3F9`?YDL-66/^")%LH!L),`0$
MX`#>D(]%QAD;F4P,V9&=])$@*2(@-@C>$`R#H)&:U)(N24DP&9-H())"@`#?
MD(\@,)(JF9,[26$]Z9-F()(+``#$X`$("0OXI0DK24\ZF92*M)1,20:Z00`&
MZ0U)1@`'$``>L!;_5HF46IE97-F58B`=668`BV``\$B4"JF/:\F6#^F641``
M?OF7?]F4WP@"FW&7M925>8E';2EY@^,0@VD%K2,*'V:8')F8+K6806=PCUD%
MQO$`Q!`!N``"!V"2DWF5%:5BJ)F:JKF:K%D.>\F73Z"9@DD$)?D-#D``B/$-
MI:E)$0!DOOF;P!F%EL-D%LED&NF$`X9``4>D!`>`9:3E*HG6ED$`!A"6VJF<`5D$)@F:08F3Y&F>]/D,
M'0`8]2@6Z^F5.[&1`=`3_R"?56``H5D0A7`(B6"<@U"=]=F@NX``4"F5_W(I
M!.6PG4+PE/`(`/\)C_\IH#C3`%ZQ"9U`F*`@"I_!H`Z:HJ;P!\4``=+ICCMA
MEN:PFU80`%X1"[/P7`6ZH"K:HY/P``E@D@N`EMT1H^=`HU5@HT%)#,8@!/95
M$.+)HSXZI7U```KPF8,5@3':G1F:H4_IH5.@I--0#=<`8U=9D:V9IFJZIFS:
MIF[ZIG`:I_EP%DH0H..9I(DB$!UFH-S0F\3YIX`:J((ZJ(1:J(9ZJ#.1GMXP
MD8CZ$D(6-Z;Y!&(*8J"09""P9`>!HE2ZJ6V`G@;9``#PHGT`/W8ZG7AJ!&A1
M$&O19=R@J9SZJDV)GPGPFG`@-U;J`$CZH:$*`O^#41B'D1A$"6*N"JO$Z@40
M^ID3BFIUA@!!Z@VY>@6:801Y=J+%6JU>@)YFV0`NBFG35);A\*S)-*S6.JY0
M`*0FF0!$&I%&\`_/:9$)P`E@&J[D.J]1(!A8JJ#JRAG@*98-,)?Q2D_B2J\"
M>P@+8)&I^H02"0ZS:@M(0)GR.K`0.P0/``%"&JR`-A;'ZIT,>P0."[`1.[">
M6@P*(*J]D!X'L`!#6IV%&:E8%;`?NZD'(*NT*@E)JS0
MF:QY%6LG.Y`Y2U,[R[/TB:TM2K+V^8UT6;0MB[14:JX>@*[R-)@OVK$Z*[4]
M>Z52F:7JV
M3="AJ\2E$`+"L)".```30C'&`-%EJ42H"S??NP0]0-
M_^.;&21!EX2`"7Y)#H"90J*(`+`5-Y!@]`$O-%"'\9EN'@`'_)I?%($FTQPYN06$C1-1I[:"'
M>YL9-V(;`&2;M4E\O']K)&"YBAA@CU=`$O<+`!#PE^WZ#0WPEYQ0""0!Q".1
MH5\,QN2``9WG#6RKPE5U"189`4C,!IJ!$A2,N@!@P>WKER;Y#73UA]Y+1+$&
MM]@;M>XSP%Z%3[I;!'F\Q_D+R./`OGX)CPI0PR*AQH`9Q@<)F!EZ8R.19GUL
MA5M%;SAQ32^)09+`ZZ'``HZY?=Z9>A_,V,8*72#+;O\]#I+)7KW,XV@[DFN:$+$)4-@*$D
M`REGN0L'@":_L]4)',`Y3;O_.VU5=+F^YB""&]"_E5&^#3"R62:C#B#2[L.B
MX1`!"2`27A8!N",C&%#6>Z"\#L0!@!T%Z@N[*"&[+!RZSU$89ZW-<,S+HWD.
M'W%GV)W;=_V?EC"]1G``SPE=
MT(&>Q("C1J#940G%!P#5OH#2/PW'H6VQS7!GM]W>3VD`#B!^2"'0[%F]%.V^
MX1V__X4=TY^0O^0PQF2+T9S9`39]&XHZJ>MZ`%^\W,W-#`C@TU;]E`I0#?6(
MWZ;@V'V,PQ0N$B_:#28E5O3BVEX`E$G`P*8ZM[QPW?L-S;R,X1+5`6:YN4S0
M`2=>WT*AXGV`CQH:R'C=W(IJTNIMW1&.VY'=G0=@T[L,F"?\VM,0SK(M:`\N
M!4Q.1'3YX^$@V<0]1/=9#/Y]!"/^X<7`W&W^DP9`Y]"YSILAU:K\H$BNH<\9
M`0/>`56NI4APSO'8NEJ;O6A``.^[Q8\M#H3>PX=.7.6+V5"`Y%7M#?9]YC_Y
MW)&M%J7KK6]]Z<61YM9+X:8%ZG8@'1T0QNX]YGX0FE8*6/\(JM122@9_$+UB
MZ9<9'@I(_L7F70S_">.!"P#TN*OUZN$R>M4AWJF?T.EUKA;HZ[-#6@H*3>RA
MK>5W/@?&P9SC4-/O,\4-"Z)#@-JF=Y7
M(*;+I0FC0`M<5KJT/=OI-@"&0-X2#@YL;IX&0`P>;P5S_NQVOL!G5H^'_ME8
M#IUYO6ZM_+-F<+NWR9D^;;TZS`E"OA>ZD;F<&PH*(-RT'A"UH-@@4%_)X.YE
ML``CG\J[G=X^RJ(<#IG_#IUJX67_`US`T_/(FG#;H;W.^7Z/05J/:Y\%$4!@
M7[[`G_#%`L[;>LL62;`)35^]M>!B>QIC-*EB(R^GAG_XB)\/C3?8B3\/RO(B
MC1_Y%3H$E7T0?>_=?]\3+S8(9^JGP-G5A>_IO-VHI%_ZIO_FISW=;'@8R!
M+++#A1H9D02&\
M(>\%!5OX"Z#2L&_HL,JLRX[J4M#5]D+]66#J19P&5YQSU@6=A8Y),3J]?+_8
MDEH+5W8(6K:J^-K\7-#57AUQQ;`(2"[]=1[M/@H$!(##D4"`D$GEDME$$CR:
MSW0J\3BQ_TYAP[,X9,%A,.$`B&`HU,_$HQ"_X7'YG"[N7).0AH&P)"@_QXVH]`MQ;'QP,D*+A@K0ZM+@$
M,)`/1`<%"2)L:I"J`X$&&`IDU)B1'T./'QOB26*@4R<']`85`IE$W4I#",H$
MV!8`@@&4+G'FU!DN`+^%KA[TW!3@)IP'"8@D*%KM@0$(0ATL`/]048F!;E>Q
M7A6TD^LE;$L.F.)$E(DXG"V[SH%9:69-=&GAQH4%S,.>5^3ZS+%:E\^ZM5`#
M`#CP5FYA65^9/%``P`#AABI=HC4$`"`X-.Z?DUF^:/ET6>/!MWX41#'&@"-^!!74!S'[E,!XJ5;^A
M_WJ-)&Q)",H?U[8478YBB!*E4N4^_N,6#[>JF0^P%:B![W7#DY<_!S'UDIPB
M*#<;>?O\.`[?:R`\[/RC!H#[-CDMKGU,.RR883*CS++=9"O0PC?JLTBBJ[:!
M[!`/0;+M0@P5:(ZB$64!H(!G/AA`0;G_]NHGC'9HI!$EA$[YR1`RV!H*@MY0
M##*+^@[P@+ALCJ/MK/Z$C`.>;TYLD@X5672QM0YZL@L+#P;HTLL++#DJJ:7>
M>'(35%:34LTFZH/@1206\&>_E41
M#;8=7_&M)->L_R1-UU\$NY'4@:R\I0)<,;85AK<(LZVTOGVO2L2<:CVJL^$Z
MG.5$T0AHQ!?6K&3U-U=\#P#VT3@$G9=9D$:QM\9R>37EDX*G.+B)U'Q,\^*=
M!WE-J'0]G#/$<'EFY0&:/U"6DW6Q:I?7>FV$"X`,3#7U@I5OVZV.;&%N^
M+VF;:,(+FW6C`C)0N$+$":]/1RE79ZUYJG/7OOM6[&>,^RY#U_\\=F&/W_;V-7M?_OOQYYO^R>S/W___L[4_P_0/@`4T8),$6!@"'I"!#91/`N6R
M0`=.D(*L@6!<)%A!#6XP+1>4&OHX&$(1RL6#:Z1CWWTXQ\!&4A!#I*0A33_Y"$1F4A%+I*1C71D(.,2`#?8
MD6)FD-XE,9E)36Z2DYWTY"=!&4I1CI*4I33E*5&92E6NDI6M#)8"@'B60N0'
M"3^:HAOAF$L8RM$8$`B%8+I((##JDI@`Y*4K%'"=#@@B$K28'+5P64QI;O"8
MLYB>.3(SS&ENN+CGOGT)^+V>8]^_I.@8@NH/09:4(5>[*#U2.A"(0J\6'XOGA&U
M*$`GZKZ*7I2C!LUH_3;:49$R]*/\"^E(42K1&9XTI2U54T/7\5"7SO0V,+6&
M3&F:4\W8M!HXU>E/_^/"4P.Q%*A%A8Y0C>%3HR[5)4A-$5&9&M7).#462I7J
M5>U!55A8%:M=96))!PA5KXZUJ6!5H%C)FE:&:/457%7K6W^X4KC.M3!L=85;
MZ9I7+-BU%7C5ZU_-8=8(HA6PA:4#7UGA5\/J%;&74.QBZ=I80SP6LG"5;!TH
M6UFU7G9*A-7L9\LB6`QZ%K2E#E.E[K5M>YUL5L2
MPRB73:ZT%RJ\&UY-PE*\Y;TD>,V;WE615[WM;0=ZW:O>-KC7,+0$@2VY$O^8
M-;W6&OI]*7*AXU\U>0!KGP)F;GWG$0$C$,"_6;"0^%N-!PN)P&MKYB2Z,F$4
M19@:&AX1AXWAX1%5>&_G@(N(+01B7*#M0BJ.!8HM1&+CSIC&-;;QC7&<8QWO
MF,7(1F>SDQ[B*
M86FQRI)!\`/I8B-!C<(6+D#*@'#W+<3A"ECXL).@`(EK1N&0:?@:
M00#>!$`'R16_N!I%(B/?=#P)PE;YR?/GF8;TIQ\JQ](3#@3IS4SBCB"X`B45
M$``"1")3M]D.)7O^&OMF;2%)]SE++,T%0QOFZ%!W^J/W[1N>0R;EY7`Z_IY(
M)TI*M$_QM:I\?:DR"22]]&",'E^M/MS@A@G,3M2("[W\,=
M`<$(&^UY!WS6-7WW^ZDVS*$+N:H%<8"BSYQV3\X4`P\*SO*,?7\O!A`X"(V_-YY,0>LFC?A"N9][I&]^G(8[^?K`G,X+#;(DF
MUM(?F[H-XZF]G3)H6A!"1T#H",#:=9SY$$)H_M"5#YE,'S\OR:=.(0XL]'ZS
MAOH-L7XPH__])&">WFE!?OK)#!F5PW_Y\6/N)A;R`$#%^K[N!M2/`6[CY"(8
M..$(&J&9PDP2?@+)%JN@(@.&'D+NPG#A#,,,\W"'`3#-`1",V9X`36')`K
M(%30$Q+0`QF!`\/,*;HL+3+0`S80`1LB$1:A`MLO?49A-MQM$,2#/"P'F[)A
KRC;#Q#K#'PA@!3>C!P=A&LQM/H00"9`P!%D#"9U`"GNL"JWP"C4H"```.S\_
`
end
XML
16
R19.xml
IDEA: Reportable Segments
2.2.0.25falsefalse0213 - Disclosure - Reportable Segmentstruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_ReportableSegmentsAbstractwpifalsenadurationReportable Segments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringReportable Segments.falsefalse3false0us-gaap_SegmentReportingDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 13 - us-gaap:SegmentReportingDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 13 —
Reportable Segments</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson has three reportable segments: Global Generics, Global
Brands and Distribution. The Global Generics segment includes
off-patent pharmaceutical products that are therapeutically
equivalent to proprietary products. The Global Brands segment
includes patent-protected products and certain trademarked
off-patent products that Watson sells and markets as brand
pharmaceutical products. The Distribution segment mainly
distributes generic pharmaceutical products manufactured by
third parties, as well as by Watson, primarily to independent
pharmacies, pharmacy chains, pharmacy buying groups and
physicians’ offices under the Anda trade name. Sales are
principally generated through an in-house telemarketing staff
and through internally developed ordering systems. The
Distribution segment operating results exclude sales by Anda of
products developed, acquired, or licensed by Watson’s
Global Generics and Global Brands segments. Arrow operating
results are included in the Global Generics segment subsequent
to the date of acquisition except for operating results from
Eden which are included in our Global Brands segment.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The accounting policies of the operating segments are the same
as those described in “NOTE 2 — Summary of
Significant Accounting Policies.” The other revenue
classification consists primarily of milestone payments,
commission revenue, royalties and revenues from research,
development and licensing fees and also includes co-promotion
revenue and revenue (including the amortization of deferred
revenue) relating to our obligation to manufacture and supply
products to third parties. The Company evaluates segment
performance based on segment contribution. Segment contribution
represents segment net revenues less cost of sales (excludes
amortization), direct R&D expenses and selling and
marketing expenses. The Company does not report total assets,
capital expenditures, corporate general and administrative
expenses, amortization, gains on disposal or impairment losses
by segment as such information has not been used by management,
or has not been accounted for at the segment level.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Segment net revenues, segment operating expenses and segment
contribution information for the Company’s Global Generics,
Global Brands and Distribution segments consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="71%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Generics Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,268.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,641.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,404.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,338.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,668.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,474.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,198.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
947.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
883.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
194.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
53.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
<b>Global Generics Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>833.0</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>526.9</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>416.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Brands Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
316.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
393.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
81.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
58.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
461.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
455.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
50.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
137.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
144.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Global Brands Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>70.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>170.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>178.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Distribution Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
560.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
511.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
59.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Distribution Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>49.2</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>38.6</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>34.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Total Segment Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>952.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>735.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>629.7</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Corporate general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
436.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
257.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
190.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
180.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
92.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
80.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Loss on asset sales and impairments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Operating income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
305.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
383.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000">
</div>
<div style="margin-top: 3pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<tr>
<td width="2%"></td>
<td width="1%"></td>
<td width="97%"></td>
</tr>
<tr>
<td align="right" valign="top">
(1) </td>
<td></td>
<td valign="bottom">
Excludes amortization of acquired intangibles including product
rights.</td>
</tr>
</table>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following geographic areas for the years
ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
United States
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,990.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,642.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,384.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
International
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
425.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
57.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following therapeutic categories for the
years ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Central nervous system
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
907.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
836.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
795.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Hormones and synthetic substitutes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
609.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cardiovascular
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
594.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
269.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
245.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Anti-infective agents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Urology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
127.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
942.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
738.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
634.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used to capture the complete disclosure of reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10% or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the comb
ined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
falsefalse12Reportable SegmentsUnKnownUnKnownUnKnownUnKnownfalsetrueXML
17
R44.xml
IDEA: Acquisitions and Divestitures (Details)
2.2.0.25falsefalse0604 - Disclosure - Acquisitions and Divestitures (Details)truefalseIn Millions, except Per Share datafalse1falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse12/31/2010
USD ($)
$BalanceAsOf_31Dec2010http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$4falsefalseUSDfalsefalse7/2/2010
USD ($)
$BalanceAsOf_02Jul2010http://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDfalsefalse12/2/2009
USD ($)
USD ($) / shares
$BalanceAsOf_02Dec2009http://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3true0wpi_DescriptionOfTransactionAbstractwpifalsenadurationDescription Of Transaction.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringDescription Of Transaction.falsefalse4false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse10500000001050.0falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse5false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1f
alsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false<
/IsNumeric>falsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse636200000636.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe acquisition-date fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(4)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 39
falsefalse6false0wpi_BusinessAcquisitionCostOfAcquiredFairValueOfMandatorilyRedeemablePreferredStockIssuedAndIssuablewpifalsedebitinstantBusiness acquisition cost of acquired fair value of mandatorily redeemable preferred stock issued and issuable.falsefalsefalsefalsefalsefalsefalsefalsefalsefals
everboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse150000000150.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryBusiness acquisition cost of acquired fair value of mandatorily redeemable preferred stock issued and issuable.No authoritative reference available.falsefalse7false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesIncurredus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsefalse
IsRatio>false00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse110000000110.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair Value of the liabilities incurred by the acquirer to former owners of the acquiree, including the fair value of any contingent consideration. If liabilities transferred as consideration remain within the combined entity after the business combination (for example, because the assets or liabilities were transferred to the acquiree rather than to its former owners), and the acquirer there
fore retains control of them; in that situation, the acquirer shall measure those liabilities at their carrying amounts immediately before the acquisition date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 39, 40, 41
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(3)
truefalse8false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePriceus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotal
label1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse19462000001946.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
truefalse9true0us-gaap_BusinessCombinationConsiderationTransferredAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse10false0us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalentsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalse<
/ShowCurrencySymbol>falsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse6490000064.9falsefalse
ShowCurrencySymbol>falsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of cash and cash equivalents acquired in a business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
falsefalse11false0us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsReceivablesus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3fal
sefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse107600000107.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to receivables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 37
-Subparagraph b
falsefalse12false0us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsInventoryus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false<
/IsNumeric>falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse187900000187.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to inventory, including finished goods, work-in-process, and raw materials.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 37
-Subparagraph c
falsefalse13false0wpi_BusinessAcquisitionPurchasePriceAllocationOtherCurrentAssetswpifalsedebitinstantBusiness acquisition purchase price allocation other current assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3
Id>falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse174500000174.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryBusiness acquisition purchase price allocation other current assets.No authoritative reference available.falsefalse14false0<
ElementName>us-gaap_BusinessAcquisitionPurchasePriceAllocationPropertyPlantAndEquipmentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse8240000082.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 37
-Subparagraph d
falsefalse15false0us-gaap_BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsNotAmortizableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse7580000075.8falsefalsefalsefalsefalse5truefalsefalse711000000711.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will not be amortized. Does not include goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-Subparagraph b
falsefalse16false0us-gaap_BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3
falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse3950000039.5falsefalsefalsefalsefalse5truefalsefalse518600000518.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
falsefalse17false0us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillAmountus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truef
alsefalse632900000632.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 53
-Subparagraph d
falsefalse18false0wpi_LongTermDeferredTaxAssetswpifalsedebitinstantLong term deferred tax assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefa
lse00falsefalsefalsefalsefalse4truefalsefalse2430000024.3falsefalsefalsefalsefalse5truefalsefalse6960000069.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryLong term deferred tax assets.No authoritative reference available.falsefalse19false0us-gaap_BusinessAcquisitionPurchasePriceAllocationOtherNoncurrentAssets<
ElementPrefix>us-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse1060000010.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to noncurrent assets of the acquired entity, except for property plant and equipment, intangible assets, and goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 98-1
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 37
-Subparagraph f
falsefalse20false0us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsef
alsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalse
IsRatio>false-306300000-306.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to current liabilities of the acquired entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 37
-Subparagraph g
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 98-1
falsefalse21false0wpi_LongTermDeferredTaxAndOtherTaxLiabilitieswpifalsecreditinstantLong term deferred tax and other tax liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefa
lsefalse-303600000-303.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryLong term deferred tax and other tax liabilities.No authoritative reference available.falsefalse22false0us-gaap_Busin
essAcquisitionPurchasePriceAllocationOtherNoncurrentLiabilitiesus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse-3900000-3.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to other noncurrent liabilities of the acquired entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
truefalse23false0us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNetus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse6200000062.0falsefalsefalsefalsefalse5truefalsefalse19462000001946.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition.Reference 1
: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 35
truefalse24true0us-gaap_BusinessAcquisitionProFormaInformationAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefa
lsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse
IsRatio>false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse25false0us-gaap_BusinessAcquisitionProFormaRevenueus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse32619000003261.9falsefalsefal
sefalsefalse2truefalsefalse31706000003170.6falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalse
falsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the periodReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph r(2, 3)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 54
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 55
falsefalse26false0us-gaap_BusinessAcquisitionProFormaNetIncomeLossus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse119300000119.3falsefalsefalsefalsefalse2truefalsefalse281500000281.5falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe pro forma net income (loss) for the period as if the business combination or combinations had been completed at the beginning of a periodReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph r(2, 3)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 54
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 55
falsefalse27true0us-gaap_EarningsPerShareAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefal
se00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse28false0us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasicus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse0.990.99falsetruefalsefalsefalse2truefalsefalse2.352.35falsetruefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseEPSus-types:perShareItemTypedecimalThe pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a periodReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph r(2, 3)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 54
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 55
falsetrue29false0us-gaap_BusinessAcquisitionProFormaEarningsPerShareDilutedus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse0.980.98falsetruefalsefalsefalse2truefalsefalse2.342.34falsetruefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseEPSus-types:perShareItemTypedecimalThe pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a periodReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph r(2, 3)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 54
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 55
falsetrue30true0us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNetAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1f
alsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false<
/IsNumeric>falsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse31false0wpi_BusinessAcquisitionPurchasePriceAllocationInvestments
ElementName>wpifalsedebitinstantBusiness Acquisition Purchase Price Allocation Investments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse1150000011.5falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryBusiness Acquisition Purchase Price Allocation Investments.No authoritative reference available.falsefalse32false0us-gaap_BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsNotAmortizableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2
falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse7580000075.8falsefalsefalsefalsefalse5truefalsefalse711000000711.0falsefalsefalsefalsefalse<
/Cells>Monetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will not be amortized. Does not include goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-Subparagraph b
falsefalse33false0us-gaap_BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3
falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse3950000039.5falsefalsefalsefalsefalse5truefalsefalse518600000518.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
falsefalse34false0wpi_LongTermDeferredTaxAssetswpifalsedebitinstantLong term deferred tax assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse2430000024.3falsefalsefalsefalsefalse5truefalsefalse6960000069.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryLong term deferred tax assets.No authoritative reference available.falsefalse35false0us-gaap_BusinessAcquisitionContingentConsiderationAtFairValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse-111000000-111.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse-198500000-198.5
falsefalsefalsefalsefalse4truefalsefalse-64800000-64.8falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
truefalse36false0wpi_BusinessAcquisitionPurchasePriceAllocationLongTermDeferredTaxLiabilitieswpifalsecreditinstantBusiness Acquisition Purchase Price Allocation Long term Deferred Tax Liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse-24300000-24.3falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryBusiness Acquisition Purchase Price Allocation Long term Deferred Tax Liabilities.No authoritative reference available.truefalse<
Id>37false0us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNetus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse6200000062.0falsetruefalsefalsefalse5truefalsefalse19462000001946.2falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 35
truefalse535Acquisitions and Divestitures (Details) (USD $)HundredThousandsUnKnownNoRoundingUnKnownfalsetrueXML
18
R35.xml
IDEA: Reportable Segments (Tables)
2.2.0.25falsefalse0513 - Disclosure - Reportable Segments (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_ReportableSegmentsTablesAbstractwpifalsenadurationReportable Segments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringReportable Segments.falsefalse3false0us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note13_table1 - us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Segment net revenues, segment operating expenses and segment
contribution information for the Company’s Global Generics,
Global Brands and Distribution segments consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="71%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Generics Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,268.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,641.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,404.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,338.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,668.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,474.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,198.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
947.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
883.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
194.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
53.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
<b>Global Generics Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>833.0</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>526.9</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>416.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 18pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Global Brands Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
316.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
393.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
81.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
58.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
397.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
461.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
455.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
50.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
137.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
144.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Global Brands Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>70.1</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>170.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>178.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Distribution Segment</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Product sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Other revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
830.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
663.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
606.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Operating expenses:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Cost of sales(1)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
560.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
511.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Research and development
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Selling and marketing
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
70.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
59.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
<b>Distribution Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>49.2</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>38.6</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>34.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Contibution margin
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
<b>Total Segment Contribution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>952.3</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>735.8</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
<b>$</b>
</td>
<td nowrap="nowrap" align="right" valign="bottom">
<b>629.7</b>
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Corporate general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
436.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
257.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
190.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
180.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
92.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
80.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Loss on asset sales and impairments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 27pt">
Operating income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
305.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
383.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000">
</div>
<div style="margin-top: 3pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<tr>
<td width="2%"></td>
<td width="1%"></td>
<td width="97%"></td>
</tr>
<tr>
<td align="right" valign="top">
(1) </td>
<td></td>
<td valign="bottom">
Excludes amortization of acquired intangibles including product
rights.</td>
</tr>
</table>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used to capture the complete disclosure about the profit or loss and total assets for each reportable segment, as a single block of text. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 27, 28
falsefalse4false0us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverbose
label1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note13_table2 - us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock-->
<div align="center" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following geographic areas for the years
ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
United States
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,990.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,642.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,384.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
International
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
425.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
57.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used to disclose in its entirety the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 38
-Subparagraph a
falsefalse5false0wpi_NetProductSalesInTherapeuticCategoriesTextBlockwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note13_table3 - wpi:NetProductSalesInTherapeuticCategoriesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s net product sales are represented by the sale
of products in the following therapeutic categories for the
years ended December 31:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="68%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Central nervous system
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
907.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
836.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
795.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Hormones and synthetic substitutes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
609.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cardiovascular
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
594.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
269.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
245.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Anti-infective agents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Urology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
127.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
942.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
738.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
634.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,415.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,699.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,407.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringNet product sales in the therapeutic categories.No authoritative reference available.falsefalse14Reportable Segments (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
19
R51.xml
IDEA: Goodwill Product Rights and Other Intangibles (Details 2)
2.2.0.25truefalse06082 - Disclosure - Goodwill Product Rights and Other Intangibles (Details 2)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse7/2/2010
USD ($)
$BalanceAsOf_02Jul2010http://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4falsefalseUSDfalsefalse12/2/2009
USD ($)
USD ($) / shares
$BalanceAsOf_02Dec2009http://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Product rights and other related intangibles [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Product_Rights_And_Other_Related_Intangibles_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseProduct rights and other related intangibles [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ProductRightsAndOtherRelatedIntangiblesMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Product rights and other related intangibles [Member]
7/2/2010
USD ($)
$BalanceAsOf_02Jul2010_Product_Rights_And_Other_Related_Intangibles_Memberhttp://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00falsefalseProduct rights and other related intangibles [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ProductRightsAndOtherRelatedIntangiblesMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7falsefalsetruefalse{us-gaap_BusinessAcquisitionAxis} : Arrow Business Acquisition [Member]
7/1/2010 - 7/31/2010
OneMonthEnded_31Jul2010_Arrow_Business_Acquisition_Memberhttp://www.sec.gov/CIK0000884629duration2010-07-01T00:00:002010-07-31T00:00:00falsefalseArrow Business Acquisition [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ArrowBusinessAcquisitionMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/inst
ancepurexbrli08falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Arrow Business Acquisition [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Arrow_Business_Acquisition_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseArrow Business Acquisition [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ArrowBusinessAcquisitionMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.o
rg/2003/iso4217USDiso42170USDUSD$9falsefalsetruefalse{us-gaap_BusinessAcquisitionAxis} : U.S.Rights Columbia Products [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_United_States_Rights_Columbia_Products_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseU.S.Rights Columbia Products [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UnitedStatesRightsColumbiaProductsMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardh
ttp://www.xbrl.org/2003/instancepurexbrli010falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : U.S.Rights Columbia Products [Member]
7/2/2010
USD ($)
$BalanceAsOf_02Jul2010_United_States_Rights_Columbia_Products_Memberhttp://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00falsefalseU.S.Rights Columbia Products [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UnitedStatesRightsColumbiaProductsMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : IPR&D [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_I_P_R_And_D_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseIPR&D [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_IPRAndDMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : IPR&D [Member]
7/2/2010
USD ($)
$BalanceAsOf_02Jul2010_I_P_R_And_D_Memberhttp://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00falsefalseIPR&D [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_IPRAndDMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USD<
/MeasureValue>iso42170USDUSD$2true0us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00fals
efalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_FutureAmortizationExpenseYearOneus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00
falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse270000000270.0falsetruefalsetruefalse6falsefalsefalse00<
/RoundedNumericAmount>falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of amortization expense expected to be recognized during the twelve-month period following the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(3)
falsefalse4false0us-gaap_FutureAmortizationExpenseYearTwous-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsef
alsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalse
IsRatio>false417500000417.5falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefa
lsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of amortization expense expected to be recognized during the second twelve-month period following the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(3)
falsefalse5false0us-gaap_FutureAmortizationExpenseYearThreeus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalse
false311500000311.5falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7false
falsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalse
IsRatio>false00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of amortization expense expected to be recognized during the third twelve-month period following the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(3)
falsefalse6false0us-gaap_FutureAmortizationExpenseYearFourus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false
falsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalse<
/IsRatio>false299300000299.3falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsef
alsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of amortization expense expected to be recognized during the fourth twelve-month period following the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(3)
falsefalse7false0us-gaap_FutureAmortizationExpenseYearFiveus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false
falsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalse<
/IsRatio>false138600000138.6falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsef
alsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of amortization expense expected to be recognized during the fifth twelve-month period following the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(3)
falsefalse8true0wpi_GoodwillProductRightsAndOtherIntangiblesTextualsAbstractwpifalsenadurationGoodwill Product Rights and Other Intangibles Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse<
Cell>3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7
Id>falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringGoodwill Product Rights and Other Intangibles Textuals Abstract.falsefalse9false0us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse16320000001632.0falsefalsefalsefalsefalse2truefalsefalse17135000001713.5falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00f
alsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8truefalsefalse11196000001119.6falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10truefalsefalse115300000115.3falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 45
falsefalse10false0us-gaap_BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsNotAmortizableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1<
/Id>falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3<
IsNumeric>truefalsefalse7580000075.8falsefalsefalsefalsefalse4truefalsefalse711000000711.0falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11truefalsefalse711000000711.0falsefalsefalsetruefalse12truefalsefalse7580000075.8falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will not be amortized. Does not include goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-Subparagraph b
falsefalse11false0us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAverageUsefulLifeus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse55falsefalsefalsefalsefalse2truefalsefalse55falsefalsefalsefalsefalse3<
/Id>falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5<
IsNumeric>falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse55falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9true<
/IsNumeric>falsefalse55falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11truefalsefalse55falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:decimalItemTypedecimalThe calculated weighted-average amortization period of a major class of finite-lived intangible assets acquired during the current period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 44
-Subparagraph a(3)
falsefalse12false0wpi_IntangibleAssetsTransferredToProductRightsAndOtherRelatedIntangibleswpifalsecreditdurationIntangibles transferred to product rights and other related intangibles.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefals
e5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11truefalsefalse142300000142.3falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryIntangibles transferred to product rights and other related intangibles.No authoritative reference available.falsefalse13false0us-gaap_BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalse
falsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse3950000039.5falsetruefalsefalsefalse4truefalsefalse518600000518.6falsetruefalsefalsefalse5truefalsefalse518600000518.6falsetruefalsetruefalse6truefalsefalse3
950000039.5falsetruefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
falsefalse14true0wpi_GoodwillProductRightsAndOtherIntangiblesAssetsAdditionalTextualsAbstractwpifalsenadurationGoodwill Product Rights and Other Intangibles Assets Additional Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverbose
label1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse
11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringGoodwill Product Rights and Other Intangibles Assets Additional Textuals Abstract.falsefalse15false0wpi_IncreaseInGoodwillwpifalsenadurationIncrease in goodwill related to acquisitions.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.640.64falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsetruefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9falsetruefalse00falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11falsetruefalse00falsefalsefalsetruefalse12falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureIncrease in goodwill related to acquisitions.No authoritative reference available.falsefalse1214Goodwill Product Rights and Other Intangibles (Details 2) (USD $)HundredThousandsUnKnownUnKnownUnKno
wntruetrueXML
20
R29.xml
IDEA: Investments in Marketable Securities and Other Investments (Tables)
2.2.0.25falsefalse0507 - Disclosure - Investments in Marketable Securities and Other Investments (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_MarketableSecuritiesAndOtherInvestmentsTablesAbst
ractwpifalsenadurationMarketable Securities and Other Investments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringMarketable Securities and Other Investments.falsefalse3false0wpi_MarketableSecuritiesAndOtherInvestmentsTextBlockwpifalsenadurationMarketable Securities and Other Investments.falsefalsefalse
falsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note7_table1 - wpi:MarketableSecuritiesAndOtherInvestmentsTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="84%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
one year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
two years
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments and other assets:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
63.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cost method and other long-term investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
21.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total investments and other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
84.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
114.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringMarketable Securities and Other Investments.No authoritative reference available.falsefalse4false0wpi_AvailableForSaleSecuritiesAmortizedCostFairValueAndUnrealizedGainsLossesTextBlockwpifalsenadurationAvailable for Sale Securities Amortized Cost Fair Value and Unrealized Gains Losses.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -
- ->
<!-- Begin Block Tagged Note Table: wpi-20101231_note7_table2 - wpi:AvailableForSaleSecuritiesAmortizedCostFairValueAndUnrealizedGainsLossesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table provides a summary of the fair value and
unrealized gains (losses) related to Watson’s
<font style="white-space: nowrap">available-for-sale</font>
securities (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2010</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2009</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringAvailable for Sale Securities Amortized Cost Fair Value and Unrealized Gains Losses.No authoritative reference available.falsefalse13Investments in Marketable Securities and Other Investments (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
21
R11.xml
IDEA: Other Income
2.2.0.25falsefalse0205 - Disclosure - Other Incometruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_NonoperatingIncomeExpenseAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsef
alsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 5 - us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 5 —
Other Income</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other income consisted of the following (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Gain (loss) on sale of securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings on equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loss on early extinguishment of debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
19.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In March 2010, we completed the sale of our outstanding shares
of Scinopharm for net proceeds of approximately
$94.0 million. The earnings on equity investments for the
year ended December 31, 2009 were higher than the current
year due to the sale of our outstanding shares of Scinopharm
during the first quarter of 2010.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDiscloses other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that should be disclosed in this note, or in the income statement, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 3, 6, 7, 9
-Article 5
falsefalse12Other IncomeUnKnownUnKnownUnKnownUnKnownfalsetrueXML
22
R10.xml
IDEA: Acquisitions and Divestitures
2.2.0.25falsefalse0204 - Disclosure - Acquisitions and Divestiturestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_AcquisitionsAndDivestituresAbstractwpifalsenadurationAcquisitions and Divestitures Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAcquisitions and Divestitures Abstract.falsefalse3false0wpi_AcquisitionsAndDivestituresTextBlockwpifalsenadurationAcquisitions And Divestitures Text Block.falsefalsefalsefalse
falsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 4 - wpi:AcquisitionsAndDivestituresTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 4 —
Acquisitions and Divestitures</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of Arrow Group</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On the Acquisition Date, Watson acquired all the outstanding
equity of privately held Arrow Group for cash, stock and certain
contingent consideration (the “Arrow Acquisition”). In
accordance with the terms of the share purchase agreement dated
June 16, 2009, as amended on November 26, 2009
(together the “Acquisition Agreement”), the Company
acquired all the outstanding equity of the Arrow Group for the
following consideration:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
The payment of cash and the assumption of certain liabilities
totaling $1.05 billion;
</td>
</tr>
<tr style="line-height: 6pt; font-size: 1pt">
<td> </td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
Approximately 16.9 million restricted shares of Common
Stock of Watson (the “Restricted Common Stock”);
</td>
</tr>
</table>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
200,000 shares of newly designated mandatorily redeemable,
non-voting Series A Preferred Stock of Watson (the
“Mandatorily Redeemable Preferred Stock”) placed in
escrow for the benefit of the former shareholders of the Arrow
Group (the “Arrow Selling Shareholders”); and
</td>
</tr>
<tr style="line-height: 6pt; font-size: 1pt">
<td> </td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<td> </td>
<td> • 
</td>
<td align="left">
Certain contingent consideration based on the after-tax gross
profits on sales of the authorized generic version of
Lipitor<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(atorvastatin) in the U.S. calculated and payable as
described in the Acquisition Agreement. For additional
information on the contingent payment, refer to
“NOTE 10 — Other Long-Term Liabilities.”
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table presents a summary of the purchase price
consideration for the Arrow Acquisition (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,050.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Restricted Common Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
636.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
150.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value estimate of atorvastatin contingent payment
consideration (refer to “NOTE 10 — Other
Long-Term Liabilities.”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Fair
Value of Consideration Transferred</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with existing U.S. GAAP, the fair value of
Restricted Common Stock issued as part of the consideration
transferred was measured on the Acquisition Date at the
then-current market price of $37.55 per share for
approximately $636.2 million.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Mandatorily Redeemable Preferred Stock was issued in the form of
zero-coupon, non-convertible preferred stock which will be
redeemable in the amount of $200.0 million, less the amount
of any indemnity payments, three years after the Acquisition
Date. The fair value of the Mandatorily Redeemable Preferred
Stock at Acquisition Date was estimated by the Company to be
$150.0 million, based on the terms they were issued under
and the cost of the Company’s other fixed rate borrowings
and is presented within long-term debt at its current fair value
at December 31, 2010 of $166.4 million. For additional
information on the Mandatorily Redeemable Preferred Stock, refer
to “NOTE 9 — Long-Term Debt.”
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company determined the acquisition date fair value of the
contingent consideration obligation based on a
probability-weighted income approach derived from atorvastatin
revenue estimates and post-tax gross profit levels and a
probability assessment with respect to the likelihood of
achieving the various earn-out criteria. The fair value
measurement is based on significant inputs not observable in the
market and thus represents a Level 3 measurement as defined
in fair value measurement accounting. The resultant
probability-weighted cash flows were discounted using an
effective annual interest rate of 10.4%. At each reporting date,
the Company adjusts the contingent consideration obligation to
estimated fair value and records changes in fair value as
expense in our consolidated statement of operations. Changes in
the fair value of the contingent consideration obligations may
result from changes in discount periods and rates, changes in
the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of
achieving the various earn-out criteria. As of December 31,
2010 the range of outcomes and the assumptions used to develop
the estimates have not changed significantly from those used at
Acquisition Date. Accretion expense related to the increase in
the net present value of the contingent liability is included in
interest expense for the period.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Divestiture
of Certain Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In order to obtain regulatory approval under the
<font style="white-space: nowrap">Hart-Scott-Rodino</font>
Antitrust Improvements Act of 1976, as amended (the “HSR
Act”), in connection with the Arrow Acquisition, Watson and
the Arrow Group were required to divest certain assets. In
conjunction with the closing, Watson sold its Abbreviated New
Drug Application (“ANDA”) for Cabergoline, the generic
equivalent to Dostinex, to Impax Laboratories, Inc. The Arrow
Group sold its pending ANDA for Dronabinol, a generic equivalent
to Marinol, to Impax Laboratories, Inc.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Resolution Chemicals Ltd., the subsidiary of the Arrow Group
that manufactures the Dronabinol active pharmaceutical
ingredient, was divested in accordance with the terms of the
consent order under the HSR Act immediately prior to the closing.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Allocation
of Consideration Transferred</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The transaction has been accounted for using the purchase method
of accounting under existing U.S. GAAP. The purchase method
under existing U.S. GAAP requires, among other things, that
assets acquired and liabilities assumed in a business purchase
combination be recognized at their fair values as of the
acquisition date and that IPR&D be recorded at fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. In addition, any common stock
consideration transferred is measured at acquisition date at the
then current market price.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table summarizes the fair values of the
tangible & identifiable intangible assets acquired and
liabilities assumed at Acquisition Date, with the excess being
allocated to goodwill. During the quarter ended June 30,
2010, management completed its allocation of intellectual
properties by tax jurisdiction and the resulting deferred tax
liabilities by legal entity, its evaluation of uncertain tax
positions and related deferred tax assets and liabilities.
These
adjustments are reflected in the values presented below and in
our revised December 31, 2009 balance sheet (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash and cash equivalents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Accounts receivable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Inventories
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
187.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other current assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
174.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Property, plant & equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
518.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
632.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current liabilties
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(306.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax and other tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(303.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Inventories</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The fair value of inventories acquired included a
<font style="white-space: nowrap">step-up</font> in
the value of inventories of approximately $26.0 million.
Approximately $14.2 million was amortized to cost of sales
during 2009 and the remaining $11.8 million was amortized
to cost of sales in the first quarter of 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Other
Current Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At Acquisition Date, included in other current assets was
$90.0 million related to the fair value of amounts due from
Sepracor, Inc. (“Sepracor”) prior to the end of 2010
(the “Sepracor Receivable”) for the transfer of
certain product rights and technology from the Arrow Group. The
entire amount due under the Sepracor Receivable was received by
December 31, 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">IPR&D
and Intangible Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the Acquisition Date, had
not established technological feasibility and had no alternative
future use. The IPR&D intangible assets are capitalized and
accounted for as indefinite-lived intangible assets and will be
subject to impairment testing until completion or abandonment of
the projects. Upon successful completion of each project and
launch of the product, Watson will make a separate determination
of useful life of the IPR&D intangible and amortization
will be recorded as an expense over the estimated useful life.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The fair value of the IPR&D and identifiable intangible
assets was determined primarily using the “income
approach,” which is a valuation technique that provides an
estimate of the fair value of an asset based on market
participant expectations of the cash flows an asset would
generate over its remaining useful life. Some of the more
significant assumptions inherent in the development of the
identifiable intangible assets valuations, from the perspective
of a market participant, include the estimated net cash flows
for each year for each project or product (including net
revenues, cost of sales, research and development costs, selling
and marketing costs and working capital/asset contributory asset
charges), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each asset’s life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The discount rate used to arrive at the present value
of IPR&D projects as of the Acquisition Date was
approximately 10.4% to reflect the internal rate of return and
incremental commercial uncertainty in the projections as the
products have not yet received regulatory approval. The major
risks and uncertainties associated with the timely and
successful completion of the IPR&D projects include legal
risk and regulatory risk. No assurances can be given that the
underlying assumptions used to prepare the discounted cash flow
analysis will not change or the timely completion of each
project to commercial success will occur. For these and other
reasons, actual results may vary significantly from estimated
results.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Intangible assets represent the Arrow Group’s CMP and have
an estimated weighted average useful life of five years.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Goodwill
Allocation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Among the primary reasons the Company entered into the Arrow
Acquisition and factors that contributed to a purchase price
allocation resulting in the recognition of goodwill were a
history of operating margins and profitability, a strong
R&D department and several first-to file opportunities,
expanded commercial footprint on a global basis and key pipeline
additions, including atorvastatin and budesonide which will
enable Watson to expand its product offerings and offer its
customers a greater breadth of product offerings. The goodwill
recognized from the Arrow Acquisition is not deductible for tax
purposes. All goodwill from the Arrow Acquisition was assigned
to the Global Generics segment.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Long-Term
Deferred Tax Liabilities and Other Tax Liabilities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Long-term deferred tax liabilities and other tax liabilities
reflects a deferred income tax liability representing the impact
of purchase accounting adjustments for the inventory fair value
<font style="white-space: nowrap">step-up,</font>
property, plant and equipment fair value adjustment,
contingencies adjustment and identifiable IPR&D and
intangible assets fair value adjustment. This determination of
deferred tax liabilities was based on the excess book basis over
the tax basis resulting from the above fair value adjustments
using the statutory tax rate for each country these fair value
adjustments were assigned.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition-Related
Expenses</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Included in general and administrative expenses in the
consolidated statement of operations for the year ended
December 31, 2009 were pretax charges totaling
$16.6 million for advisory, legal and regulatory costs in
connection with the Arrow Acquisition.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Unaudited
Pro Forma Results of Operations</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table presents the unaudited pro forma operating
results for the Company, assuming the Arrow Acquisition had
occurred as of the beginning of each period presented. The
unaudited pro forma results reflect certain adjustments related
to the acquisition, such as increased depreciation and
amortization expense on the fair valuation of assets acquired,
the impact of acquisition financing in place at
December 31, 2009 and the related tax effects. The pro
forma results do not include any anticipated synergies which may
be achievable subsequent to the Acquisition Date. Accordingly,
such pro forma amounts are not necessarily indicative of the
results that actually would have occurred had the acquisition
been completed on the dates indicated, nor are they indicative
of the future operating results of the combined company.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="3%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="3%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Year Ended December 31,</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>(In millions, except<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>per share amounts)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,261.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,170.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
281.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings per share:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.99
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.35
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.98
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.34
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of
Crinone<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and
Prochieve<sup style="font-size: 85%; vertical-align: text-top">®</sup>
Assets from Columbia Laboratories, Inc.
(“Columbia”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On July 2, 2010, the Company completed the acquisition of
the U.S. rights to Columbia products
Crinone<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and
Prochieve<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and acquired 11.2 million shares of Columbia’s common
stock, representing approximately a 13% ownership share, for
initial cash consideration of $62.0 million and certain
contingent consideration of up to an additional
$45.5 million based upon the successful completion of
certain milestones and regulatory approvals.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The transaction was accounted for using the purchase method of
accounting under existing U.S. GAAP with assets acquired
and liabilities assumed recorded at their fair values as of the
acquisition date. The purchase price for the Columbia
acquisition was allocated to tangible and identifiable
intangible assets
acquired and liabilities assumed based on their estimated fair
values at the acquisition date as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="92%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
62.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pro forma results of operations have not been presented because
the effect of the acquisition was not material.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Acquisition
of Equity Interest in Moksha8 Pharmaceuticals, Inc.
(“Moksha8”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On October 4, 2010, the Company entered into an agreement
with Moksha8 to expand into markets in Brazil and Mexico. The
Company made an initial investment of $30.0 million in cash
in Moksha8 in exchange for an approximate 22% ownership share in
Moksha8. The Company is also committed to invest an additional
$20.0 million in Moksha8 contingent upon the successful
execution by Moksha8 of additional third-party product
acquisitions over the next year which will increase our
ownership share to approximately 31%.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Sale
of Scinopharm Taiwan Ltd. (“Scinopharm”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On March 24, 2010, all closing conditions were satisfied in
our agreement with Uni-President Enterprises Corporation to sell
our outstanding shares of Scinopharm. Under the terms of the
stock purchase agreement, we sold our entire holdings of common
shares for net proceeds of approximately $94.0 million
resulting in a gain on sale of securities in the amount of
$23.4 million.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringAcquisitions And Divestitures Text Block.No authoritative reference available.falsefalse12Acquisitions and DivestituresUnKnownUnKnownUnKnown
UnKnownfalsetrueXML
23
R60.xml
IDEA: Stockholders' Equity (Details Textual)
2.2.0.25truefalse06122 - Disclosure - Stockholders' Equity (Details Textual)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDfalsefalse12/2/2009
USD ($)
USD ($) / shares
$BalanceAsOf_02Dec2009http://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalsefalsefalse12/31/1992
BalanceAsOf_31Dec1992http://www.sec.gov/CIK0000884629instant1992-12-31T00:00:000001-01-01T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli02true0wpi_AdditionalStockholdersEquityTextualsAbstractwpifalsenadurationAdditional Stockholders Equity Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Stockholders Equity Textuals Abstract.falsefalse3false0wpi_RestrictedStockAwardsRestrictionsEliminatedPeriodwpifalsenadurationRestricted stock awards restrictions eliminated period.falsefalsefalsefalse<
IsTuple>falsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00one- to four-yearfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringRestricted stock awards restrictions eliminated period.No authoritative reference available.falsefalse4true0wpi_StockholdersEquityTextualsAbstractwpifalsenadurationStockholders Equity.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefals
efalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringStockholders Equity.falsefalse5false0us-gaap_PreferredStockSharesAuthorizedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse25000002.5falsefalsefalsefalsefalse2truefalsefalse25000002.5falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse25000002.5falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
falsefalse6false0us-gaap_RedeemablePreferredStockSharesIssuedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefa
lsefalse00falsefalsefalsefalsefalse4truefalsefalse2000000.2falsefalsefalsefalsefalse5falsef
alsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of redeemable preferred shares that have been sold (or granted) to the entity's shareholders. Shares issued includes shares outstanding and shares held in treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 28
-Article 5
falsefalse7false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse52000005.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse<
/Cell>3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe maximum number of shares originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the share-based compensation plan. As stock options and equity instruments other than options are awarded to participants, the shares remain authorized and become reserved fo
r issuance under outstanding awards (not necessarily vested).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph a
falsefalse8false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00Over three to five yearsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:durationStringItemTypenormalizedstringDescription of the period of time over which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, which may be expressed in a variety of ways (for examp
le, in years, month and year).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph a
falsefalse9false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationDatingus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00ten yearsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:dateStringItemTypenormalizedstringReflects the dating as to when the share-based award expires as specified in the award agreement, which may be presented in a variety of ways (for example, year, month and year, day, month and year, quarter of a year).Reference 1: http://www.xbrl.org/2003/role/presentationRe
f
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph a
falsefalse10false0wpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnrecognizedCompensationExpenseNetOfForfeitureswpifalsedebitinstantShare Based Compensation Arrangement By Share Based Payment Award Options Unrecognized Compensation Expense Net Of...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse5000000.5falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryShare Based Compensation Arrangement By Share Based Payment Award Options Unrecognized Compensation Expense Net Of Forfeitures.No authoritative reference available.falsefalse11false0wpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnrecognizedCompensationExpenseRemainingWeightedAveragePeriodForRecognitionwpifalsenainstantShare Based Compensation Arrangement By Share Based Payment Award Options Unrecognized Compensation Expense Remaining...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1.11.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalShare Based Compensation Arrangement By Share Based Payment Award Options Unrecognized Compensation Expense Remaining Weighted Average Period For Recognition.No authoritative reference available.falsefalse12false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValueus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1840000018.4falsefalsefalsefalsefalse2truefalsefalse74000007.4falsefalsef
alsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalse<
/DisplayDateInUSFormat>falsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph c(2)
falsefalse13false0us-gaap_TreasuryStockSharesAcquiredus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1true
falsefalse1000000.1falsefalsefalsefalsefalse2truefalsefalse1000000.1falsefalsefalsefalsefalse3false<
IsRatio>falsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares that have been repurchased during the period and are being held in treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
falsefalse14false0us-gaap_PaymentsForRepurchaseOfCommonStockus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefal
sefalse63000006.3falsefalsefalsefalsefalse2truefalsefalse36000003.6falsefalsefalsefalsefalse3truefalsefalse9000000.9falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5false<
IsRatio>falsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow to reacquire common stock during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 20
-Subparagraph a
falsefalse15false0us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTaxus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse92000009.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefals
e3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAccumulated appreciation or loss, net of tax, in value of the total of unsold securities at the end of an accounting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 26
falsefalse16false0us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTaxus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsever
boselabel1truefalsefalse-11700000-11.7falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefals
efalse5falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAccumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency
translation gains (losses).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 12, 13
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 31
-Subparagraph a
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 18, 19, 22, 23, 24, 25, 26
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
falsefalse17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/stockholdersequitydetailstextual
1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsetruefalse{us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis} : Director [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Director_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseDirector [Member]us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_DirectorMemberus-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxisexplicitMember<
/MCU>OthernaNo definition available.No authoritative reference available.falsefalse18true0wpi_AdditionalStockholdersEquityTextualsAbstractwpifalsenadurationAdditional Stockholders Equity Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Stockholders Equity
Textuals Abstract.falsefalse19false0wpi_RestrictedStockAwardsRestrictionsEliminatedPeriodwpifalsenadurationRestricted stock awards restrictions eliminated period.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00After one yearfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringRestricted stock awards restrictions eliminated period.No authoritative reference available.falsefalse21false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/stockholdersequitydetailstextual1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse7falsefalsetruefalse{us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis} : Employees [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Employees_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseEmployees [Member]us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_EmployeesMemberus-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxisexplicitMember
MCU>OthernaNo definition available.No authoritative reference available.falsefalse22true0wpi_AdditionalStockholdersEquityTextualsAbstractwpifalsenadurationAdditional Stockholders Equity Textuals Abstract.falsefalsefalsefalsefalse<
IsEquityPrevioslyReportedAsRow>falsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Stockholders Equity
Textuals Abstract.falsefalse23false0wpi_RestrictedStockAwardsRestrictionsEliminatedPeriodwpifalsenadurationRestricted stock awards restrictions eliminated period.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00two- to four-yearfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalse
false3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringRestricted stock awards restrictions eliminated period.No authoritative reference available.falsefalse521Stockholders' Equity (Details Textual) (USD $)HundredThousandsHundredThousandsUnKnownUnKnowntruetrueXML
24
R30.xml
IDEA: Goodwill Product Rights and Other Intangibles (Tables)
2.2.0.25falsefalse0508 - Disclosure - Goodwill Product Rights and Other Intangibles (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_GoodwillProductRightsAndOtherIntangiblesTablesAbs
tractwpifalsenadurationGoodwill Product Rights And Other Intangibles.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringGoodwill Product Rights And Other Intangibles.falsefalse3false0us-gaap_ScheduleOfGoodwillTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table1 - us-gaap:ScheduleOfGoodwillTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill for the Company’s reporting units consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Brands segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
371.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
348.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Generics segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,070.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,066.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Distribution segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,528.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,501.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThe carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill during the period in total and for each reportable segment. At least annually, an Entity must evaluate its goodwill for impairment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 47
falsefalse4false0us-gaap_ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false
falsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table2 - us-gaap:ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with definite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product rights and other related intangibles
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,049.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,855.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Core technology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Customer relationships
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,151.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,957.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less accumulated amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,211.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,031.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDisclosure of amortizable intangibles assets, in total and by major class, including the gross carrying amount and accumulated amortization. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a
falsefalse5false0us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsByMajorClassTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table3 - us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsByMajorClassTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
940.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
926.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with indefinite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
IPR&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
615.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade Name
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
691.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
787.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total product rights and related intangibles, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,632.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,713.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDisclosure of the carrying value of intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph b
falsefalse6false0wpi_FiniteLivedIntangibleAssetsFutureAmortizationExpenseTextBlockwpifalsenadurationFinite Lived Intangible Assets Future Amortization Expense.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note8_table4 - wpi:FiniteLivedIntangibleAssetsFutureAmortizationExpenseTextBlock-->
<div align="center" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Assuming no additions, disposals or adjustments are made to the
carrying values
<font style="white-space: nowrap">and/or</font>
useful lives of the assets, annual amortization expense on
product rights and related over the next five years is estimated
to be as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="93%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2011
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
270.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2012
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
417.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2013
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
311.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2014
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
299.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2015
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
138.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringFinite Lived Intangible Assets Future Amortization Expense.No authoritative reference available.falsefalse15Goodwill Product Rights and Other Intangibles (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
25
R54.xml
IDEA: Other Long-Term Liabilities (Details)
2.2.0.25truefalse0610 - Disclosure - Other Long-Term Liabilities (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse7/2/2010
USD ($)
$BalanceAsOf_02Jul2010http://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3falsefalseUSDfalsefalse12/31/2009
USD ($)
$BalanceAsOf_31Dec2009http://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$4falsefalseUSDfalsefalse12/2/2009
USD ($)
USD ($) / shares
$BalanceAsOf_02Dec2009http://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_OtherLiabilitiesNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_OtherNoncurrentLiabilitiesus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1350000013.5falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse77000007.7falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryObligations not otherwise itemized or previously categorized that
are due beyond one year (or operating cycle, if longer) from the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5
truefalse4false0wpi_OtherLongTermLiabilitiesGrosswpifalsecreditinstantOther long-term liabilities, gross.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse
false212000000212.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse118700000118.7falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryOther long-term liabilities, gross.No authoritative reference available.falsefalse5false0wpi_CurrentPortionOfOtherLongTermLiabilitieswpifalsedebitinstantCurrent Portion of Other long term liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse2890000028.9falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCurrent Portion of Other long term liabilities.No authoritative reference available.truefalse6false0us-gaap_OtherLiabilitiesNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse183100000183.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse118700000118.7falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet due to materiality considerations. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.o
rg/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5
truefalse7true0wpi_OtherLongTermLiabilitiesTextualsAbstractwpifalsenadurationOther long-term liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefal
sefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOther long-term liabilities.falsefalse8false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse10500000001050.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse9false0us-gaap_BusinessAcquisitionContingentConsiderationAtFairValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse198500000198.5falsefalsefalsefalsefalse2truefalsefalse6480000064.8falsefalsefalsefalsefalse3true<
/IsNumeric>falsefalse111000000111.0falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
falsefalse10true0wpi_OtherLongTermLiabilitiesAdditionalTextualsAbstractwpifalsenadurationOther Long Term Liabilities Additional Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOther Long Term Liabilities Additional Textuals Abstract.falsefalse11false0wpi_ConditionOneForDeterminationOfContingentPaymentAmountswpifalsenadurationCondition One for determination of contingent payment amounts.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse0050% of the post-tax gross profitsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringCondition One for determination of contingent payment amounts.No authoritative reference available.falsefalse12false0wpi_ConditionTwoDeterminationOfContingentPaymentAmountswpifalsenadurationCondition Two determination of contingent payment amounts.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00Either 85% of the post-tax gross profits or 15% of the
post-tax gross profitsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringConditi
on Two determination of contingent payment amounts.No authoritative reference available.falsefalse13false0us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPaymentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefals
efalsefalsefalseverboselabel1truefalsefalse250000000250.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of potential cash payments that could result from the contingent consideration arrangement.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
falsefalse14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/otherlongtermliabilitiesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Arrow Business Acquisition [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Arrow_Business_Acquisition_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseArrow Business Acquisition [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ArrowBusinessAcquisitionMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.o
rg/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Arrow Business Acquisition [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Arrow_Business_Acquisition_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseArrow Business Acquisition [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ArrowBusinessAcquisitionMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.o
rg/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse16true0wpi_OtherLongTermLiabilitiesTextualsAbstractwpifalsenadur
ationOther long-term liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOther long-term liabilities.falsefalse17false0us-gaap_Busine
ssAcquisitionContingentConsiderationAtFairValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse123100000123.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse111000000111.0falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair value, as of the acquisition date, of potential payments under the conti
ngent consideration arrangement including cash and shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
falsefalse19false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/otherlongtermliabilitiesdetails1false
falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse
false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Atorvastatin contingent consideration liability [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Atorvastatin_Contingent_Consideration_Liability_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseAtorvastatin contingent consideration liability [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AtorvastatinContingentConsiderationLiabilityMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStanda
rdhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Atorvastatin contingent consideration liability [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Atorvastatin_Contingent_Consideration_Liability_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseAtorvastatin contingent consideration liability [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AtorvastatinContingentConsiderationLiabilityMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStanda
rdhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse20true0us-gaap_OtherLiabilitiesNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse21false0us-gaap_OtherNoncurrentLiabilitiesus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse123100000123.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse111000000111.0falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryObligations not otherwise ite
mized or previously categorized that are due beyond one year (or operating cycle, if longer) from the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5
truefalse24false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/otherlongtermliabilitiesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse
false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse9falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Columbia contingent consideration liability [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Columbia_Contingent_Consideration_Liability_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseColumbia contingent consideration liability [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ColumbiaContingentConsiderationLiabilityMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Columbia contingent consideration liability [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Columbia_Contingent_Consideration_Liability_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseColumbia contingent consideration liability [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ColumbiaContingentConsiderationLiabilityMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse25true0us-gaap_OtherLiabilitiesNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefals
efalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse26false0us-gaap_OtherNoncurrentLiabilitiesus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse7540000075.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryObligations not otherwise itemized or previously categorized th
at are due beyond one year (or operating cycle, if longer) from the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5
truefalse27true0wpi_OtherLongTermLiabilitiesTextualsAbstractwpifalsenadurationOther long-term liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefal
sefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOther long-term liabilities.falsefalse28false0us-gaap_BusinessAcquisitionContingentConsiderationAtFairValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse4650000046.5falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
falsefalse29false0wpi_FairValueOfContingentLiabilityWhichExcludesAccountsPayableAndCurrentLiabilitieswpifalsecreditinstantFair Value of Contingent Liability Which Excludes Accounts Payable and Current Liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2890000028.9falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair Value of Contingent Liability Which Excludes Accounts Payable and Current Liabilities.No authoritative reference available.falsefalse31false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/otherlongtermliabilitiesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse0<
RoundedNumericAmount>0falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse11falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : U.S.Rights Columbia Products [Member]
7/2/2010
USD ($)
$BalanceAsOf_02Jul2010_United_States_Rights_Columbia_Products_Memberhttp://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00falsefalseU.S.Rights Columbia Products [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UnitedStatesRightsColumbiaProductsMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse33true0wpi_OtherLongTermLiabilitiesTextualsAbstractwpifalsenadurationOther long-term liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOther long-term liabilities.falsefalse34false0<
ElementName>us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse6200000062.0falsetruefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse427Other Long-Term Liabilities (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
26
R8.xml
IDEA: Summary of Significant Accounting Policies
2.2.0.25falsefalse0202 - Disclosure - Summary of Significant Accounting Policiestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_SummaryOfSignificantAccountingPoliciesAbstractwpifalsenadurationSummary of Significant Accounting Policies.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSummary of Significant Accounting Policies.falsefalse3false0us-gaap_SignificantAccountingPoliciesTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock-->
<div align="left" style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 2 —
Summary of Significant Accounting Policies</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Basis
of Presentation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s consolidated financial statements are
prepared in accordance with accounting principles generally
accepted in the U.S. (“GAAP”). The consolidated
financial statements include the accounts of wholly-owned
subsidiaries, after elimination of intercompany accounts and
transactions. Certain prior year amounts have been reclassified
to conform to the current-year presentation.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Our consolidated financial statements include the financial
results of the Arrow Group subsequent to the Acquisition Date.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Use of
Estimates</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Management is required to make certain estimates and assumptions
in order to prepare consolidated financial statements in
conformity with GAAP. Such estimates and assumptions affect the
reported amounts of assets, liabilities, revenues and expenses
and disclosure of contingent assets and liabilities in the
consolidated financial statements and accompanying notes. The
Company’s most significant estimates relate to the
determination of sales returns and allowances (“SRA”)
for accounts receivable and accrued liabilities, valuation of
inventory balances, the determination of useful lives for
intangible assets and the assessment of expected cash flows used
in evaluating goodwill and other long-lived assets for
impairment. The estimation process required to prepare the
Company’s consolidated financial statements requires
assumptions to be made about future events and conditions, and
as such, is inherently subjective and uncertain. Watson’s
actual results could differ materially from those estimates.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Foreign
Currency Translation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For most of the Company’s international operations, the
local currency has been determined to be the functional
currency. We translate functional currency assets and
liabilities to their U.S. dollar equivalents at rates in
effect at the balance sheet date and record these translation
adjustments as a component of accumulated other comprehensive
income (loss) within stockholders’ equity in the
consolidated balance sheets. We translate functional currency
statement of income amounts to their U.S. dollar
equivalents at the average rates for the period. The effects of
converting non-functional currency assets and liabilities into
the functional currency are recorded as general and
administrative expenses in the consolidated statements of
operations.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Cash
and Cash Equivalents</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company considers cash and cash equivalents to include cash
in banks, commercial paper and deposits with financial
institutions that can be liquidated without prior notice or
penalty. The Company considers all highly liquid investments
with an original maturity of three months or less to be cash
equivalents.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Fair
Value of Other Financial Instruments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s financial instruments consist primarily of
cash and cash equivalents, marketable securities, accounts and
other receivables, investments, trade accounts payable, our
$450.0 million aggregate principal amount of
5.000% notes due August 14, 2014 (the “2014
Notes”) and $400.0 million aggregate principal amount
of 6.125% notes due August 14, 2019 (the “2019
Notes”) (together the “Senior Notes”) and our
Senior Credit Facility with Canadian Imperial Bank of Commerce,
acting through its New York agency, as administrative agent (the
“2006 Credit Facility”). The carrying amounts of cash
and cash equivalents, marketable securities, accounts and other
receivables and trade accounts payable are representative of
their respective fair values due to their relatively short
maturities. The fair values of investments in companies that are
publicly traded are based on quoted market prices. The Company
estimates the fair value of its fixed rate long-term obligations
based on quoted market rates of interest and maturity schedules
for similar issues. At December 31, 2010, the fair value of
our Senior Notes was approximately $71.0 million greater
than the carrying value.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Inventories</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Inventories consist of finished goods held for sale and
distribution, raw materials and work in process. Included in
inventory at December 31, 2010 and 2009 is approximately
$4.6 million and $14.1 million, respectively, of
inventory that is pending approval by the U.S. Food and
Drug Administration (“FDA”), by other regulatory
agencies or has not been launched due to contractual
restrictions. This inventory consists of generic pharmaceutical
products that are capitalized only when the bioequivalence of
the product is demonstrated or the product has already received
regulatory approval and is awaiting a contractual triggering
event to enter the marketplace. Inventories are stated at the
lower of cost
<font style="white-space: nowrap">(first-in,</font>
first-out method) or market (net realizable value). The Company
writes down inventories to net realizable value based on
forecasted demand and market conditions, which may differ from
actual results.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Property
and Equipment</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Property and equipment are stated at cost, less accumulated
depreciation. Major renewals and improvements are capitalized,
while routine maintenance and repairs are expensed as incurred.
Costs associated with internally developed software are
accounted for in accordance with the guidance for the treatment
of costs associated with computer software development that
defines those costs to be capitalized and those to be expensed.
The Company capitalizes interest on qualified construction
projects. At the time property and equipment are retired from
service, the cost and accumulated depreciation is removed from
the respective accounts and the related gains or losses are
reflected in income.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Depreciation expense is computed principally on the
straight-line method, over estimated useful lives of the related
assets. The following table provides the range of estimated
useful lives used for each asset type:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="88%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="10%"> </td><!-- colindex=02 type=maindata -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Computer software / hardware
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
3-7 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-18 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Buildings, improvements, leasehold improvements and other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-40 years
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company assesses property and equipment for impairment
whenever events or changes in circumstances indicate that an
asset’s carrying amount may not be recoverable.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s equity investments are accounted for under
the equity method when the Company can exert significant
influence and ownership does not exceed 50%. Watson accounts for
its joint ventures using the equity method. The Company records
equity method investments at cost and adjust for the appropriate
share of investee net earnings or losses. Investments in which
the Company owns less than a 20% interest and cannot exert
significant influence are accounted for using the cost method if
the fair value of such investments is not readily determinable.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Marketable
Securities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s marketable securities consist of
U.S. Treasury and agency securities and equity securities
of publicly-held companies. The Company’s marketable
securities are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value, based upon quoted market prices.
Unrealized temporary adjustments to fair value are included on
the balance sheet in a separate component of stockholders’
equity as unrealized gains and losses and reported as a
component of accumulated other comprehensive income. No gains or
losses on marketable securities are realized until shares are
sold or a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary.</font>
If a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary,</font>
an impairment charge is recorded and a new cost basis in the
investment is established.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Goodwill
and Intangible Assets with Indefinite-Lives</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
We test goodwill and intangible assets with indefinite-lives for
impairment annually at the end of the second quarter by
comparing the fair value of each of the Company’s reporting
units to the respective carrying value of the reporting units.
Additionally, we may perform tests between annual tests if an
event occurs or circumstances change that could potentially
reduce the fair value of a reporting unit below its carrying
amount. The Company’s reporting units have been identified
by Watson as Global Generics, Global Brands and Distribution.
The carrying value of each reporting unit is determined by
assigning the assets and liabilities, including the existing
goodwill and intangible assets, to those reporting units.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill is considered impaired if the carrying amount of the
net assets exceeds the fair value of the reporting unit.
Impairment, if any, would be recorded in operating income and
this could result in a material reduction in net income and
earnings per share. During the second quarter of 2010, the
Company performed its annual impairment assessment of goodwill,
acquired in-process research and development
(“IPR&D”) intangibles and trade name intangible
assets with indefinite-lives and determined there was no
impairment. Due to changes in market conditions in certain
international locations, the Company performed an off-cycle
impairment review in the fourth quarter of 2010 and recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. (Refer to
“Note 8 — Goodwill, Product Rights and Other
Intangibles” for additional details.)
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Included in intangible assets with indefinite-lives are trade
name intangible assets acquired prior to January 1, 2009
and IPR&D intangibles acquired after January 1, 2009.
Upon adoption of Financial Accounting Standards Board
(“FASB”) issued authoritative guidance on
January 1, 2009, using the purchase method of accounting,
IPR&D intangible assets are recognized at their fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. Prior to January 1,
2009, amounts allocated to IPR&D intangible assets were
expensed at the date of acquisition.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the date acquired,
represent the right to develop, use, sell
<font style="white-space: nowrap">and/or</font> offer
for sale a product or other intellectual property that we have
acquired with respect to products
<font style="white-space: nowrap">and/or</font>
processes that have not been completed or approved. The
IPR&D intangible assets are subject to impairment testing
until completion or abandonment of each project. Impairment
testing requires the development of significant estimates and
assumptions involving the determination of estimated net cash
flows for each year for each project or product (including net
revenues, cost of sales, R&D costs, selling and marketing
costs), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each asset’s life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The major risks and uncertainties associated with the
timely and successful completion of the IPR&D projects
include legal risk and regulatory risk. Changes in these
assumptions or uncertainties could result in future impairment
charges. No assurances can be given that the underlying
assumptions used to prepare the discounted cash flow analysis
will not change or the timely completion of each project to
commercial success will occur. For these and other reasons,
actual results may vary significantly from estimated results.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon successful completion of each project and launch of the
product, Watson will make a separate determination of the useful
life of the intangible, transfer the amount to currently
marketed products (“CMP”) and amortization expense
will be recorded over the estimated useful life.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Contingent
Consideration</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Subsequent to January 1, 2009, contingent consideration is
recorded at the acquisition date estimated fair value of the
contingent payment for all acquisitions. The fair value of the
contingent consideration is remeasured at each reporting period
with any adjustments in fair value included in our consolidated
statement of operations.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Revenue
Recognition</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Revenue is generally realized or realizable and earned when
persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the seller’s price
to the buyer is fixed or determinable, and collectability is
reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to
the customer, which is typically upon delivery to the customer.
Revenues recognized from research, development and licensing
agreements (including milestone receipts) are recorded on the
“contingency-adjusted performance model” which
requires deferral of revenue until such time as contract
milestone requirements, as specified in the individual
agreements, have been met. Under this model, revenue related to
each payment is recognized over the entire contract performance
period, starting with the contract’s commencement, but not
prior to earning
<font style="white-space: nowrap">and/or</font>
receiving the milestone amount (i.e., removal of any
contingency). The amount of revenue recognized is based on the
ratio of costs incurred to date to total estimated cost to be
incurred. Royalty and commission revenue is recognized in
accordance with the terms of their respective contractual
agreements when collectability is reasonably assured and revenue
can be reasonably measured.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Provisions
for Sales Returns and Allowances</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As is customary in the pharmaceutical industry, the
Company’s gross product sales are subject to a variety of
deductions in arriving at reported net product sales. When the
Company recognizes revenue from the sale of its products, an
estimate of SRA is recorded which reduces product sales.
Accounts receivable
<font style="white-space: nowrap">and/or</font>
accrued liabilities are also reduced
<font style="white-space: nowrap">and/or</font>
increased by the SRA amount. These adjustments include estimates
for chargebacks, rebates, cash discounts and returns and other
allowances. These provisions are estimated based on historical
payment experience, historical relationship to revenues,
estimated customer inventory levels and current contract sales
terms with direct and indirect customers. The estimation process
used to determine our SRA provision has been applied on a
consistent basis and no material adjustments have been necessary
to increase or decrease our reserves for SRA as a result of a
significant change in underlying estimates. The Company uses a
variety of methods to assess the adequacy of our SRA reserves to
ensure that our consolidated financial statements are fairly
stated. This includes periodic reviews of customer inventory
data, customer contract programs and product pricing trends to
analyze and validate the SRA reserves.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Chargebacks — </i>The provision for chargebacks is
our most significant sales allowance. A chargeback represents an
amount payable in the future to a wholesaler for the difference
between the invoice price paid to the Company by our wholesale
customer for a particular product and the negotiated contract
price that the wholesaler’s customer pays for that product.
The Company’s chargeback provision and related reserve vary
with changes in product mix, changes in customer pricing and
changes to estimated wholesaler inventories. The provision for
chargebacks also takes into account an estimate of the expected
wholesaler sell-through levels to indirect customers at contract
prices. The Company validates the chargeback accrual quarterly
through a review of the inventory reports obtained from our
largest wholesale customers. This customer inventory information
is used to verify the estimated liability for future chargeback
claims based on historical chargeback and contract rates. These
large wholesalers represent 85% — 90% of the
Company’s chargeback payments. The Company continually
monitors current pricing trends and wholesaler inventory levels
to ensure the liability for future chargebacks is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Rebates — </i>Rebates include volume related
incentives to direct and indirect customers and Medicaid rebates
based on claims from Medicaid benefit providers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Volume rebates are generally offered to customers as an
incentive to continue to carry our products and to encourage
greater product sales. These rebate programs include contracted
rebates based on customer’s purchases made during an
applicable monthly, quarterly or annual period. The provision
for rebates is estimated based on our customers’ contracted
rebate programs and our historical experience of rebates paid.
Any significant changes to our customer rebate programs are
considered in establishing our provision for rebates. The
Company continually monitors its customer rebate programs to
ensure that the liability for accrued rebates is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The provision for Medicaid rebates is based upon historical
experience of claims submitted by the various states. The
Company monitors Medicaid legislative changes to determine what
impact such legislation may have on our provision for Medicaid
rebates. Our accrual of Medicaid rebates is based on historical
payment rates and is reviewed on a quarterly basis against
actual claim data to ensure the liability is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Returns and Other Allowances — </i>Our provision
for returns and other allowances include returns, pricing
adjustments, promotional allowances and billback adjustments.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Consistent with industry practice, the company maintains a
return policy that allows our customers to return product for
credit. In accordance with our return goods policy, credit for
customer returns of product is applied against outstanding
account activity or by check. Product exchanges are not
permitted. Customer returns of product are not resalable unless
the return is due to a shipping error. Our estimate of the
provision for returns is based upon historical experience and
current trends of actual customer returns. Additionally, we
consider other factors when estimating our current period return
provision, including levels of inventory in our distribution
channel as well as significant market changes which may impact
future expected returns, and make adjustments to our current
period provision for returns when it appears product returns may
differ from our original estimates.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pricing adjustments, which include shelf stock adjustments, are
credits issued to reflect price decreases in selling prices
charged to our direct customers. Shelf stock adjustments are
based upon the amount of product
our customers have in their inventory at the time of an
<font style="white-space: nowrap">agreed-upon</font>
price reduction. The provision for shelf stock adjustments is
based upon specific terms with our direct customers and includes
estimates of existing customer inventory levels based upon their
historical purchasing patterns. The Company regularly monitors
all price changes to help evaluate our reserve balances. The
adequacy of these reserves is readily determinable as pricing
adjustments and shelf stock adjustments are negotiated and
settled on a
<font style="white-space: nowrap">customer-by-customer</font>
basis.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Promotional allowances are credits, which are issued in
connection with a product launch or as an incentive for
customers to begin carrying our product. The Company establishes
a reserve for promotional allowances based upon these
contractual terms.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Billback adjustments are credits that are issued to certain
customers who purchase directly from the Company as well as
indirectly through a wholesaler. These credits are issued in the
event there is a difference between the customer’s direct
and indirect contract price. The provision for billbacks is
estimated based upon historical purchasing patterns of qualified
customers who purchase product directly from the Company and
supplement their purchases indirectly through the Company’s
wholesale customers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Cash Discounts — </i>Cash discounts are provided to
customers that pay within a specific period. The provision for
cash discounts are estimated based upon invoice billings,
utilizing historical customer payment experience. Our
customer’s payment experience is fairly consistent and most
customer payments qualify for the cash discount. Accordingly,
our reserve for cash discounts is readily determinable.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Net revenues and accounts receivable balances in the
Company’s consolidated financial statements are presented
net of SRA estimates. In addition, certain SRA balances are
included in accounts payable and accrued liabilities. Accounts
receivable are presented net of SRA balances of
$320.5 million and $335.0 million at December 31,
2010 and 2009, respectively. Accounts payable and accrued
liabilities include $106.5 million and $83.6 million
at December 31, 2010 and 2009, respectively, for certain
rebates and other amounts due to indirect customers.
The
following table summarizes the activity in the Company’s
major categories of SRA (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="42%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Returns and Other<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Chargebacks</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Rebates</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Allowances</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Cash Discounts</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2007
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
164.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
154.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
387.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,224.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
309.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
179.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,780.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,267.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(337.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(67.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,839.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
125.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
328.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Arrow Acquisition
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,169.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
415.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,840.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,177.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(389.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(167.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(71.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,805.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2009 (Revised)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
188.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
97.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
418.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,175.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
755.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
206.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,192.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(723.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(214.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(88.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2,219.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
100.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
219.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
427.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company does not expect future payments of SRA to materially
exceed our current estimates. However, if future SRA payments
were to materially exceed our estimates, such adjustments may
have a material adverse impact on our financial position,
results of operations and cash flows.
</div>
<div style="margin-top: 9pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Shipping
and Handling Costs</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company records shipping and handling costs in selling and
marketing expenses. These expenses were $66.5 million,
$51.9 million and $50.8 million in 2010, 2009 and
2008, respectively.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Concentration
of Major Customers and Suppliers</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For the year ended December 31, 2010, the Company’s
three largest customers accounted for 14%, 11%, and 6%,
individually, of the Company’s net revenues. For the year
ended December 31, 2009, the Company’s three largest
customers accounted for 13%, 11%, and 9%, individually, of the
Company’s net revenues. For the year ended
December 31, 2008, the Company’s three largest
customers accounted for 11%, 11%, and 9%, individually, of the
Company’s net revenues. No other individual customers
accounted for more than 10% of net revenues.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is subject to a concentration of credit risk with
respect to its accounts receivable balance, all of which is due
from wholesalers, distributors, chain drug stores and service
providers in the health care and pharmaceutical industries
throughout the U.S. and international markets in which we
operate. Approximately 52% and 53% of the gross accounts
receivable balance consists of amounts due from the four largest
customers at December 31, 2010 and 2009, respectively. The
Company performs ongoing credit evaluations of its customers and
maintains an allowance for potential uncollectible accounts.
Actual losses from uncollectible accounts have been minimal.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Certain of the Company’s finished products and raw
materials are obtained from single source suppliers. Although
the Company seeks to identify more than one source for its
various finished products and raw materials, loss of a single
source supplier could have an adverse effect on the
Company’s results of operations, financial condition and
cash flows. Third-party manufactured products accounted for
approximately 33%, 38% and 44% of our Global Generics and Global
Brands product net revenues in 2010, 2009 and 2008, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Research
and Development Activities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
R&D activities are expensed as incurred and consist of
self-funded R&D costs and the costs associated with work
performed under collaborative R&D agreements. R&D
expenses include direct and allocated expenses. R&D
expenses incurred under collaborative agreements were
approximately $11.1 million, $6.8 million, and
$5.9 million for the years ended December 31, 2010,
2009 and 2008, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Income
Taxes</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income taxes are accounted for using an asset and liability
approach that requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of
temporary differences between the financial statement and tax
bases of assets and liabilities at the applicable tax rates. A
valuation allowance is provided when it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The Company evaluates the realizability of its
deferred tax assets by assessing its valuation allowance and by
adjusting the amount of such allowance, if necessary. The
factors used to assess the likelihood of realization include the
Company’s forecast of future taxable income and available
tax planning strategies that could be implemented to realize the
net deferred tax assets. Failure to achieve forecasted taxable
income in applicable tax jurisdictions could affect the ultimate
realization of deferred tax assets and could result in an
increase in the Company’s effective tax rate on future
earnings.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income tax positions must meet a more-likely-than-not
recognition threshold to be recognized. Income tax positions
that previously failed to meet the more-likely-than-not
threshold are recognized in the first subsequent financial
reporting period in which that threshold is met. Previously
recognized tax positions that no longer meet the
more-likely-than-not threshold are derecognized in the first
subsequent financial reporting period in which that threshold is
no longer met. We recognize potential accrued interest and
penalties related to unrecognized tax benefits within the
consolidated statements of income as income tax expense.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Comprehensive
Income</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Comprehensive income includes all changes in equity during a
period except those that resulted from investments by or
distributions to the Company’s stockholders. Other
comprehensive income refers to revenues, expenses, gains and
losses that, under GAAP, are included in comprehensive income,
but excluded from net income as these amounts are recorded
directly as an adjustment to stockholders’ equity.
Watson’s other comprehensive income (loss) is composed of
unrealized gains (losses) on its holdings of publicly traded
equity securities, net of realized gains (losses) included in
net income and foreign currency translation adjustments.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Earnings
Per Share (“EPS”)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Basic EPS is computed by dividing net income attributable to
common shareholders by the weighted average common shares
outstanding during a period. Diluted EPS is based on the
treasury stock method and includes the effect from potential
issuance of common stock, such as shares issuable upon
conversion of our convertible contingent senior debentures
(“CODES”), and shares issuable pursuant to the
exercise of stock options, assuming the exercise of all
<font style="white-space: nowrap">in-the-money</font>
stock options. Common share equivalents have been excluded where
their inclusion would be anti-dilutive. The Company is required
to add the weighted average potential common shares outstanding
associated with the conversion of the CODES to the number of
shares outstanding for the calculation of diluted EPS for all
periods in which the securities were outstanding. On
September 14, 2009 the CODES were redeemed in accordance
with the terms of the CODES.
A reconciliation of the
numerators and denominators of basic and diluted EPS consisted
of the following (in millions, except per share amounts):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="74%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — basic</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.51
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.32
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — assuming dilution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Interest expense on CODES, net of tax
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income, adjusted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
246.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effect of dilutive securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Conversion of CODES
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Dilutive stock awards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
124.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.48
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.96
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.09
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Stock awards to purchase 1.1 million, 3.5 million and
8.1 million common shares in 2010, 2009 and 2008,
respectively, were outstanding but not included in the
computation of diluted EPS as the awards were anti-dilutive.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Share-based
Compensation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company recognizes compensation expense for all share-based
compensation awards made to employees and directors based on
estimated fair values. The Company estimates the fair value of
its stock option plans using the Black-Scholes option pricing
model (the “Option Model”). The Option Model requires
the use of subjective and complex assumptions, including the
option’s expected term and the estimated future price
volatility of the underlying stock, which determine the fair
value of the share-based awards. The Company’s estimate of
expected term was determined based on the weighted average
period of time that options granted are expected to be
outstanding considering current vesting schedules and the
historical exercise patterns of existing option plans. The
expected volatility assumption used in the Option Model is based
on implied volatility based on traded options on the
Company’s stock. The risk-free interest rate used in the
Option Model is based on the yield of U.S. Treasuries with
a maturity closest to the expected term of the Company’s
stock options. No stock options were granted during the years
ended December 31, 2010, 2009 or 2008.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Share-based compensation expense recognized during a period is
based on the value of the portion of share-based awards that are
expected to vest with employees. Accordingly, the recognition of
share-based compensation expense has been reduced for estimated
future forfeitures. These estimates will be revised in future
periods if actual forfeitures differ from the estimates. Changes
in forfeiture estimates impact compensation expense in the
period in which the change in estimate occurs.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Recent
Accounting Pronouncements</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In October 2009, the FASB issued an amendment to its accounting
guidance on revenue arrangements with multiple deliverables,
which addresses the unit of accounting for arrangements
involving multiple deliverables and how consideration should be
allocated to separate units of accounting, when applicable. The
amendment requires that arrangement considerations be allocated
at the inception of the arrangement to all deliverables using
the relative selling price method and provides for expanded
disclosures related to such arrangements. The amendment is
effective for revenue arrangements entered into or materially
modified in fiscal years beginning on or after June 15,
2010. Early adoption is allowed. The adoption of this guidance
will not have a material impact on the Company’s
consolidated financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In January 2010, the FASB issued an amendment to the disclosure
requirements for fair value measurements. The amendment requires
an entity to: (i) disclose separately the amounts of
significant transfers in and out of Level 1 and
Level 2 fair value measurements and describe the reasons
for the transfers, and (ii) present separate information
for Level 3 activity pertaining to gross purchases, sales,
issuances and settlements. The new disclosures are effective for
interim and annual reporting periods beginning after
December 15, 2009, except for the Level 3 disclosures,
which are effective for fiscal years beginning after
December 15, 2010. The adoption of this guidance will not
have a material impact on the Company’s consolidated
financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In March 2010, the FASB ratified accounting guidance on defining
a milestone and determining when it may be appropriate to apply
the milestone method of revenue recognition for research or
development transactions. This guidance provides criteria that
must be met to recognize consideration that is contingent upon
achievement of a substantive milestone in its entirety in the
period in which the milestone is achieved. The amendment is
effective for milestones achieved in fiscal years beginning on
or after June 15, 2010. Early adoption is allowed. The
adoption of this guidance will not have a material impact on the
Company’s consolidated financial statements.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used to describe all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 8
falsefalse12Summary of Significant Accounting PoliciesUnKnownUnKnownUnKnownUnKnownfalsetrueXML
27
R36.xml
IDEA: Business Restructuring Charges (Tables)
2.2.0.25falsefalse0514 - Disclosure - Business Restructuring Charges (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_BusinessRestructuringChargesTablesAbstractwpifalsenadurationBusiness Restructuring Charges.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringBusiness Restructuring Charges.falsefalse3false0us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note14_table1 - us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities involving facilities at Carmel, New York;
Mississauga, Canada; and Melbourne, Australia for the year ended
December 31, 2010 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Severance and retention
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product transfer costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Facility decommission costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(18.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation — R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities at Carmel, New York and Brewster, New York for the
year ended December 31, 2009 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(22.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDisclosure of changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total,
and explanation of changes that occurred in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 20
-Subparagraph b(2)
falsefalse12Business Restructuring Charges (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
28
R41.xml
IDEA: Summary of Significant Accounting Policies (Details 2)
2.2.0.25truefalse06022 - Disclosure - Summary of Significant Accounting Policies (Details 2)truefalseIn Millions, except Per Share data, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_EarningsPerShareBasicAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_NetIncomeLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse184400000184.4falsetruefalsefalsefalse2truefalsefalse222000000222.0falsetruefalsefalsefalse3truefalsefalse238400000238.4falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe portion of consolidated pro
fit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
falsefalse4false0us-gaap_WeightedAverageNumberOfSharesOutstandingBasicus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse122400000122.4falsefalsefalsefalsefalse2truefalsefalse105000000105.0falsefalsefalsefalsefalse3truefalsefalse102800000102.8falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
falsefalse5false0us-gaap_EarningsPerShareBasicus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1true
falsefalse1.511.51falsetruefalsefalsefalse2truefalsefalse2.112.11falsetruefalsefalsefalse3truefalsefalse2.322.32falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe amount of net income or loss for the period per each share of common stock outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7
falsetrue6true0us-gaap_EarningsPerShareDilutedAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse7false0us-gaap_NetIncomeLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse184400000184.4falsefalsefalsefalsefalse2truefalsefalse222000000222.0falsefalsefalsefalsefalse3truefalsefalse238400000238.4falsefalsefalsefalse<
/hasSegments>falseMonetaryxbrli:monetaryItemTypemonetaryThe portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
falsefalse8false0us-gaap_InterestOnConvertibleDebtNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse55000005.5falsefalsefalsefalsefalse3truefalsefalse79000007.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIn computing the dilutive effect of convertible debt, the earnings per share numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 11
falsefalse9false0wpi_AdjustedNetIncomewpifalsecreditdurationNet income, adjusted.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse184400000184.4falsefalsefalsefalsefalse2truefalsefalse227500000227.5falsefalsefalsefalsefalse3truefalsefalse246300000246.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryNet income, adjusted.No authoritative reference available.falsefalse10false0us-gaap_WeightedAverageNumberOfSharesOutstandingBasicus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse122400000122.4falsefalsefalsefalsefalse2truefalsefalse105000000105.0falsefalsefalsefalsefalse3truefalsefalse102800000102.8falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
falsefalse11true0us-gaap_DilutiveSecuritiesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false<
IsRatio>falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse12false0us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse1010000010.1falsefalsefalsefalsefalse3truefalsefalse1440000014.4falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesDebt securities outstanding shall be assumed to have been converted at the beginning of the period (or at time of issuance, if later), and the resulting common shares shall be included in common shares used to calculate diluted earnings per shares. The dilutive effect of convertible debt securities shall be reflected in diluted Earnings Per Share by application of the if-converted method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 26, 27, 28
falsefalse13false0us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangementsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1true
IsNumeric>falsefalse18000001.8falsefalsefalsefalsefalse2truefalsefalse13000001.3falsefalsefalsefalsefalse3truefalsefalse5000000.5falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesAggregate awards of share options and nonvested shares to be issued to an employee under a share-based compensation arrangement are considered options for purposes of computing diluted earnings per share. Such share-based awards shall be considered to be outstanding as of the grant date for purposes of computing diluted earnings per share even though their
exercise may be contingent upon vesting. Those share-based awards are included in the diluted Earnings Per Share (EPS) computation even if the employee may not receive (or be able to sell) the stock until some future date. Accordingly, all shares to be issued shall be included in computing diluted EPS if the effect is dilutive. The dilutive effect of share-based compensation arrangements shall be computed using the treasury stock method. If the equity share options or other equity instruments are outstanding for only part of a period, the shares issuable shall be weighted to reflect the portion of the period during which the equity instruments were outstanding.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 20
falsefalse14false0us-gaap_WeightedAverageNumberOfDilutedSharesOutstandingus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1true
falsefalse124200000124.2falsefalsefalsefalsefalse2truefalsefalse116400000116.4falsefalsefalsefalsefalse3truefalsefalse117700000117.7falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
falsefalse15false0us-gaap_EarningsPerShareDilutedus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1.481.48falsetruefalsefalsefalse2truefalsefalse1.961.96falsetruefalsefalsefalse3truefalsefalse2.092.09falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 11, 12, 36
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
falsetrue17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificantaccountingpoliciesdetail1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsef
alse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{us-gaap_DebtInstrumentAxis} : Notes 5% Due August 14, 2014 [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Notes5_Percent_Due_August142014_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseNotes 5% Due August 14, 2014 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_Notes5PercentDueAugust142014Memberus-gaap_DebtInstrumentAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003
/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$OthernaNo definition available.No authoritative reference available.falsefalse21true0wpi_FairValueOfOtherFinancialInstrumentsAbstractwpifalsenadurationFair Value of Other Financial Instruments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringFair Value of Other Financial Instruments.falsefalse22false0us-gaap_DebtInstrumentFaceAmountus-gaaptruecreditinstantNo definition available.false
falsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse450000000450.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 21
-Paragraph 16, 20
falsefalse23false0us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.050000.05000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:percentItemTypepureInterest rate stated in the contractual debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
falsefalse24false0us-gaap_DebtInstrumentMaturityDateus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse002014-08-14falsefalsetruefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse<
/IsRatio>false00falsefalsefalsefalsefalseOtherxbrli:dateItemTypedateDate when the debt instrument is scheduled to be fully repaid, which may be presented in a variety of ways (year, month and year, day, month and year, quarter, etc.).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
falsefalse25false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificantaccountingpoliciesdetail1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_DebtInstrumentAxis} : Notes 6.125% due August 14, 2019 [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Notes6_Point125_Percent_Due_August142019_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseNotes 6.125% due August 14, 2019 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_Notes6Point125PercentDueAugust142019Memberus-gaap_DebtInstrumentAxisexplicitMemberUSDStandardhttp
://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0$OthernaNo definition available.No authoritative reference available.falsefalse<
Row>29true0wpi_FairValueOfOtherFinancialInstrumentsAbstractwpifalsenadurationFair Value of Other Financial Instruments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringFair Value of Other Financial Instruments.falsefalse30false0us-gaap_DebtInstrumentFaceAmountus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse400000000400.0falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse<
/Cells>Monetaryxbrli:monetaryItemTypemonetaryThe stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 21
-Paragraph 16, 20
falsefalse31false0us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.061250.06125falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:percentItemTypepureInterest rate stated in the contractual debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
falsefalse32false0us-gaap_DebtInstrumentMaturityDateus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse002019-08-14falsefalsetruefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse<
/IsRatio>false00falsefalsefalsefalsefalseOtherxbrli:dateItemTypedateDate when the debt instrument is scheduled to be fully repaid, which may be presented in a variety of ways (year, month and year, day, month and year, quarter, etc.).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
falsefalse324Summary of Significant Accounting Policies (Details 2) (USD $)HundredThousandsHundredThousandsNoRoundingUnKnowntruetrueXML
29
R66.xml
IDEA: Fair Value Measurement (Details 1)
2.2.0.25truefalse06151 - Disclosure - Fair Value Measurement (Details 1)truefalseIn Millionsfalse1falsefalseUSDtruefalse{us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityTypeAxis} : Contingent consideration obligation [member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Contingent_Consideration_Obligation_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseContingent consideration obligation [member]us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ContingentConsiderationObligationMemberus-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2falsefalseUSDtruefalse{us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityTypeAxis} : Contingent consideration obligation [member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Contingent_Consideration_Obligation_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseContingent consideration obligation [member]us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ContingentConsiderationObligationMemberus-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2true0us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsef
alsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse3false0wpi_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValuewpifalsecreditinstantFair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse11
1000000111.0falsetruefalsefalsefalse2truefalsefalse00falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value.No authoritative reference available.falsefalse4false0us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents [net] transfers in to and out of liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) which have taken place during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph c(3)
falsefalse5false0us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse6480000064.8falsefalsefalsefalsefalse2truefalsefalse110000000110.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents purchases, sales, issuances, and settlements (net) which have taken place during the period in relation to liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph c(2)
falsefalse6false0us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2270000022.7falsefalsefalsefalsefalse2truefalsefalse10000001.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents total gains or losses for the period (realized and unrealized), arising from liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in net asset value.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph c(1)
falsefalse7false0wpi_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValuewpifalsecreditinstantFair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value.falsefalsefalsefalsefalsefalsefalsefalsetruefalse
periodendlabel1truefalsefalse198500000198.5falsetruefalsefalsefalse2truefalsefalse111000000111.0falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value.No authoritative reference available.falsefalse
26Fair Value Measurement (Details 1) (Contingent consideration obligation [member], USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
30
R58.xml
IDEA: Stockholders' Equity (Details)
2.2.0.25falsefalse0612 - Disclosure - Stockholders' Equity (Details)truefalseIn Millions, except Per Share data, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3true0wpi_SummaryOfCompanyStockOptionPlansAbstractwpifalsenadurationSummary of the Company's stock option plans.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSummary of the Company's stock option plans.falsefalse4false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse53000005.3falsefalsefalsefalsefalseSharesxbrli:
sharesItemTypesharesThe number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance-sheet date, including vested options.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(b)
falsefalse5false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe quantity of shares issuable on stock options awarded under the plan during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(d)
falsefalse6false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1t
ruefalsefalse-1700000-1.7falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe decrease in the number of reserved shares that could potentially be issued attributable to the exercise or conversion during the reporting period of previously issued stock options under the option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(e)
falsefalse7false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse-500000-0.5falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(f)
truefalse8false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse31000003.1falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance-sheet date, including vested options.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(b)
falsefalse9false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumberus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse30000003.0falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesAs of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph d(1)
truefalse10false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse28000002.8falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of shares into which fully or partially vested stock options outstanding as of the balance-sheet date can be currently converted under the option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(c), d(2)
truefalse11false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel<
Cells>1truefalsefalse36.9136.91falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average price as of the beginning of the year at which grantees can acquire the shares reserved for issuance under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(a)
falsetrue12false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselab
el1truefalsefalse00falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on stock options awarded under the plan during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(d)
falsetrue13false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse33.3033.30falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average price at which option holders acquired shares when converting their stock options into shares under the plan during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(e)
falsetrue14false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse49.4949.49falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated during the reporting period due to noncompliance with plan terms during the reporting period.Reference 1: http://www.xbrl.or
g/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(f)
truetrue15false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel<
FootnoteIndexer />1truefalsefalse36.6336.63falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average price as of the beginning of the year at which grantees can acquire the shares reserved for issuance under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(a)
falsetrue16false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse36.7136.71falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalAs of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph d(1)
truetrue17false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse37.3037.30falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.Reference 1: http://www.xbrl.org/2003/
role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(1)(c)
truetrue18false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse3.23.2falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe weighted average period between the balance-sheet date and expiration for all awards outstanding under the plan, which may be expressed in a decimal value for number of years.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph a
truefalse19false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse
totallabel1truefalsefalse2.82.8falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe weighted average period between the balance-sheet date and expiration for all vested portions of options outstanding and currently exercisable (or convertible) under the plan, which may be expressed in a decimal value for number of years.No authoritative reference available.truefalse20false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTermus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse3.13.1falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe weighted-average period between the balance-sheet date and expiration date for fully vested and expected to vest options outstanding, which may be expressed in a decimal value for number of years.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph d(1)
truefalse21false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotalla
bel1truefalsefalse4860000048.6falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices pertaining to options outstanding under the plan as of the balance-sheet date.Reference 1: http://www.xbrl.org/2003/role/pr
esentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph d(1)
truefalse22false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse4760000047.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAs of the balance sheet date, the total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of fully vested and expected to vest options outstanding.Reference 1: http://www.xbrl.org/2003/role/pr
esentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph d(1)
truefalse23false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValueus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel<
FootnoteIndexer />1truefalsefalse4200000042.0falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of vested portions of options outstanding and currently exercisable under the option plan as of the balance-sheet date.No authoritative reference av
ailable.truefalse121Stockholders' Equity (Details) (USD $)HundredThousandsHundredThousandsNoRoundingUnKnowntruetrueXML
31
R22.xml
IDEA: Commitments and Contingencies
2.2.0.25falsefalse0216 - Disclosure - Commitments and Contingenciestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_CommitmentsAndContingenciesAbstractwpifalsenadurationCommitments and Contingencies.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00false
falsefalsefalsefalseOtherxbrli:stringItemTypestringCommitments and Contingencies.falsefalse3false0us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 16 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 16 —
Commitments and Contingencies</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Facility
and Equipment Leases</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has operating leases for certain facilities and
equipment. The terms of the operating leases for the
Company’s facilities require the Company to pay property
taxes, normal maintenance expenses and maintain minimum
insurance coverage. Total rental expense for operating leases in
2010, 2009 and 2008 was $26.0 million, $20.0 million
and $19.0 million, respectively.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At December 31, 2010, future minimum lease payments under
all non-cancelable operating leases are approximately,
$24.4 million in 2011, $18.6 million in 2012,
$14.6 million in 2013, $12.5 million in 2014,
$12.8 million in 2015 and $53.0 million thereafter.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Employee
Retirement Plans</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company maintains certain defined contribution retirement
plans covering substantially all
<font style="white-space: nowrap">U.S.-based</font>
employees. The Company contributes to the plans based upon the
employee contributions. Watson’s contributions to these
retirement plans were $9.5 million, $11.0 million and
$10.6 million in the years ended December 31, 2010,
2009 and 2008, respectively. The Company does not sponsor any
defined benefit retirement plans or postretirement benefit plans.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Legal
Matters</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson and its affiliates are involved in various disputes,
governmental
<font style="white-space: nowrap">and/or</font>
regulatory inspections, inquires, investigations and
proceedings, and litigation matters that arise from time to time
in the ordinary course of business. The process of resolving
matters through litigation or other means is inherently
uncertain and it is possible that an unfavorable resolution of
these matters will adversely affect the Company, its results of
operations, financial condition and cash flows. The
Company’s regular practice is to expense legal fees as
services are rendered in connection with legal matters, and to
accrue for liabilities when losses are probable and reasonably
estimable.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Cipro</i><sup style="font-size: 85%; vertical-align: text-top">®</sup>
<i>Litigation.</i>  Beginning in July 2000, a number
of suits were filed against Watson, The Rugby Group, Inc.
(“Rugby”) and other company affiliates in various
state and federal courts alleging claims under various federal
and state competition and consumer protection laws. Several
plaintiffs have filed amended complaints and motions seeking
class certification. Approximately 42 cases have been filed
against Watson, Rugby and other Watson entities. Twenty-two of
these actions have been consolidated in the U.S. District
Court for the Eastern District of New York (<i>In re:
Ciprofloxacin Hydrochloride Antitrust Litigation, MDL Docket
No. 001383</i>). On May 20, 2003, the court hearing
the consolidated action granted Watson’s motion to dismiss
and made rulings limiting the theories under which plaintiffs
can seek recovery against Rugby and the other defendants. On
March 31, 2005, the court hearing the consolidated action
granted summary judgment in favor of the defendants on all of
plaintiffs’ claims and denied the plaintiffs’ motions
for class certification. On May 7, 2005, three groups of
plaintiffs from the consolidated action (the direct purchaser
plaintiffs, the indirect purchaser plaintiffs and plaintiffs
Rite Aid and CVS) filed notices of appeal in the United States
Court of Appeals for the Second Circuit, appealing, among other
things, the May 20, 2003 order dismissing Watson and the
March 31, 2005 order granting summary judgment in favor of
the defendants. On November 7, 2007, the U.S. Court of
Appeals for the Second Circuit ordered the appeal by the
indirect purchaser plaintiffs transferred to the United States
Court of Appeals for the Federal Circuit. On October 15,
2008, the United States Court of Appeals for the Federal
Circuit affirmed the dismissal of the indirect purchasers’
claims, and on December 22, 2008, denied the indirect
purchaser plaintiffs’ petition for rehearing and rehearing
en banc. On June 22, 2009, the Supreme Court denied the
indirect purchaser plaintiffs’ petition for writ of
certiorari. In the appeal in the United States Court of Appeals
for the Second Circuit by the direct purchaser plaintiffs and
plaintiffs CVS and Rite Aid, on April 29, 2010, the United
States Court of Appeals
for the Second Circuit affirmed the ruling of the District Court
granting summary judgment in favor of the defendants, and on
September 7, 2010, denied the appellants’ petition for
rehearing en banc. On December 6, 2010, the appellants
filed a petition for writ of certiorari with the United States
Supreme Court seeking review of the Second Circuit’s
decision. The defendants filed their opposition to the petition
on February 7, 2011. Other actions are pending in various
state courts, including California, Kansas, Tennessee, and
Florida. The actions generally allege that the defendants
engaged in unlawful, anticompetitive conduct in connection with
alleged agreements, entered into prior to Watson’s
acquisition of Rugby from Sanofi Aventis (“Sanofi”),
related to the development, manufacture and sale of the drug
substance ciprofloxacin hydrochloride, the generic version of
Bayer’s brand drug,
Cipro<sup style="font-size: 85%; vertical-align: text-top">®</sup>.
The actions generally seek declaratory judgment, damages,
injunctive relief, restitution and other relief on behalf of
certain purported classes of individuals and other entities. In
the action pending in Kansas, the court has administratively
terminated the matter pending the outcome of the appeals in the
consolidated case. In the action pending in the California
Superior Court for the County of San Diego (<i>In re: Cipro
Cases I & II, JCCP Proceeding Nos. 4154 &
4220</i>), on July 21, 2004, the California Court of Appeal
ruled that the majority of the plaintiffs would be permitted to
pursue their claims as a class. On August 31, 2009, the
California Superior Court granted defendants’ motion for
summary judgment, and final judgment was entered on
September 24, 2009. On November 19, 2009, the
plaintiffs filed a notice of appeal. The appeal remains pending.
In addition to the pending actions, Watson understands that
various state and federal agencies are investigating the
allegations made in these actions. Sanofi has agreed to defend
and indemnify Watson and its affiliates in connection with the
claims and investigations arising from the conduct and
agreements allegedly undertaken by Rugby and its affiliates
prior to Watson’s acquisition of Rugby, and is currently
controlling the defense of these actions.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Governmental Reimbursement Investigations and Drug Pricing
Litigation.</i>  In November 1999,
Schein Pharmaceutical, Inc., now known as Watson Pharma,
Inc. (“Watson Pharma”) was informed by the
U.S. Department of Justice that it, along with numerous
other pharmaceutical companies, is a defendant in a <i>qui tam
</i>action brought in 1995 under the U.S. False Claims Act
currently pending in the U.S. District Court for the
Southern District of Florida. Watson Pharma has not been served
in the <i>qui tam </i>action. A <i>qui tam </i>action is a civil
lawsuit brought by an individual or a company (the “qui tam
relator”) for an alleged violation of a federal statute, in
which the U.S. Department of Justice has the right to
intervene and take over the prosecution of the lawsuit at its
option. Pursuant to applicable federal law, the <i>qui tam
</i>action is under seal as to Watson Pharma. The Company
believes that the <i>qui tam </i>action relates to whether
allegedly improper price reporting by pharmaceutical
manufacturers led to increased payments by Medicare
<font style="white-space: nowrap">and/or</font>
Medicaid. The <i>qui tam</i> action may seek to recover damages
from Watson Pharma based on its price reporting practices.
Watson Pharma subsequently also received and responded to
notices or subpoenas from the Attorneys General of various
states, including Florida, Nevada, New York, California and
Texas, relating to pharmaceutical pricing issues and whether
allegedly improper actions by pharmaceutical manufacturers led
to excessive payments by Medicare
<font style="white-space: nowrap">and/or</font>
Medicaid. On June 26, 2003, the Company received a request
for records and information from the U.S. House Committee
on Energy and Commerce in connection with that committee’s
investigation into pharmaceutical reimbursements and rebates
under Medicaid. The Company produced documents in response to
the request. Other state and federal inquiries regarding pricing
and reimbursement issues are anticipated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Beginning in July 2002, the Company and certain of its
subsidiaries, as well as numerous other pharmaceutical
companies, were named as defendants in various state and federal
court actions alleging improper or fraudulent reporting
practices related to the reporting of average wholesale prices
and wholesale acquisition costs of certain products, and that
the defendants committed other improper acts in order to
increase prices and market shares. Some of these actions have
been consolidated in the U.S. District Court for the
District of Massachusetts (<i>In re: Pharmaceutical Industry
Average Wholesale Price Litigation, MDL Docket
No. 145</i>). The consolidated amended Class Action
complaint in that case alleges that the defendants’ acts
improperly inflated the reimbursement amounts of certain drugs
paid by various public and private plans and programs. Certain
defendants, including the Company, have entered into a
settlement agreement resolving
all claims against them in the Consolidated Class Action.
The total amount of the settlement for all of the settling
defendants is $125 million. The amount to be paid by each
settling defendant is confidential. On July 2, 2008, the
United States District Court for the District of Massachusetts
preliminarily approved the Track Two settlement. On
April 27, 2009, the Court held a hearing to further
consider the fairness of the proposed settlement. The Court
adjourned the hearing without ruling on the fairness of the
proposed settlement until additional notices are provided to
certain of the class members in the action. The settlement is
not expected to materially adversely affect the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company and certain of its subsidiaries also are named as
defendants in various lawsuits filed by numerous states and qui
tam relators, including Texas, Kansas, Nevada, Montana,
Massachusetts, Wisconsin, Kentucky, Alabama, Illinois,
Mississippi, Florida, Arizona, Missouri, Alaska, Idaho, South
Carolina, Hawaii, Utah, Iowa, Oklahoma and Louisiana captioned
as follows: <i>State of Nevada v. American Home Products,
et al., Civil Action
<font style="white-space: nowrap">No. 02-CV-12086-PBS,</font>
United States District Court for the District of Massachusetts;
State of Montana v. Abbott Laboratories, et al., Civil
Action
<font style="white-space: nowrap">No. 02-CV-12084-PBS,</font>
United States District Court for the District of Massachusetts;
Commonwealth of Massachusetts v. Mylan Laboratories, et
al., Civil Action
<font style="white-space: nowrap">No. 03-CV-11865-PBS,</font>
United States District Court for the District of Massachusetts;
State of Wisconsin v. Abbott Laboratories, et al., Case
<font style="white-space: nowrap">No. 04-cv-1709,</font>
Wisconsin Circuit Court for Dane County; Commonwealth of
Kentucky v. Alpharma, Inc., et al., Case Number 04-CI-1487,
Kentucky Circuit Court for Franklin County; State of
Alabama v. Abbott Laboratories, Inc. et al., Civil Action
<font style="white-space: nowrap">No. CV05-219,</font>
Alabama Circuit Court for Montgomery County; State of
Illinois v. Abbott Laboratories, Inc. et al., Civil Action
<font style="white-space: nowrap">No. 05-CH-02474,</font>
Illinois Circuit Court for Cook County; State of
Mississippi v. Abbott Laboratories, Inc. et al., Civil
Action
<font style="white-space: nowrap">No. G2005-2021</font>
S/2, Mississippi Chancery Court of Hinds County; State of
Florida ex rel.
<font style="white-space: nowrap">Ven-A-Care,</font>
Civil Action No
<font style="white-space: nowrap">98-3032G,</font>
Florida Circuit Court in Leon County (the “Florida
<font style="white-space: nowrap">Ven-A-Care</font>
Action”); State of Arizona ex rel. Terry Goddard,
No. CV
<font style="white-space: nowrap">2005-18711,</font>
Arizona Superior Court for Maricopa County; State of Missouri ex
rel. Jeremiah W. (Jay) Nixon v. Mylan Laboratories, et al,
Case
<font style="white-space: nowrap">No. 054-2486,</font>
Missouri Circuit Court of St. Louis; State of
Alaska v. Alpharma Branded Products Division Inc., et
al., In the Superior Court for the State of Alaska Third
Judicial District at Anchorage, C.A.
<font style="white-space: nowrap">No. 3AN-06-12026</font>
CI; State of Idaho v. Alpharma USPD Inc. et al., In the
District Court of the Fourth Judicial District of the State of
Idaho, in and for the County of Ada, C.A.
<font style="white-space: nowrap">No. CV0C-0701847;</font>
State of South Carolina and Henry D. McMaster v. Watson
Pharmaceuticals (New Jersey), Inc., In the Court of Common Pleas
for the Fifth Judicial Circuit, State of South Carolina, County
of Richland, C.A.
<font style="white-space: nowrap">No. 2006-CP-40-7152;</font>
State of South Carolina and Henry D. McMaster v. Watson
Pharmaceuticals (New Jersey), Inc., In the Court of Common Pleas
for the Fifth Judicial Circuit, State of South Carolina, County
of Richland, C.A.
<font style="white-space: nowrap">No. 2006-CP-40-7155;</font>
State of Hawaii v. Abbott Laboratories, Inc. et al., In the
Circuit Court of the First Circuit, State of Hawaii, C.A.
<font style="white-space: nowrap">No. 06-1-0720-04</font>
EEH; State of Utah v. Actavis U.S., Inc., et al., In the
Third Judicial District Court of Salt Lake County, Civil
<font style="white-space: nowrap">No. 07-0913719;</font>
State of Iowa v. Abbott Laboratories, Inc., et al., In the
U.S. District Court for the Southern District of Iowa,
Central Division, Case
<font style="white-space: nowrap">No. 07-CV-00461</font>
(the “Iowa AG Action”); State of Texas ex rel.
<font style="white-space: nowrap">Ven-A-Care</font>
of the Florida Keys, Inc. v. Alpharma Inc., et al, Case
<font style="white-space: nowrap">No. 08-001565,</font>
in the District Court of Travis County, Texas (the “Texas
<font style="white-space: nowrap">Ven-A-Care</font>
Action”); United States of America ex rel.
<font style="white-space: nowrap">Ven-A-Care</font>
of the Florida Keys, Inc.,v. Actavis Mid-Atlantic LLC, Civil
Action
<font style="white-space: nowrap">No. 08-10852,</font>
in the U.S. District Court for the District of
Massachussetts (the “Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Action”); State of Kansas ex rel. Steve Six v.
Watson Pharmaceuticals, Inc. and Watson Pharma, Inc., Case
Number: 08CV2228, District Court of Wyandotte County, Kansas,
Civil Court Department; State of Oklahoma, ex rel., W.A. Drew
Edmondson, Attorney General of Oklahoma v. Abbott
Laboratories, Inc., et al., Case
<font style="white-space: nowrap">No. CJ-2010-474,</font>
District Court of Pottawatomie County, Oklahoma, and State of
Louisiana V. Abbott Laboratories, Inc., et al., Case
No. 596144, Parish of East Baton Rouge,
19<sup style="font-size: 85%; vertical-align: top">th</sup></i>
<i>Judicial District. </i>In December of 2010, the State of Utah
served the Company with a Civil Investigative Demand seeking
additional information relating to the Company’s pricing
practices.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On August 4, 2004, the City of New York filed an action
against the Company and numerous other pharmaceutical defendants
alleging similar claims. The case has been consolidated with
similar cases filed by forty one individual New York counties.
(<i>City of New York v. Abbott Laboratories, Inc., et al.,
Civil Action
<font style="white-space: nowrap">No. 01-CV-12257-PBS,</font>
United States District Court for the District of
Massachusetts</i>) (hereinafter the “Consolidated NY
Counties Actions”), as well as by four additional New York
counties, with three of these cases pending in New York state
courts. On January 27, 2010, the U.S. District Court
granted Plaintiffs’ motion in the Consolidated NY Counties
Actions for partial summary judgment as to each of the generic
defendants, including Watson, with respect to some of
Watson’s drugs reimbursed at the Federal Upper Limit, and
found violations of New York’s state false claims act
statute.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In August 2010, the Company reached an agreement in principle to
settle each of the following pending actions: the Texas
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Florida
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Action, the Iowa AG Action, and the Consolidated New York
Counties Action (collectively the
<font style="white-space: nowrap">“Ven-A-Care</font>
Settlement”). The
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement was contingent upon approval of the United States
Department of Justice and the execution of definitive settlement
documents. In December of 2010, after the parties failed to
finalize the
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement, the Company reached an agreement in principle to
settle the following pending actions: the Texas
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Florida
<font style="white-space: nowrap">Ven-a-Care</font>
Action, the Iowa AG Action, and the Consolidated New York
Counties Action (the “State
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement”). In addition, at the same time the Company
reached an agreement in principle to settle claims pending in
the Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Action relative to the Texas, Florida, Iowa and New York
Medicaid programs (the “Federal
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement,” and collectively with the State
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement, the “December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement”). The total amount to be paid by the Company
under the terms of the proposed December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement is $79 million. The December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement is contingent upon obtaining final approval by the
U.S. Department of Justice and the execution of definitive
settlement documents.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The cases against the Company on behalf of Arizona, Hawaii and
Massachusetts have been settled. The case against the Company on
behalf of Alabama was tried in 2009. The jury was unable to
reach a verdict, and the court declared a mistrial and ordered
the case to be retried. New trials against the Company and
Andrx Corporation, a Company subsidiary, are scheduled for
May and August of 2011, respectively. The case against the
Company on behalf of Kentucky is scheduled for trial in November
of 2011. The case against the Company on behalf of Mississippi
is scheduled for trial in June 2011. The case against the
Company on behalf of Alaska is scheduled for trial in January of
2012. The case against the Company on behalf of Idaho is
scheduled for trial in March 2012. The case against the Company
on behalf of Missouri is scheduled for trial in June of 2012.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has accrued a $129.9 million liability reserve
on its balance sheet in connection with the December 2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement and the remaining drug pricing actions. The December
2010
<font style="white-space: nowrap">Ven-A-Care</font>
Settlement will resolve a considerable portion of the damages
claims asserted against the Company and its affiliates in the
various pending pricing litigations. With regard to the
remaining drug pricing actions, the Company believes that it has
meritorious defenses and intends to vigorously defend itself in
those actions. The Company continually monitors the status of
these actions and may settle or otherwise resolve some or all of
these matters on terms that the Company deems to be in its best
interests. However, the
Company can give no assurance that it will be able to settle the
remaining actions on terms it deems reasonable, or that such
settlements or adverse judgments in the remaining actions, if
entered, will not exceed the amounts of the liability reserves.
Additional actions by other states, cities
<font style="white-space: nowrap">and/or</font>
counties are anticipated. These actions
<font style="white-space: nowrap">and/or</font> the
actions described above, if successful, could adversely affect
the Company and could have a material adverse effect on the
Company’s business, results of operations, financial
condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Medicaid Drug Reimbursement Litigation.</i>  In
December 2009, the Company learned that numerous pharmaceutical
companies, including certain subsidiaries of the Company, have
been named as defendants in a qui tam action pending in the
United States District Court for the District of Massachusetts
(<i>United States of America ex rel. Constance A. Conrad v.
Actavis Mid-Atlantic, LLC, f/k/a Biovail Pharmaceuticals, LLC,
et. al.,USDC Case
<font style="white-space: nowrap">No. 02-CV-11738-NG).</font>
</i>The seventh amended complaint, which was served on certain
of the Company’s subsidiaries in December 2009, alleges
that the defendants falsely reported to the United States that
certain pharmaceutical products were eligible for Medicaid
reimbursement and thereby allegedly caused false claims for
payment to be made through the Medicaid program. In December
2010 the plaintiff served a ninth amended complaint that unseals
the action in its entirety and continues to allege the
previously asserted claims against certain subsidiaries of the
Company. The Company believes that it has meritorious defenses
to the claims and intends to vigorously defend itself in the
action. However, this action, if successful, could adversely
affect the Company and could have a material adverse effect on
the Company’s business, results of operations, financial
condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>FDA Matters.</i>  In May 2002, Watson reached an
agreement with the FDA on the terms of a consent decree with
respect to its Corona, California manufacturing facility. The
court approved the consent decree on May 13, 2002
(<i>United States of America v. Watson Laboratories, Inc.,
and Allen Y. Chao</i>, United States District Court for the
Central District of California, EDCV-02-412-VAP). The consent
decree with the FDA does not require any fine, a facility
shutdown, product recalls or any reduction in production or
service at the Company’s Corona facility. The consent
decree applies only to the Corona facility and not other
manufacturing sites. On July 9, 2008, the court entered an
order dismissing Allen Y. Chao, the Company’s former
President and Chief Executive Officer, from the action and from
the consent decree. The decree requires Watson to ensure that
its Corona, California facility complies with the FDA’s
current Good Manufacturing Practices (“cGMP”)
regulations.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pursuant to the agreement, Watson hired an independent expert to
conduct inspections of the Corona facility at least once each
year. In each year since 2002, the independent expert has
reported its opinion to the FDA that, based on the findings of
the audit of the facility, the FDA’s applicable cGMP
requirements, applicable FDA regulatory guidance, and the
collective knowledge, education, qualifications and experience
of the expert’s auditors and reviewers, the systems at
Watson’s Corona facility audited and evaluated by the
expert are in compliance with the FDA’s cGMP regulations.
However, the FDA is not required to accept or agree with the
independent expert’s opinion. The FDA has conducted
periodic inspections of the Corona facility since the entry of
the consent decree. The FDA’s most recent inspection was
conducted from August 2, 2010 through August 13, 2010.
At the conclusion of the inspection no formal observations were
made and no FDA Form 483 was issued. However, if in the
future, the FDA determines that, with respect to its Corona
facility, Watson has failed to comply with the consent decree or
FDA regulations, including cGMPs, or has failed to adequately
address the FDA’s inspectional observations, the consent
decree allows the FDA to order Watson to take a variety of
actions to remedy the deficiencies. These actions could include
ceasing manufacturing and related operations at the Corona
facility, and recalling affected products. Such actions, if
taken by the FDA, could have a material adverse effect on the
Company, its results of operations, financial position and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Federal Trade Commission Investigations.</i>  The
Company has received Civil Investigative Demands or requests for
information from the Federal Trade Commission seeking
information and documents related to the terms on which the
Company has settled lawsuits initiated by patentees under the
Hatch-Waxman Act, and
other commercial arrangements between the Company and third
parties. These investigations include the Company’s August
2006 settlement with Cephalon, Inc. related to the
Company’s generic version of
Provigil<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(modafinil). The Company believes these agreements comply with
applicable laws and rules. However, if the Federal Trade
Commission concludes that any of these agreements violate
applicable antitrust laws or rules, it could initiate legal
action against the Company. These actions, if successful, could
have a material adverse effect on the Company’s business,
results of operations, financial condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Androgel</i><sup style="font-size: 85%; vertical-align: text-top">®</sup>
<i>Antitrust Litigation.</i>  On January 29,
2009, the U.S. Federal Trade Commission and the State of
California filed a lawsuit in the United States District Court
for the Central District of California <i>(Federal Trade
Commission, et. al. v. Watson Pharmaceuticals, Inc., et.
al., USDC Case No. CV
<font style="white-space: nowrap">09-00598)</font>
</i>alleging that the Company’s September 2006 patent
lawsuit settlement with Solvay Pharmaceuticals, Inc., related to
AndroGel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
1% (testosterone gel) CIII is unlawful. The complaint generally
alleged that the Company improperly delayed its launch of a
generic version of
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
in exchange for Solvay’s agreement to permit the Company to
co-promote
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
for consideration in excess of the fair value of the services
provided by the Company, in violation of federal and state
antitrust and consumer protection laws. The complaint sought
equitable relief and civil penalties. On February 2 and 3, 2009,
three separate lawsuits alleging similar claims were filed in
the United States District Court for the Central District of
California by various private plaintiffs purporting to represent
certain classes of similarly situated claimants <i>(Meijer,
Inc., et. al., v. Unimed Pharmaceuticals, Inc., et. al.,
USDC Case No. EDCV
<font style="white-space: nowrap">09-0215);</font>
(Rochester Drug Co-Operative, Inc. v. Unimed
Pharmaceuticals Inc., et. al., Case No. EDCV
<font style="white-space: nowrap">09-0226);</font>
(Louisiana Wholesale Drug Co. Inc. v. Unimed
Pharmaceuticals Inc., et. al, Case No. EDCV
<font style="white-space: nowrap">09-0228)</font></i>.
On April 8, 2009, the Court transferred the government and
private cases to the United States District Court for the
Northern District of Georgia. On April 21, 2009 the State
of California voluntarily dismissed its lawsuit against the
Company without prejudice. The Federal Trade Commission and the
private plaintiffs in the Northern District of Georgia filed
amended complaints on May 28, 2009. The private plaintiffs
amended their complaints to include allegations concerning
conduct before the U.S. Patent and Trademark Office,
conduct in connection with the listing of Solvay’s patent
in the Food and Drug Administration’s “Orange
Book,” and sham litigation. Additional actions alleging
similar claims have been filed in various courts by other
private plaintiffs purporting to represent certain classes of
similarly situated direct or indirect purchasers of
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(<i>Stephen L. LaFrance Pharm., Inc. d/b/a SAJ Dist. v.
Unimed Pharms., Inc., et al.,D. NJ Civ.
<font style="white-space: nowrap">No. 09-1507</font></i>);
( <i>Fraternal Order of Police, Fort Lauderdale Lodge 31,
Insurance Trust Fund v. Unimed Pharms. Inc., et al.,D.
NJ Civ.
<font style="white-space: nowrap">No. 09-1856</font>
</i>); (<i>Scurto v. Unimed Pharms., Inc., et al., D. NJ
Civ.
<font style="white-space: nowrap">No. 09-1900</font></i>);
(<i>United Food and Commercial Workers Unions and Employers
Midwest Health Benefits Fund v. Unimed Pharms., Inc., et
al., D. MN Civ.
<font style="white-space: nowrap">No. 09-1168</font></i>);
( <i>Rite Aid Corp. et al. v. Unimed Pharms., Inc. et
al., M.D. PA Civ.
<font style="white-space: nowrap">No. 09-1153);</font>
(Walgreen Co., et al. v. Unimed Pharms.,LLC, et al., MD. PA
Civ.
<font style="white-space: nowrap">No. 09-1240</font></i>);
(<i>Supervalu, Inc. v. Unimed Pharms., LLC, et al, </i>ND.
GA Civ.
<font style="white-space: nowrap">No. 10-1024);</font>
(<i>LeGrand v. Unimed Pharms., Inc., et al</i>., ND. GA
Civ.
<font style="white-space: nowrap">No. 10-2883);</font>
(<i>Jabo’s Pharmacy Inc. v. Solvay Pharmaceuticals,
Inc., et al </i>., Cocke County, TN Circuit Court Case
No. 31,837). On April 20, 2009, the Company was
dismissed without prejudice from the <i>Stephen L. LaFrance
</i>action pending in the District of New Jersey. On
October 5, 2009, the Judicial Panel on Multidistrict
Litigation transferred all actions then pending outside of the
United States District Court for the Northern District of
Georgia to that district for consolidated pre-trial proceedings
(<i>In re: AndroGel
</i><sup style="font-size: 85%; vertical-align: text-top">®</sup>
<i>Antitrust Litigation (No. II), MDL Docket
No. 2084</i>), and all currently-pending related actions
are presently before that court. On February 22, 2010, the
judge presiding over all the consolidated litigations related to
Androgel<sup style="font-size: 85%; vertical-align: text-top">®</sup>
then pending in the United States District Court for the
Northern District of Georgia granted the Company’s motions
to dismiss the complaints, except the portion of the private
plaintiffs’ complaints that include allegations concerning
sham litigation. On July 20, 2010, the plaintiff in the
<i>Fraternal Order of Police </i>action filed an amended
complaint adding allegations concerning conduct before the
U.S. Patent and Trademark Office, conduct in connection
with the listing of Solvay’s patent in the Food and Drug
Administration’s “Orange Book,” and sham
litigation similar to the claims raised in the direct purchaser
actions. On October 28, 2010, the judge presiding over MDL
2084 entered an order pursuant to which the <i>LeGrand
</i>action, filed on September 10, 2010, was consolidated
for pretrial purposes with the
other indirect purchaser class action as part of MDL 2084 and
made subject to the Court’s February 22, 2010 order on
the motion to dismiss. Discovery in the private actions is
ongoing. Final judgment in favor of the defendants was entered
in the Federal Trade Commission’s action on April 21,
2010. On June 10, 2010, the Federal Trade Commission filed
a notice of appeal to the Eleventh Circuit Court of Appeals,
appealing the district court’s dismissal of its complaint.
The appeal is pending.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company believes that these actions are without merit and
intends to defend itself vigorously. However, these actions, if
successful, could have a material adverse effect on the
Company’s business, results of operations, financial
condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Hormone Replacement Therapy
Litigation.</i>  Beginning in early 2004 a number of
product liability suits were filed against the Company and
certain Company affiliates for personal injuries allegedly
arising out of the use of hormone replacement therapy products,
including but not limited to estropipate and estradiol. These
complaints also name numerous other pharmaceutical companies as
defendants, and allege various injuries, including ovarian
cancer, breast cancer and blood clots. Approximately 100 cases
are pending against Watson
<font style="white-space: nowrap">and/or</font> its
affiliates in state and federal courts representing claims by
approximately 100 plaintiffs. Many of the cases involve multiple
plaintiffs. The majority of the cases have been transferred to
and consolidated in the United States District Court for the
Eastern District of Arkansas (<i>In re: Prempro Products
Liability Litigation, MDL Docket No. 1507</i>). Discovery
in these cases is ongoing. The Company believes it has
substantial meritorious defenses to these cases and maintains
product liability insurance against such cases. However,
litigation is inherently uncertain and the Company cannot
predict the outcome of this litigation. These actions, if
successful, or if insurance does not provide sufficient coverage
against such claims, could adversely affect the Company and
could have a material adverse effect on the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Fentanyl Transdermal System
Litigation.</i>  Beginning in 2009, a number of
product liability suits were filed against the Company and
certain Company affiliates, as well as other manufacturers and
distributors of fentanyl transdermal system products, for
personal injuries or deaths allegedly arising out of the use of
the fentanyl transdermal system products. Approximately 38 cases
are pending against the Company
<font style="white-space: nowrap">and/or</font> its
affiliates in state and federal courts, representing claims by
approximately 110 plaintiffs. Discovery is ongoing. The Company
believes it has substantial meritorious defenses to these cases
and maintains product liability insurance against such cases.
However, litigation is inherently uncertain and the Company
cannot predict the outcome of this litigation. These actions, if
successful, or if insurance does not provide sufficient coverage
against such claims, could adversely affect the Company and
could have a material adverse effect on the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Metoclopramide Litigation.</i>  Beginning in 2009,
a number of product liability suits were filed against the
Company and certain Company affiliates, as well as other
manufacturers and distributors of metoclopramide, for personal
injuries allegedly arising out of the use of metoclopramide.
Approximately 300 cases are pending against the Company
<font style="white-space: nowrap">and/or</font> its
affiliates in state and federal courts, representing claims by
approximately 800 plaintiffs. These cases are generally at
their preliminary stages and discovery is ongoing. The Company
believes that it will be indemnified for the majority of these
claims by Pliva, Inc., an affiliate of Teva Pharmaceutical
Industries, Ltd., from whom the Company purchased its
metoclopramide product in late 2008. Further, the Company
believes that it has substantial meritorious defenses to these
cases and maintains product liability insurance against such
cases. However, litigation is inherently uncertain and the
Company cannot predict the outcome of this litigation. These
actions, if successful, or if our indemnification arrangements
or insurance do not provide sufficient coverage against such
claims, could adversely affect the Company and could have a
material adverse effect on the Company’s business, results
of operations, financial condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Medical West Ballas Pharmacy, LTD, et al. v. Anda, Inc.,
</i>(Circuit Court of the County of St. Louis, State of
Missouri, Case
<font style="white-space: nowrap">No. 08SL-CC00257).</font>
In January 2008, Medical West Ballas Pharmacy, LTD, filed a
purported class action complaint against the Company alleging
conversion and alleged violations of the Telephone Consumer
Protection Act (“TCPA”) and Missouri Consumer Fraud
and Deceptive Business Practices Act. In April 2008, plaintiff
filed an amended complaint substituting Anda, Inc., a subsidiary
of the Company, as the defendant. The amended complaint alleges
that by sending unsolicited facsimile advertisements, Anda
misappropriated the class members’ paper, toner, ink and
employee time when they received the alleged unsolicited faxes,
and that the alleged unsolicited facsimile advertisements were
sent to the plaintiff in violation of the TCPA and Missouri
Consumer Fraud and Deceptive Business Practices Act. The
complaint seeks to assert class action claims on behalf of the
plaintiff and other similarly situated third parties. In April
2008, Anda filed an answer to the amended complaint, denying the
allegations. In November 2009, the court granted
plaintiff’s motion to expand the class of plaintiffs from
individuals for which Anda lacked evidence of express permission
or an established business relationship to “All persons who
on or after four years prior to the filing of this action, were
sent telephone facsimile messages advertising pharmaceutical
drugs and products by or on behalf of Defendant.” In
November 2010, the plaintiff filed a second amended complaint
further expanding the definition and scope of the proposed class
of plaintiffs. On November 30, 2010, Anda filed a petition
with the Federal Communications Commission (“FCC”),
asking the FCC to clarify the statutory basis for its regulation
requiring “opt-out” language on faxes sent with
express permission of the recipient. The FCC’s ruling on
Anda’s petition may determine whether fax recipients who
expressly agree to receive faxes may assert claims for receipt
of such faxes pursuant to the TCPA. On December 2, 2010,
Anda filed a motion to dismiss claims the plaintiff is seeking
to assert on behalf of putative class members who expressly
consented or agreed to receive faxes from Defendant, or in the
alternative, to stay the court proceedings pending resolution of
Anda’s petition to the FCC. The motion remains pending. No
trial date has been set. Anda intends to defend the action
vigorously. However, this action, if successful, could have an
adverse effect on the Company’s business, results of
operations, financial condition and cash flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Drospirenone/Ethinyl Estradiol Tablets (Generic version of
Yasmin</i><sup style="font-size: 85%; vertical-align: text-top">®</sup><i>).</i>  On
April 7, 2008, Bayer Schering Pharma AG sued the Company in
the United States District Court for the Southern District of
New York, alleging that sales of the Company’s
drospirenone/ethinyl estradiol tablets, a generic version of
Bayer’s
Yasmin<sup style="font-size: 85%; vertical-align: text-top">®</sup>
tablets, infringes Bayer’s U.S. Patent
No. 5,569,652 (<i>Bayer Schering Pharma AG v. Watson
Pharmaceuticals, Inc., et. al., Case No. 08cv3710</i>). The
complaint sought damages and injunctive relief. On
September 28, 2010, the district court granted the
Company’s motion for judgment on the pleadings and
dismissed the case with prejudice. Final judgment was entered on
January 7, 2011. On January 21, 2011, Bayer filed a
Notice of Appeal with the United States Court of Appeals for the
Second Circuit. The Company believes it has substantial
meritorious defenses to the case. However, the Company has sold
and is continuing to sell its generic version of
Yasmin<sup style="font-size: 85%; vertical-align: text-top">®</sup>.
Therefore, an adverse ruling on the appeal or a subsequent final
determination that the Company has infringed the patent in suit
could have a material adverse effect on the Company’s
business, results of operations, financial condition and cash
flows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson and its affiliates are involved in various other
disputes, governmental
<font style="white-space: nowrap">and/or</font>
regulatory inspections, inquires, investigations and proceedings
that could result in litigation, and other litigation matters
that arise from time to time. The process of resolving matters
through litigation or other means is inherently uncertain and it
is possible that an unfavorable resolution of these matters will
adversely affect the Company, its results of operations,
financial condition and cash flows.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringIncludes disclosure of commitments and contingencies. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
falsefalse12Commitments and ContingenciesUnKnownUnKnownUnKnownUnKnownfalsetrueXML
32
R31.xml
IDEA: Long Term Debt (Tables)
2.2.0.25falsefalse0509 - Disclosure - Long Term Debt (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_LongTermDebtTablesAbstractwpifalsenadurationLong-Term Debt.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringLong-Term Debt.falsefalse3false0us-gaap_LongTermDebtTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note9_table1 - us-gaap:LongTermDebtTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Long-term debt consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes,
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2014 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2019 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Unamortized discount
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2006 Credit Facility
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
151.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loan with Lombard Odier Darier Hentsch & Cie.
(“Lombard Loan”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other notes payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,457.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
307.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total long-term debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,150.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used as a single block of text to encapsulate the entire disclosure for long-term borrowings including data and tables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
falsefalse4false0wpi_AnnualDebtMaturitiesTextBlockwpifalsenadurationAnnual debt maturities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00Annual Debt MaturitiesAnnual Debt MaturitiesfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringAnnual debt maturities.No authoritative reference available.falsefalse13Long Term Debt (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
33
R45.xml
IDEA: Acquisitions and Divestitures (Details) (Textual)
2.2.0.25truefalse06041 - Disclosure - Acquisitions and Divestitures (Details) (Textual)truefalseIn Millions, except Share data, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 3/31/2010
USD ($)
$ThreeMonthsEnded_31Mar2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-03-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalseUSDfalsefalse12/2/2009
USD ($)
USD ($) / shares
$BalanceAsOf_02Dec2009http://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$6falsefalseUSDtruefalse{us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis} : Moksha8 [Member]
10/4/2010
USD ($)
$BalanceAsOf_04Oct2010_Moksha_Eight_Memberhttp://www.sec.gov/CIK0000884629instant2010-10-04T00:00:000001-01-01T00:00:00falsefalseMoksha8 [Member]us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_MokshaEightMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7falsefalseUSDtruefalse{us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis} : Scinopharm [Member]
1/1/2010 - 3/31/2010
USD ($)
$ThreeMonthsEnded_31Mar2010_Scinopharm_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseScinopharm [Member]us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ScinopharmMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis} : Columbia Laboratories [Member]
7/2/2010
USD ($)
$BalanceAsOf_02Jul2010_Columbia_Laboratories_Memberhttp://www.sec.gov/CIK0000884629instant2010-07-02T00:00:000001-01-01T00:00:00falsefalseColumbia Laboratories [Member]us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ColumbiaLaboratoriesMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberPureStandar
dhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_AcquisitionsAndDivestituresAdditionalTextualsAbstractwpifalsenadurationAcquisitions And Divestitures.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00
falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringAcquisitions And D
ivestitures.falsefalse3false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse10500000001050.0falsetruefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8truefalsefalse6200000062.0falsetruefalsetruefalse<
/Cells>Monetaryxbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse4false0us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPaymentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse250000000250.0falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8truefalsefalse4550000045.5falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of potential cash payments that could result from the contingent consideration arrangement.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
falsefalse5false0wpi_CommitmentToMakeInvestmentContingentUponSucessfulAcquisitionOfAdditionalThirdPartyProductAcquisitionwpifalsedebitinstantCommitment to make investment contingent upon sucessful acquisition of additional third party product acquisition.falsefalsefalsefalsefalsefalsefalsefalsefalse
falseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalse
DisplayDateInUSFormat>falsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6truefalsefalse2000000020.0falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryCommitment to make investment contingent upon sucessful acquisition of additional third party product acquisition.No authoritative reference available.falsefalse6false0wpi_PercentageIncreaseInOwnershipShareAfterAdditionalInvestmentwpifalsenainstantPercentage Increase in ownership share after additional investment.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsefalsefalse6truetruefalse0.310.31falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepurePercentage Increase in ownership share after additional investment.No authoritative reference available.falsefalse7false0us-gaap_EquityMethodInvestmentsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00false<
ShowCurrencySymbol>falsefalsefalsefalse2truefalsefalse6320000063.2falsefalsefalsefalsefalse3truefalsefalse7540000075.4falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6truefalsefalse3000000030.0falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indica
tor of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment losses recognized.No authoritative reference available.falsefalse8false0us-gaap_EquityMethodInvestmentOwnershipPercentageus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsefalsefalse6truetruefalse0.220.22falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph f
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 20
-Subparagraph a (1)
truefalse9false0us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestmentsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse9540000095.4falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse82000008.2falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7true<
IsRatio>falsefalse9400000094.0falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse<
Unit>Monetaryxbrli:monetaryItemTypemonetaryThe cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15, 16
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 31
falsefalse10false0us-gaap_GainLossOnSaleOfInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefa
lsefalse00falsefalsefalsefalsefalse2truefalsefalse2730000027.3falsefalsefalsefalsefalse3truefalsefalse-1100000-1.1falsefalsefalsefalsefalse4truefalsefalse96000009.6falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse2340000023.4falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe net realized gain or loss on investments sold during the period, which, for cash flow reporting, is a component of proceeds from investing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse11false0us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquiredus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetr
uefalse00falsefalsefalsefalsefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8truetruefalse0.130.13falsefalsefalsetruefalseOtherus-types:percentItemTypepurePercentage of voting equity interests acquired in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph c
falsefalse12false0wpi_BusinessAcquisitionsEquityInterestIssuedOrIssuableNumberOfSharesIssuedwpifalsenainstantBusiness acquisitions equity interest issued or issuable number of shares issued.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverbose
label1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8truefalsefalse1120000011200000falsefalsefalsetruefalseSharesxbrli:sharesItemTypesharesBusiness acquisitions equity interest issued or issuable number of shares issued.No authoritative reference available.falsefalse13true0wpi_AcquisitionsAndDivestituresTextualsAbstractwpifalsenadurationAcquisitions And Divestitures Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringAcquisitions And Divestitures Textuals Abstract.falsefalse14false0us-gaap_StockIssuedDuringPeriodSharesAcquisitionsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse
2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse1690000016900000falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse<
Id>6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseSharesxbrli:sharesItemTypesharesNumber of shares of stock issued during the period pursuant to acquisitions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 53
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
falsefalse15false0us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssuedus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse<
Cell>3truefalsefalse200000200000falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseSharesxbrli:integerItemTypeintegerNumber of shares of equity interests issued or issuable to acquire entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse16false0wpi_CurrentMarketPricePerShareOfRestrictedCommonStockwpifalsenainstantCurrent market price per share of restricted common stock.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse37.5537.55falsetruefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseEPSus-types:perShareItemTypedecimalCurrent market price per share of restricted common stock.No authoritative reference available.falsetrue17false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalse<
IsEquityPrevioslyReportedAsRow>falsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse636200000636.2falsefalsefalsefalsefalse6falsefalsefalse00<
NonNumbericText />falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe acquisition-date fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(4)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 39
falsefalse18false0us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5t
ruefalsefalse200000000200.0falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryValue of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 99-12
falsefalse19false0us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosureus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1<
IsNumeric>falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5
truefalsefalse150000000150.0falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of mandatorily redeemable preferred stock which the Company has issued and which is outstanding as of the balance sheet date. A financial instrument issued in the form of shares is mandatorily redeemable if it embodies an unconditional obligation requiring the issuer to redeem the instrument by transferring its assets at a specified or determinable date (or dates) or upon an event certain to occur. A financ
ial instrument that embodies a conditional obligation to redeem the instrument by transferring assets upon an event not certain to occur becomes mandatorily redeemable - and, therefore, becomes a liability - if that event occurs, the condition is resolved, or the event becomes certain to occur. A mandatorily redeemable financial instrument shall be classified as a liability unless the redemption is required to occur only upon the liquidation or termination of the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 150
-Paragraph 9, 10
falsefalse20false0us-gaap_BusinessAcquisitionPurchasePriceAllocationNoncurrentLiabilitiesLongTermDebtus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse166400000166.4falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to the noncurrent portion of the long-term debt assumed from the acquired entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 37
-Subparagraph g
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 98-1
falsefalse21false0wpi_EffectiveAnnualInterestRateUsingForProbabilityWeightedCashFlowsWereDiscountedwpifalsenainstantEffective annual interest rate using for probability-weighted cash flows were discounted.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5truetruefalse0.1040.104falsefalsefalsefalsefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse
hasScenarios>Otherus-types:percentItemTypepureEffective annual interest rate using for probability-weighted cash flows were discounted.No authoritative reference available.falsefalse22false0us-gaap_InventoryWriteDownus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse2600000026.0falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryCharge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Section 7
-Paragraph 14
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Concepts (CON)
-Number 6
-Paragraph 86
falsefalse23false0us-gaap_CostOfGoodsSoldAmortizationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse1420000014.2falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7false<
IsRatio>falsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonet
aryxbrli:monetaryItemTypemonetaryThe amount of expense recognized in the current period that reflects the allocation of the costs of intangible assets over the expected benefit period of such assets. This element applies only to intangible assets used in the production of goods.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse24false0wpi_AmortizationOfCostOfSalesRemainingValuewpifalsedebitdurationAmortization of cost of sales ,remaining value.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1180000011.8falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3<
/Id>falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5<
IsNumeric>falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmortization of cost of sales ,remaining value.No authoritative reference available.falsefalse25false0wpi_FairValueOfAmountsDueForTransferOfCertainProductRightsAndTechnologywpifalsedebitinstantFair value of amounts due for the transfer of certain product rights and technology.falsefalsefalsefalsefalse<
IsEquityPrevioslyReportedAsRow>falsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse9000000090.0falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryFair value of amounts due for the transfer of certain product rights and technology.No authoritative reference available.falsefalse26false0us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAverageUsefulLifeus-gaap
truenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse55falsefalsefalsefalsefalse3truefalsefalse55falsefal
sefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:decimalItemTypedecimalThe calculated weighted-average amortization period of a major class of finite-lived intangible assets acquired during the current period either individually or as part of a group of assets (in either an a
sset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 44
-Subparagraph a(3)
falsefalse27false0us-gaap_BusinessCombinationAcquisitionRelatedCostsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3tr
uefalsefalse1660000016.6falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsetruefalse7false
falsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 59
falsefalse826Acquisitions and Divestitures (Details) (Textual) (USD $)HundredThousandsNoRoundingUnKnownUnKnowntruetrueXML
34
R43.xml
IDEA: Share-Based Compensation (Details)
2.2.0.25falsefalse0603 - Disclosure - Share-Based Compensation (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3true0wpi_ShareBasedCompensationDetailsTextualsAbstract
wpifalsenadurationShare Based Compensation.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringShare Based Compensation.falsefalse4false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse52000005.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe maximum number of shares originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the share-based compensation plan. As stock options and equity instruments other than options are awarded to participants, the shares remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph a
falsefalse5false0wpi_OptionAwardPlanExercisableOverPeriodwpifalsenadurationOption award plan exercisable over period.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00three to five yearsthree to five yearsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOption award plan exercisable over period.No authoritative reference available.falsefalse6false0wpi_OptionAwardPlanExpireswpifalsenadurationOption award plan expires.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse0010 years
NonNumbericText>10 yearsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00
RoundedNumericAmount>falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOption award plan expires.No authoritative reference available.falsefalse7false0wpi_DurationOverWhichRestrictionsEliminatedFromRestrictedStockAwardswpifalsenadu
rationDuration over which restrictions eliminated from restricted stock awards.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00over
a one to four year periodover
a one to four year periodfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringDuration over which restrictions eliminated from restricted stock awards.No authoritative reference available.falsefalse8false0wpi_LapseOfRestrictionsForNonemployeeDirectorswpifalsenadurationLapse of restrictions for non-employee directors.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00after one yearafter one yearfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00f
alsefalsefalsefalsefalseOtherxbrli:stringItemTypestringLapse of restrictions for non-employee directors.No authoritative reference available.falsefalse9false0wpi_LapseOfRestrictionsForEmployeeswpifalsenadurationLapse Of Restrictions For Employeesfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00two to four year periodtwo to four year periodfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefal
seOtherxbrli:stringItemTypestringLapse Of Restrictions For EmployeesNo authoritative reference available.falsefalse10false0us-gaap_ShareBasedCompensationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse2350000023.5falsetruefalsefalsefalse2truefalsefalse1910000019.1falsetruefalsefalsefalse3truefalsefalse1850000018.5falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration.
This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse11false0wpi_ShareBasedCompensationCapitalizedToInventorywpifalsedebitdurationShare-based compensation capitalized to inventory.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse36000003.6falsetruefalsefalsefalse2truefalsefalse27000002.7falsetruefalsefalsefalse3truefalsefalse33000003.3falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryShare-based compensation capitalized to inventory.No authoritative reference available.falsefalse39Share-Based Compensation (Details) (USD $)HundredThousandsHundredThousandsUnKnownUnKnownfalsetrueXML
35
R49.xml
IDEA: Goodwill, Product Rights and Other Intangibles (Details)
2.2.0.25truefalse0608 - Disclosure - Goodwill, Product Rights and Other Intangibles (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse12/31/2010
USD ($)
$BalanceAsOf_31Dec2010http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse12/31/2009
USD ($)
$BalanceAsOf_31Dec2009http://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0wpi_ScheduleOfGoodwillBySegmentAbstractwpifalsenadurationSchedule Of Goodwill By Segment Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSchedule Of Goodwill By Segment Abstract.falsefalse3false0us-gaap_Goodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse15281000001528.1falsetruefalsefalsefalse2truefalsefalse15010000001501.0falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
falsefalse4false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Brands segment [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Global_Brands_Contribution_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseGlobal Brands segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalBrandsContributionMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www
.xbrl.org/2003/iso4217USDiso42170USDUSD$4falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Brands segment [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Global_Brands_Contribution_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseGlobal Brands segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalBrandsContributionMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www
.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse5true0wpi_ScheduleOfGoodwillBySegmentAbstractwpifalsenadurationSchedule Of Goodwill By Segment Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSchedule Of Goodwill By Segment Abstract.falsefalse6false0us-gaap_Goodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse371600000371.6falsefalsefalsefalsefalse2truefalsefalse348200000348.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any im
pairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
falsefalse7false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Generics segment [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Global_Generics_Segment_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseGlobal Generics segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalGenericsSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbr
l.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Generics segment [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Global_Generics_Segment_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseGlobal Generics segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalGenericsSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbr
l.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse8true0wpi_ScheduleOfGoodwillBySegmentAbstractwpifalsenadurationSchedule Of Goodwill By Segment Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSchedule Of Goodwill By Segment Abstract.falsefalse9false0us-gaap_Goodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10702000001070.2falsefalsefalsefalsefalse2truefalsefalse10665000001066.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for an
y impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
falsefalse10false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Distribution segment [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Distribution_Segment_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseDistribution segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_DistributionSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/20
03/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Distribution segment [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Distribution_Segment_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseDistribution segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_DistributionSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/20
03/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse11true0wpi_ScheduleOfGoodwillBySegmentAbstractwpifalsenadurationSchedule Of Goodwill By Segment Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefal
sefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSchedule Of Goodwill By Segment Abstract.falsefalse12false0us-gaap_Goodwillu
s-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse8630000086.3falsetruefalsefalsefalse2truefalsefalse8630000086.3falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any impairment charges,
in excess of the fair value of net assets acquired in one or more business combination transactions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
falsefalse211Goodwill, Product Rights and Other Intangibles (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
36
R53.xml
IDEA: Long-Term Debt (Details Textual)
2.2.0.25truefalse06091 - Disclosure - Long-Term Debt (Details Textual)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalsefalsefalse12/2/2012
BalanceAsOf_02Dec2012http://www.sec.gov/CIK0000884629instant2012-12-02T00:00:000001-01-01T00:00:00PureStandardhttp://www.xbrl.org/2003/instancepurexbrli04falsefalseUSDfalsefalse12/2/2009
USD ($)
USD ($) / shares
$BalanceAsOf_02Dec2009http://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2014 [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Senior_Notes_Due_Two_Thousand_Fourteen_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2014 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandFourteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalsetruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2014 [Member]
2/15/2010
BalanceAsOf_15Feb2010_Senior_Notes_Due_Two_Thousand_Fourteen_Memberhttp://www.sec.gov/CIK0000884629instant2010-02-15T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2014 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandFourteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberPureStandardhttp://www.xbrl.org/20
03/instancepurexbrli07falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2014 [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Senior_Notes_Due_Two_Thousand_Fourteen_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2014 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandFourteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2019 [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Senior_Notes_Due_Two_Thousand_Nineteen_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2019 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandNineteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalsetruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2019 [Member]
8/15/2010
BalanceAsOf_15Aug2010_Senior_Notes_Due_Two_Thousand_Nineteen_Memberhttp://www.sec.gov/CIK0000884629instant2010-08-15T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2019 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandNineteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberPureStandardhttp://www.xbrl.org/20
03/instancepurexbrli010falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2019 [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Senior_Notes_Due_Two_Thousand_Nineteen_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2019 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandNineteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Senior_Notes_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SeniorNotesMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Senior_Notes_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SeniorNotesMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Mandatorily Redeemable Preferred Stock [Member]
1/1/2009 - 12/31/2009
TwelveMonthsEnded_31Dec2009_Mandatorily_Redeemable_Preferred_Stock_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseMandatorily Redeemable Preferred Stock [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MandatorilyRedeemablePreferredStockMemberus-gaap_LongtermDebtTypeAxisexplicitMemberSharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$14falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Mandatorily Redeemable Preferred Stock [Memb
er]
12/2/2012
USD ($)
$BalanceAsOf_02Dec2012_Mandatorily_Redeemable_Preferred_Stock_Memberhttp://www.sec.gov/CIK0000884629instant2012-12-02T00:00:000001-01-01T00:00:00falsefalseMandatorily Redeemable Preferred Stock [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MandatorilyRedeemablePreferredStockMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Mandatorily Redeemable Preferred Stock [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Mandatorily_Redeemable_Preferred_Stock_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseMandatorily Redeemable Preferred Stock [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MandatorilyRedeemablePreferredStockMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Mandatorily Redeemable Preferred Stock [Member]
12/2/2009
USD ($)
$BalanceAsOf_02Dec2009_Mandatorily_Redeemable_Preferred_Stock_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-02T00:00:000001-01-01T00:00:00falsefalseMandatorily Redeemable Preferred Stock [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MandatorilyRedeemablePreferredStockMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Loan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Lombard_Loan_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseLoan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_LombardLoanMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhtt
p://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Loan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Lombard_Loan_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseLoan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_LombardLoanMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhtt
p://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Loan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]
11/25/2009
USD ($)
$BalanceAsOf_25Nov2009_Lombard_Loan_Memberhttp://www.sec.gov/CIK0000884629instant2009-11-25T00:00:000001-01-01T00:00:00falsefalseLoan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_LombardLoanMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www
.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalsetruefalse{us-gaap_LineOfCreditFacilityAxis} : Term Facility [Member]
7/1/2010 - 7/31/2010
OneMonthEnded_31Jul2010_Term_Facility_Memberhttp://www.sec.gov/CIK0000884629duration2010-07-01T00:00:002010-07-31T00:00:00falsefalseTerm Facility [Member]us-gaap_LineOfCreditFacilityAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_TermFacilityMemberus-gaap_LineOfCreditFacilityAxisexplicitMember21falsefalseUSDtruefalse{us-gaap_LineOfCreditFacilityAxis} : Term Facility [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Term_Facility_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseTerm Facility [Member]us-gaap_LineOfCreditFacilityAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_TermFacilityMemberus-gaap_LineOfCreditFacilityAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$22falsefalseUSDtruefalse{us-gaap_LineOfCreditFacilityAxis} : 2006 Credit Facility [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Line_Of_Credit_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalse2006 Credit Facility [Member]us-gaap_LineOfCreditFacilityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LineOfCreditMemberus-gaap_LineOfCreditFacilityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23falsefalseUSDtruefalse{us-gaap_LineOfCreditFacilityAxis} : Revolving credit facility [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Revolving_Credit_Facility_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseRevolving credit facility [Member]us-gaap_LineOfCreditFacilityAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_RevolvingCreditFacilityMemberus-gaap_LineOfCreditFacilityAxisexplicitMemberUSDStandardhttp://www.xbrl.or
g/2003/iso4217USDiso42170USDUSD$2true0wpi_LongTermDebtTextualsAbstractwpifalsenadurationLong Term Debt Textuals.falsefalsefalsefalsefalsefalsefals
efalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00fal
sefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringLong Term Debt Textuals.falsefalse3false0us-gaap_DebtInstrumentInterestRateEffectivePercentageus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsetruefalse6truetruefalse0.05430.0543falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9truetruefalse0.06350.0635falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11falsetruefalse00falsefalsefalsetruefalse12falsetruefalse00falsefalsefalsetruefalse13falsetruefalse00falsefalsefalsetruefalse14falsetruefalse00falsefalsefalsetruefalse15falsetruefalse00falsefalsefalsetruefalse16falsetruefalse00falsefalsefalsetruefalse17falsetruefalse00<
FootnoteIndexer />falsefalsefalsetruefalse18falsetruefalse00falsefalsefalsetruefalse19falsetruefalse00falsefalsefalsetruefalse20falsetruefalse00falsefalsefalsetruefalse21falsetruefalse00falsefalsefalsetruefalse22falsetruefalse00falsefalsefalsetruefalse23falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
falsefalse4false0wpi_MinimumPeriodForRedemptionOfSeniorNoteswpifalsenadurationMinimum Period For Redemption Of Senior Notes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1515falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5false<
IsRatio>falsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalse<
/IsRatio>false00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalse<
DisplayZeroAsNone>false00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefa
lse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse
DisplayZeroAsNone>00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerMinimum Period For Redemption Of Senior Notes.No authoritative reference available.falsefalse5false0wpi_MaximumPeriodForRedemptionOfSeniorNoteswpifalsenadurationMaximum Period For Redemption Of Senior Notes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse6060falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00fa
lsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00false
IsIndependantCurrency>falsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefa
lsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalse
ShowCurrencySymbol>falsetruefalseOtherxbrli:integerItemTypeintegerMaximum Period For Redemption Of Senior Notes.No authoritative reference available.falsefalse6false0wpi_DescriptionOfRedemptionPriceOfSeniorNoteswpifalsenadurationDescription of Redemption price of the Senior Notes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00Equal to the greater of 100% of the principal amount of the Senior Notes to be redeemed and the sum of the present values of the remaining scheduled payments plus 40 basis pointsEqual to the greater of 100% of the principal amount of the Senior Notes to be redeemed and the sum of the present values of the remaining sched
uled paymentsfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringDescription of Redemption price of the Senior Notes.No authoritative reference available.falsefalse7false0us-gaap_DebtInstrumentFairValueus-gaaptruecreditinstantNo d
efinition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefals
e2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse
Cell>8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11truefalsefalse7100000071000000falsetruefalsetruefalse
Cell>12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse
18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryEstimated fair value of the debt instrument at the balance-sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
falsefalse8false0wpi_DescriptionOfRepurchasePriceOfSeniorNoteswpifalsenadurationDescription of Repurchase Price of the Senior Notes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00101% of the principal amount of the Senior Notes to be repurchased plus accrued and unpaid interest to the date of purchase101% of the principal amount of the Senior Notes to be repurchased plus accrued and unpaid interest to the date of purchasefalsefalsefalsefalsefalse2falsefalsefalse00<
FootnoteIndexer />falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringDescription of Repurchase Price of the Senior Notes.No authoritative reference avai
lable.falsefalse9false0us-gaap_LineOfCreditFacilityCovenantComplianceus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00The Company is subject to, and, as of December 31, 2010, was in compliance with, financial and operation covenants under the terms of the 2006 Credit FacilityThe Company is subject to, and, as of December 31, 2010, was in compliance with, financial and operation covenants under the terms of the 2006 Creditfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00
RoundedNumericAmount>falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringIdentification of whether the entity ha
s been in compliance with any credit facility debt covenants during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 22
-Article 5
falsefalse10false0us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssuedus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1<
IsNumeric>falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse200000200000falsefalsefalsefalsefalse3
Id>falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9false
falsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13truefalsefalse200000200000falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21false
falsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalse
false00falsefalsefalsetruefalseSharesxbrli:integerItemTypeintegerNumber of shares of equity interests issued or issuable to acquire entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse11false0wpi_BusinessAcquisitionEquityInterestIssuedOrIssuablePerShareStatedValuewpifalsenainstantBusiness Acquisition Equity Interest Issued Or Issuable per share Stated Value.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse
verboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalse<
/hasSegments>false3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefal
se13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse10001000falsetruefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseEPSus-types:perShareItemTypedecimalBusiness Acquisition Equity Interest Issued Or Issuable per share Stated Value.No authoritative reference available.falsetrue12false0us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse200000000200000000falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse200000000200000000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryValue of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 99-12
falsefalse13false0us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsSettlementDateus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsetruefalsefalse2falsefalsefalse00falsefalsetruefalsefalse3
falsefalsefalse00falsefalsetruefalsefalse4falsefalsefalse00falsefalsetruefalsefalse5false
IsNumeric>falsefalse00falsefalsetruetruefalse6falsefalsefalse00falsefalsetruetruefalse7falsefalsefalse00falsefalsetruetruefalse8falsefalsefalse00falsefalsetruetruefalse9falsefalsefalse00falsefalsetruetruefalse10falsefalsefalse00falsefalsetruetruefalse11falsefalse<
/IsRatio>false00falsefalsetruetruefalse12falsefalsefalse00falsefalsetruetruefalse13falsefalsefalse00falsefalsetruetruefalse14falsefalsefalse00falsefalsetruetruefalse15falsefalsefalse002012-12-022012-12-02falsefalsetruetruefalse16falsefalsefalse00falsefalsetruetruefalse17falsefalsefalse00falsefalsetruetruefalse18falsefalsefalse00falsefalsetruetruefalse19fal
sefalsefalse00falsefalsetruetruefalse20falsefalsefalse00falsefalsetruetruefalse21falsefalsefalse00falsefalsetruetruefalse22falsefalsefalse00falsefalsetruetruefalse23falsefalsefalse00falsefalsetruetruefalseOtherxbrli:dateItemTypedateFor a forward contract or an option indexed to the issuer's equity shares, the settlement date or dates of the contract, as applicable.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 150
-Paragraph 27
-Subparagraph f
falsefalse14false0us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosureus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse<
Cell>3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse150000000150000000falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse1
1falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse150000000150000000falsefalsefalsetruefalse1
7falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be
used in both the balance sheet and disclosure in the same submission. This item represents the amount of mandatorily redeemable preferred stock which the Company has issued and which is outstanding as of the balance sheet date. A financial instrument issued in the form of shares is mandatorily redeemable if it embodies an unconditional obligation requiring the issuer to redeem the instrument by transferring its assets at a specified or determinable date (or dates) or upon an event certain to occur. A financial instrument that embodies a conditional obligation to redeem the instrument by transferring assets upon an event not certain to occur becomes mandatorily redeemable - and, therefore, becomes a liability - if that event occurs, the condition is resolved, or the event becomes certain to occur. A mandatorily redeemable financial instrument shall be classified as a liability unless the redemption is required to occur only upon the liquidation or termination of the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 150
-Paragraph 9, 10
falsefalse15false0us-gaap_LongTermDebtus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefa
lsefalse10161000001016100000falsefalsefalsefalsefalse2truefalsefalse14578000001457800000falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5fal
sefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11truefalsefalse847900000847900000falsefalsefalsetruefalse12truefalsefalse847500000847500000falsefalsefalsetruefalse13truefalsefalse151200000151200000falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15truefalsefalse166400000166400000falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17truefalsefalse00falsefalsefalsetruefalse18truefalsefalse5500000055000000falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle,
if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse16false0wpi_MandatoryRedemptionValueForMandatorilyRedeemablePreferredStockwpifalsecreditinstantMandatory redemption value for Mandatorily Redeemable Preferred Stock.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse
5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7<
IsNumeric>falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11fa
lsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13false
IsNumeric>falsefalse00falsefalsefalsetruefalse14truefalsefalse200000000200000000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17fa
lsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19false
IsNumeric>falsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryMandatory redemption value for Mandatorily Redeemable Preferred Stock.No authoritative reference available.falsefalse17false0wpi_DiscountRateOfMandatorilyRedeemablePreferredStockwpifalsenainstantDiscount Rate Of Mandatorily Redeemable Preferred Stock.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3truetruefalse0.09630.0963falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsetruefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9falsetruefalse00<
FootnoteIndexer />falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11falsetruefalse00falsefalsefalsetruefalse12falsetruefalse00falsefalsefalsetruefalse13falsetruefalse00falsefalsefalsetruefalse14falsetruefalse00falsefalsefalsetruefalse15falsetruefalse00falsefalsefalsetruefalse16falsetruefalse00falsefalsefalsetruefalse17falsetruefalse00falsefalsefalsetruefalse18falsetruefalse00falsefalsefalsetruefalse19falsetruefalse00<
CurrencySymbol />falsefalsefalsetruefalse20falsetruefalse00falsefalsefalsetruefalse21falsetruefalse00falsefalsefalsetruefalse22falsetruefalse00falsefalsefalsetruefalse23falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureDiscount Rate Of Mandatorily Redeemable Preferred Stock.No authoritative reference available.falsefalse18false0wpi_UnamortizedAccretionExpenseForPreferredStockwpifalsedebitinstantUnamortized Accretion Expense For The Preferre
d Stock.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse<
/Cell>4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse<
Id>8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10
Id>falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13truefalsefalse3360000033600000falsefalsefalsetruefalse1
4falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22fal
sefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryUnamortized Accretion Expense For The Preferred Stock.No authoritative reference available.falsefalse19false0us-gaap_DebtInstrumentFaceAmountus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00fals
efalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19truefalsefalse9000000090000000falsefalsefalsetruefalse20falsefalsefalse00false<
/IsIndependantCurrency>falsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or d
iscount.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 21
-Paragraph 16, 20
falsefalse20false0us-gaap_RepaymentsOfLongTermDebtus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false<
/IsNumeric>falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefals
efalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17truefalsefalse5500000055000000falsefalsefalsetruefalse18truefalsefalse3500000035000000falsefalsefalsetruefalse19falsefal
sefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 20
-Subparagraph b
falsefalse21false0us-gaap_DebtInstrumentCarryingAmountus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse<
DisplayZeroAsNone>false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse450000000450000000falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse450000000450000000falsefalsefalsetruefalse8truefalsefalse400000000400000000falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10truefalsefalse400000000400000000falsefalsefalsetruefalse11true
IsNumeric>falsefalse850000000850000000falsefalsefalsetruefalse12truefalsefalse850000000850000000falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15
Id>falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21f
alsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23false<
/IsNumeric>falsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date before deducting unamortized discount or premiums (if any). May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or be
yond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number APB14-1
-Paragraph 31
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
falsefalse22true0us-gaap_LineOfCreditFacilityLineItemsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse
00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.falsefalse23false0us-gaap_LineOfCreditFacilityMaximumBorrowingCapacityu
s-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefa
lsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21truefalsefalse650000000650000000falsefalsefalsetruefalse22truefalsefalse11500000001150000000falsefalsefalsetruefalse23truefalsefalse500000000500000000falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 22
-Article 5
falsefalse24false0wpi_CreditFacilityTimePeriodwpifalsenadurationCredit Facility time period.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsef
alse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21truefalsefalse55falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerCredit Facility time period.No authoritative reference available.falsefalse25false0us-gaap_LineOfCreditFacilityInterestRateDescriptionus-gaaptrue<
BalanceType>nadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefa
lsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalse
DisplayDateInUSFormat>truefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetrue
false20falsefalsefalse00LIBOR plus 0.625%LIBOR plus 0.625%falsefalsefalsetruefalse21falsefalsefalse00LIBOR plus 0.75% (subject to certain
adjustments)LIBOR plus 0.75% (subject to certain
adjustments)falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringDescription of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 22
-Article 5
falsefalse26false0us-gaap_LineOfCreditFacilityDecreaseRepaymentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse400000000400000000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefal
sefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefals
e00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryDecrease for amounts repaid on the credit facility for the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph f
-Article 4
falsefalse27true0wpi_AnnualDebtMaturitiesAbstractwpifalsenadurationAnnual debt maturities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefal
se00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringAnnual debt maturities.falsefalse28false0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse100000100000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefals
e8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse<
/Cell>14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22
Id>falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of long-term debt maturing within the next twelve months following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 47
-Paragraph 10
-Subparagraph b
falsefalse29false0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwous-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse
IsRatio>false200100000200100000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsef
alsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsef
alse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse<
/DisplayZeroAsNone>00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of long-term debt maturing in year two following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 47
-Paragraph 10
-Subparagraph b
falsefalse30false0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse
false100000100000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false
falsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalse
false00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalse
false00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse
00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of long-term debt maturing in year three following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed of determinable prices and dates.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 47
-Paragraph 10
-Subparagraph b
falsefalse31false0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse<
/IsRatio>false450100000450100000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5false
falsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalse
IsRatio>false00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalse
false00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse
00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of long-term debt maturing in year four following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed of determinable prices and dates.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 47
-Paragraph 10
-Subparagraph b
falsefalse32false0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse<
/IsRatio>false14000001400000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefals
efalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefals
e00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of long-term debt maturing in year five following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed of determinable prices and dates.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 47
-Paragraph 10
-Subparagraph b
falsefalse33false0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFiveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse400000000400000000falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalse
false00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefal
se00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of long-term debt maturities after year five following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed of determinable prices and dates.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 47
-Paragraph 10
-Subparagraph b
falsefalse2332Long-Term Debt (Details Textual) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruetrueXML
37
R18.xml
IDEA: Stockholders' Equity
2.2.0.25falsefalse0212 - Disclosure - Stockholders' Equitytruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_StockholdersEquityNoteAbstract<
ElementPrefix>us-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefals
efalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_StockholdersEquityNoteDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 12 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 12 —
Stockholders’ Equity</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Preferred
stock</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In 1992, the Company authorized 2.5 million shares of no
par preferred stock. The Board has the authority to fix the
rights, preferences, privileges and restrictions, including but
not limited to, dividend rates, conversion and voting rights,
terms and prices of redemptions and liquidation preferences
without vote or action by the stockholders. On December 2,
2009 the Company issued 0.2 million shares of
Mandatorily Redeemable Preferred Stock. The Mandatorily
Redeemable Preferred Stock is redeemable in cash on
December 2, 2012 and is accordingly, included within
long-term debt in the consolidated balance sheet at
December 31, 2010 (for additional information on the
Mandatorily Redeemable Preferred Stock refer to
“NOTE 9 — Long-Term Debt”).
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Stock
option plans</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has adopted several stock option plans, all of which
have been approved by the Company’s shareholders that
authorize the granting of options to purchase the Company’s
common shares subject to certain conditions. At
December 31, 2010, the Company had reserved
5.2 million of its common shares for issuance upon exercise
of options granted or to be granted under these plans and for
restricted stock grants (see discussion below). The option award
plans require options to be granted at the fair value of the
shares underlying the options at the date of the grant and
generally become exercisable over periods ranging from three to
five years and expire in ten years. In conjunction with certain
of the Company’s acquisitions, Watson assumed stock option
and warrant plans from the acquired companies. The options and
warrants in these plans were adjusted by the individual exchange
ratios specified in each transaction. No additional options or
warrants will be granted under any of the assumed plans.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the Company’s stock option plans consisted of
the following (options and aggregate intrinsic value in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="57%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Exercise<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Options</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Price</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.91
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Exercised
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.49
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.63
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
48.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Vested and expected to vest at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.71
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
47.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Options exercisable at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
42.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As of December 31, 2010, the Company had $0.5 million
of total unrecognized compensation expense, net of estimated
forfeitures, related to stock option grants, which will be
recognized over the remaining weighted average period of
1.1 years. Total intrinsic value of options exercised for
the year ended December 31, 2010 and 2009 was
$18.4 million and $7.4 million, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Restricted
Stock Plan</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Beginning in 2005, the Compensation Committee of the Board
authorized and issued restricted stock to the Company’s
Participants under the Company’s equity compensation plans.
The restricted stock award program offers Participants the
opportunity to earn shares of our common stock over time, rather
than options that give Participants the right to purchase stock
at a set price. Restricted stock awards are grants that entitle
the holder to shares of common stock subject to certain terms.
Watson’s restricted stock awards generally have
restrictions eliminated over a one- to four-year period.
Restrictions generally lapse for non-employee directors after
one year. Restrictions generally lapse for employees over a two-
to four-year period. The fair value of restricted stock grants
is based on the fair market value of our common stock on the
respective grant dates. Restricted stock compensation is being
amortized and charged to operations over the same period as the
restrictions are eliminated for the Participants.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the changes in restricted stock grants during the
year ended December 31, 2010 is presented below (shares and
aggregate intrinsic value in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="60%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Grant Date<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Shares</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.79
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.03
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
43.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Vested
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.74
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.55
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.33
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
79.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As of December 31, 2010, the Company had $28.6 million
of total unrecognized compensation expense, net of estimated
forfeitures, related to restricted stock grants, which will be
recognized over the remaining weighted average period of
1.6 years.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Stock
Repurchases</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During the years ended December 31, 2010 and 2009, the
Company repurchased approximately 0.1 million and
0.1 million shares, respectively, of its common stock
surrendered to the Company to satisfy tax withholding
obligations in connection with the vesting of restricted stock
issued to employees for total consideration of $6.3 million
and $3.6 million, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Accumulated
Other Comprehensive Income (Loss)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Accumulated other comprehensive income (loss) at
December 31, 2010 consists of unrealized gains on
securities of $9.2 million and foreign currency translation
adjustments of ($11.7) million.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDisclosures related to accounts comprising shareholders' equity, including other comprehensive income. Includes: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion
, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms and number o
f warrants or rights outstanding; (15) shares under subscription and subscription receivables; effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C, E
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4
falsefalse12Stockholders' EquityUnKnownUnKnownUnKnownUnKnownfalsetrueXML
38
R32.xml
IDEA: Other Long-Term Liabilities (Tables)
2.2.0.25falsefalse0510 - Disclosure - Other Long-Term Liabilities (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_OtherLongTermLiabilitiesTablesAbstractwpifalsenadurationOther Long-Term Liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringOther Long-Term Liabilities.falsefalse3false0wpi_OtherLongTermLiabilitiesTextBlockwpifalsenadurationOther Long-Term Liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note10_table1 - wpi:OtherLongTermLiabilitiesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other long-term liabilities consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="83%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Atorvastatin contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
123.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Columbia contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
212.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion included in accounts payable and accrued
expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringOther Long-Term Liabilities.No authoritative reference available.falsefalse12Other Long-Term Liabilities (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
39
R67.xml
IDEA: Commitments and Contingencies (Details)
2.2.0.25truefalse0616 - Disclosure - Commitments and Contingencies (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_AdditionalCommitmentsAndContingenciesTextuals
AbstractwpifalsenadurationAdditional Commitments And Contingencies.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Commitments And Contingencies.falsefalse3false0wpi_TotalAmountOfSettlementForAllOfSettlingDefendantsUnderGovernmentalReimbursementInvestigationAndDrugPricingLitigationwpifalsedebitdurationTotal amount of the settlement for all of the settling defendants unde
r governmental reimbursement investigation and drug...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse125000000125.0falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal amount of the settlement for all of the settling defendants under governmental reimbursement investigation and drug pricing litigation.No authoritative reference available.falsefalse4true0wpi_CommitmentsAndContingenciesTextualsAbstractwpifalsenadurationCommitments and Contingencies.falsefa
lsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalse<
DisplayZeroAsNone>false00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringCommitments and Contingencies.falsefalse5false0us-gaap_LeaseAndRentalExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2600000026.0falsefalsefalsefalsefalse2truefalsefalse2000000020.0falsefalsefalse
falsefalse3truefalsefalse1900000019.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryRental expense incurred for leased assets including furniture and equipment which has not been recognized in costs and expenses applicable to sales and revenues; for example, cost of goods sold or other operating costs and expens
es.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph c
falsefalse6false0us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1tr
uefalsefalse2440000024.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within one year of the balance sheet date relating to leases defined as operating.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 122
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph b(i)
falsefalse7false0us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYearsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1860000018.6falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the second year of the balance sheet date relating to leases defined as operating.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 122
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph b(i)
falsefalse8false0us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYearsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1460000014.6falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the third year of the balance sheet date relating to leases defined as operating.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 122
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph b(i)
falsefalse9false0us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYearsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1250000012.5falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the fourth year of the balance sheet date relating to leases defined as operating.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 122
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph b(i)
falsefalse10false0us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1280000012.8falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the fifth year of the balance sheet date relating to leases defined as operating.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 122
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph b(i)
falsefalse11false0us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafterus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse5300000053.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due after the fifth year from the balance sheet date on leases defined as operating.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 122
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 13
-Paragraph 16
-Subparagraph b(i)
falsefalse12false0us-gaap_DefinedBenefitPlanContributionsByEmployerus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse95000009.5falsefalsefalsefalsefalse2truefalsefalse1100000011.0falsefalsefalsefalsefalse
hasScenarios>3truefalsefalse1060000010.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of contributions made by the employer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
falsefalse13false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/commitmentsandcontingenciesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{dei_LegalEntityAxis} : Ven-A-Care [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Vena_Care_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseVen-A-Care [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_VenaCareMemberdei_LegalEntityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse14true0wpi_AdditionalCommitmentsAndContingenciesTextualsAbstractwpifalsenadurationAdditional Commitments And Contingencie
s.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Commitments And Contingencies.falsefalse15false0wpi_TotalAmountToBePaidUnderSettlementwpifalsecreditdurationTotal amount to be paid under settlement.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse7900000079falsefalsefalsefalsefalse2falsefalsefalse00
falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal amount to be paid under settlement.No authoritative reference available.falsefalse16false0us-gaap_LitigationReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefa
lsefalse129900000129.9falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.No authoritative reference available.falsefalse315Commitments and Contingencies (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
40
R57.xml
IDEA: Income Taxes (Details Textual)
2.2.0.25truefalse06112 - Disclosure - Income Taxes (Details Textual)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDfalsefalse12/31/2007
USD ($)
$BalanceAsOf_31Dec2007http://www.sec.gov/CIK0000884629instant2007-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4true0wpi_IncomeTaxesTextualsAbstractwpifalsenadurationIncome Taxes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringIncome Taxes.falsefalse5false0us-gaap_TaxBenefitFromStockOptionsExercisedus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse-6700000-6.7falsetruefalsefalsefalse2truefalsefalse-2300000-2.3falsetruefalsefalsefalse3truefalsefalse-200000-0.2falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReductions in the entity's income taxes that arise when
compensation cost (from non-qualified stock options) recognized on the entity's tax return exceeds compensation cost from non-qualified stock options recognized on the income statement. This element increases net cash provided by operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A132
falsefalse6false0wpi_UndistributedEarningOfForeignSubsidiarieswpifalsecreditinstantUndistributed earning of the foreign subsidiaries.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse8930000089.3falsefalsefalsefalsefalse2truefalsefalse3610000036.1falsefalsefalsefalsefalse<
Id>3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryUndistributed earning of the foreign subsidiaries.No authoritative reference available.falsefalse7false0us-gaap_UnrecognizedTaxBenefitsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse6800000068.0falsefalsefalsefalsefalse2truefalsefalse7220000072.2falsefalsefalsefalsefalse3truefalsefalse6130000061.3falsefalsefalsefalsefalse4truefalsefalse7120000071.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of unrecognized tax benefits (tax reductions recognized in financial reports but excluded from tax returns) pertaining to uncertain tax positions taken in tax returns as of the beginning balance sheet date, excluding amounts pertaining to examined tax returns.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a
falsefalse8false0us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRateus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse6020000060.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse<
/Cell>3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph b
falsefalse9false0us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-2300000-2.3falsefalsefalsefalsefalse2truefalsefalse14000001.4falsefalsefalsefalsefalse3truefalsefalse-800000-0.8falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the total of interest expense recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties in the period in which the entity claims or expects to claim a tax position, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 16
falsefalse10false0us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse24000002.4falsefalsefalsefalsefalse2truefalsefalse51000005.1falsefalsefalsefalsefalse3truefalsefalse39000003.9falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the total of accruals as of the date of the statement of financial position for interest recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties for a tax position claimed or expected to be claimed by the entity, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 16
falsefalse11false0us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccruedus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse18000001.8falsefalsefalsefalsefalse2truefalsefalse31000003.1falsefalsefalsefalsefalse<
/Cell>3truefalsefalse23000002.3falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.No authoritative reference available.falsefalse12false0wpi_ReductionInIncomeTaxExpenseDueToAndrxExaminationwpifalsecreditdurationReduction in Income Tax Expense Due To Andrx Examination.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse47000004.7falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReduction in Income Tax Expense Due To Andrx Examination.No authoritative reference available.falsefalse13false0wpi_ReductionInIncomeTaxExpenseDueToCompanyExaminationwpifalsecreditdurationReduction in Income Tax Expense Due to company Examination.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1390000013.9falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReduction in Income Tax Expense Due to company Examination.No authoritative reference a
vailable.falsefalse14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/incometaxesdetailstextual1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_OperatingLossCarryforwardsByTaxAuthorityAxis} : Foreign Country [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Foreign_Country_Member_2http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseForeign Country [Member]us-gaap_OperatingLossCarryforwardsByTaxAuthorityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ForeignCountryMemberus-gaap_OperatingLossCarryforwardsByTaxAuthorityAxisexplicitMemberUSDStandardh
ttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse15true0wpi_AdditionalIncomeTaxesTextualsAbstractwpifalsenadurationAdditional Income Taxes Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Income Taxes Textuals Abstract.falsefalse16false0us-gaap_OperatingLossCarryforwardsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse9600000096.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, av
ailable to reduce future taxable income under enacted tax laws.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 48
-Subparagraph a
falsefalse19false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/incometaxesdetailstextual1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse
false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse6falsefalseUSDtruefalse{wpi_TaxCreditCarryforwardByTaxAuthorityAxis} : Foreign Country [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Foreign_Country_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseForeign Country [Member]wpi_TaxCreditCarryforwardByTaxAuthorityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ForeignCountryMemberwpi_TaxCreditCarryforwardByTaxAuthorityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2
003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse21true0wpi_IncomeTaxesTextualAbstractwpifalsenadurationIncom
e Taxes Textual Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefals
e4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringIncome Taxes Textual Abstract.falsefalse22false0us-gaap_TaxCreditCarryforwardAmountus
- -gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse3600000036.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 48
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 17
-Subparagraph a
falsefalse24false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/incometaxesdetailstextual1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_OperatingLossCarryforwardsByTaxAuthorityAxis} : State and Local Jurisdiction [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_State_And_Local_Jurisdiction_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseState and Local Jurisdiction [Member]us-gaap_OperatingLossCarryforwardsByTaxAuthorityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_StateAndLocalJurisdictionMemberus-gaap_OperatingLossCarryforwardsByTaxAuthorityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse25true0wpi_AdditionalIncomeTaxesTextualsAbstractwpifalsenadurationAdditional Income Taxes Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Income Taxes Textuals Abstract.falsefalse26false0us-gaap_OperatingLossCarryforwardsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse197000000197.0falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe sum of domestic, foreign and state
and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 48
-Subparagraph a
falsefalse419Income Taxes (Details Textual) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
41
R12.xml
IDEA: Balance Sheet Components
2.2.0.25falsefalse0206 - Disclosure - Balance Sheet Componentstruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_BalanceSheetComponentsAbstractwpifalsenadurationBalance Sheet Components.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringBalance Sheet Components.falsefalse3false0wpi_BalanceSheetComponentsTextBlockwpifalsenadurationBalance Sheet Components.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 6 - wpi:BalanceSheetComponentsTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 6 —
Balance Sheet Components</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Selected balance sheet components consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Inventories:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Raw materials
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
178.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
196.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
<font style="white-space: nowrap">Work-in-process</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Finished goods
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
465.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
509.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
770.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Inventory reserves
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Inventories, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
631.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
692.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Property and equipment:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
570.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Buildings and improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
385.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
382.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
106.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Leasehold improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
78.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
46.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
45.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Land and land improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Construction in progress
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, at cost
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,265.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,197.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Less accumulated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(623.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(503.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
642.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
694.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Accounts payable and accrued expenses:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade accounts payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
215.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
263.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Proposed legal settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
129.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued payroll and related benefits
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued third-party rebates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
83.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
60.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Royalties and sales agent payables
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current portion of contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued indirect returns
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Interest payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued severence, retention and other shutdown costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
98.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
95.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total accounts payable and accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
741.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
614.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<!-- XBRL Pagebreak End -->
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringBalance Sheet Components.No authoritative reference available.falsefalse12Balance Sheet ComponentsUnKnownUnKnownUnKnownUnKnownfalsetrueXML
42
R3.xml
IDEA: Consolidated Balance Sheets (Parenthetical)
2.2.0.25falsefalse0111 - Statement - Consolidated Balance Sheets (Parenthetical)truefalseIn Millions, except Per Share datafalse1falsefalseUSDfalsefalse12/31/2010
USD ($)
$BalanceAsOf_31Dec2010http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse12/31/2009
USD ($)
$BalanceAsOf_31Dec2009http://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$3true0us-gaap_AssetsCurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse4false0us-gaap_AllowanceForDoubtfulAccountsReceivableCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalse<
IsEquityPrevioslyReportedAsRow>falsefalsetruefalsefalseperiodstartlabel1truefalsefalse1250000012.5falsetruefalsefalsefalse2truefalsefalse54000005.4falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryA valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5
falsefalse5true0us-gaap_StockholdersEquityAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse6false0us-gaap_PreferredStockParOrStatedValuePerShareus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverbos
elabel1truefalsefalse00falsetruefalsefalsefalse2truefalsefalse00falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalFace amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
falsetrue7false0us-gaap_PreferredStockSharesAuthorizedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse25000002.5falsefalsefalsefalsefalse2truefalsefalse25000002.5falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
falsefalse8false0us-gaap_CommonStockParOrStatedValuePerShareus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse0.00330.0033falsetruefalsefalsefalse2truefalsefalse0.00330.0033falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalFace amount or stated value of common stock per share; generally not indicative of the fair market value per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 4
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
falsetrue9false0us-gaap_CommonStockSharesAuthorizedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse500000000500.0falsefalsefalsefalsefalse2truefalsefalse500000000500.0falsefalsefalsefalsefalseShares<
/Unit>xbrli:sharesItemTypesharesThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
falsefalse10false0us-gaap_CommonStockSharesIssuedus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse135500000135.5falsefalsefalsefalsefalse2truefalsefalse133000000133.0falsefalsefalsefalsefalseS
haresxbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
falsefalse11false0us-gaap_CommonStockSharesOutstandingus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse125800000125.8falsefalsefalsefalsefalse2truefalsefalse123400000123.4falsefalsefalsefalsefalse
Sharesxbrli:sharesItemTypesharesTotal number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Excludes common shares repurchased by the entity and held as Treasury shares. Shares outstanding equals shares issued minus shares held in treasury. Does not include common shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
falsefalse12false0us-gaap_TreasuryStockSharesus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse97000009.7falsefalsefalsefalsefalse2truefalsefalse96000009.6falsefalsefalsefalsefalseSharesxbrli:sharesI
temTypesharesNumber of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
falsefalse210Consolidated Balance Sheets (Parenthetical) (USD $)HundredThousandsHundredThousandsNoRoundingUnKnownfalsetrueXML
43
R14.xml
IDEA: Goodwill, Product Rights and Other Intangibles
2.2.0.25falsefalse0208 - Disclosure - Goodwill, Product Rights and Other Intangiblestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_GoodwillProductRightsAndOtherIntangiblesAbstract<
/ElementName>wpifalsenadurationGoodwill, Product Rights and Other Intangibles.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringGoodwill, Product Rights and Other Intangibles.falsefalse3false0us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 8 - us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 8 —
Goodwill, Product Rights and Other Intangibles</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill for the Company’s reporting units consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Brands segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
371.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
348.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Global Generics segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,070.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,066.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Distribution segment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,528.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,501.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The increase in goodwill in 2010 primarily relates to the
acquisition of the remaining 64% of Eden as discussed in
“NOTE 1 — Description of Business”.
Goodwill for the Company’s Global Generics segment as of
December 31, 2009 has been revised from the amount
presented in our Annual report on
<font style="white-space: nowrap">Form 10-K</font>
for the year ended December 31, 2009. (Refer to
“NOTE 4 — Acquisitions and
Divestitures” for additional details.)
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other intangible assets consist primarily of product rights. The
original cost and accumulated amortization of these intangible
assets, where applicable, consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised) </b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with definite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product rights and other related intangibles
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,049.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,855.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Core technology
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
52.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Customer relationships
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,151.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,957.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less accumulated amortization
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,211.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,031.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
940.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
926.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangibles with indefinite lives
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
IPR&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
615.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade Name
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
76.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
691.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
787.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total product rights and related intangibles, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,632.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 1,713.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Intangible assets acquired with the Arrow Acquisition amounted
to $1,119.6 million, including $518.6 million relating
to CMP and $711.0 relating to IPR&D intangibles. CMP
intangibles have been included in product rights and other
related intangibles and will be amortized over a weighted
average useful life of approximately five years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In July 2010, the Company acquired intangible assets in
connection with the acquisition of the U.S rights to certain
Columbia products amounting to $115.3 million, including
$39.5 million relating to CMP and $75.8 million
relating to IPR&D intangibles. CMP intangibles have been
included in product rights and other related intangibles and
will be amortized using a weighted average useful life of
approximately five years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During 2010 approximately $142.3 million of IPR&D
intangibles were transferred to product rights and other related
intangibles as products received regulatory approval.
Amortization of these intangibles commenced upon product launch
using a weighted average useful life of approximately five years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson re-evaluates the carrying value of identifiable
intangible and long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying value may
not be recoverable. The Company continually evaluates the
appropriateness of useful lives assigned to long-lived assets,
including product rights.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During the fourth quarter of 2010, the Company recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. The
impairment charge results from the Company’s current
estimate of the fair value of these IPR&D assets, based on
updated forecasts, compared to their assigned fair values on
Acquisition Date. The fair value of acquired identifiable
intangible assets generally is determined using an income
approach, based on a forecast of all expected future net cash
flows related to the asset which are adjusted to present value
using appropriate discount rates. Forecasts used to determine
fair values of IPR&D assets are based on appropriate
assumptions which include, among other factors, the impact of
changes to the development programs, the current competitive
environment, the regulatory timeframes impacting future product
launch dates and the risk associated with these assets.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Assuming no additions, disposals or adjustments are made to the
carrying values
<font style="white-space: nowrap">and/or</font>
useful lives of the assets, annual amortization expense on
product rights and related over the next five years is estimated
to be as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="93%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2011
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
270.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2012
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
417.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2013
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
311.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2014
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
299.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2015
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
138.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The above amortization expense is an estimate. Actual amounts
may change from such estimated amounts due to fluctuations in
foreign currency exchange rates, additional intangible asset
acquisitions, potential impairments, accelerated amortization or
other events. The Company’s current product rights and
related intangibles have a weighted average remaining useful
life of approximately five years.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDiscloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and writte
n off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. Fo
r each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to incl
ude the entire intangible asset disclosure including data and tables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 43, 44, 45, 46, 47
falsefalse12Goodwill, Product Rights and Other IntangiblesUnKnownUnKnownUnKnownUnKnownfalsetrueXML
44
R48.xml
IDEA: Investments in Marketable Securities and Other Investments (Details)
2.2.0.25truefalse0607 - Disclosure - Investments in Marketable Securities and Other Investments (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDtruefalse{us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis} : U.S. Treasury and agency securities maturing within one year [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_U_S_Treasury_And_Agency_Securities_Maturing_Within_One_Year_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseU.S. Treasury and agency securities maturing within one year [Member]us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_USTreasuryAndAgencySecuritiesMaturingWithinOneYearMemberus-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxisexpl
icitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis} : U.S. Treasury and agency securities maturing within one year [Member
]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_U_S_Treasury_And_Agency_Securities_Maturing_Within_One_Year_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseU.S. Treasury and agency securities maturing within one year [Member]us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_USTreasuryAndAgencySecuritiesMaturingWithinOneYearMemberus-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxisexpl
icitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis} : U.S. Treasury and agency securities maturing within two years [Membe
r]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_U_S_Treasury_And_Agency_Securities_Maturing_Within_Two_Years_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseU.S. Treasury and agency securities maturing within two years [Member]us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_USTreasuryAndAgencySecuritiesMaturingWithinTwoYearsMemberus-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxise
xplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7falsefalseUSDtruefalse{us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis} : U.S. Treasury and agency securities maturing within two years [M
ember]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_U_S_Treasury_And_Agency_Securities_Maturing_Within_Two_Years_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseU.S. Treasury and agency securities maturing within two years [Member]us-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_USTreasuryAndAgencySecuritiesMaturingWithinTwoYearsMemberus-gaap_ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxise
xplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis} : Moksha8 [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Moksha_Eight_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseMoksha8 [Member]us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_MokshaEightMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis} : Moksha8 [Member]
10/4/2010
USD ($)
$BalanceAsOf_04Oct2010_Moksha_Eight_Memberhttp://www.sec.gov/CIK0000884629instant2010-10-04T00:00:000001-01-01T00:00:00falsefalseMoksha8 [Member]us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_MokshaEightMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2true0us-gaap_AvailableForSaleSecuritiesAbstractus-gaaptruenadurationNo definition availabl
e.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse
Cell>2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse<
Id>6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1030000010.3falsetruefalsefalsefalse2truefalsefalse1230000012.3falsetruefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse48000004.8falsetruefalsetruefalse5truefalsefalse60000006.0falsetruefalsetruefalse6truefalsefalse55000005.5falsetrue
ShowCurrencySymbol>falsetruefalse7truefalsefalse63000006.3falsetruefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, which
ever is longer. Such securities are reported at fair value; unrealized gains and losses of such securities are excluded from earnings and included in other comprehensive income, a separate component of shareholders' equity, unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 4, 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
falsefalse4false0us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse8000000.8falsefalsefalsefalsefalse2truefalsefalse13000001.3falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7fa
lsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents equity securities categorized neither as held-to-maturity nor trading which are intended to be sold within one year from the balance sheet date or the normal operating cycle, whichever is longer. Equity securities represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership intere
st is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 4, 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3
-Subparagraph c
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
truefalse5false0us-gaap_MarketableSecuritiesCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1110000011.1falsefalsefalsefalsefalse2truefalsefalse1360000013.6falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalse<
DisplayZeroAsNone>false00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryTotal debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2
-Article 5
truefalse6true0wpi_InvestmentsAndOtherAssetAbstractwpifalsenadurationInvestments and other assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse<
DisplayZeroAsNone>false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefa
lse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringInvestments and other assets.falsefalse7false0us-gaap_EquityMethodInvestmentsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse6320000063.2falsefalsefalsefalsefalse2truefalsefalse7540000075.4falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalse
hasSegments>false4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9truefalsefalse3000000030.0falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment losses recognized.No authoritative reference available.falsefalse8false0wpi_CostMethodAndOtherLongTermInvestmentswpifalsedebitinstantCost Method and Other Long Term Investments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse3000000.3falsefalsefalsefalsefalse2truefalsefalse94000009.4falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalse<
/ShowCurrencySymbol>falsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryCost Method and Other Long Term Investments.No authoritative reference available.falsefalse9false0us-gaap_OtherAssetsNoncurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse2100000021.0falsefalsefalsefalsefalse2truefalsefalse2970000029.7falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse
00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemoneta
ryAggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 17
-Article 5
truefalse10false0wpi_InvestmentsAndOtherAssetswpifalsedebitinstantInvestments and other assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse8450000084.5falsefalsefalsefalsefalse2truefalsefalse114500000114.5falsefalsefalsefalsefalse3falsefalse<
DisplayZeroAsNone>false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefa
lse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryInvestments and other assets.No authoritative reference available.truefalse11true0wpi_InvestmentInEquityMethodInvestmentsTextualsAbstractwpifalsenadurationInvestment in Equity Method Investments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalse<
/ShowCurrencySymbol>falsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringInvestment in Equity Method Investments.falsefalse12false0us-gaap_PaymentsToAcquireEquityMethodInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefa
lsefalsefalsefalsefalsetruenegated1truefalsefalse-43700000-43.7falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8truefalsefalse2000000020.0falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash ou
tflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph b
falsefalse13true0wpi_AvailableForSaleSecuritiesAmortizedCostFairValueAndUnrealizedGainsLossesAbstractwpifalsenadurationAvailable for sale securities amortized cost fair value and unrealized gains losses.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabe
l1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefals
e9falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringAvailable for sale securities amortized cost fair value and unrealized gains losses.falsefalse14false0wpi_AvailableForSaleSecuritiesDebtSecuritiesCurrentAmortizedCostwpifalsedebitinstantAvailable for Sale Securities Debt Securities-Current Amortized Cost.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1030000010.3falsefalsefalsefalsefalse2truefalsefalse1230000012.3falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Debt Securities-Current Amortized Cost.No authoritative reference available.falsefalse15false0wpi_AvailableForSaleSecuritiesDebtSecuritiesCurrentGrossUnrealizedGainswpifalsecreditinstantAvailable for Sale Securities Debt Securities Current Gross Unrealized Gains.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00false
falsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Debt Securities Current Gross Unrealized Gains.No authoritative reference available.falsefalse16false0wpi_AvailableForSaleSecuritiesDebtSecuritiesCurrentGrossUnrealizedLosswpifalsedebitinstantAvailable for Sale Securities Debt Secu
rities Current Gross Unrealized Loss.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruef
alse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Debt Securities Current Gross Unrealized Loss.No authoritative reference available.falsefalse17false0us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefals
efalsefalsefalsefalsefalseterselabel1truefalsefalse1030000010.3falsefalsefalsefalsefalse2truefalsefalse123000001
2.3falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse48000004.8falsefalsefalsetruefalse5truefalsefalse60000006.0falsefalsefalsetruefalse6truefalsefalse55000005.5falsefalsefalsetruefalse7truefalsefalse63000006.3falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer. Such securities are reported at fair value; unrealized gains and losses of such securities are excluded from earnings and included in other comprehensive income, a separate component of shareholders' equity, unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 4, 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
falsefalse18false0wpi_AvailableForSaleSecuritiesEquitySecuritiesCurrentAmortizedCostwpifalsedebitinstantAvailable for Sale Securities Equity Securities Current Amortized Cost.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse7000000.7falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefa
lse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Equity Securities Current Amortized Cost.No authoritative reference available.truefalse19fal
se0wpi_AvailableForSaleSecuritiesEquitySecuritiesCurrentGrossUnrealizedGainswpifalsecreditinstantAvailable for Sale Securities Equity Securities Current Gross Unrealized Gains.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse8000000.8falsefalsefalsefalsefalse2truefalsefalse6000000.6falsefalsefalsefalsefalse3falsefalsefalse0<
/NumericAmount>0falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Equity Securities Current Gross Unrealized Gains.No authoritative reference available.truefalse20false0wpi_AvailableForSaleSecuritiesEquitySecuritiesCurrentGrossUnrealizedLosswpifalsedebitinstantAvailable for Sale Securities Equity Securities Current Gross Unrealized Loss.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00f
alsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Equity Securities Current Gross Unrealized Loss.No authoritative reference available.truefalse21false0us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrentus-gaaptruedebitinstantNo definition available.
ShortDefinition>falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse8000000.8falsefalsefalsefalsefalse
Cell>2truefalsefalse13000001.3falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse<
Id>8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents equity securities categorized neither as held-to-maturity nor trading which are intended to be sold within one year from the balance sheet date or the normal operating cycle, whichever is longer. Equity securities represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership interest is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a he
dge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 4, 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3
-Subparagraph c
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
falsefalse22false0wpi_AvailableForSaleSecuritiesCurrentAmortizedCostwpifalsedebitinstantAvailable for Sale Securities Current Amortized Cost.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1030000010.3falsefalsefalsefalsefalse2truefalsefalse1300000013.0falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Current Amortized Cost.No authoritative reference available.falsefalse23false0wpi_Availa
bleForSaleSecuritiesCurrentGrossUnrealizedGainswpifalsecreditinstantAvailable for Sale Securities Current Gross Unrealized Gains.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse8000000.8falsefalsefalsefalsefalse2truefalsefalse6000000.6falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Current Gross Unrealized Gains.No authoritative reference available.falsefalse24false0wpi_AvailableForSaleSecuritiesCurrentGrossUnrealizedLosswpifalsedebitinstantAv
ailable for Sale Securities Current Gross Unrealized Loss.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalse
falsefalse2truefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalse<
/hasSegments>false4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetrue<
hasScenarios>false8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Current Gross Unrealized Loss.No authoritative reference available.falsefalse25false0us-gaap_MarketableSecuritiesCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalse
falsefalsefalsefalsefalseterselabel1truefalsefalse1110000011.1falsefalsefalsefalsefalse2truefalsefalse1360000013.6falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryTotal debt and equity financial instruments including:
(1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2
-Article 5
falsefalse26false0wpi_AvailableForSaleSecuritiesEquitySecuritiesNoncurrentAmortizedCostwpifalsedebitinstantAvailable for Sale Securities Equity Securities Noncurrent Amortized Cost.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse1000000.1falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9
falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Equity Securities Noncurrent Amortized Cost.No authoritative reference available.truefalse27false0wpi_AvailableForSaleSecuritiesEquitySecuritiesNoncurrentGrossUnrealizedGainswpifalsecreditinstantAvailable for Sale Securities Equity Securities Noncurrent Gross Unrealized Gains.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1000000.1falsefalsefalsefalsefalse2truefalsefalse29000002.9falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Equity Securities Noncurrent Gross Unrealized Gains.No authoritative reference available.truefalse28false0wpi_AvailableForSaleSecuritiesEquitySecuritiesNoncurrentGrossUnrealizedLosswpifalsedebitinstantAvailable for Sale Securities Equity Securities Noncurrent Gross Unrealized Loss.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Equity Securities Noncurrent Gross Unrealized Loss.No authoritative reference available.truefalse29false0us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrentus-gaaptruedebitinstantNo definiti
on available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1000000.1falsefalsefalsefalsefalse
hasScenarios>2truefalsefalse30000003.0falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse
4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents equity securities categorized neither as held-to-maturity nor trading which are intended be sold more than one year from the balance sheet date or operating cycle, if longer. Equity securities represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership interest is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than tem
porary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 86-40
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3
-Subparagraph c
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
truefalse30false0us-gaap_AvailableForSaleSecuritiesAmortizedCostus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1030000010.3falsefalsefalsefalsefalse2truefalsefalse1310000013.1falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5fal
sefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 7
-Footnote 2
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19
truefalse31false0wpi_AvailableForSaleSecuritiesGrossUnrealizedGainwpifalsecreditinstantAvailable for Sale Securities Gross Unrealized Gain.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1true
falsefalse9000000.9falsefalsefalsefalsefalse2truefalsefalse35000003.5falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5fa
lsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Securities Gross Unrealized Gain.No authoritative reference available.truefalse32false0wpi_AvailableForSaleSecurityGross
UnrealizedLosswpifalsecreditinstantAvailable for Sale Security Gross Unrealized Loss.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAvailable for Sale Security Gross Unrealized Loss.No authoritative reference available.truefalse33false0us-gaap_AvailableForSaleSecuritiesus-gaaptruedebitinstantNo definition available.false
falsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1120000011.2falsefalsefalsefalsefalse2truefalsefalse1660000016.6falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefal
sefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryFor an unclassified balance sheet, this item represents investments in debt and equity securities which are categorized neither as held-to-maturity nor trading. Such securities are reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 14
truefalse34true0wpi_InvestmentsInMarketableSecuritiesAndOtherInvestmentsTextualsAbstractwpifalsenadurationInvestments in Marketable Securities and Other Investments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel<
Id>1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3<
/Id>falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9false
falsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringInvestments in Marketable Securities and Other Investments.falsefalse35false0us-gaap_IncomeLossFromEquityMethodInvestments<
/ElementName>us-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse16000001.6falsetruefalsefalsefalse2truefalsefalse1080000010.8falsetruefalsefalsefalse3truefalsefalse1060000010.6falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00fa
lsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 19
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 11
-Article 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 6
-Subparagraph b
falsefalse36false0wpi_OwnershipPercentageInCostMethodInvestmentwpifalsenainstantOwnership percentage in Cost method investment.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00under 20%falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5
falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringOwnership percentage in Cost method investment.No authoritative reference available.falsefalse935Investments
in Marketable Securities and Other Investments (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
45
R15.xml
IDEA: Long Term Debt
2.2.0.25falsefalse0209 - Disclosure - Long Term Debttruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_LongTermDebtAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_DebtDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 9 - us-gaap:DebtDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 9 —
Long-Term Debt</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Long-term debt consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes,
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2014 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
2019 Notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
850.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Unamortized discount
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Senior Notes, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
847.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
2006 Credit Facility
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
151.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loan with Lombard Odier Darier Hentsch & Cie.
(“Lombard Loan”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other notes payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,457.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
307.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total long-term debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,016.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,150.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Senior
Notes</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The offering of $450.0 million of 2014 Notes and
$400.0 million of 2019 Notes was registered under an
“automatic shelf” registration statement filed with
the Securities and Exchange Commission (“SEC”). The
Senior Notes were issued pursuant to a senior note indenture
dated as of August 24, 2009 between the Company and Wells
Fargo Bank, National Association, as trustee, as supplemented by
a first supplemental indenture dated August 24, 2009
(together the “Senior Note Indentures”).
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Interest payments are due on the Senior Notes semi-annually in
arrears on February 15 and August 15, respectively,
beginning February 15, 2010 at an effective annual interest
rate of 5.43% on the 2014 Notes and 6.35% on the 2019 Notes.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company may redeem the Senior Notes on at least 15 days
but no more than 60 days prior written notice for cash for
a redemption price equal to the greater of 100% of the principal
amount of the Senior Notes to be redeemed and the sum of the
present values of the remaining scheduled payments, as defined
by the Senior Note Indentures, of the Senior Notes to be
redeemed, discounted to the date of redemption at the applicable
treasury rate, as defined by the Senior Note Indentures, plus
40 basis points. As of December 31, 2010, the fair
value of our Senior Notes was approximately $71.0 million
greater than the carrying value.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon a change of control triggering event, as defined by the
Senior Note Indentures, the Company is required to make an offer
to repurchase the Senior Notes for cash at a repurchase price
equal to 101% of the principal amount of the Senior Notes to be
repurchased plus accrued and unpaid interest to the date of
purchase.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Net proceeds from the offering of Senior Notes in 2009 were used
to repay certain amounts under the 2006 Credit Facility and to
redeem other debt with the remaining net proceeds being used to
fund a portion of the cash consideration for the Arrow
Acquisition.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">2006
Credit Facility</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In November 2006, the Company entered into the 2006 Credit
Facility with Canadian Imperial Bank of Commerce, acting through
its New York agency, as Administrative Agent, Wachovia Capital
Markets, LLC, as Syndication Agent, and a syndicate of banks.
The 2006 Credit Facility provides an aggregate of
$1.15 billion of senior financing to Watson, consisting of
a $500.0 million revolving credit facility (“Revolving
Facility”) and a $650.0 million senior term loan
facility (“Term Facility”) and an initial interest
rate equal to LIBOR plus 0.75% (subject to certain adjustments).
In July 2010, the interest rate on the 2006 Credit Facility was
reduced to LIBOR plus 0.625%.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The 2006 Credit Facility has a five-year term and matures in
November 2011. The indebtedness under the 2006 Credit Facility
is guaranteed by Watson’s material domestic subsidiaries,
other than minor subsidiaries, on a joint and several basis. The
Revolving Facility is available for working capital and other
general corporate requirements subject to the satisfaction of
certain conditions. During 2010, the Company repaid
$400.0 million on the 2006 Credit Facility. As of
December 31, 2010, no amounts were outstanding on either
the Revolving Facility or the Term Facility of the 2006 Credit
Facility.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is subject to, and, as of December 31, 2010,
was in compliance with, all financial and operation covenants
under the terms of the 2006 Credit Facility.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Mandatorily
Redeemable Preferred Stock</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In connection with the Arrow Acquisition, on December 2,
2009, pursuant to the Purchase Agreement, Watson issued
0.2 million shares of newly designed non-voting
Series A Preferred Stock of Watson, having a stated value
of $1,000 per share (the “Stated Value”), or an
aggregate stated value of $200.0 million, which have been
placed in an indemnity escrow account for a period of three
years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The provisions for the Mandatorily Redeemable Preferred Stock
are as follows:
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Dividends</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The holders of Mandatorily Redeemable Preferred Stock shall be
entitled to receive dividends, when and of declared by the board
of directors.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Liquidation
Preference</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, the holders of the
Mandatorily Redeemable Preferred Stock will be paid out of the
assets of Watson available for
distribution to Watson’s shareholders before any payment
shall be paid to the holders of Watson’s common stock, an
amount equal to the Stated Value of the Mandatorily Redeemable
Preferred Stock.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Mandatory
Redemption</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Each share of Mandatorily Redeemable Preferred Stock is
mandatorily redeemable by Watson in cash on December 2,
2012, the third anniversary of its issuance at the Stated Value.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Change
in Control Redemption</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon occurrence of a Change in Control event (as defined in the
Certificate of Designations of the Mandatorily Redeemable
Preferred Stock that was previously filed with the SEC on
December 2, 2009), Watson shall have the right to redeem
all of the outstanding Mandatorily Redeemable Preferred Stock in
cash for a price per share equal to the Stated Value.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Voting
Rights</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The holders of the Mandatorily Redeemable Preferred Stock are
not entitled to vote on any matters presented to the
shareholders of Watson for their actions or consideration at any
meetings of the shareholders of Watson (or by written consent of
shareholders in lieu of the meetings), except that the written
consent or affirmative vote of at least two thirds of the then
outstanding shares of Mandatorily Redeemable Preferred Stock
consenting or voting separately as a class is required on any
matters that would amend, alter or repeal any terms,
preferences, special rights or powers of the Mandatorily
Redeemable Preferred Stock. The holders of the Mandatorily
Redeemable Preferred Stock may also vote on any matters required
by law.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with the existing U.S. GAAP, the Mandatorily
Redeemable Preferred Stock has been reported as long-term debt
and accretion expense has been classified as interest expense.
The fair value of the Mandatorily Redeemable Preferred Stock was
estimated to be $150.0 million at Acquisition Date based on
the mandatory redemption value of $200.0 million on
December 2, 2012 using a discount rate of 9.63% per annum.
At December 31, 2010, the fair value of the Mandatorily
Redeemable Preferred Stock was $166.4 million and the
unamortized accretion expense was $33.6 million.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Lombard
Loan</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On November 25, 2009, prior to closing the Arrow
Acquisition, the Arrow Group received loan proceeds from Lombard
Odier Darier Hentsch & Cie. in the amount of
$90.0 million.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with the terms of the Lombard Loan,
$35.0 million was paid in December 2009 and the remaining
balance of $55.0 million was paid in 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<i><font style="font-family: 'Times New Roman', Times">Fair
Value of Outstanding Debt</font></i>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Based on quoted market rates of interest and maturity schedules
for similar debt issues, we estimate that the fair values of our
2006 Credit Facility and our other notes payable approximated
their carrying values on December 31, 2010. As of
December 31, 2010, the fair value of our Senior Notes was
$71.0 million greater than the carrying value. While
changes in market interest rates may affect the fair value of
our fixed-rate debt, we believe the effect, if any, of
reasonably possible near-term changes in the fair value of such
debt on our financial condition, results of operations or cash
flows will not be material.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Annual
Debt Maturities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
At December 31, 2010, annual maturities of long-term debt
were as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="93%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2011
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2012
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
200.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2013
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2014
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
450.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
2015
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
Thereafter
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
400.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Amounts represent total anticipated cash payments on our Senior
Notes, Mandatorily Redeemable Preferred Stock and other current
and long-term debt assuming existing debt maturity schedules.
Any early settlement of our Senior Notes through redemption or
repurchase privileges, as defined under the terms of the Senior
Notes, would change the timing of principal amounts due under
the Company’s long-term debt obligations.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringInformation about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters
important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 20, 22
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
falsefalse12Long Term DebtUnKnownUnKnownUnKnownUnKnownfalsetrueXML
46
R24.xml
IDEA: Summary of Significant Accounting Policies (Policies)
2.2.0.25falsefalse0402 - Disclosure - Summary of Significant Accounting Policies (Policies)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_SummaryOfSignificantAccountingPoliciesPoliciesAbs
tractwpifalsenadurationSummary of Significant Accounting Policies.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSummary of Significant Accounting Policies.falsefalse3false0us-gaap_ConsolidationPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsef
alsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table1 - us-gaap:ConsolidationPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s consolidated financial statements are
prepared in accordance with accounting principles generally
accepted in the U.S. (“GAAP”). The consolidated
financial statements include the accounts of wholly-owned
subsidiaries, after elimination of intercompany accounts and
transactions. Certain prior year amounts have been reclassified
to conform to the current-year presentation.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Our consolidated financial statements include the financial
results of the Arrow Group subsequent to the Acquisition Date.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of a
ccounting. An entity also may describe its accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph k
-Article 1
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5, 6, 16-19
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02, 03
-Article 3A
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 140
-Paragraph 46
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 20
-Subparagraph a(2)
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph d
Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 97-2
Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 96-16
Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 14, 15
falsefalse4false0wpi_UseOfEstimatesPolicyTextBlockwpifalsenadurationUse of Estimates.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table2 - wpi:UseOfEstimatesPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Management is required to make certain estimates and assumptions
in order to prepare consolidated financial statements in
conformity with GAAP. Such estimates and assumptions affect the
reported amounts of assets, liabilities, revenues and expenses
and disclosure of contingent assets and liabilities in the
consolidated financial statements and accompanying notes. The
Company’s most significant estimates relate to the
determination of sales returns and allowances (“SRA”)
for accounts receivable and accrued liabilities, valuation of
inventory balances, the determination of useful lives for
intangible assets and the assessment of expected cash flows used
in evaluating goodwill and other long-lived assets for
impairment. The estimation process required to prepare the
Company’s consolidated financial statements requires
assumptions to be made about future events and conditions, and
as such, is inherently subjective and uncertain. Watson’s
actual results could differ materially from those estimates.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringUse of Estimates.No authoritative reference available.falsefalse5false0us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table3 - us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For most of the Company’s international operations, the
local currency has been determined to be the functional
currency. We translate functional currency assets and
liabilities to their U.S. dollar equivalents at rates in
effect at the balance sheet date and record these translation
adjustments as a component of accumulated other comprehensive
income (loss) within stockholders’ equity in the
consolidated balance sheets. We translate functional currency
statement of income amounts to their U.S. dollar
equivalents at the average rates for the period. The effects of
converting non-functional currency assets and liabilities into
the functional currency are recorded as general and
administrative expenses in the consolidated statements of
operations.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes a reporting enterprise's accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.Ref
erence 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 5, 7-20, 80
falsefalse6false0us-gaap_CashAndCashEquivalentsPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsef
alsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table4 - us-gaap:CashAndCashEquivalentsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company considers cash and cash equivalents to include cash
in banks, commercial paper and deposits with financial
institutions that can be liquidated without prior notice or
penalty. The Company considers all highly liquid investments
with an original maturity of three months or less to be cash
equivalents.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringA description of a company's cash and cash equivalents accounting policy. An entity shall disclose its policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash eq
uivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. In addition, cash equivalents include short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualif
y as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. For a bank, may include explanation and amount of requirement to maintain reserves against deposits.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 203
-Paragraph 02-03
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 8, 9, 10
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Technical Practice Aid (TPA)
-Number 2110
-Paragraph 6
falsefalse7false0wpi_FairValueOfOtherFinancialInstrumentsPolicyTextBlockwpifalsenadurationFair Value of Other Financial Instruments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false
falsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table5 - wpi:FairValueOfOtherFinancialInstrumentsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s financial instruments consist primarily of
cash and cash equivalents, marketable securities, accounts and
other receivables, investments, trade accounts payable, our
$450.0 million aggregate principal amount of
5.000% notes due August 14, 2014 (the “2014
Notes”) and $400.0 million aggregate principal amount
of 6.125% notes due August 14, 2019 (the “2019
Notes”) (together the “Senior Notes”) and our
Senior Credit Facility with Canadian Imperial Bank of Commerce,
acting through its New York agency, as administrative agent (the
“2006 Credit Facility”). The carrying amounts of cash
and cash equivalents, marketable securities, accounts and other
receivables and trade accounts payable are representative of
their respective fair values due to their relatively short
maturities. The fair values of investments in companies that are
publicly traded are based on quoted market prices. The Company
estimates the fair value of its fixed rate long-term obligations
based on quoted market rates of interest and maturity schedules
for similar issues. At December 31, 2010, the fair value of
our Senior Notes was approximately $71.0 million greater
than the carrying value.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringFair Value of Other Financial Instruments.No authoritative reference available.falsefalse8false0us-gaap_InventoryPolicyTextBlockus-gaaptruenaduration<
/PeriodType>No definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table6 - us-gaap:InventoryPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Inventories consist of finished goods held for sale and
distribution, raw materials and work in process. Included in
inventory at December 31, 2010 and 2009 is approximately
$4.6 million and $14.1 million, respectively, of
inventory that is pending approval by the U.S. Food and
Drug Administration (“FDA”), by other regulatory
agencies or has not been launched due to contractual
restrictions. This inventory consists of generic pharmaceutical
products that are capitalized only when the bioequivalence of
the product is demonstrated or the product has already received
regulatory approval and is awaiting a contractual triggering
event to enter the marketplace. Inventories are stated at the
lower of cost
<font style="white-space: nowrap">(first-in,</font>
first-out method) or market (net realizable value). The Company
writes down inventories to net realizable value based on
forecasted demand and market conditions, which may differ from
actual results.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policies covering its major classes of inventories, bases of stating inventories (for example lower of cost or market), methods by which amounts are added and removed from inventory classes (for example FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this description includes the nature of the cost elements included in inventory.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 206
-Chapter 2
-Paragraph b
-Subparagraph i, ii
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Paragraph 3, 5-10, 15, 16, 17
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 9
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 81-1
-Paragraph 69-75
falsefalse9false0us-gaap_PropertyPlantAndEquipmentPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table7 - us-gaap:PropertyPlantAndEquipmentPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Property and equipment are stated at cost, less accumulated
depreciation. Major renewals and improvements are capitalized,
while routine maintenance and repairs are expensed as incurred.
Costs associated with internally developed software are
accounted for in accordance with the guidance for the treatment
of costs associated with computer software development that
defines those costs to be capitalized and those to be expensed.
The Company capitalizes interest on qualified construction
projects. At the time property and equipment are retired from
service, the cost and accumulated depreciation is removed from
the respective accounts and the related gains or losses are
reflected in income.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Depreciation expense is computed principally on the
straight-line method, over estimated useful lives of the related
assets. The following table provides the range of estimated
useful lives used for each asset type:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="88%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="10%"> </td><!-- colindex=02 type=maindata -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Computer software / hardware
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
3-7 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-18 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-10 years
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Buildings, improvements, leasehold improvements and other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
5-40 years
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company assesses property and equipment for impairment
whenever events or changes in circumstances indicate that an
asset’s carrying amount may not be recoverable.
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 9
-Section C
-Paragraph 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 12, 13
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 34
-Paragraph 8, 9
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-Subparagraph d
falsefalse10false0us-gaap_InvestmentPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table8 - us-gaap:InvestmentPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s equity investments are accounted for under
the equity method when the Company can exert significant
influence and ownership does not exceed 50%. Watson accounts for
its joint ventures using the equity method. The Company records
equity method investments at cost and adjust for the appropriate
share of investee net earnings or losses. Investments in which
the Company owns less than a 20% interest and cannot exert
significant influence are accounted for using the cost method if
the fair value of such investments is not readily determinable.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policies for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the description may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, fo
r all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 7-16
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2, 12
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 7-18
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10, 11
falsefalse11false0wpi_MarketableSecuritiesPolicyTextBlockwpifalsenadurationMarketable Securities.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table9 - wpi:MarketableSecuritiesPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s marketable securities consist of
U.S. Treasury and agency securities and equity securities
of publicly-held companies. The Company’s marketable
securities are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value, based upon quoted market prices.
Unrealized temporary adjustments to fair value are included on
the balance sheet in a separate component of stockholders’
equity as unrealized gains and losses and reported as a
component of accumulated other comprehensive income. No gains or
losses on marketable securities are realized until shares are
sold or a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary.</font>
If a decline in fair value is determined to be
<font style="white-space: nowrap">other-than-temporary,</font>
an impairment charge is recorded and a new cost basis in the
investment is established.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringMarketable Securities.No authoritative reference available.falsefalse12false0us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table10 - us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
We test goodwill and intangible assets with indefinite-lives for
impairment annually at the end of the second quarter by
comparing the fair value of each of the Company’s reporting
units to the respective carrying value of the reporting units.
Additionally, we may perform tests between annual tests if an
event occurs or circumstances change that could potentially
reduce the fair value of a reporting unit below its carrying
amount. The Company’s reporting units have been identified
by Watson as Global Generics, Global Brands and Distribution.
The carrying value of each reporting unit is determined by
assigning the assets and liabilities, including the existing
goodwill and intangible assets, to those reporting units.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Goodwill is considered impaired if the carrying amount of the
net assets exceeds the fair value of the reporting unit.
Impairment, if any, would be recorded in operating income and
this could result in a material reduction in net income and
earnings per share. During the second quarter of 2010, the
Company performed its annual impairment assessment of goodwill,
acquired in-process research and development
(“IPR&D”) intangibles and trade name intangible
assets with indefinite-lives and determined there was no
impairment. Due to changes in market conditions in certain
international locations, the Company performed an off-cycle
impairment review in the fourth quarter of 2010 and recorded a
$28.6 million impairment charge related to certain
IPR&D assets acquired in the Arrow Acquisition. (Refer to
“Note 8 — Goodwill, Product Rights and Other
Intangibles” for additional details.)
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Included in intangible assets with indefinite-lives are trade
name intangible assets acquired prior to January 1, 2009
and IPR&D intangibles acquired after January 1, 2009.
Upon adoption of Financial Accounting Standards Board
(“FASB”) issued authoritative guidance on
January 1, 2009, using the purchase method of accounting,
IPR&D intangible assets are recognized at their fair value
on the balance sheet regardless of the likelihood of success of
the related product or technology. Prior to January 1,
2009, amounts allocated to IPR&D intangible assets were
expensed at the date of acquisition.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
IPR&D intangible assets represent the value assigned to
acquired R&D projects that, as of the date acquired,
represent the right to develop, use, sell
<font style="white-space: nowrap">and/or</font> offer
for sale a product or other intellectual property that we have
acquired with respect to products
<font style="white-space: nowrap">and/or</font>
processes that have not been completed or approved. The
IPR&D intangible assets are subject to impairment testing
until completion or abandonment of each project. Impairment
testing requires the development of significant estimates and
assumptions involving the determination of estimated net cash
flows for each year for each project or product (including net
revenues, cost of sales, R&D costs, selling and marketing
costs), the appropriate discount rate to select in order to
measure the risk inherent in each future cash flow stream, the
assessment of each asset’s life cycle, competitive trends
impacting the asset and each cash flow stream as well as other
factors. The major risks and uncertainties associated with the
timely and successful completion of the IPR&D projects
include legal risk and regulatory risk. Changes in these
assumptions or uncertainties could result in future impairment
charges. No assurances can be given that the underlying
assumptions used to prepare the discounted cash flow analysis
will not change or the timely completion of each project to
commercial success will occur. For these and other reasons,
actual results may vary significantly from estimated results.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Upon successful completion of each project and launch of the
product, Watson will make a separate determination of the useful
life of the intangible, transfer the amount to currently
marketed products (“CMP”) and amortization expense
will be recorded over the estimated useful life.
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 7-18, 22
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 4, 11-23, 26, 34
falsefalse13false0us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table11 - us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Subsequent to January 1, 2009, contingent consideration is
recorded at the acquisition date estimated fair value of the
contingent payment for all acquisitions. The fair value of the
contingent consideration is remeasured at each reporting period
with any adjustments in fair value included in our consolidated
statement of operations.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes the entity's accounting policies for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 9, 10, 11, 12, 13
falsefalse14false0us-gaap_RevenueRecognitionPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table12 - us-gaap:RevenueRecognitionPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Revenue is generally realized or realizable and earned when
persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the seller’s price
to the buyer is fixed or determinable, and collectability is
reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to
the customer, which is typically upon delivery to the customer.
Revenues recognized from research, development and licensing
agreements (including milestone receipts) are recorded on the
“contingency-adjusted performance model” which
requires deferral of revenue until such time as contract
milestone requirements, as specified in the individual
agreements, have been met. Under this model, revenue related to
each payment is recognized over the entire contract performance
period, starting with the contract’s commencement, but not
prior to earning
<font style="white-space: nowrap">and/or</font>
receiving the milestone amount (i.e., removal of any
contingency). The amount of revenue recognized is based on the
ratio of costs incurred to date to total estimated cost to be
incurred. Royalty and commission revenue is recognized in
accordance with the terms of their respective contractual
agreements when collectability is reasonably assured and revenue
can be reasonably measured.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction should be disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may e
ncompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section B
-Paragraph Question 1
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 8, 12, 13
falsefalse15false0wpi_ProvisionsForSalesReturnsAndAllowancesPolicyTextBlockwpifalsenadurationProvisions for Sales Returns and Allowances.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false<
/IsNumeric>falsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table13 - wpi:ProvisionsForSalesReturnsAndAllowancesPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As is customary in the pharmaceutical industry, the
Company’s gross product sales are subject to a variety of
deductions in arriving at reported net product sales. When the
Company recognizes revenue from the sale of its products, an
estimate of SRA is recorded which reduces product sales.
Accounts receivable
<font style="white-space: nowrap">and/or</font>
accrued liabilities are also reduced
<font style="white-space: nowrap">and/or</font>
increased by the SRA amount. These adjustments include estimates
for chargebacks, rebates, cash discounts and returns and other
allowances. These provisions are estimated based on historical
payment experience, historical relationship to revenues,
estimated customer inventory levels and current contract sales
terms with direct and indirect customers. The estimation process
used to determine our SRA provision has been applied on a
consistent basis and no material adjustments have been necessary
to increase or decrease our reserves for SRA as a result of a
significant change in underlying estimates. The Company uses a
variety of methods to assess the adequacy of our SRA reserves to
ensure that our consolidated financial statements are fairly
stated. This includes periodic reviews of customer inventory
data, customer contract programs and product pricing trends to
analyze and validate the SRA reserves.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Chargebacks — </i>The provision for chargebacks is
our most significant sales allowance. A chargeback represents an
amount payable in the future to a wholesaler for the difference
between the invoice price paid to the Company by our wholesale
customer for a particular product and the negotiated contract
price that the wholesaler’s customer pays for that product.
The Company’s chargeback provision and related reserve vary
with changes in product mix, changes in customer pricing and
changes to estimated wholesaler inventories. The provision for
chargebacks also takes into account an estimate of the expected
wholesaler sell-through levels to indirect customers at contract
prices. The Company validates the chargeback accrual quarterly
through a review of the inventory reports obtained from our
largest wholesale customers. This customer inventory information
is used to verify the estimated liability for future chargeback
claims based on historical chargeback and contract rates. These
large wholesalers represent 85% — 90% of the
Company’s chargeback payments. The Company continually
monitors current pricing trends and wholesaler inventory levels
to ensure the liability for future chargebacks is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Rebates — </i>Rebates include volume related
incentives to direct and indirect customers and Medicaid rebates
based on claims from Medicaid benefit providers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Volume rebates are generally offered to customers as an
incentive to continue to carry our products and to encourage
greater product sales. These rebate programs include contracted
rebates based on customer’s purchases made during an
applicable monthly, quarterly or annual period. The provision
for rebates is estimated based on our customers’ contracted
rebate programs and our historical experience of rebates paid.
Any significant changes to our customer rebate programs are
considered in establishing our provision for rebates. The
Company continually monitors its customer rebate programs to
ensure that the liability for accrued rebates is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The provision for Medicaid rebates is based upon historical
experience of claims submitted by the various states. The
Company monitors Medicaid legislative changes to determine what
impact such legislation may have on our provision for Medicaid
rebates. Our accrual of Medicaid rebates is based on historical
payment rates and is reviewed on a quarterly basis against
actual claim data to ensure the liability is fairly stated.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Returns and Other Allowances — </i>Our provision
for returns and other allowances include returns, pricing
adjustments, promotional allowances and billback adjustments.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Consistent with industry practice, the company maintains a
return policy that allows our customers to return product for
credit. In accordance with our return goods policy, credit for
customer returns of product is applied against outstanding
account activity or by check. Product exchanges are not
permitted. Customer returns of product are not resalable unless
the return is due to a shipping error. Our estimate of the
provision for returns is based upon historical experience and
current trends of actual customer returns. Additionally, we
consider other factors when estimating our current period return
provision, including levels of inventory in our distribution
channel as well as significant market changes which may impact
future expected returns, and make adjustments to our current
period provision for returns when it appears product returns may
differ from our original estimates.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Pricing adjustments, which include shelf stock adjustments, are
credits issued to reflect price decreases in selling prices
charged to our direct customers. Shelf stock adjustments are
based upon the amount of product
our customers have in their inventory at the time of an
<font style="white-space: nowrap">agreed-upon</font>
price reduction. The provision for shelf stock adjustments is
based upon specific terms with our direct customers and includes
estimates of existing customer inventory levels based upon their
historical purchasing patterns. The Company regularly monitors
all price changes to help evaluate our reserve balances. The
adequacy of these reserves is readily determinable as pricing
adjustments and shelf stock adjustments are negotiated and
settled on a
<font style="white-space: nowrap">customer-by-customer</font>
basis.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Promotional allowances are credits, which are issued in
connection with a product launch or as an incentive for
customers to begin carrying our product. The Company establishes
a reserve for promotional allowances based upon these
contractual terms.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Billback adjustments are credits that are issued to certain
customers who purchase directly from the Company as well as
indirectly through a wholesaler. These credits are issued in the
event there is a difference between the customer’s direct
and indirect contract price. The provision for billbacks is
estimated based upon historical purchasing patterns of qualified
customers who purchase product directly from the Company and
supplement their purchases indirectly through the Company’s
wholesale customers.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<i>Cash Discounts — </i>Cash discounts are provided to
customers that pay within a specific period. The provision for
cash discounts are estimated based upon invoice billings,
utilizing historical customer payment experience. Our
customer’s payment experience is fairly consistent and most
customer payments qualify for the cash discount. Accordingly,
our reserve for cash discounts is readily determinable.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Net revenues and accounts receivable balances in the
Company’s consolidated financial statements are presented
net of SRA estimates. In addition, certain SRA balances are
included in accounts payable and accrued liabilities. Accounts
receivable are presented net of SRA balances of
$320.5 million and $335.0 million at December 31,
2010 and 2009, respectively. Accounts payable and accrued
liabilities include $106.5 million and $83.6 million
at December 31, 2010 and 2009, respectively, for certain
rebates and other amounts due to indirect customers.
The
following table summarizes the activity in the Company’s
major categories of SRA (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="42%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Returns and Other<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Chargebacks</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Rebates</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Allowances</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Cash Discounts</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2007
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
164.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
154.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
56.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
387.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,224.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
309.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
179.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,780.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,267.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(337.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(166.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(67.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,839.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
125.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
328.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Arrow Acquisition
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,169.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
415.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,840.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,177.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(389.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(167.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(71.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,805.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2009 (Revised)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
188.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
97.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
418.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Provision related to sales in 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,175.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
755.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
206.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Credits and payments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,192.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(723.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(214.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(88.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2,219.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
100.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
219.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
89.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
427.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company does not expect future payments of SRA to materially
exceed our current estimates. However, if future SRA payments
were to materially exceed our estimates, such adjustments may
have a material adverse impact on our financial position,
results of operations and cash flows.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringProvisions for Sales Returns and Allowances.No authoritative reference available.falsefalse16false0us-gaap_ShippingAndHandlingCostPolicyTextBlockus-gaaptruena
durationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table14 - us-gaap:ShippingAndHandlingCostPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company records shipping and handling costs in selling and
marketing expenses. These expenses were $66.5 million,
$51.9 million and $50.8 million in 2010, 2009 and
2008, respectively.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescription of the accounting policy associated with the classification of shipping and handling costs including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 8
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 00-10
-Paragraph 6
falsefalse
17false0wpi_ConcentrationOfMajorCustomersAndSuppliersPolicyTextBlockwpifalsenadurationConcentration of Major Customers and Suppliers.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table15 - wpi:ConcentrationOfMajorCustomersAndSuppliersPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
For the year ended December 31, 2010, the Company’s
three largest customers accounted for 14%, 11%, and 6%,
individually, of the Company’s net revenues. For the year
ended December 31, 2009, the Company’s three largest
customers accounted for 13%, 11%, and 9%, individually, of the
Company’s net revenues. For the year ended
December 31, 2008, the Company’s three largest
customers accounted for 11%, 11%, and 9%, individually, of the
Company’s net revenues. No other individual customers
accounted for more than 10% of net revenues.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is subject to a concentration of credit risk with
respect to its accounts receivable balance, all of which is due
from wholesalers, distributors, chain drug stores and service
providers in the health care and pharmaceutical industries
throughout the U.S. and international markets in which we
operate. Approximately 52% and 53% of the gross accounts
receivable balance consists of amounts due from the four largest
customers at December 31, 2010 and 2009, respectively. The
Company performs ongoing credit evaluations of its customers and
maintains an allowance for potential uncollectible accounts.
Actual losses from uncollectible accounts have been minimal.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Certain of the Company’s finished products and raw
materials are obtained from single source suppliers. Although
the Company seeks to identify more than one source for its
various finished products and raw materials, loss of a single
source supplier could have an adverse effect on the
Company’s results of operations, financial condition and
cash flows. Third-party manufactured products accounted for
approximately 33%, 38% and 44% of our Global Generics and Global
Brands product net revenues in 2010, 2009 and 2008, respectively.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringConcentration of Major Customers and Suppliers.No authoritative reference available.falsefalse18false0us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table16 - us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
R&D activities are expensed as incurred and consist of
self-funded R&D costs and the costs associated with work
performed under collaborative R&D agreements. R&D
expenses include direct and allocated expenses. R&D
expenses incurred under collaborative agreements were
approximately $11.1 million, $6.8 million, and
$5.9 million for the years ended December 31, 2010,
2009 and 2008, respectively.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.Reference
1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 8, 12, 13
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 3-12
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 4
-Paragraph 4, 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 98-1
-Paragraph 12, 17-38, 41
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 00-2
falsefalse19false0us-gaap_IncomeTaxPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalse<
/IsRatio>false00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table17 - us-gaap:IncomeTaxPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income taxes are accounted for using an asset and liability
approach that requires the recognition of deferred tax assets
and liabilities for the expected future tax consequences of
temporary differences between the financial statement and tax
bases of assets and liabilities at the applicable tax rates. A
valuation allowance is provided when it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The Company evaluates the realizability of its
deferred tax assets by assessing its valuation allowance and by
adjusting the amount of such allowance, if necessary. The
factors used to assess the likelihood of realization include the
Company’s forecast of future taxable income and available
tax planning strategies that could be implemented to realize the
net deferred tax assets. Failure to achieve forecasted taxable
income in applicable tax jurisdictions could affect the ultimate
realization of deferred tax assets and could result in an
increase in the Company’s effective tax rate on future
earnings.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Income tax positions must meet a more-likely-than-not
recognition threshold to be recognized. Income tax positions
that previously failed to meet the more-likely-than-not
threshold are recognized in the first subsequent financial
reporting period in which that threshold is met. Previously
recognized tax positions that no longer meet the
more-likely-than-not threshold are derecognized in the first
subsequent financial reporting period in which that threshold is
no longer met. We recognize potential accrued interest and
penalties related to unrecognized tax benefits within the
consolidated statements of income as income tax expense.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes an entity's accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.Reference 1: http://ww
w.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 4
-Paragraph 11
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 20
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 6-34, 43, 47, 49
falsefalse20false0wpi_ComprehensiveIncomePolicyTextBlockwpifalsenadurationComprehensive Income.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table18 - wpi:ComprehensiveIncomePolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Comprehensive income includes all changes in equity during a
period except those that resulted from investments by or
distributions to the Company’s stockholders. Other
comprehensive income refers to revenues, expenses, gains and
losses that, under GAAP, are included in comprehensive income,
but excluded from net income as these amounts are recorded
directly as an adjustment to stockholders’ equity.
Watson’s other comprehensive income (loss) is composed of
unrealized gains (losses) on its holdings of publicly traded
equity securities, net of realized gains (losses) included in
net income and foreign currency translation adjustments.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringComprehensive Income.No authoritative reference available.falsefalse21false0us-gaap_EarningsPerSharePolicyTextBlockus-gaaptruenadurationNo de
finition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table19 - us-gaap:EarningsPerSharePolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Basic EPS is computed by dividing net income attributable to
common shareholders by the weighted average common shares
outstanding during a period. Diluted EPS is based on the
treasury stock method and includes the effect from potential
issuance of common stock, such as shares issuable upon
conversion of our convertible contingent senior debentures
(“CODES”), and shares issuable pursuant to the
exercise of stock options, assuming the exercise of all
<font style="white-space: nowrap">in-the-money</font>
stock options. Common share equivalents have been excluded where
their inclusion would be anti-dilutive. The Company is required
to add the weighted average potential common shares outstanding
associated with the conversion of the CODES to the number of
shares outstanding for the calculation of diluted EPS for all
periods in which the securities were outstanding. On
September 14, 2009 the CODES were redeemed in accordance
with the terms of the CODES.
A reconciliation of the
numerators and denominators of basic and diluted EPS consisted
of the following (in millions, except per share amounts):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="74%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — basic</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.51
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.32
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>EPS — assuming dilution</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income attributable to common shareholders
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
222.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
238.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Add: Interest expense on CODES, net of tax
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net income, adjusted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
184.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
227.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
246.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
122.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
105.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
102.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effect of dilutive securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Conversion of CODES
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Dilutive stock awards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted weighted average common shares outstanding
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
124.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
117.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
EPS — diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.48
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.96
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.09
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Stock awards to purchase 1.1 million, 3.5 million and
8.1 million common shares in 2010, 2009 and 2008,
respectively, were outstanding but not included in the
computation of diluted EPS as the awards were anti-dilutive.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDiscloses the methodology and assumptions used to compute basic and diluted earnings (loss) per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.Referenc
e 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 6, 8-16, 60
falsefalse22false0us-gaap_CompensationRelatedCostsPolicyTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false
falsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table20 - us-gaap:CompensationRelatedCostsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company recognizes compensation expense for all share-based
compensation awards made to employees and directors based on
estimated fair values. The Company estimates the fair value of
its stock option plans using the Black-Scholes option pricing
model (the “Option Model”). The Option Model requires
the use of subjective and complex assumptions, including the
option’s expected term and the estimated future price
volatility of the underlying stock, which determine the fair
value of the share-based awards. The Company’s estimate of
expected term was determined based on the weighted average
period of time that options granted are expected to be
outstanding considering current vesting schedules and the
historical exercise patterns of existing option plans. The
expected volatility assumption used in the Option Model is based
on implied volatility based on traded options on the
Company’s stock. The risk-free interest rate used in the
Option Model is based on the yield of U.S. Treasuries with
a maturity closest to the expected term of the Company’s
stock options. No stock options were granted during the years
ended December 31, 2010, 2009 or 2008.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Share-based compensation expense recognized during a period is
based on the value of the portion of share-based awards that are
expected to vest with employees. Accordingly, the recognition of
share-based compensation expense has been reduced for estimated
future forfeitures. These estimates will be revised in future
periods if actual forfeitures differ from the estimates. Changes
in forfeiture estimates impact compensation expense in the
period in which the change in estimate occurs.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes the entity's accounting policies for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to its employees, including share-based arrangements; describes its methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 4, 9-15, A240
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 9, 11, 12, 13
falsefalse23false0wpi_RecentAccountingPronouncementsPolicyTextBlockwpifalsenadurationRecent Accounting Pronouncements.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: wpi-20101231_note2_accounting_policy_table21 - wpi:RecentAccountingPronouncementsPolicyTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In October 2009, the FASB issued an amendment to its accounting
guidance on revenue arrangements with multiple deliverables,
which addresses the unit of accounting for arrangements
involving multiple deliverables and how consideration should be
allocated to separate units of accounting, when applicable. The
amendment requires that arrangement considerations be allocated
at the inception of the arrangement to all deliverables using
the relative selling price method and provides for expanded
disclosures related to such arrangements. The amendment is
effective for revenue arrangements entered into or materially
modified in fiscal years beginning on or after June 15,
2010. Early adoption is allowed. The adoption of this guidance
will not have a material impact on the Company’s
consolidated financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In January 2010, the FASB issued an amendment to the disclosure
requirements for fair value measurements. The amendment requires
an entity to: (i) disclose separately the amounts of
significant transfers in and out of Level 1 and
Level 2 fair value measurements and describe the reasons
for the transfers, and (ii) present separate information
for Level 3 activity pertaining to gross purchases, sales,
issuances and settlements. The new disclosures are effective for
interim and annual reporting periods beginning after
December 15, 2009, except for the Level 3 disclosures,
which are effective for fiscal years beginning after
December 15, 2010. The adoption of this guidance will not
have a material impact on the Company’s consolidated
financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In March 2010, the FASB ratified accounting guidance on defining
a milestone and determining when it may be appropriate to apply
the milestone method of revenue recognition for research or
development transactions. This guidance provides criteria that
must be met to recognize consideration that is contingent upon
achievement of a substantive milestone in its entirety in the
period in which the milestone is achieved. The amendment is
effective for milestones achieved in fiscal years beginning on
or after June 15, 2010. Early adoption is allowed. The
adoption of this guidance will not have a material impact on the
Company’s consolidated financial statements.
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block TaggedfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringRecent Accounting Pronouncements.No authoritative reference available.falsefalse122Summary of Significant Accounting Policies (Policies)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
47
R20.xml
IDEA: Business Restructuring Charges
2.2.0.25falsefalse0214 - Disclosure - Business Restructuring Chargestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_RestructuringChargesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalse<
/ShowCurrencySymbol>falsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 14 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 14 —
Business Restructuring Charges</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities involving facilities at Carmel, New York;
Mississauga, Canada; and Melbourne, Australia for the year ended
December 31, 2010 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Severance and retention
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Product transfer costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Facility decommission costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
30.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(18.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accelerated depreciation — R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Activity related to our business restructuring and facility
rationalization activities primarily consisted of restructuring
activities at Carmel, New York and Brewster, New York for the
year ended December 31, 2009 as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="43%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="2%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="9%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Accrual<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Charged<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Non-Cash<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>to Expense</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Payments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Adjustments</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="18" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cost of sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(22.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Operating expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
R&D
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Selling, general and administrative
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total restructuring activity
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(25.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Product transfer costs consist of documentation, testing and
shipping costs to transfer product to other facilities.
Operating expenses include severance, retention and accelerated
depreciation. Retention is expensed only to the extent earned by
employees. Activity related to our business restructuring and
facility rationalization activities is primarily attributable to
our Global Generics segment.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
During the first quarter of 2008, we announced steps to improve
our operating cost structure and achieve operating efficiencies
through our Global Supply Chain Initiative (“GSCI”).
These 2008 GSCI’s include the planned closure of
manufacturing facilities in Carmel, New York, our distribution
center in Brewster, New York and the transition of
manufacturing to our other manufacturing locations within the
U.S. and India. Distribution activities at our distribution
center in Brewster, New York ceased in July 2009. Product
manufacturing ceased in Carmel, New York by December 31,
2010 and we expect a closure of the facility by early 2011.
During the second quarter of 2010, the Company announced
additional measures to reduce its cost structure involving a
manufacturing facility and certain R&D activities in Canada
and certain R&D activities in Australia. In January 2011,
the Company announced the closure of R&D activities in
Corona, California. These additional restructuring activities,
and the transfer of development activities to existing R&D
sites, are expected to be completed in Australia by early 2011,
in Corona by the end of 2011 and in Canada by late 2012.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescription of restructuring activities including exit and disposal activities, which should include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. This description does not include restructuring costs in connection with a business combination or discontinued operations and long-liv
ed assets (disposal groups) sold or classified as held for sale. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 20
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse12Business Restructuring ChargesUnKnownUnKnownUnKnownUnKnownfalsetrueXML
48
R4.xml
IDEA: Consolidated Statements of Operations
2.2.0.25falsefalse0120 - Statement - Consolidated Statements of OperationstruefalseIn Millions, except Per Share datafalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_IncomeStatementAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalse
ShowCurrencySymbol>falsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefal
sefalsefalsefalsefalsetotallabel1truefalsefalse35669000003566.9falsetruefalsefalsefalse2truefalsefalse27930000002793.0falsetruefalsefalsefalse3truefalsefalse25355000002535.5falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue
during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
truefalse4true0us-gaap_CostsAndExpensesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefal
se00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse5false0us-gaap_CostOfGoodsSoldus-gaaptruedebitdurationNo defin
ition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse19985000001998.5falsefalsefalsefalsefalse2truefalsefalse15968000001596.8falsefalsefalsefalsefalse3truefalsefalse15028000001502.8falsefalsefalsefalse
hasSegments>falseMonetaryxbrli:monetaryItemTypemonetaryTotal costs related to goods produced and sold during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 2
-Article 5
falsefalse6false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1true
IsNumeric>falsefalse296100000296.1falsefalsefalsefalsefalse2truefalsefalse197300000197.3falsefalsefalsefalsefalse3truefalsefalse170100000170.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate resear
ch findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph g
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
falsefalse7false0us-gaap_SellingAndMarketingExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse320000000320.0falsefalsefalsefalsefalse2truefalsefalse263100000263.1falsefalsefalsefalsefalse3truefalsefalse232900000232.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total amount of expenses directly related to the marketing or selling of products or services.No authoritative reference available.falsefalse8false0
us-gaap_GeneralAndAdministrativeExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse436100000436.1falsefalsefalsefalsefalse2truefalsefalse257100000257.1falsefalsefalsefalsefalse3truefalsefalse190500000190.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.No authoritative reference available.falsefalse9false0us-gaap_AdjustmentF
orAmortizationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse180000000180.0falsefalsefalsefalsefalse2truefalsefalse9260000092.6falsefalsefalsefalsefalse3truefalsefalse8070000080.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of intangible assets over their estimated remaining economic lives.No authoritative reference available.falsefalse10false0wpi_LossGainOnAssetSalesAndImpairmentwpifalsedebit
durationLoss Gain on asset sales and Impairment.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse3080000030.8falsefalsefa
lsefalsefalse2truefalsefalse22000002.2falsefalsefalsefalsefalse3truefalsefalse3000000.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryLoss Gain on asset sales and Impairment.No authoritative reference available.falsefalse
11false0us-gaap_CostsAndExpensesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse32615000003261.5falsefalsefalsefalsefalse2truefalsefalse24091000002409.1falsefalsefalsefalsefalse3truefalsefalse21773000002177.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetary
Total costs of sales and operating expenses for the period.No authoritative reference available.truefalse12false0us-gaap_OperatingIncomeLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsef
alsetotallabel1truefalsefalse305400000305.4falsefalsefalsefalsefalse2truefalsefalse383900000383.9falsefalsefalsefalsefalse3truefalsefalse358200000358.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No authoritative reference available.truefalse13true0us-gaap_NonoperatingIncomeExpenseAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse14false0us-gaap_InvestmentIncomeInterestus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse16000001.6falsefalsefalsefalsefalse2truefalsefalse50000005.0falsefalsefalsefalsefalse3truefalsefalse90000009.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncome derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 14
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 7
-Article 5
falsefalse15false0us-gaap_InterestExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse
-84100000-84.1falsefalsefalsefalsefalse2truefalsefalse-34200000-34.2falsefalsefalsefalsefalse3truefalsefalse-28200000-28.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cost of borrowed funds accounted for as interest that was charged against earnings during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 34
-Paragraph 21
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher OTS
-Name Federal Regulation (FR)
-Number Title 12
-Chapter V
-Section 563c.102
-Paragraph 9
-Subsection II
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 9
-Article 9
falsefalse16false0us-gaap_OtherNonoperatingIncomeExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse2770000027.7falsefalsefalsefalsefalse2truefalsefalse79000007.9falsefalsefalsefalsefalse3truefalse
IsRatio>false1930000019.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
truefalse17false0us-gaap_NonoperatingIncomeExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse-54800000-54.8falsefalsefalsefalsefalse2truefalsefalse-21300000-21.3falsefalsefalsefalsefalse3truefalsefalse1000000.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of income (expense) from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 7
-Article 5
truefalse18false0us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse250600000250.6falsefalsefalsefalsefalse2truefalsefalse362600000362.6falsefalsefalsefalse<
hasScenarios>false3truefalsefalse358300000358.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest.Reference 1: ht
tp://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Subparagraph 1(i)
-Article 4
falsefalse19false0us-gaap_IncomeTaxExpenseBenefitus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse6730000067.3falsefalsefalsefalsefalse2truefalsefalse140600000140.6falsefalsefalsefalsefalse3truefalsefalse119900000119.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph a, b
truefalse20false0us-gaap_ProfitLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse183300000183.3falsefalsefalsefalsefalse2truefalsefalse222000000222.0falsefalsefalsefalsefalse3truefalsefalse238400000238.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A1, A4, A5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 5
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(1)
falsefalse21false0us-gaap_NetIncomeLossAttributableToNoncontrollingInterestus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalse
false11000001.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefa
lsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe portion of net income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(1)
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A1, A4, A5
truefalse22false0us-gaap_NetIncomeLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalse<
/IsRatio>false184400000184.4falsetruefalsefalsefalse2truefalsefalse222000000222.0falsetruefalsefalsefalse3truefalsefalse238400000238.4falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
truefalse23true0us-gaap_EarningsPerShareAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefa
lsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse24false0us-gaap_EarningsPerShareBasicus-gaaptruenaduratio
nNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1.511.51falsetruefalse
falsefalse2truefalsefalse2.112.11falsetruefalsefalsefalse3truefalsefalse2.322.32falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe amount of net income or loss for the period per each share of common stock outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7
truetrue25false0us-gaap_EarningsPerShareDilutedus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1.481.48falsetruefalsefalsefalse2truefalsefalse1.961.96falsetruefalsefalsefalse3truefalsefalse
2.092.09falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 11, 12, 36
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
truetrue26true0wpi_WeightedAverageSharesOutstandingAbstractwpifalsenadurationWeighted average shares outstanding.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalse<
DisplayZeroAsNone>false00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringWeighted average shares outstanding.falsefalse27false0us-gaap_WeightedAverageNumberOfSharesOutstandingBasicus-gaaptruen
adurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse122400000122.4falsefalsef
alsefalsefalse2truefalsefalse105000000105.0falsefalsefalsefalsefalse3truefalsefalse102800000102.8falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
truefalse28false0us-gaap_WeightedAverageNumberOfDilutedSharesOutstandingus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse124200000124.2falsefalsefalsefalsefalse2truefalsefalse116400000116.4falsefalsefalsefalsefalse3true
falsefalse117700000117.7falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
truefalse327Consolidated Statements of Operations (USD $)HundredThousandsHundredThousandsNoRoundingUnKnownfalsetrueXML
49
R27.xml
IDEA: Other Income (Tables)
2.2.0.25falsefalse0505 - Disclosure - Other Income (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_OtherIncomeTablesAbstractwpifalsenadurationOther Income.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalse<
DisplayDateInUSFormat>falsefalsefalseOtherxbrli:stringItemTypestringOther Income.falsefalse3false0wpi_ComponentOfOtherIncomeTextBlockwpifalsenadurationComponent of other income.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note5_table1 - wpi:ComponentOfOtherIncomeTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other income consisted of the following (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="77%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Gain (loss) on sale of securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
25.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings on equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Loss on early extinguishment of debt
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
19.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringComponent of other income.No authoritative reference available.falsefalse12Other Income (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
50
R39.xml
IDEA: Summary of Significant Accounting Policies (Details)
2.2.0.25truefalse0602 - Disclosure - Summary of Significant Accounting Policies (Details)truefalsefalse1falsefalsetruefalse{us-gaap_PropertyPlantAndEquipmentByTypeAxis} : Computer software/hardware [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Computer_Equipment_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseComputer software/hardware [Member]us-gaap_PropertyPlantAndEquipmentByTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ComputerEquipmentMemberus-gaap_PropertyPlantAndEquipmentByTypeAxisexplicitMemberPureStandardhttp://www.x
brl.org/2003/instancepurexbrli01false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificantaccountingpoliciesdetails1falsefalsefalse00falsefalsefalsefalsefalse1falsefalsetruefalse{us-gaap_PropertyPlantAndEquipmentByTypeAxis} : Computer software/hardware [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Computer_Equipment_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseComputer software/hardware [Member]us-gaap_PropertyPlantAndEquipmentByTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ComputerEquipmentMemberus-gaap_PropertyPlantAndEquipmentByTypeAxisexplicitMemberPureStandardhttp://www.x
brl.org/2003/instancepurexbrli0OthernaNo definition available.No authoritative reference available.falsefalse2true0wpi_RangeOfEstimatedUsefulLivesUsedForEachAssetsAbstractwpifalsenadurationRange of estimated use
ful lives used for each Assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalse
falseOtherxbrli:stringItemTypestringRange of estimated useful lives used for each Assets.falsefalse3false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMinimumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse33falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe minimum useful life of long lived, physical assets used in the normal conduct of business and not i
ntended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse4false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMaximumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse77falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse5false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificantaccountingpoliciesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsetruefalse{us-gaap_PropertyPlantAndEquipmentByTypeAxis} : Machinery and equipment [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Machinery_And_Equipment_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseMachinery and equipment [Member]us-gaap_PropertyPlantAndEquipmentByTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MachineryAndEquipmentMemberus-gaap_PropertyPlantAndEquipmentByTypeAxisexplicitMemberPureStandardhttp:/
/www.xbrl.org/2003/instancepurexbrli0OthernaNo definition available.No authoritative reference available.falsefalse6true0wpi_RangeOfEstimatedUsefulLivesUsedForEachAssetsAbstractwpifalsenadurationRange of estimated useful lives used for each Assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalse
falseOtherxbrli:stringItemTypestringRange of estimated useful lives used for each Assets.falsefalse7false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMinimumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse55falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe minimum useful life of long lived, physical assets used in the normal c
onduct of business and not intended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse8false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMaximumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1818falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land and improvements, buildings, and productio
n equipment.No authoritative reference available.falsefalse9false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificantaccountingpoliciesdetails1falsefalsefalse00falsefalsefalsefalsefalse3falsefalsetruefalse{us-gaap_PropertyPlantAndEquipmentByTypeAxis} : Research and laboratory equipment [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Research_And_Laboratory_Equipment_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseResearch and laboratory equipment [Member]us-gaap_PropertyPlantAndEquipmentByTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ResearchAndLaboratoryEquipmentMemberus-gaap_PropertyPlantAndEquipmentByTypeAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0OthernaNo definition available.No authoritative reference available.falsefalse10true0wpi_RangeOfEstimatedUsefulLivesUsedForEachAssetsAbstractwpifalsenadurationRange of estimated useful lives used for each Assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsef
alsefalsefalseOtherxbrli:stringItemTypestringRange of estimated useful lives used for each Assets.falsefalse11false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMinimumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse55falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe minimum useful life of l
ong lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse12false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMaximumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalse<
IsBeginningBalance>falsefalsefalseverboselabel1truefalsefalse1010falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include
land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse13false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificanta
ccountingpoliciesdetails1falsefalsefalse00falsefalsefalsefalsefalse4falsefalsetruefalse{us-gaap_PropertyPlantAndEquipmentByTypeAxis} : Furniture and fixtures [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Furniture_And_Fixtures_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseFurniture and fixtures [Member]us-gaap_PropertyPlantAndEquipmentByTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FurnitureAndFixturesMemberus-gaap_PropertyPlantAndEquipmentByTypeAxisexplicitMemberPureStandardhttp://ww
w.xbrl.org/2003/instancepurexbrli0OthernaNo definition available.No authoritative reference available.falsefalse14true0wpi_RangeOfEstimatedUsefulLivesUsedForEachAssetsAbstractwpifalsenadurationRange of estimated useful lives used for each Assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringRange of estimated useful lives used for each Assets.falsefalse15false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMinimumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse55falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe minimum useful life of long lived, physical assets used in the normal cond
uct of business and not intended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse16false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMaximumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1010falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land and improvements, buildings, and production
equipment.No authoritative reference available.falsefalse17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/summaryofsignificantaccountingpoliciesdetails1falsefalsefalse00falsefalsefalsefalsefalse5falsefalsetruefalse{us-gaap_PropertyPlantAndEquipmentByTypeAxis} : Buildings, improvements, leasehold improvements and other [Member]
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Land_Buildings_And_Improvements_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseBuildings, improvements, leasehold improvements and other [Member]us-gaap_PropertyPlantAndEquipmentByTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LandBuildingsAndImprovementsMemberus-gaap_PropertyPlantAndEquipmentByTypeAxisexplicitMemberPureStandard
http://www.xbrl.org/2003/instancepurexbrli0OthernaNo definition available.No authoritative reference available.falsefalse18true0wpi_RangeOfEstimatedUsefulLivesUsedForEachAssetsAbstractwpifalsenadurationRange of estimated useful lives used for each Assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringRange of estimated useful lives used for each Assets.falsefalse19false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMinimumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse55falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse20false0us-gaap_PropertyPlantAndEquipmentUsefulLifeMaximumus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse4040falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe maximum useful life of long-lived, physical assets used in the
normal conduct of business and not intended for resale. Examples include land and improvements, buildings, and production equipment.No authoritative reference available.falsefalse120Summary of Significant Accounting Policies (Details)UnKnownUnKnownUnKnownUnKnowntruetrueXML
51
R68.xml
IDEA: Schedule II Valuation and Qualifying Accounts (Details)
2.2.0.25truefalse0701 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_ValuationAndQualifyingAccountsDisclosureL
ineItemsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00false<
ShowCurrencySymbol>falsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.falsefalse3false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse418600000418.6falsetruefalsefalsefalse<
/Cell>2truefalsefalse328200000328.2falsetruefalsefalsefalse3truefalsefalse387700000387.7falsetruefalsefalsefalse<
/hasScenarios>Monetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse4false0us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse22275000002227.5falsefalsefalsefalsefalse2truefalsefalse18407000001840.7falsefalsefalsefalsefalse3
Id>truefalsefalse17801000001780.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.Reference 1: http://w
ww.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse5false0us-gaap_ValuationAllowancesAndReservesDeductionsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefal
sefalse-2219100000-2219.1falsefalsefalsefalsefalse2truefalsefalse-1805400000-1805.4falsefalsefalsefalsefalse3tru
efalsefalse-1839600000-1839.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of
the reserves utilized, respectively.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse6false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalse
false427000000427.0falsefalsefalsefalsefalse2truefalsefalse418600000418.6falsefalsefalsefalsefalse3truefalsefalse328200000328.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse7false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/valuationandqualifyingaccountsdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Allowance for Doubtful Accounts [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Allowance_For_Doubtful_Accounts_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAllowance for Doubtful Accounts [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AllowanceForDoubtfulAccountsMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Allowance for Doubtful Accounts [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Allowance_For_Doubtful_Accounts_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAllowance for Doubtful Accounts [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AllowanceForDoubtfulAccountsMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Allowance for Doubtful Accounts [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Allowance_For_Doubtful_Accounts_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAllowance for Doubtful Accounts [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AllowanceForDoubtfulAccountsMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse8true0us-gaap_ValuationAndQualifyingAccountsDisclosureLineItemsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.falsefalse9false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse54000005.4falsefalsefalsefalsefalse2truefalsefalse33000003.3falsefalsefalsefalsefalse3truefalsefalse38000003.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse10false0us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1true
IsNumeric>falsefalse95000009.5falsefalsefalsefalsefalse2truefalsefalse34000003.4falsefalsefalsefalsefalse3truefalsefalse12000001.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.Reference 1: http://www.xbrl.org/2003/
role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse11false0us-gaap_ValuationAllowancesAndReservesDeductionsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefa
lsefalse-2400000-2.4falsefalsefalsefalsefalse2truefalsefalse-3100000-3.1falsefalsefalsefalsefalse3truefalsefalse-1700000-1.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves uti
lized, respectively.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse12false0us-gaap_ValuationAllowancesAndReservesChargedToOtherAccountsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse18000001.8falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to accounts other than costs and expenses in a given periodReference 1: http://www
.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse13false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse1250000012.5falsefalsefalsefalsefalse2truefalsefalse54000005.4falsefalsefalsefalsefalse3truefalsefalse33000003.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/valuationandqualifyingaccountsdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Inventory reserves [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Inventory_Valuation_Reserve_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseInventory reserves [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InventoryValuationReserveMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Inventory reserves [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Inventory_Valuation_Reserve_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseInventory reserves [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InventoryValuationReserveMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Inventory reserves [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Inventory_Valuation_Reserve_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseInventory reserves [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InventoryValuationReserveMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse15true0us-gaap_ValuationAndQualifyingAccountsDisclosureLineItemsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalse<
hasSegments>falsefalseOtherxbrli:stringItemTypestringLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.falsefalse16false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse7770000077.7falsefalsefalsefalsefalse2truefalsef
alse3470000034.7falsefalsefalsefalsefalse3truefalsefalse4770000047.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse17false0us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1true
IsNumeric>falsefalse5000000050.0falsefalsefalsefalsefalse2truefalsefalse5100000051.0falsefalsefalsefalsefalse3truefalsefalse4570000045.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.Reference 1: http://www.xbrl.org
/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse18false0us-gaap_ValuationAllowancesAndReservesDeductionsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefa
lsefalse-76300000-76.3falsefalsefalsefalsefalse2truefalsefalse-22400000-22.4falsefalsefalsefalsefalse3truefalsefalse-58700000-58.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserv
es utilized, respectively.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse19false0us-gaap_ValuationAllowancesAndReservesChargedToOtherAccountsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse1440000014.4falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to accounts other than costs and expenses in a given periodReference 1: http://w
ww.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse20false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse5140000051.4falsefalsefalsefalsefalse2truefalsefalse7770000077.7falsefalsefalsefalsefalse3truefalse
IsRatio>false3470000034.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse21false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/valuationandqualifyingaccountsdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse10falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Tax valuation allowance [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Valuation_Allowance_Of_Deferred_Tax_Assets_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseTax valuation allowance [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ValuationAllowanceOfDeferredTaxAssetsMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDS
tandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Tax valuation allowance [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Valuation_Allowance_Of_Deferred_Tax_Assets_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseTax valuation allowance [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ValuationAllowanceOfDeferredTaxAssetsMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDS
tandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_ValuationAllowancesAndReservesTypeAxis} : Tax valuation allowance [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Valuation_Allowance_Of_Deferred_Tax_Assets_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseTax valuation allowance [Member]us-gaap_ValuationAllowancesAndReservesTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ValuationAllowanceOfDeferredTaxAssetsMemberus-gaap_ValuationAllowancesAndReservesTypeAxisexplicitMemberUSDS
tandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse22true0us-gaap_ValuationAndQualifyingAccountsDisclosureLineItemsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.falsefalse23false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse2840000028.4falsefalsefalsefalsefalse2truefalsefalse81000008.1falsefalsefalsefalsefalse3truefalsefalse1250000012.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse24false0us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1true
IsNumeric>falsefalse73000007.3falsefalsefalsefalsefalse2truefalsefalse2000000.2falsefalsefalsefalsefalse3truefalsefalse-600000-0.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.Reference 1: http://www.xbrl.org/2003/
role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse25false0us-gaap_ValuationAllowancesAndReservesDeductionsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefa
lsefalse-6000000-6.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse-3800000-3.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, re
spectively.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse26false0us-gaap_ValuationAllowancesAndReservesChargedToOtherAccountsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse2010000020.1falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to accounts other than costs and expenses in a given periodReference 1: http://w
ww.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse27false0us-gaap_ValuationAllowancesAndReservesBalanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse2970000029.7falsetruefalsefalsefalse2truefalsefalse2840000028.4falsetruefalsefalsefalse3truefalsefalse81000008.1falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costsReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse326Schedule II Valuation and Qualifying Accounts (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
52
R50.xml
IDEA: Goodwill Product Rights and Other Intangibles (Details 1)
2.2.0.25truefalse06081 - Disclosure - Goodwill Product Rights and Other Intangibles (Details 1)truefalseIn Millionsfalse1falsefalseUSDfalsefalse12/31/2010
USD ($)
$BalanceAsOf_31Dec2010http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse12/31/2009
USD ($)
$BalanceAsOf_31Dec2009http://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0us-gaap_FiniteLivedIntangibleAssetsNetAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00f
alsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_FiniteLivedIntangibleAssetsGrossus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse21513000002151.3falsetruefalsefalsefalse2truefalsefalse19574000001957.4falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets having statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(1)
falsefalse4false0us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortizationus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1tr
uefalsefalse-1211100000-1211.1falsefalsefalsefalsefalse2truefalsefalse-1031100000-1031.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(1)
truefalse5false0us-gaap_FiniteLivedIntangibleAssetsNetus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse940200000940.2falsefalsefalsefalsefalse2truefalsefalse926300000926.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(1)
truefalse6true0us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1fa
lsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse7false0us-gaap_IndefiniteLivedIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse691800000691.8falsefalsefalsefalsefalse2truefalsefalse787200000787.2falsefalse<
DisplayDateInUSFormat>falsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount of intangible assets, excluding goodwill, which have a projected indefinite period of benefit (hence are not amortized), allocated to the reportable segment. These assets, acquired either individually or as part of a group of assets, in either an asset acquisition or business combination, are assessed at least annually for impairment. Examples may include trade secrets, contractual rights, trade names, and licensing agreements.No authoritative reference available.truefalse8false0us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse16320000001632.0falsefalsefalsefalsefalse2truefalsefalse17135000001713.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the carrying amounts of all intang
ible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 45
truefalse9false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails11falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse<
Id>3falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Product rights and other related intangibles [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Product_Rights_And_Other_Related_Intangibles_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseProduct rights and other related intangibles [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ProductRightsAndOtherRelatedIntangiblesMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Product rights and other related intangibles [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Product_Rights_And_Other_Related_Intangibles_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseProduct rights and other related intangibles [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ProductRightsAndOtherRelatedIntangiblesMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse10true0us-gaap_FiniteLivedIntangibleAssetsNetAbstrac
tus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00false<
/IsIndependantCurrency>falsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse11false0us-gaap_FiniteLivedIntangibleAssetsGrossus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2049700000204
9.7falsefalsefalsefalsefalse2truefalsefalse18558000001855.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets having statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(1)
falsefalse13false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails11false
falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Core technology [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Core_Technology_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseCore technology [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CoreTechnologyMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://ww
w.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Core technology [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Core_Technology_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseCore technology [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CoreTechnologyMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://ww
w.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse14true0us-gaap_FiniteLivedIntangibleAssetsNetAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalse
hasSegments>false2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse15false0us-gaap_FiniteLivedIntangibleAssetsGrossus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse5250000052.5
falsefalsefalsefalsefalse2truefalsefalse5250000052.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets having
statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(1)
falsefalse17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails11false
falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Customer relationships [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Customer_Relationships_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseCustomer relationships [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CustomerRelationshipsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis} : Customer relationships [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Customer_Relationships_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseCustomer relationships [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CustomerRelationshipsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse18true0us-gaap_FiniteLivedIntangibleAssetsNetAbstractus-gaaptruen
adurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse19false0us-ga
ap_FiniteLivedIntangibleAssetsGrossus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse4910000049.1falsefalsefalsefalsefalse2truefalsefalse4910000049.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the gross carrying amounts before accumulated amortization as of the balance she
et date of all intangible assets having statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(1)
falsefalse21false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails11false
falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse9falsefalseUSDtruefalse{us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : IPR&D [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_I_P_R_And_D_Member_2http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseIPR&D [Member]us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_IPRAndDMemberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.
org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : IPR&D [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_I_P_R_And_D_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseIPR&D [Member]us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_IPRAndDMemberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.or
g/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse23true0us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse24false0us-gaap_IndefiniteLivedIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse615600000615.6fa
lsefalsefalsefalsefalse2truefalsefalse711000000711.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount of intangible assets, excluding goodwill, which have a projected indefinite period of benefit (hence are not a
mortized), allocated to the reportable segment. These assets, acquired either individually or as part of a group of assets, in either an asset acquisition or business combination, are assessed at least annually for impairment. Examples may include trade secrets, contractual rights, trade names, and licensing agreements.No authoritative reference available.truefalse25false0natruenanaNo definition available.falsetruefalsefalsefalsefalse
falsefalsefalsefalsehttp://watson.com/role/goodwillproductrightsandotherintangiblesdetails11falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00
RoundedNumericAmount>falsefalsefalsefalsefalse11falsefalseUSDtruefalse{us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : Trade Names [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Trade_Names_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseTrade Names [Member]us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_TradeNamesMemberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://ww
w.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : Trade Names [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Trade_Names_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseTrade Names [Member]us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_TradeNamesMemberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://ww
w.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse27true0us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstractus-gaaptruenadu
rationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse28false0us-gaap_IndefiniteLivedIntangibl
eAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse7620000076.2falsetruefalsefalsefalse2truefalsefalse7620000076.2falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount of intangible assets, excluding goodwill, which have a projected indefinite period of benefit (hence ar
e not amortized), allocated to the reportable segment. These assets, acquired either individually or as part of a group of assets, in either an asset acquisition or business combination, are assessed at least annually for impairment. Examples may include trade secrets, contractual rights, trade names, and licensing agreements.No authoritative reference available.truefalse222Goodwill Product Rights and Other Intangibles (Details 1) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
53
R33.xml
IDEA: Income Taxes (Tables)
2.2.0.25falsefalse0511 - Disclosure - Income Taxes (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_IncomeTaxesTablesAbstractwpifalsenadurationIncome Taxes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalse<
DisplayDateInUSFormat>falsefalsefalseOtherxbrli:stringItemTypestringIncome Taxes.falsefalse3false0wpi_IncomeBeforeProvisionOfIncomeTaxesTextBlockwpifalsenadurationIncome before provision of income taxes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table1 - wpi:IncomeBeforeProvisionOfIncomeTaxesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s income before provision for income taxes was
generated from the United States and international operations as
follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="73%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Income before income taxes:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. 
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
391.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
366.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
353.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(141.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Income before income taxes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
250.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
362.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
358.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringIncome before provision of income taxes.No authoritative reference available.falsefalse4false0wpi_ProvisionForIncomeTaxesTextBlockwpifalsenaduratio
nProvision for income taxes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table2 - wpi:ProvisionForIncomeTaxesTextBlock-->
<div align="center" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s provision for income taxes consisted of the
following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="73%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Years Ended December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current provision:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Federal
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
161.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
133.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
State
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total current provision
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
185.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
159.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
116.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Deferred (benefit) provision:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Federal
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(54.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
State
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Foreign
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(54.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total deferred (benefit) provision
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(118.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(19.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total provision for income taxes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
67.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
140.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringProvision for income taxes.No authoritative reference available.falsefalse5false0wpi_ReconciliationsBetweenStatutoryFederalIncomeTaxRateAndCompanysEffectiveIncomeTaxRateTextBlockwpifalse
nadurationReconciliations between the statutory federal income tax rate and the Company's effective income tax rate.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -
- ->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table3 - wpi:ReconciliationsBetweenStatutoryFederalIncomeTaxRateAndCompanysEffectiveIncomeTaxRateTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Reconciliations between the statutory federal income tax rate
and the Company’s effective income tax rate were as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="78%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="4%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="4%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="2%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Federal income tax at statutory rates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
State income taxes, net of federal benefit
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Foreign rate differential
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Non-deductible expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
R&D credit and U.S. manufacturing deduction
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Charitable contributions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Favorable tax audit outcomes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Valuation allowance
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Transaction costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Sale of subsidiary
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)%
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Effective income tax rate
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
26.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
%
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringReconciliations between the statutory federal income tax rate and the Company's effective income tax rate.No authoritative reference available.falsefalse6false0wpi_ComponentsOfCompanysNetDeferredT
axAssetsLiabilitiesTextBlockwpifalsenadurationComponents of the Company's net deferred tax assets (liabilities).falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XH
TML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table4 - wpi:ComponentsOfCompanysNetDeferredTaxAssetsLiabilitiesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
The
significant components of the Company’s net deferred tax
assets (liabilities) consisted of the following:
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Benefits from net operating loss and tax credit carryforwards
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
86.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Differences in financial statement and tax accounting for:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Inventories, receivables and accruals
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
145.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
101.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Property, equipment and intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(305.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(366.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Deferred revenue
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Deferred interest expense
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Share-based compensation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total deferred tax liability, gross
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(112.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(216.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Valuation allowance
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Total deferred tax liability, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(141.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(245.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringComponents of the Company's net deferred tax assets (liabilities).No authoritative reference available.falsefalse7false0us-gaap_SummaryOfIncomeTaxContingenciesTextBlockus-gaapt
ruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note11_table5 - us-gaap:SummaryOfIncomeTaxContingenciesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="75%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="10" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at the beginning of the year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
61.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
71.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Increases for current year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Increases for prior year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Decreases for prior year tax positions
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(27.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(11.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(4.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(10.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Lapse of applicable statue of limitations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Balance at the end of the year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
68.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
72.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
61.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThe disclosure required for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecogni
zed tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
falsefalse16Income Taxes (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
54
R16.xml
IDEA: Other Long-Term Liabilities
2.2.0.25falsefalse0210 - Disclosure - Other Long-Term Liabilitiestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract
us-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_OtherLiabilitiesDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 10 - us-gaap:OtherLiabilitiesDisclosureTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 10 —
Other Long-Term Liabilities</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other long-term liabilities consisted of the following:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="83%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Atorvastatin contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
123.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Columbia contingent consideration liability
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
212.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Less: Current portion included in accounts payable and accrued
expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Total other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
183.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
118.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company determines the acquisition date fair value of
contingent consideration obligations based on a
probability-weighted income approach derived from revenue
estimates and a probability assessment with respect to the
likelihood of achieving contingent obligations including
contingent payments such as milestone obligations, royalty
obligations and contract earn-out criteria, where applicable.
The fair value measurement is based on significant inputs not
observable in the market and thus represents a Level 3
measurement as defined in fair value measurement accounting. The
resultant probability-weighted cash flows are discounted using
an appropriate effective annual interest rate to reflect the
internal rate of return and incremental commercial uncertainty,
major risks and uncertainties associated with the successful
completion of the projects triggering the contingent obligation.
At each reporting date, the Company will revalue the contingent
consideration obligation to estimated fair value and record
changes in fair value as income or expense in our consolidated
statement of operations. Changes in the fair value of the
contingent consideration obligations may result from changes in
discount periods and rates, changes in the timing and amount of
revenue estimates and changes in probability assumptions with
respect to the likelihood of achieving the various contingent
consideration obligations. Accretion expense related to the
increase in the net present value of the contingent liability is
included in interest expense for the period.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Atorvastatin
Contingent Consideration Liability</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In accordance with the Acquisition Agreement, the Arrow Selling
Shareholders will have the right to receive certain contingent
payments based on the after-tax gross profits on sales of
atorvastatin within the
U.S. (the “Territory”) from product launch date
up to and including May 31, 2013 (the “Contingent
Payment Period”). The determination of contingent payment
amounts is dependent upon the existence of generic competition
within the Territory and post-tax gross profits earned, as
defined in the Acquisition Agreement. Should there be no
competing generic product launched in the Territory during the
Contingent Payment Period, payment of contingent consideration
will be calculated as 50% of the post-tax gross profits, as
defined in the Acquisition Agreement. Should there be a
competing product to atorvastatin launched in the Territory
during the Contingent Payment Period, the contingent
consideration will be calculated as either 85% of the post-tax
gross profits or 15% of the post-tax gross profits, as defined
in the Acquisition Agreement, with total contingent payments
being limited to $250.0 million during the Contingent
Payment Period.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As of December 31, 2010 the range of outcomes and the
assumptions used to develop the estimates have not changed
significantly from those used at Acquisition Date. Other
long-term liabilities at December 31, 2010 and 2009
includes the fair value of the atorvastatin contingent liability
of $123.1 million and $111.0 million, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Columbia
Contingent Consideration Liability</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On July 2, 2010, the Company completed the acquisition of
the U.S. rights to Columbia products
Crinone<sup style="font-size: 85%; vertical-align: text-top">®</sup>
and
Prochieve<sup style="font-size: 85%; vertical-align: text-top">®</sup>
for initial cash consideration of $62.0 million and
acquired certain assets and assumed certain contingent
consideration obligations. The transaction was accounted for
using the purchase method of accounting under existing
U.S. GAAP with assets acquired and liabilities assumed
recorded at their fair values as of the acquisition date. The
purchase price for the Columbia acquisition was allocated to
tangible and identifiable intangible assets acquired and
liabilities assumed based on their estimated fair values at the
acquisition date. Fair value determinations of Columbia’s
contingent payment obligations on acquisition date were based
on, among other factors, estimates of expected future cash
flows, estimates of appropriate discount rates used to present
value expected future cash flow streams, the timing of approvals
for IPR&D projects and the timing of related product launch
dates and other factors. Contingent consideration obligations
primarily relate to anticipated future milestone payments and
royalty payments due to Columbia in accordance with the terms of
the Columbia acquisition agreement.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other long-term liabilities at December 31, 2010 include
the fair value of the Columbia contingent consideration
liability of $46.5 million (which excludes the current
amount of $28.9 million presented within accounts payable
and current liabilities).
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used as a single block of text to encapsulate the entire disclosure for other liabilities including data and tables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 24
-Article 5
falsefalse12Other Long-Term LiabilitiesUnKnownUnKnownUnKnownUnKnownfalsetrueXML
55
R28.xml
IDEA: Balance Sheet Components (Tables)
2.2.0.25falsefalse0506 - Disclosure - Balance Sheet Components (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_BalanceSheetComponentsTablesAbstractwpifalsenadurationBalance Sheet Components.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefals
efalsefalsefalseOtherxbrli:stringItemTypestringBalance Sheet Components.falsefalse3false0us-gaap_FairValueByBalanceSheetGroupingTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note6_table1 - us-gaap:FairValueByBalanceSheetGroupingTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Selected balance sheet components consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="79%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>(Revised)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Inventories:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Raw materials
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
178.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
196.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
<font style="white-space: nowrap">Work-in-process</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
38.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Finished goods
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
465.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
509.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
770.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Less: Inventory reserves
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Inventories, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
631.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
692.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Property and equipment:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Machinery and equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
570.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
525.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Buildings and improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
385.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
382.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Research and laboratory equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
106.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
94.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Leasehold improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
90.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
78.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Furniture and fixtures
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
46.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
45.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Land and land improvements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Construction in progress
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
32.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, at cost
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,265.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,197.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Less accumulated depreciation
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(623.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(503.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total property and equipment, net
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
642.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
694.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Accounts payable and accrued expenses:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Trade accounts payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
215.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
263.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Proposed legal settlements
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
129.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued payroll and related benefits
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
88.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued third-party rebates
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
83.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
60.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Royalties and sales agent payables
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
35.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current portion of contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued indirect returns
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Interest payable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
17.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Accrued severence, retention and other shutdown costs
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
15.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
98.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
95.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total accounts payable and accrued expenses
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
741.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
614.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis item represents certain of the disclosures concerning the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such
estimates of fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a, c(1), c(2), c(3), d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph c(2), d, e, f
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 19
-Subparagraph a, b, c(1), d(1)
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 14
-Subparagraph a
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15
-Subparagraph b-d
falsefalse12Balance Sheet Components (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
56
R52.xml
IDEA: Long-Term Debt (Details)
2.2.0.25truefalse0609 - Disclosure - Long-Term Debt (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse12/31/2010
USD ($)
$BalanceAsOf_31Dec2010http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse12/31/2009
USD ($)
$BalanceAsOf_31Dec2009http://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_LongTermDebtus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse10161000001016.1falsetruefalsefalsefalse2truefalsefalse14578000001457.8falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse4false0us-gaap_DebtCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse
DisplayZeroAsNone>00falsefalsefalsefalsefalse2truefalsefalse307600000307.6falsefalsefalsefalsefalseMonetaryxbrli:mon
etaryItemTypemonetaryCarrying value as of the balance sheet date of the sum of short-term debt and current maturities of long-term debt and capital lease obligations, which are due within one year (or one business cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19
-Article 5
truefalse5false0us-gaap_LongTermDebtNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse10161000001016.1falsefalsefalsefalsefalse2truefalsefalse11502000001150.2falsefalsefalsefalsefalseMonetary
xbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
truefalse6false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2014 [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Senior_Notes_Due_Two_Thousand_Fourteen_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2014 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandFourteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$4falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2014 [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Senior_Notes_Due_Two_Thousand_Fourteen_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2014 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandFourteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse7true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse8false0us-gaap_DebtInstrumentCarryingAmountus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse450000000450.0fals
efalsefalsefalsefalse2truefalsefalse450000000450.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date before
deducting unamortized discount or premiums (if any). May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number APB14-1
-Paragraph 31
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
falsefalse9false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2019 [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Senior_Notes_Due_Two_Thousand_Nineteen_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2019 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandNineteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes Due 2019 [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Senior_Notes_Due_Two_Thousand_Nineteen_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes Due 2019 [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeniorNotesDueTwoThousandNineteenMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse10true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse11false0us-gaap_DebtInstrumentCarryingAmountus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse400000000400.0fa
lsefalsefalsefalsefalse2truefalsefalse400000000400.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date befo
re deducting unamortized discount or premiums (if any). May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number APB14-1
-Paragraph 31
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
falsefalse12false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Senior_Notes_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SeniorNotesMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Senior Notes [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Senior_Notes_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseSenior Notes [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SeniorNotesMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse13true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse14false0us-gaap_DebtInstrumentCarryingAmountus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse850000000850.0falsefalsefalsefalsefalse2truefalsefalse850000000850.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date before deducting unamortized discount or premiums (if any). May include not
es payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number APB14-1
-Paragraph 31
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
falsefalse15false0us-gaap_DebtInstrumentUnamortizedDiscountus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse-2100000-2.1falsefalsefalsefalsefalse2truefalsefalse-2500000-2.5falsefalsefalsefalsefalseM
onetaryxbrli:monetaryItemTypemonetaryThe amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number APB14-1
-Paragraph 31
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 21
-Paragraph 16, 20
truefalse16false0us-gaap_LongTermDebtus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse847900000847.9falsefalsefalsefalsefalse2truefalsefalse847500000847.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse9falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : 2006 Credit Facility [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Line_Of_Credit_Member_2http://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalse2006 Credit Facility [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LineOfCreditMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : 2006 Credit Facility [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Line_Of_Credit_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalse2006 Credit Facility [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LineOfCreditMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217<
MeasureValue>USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse18true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaaptruenadurationNo
definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefa
lse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse19false0us-gaap_LongTermDebtus-gaaptr
uecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse400000000400.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans,
convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse20false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse11falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Mandatorily Redeemable Preferred Stock [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Mandatorily_Redeemable_Preferred_Stock_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseMandatorily Redeemable Preferred Stock [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MandatorilyRedeemablePreferredStockMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Mandatorily Redeemable Preferred Stock [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Mandatorily_Redeemable_Preferred_Stock_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseMandatorily Redeemable Preferred Stock [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MandatorilyRedeemablePreferredStockMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse21true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaap
truenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse22false0<
ElementName>us-gaap_LongTermDebtus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse166400000166.4falsefalsefalsefalsefalse2truefalsefalse151200000151.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term bor
rowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse23false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse13falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Loan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Lombard_Loan_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseLoan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_LombardLoanMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www
.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Loan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Lombard_Loan_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseLoan with Lombard Odier Darier Hentsch & Cie. ( Lombard Loan ) [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_LombardLoanMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://www
.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse24true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaap<
/ElementPrefix>truenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse25false0us-gaap_LongTermDebtus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse5500000055.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount
of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse26false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/longtermdebtdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse15falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Notes Payable, Other Notes Payable [Member]
12/31/2010
USD ($)
$BalanceAsOf_31Dec2010_Notes_Payable_Other_Payables_Memberhttp://www.sec.gov/CIK0000884629instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseNotes Payable, Other Notes Payable [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_NotesPayableOtherPayablesMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://w
ww.xbrl.org/2003/iso4217USDiso42170USDUSD$16falsefalseUSDtruefalse{us-gaap_LongtermDebtTypeAxis} : Notes Payable, Other Notes Payable [Member]
12/31/2009
USD ($)
$BalanceAsOf_31Dec2009_Notes_Payable_Other_Payables_Memberhttp://www.sec.gov/CIK0000884629instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseNotes Payable, Other Notes Payable [Member]us-gaap_LongtermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_NotesPayableOtherPayablesMemberus-gaap_LongtermDebtTypeAxisexplicitMemberUSDStandardhttp://w
ww.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse27true0us-gaap_LongtermDebtCurrentAndNoncurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse28false0us-gaap_LongTermDebt
us-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse18000001.8falsetruefalsefalsefalse2truefalsefalse41000004.1falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncluding current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May
include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20, 22
-Article 5
falsefalse227Long-Term Debt (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
57
R62.xml
IDEA: Reportable Segments (Geographic Area) (Details 1)
2.2.0.25falsefalse06131 - Disclosure - Reportable Segments (Geographic Area) (Details 1)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3true0us-gaap_EntityWideInformationAboutGeographicAreas
Abstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00fals
efalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse4false0us-gaap_EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicileus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse29901000002990.1falsetruefalsefalsefalse2truefalsefalse26422000002642.2falsetruefalsefalsefalse3truefalsefalse23847000002384.7falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryRevenues from external customers attributed to the entity's country of domicile.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 38
-Subparagraph a(1)
falsefalse5false0us-gaap_EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToForeignCountriesus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1
truefalsefalse425800000425.8falsefalsefalsefalsefalse2truefalsefalse5710000057.1falsefalsefalsefalsefalse3truefalsefalse2250000022.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryRevenues from external customers attributed to all foreign countries in total from which the entity derives revenues.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 38
-Subparagraph a(2)
truefalse6false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse34159000003415.9falsetruefalsefalsefalse2truefalsefalse26993000002699.3falsetruefalsefalsefalse3truefals
efalse24072000002407.2falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
falsefalse34Reportable Segments (Geographic Area) (Details 1) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
58
R9.xml
IDEA: Share Based Compensation
2.2.0.25falsefalse0203 - Disclosure - Share Based Compensationtruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_ShareBasedCompensationAbstract<
ElementPrefix>us-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefals
efalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalse<
IsEquityPrevioslyReportedAsRow>falsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 3 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 3 —
Share-Based Compensation</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
As indicated above, the Company recognizes compensation expense
for all share-based compensation awards made to employees and
directors based on estimated fair values. A summary of the
Company’s share-based compensation plans is presented below.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Equity
Award Plans</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company has adopted several equity award plans, all of which
have been approved by the Company’s shareholders that
authorize the granting of options, restricted stock and other
forms of equity awards of the Company’s common shares
subject to certain conditions. At December 31, 2010, the
Company had reserved 5.2 million of its common shares for
issuance of share-based compensation awards under the
Company’s equity award plans.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Option award plans require options to be granted at the fair
value of the shares underlying the options at the date of the
grant and generally become exercisable over periods ranging from
three to five years and expire in ten years. In conjunction with
certain of the Company’s acquisitions, Watson assumed stock
option and warrant plans from the acquired companies. The
options and warrants in these plans were adjusted by the
individual exchange ratios specified in each transaction. No
additional options or warrants have been granted under any of
the assumed plans.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Beginning in 2005, the Compensation Committee of the board of
directors of the Company (the “Board”) authorized and
issued restricted stock to the Company’s employees,
including its executive officers and certain non-employee
directors (the “Participants”) under the
Company’s equity compensation plans. The restricted stock
award program offers Participants the opportunity to earn shares
of our common stock over time, rather than options that give
Participants the right to purchase stock at a set price.
Restricted stock awards are grants that entitle the holder to
shares of common stock subject to certain terms. Restricted
stock awards generally have restrictions eliminated over a one
to four year period. Restrictions generally lapse for
non-employee directors after one year. Restrictions generally
lapse for employees over a two to four year period. The fair
value of restricted stock grants is based on the fair market
value of our common stock on the respective grant dates.
Restricted stock compensation is being amortized and charged to
operations over the same period as the restrictions are
eliminated for the Participants.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Share-Based
Compensation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Share-based compensation expense recognized in the
Company’s results of operations for the years ended
December 31, 2010, 2009 and 2008 was $23.5 million,
$19.1 million and $18.5 million, respectively.
Share-based compensation capitalized to inventory was
$3.6 million, $2.7 million and $3.3 million for
the years ended December 31, 2010, 2009 and 2008,
respectively.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDisclosure of compensation-related costs for share-based compensation which may include disclosure of policies, compensation plan details, allocation of stock compensation, incentive distributions, share-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
falsefalse12Share Based CompensationUnKnownUnKnownUnKnownUnKnownfalsetrueXML
59
R6.xml
IDEA: Consolidated Statements of Stockholders' Equity and Comprehensive Income
2.2.0.25truefalse0140 - Statement - Consolidated Statements of Stockholders' Equity and Comprehensive IncometruefalseIn Millionsfalse1falsefalseUSDtruefalse{us-gaap_StatementEquityComponentsAxis} : Common Stock
1/1/2010 - 12/31/2010
TwelveMonthsEnded_31Dec2010_Common_Stock_Memberhttp://www.sec.gov/CIK0000884629na0001-01-01T00:00:000001-01-01T00:00:00falsefalseus-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberSharesStandardhttp://www.xbrl.org/2003/instance<
MeasureValue>sharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$2falsefalseUSDtruefalse{us-gaap_StatementEquityComponentsAxis} : Additional Paid-in Capital
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Memberhttp://www.sec.gov/CIK0000884629na0001-01-01T00:00:000001-01-01T00:00:00falsefalseus-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3falsefalseUSDtruefalse{us-gaap_StatementEquityComponentsAxis} : Retained Earnings
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Retained_Earnings_Memberhttp://www.sec.gov/CIK0000884629na0001-01-01T00:00:000001-01-01T00:00:00falsefalseus-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/20
03/iso4217USDiso42170USDUSD$4falsefalseUSDtruefalse{us-gaap_StatementEquityComponentsAxis} : Accumulated Other Comprehensive Income (Loss)
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Accumulated_Other_Comprehensive_Income_Memberhttp://www.sec.gov/CIK0000884629na0001-01-01T00:00:000001-01-01T00:00:00falsefalseus-gaap_AccumulatedOtherComprehensiveIncomeMemberus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccumulatedOtherComprehensiveIncomeMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_StatementEquityComponentsAxis} : Treasury Stock
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Treasury_Stock_Memberhttp://www.sec.gov/CIK0000884629na0001-01-01T00:00:000001-01-01T00:00:00falsefalseus-gaap_TreasuryStockMemberus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_TreasuryStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberSharesStandardhttp://www.xbrl.org/2003/ins
tancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629na0001-01-01T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp
://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$1false0us-gaap_StockholdersEquityus-gaaptruecreditinstantNo definition available.falsefalsefalsetruefalsefalsefalsetruefalsefalseperiodstartlabelinstant2008-01-01T00:00:000001-01-01T00:00:001truefalsefalse4000000.4falsetruefalsetruefalse2truefalsefalse968800000968.8falsetruefalsetruefalse3truefalsefalse11797000001179.7falsetruefalsetruefalse4truefalsefalse24000002.4falsetruefalsetruefalse5truefalsefalse-301700000-301.7falsetruefalsetruefalse6truefalsefalse18496000001849.6falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of all Stockholders' Equity (d
eficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
falsefalse2false0us-gaap_SharesIssuedus-gaaptruenainstantNo definition available.falsefalsefalsetruefalsefalsefalsetruefalsefalseperiodstartlabelinstant2008-01-01T00:00:0000
01-01-01T00:00:001truefalsefalse113100000113.1falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalse<
hasSegments>truefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse-9500000-9.5falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.No authoritative reference available.falsefalse3true0us-gaap_ComprehensiveIncomeNetOfTaxAbstractus-gaaptruenadurationNo definition available.falsefa
lsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse4false0us-gaap_NetIncomeLossus-gaaptruecreditdurationN
o definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsetruefals
e2falsefalsefalse00falsefalsefalsetruefalse3truefalsefalse238400000238.4falsefalsefalsetrue
false4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse
hasScenarios>6truefalsefalse238400000238.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.Reference 1: http
://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
falsefalse5false0us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1<
IsNumeric>falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse-1000000-1.0falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse-1000000-1.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAppreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain or loss, net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain or loss at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains or losses realized upon the sale of securities, after tax; and (3) the unrealized gains or losses realized upon the write-down of securities, after tax.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
falsefalse6false0us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse9000000.9falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse9000000.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryChange in accumulated gains and losses from derivative instrument designated and qualifying as the effective portion of cash flow hedges, net of tax effect. The after tax effect change includes an entity's share of an equity investee's increase (decrease) in deferred hedging gains or losses.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 20
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 121
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 46
falsefalse7false0us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse<
/hasScenarios>3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse-5500000-5.5falsefalsefalsetruefals
e5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse-5500000-5.5falsefalsefalsefalsef
alseMonetaryxbrli:monetaryItemTypemonetaryChange in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity for the period being reported, net of tax. If an entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. Includes gain (loss) on foreign currency forward exchange contracts. Includes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial state
ments. Includes the gain or loss on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain or loss under FAS 52 and that have been designated and have qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 13, 20, 31
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17
truefalse8false0us-gaap_ComprehensiveIncomeNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse232800000232.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
falsefalse9false0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse1850000018.5falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse1850000018.5falsefalsefalsefalsefalse
Cell>Monetaryxbrli:monetaryItemTypemonetaryThis element represents the amount of recognized share-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 39
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A91
falsefalse10false0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse84000008.4falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse84000008.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryValue of stock issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
falsefalse11false0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse10000001.0falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5f
alsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 5
falsefalse12false0us-gaap_TaxBenefitFromStockOptionsExercisedus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1false
falsefalse00falsefalsefalsetruefalse2truefalsefalse2000000.2falsefalsefalsetruefalse3false<
/IsNumeric>falsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse2000000.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReductions in the entity's income taxes that arise when compensation cost (from non-qualified stock options) recognized on the entity's tax return exceeds compensation cost from non-qualified stock options recognized on the income statement. This element increases net cash provided by operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A132
falsefalse13false0us-gaap_TreasuryStockValueAcquiredParValueMethodus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalse<
/IsRatio>false-900000-0.9falsefalsefalsetruefalse6truefalsefalse-900000-0.9falsefalsefalsefalsefalseM
onetaryxbrli:monetaryItemTypemonetaryCost of common and preferred stock that were repurchased during the period. Recorded using the par value method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7
-Subparagraph b
falsefalse14false0us-gaap_StockholdersEquityus-gaaptruecreditinstantNo definition available.falsefalsefalsetruefalsefalsefalsefalsetruefalseperiodendlabelinstant2008-12-31T00:00:000
001-01-01T00:00:001truefalsefalse4000000.4falsefalsefalsetruefalse2truefalsefalse995900000995.9falsefalsefalsetruefalse3truefalsefalse14181000001418.1falsefalsefalsetruefalse4truefalsefalse-3200000-3.2falsefalsefalsetruefalse5truefalsefalse-302600000-302.6falsefalsefalsetruefalse6truefalsefalse21086000002108.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
falsefalse15false0us-gaap_SharesIssuedus-gaaptruenainstantNo definition available.falsefalsefalsetruefalsefalsefalsefalsetruefalseperiodendlabelinstant2008-12-31T00:00:000001-0
1-01T00:00:001truefalsefalse114100000114.1falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse-9500000-9.5falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.No authoritative reference available.falsefalse16true0us-gaap_ComprehensiveIncomeNetOfTaxAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefal
se00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse17false0us-gaap_NetIncomeLossus-gaaptruecreditdurationNo def
inition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3truefalsefalse222000000222.0falsefalsefalsetruefalse
4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse222000000222.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.Reference 1: http://ww
w.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
falsefalse18false0us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse33000003.3falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse33000003.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAppreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain or loss, net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain or loss at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains or losses realized upon the sale of securities, after tax; and (3) the unrealized gains or losses realized upon the write-down of securities, after tax.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
falsefalse19false0us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetrue
false3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse18000001.8falsefalsefalsetrue
false5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse18000001.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryChange in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity for the period being reported, net of tax. If an entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. Includes gain (loss) on foreign currency forward exchange contracts. Includes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial sta
tements. Includes the gain or loss on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain or loss under FAS 52 and that have been designated and have qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 13, 20, 31
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17
truefalse20false0us-gaap_ComprehensiveIncomeNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse227100000227.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
falsefalse21false0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse1910000019.1falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse1910000019.1falsefalsefalsefalsefalse<
/Cell>Monetaryxbrli:monetaryItemTypemonetaryThis element represents the amount of recognized share-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 39
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A91
falsefalse22false0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse3340000033.4falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse3340000033.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryValue of stock issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
falsefalse23false0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse20000002.0falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5f
alsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 5
falsefalse24false0us-gaap_StockIssuedDuringPeriodValueAcquisitionsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse636200000636.2falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse636200000636.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryValue of stock issued pursuant to acquisitions during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
falsefalse25false0us-gaap_StockIssuedDuringPeriodSharesAcquisitionsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1690000016.9falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse1690000016.9falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares of stock issued during the period pursuant to acquisitions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 53
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
falsefalse26false0us-gaap_TaxBenefitFromStockOptionsExercisedus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse23000002.3falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse23000002.3falsefalsefalsefalsefalseMon
etaryxbrli:monetaryItemTypemonetaryReductions in the entity's income taxes that arise when compensation cost (from non-qualified stock options) recognized on the entity's tax return exceeds compensation cost from non-qualified stock options recognized on the income statement. This element increases net cash provided by operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A132
falsefalse27false0us-gaap_TreasuryStockValueAcquiredParValueMethodus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalse<
/IsRatio>false-3600000-3.6falsefalsefalsetruefalse6truefalsefalse-3600000-3.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCost of common and preferred stock that were repurchased during the period. Recorded using the par value method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7
-Subparagraph b
falsefalse28false0us-gaap_TreasuryStockSharesAcquiredus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse-100000-0.1falsefalsefalsetruefalse6truefalsefalse-100000-0.1falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares that have been repurchased during the period and are being held in treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
falsefalse29false0us-gaap_StockholdersEquityus-gaaptruecreditinstantNo definition available.falsefalsefalsetruefalsefalsefalsefalsetruefalseperiodendlabelinstant2009-12-31T00:00:000001-01-01T00:00:001truefalsefalse4000000.4falsefalsefalsetruefalse2truefalsefalse16869000001686.9falsefalsefalsetruefalse3truefalsefalse16401000001640.1falsefalsefalsetruefalse4truefalsefalse19000001.9falsefalse
falsetruefalse5truefalsefalse-306200000-306.2falsefalsefalsetruefalse6truefalsefalse30231000003023.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
falsefalse30false0us-gaap_SharesIssuedus-gaaptruenainstantNo definition available.falsefalsefalsetruefalsefalsefalsefalsetruefalseperiodendlabelinstant2009-12-31T00:00:000001-0
1-01T00:00:001truefalsefalse133000000133.0falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse-9600000-9.6falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.No authoritative reference available.falsefalse31true0us-gaap_ComprehensiveIncomeNetOfTaxAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefal
se00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse32false0us-gaap_NetIncomeLossus-gaaptruecreditdurationNo def
inition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3truefalsefalse184400000184.4falsefalsefalsetruefalse
4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse184400000184.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.Reference 1: http://ww
w.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
falsefalse33false0us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse71000007.1falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse71000007.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAppreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain or loss, net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain or loss at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains or losses realized upon the sale of securities, after tax; and (3) the unrealized gains or losses realized upon the write-down of securities, after tax.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
falsefalse34false0us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetrue
false3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse-11500000-11.5falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse-11500000-11.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryChange in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity for the period being reported, net of tax. If an entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. Includes gain (loss) on foreign currency forward exchange contracts. Includes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's finan
cial statements. Includes the gain or loss on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain or loss under FAS 52 and that have been designated and have qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 13, 20, 31
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17
truefalse35false0us-gaap_ComprehensiveIncomeNetOfTaxus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse180000000180.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
falsefalse36false0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse2350000023.5falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse2350000023.5falsefalsefalsefalsefalse<
/Cell>Monetaryxbrli:monetaryItemTypemonetaryThis element represents the amount of recognized share-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 39
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A91
falsefalse37false0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsetruefalse2truefalsefalse5470000054.7falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse5470000054.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryValue of stock issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
falsefalse38false0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse25000002.5falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5f
alsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares issued during the period as a result of any share-based compensation plan other than an employee stock ownership plan (ESOP).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 5
falsefalse39false0us-gaap_TaxBenefitFromStockOptionsExercisedus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1false
falsefalse00falsefalsefalsetruefalse2truefalsefalse67000006.7falsefalsefalsetruefalse3false
falsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse67000006.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReductions in the entity's income taxes that arise when compensation cost (from non-qualified stock options) recognized on the entity's tax return exceeds compensation cost from non-qualified stock options recognized on the income statement. This element increases net cash provided by operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A132
falsefalse40false0us-gaap_TreasuryStockValueAcquiredParValueMethodus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalse<
/IsRatio>false-6300000-6.3falsefalsefalsetruefalse6truefalsefalse-6300000-6.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCost of common and preferred stock that were repurchased during the period. Recorded using the par value method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7
-Subparagraph b
falsefalse41false0us-gaap_TreasuryStockSharesAcquiredus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1falsefalsefalse00falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse-100000-0.1falsefalsefalsetruefalse6truefalsefalse-100000-0.1falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares that have been repurchased during the period and are being held in treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
falsefalse42false0us-gaap_StockholdersEquityus-gaaptruecreditinstantNo definition available.falsefalsefalsetruefalsefalsefalsefalsetruefalseperiodendlabelinstant2010-12-31T00:00:000001-01-01T00:00:001truefalsefalse4000000.4falsetruefalsetruefalse2truefalsefalse17718000001771.8falsetruefalsetruefalse3truefalsefalse18245000001824.5falsetruefalsetruefalse4truefalsefalse-2500000-2.5falsetruefa
lsetruefalse5truefalsefalse-312500000-312.5falsetruefalsetruefalse6truefalsefalse32817000003281.7falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
falsefalse43false0us-gaap_SharesIssuedus-gaaptruenainstantNo definition available.falsefalsefalsetruefalsefalsefalsefalsetruefalseperiodendlabelinstant2010-12-31T00:00:000001-0
1-01T00:00:001truefalsefalse135500000135.5falsefalsefalsetruefalse2falsefalsefalse00falsefalsefalsetruefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse-9700000-9.7falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.No authoritative reference available.falsefalse643Consolidated Statements of Stockholders' Equity and Comprehensive Income (USD $)HundredThousandsHundredThousandsUnKnownUnKnownfalsetrueXML
60
R61.xml
IDEA: Reportable Segments (Details)
2.2.0.25truefalse0613 - Disclosure - Reportable Segments (Details)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_SegmentReportingInformationOperatingIncom
eLossAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse34159000003415.9falsetruefalsefalsefalse2truefalsefalse26993000002699.3falsetruefalsefalsefalse3truefalsefalse24072000002407.2falsetruefalsefalsefalseMonetaryxbrli:moneta
ryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
falsefalse4false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse35669000003566.9falsefalsefalsefalsefalse2truefalsefalse27930000002793.0falsefalsefalsefalsefalse3truefalsefalse25355000002535.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse5true0us-gaap_CostsAndExpensesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefa
lse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse6false0us-gaap_CostOfGoodsSoldus-gaaptruedebitdurationNo defi
nition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse19985000001998.5falsefalsefalsefalsefalse2truefalsefalse15968000001596.8falsefalsefalsefalsefalse3truefalsefalse15028000001502.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal costs related to goods produced and sold during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 2
-Article 5
falsefalse7false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse296100000296.1falsefalsefalsefalsefalse2truefalsefalse197300000197.3falsefalsefalsefalsefalse3truefalse
false170100000170.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a pla
n or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph g
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
falsefalse8false0us-gaap_SellingAndMarketingExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalse<
DisplayZeroAsNone>false320000000320.0falsefalsefalsefalsefalse2truefalsefalse263100000263.1falsefalsefalsefalsefalse3truefalsefalse232900000232.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total amount of expenses directly related to the marketing or selling of products or services.No authoritative reference available.truefalse9false0us-gaap_SegmentReportingSegmentOperatingProfitLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse952300000952.3falsefalsefalsefalsefalse2truefalsefalse735800000735.8falsefalsefalsefalsefalse3truefalsefalse629700000629.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total amount of profit or loss for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph b
truefalse10false0us-gaap_GeneralAndAdministrativeExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse436100000436.1falsefalsefalsefalsefalse2truefalsefalse257100000257.1falsefalsefalsefalsefalse3true<
IsRatio>falsefalse190500000190.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.No authoritative reference available.falsefalse11false0us-gaap_AdjustmentForAmortizationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse180000000180.0falsefalsefalsefalsefalse2truefalsefalse9260000092.6falsefalsefalsefalsefalse3truefalsefalse8070000080.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of intangible assets over their estimated remaining economic lives.No authoritative reference available.falsefalse12false0wpi_LossGainOnAssetSalesAndImpairmentwpifalsedebitdurationLoss Gain on asset sales and Impairment.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse3080000030.8falsefalsefalsefalsefalse2truefalsefalse22000002.2falsefalsefalsefalsefalse3truefalsefalse3000000.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryLoss Gain on asset sales and Impairment.No authoritative reference available.truefalse13false0us-gaap_OperatingIncomeLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse305400000305.4falsefalsefalsefalsefalse2truefalsefalse383900000383.9falsefalsefalsefalsefalse3truefalsefalse358200000358.2falsefalsefalsefalse
falseMonetaryxbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No authoritative reference available.truefalse14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Generics segment [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Global_Generics_Segment_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseGlobal Generics segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalGenericsSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$5falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Generics segment [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Global_Generics_Segment_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseGlobal Generics segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalGenericsSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$6falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Generics segment [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Global_Generics_Segment_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseGlobal Generics segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalGenericsSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://
www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse15true0us-gaap_SegmentReportingInformationOperatingIncomeLossAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse16false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse22689000002268.9falsefalsefalsefalse
hasSegments>false2truefalsefalse16418000001641.8falsefalsefalsefalsefalse3truefalsefalse14040000001404.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
falsefalse17false0wpi_SegmentReportingSegmentRevenueOtherwpifalsecreditdurationSegment reporting segment revenue other.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalse
IsRatio>false6950000069.5falsefalsefalsefalsefalse2truefalsefalse2640000026.4falsefalsefalsefalsefalse3truefalsefalse7030000070.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySegment reporting segment revenue other.No authoritative reference available.truefalse18false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse23384000002338.4falsefalsefalsefalsefalse2truefalsefalse16682000001668.2falsefalsefalsefalsefalse3truefalsefalse14743000001474.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse19true0us-gaap_CostsAndExpensesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsef
alse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse20false0us-gaap_CostOfGoodsSoldus-gaaptruedebitdurationNo de
finition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse11989000001198.9falsefalsefalsefalsefalse2truefalsefalse947100000947.1falsefalsefalsefalsefalse3truefalsefalse883800000883.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal costs related to goods produced and sold during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 2
-Article 5
falsefalse21false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse194600000194.6falsefalsefalsefalsefalse2truefalsefalse140400000140.4falsefalsefalsefalsefalse3truefals
efalse119200000119.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a pl
an or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph g
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
falsefalse22false0us-gaap_SellingAndMarketingExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse111900000111.9falsefalsefalsefalsefalse2truefalsefalse5380000053.8falsefalsefalsefalsefalse3true
falsefalse5520000055.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total amount of expenses directly related to the marketing or selling of products or services.No authoritative reference available.truefalse23false0us-gaap_SegmentReportingSegmentOperatingProfitLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse833000000833.0falsefalsefalsefalsefalse2truefalsefalse526900000526.9falsefalsefalsefalsefalse3truefalsefalse416100000416.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total amount of profit or loss for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph b
truefalse24false0wpi_ContributionMarginwpifalsenadurationContribution margin.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruef
alse0.3560.356falsefalsefalsefalsefalse2truetruefalse0.3160.316falsefalsefalsefalsefalse3truetruefalse0.2820.282falsefalsefalsefalsefalseOtherus-types:percentItemTypepureContribution margin.No authoritative reference available.falsefalse25false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails1falsefalsefalse00falsefalsefalse
falsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Brands segment [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Global_Brands_Contribution_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseGlobal Brands segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalBrandsContributionMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhtt
p://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$8falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Brands segment [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Global_Brands_Contribution_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseGlobal Brands segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalBrandsContributionMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberPureStandardht
tp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Global Brands segment [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Global_Brands_Contribution_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseGlobal Brands segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_GlobalBrandsContributionMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhtt
p://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse26true0us-gaap_SegmentReportingInformationOperatingIncomeLossAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse27false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse316300000316.3falsefalsefalsefalsefalse2truefalsefalse393700000393.7falsefalsefalsefalsefalse3truefalsefalse397000000397.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
falsefalse28false0wpi_SegmentReportingSegmentRevenueOtherwpifalsecreditdurationSegment reporting segment revenue other.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalse
IsRatio>false8150000081.5falsefalsefalsefalsefalse2truefalsefalse6730000067.3falsefalsefalsefalsefalse3truefalsefalse5800000058.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySegment reporting segment revenue other.No authoritative reference available.truefalse29false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse397800000397.8falsefalsefalsefalsefalse2truefalsefalse461000000461.0falsefalsefalsefalsefalse3truefalsefalse455000000455.0f
alsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse30true0us-gaap_CostsAndExpensesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsef
alse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse31false0us-gaap_CostOfGoodsSoldus-gaaptruedebitdurationNo de
finition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse8840000088.4falsefalsefalsefalsefalse2truefalsefalse8930000089.3falsefalsefalsefalsefalse3truefalsefalse107100000107.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal costs related to goods produced and sold during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 2
-Article 5
falsefalse32false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse101500000101.5falsefalsefalsefalsefalse2truefalsefalse5690000056.9falsefalsefalsefalsefalse3truefalse<
/IsRatio>false5090000050.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan o
r design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph g
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
falsefalse33false0us-gaap_SellingAndMarketingExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse137800000137.8falsefalsefalsefalsefalse2truefalsefalse144500000144.5falsefalsefalsefalsefalse3truefalsefalse118200000118.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total amount of expenses directly related to the marketing or selling of products or services.No authoritative reference available.truefalse34false0<
/Level>us-gaap_SegmentReportingSegmentOperatingProfitLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse7010000070.1falsefalsefalsefalsefalse2truefalsefalse170300000170.3falsefalsefalsefalsefalse3truefalsefalse178800000178.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total amount of profit or loss for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph b
truefalse35false0wpi_ContributionMarginwpifalsenadurationContribution margin.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruef
alse0.1760.176falsefalsefalsefalsefalse2truetruefalse0.3690.369falsefalsefalsefalsefalse3truetruefalse0.3930.393falsefalsefalsefalsefalseOtherus-types:percentItemTypepureContribution margin.No authoritative reference available.falsefalse36false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails1falsefalsefalse00falsefalsefalse
falsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse10falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Distribution segment [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Distribution_Segment_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseDistribution segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_DistributionSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbrl
.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$11falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Distribution segment [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Distribution_Segment_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseDistribution segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_DistributionSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbrl
.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$12falsefalseUSDtruefalse{us-gaap_StatementBusinessSegmentsAxis} : Distribution segment [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Distribution_Segment_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseDistribution segment [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_DistributionSegmentMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberUSDStandardhttp://www.xbrl
.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse
Row>37true0us-gaap_SegmentReportingInformationOperatingIncomeLossAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse38false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationN
o definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse830700000830.7falsefalsefalsefalsefalse2truefalsefalse663800000663.8falsefalsefalsefalsefalse3truefalsefalse606200000606.2falsefalsefalsefalse<
/hasSegments>falseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
falsefalse39false0wpi_SegmentReportingSegmentRevenueOtherwpifalsecreditdurationSegment reporting segment revenue other.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalse
IsRatio>false00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySegment reporting segment revenue other.No authoritative reference available.truefalse40false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse830700000830.7falsefalsefalsefalsefalse2truefalsefalse663800000663.8falsefalsefalsefalsefalse3truefalsefalse606200000606.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse41true0us-gaap_CostsAndExpensesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsef
alse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse42false0us-gaap_CostOfGoodsSoldus-gaaptruedebitdurationNo de
finition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse711200000711.2falsefalsefalsefalsefalse2truefalsefalse560400000560.4falsefalsefalsefalsefalse3truefalsefalse511900000511.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal costs related to goods produced and sold during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 2
-Article 5
falsefalse43false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or
process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph g
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
falsefalse44false0us-gaap_SellingAndMarketingExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse7030000070.3falsefalsefalsefalsefalse2truefalsefalse6480000064.8falsefalsefalsefalsefalse3truefa
lsefalse5950000059.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate total amount of expenses directly related to the marketing or selling of products or services.No authoritative reference available.truefalse45false0us-gaap_SegmentReportingSegmentOperatingProfitLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse4920000049.2falsetruefalsefalsefalse2truefalsefalse3860000038.6falsetruefalsefalsefalse3truefalsefalse3480000034.8falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe total amount of profit or loss for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph b
truefalse46false0wpi_ContributionMarginwpifalsenadurationContribution margin.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruef
alse0.0590.059falsefalsefalsefalsefalse2truetruefalse0.0580.058falsefalsefalsefalsefalse3truetruefalse0.0570.057falsefalsefalsefalsefalseOtherus-types:percentItemTypepureContribution margin.No authoritative reference available.falsefalse345Reportable Segments (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruetrueXML
61
R5.xml
IDEA: Consolidated Statements of Cash Flows
2.2.0.25falsefalse0130 - Statement - Consolidated Statements of Cash FlowstruefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3true0us-gaap_NetCashProvidedByUsedInOperatingActivitie
sAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00fal
sefalsefalsefalsefalseOtherxbrli:stringItemTypestringThe net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities include all transactions and events that are not defined as investing or financing activities. Operating activities generally involve producing and delivering goods and providing services. Cash flows from operating activities are generally the cash effects of transactions and other events that enter into the determination of net income.falsefalse4false0us-gaap_ProfitLossus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse183300000183.3falsetruefalsefalsefalse2truefalsefalse222000000222.0falsetruefalsefalsefalse3truefalsefalse238400000238.4falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A1, A4, A5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 5
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(1)
truefalse5true0us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1
falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false
falsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse6false0us-gaap_Depreciationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse101900000101.9falsefalsefalsefalsefalse2truefalsefalse9640000096.4falsefalsefalsefalsefalse3truefalsefalse9000000090.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
falsefalse7false0us-gaap_AdjustmentForAmortizationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse180000000180.0falsefalsefalsefalsefalse2truefalsefalse9260000092.6falsefalsefalsefalsefalse3truefalsefalse8070000080.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of intangible assets over their estimated remaining economic lives.No authoritative reference available.falsefalse8false0wpi_ProvisionForInventoryReservewpifalsedebitdurationProvision for inventory reserve.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse5000000050.0falsefalsefalsefalsefalse2truefalsefalse5100000051.0falsefalsefalsefalsefalse3truefalsefalse4570000045.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryProvision for inventory reserve.No authoritative reference available.falsefalse9false0us-gaap_ShareBasedCompensationus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2350000023.5falsefalsefalsefalsefalse2truefalsefalse1910000019.1falsefalsefalsefalsefalse3truefalsefalse1850000018.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse10false0us-gaap_DeferredIncomeTaxExpenseBenefitus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-118300000-118.3falsefalsefalsefalsefalse2truefalsefalse-19000000-19.0falsefalsefalsefalsefalse3truefalsefalse35000003.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4
falsefalse11false0us-gaap_GainLossOnSaleOfInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefa
lsefalse-27300000-27.3falsefalsefalsefalsefalse2truefalsefalse11000001.1falsefalsefalsefalsefalse3truefalsefalse-9600000-9.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net realized gain or loss on investments sold during the period, which, for cash flow reporting, is a component of proceeds from investing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse12false0wpi_LossOnAssetSalesAndImpairmentwpifalsedebitdurationLoss on asset sales and impairment.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2980000029.8falsefalsefalsefalsefalse2truefalsefalse26000002.6falsefalsefalsefalsefalse3truefalsefalse3000000.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryLoss on asset sales and impairment.No authoritative reference available.falsefalse13false0us-gaap_ProvisionForDoubtfulAcco
untsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse95000009.5falsefalsefalsefalsefalse2truefalsefalse34000003.4falsefalsefalsefalsefalse3truefalsefalse12000001.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 5
-Article 5
falsefalse14false0us-gaap_OtherPreferredStockDividendsAndAdjustmentsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1tru
efalsefalse3840000038.4falsefalsefalsefalsefalse2truefalsefalse22000002.2falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryOther preferred stock dividends and adjustments, not otherwise defined in the taxonomy, that are necessary to adjust net income to obtain net income applicable to common stockholders.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section Q
falsefalse15false0us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesOtherus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1130000011.3falsefalsefalsefalsefalse2truefalsefalse-7600000-7.6falsefalsefalsefals
efalse3truefalsefalse-13900000-13.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTransactions that do not result in cash inflows or outflows in the period in which they occur, but affect net income and thus are removed when calculating net cash flow from operating activities using the indirect cash flow method. This element is used when there is n
ot a more specific and appropriate element.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse16true0us-gaap_IncreaseDecreaseInOperatingCapitalAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse17false0us-gaap_IncreaseDecreaseInAccountsReceivableus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-57100000-57.1falsefalsefalsefalsefalse2truefalsefalse-108200000-108.2falsefalsefalsefalsefalse3truefalsefalse-39100000-39.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse18false0us-gaap_IncreaseDecreaseInInventoriesus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse1050000010.5falsefalsefalsefalsefalse2truefalsefalse-82200000-82.2falsefalsefalsefalsefalse3true
falsefalse-28200000-28.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse19false0us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefal
sefalse5540000055.4falsefalsefalsefalsefalse2truefalsefalse91000009.1falsefalsefalsefalsefalse3true<
IsRatio>falsefalse3330000033.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the reporting period in the value of this group of assets within the working capital section.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse20false0us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse9650000096.5falsefalsefalsefalsefalse2truefalsefalse7200000072.0falsefalsefalsefalsefalse<
Id>3truefalsefalse-17600000-17.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the reporting period in the aggregate amount of obligations and expenses incurred but not paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse21false0us-gaap_IncreaseDecreaseInDeferredRevenueus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-10600000-10.6falsefalsefalsefalsefalse2truefalsefalse20000002.0falsefalsefalsefalsefalse3true<
/IsNumeric>falsefalse-14500000-14.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse22false0us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayableus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefals
efalse-20800000-20.8falsefalsefalsefalsefalse2truefalsefalse1690000016.9falsefalsefalsefalsefalse3truefalsefalse2460000024.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the period in the amount of cash payments due to taxing authorities for taxes that are based on the reporting entity's earnings.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
falsefalse23false0us-gaap_IncreaseDecreaseInOtherOperatingAssetsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalse
false1500000015.0falsefalsefalsefalsefalse2truefalsefalse34000003.4falsefalsefalsefalsefalse3truefalsefalse33000003.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change during the reporting period in other operating assets not otherwise defined in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
truefalse24false0us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1tru
efalsefalse387700000387.7falsefalsefalsefalsefalse2truefalsefalse154800000154.8falsefalsefalsefalsefalse3
Id>truefalsefalse178200000178.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.Reference 1: http://www.xbrl.org/2003/role/pre
sentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
truefalse25false0us-gaap_NetCashProvidedByUsedInOperatingActivitiesus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse571000000571.0falsefalsefalsefalsefalse2truefalsefalse376800000376.8falsefalsefalsefalsefalse3truefalsefalse416600000416.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing act
ivities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
truefalse26true0us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1fa
lsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false
IsNumeric>falsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse27false0us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-56600000-56.6falsefalsefalsefalsefalse2truefalsefalse-55400000-55.4falsefalsefalsefalsefalse3truefalsefalse-63500000-63.5falsefalse
ShowCurrencySymbol>falsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph c
falsefalse28false0us-gaap_PaymentsToAcquireIntangibleAssetsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1true
falsefalse-10900000-10.9falsefalsefalsefalsefalse2truefalsefalse-16500000-16.5falsefalsefalsefalsefalse3truefalsefalse-37000000-37.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph c
falsefalse29false0us-gaap_PaymentsToAcquireMarketableSecuritiesus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-5500000-5.5falsefalsefalsefalsefalse2truefalsefalse-8000000-8.0falsefalsefalsefalsefalse3truefalsefalse-8200000-8.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph a
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph b
falsefalse30false0us-gaap_PaymentsToAcquireEquityMethodInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-43700000-43.7falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph b
falsefalse31false0us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipmentus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse27000002.7falsefalsefalsefalsefalse2truefalsefalse30000003.0falsefalsefalsefalsefalse3fa
lsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph c
falsefalse32false0us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecuritiesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse95000009.5falsefalsefalsefalsefalse2truefalsefalse90000009.0falsefalsefalsefalsefalse3
Id>truefalsefalse67000006.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (trading, held-to-maturity, or available-for-sale) during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph a
falsefalse33false0us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestmentsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1
truefalsefalse9540000095.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse82000008.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15, 16
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 31
falsefalse34false0us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-67500000-67.5falsefalsefalsefalsefalse2truefalsefalse-968200000-968.2falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15, 17
falsefalse35false0us-gaap_PaymentsForProceedsFromOtherInvestingActivitiesus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse25000002.5falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse4000000.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net cash outflow (inflow) from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
truefalse36false0us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse-74100000-74.1falsefalsefalsefalsefalse2truefalsefalse-1036100000-1036.1falsefalsefalsefalsefalse3truefalsefalse-93400000-93.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net cash inflow (outflow) from investing activity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
truefalse37true0us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1false<
/IsNumeric>falsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse38false0us-gaap_ProceedsFromIssuanceOfLongTermDebtus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse11099000001109.9falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph b
falsefalse39false0wpi_PrincipalPaymentsOnDebtAndOtherLongTermLiabilitieswpifalsecreditdurationPrincipal payments on debt and other long-term liabilities.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-459700000-459.7falsefalsefalsefalsefalse2truefalsefalse-786600000-786.6falsefalsefalsefalsefalse3truefalsefalse-95600000-95.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryPrincipal payments on debt and other long-term liabilities.No authoritative reference available.falsefalse40false0us-gaap_ProceedsFromRepaymentsOfShortTermDebtus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse6790000067.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net cash inflow (outflow) for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
falsefalse41false0us-gaap_ProceedsFromStockPlansus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse5470000054.7falsefalsefalsefalsefalse2truefalsefalse3340000033.4falsefalsefalsefalsefalse3truefalsefalse84000008.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from the stock plan during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
falsefalse42false0us-gaap_PaymentsForRepurchaseOfCommonStockus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefals
efalse-6300000-6.3falsefalsefalsefalsefalse2truefalsefalse-3600000-3.6falsefalsefalsefalsefalse3truefalsefalse-900000-0.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash outflow to reacquire common stock during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 20
-Subparagraph a
truefalse43false0us-gaap_NetCashProvidedByUsedInFinancingActivitiesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse-411300000-411.3falsefalsefalsefalsefalse2truefalsefalse353100000353.1falsefalsefalsefalsefalse3true
falsefalse-20200000-20.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net cash inflow (outflow) from financing activity for the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
truefalse44false0us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse-4200000-4.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe effect of exchange rate changes on cash balances held in foreign currencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 25
truefalse45false0us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse8140000081.4falsefalsefalsefalsefalse2truefalsefalse-306200000-306.2falsefalsefalsefalsefalse3truefalsefalse303000000303.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net change between the beginning and ending balance of cash and cash equivalents.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
falsefalse46false0us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse201400000201.4falsefalsefalsefalsefalse2truefalsefalse507600000507.6falsefalsefalsefalsefalse<
Id>3truefalsefalse204600000204.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncludes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalt
y. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered
into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5
falsefalse47false0us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1tru
efalsefalse282800000282.8falsefalsefalsefalsefalse2truefalsefalse201400000201.4falsefalsefalsefalsefalse3
Id>truefalsefalse507600000507.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncludes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cas
h equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into w
ith others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5
falsefalse49true0wpi_CashPaidDuringYearForAbstractwpifalsenadurationCash paid during the year for.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsef
alsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringCash paid during the year for.falsefalse50false0us-gaap_InterestPaidus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse4940000049.4falsefalsefalsefalsefalse2truefalsefalse1730000017.3falsefalsefalsefalsefalse3truefalsefalse2440000024.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of cash paid during the current period for interest owed on money borrowed; includes amount of interest capitalizedReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 29
truefalse51false0us-gaap_IncomeTaxesPaidNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse
193900000193.9falsetruefalsefalsefalse2truefalsefalse142700000142.7falsetruefalsefalsefalse3truefalsefalse9180000091.8falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 29
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 27
-Subparagraph f
truefalse348Consolidated Statements of Cash Flows (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
62
R23.xml
IDEA: Valuation and Qualifying Accounts
2.2.0.25falsefalse0301 - Schedule - Valuation and Qualifying Accountstruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_ValuationAndQualifyingAccountsAbstractwpifalsenadurationValuation and Qualifying Accountsfalsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringValuation and Qualifying Accountsfalsefalse3false0us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalse<
IsTuple>falsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 69 - us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-->
<!-- xbrl,nx -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times"></font></b>
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<b></b>
</div>
<div style="margin-top: 0pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<b>
Valuation and Qualifying Accounts</b>
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<b>
Years Ended December 31, 2010,
2009 and 2008</b>
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="51%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="3%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="3%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="3%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Charged to<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Beginning of<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Costs and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Deductions/<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>End of<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Period</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Expenses</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Write-offs</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Other*</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Period</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="19" align="center" valign="bottom">
<b>(In millions)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Allowance for doubtful accounts:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Inventory reserves:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
50.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(76.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
51.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(22.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
14.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
77.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
47.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
45.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(58.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Tax valuation allowance:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
20.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="top">
<div style="text-indent: -10pt; margin-left: 20pt">
Year ended December 31, 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000">
</div>
<div style="margin-top: 3pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<tr>
<td width="1%"></td>
<td width="1%"></td>
<td width="98%"></td>
</tr>
<tr>
<td valign="top">
* </td>
<td></td>
<td valign="bottom">
Represents opening balances of businesses acquired in the period.</td>
</tr>
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringAn element designated to encapsulate the entire schedule of any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
falsefalse12Valuation and Qualifying AccountsUnKnownUnKnownUnKnownUnKnownfalsetrueXML
63
defnref.xml
IDEA: XBRL DOCUMENT
No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Acquisitions And Divestitures Text Block.No authoritative reference available.No authoritative reference available.No authoritative reference available.Gross accounts receivable of amounts due from the four largest customers.No authoritative reference available.Number of Reportable Segments.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Equity Securities Current Gross Unrealized Gains.No authoritative reference available.Deferred Tax Assets Liabilities Gross.No authoritative reference available.Income before provision of income taxes.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Prepaid expenses and other current assets.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Segment reporting segment revenue other.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Components of the Company's net deferred tax assets (liabilities).No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Royalties and sales agent payables.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Accrued severence, retention and shutdown costs.No authoritative reference available.Long term deferred tax assets.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Equity Securities Noncurrent Amortized Cost.No authoritative reference available.No authoritative reference available.No authoritative reference available.Net income, adjusted.No authoritative reference available.Business Acquisition Equity Interest Issued Or Issuable per share Stated Value.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Component of other income.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Number of largest customers as percentage to net revenue.No authoritative reference available.Business acquisition purchase price allocation other current assets.No authoritative reference available.Provision for inventory reserve.No authoritative reference available.No authoritative reference available.No authoritative reference available.Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Fair Value of Other Financial Instruments.No authoritative reference available.No authoritative reference available.No authoritative reference available.Deferred Tax Assets Inventories, receivables and accruals.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Minimum Period For Redemption Of Senior Notes.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Marketable Securities and Other Investments.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Fair Value of Contingent Liability Which Excludes Accounts Payable and Current Liabilities.No authoritative reference available.Inventory Pending for approval By regulatories.No authoritative reference available.Accrued indirect returns.No authoritative reference available.No authoritative reference available.No authoritative reference available.Loss on asset sales and impairment.No authoritative reference available.No authoritative reference available.No authoritative reference available.Business acquisitions equity interest issued or issuable number of shares issued.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Tangible and identifiable intangible assets acquired and liabilities assumed based on estimated fair values.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Other long-term liabilities, gross.No authoritative reference available.No authoritative reference available.No authoritative reference available.Deferred Tax Liabilities Tax Deferred Interest Expense.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Discount Rate Of Mandatorily Redeemable Preferred Stock.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Condition One for determination of contingent payment amounts.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Percentage Increase in ownership share after additional investment.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Sales return allowance netted from account receivable.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Share Based Compensation Arrangement By Share Based Payment Award Options Unrecognized Compensation Expense Remaining Weighted Average Period For Recognition.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Third-party manufactured as percentage of Product net revenue.No authoritative reference available.Reduction in Income Tax Expense Due to company Examination.No authoritative reference available.Current market price per share of restricted common stock.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Maximum percentage of investment for Cost method accounting.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Total amount of the settlement for all of the settling defendants under governmental reimbursement investigation and drug pricing litigation.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Reduction in Income Tax Expense Due To Andrx Examination.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Share Based Compensation Arrangement By Share Based Payment Award Options Unrecognized Compensation Expense Net Of Forfeitures.No authoritative reference available.No authoritative reference available.No authoritative reference available.Ownership percentage in Cost method investment.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Undistributed earning of the foreign subsidiaries.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Number of other individual customers as percentage to net revenue.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Security Gross Unrealized Loss.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Fair value assets and liabilities measured on recurring basis.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Description of Redemption price of the Senior Notes.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Fair value of amounts due for the transfer of certain product rights and technology.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Lapse Of Restrictions For EmployeesNo authoritative reference available.Finite Lived Intangible Assets Future Amortization Expense.No authoritative reference available.Annual debt maturities.No authoritative reference available.Available for Sale Securities Current Amortized Cost.No authoritative reference available.Mandatory redemption value for Mandatorily Redeemable Preferred Stock.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Principal payments on debt and other long-term liabilities.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Use of Estimates.No authoritative reference available.No authoritative reference available.No authoritative reference available.Summary of the Company's stock option plans.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Current portion of contingent consideration obligations.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Proposed legal settlements.No authoritative reference available.No authoritative reference available.No authoritative reference available.Long term deferred tax and other tax liabilities.No authoritative reference available.Available for Sale Securities Amortized Cost Fair Value and Unrealized Gains Losses.No authoritative reference available.Loss Gain on asset sales and Impairment.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Accrued third-party rebates.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Contribution margin.No authoritative reference available.No authoritative reference available.No authoritative reference available.Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Remaining Contractual Term.No authoritative reference available.No authoritative reference available.No authoritative reference available.Commitment to make investment contingent upon sucessful acquisition of additional third party product acquisition.No authoritative reference available.Current Portion of Other long term liabilities.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Equity Securities Current Amortized Cost.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Debt Securities Current Gross Unrealized Gains.No authoritative reference available.Maximum percentage of investment for equity method investment.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Unaudited pro forma results of operations.No authoritative reference available.Land and land improvements.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Other incomes.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Difference of fair value of our senior notes and carrying value.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Equity Securities Noncurrent Gross Unrealized Gains.No authoritative reference available.No authoritative reference available.No authoritative reference available.Share-based compensation capitalized to inventory.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Intangibles transferred to product rights and other related intangibles.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Reconciliations between the statutory federal income tax rate and the Company's effective income tax rate.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Business Acquisition Purchase Price Allocation Investments.No authoritative reference available.Available for Sale Securities Current Gross Unrealized Loss.No authoritative reference available.No authoritative reference available.No authoritative reference available.Comprehensive Income.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Equity Securities Noncurrent Gross Unrealized Loss.No authoritative reference available.No authoritative reference available.No authoritative reference available.Provision for income taxes.No authoritative reference available.Other Long-Term Liabilities.No authoritative reference available.Recent Accounting Pronouncements.No authoritative reference available.No authoritative reference available.No authoritative reference available.Concentration of Major Customers and Suppliers.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Sales return allowance included in the accounts payable and accrued liabilities.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Credit Facility time period.No authoritative reference available.Provisions for Sales Returns and Allowances.No authoritative reference available.Lapse of restrictions for non-employee directors.No authoritative reference available.Investments and other assets.No authoritative reference available.No authoritative reference available.No authoritative reference available.Effective annual interest rate using for probability-weighted cash flows were discounted.No authoritative reference available.Effective income tax rate reconciliation transaction costs.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Increase in goodwill related to acquisitions.No authoritative reference available.Option award plan exercisable over period.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Allocation of consideration transferred.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Maximum Period For Redemption Of Senior Notes.No authoritative reference available.Duration over which restrictions eliminated from restricted stock awards.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Description of Repurchase Price of the Senior Notes.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Unamortized Accretion Expense For The Preferred Stock.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Restricted stock awards restrictions eliminated period.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Research and laboratory equipment.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Net product sales in the therapeutic categories.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Debt Securities-Current Amortized Cost.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Provisions for Sales Returns and Allowances.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Balance Sheet Components.No authoritative reference available.Available for Sale Securities Equity Securities Current Gross Unrealized Loss.No authoritative reference available.No authoritative reference available.No authoritative reference available.Condition Two determination of contingent payment amounts.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Effective Income Tax Rate Reconciliation Reasearch and developement credit And Us Manufacturing Deduction.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Debt Securities Current Gross Unrealized Loss.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Option award plan expires.No authoritative reference available.No authoritative reference available.No authoritative reference available.Cost Method and Other Long Term Investments.No authoritative reference available.Large wholesalers customers represents the company's chargeback payments.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Business acquisition cost of acquired fair value of mandatorily redeemable preferred stock issued and issuable.No authoritative reference available.No authoritative reference available.No authoritative reference available.Amortization of cost of sales ,remaining value.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Total amount to be paid under settlement.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.No authoritative reference available.Marketable Securities.No authoritative reference available.No authoritative reference available.No authoritative reference available.Effective Income Tax Rate Reconciliation Sale of Subsidiary.No authoritative reference available.Available for Sale Securities Gross Unrealized Gain.No authoritative reference available.No authoritative reference available.No authoritative reference available.Available for Sale Securities Current Gross Unrealized Gains.No authoritative reference available.Business Acquisition Purchase Price Allocation Long term Deferred Tax Liabilities.No authoritative reference available.Large wholesalers customer represents the companys chargeback payments.No authoritative reference available.No authoritative reference available.No authoritative reference available.Summary of the changes in restricted stock grants.No authoritative reference available.Research and development expenses incurred under collaborative agreements.No authoritative reference available.XML
64
R46.xml
IDEA: Other Income (Details)
2.2.0.25truefalse0605 - Disclosure - Other Income (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDtruefalse{us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis} : Scinopharm [Member]
1/1/2010 - 3/31/2010
USD ($)
$ThreeMonthsEnded_31Mar2010_Scinopharm_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseScinopharm [Member]us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ScinopharmMemberus-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2true0wpi_OtherIncomeTextualsAbstractwpifalsenadurationOther income.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00<
CurrencyCode />falsefalsefalsetruefalseOtherxbrli:stringItemTypestringOther income.falsefalse3false0us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestmentsus-gaaptruedebitdurationNo definition available.falsefalsefalse<
/IsSubReportEnd>falsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse9540000095.4falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse82000008.2falsetruefalsefalsefalse4truefalsefalse9400000094.0falsetruefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 18
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15, 16
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 31
falsefalse4true0us-gaap_NonoperatingIncomeExpenseAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefa
lsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse
IsRatio>false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse5false0us-gaap_GainLossOnInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2560000025.6falsefalsefalsefalsefalse2truefalsefalse-1100000-1.1falsefalsefalsefalsefalse3truefalsefalse96000009.6falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain or loss of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain or loss which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains or losses realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for oth
er than temporary impairments of the subject investments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 7
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 22
falsefalse6false0us-gaap_IncomeLossFromEquityMethodInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse16000001.6falsefalsefalsefalsefalse2truefalsefalse1080000010.8falsefalsefalsefalsefalse3truefalsefalse1060000010.6falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 19
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 11
-Article 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 6
-Subparagraph b
falsefalse7false0us-gaap_GainsLossesOnExtinguishmentOfDebtus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-500000-0.5falsefalsefalsefalsefalse2truefalsefalse-2000000-2.0falsefalsefalsefalsefalse3true
IsNumeric>falsefalse-1100000-1.1falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 26
-Paragraph 20, 21
falsefalse8false0wpi_OtherIncomeswpifalsecreditdurationOther incomes.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalse
false10000001.0falsefalsefalsefalsefalse2truefalsefalse2000000.2falsefalsefalsefalsefalse3truefalsefalse2000000.2falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryOther incomes.No authoritative reference available.truefalse9false0us-gaap_OtherNonoperatingIncomeExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse2770000027.7falsetruefalsefalsefalse2truefalsefalse79000007.9falsetruefalsefalsefalse3truefalsefalse1930000019.3falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
truefalse48Other Income (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
65
R21.xml
IDEA: Fair Value Measurement
2.2.0.25falsefalse0215 - Disclosure - Fair Value Measurementtruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_FairValueMeasurementAbstractwpifalsenadurationFair Value Measurement.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringFair Value Measurement.falsefalse3false0us-gaap_FairValueDisclosuresTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 15 - us-gaap:FairValueDisclosuresTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 15 —
Fair Value Measurement</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In September 2006, the FASB issued authoritative guidance for
fair value measurements, which defines fair value, establishes a
framework for measuring fair value in U.S. GAAP and expands
disclosures about fair value measurements. The Company adopted
the provisions of the guidance effective January 1, 2008
for all financial assets and liabilities and any other assets
and liabilities that are recognized or disclosed at fair value
on a recurring basis. The Company adopted the provisions of the
guidance for nonfinancial assets and liabilities measured at
fair value on a non-recurring basis effective January 1,
2009. Although the adoption of the guidance did not materially
impact the Company’s financial condition, results of
operations or cash flows, we are required to provide additional
disclosures within our consolidated financial statements.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The guidance defines fair value as the price that would be
received to sell an asset or paid to transfer the liability (an
exit price) in an orderly transaction between market
participants and also establishes a fair value hierarchy which
requires an entity to maximize the use of observable inputs and
minimize the use of unobservable inputs when measuring fair
value. The fair value hierarchy within the guidance
distinguishes three levels of inputs that may be utilized when
measuring fair value, including level 1 inputs (using
quoted prices in active markets for identical assets or
liabilities), level 2 inputs (using inputs other than
level 1 prices such as quoted prices for similar assets and
liabilities in active markets or inputs that are observable for
the asset or liability) and level 3 inputs (using
unobservable inputs supported by little or no market activity
based
on our own assumptions used to measure assets and liabilities).
A financial asset or liability’s classification within the
above hierarchy is determined based on the lowest level input
that is significant to the fair value measurement.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Financial assets and liabilities measured at fair value or
disclosed at fair value on a recurring basis as at
December 31, 2010 and 2009 consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2010
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2009
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Marketable securities and investments consist of
<font style="white-space: nowrap">available-for-sale</font>
investments in U.S. Treasury and agency securities and
publicly traded equity securities for which market prices are
readily available. Unrealized gains or losses on marketable
securities and investments are recorded in accumulated other
comprehensive (loss) income.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The fair value measurement of the contingent consideration
obligations is determined using Level 3 inputs. The fair
value of contingent consideration obligations is based on a
probability-weighted income approach. The measurement is based
upon unobservable inputs supported by little or no market
activity based on our own assumptions. Changes in the fair value
of the contingent consideration obligations are recorded as a
component of operating income in our consolidated statement of
operations.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The tables below provide a summary of the changes in fair value,
including net transfers in
<font style="white-space: nowrap">and/or</font> out,
of all financial assets and liabilities measured at fair value
on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December 31, 2010
and 2009 (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis item represents the complete disclosure regarding the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value,
disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the Company is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risk is are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to
understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
falsefalse12Fair Value MeasurementUnKnownUnKnownUnKnownUnKnownfalsetrueXML
66
R13.xml
IDEA: Investments in Marketable Securities and Other Investments
2.2.0.25falsefalse0207 - Disclosure - Investments in Marketable Securities and Other Investmentstruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_InvestmentsAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalse
falsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 7 - us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-->
<div style="margin-left: 0%">
<div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">NOTE 7 —
Investments in Marketable Securities and Other
Investments</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="84%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>December 31,</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="6" align="center" valign="bottom">
<b>(In millions)</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
one year
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities — maturing within
two years
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments and other assets:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity method investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
63.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cost method and other long-term investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
21.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total investments and other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
84.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
114.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Watson’s marketable securities and other long-term
investments are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value based on quoted market prices
using the specific identification method. These investments are
classified as either current or non-current, as appropriate, in
the Company’s Consolidated Balance Sheets.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table provides a summary of the fair value and
unrealized gains (losses) related to Watson’s
<font style="white-space: nowrap">available-for-sale</font>
securities (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2010</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="40%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="12%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Gross Unrealized<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="left" valign="bottom" style="border-bottom: 1px solid #000000">
<b>At December 31, 2009</b>
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amortized Cost</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Gains</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Losses</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="white-space: nowrap">Available-for-sale:</font>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
U.S. Treasury and agency securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
12.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Equity securities — non-current
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 30pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
16.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Current
Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company invests in U.S. Treasury and agency securities.
These investments are included in marketable securities on the
Company’s Consolidated Balance Sheets at December 31,
2010 and 2009. Current investments are classified as
<font style="white-space: nowrap">available-for-sale</font>
and are recorded at fair value based on quoted market prices.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Investment
in Equity Method Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s investments in equity method investments at
December 31, 2010 consist of its investments in Columbia
and Moksha8 and certain equity method investments in privately
held companies acquired as part of Arrow Acquisition. (Refer to
“NOTE 4 — Acquisition and Divestitures”
for additional information on Columbia and Moksha8.)
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
On March 24, 2010, the Company sold its entire holdings of
common shares in the equity of Scinopharm to Uni-President
Enterprises Corporation. (Refer to “NOTE 4 —
Acquisition and Divestitures” for additional information on
Scinopharm).
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company recorded net earnings from equity method investments
of $1.6 million in 2010, $10.8 million in 2009 and
$10.6 million in 2008, respectively.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company is not required to provide ongoing investments or
additional funding to its joint ventures with the exception of a
commitment to invest an additional $20.0 million in Moksha8
upon Moksha8 meeting certain conditions. (Refer to
“NOTE 4 — Acquisition and Divestitures”
for additional information on Moksha8.)
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Cost
Method Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The Company’s cost method investments consist primarily of
investments in common shares of a number of private and public
companies where our ownership interest is under 20% or where we
do not have the ability to exercise significant influence.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Other
Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Other assets include security and equipment deposits and
deferred financing fees, net of amortization.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis item represents the entire disclosure related to Investments in Certain Debt and Equity Securities (and certain other trading assets) which include all debt and equity securities (other than those equity securities accounted for under the equity or cost methods of accounting) with readily determinable fair values. Other trading assets include assets that are carried on the balance sheet at fair value and held for trading purposes. A debt security represents a creditor relationship with an enterprise t
hat is in the form of a security. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities (and other trading assets).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
falsefalse12Investments in Marketable Securities and Other InvestmentsUnKnownUnKnownUnKnownUnKnownfalsetrueXML
67
R34.xml
IDEA: Stockholders' Equity (Tables)
2.2.0.25falsefalse0512 - Disclosure - Stockholders' Equity (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3false0wpi_SummaryOfCompanyStockOptionPlansTextBlockwpifalsenadurationSummary of the Company's stock option plans.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DT
D/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note12_table1 - wpi:SummaryOfCompanyStockOptionPlansTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the Company’s stock option plans consisted of
the following (options and aggregate intrinsic value in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="57%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="11%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Exercise<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Options</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Price</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.91
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Exercised
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
33.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
49.49
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Outstanding, December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.63
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
48.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Vested and expected to vest at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
36.71
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
47.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Options exercisable at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
37.30
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
42.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringSummary of the Company's stock option plans.No authoritative reference available.falsefalse4false0wpi_SummaryOfChangesInRestrictedStockGrantsTextBlockwpifalsenadurationSummary of the changes in restricted stock grants.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note12_table2 - wpi:SummaryOfChangesInRestrictedStockGrantsTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
A summary of the changes in restricted stock grants during the
year ended December 31, 2010 is presented below (shares and
aggregate intrinsic value in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="60%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="3%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="2%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="2%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="8%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="2%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Weighted<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Average<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Remaining<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Aggregate<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Grant Date<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Contractual<br />
</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b>Intrinsic<br />
</b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Shares</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Term (Years)</b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Value</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
28.79
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Granted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
41.03
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
43.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Vested
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
27.74
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(12.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Cancelled
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(0.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
31.55
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Restricted shares outstanding at December 31, 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
34.33
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
79.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringSummary of the changes in restricted stock grants.No authoritative reference available.falsefalse12Stockholders' Equity (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
68
R26.xml
IDEA: Acquisitions and Divestitures (Tables)
2.2.0.25falsefalse0504 - Disclosure - Acquisitions and Divestitures (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_AcquisitionsAndDivestituresTablesAbstractwpifalsenadurationAcquisitions and Divestitures Tables Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAcquisitions and Divestitures Tables Abstract.falsefalse3false0us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table1 - us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock-->
<div align="left" style="font-size: 1pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The following table presents a summary of the purchase price
consideration for the Arrow Acquisition (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,050.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Restricted Common Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
636.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value of Mandatorily Redeemable Preferred Stock
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
150.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Fair value estimate of atorvastatin contingent payment
consideration (refer to “NOTE 10 — Other
Long-Term Liabilities.”)
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringSchedule of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This schedule does not include leveraged buyouts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph a
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F
falsefalse4false0wpi_AllocationOfConsiderationTransferredTextBlockwpifalsenadurationAllocation of consideration transferred.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table2 - wpi:AllocationOfConsiderationTransferredTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
These
adjustments are reflected in the values presented below and in
our revised December 31, 2009 balance sheet (in millions):
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="90%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Cash and cash equivalents
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Accounts receivable
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
107.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Inventories
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
187.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other current assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
174.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Property, plant & equipment
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
82.4
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
711.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
518.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Goodwill
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
632.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
69.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Current liabilties
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(306.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax and other tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(303.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Other long-term liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,946.2
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringAllocation of consideration transferred.No authoritative reference available.falsefalse5false0wpi_UnauditedProFormaResultsOfOperationsTextBlockwpifalsenadurationUnaudited pro forma results of operations.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table3 - wpi:UnauditedProFormaResultsOfOperationsTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="81%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="3%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="3%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="3%" align="left"> </td><!-- colindex=03 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Year Ended December 31,</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>(In millions, except<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="7" nowrap="nowrap" align="center" valign="bottom">
<b>per share amounts)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net revenues
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,261.9
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,170.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net income
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
119.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
281.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Earnings per share:
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Basic
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.99
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.35
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Diluted
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
0.98
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2.34
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringUnaudited pro forma results of operations.No authoritative reference available.falsefalse6false0wpi_TangibleAndIdentifiableIntangibleAssetsAcquiredAndLiabilitiesAssumedBasedOnEstimatedFairValuesTextBlockwpifalsenadurationTangible and identifiable intangible assets acquired and liabilities assumed based on estimated fair values.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.or
g/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note4_table4 - wpi:TangibleAndIdentifiableIntangibleAssetsAcquiredAndLiabilitiesAssumedBasedOnEstimatedFairValuesTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The transaction was accounted for using the purchase method of
accounting under existing U.S. GAAP with assets acquired
and liabilities assumed recorded at their fair values as of the
acquisition date. The purchase price for the Columbia
acquisition was allocated to tangible and identifiable
intangible assets
acquired and liabilities assumed based on their estimated fair
values at the acquisition date as follows (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="92%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Amount</b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
IPR&D intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
75.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Intangible assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
39.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax assets
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Long-term deferred tax liabilities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(24.3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td style="border-top: 1px solid #000000">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Net assets acquired
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
62.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td style="border-top: 3px double #000000">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringTangible and identifiable intangible assets acquired and liabilities assumed based on estimated fair values.No authoritative reference available.falsefalse15Acquisitions and Divestitures (Tab
les)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
69
R59.xml
IDEA: Stockholders' Equity (Details 1)
2.2.0.25truefalse06121 - Disclosure - Stockholders' Equity (Details 1)truefalseIn Millions, except Per Share data, unless otherwise specifiedfalse1falsefalseUSDtruefalse{us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis} : Restricted Stock [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Restricted_Stock_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseRestricted Stock [Member]us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RestrictedStockMemberus-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxisexplicitMemberSharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0wpi_SummaryOfChangesInRestrictedStockGrantsAbstractwpifalsenadurationSummary of the changes in restricted stock grants.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSummary of the changes in restricted stock grants.falsefalse3false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse19000001.9false
falsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of outstanding awards on nonstock option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(b)
falsefalse4false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse10000001.0falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of shares issuable under a share-based award plan pertaining to grants made during the period on other than stock option plans (for example, phantom stock plan, stock appreciation rights plan, performance target plan).Reference 1: http://www.x
brl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(c)
falsefalse5false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-400000-0.4falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe decrease in the number of shares potentially issuable under a share-based award plan pertaining to awards for which the grantee has gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares, other instruments, or cash in accordance with the terms of the arrangement.<
/ElementDefenition>Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(d)
falsefalse6false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse-200000-0.2falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of shares under a share-based award plan other than a stock option plan that were settled during the reporting period due to a failure to satisfy vesting conditions pertaining to all option plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(e)
truefalse7false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse23000002.3falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesThe number of outstanding awards on nonstock option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance
criteria necessary to gain title to proceeds from the sale of the award or underlying shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(b)
falsefalse8false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse28.7928.79falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average fair value of nonvested awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to is
sue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(b)
falsetrue9false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse41.0341.03falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average fair value at grant for nonvested share-based awards issued during the period on other than stock option plans (for example, phantom stock plan, stock appreciation rights plan, performance target plan).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(c)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph c(1)
falsetrue10false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse27.7427.74falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average fair value as of grant dates pertaining to a share-based award plan other than a stock option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares
, other instruments, or cash in accordance with the terms of the arrangement.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(d)
falsetrue11false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageGrantDateFairValueus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse31.5531.55falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average fair value as of the grant date of share-based award plans other than stock option plans that were not exercised or put into effect during the reporting period as a result of the occurrence of a terminating event specified in the contractual agree
ment of the plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(e)
truetrue12false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalse
periodendlabel1truefalsefalse34.3334.33falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe weighted average fair value of nonvested awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equ
ity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(b)
falsetrue13false0wpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTermwpifalsenainstantShare Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted...falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse1.71.7falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalShare Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Remain
ing Contractual Term.No authoritative reference available.falsefalse14false0wpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTermwpifalsenainstantShare Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted...falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse1.61.6falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalShare Based Compensation
Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Remaining Contractual Term.No authoritative reference available.falsefalse15false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse5570000055700000falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe intrinsic value of
nonvested awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares, as calculated by applying the disclosed pricing methodology.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(b)
falsetrue16false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValueus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse4370000043700000falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe intrinsic value of share-based payment equity instruments, excluding stock options, granted during the reporting period as calculated by applying the disclosed option pricing methodology.Reference 1: http://ww
w.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(c)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph c(1)
falsetrue17false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValueus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-12900000-12900000falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe intrinsic value of share-based payment equity instruments, excluding stock options, that vested during the reporting period as calculated by applying the disclosed pricing methodology.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(d)
falsetrue18false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodIntrinsicValueus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse-6900000-6900000falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe intrinsic value of share-based payment equity instruments, excluding stock options, that were forfeited during the reporting period, as calculated by applying the disclosed pricing methodology.Reference 1: http://www.xbrl.org/2003/role/presentationRe
f
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(e)
truetrue19false0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse7960000079600000falsetruefalsefalsefalseEPSus-types:perShareItemTypedecimalThe intrinsic value of nonvested awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to
an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares, as calculated by applying the disclosed pricing methodology.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(a)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph b(2)(b)
falsetrue20true0wpi_AdditionalStockholdersEquityTextualsAbstractwpifalsenadurationAdditional Stockholders Equity Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAdditional Stockholders Equity Textuals Abstract.falsefalse21false0us-gaap_EmployeeServiceShareBasedCom
pensationUnrecognizedCompensationCostsOnNonvestedAwardsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2860000028.6falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAs of the latest balance-sheet date presented, the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized (will be charged against earnings as services are performed or other vesting criteria are met).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph h
falsefalse22false0us-gaap_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsOnNonvestedAwardsWeightedAveragePeriodOfRecognitionus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1.61.6falsefalsefalsefalsefalseOtherxbrli:decimalItemTypedecimalThe weighted average period over which unrecognized share-based compensation costs are expected to be reported.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph h
falsefalse121Stockholders' Equity (Details 1) (Restricted Stock [Member], USD $)HundredThousandsHundredThousandsNoRoundingUnKnowntruetrueXML
70
R64.xml
IDEA: Business Restructuring Charges (Details)
2.2.0.25truefalse0614 - Disclosure - Business Restructuring Charges (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse3false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse1590000015.9falsetruefalsefalsefalse2truefalsefalse1610000016.1falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse4false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefals
efalse4150000041.5falsefalsefalsefalsefalse2truefalsefalse3260000032.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse5false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-25600000-25.6falsefalsefalsefalsefalse2truefalsefalse-25200000-25.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse6false0us-gaap_RestructuringReserveAccrualAdjustmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-11800000-11.8falsefalsefalsefalsefalse2truefalsefalse-7600000-7.6falsefalsefalsefalsefalseMon
etaryxbrli:monetaryItemTypemonetaryAmount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse7false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse2000000020.0falsefalsefalsefalsefalse2truefalsefalse1590000015.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse8false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3false
IsAbstractGroupTitle>falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Severance and retention [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Severance_And_Retention_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSeverance and retention [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SeveranceAndRetentionMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse9true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse10false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse1310000013.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse11false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse59000005.9falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMoneta
ryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse12false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-6100000-6.1falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse13false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse1290000012.9falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse4false<
/IsAbstractGroupTitle>falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Product transfer costs [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Product_Transfer_Costs_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseProduct transfer costs [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_ProductTransferCostsMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse15true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalse
falsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse16false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse10000001.0falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse17false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse33000003.3falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMoneta
ryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse18false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-2900000-2.9falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse19false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse14000001.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetary
xbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse20false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse5false<
/IsAbstractGroupTitle>falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Facility decommission costs [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Facility_Closing_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseFacility decommission costs [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FacilityClosingMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse21true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse22false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse2000000.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse23false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse1070000010.7falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMone
taryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse24false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-9300000-9.3falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse25false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse16000001.6falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetary
xbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse26false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse6false<
/IsAbstractGroupTitle>falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Accelerated depreciation [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Accelerated_Depreciation_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAccelerated depreciation [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AcceleratedDepreciationMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse27true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse28false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1040000010.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse29false0us-gaap_RestructuringReserveAccrualAdjustmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse
IsRatio>false-10400000-10.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMoneta
ryxbrli:monetaryItemTypemonetaryAmount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse30false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryx
brli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse31false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse7false<
/IsAbstractGroupTitle>falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Cost of sales [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Cost_Of_Sales_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseCost of sales [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CostOfSalesMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardh
ttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Cost of sales [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Cost_Of_Sales_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseCost of sales [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CostOfSalesMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardh
ttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse32true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadura
tionNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse33
Id>false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse1430000014.3<
NonNumbericText />falsefalsefalsefalsefalse2truefalsefalse1460000014.6falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying
amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse34false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse3030000030.3falsefalsefalsefalsefalse2truefalsefalse2930000029.3falsefalsefalsefalsefalse<
Unit>Monetaryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse35false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-18300000-18.3falsefalsefalsefalsefalse2truefalsefalse-22400000-22.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse36false0us-gaap_RestructuringReserveAccrualAdjustmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-10400000-10.4falsefalsefalsefalsefalse2truefalsefalse-7200000-7.2falsefalsefalsefalsefalseMo
netaryxbrli:monetaryItemTypemonetaryAmount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse37false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse1590000015.9falsefalsefalsefalsefalse2truefalsefalse1430000014.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse38false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse9false<
/IsAbstractGroupTitle>falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : R&D [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Research_And_Development_Arrangement_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseR&D [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentArrangementMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : R&D [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Research_And_Development_Arrangement_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseR&D [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentArrangementMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse39true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse40false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse8000000.8
falsefalsefalsefalsefalse2truefalsefalse7000000.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse41false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse81000008.1falsefalsefalsefalsefalse2truefalsefalse23000002.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse42false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-5800000-5.8falsefalsefalsefalsefalse2truefalsefalse-1800000-1.8falsefalsefalsefalsefalseMo
netaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse43false0us-gaap_RestructuringReserveAccrualAdjustmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse-400000-0.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse44false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse31000003.1falsefalsefalsefalsefalse2truefalsefalse8000000.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse45false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse11false
falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Accelerated depreciation - R&D [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Accelerated_Depreciation_Research_And_Development_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAccelerated depreciation - R&D [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AcceleratedDepreciationResearchAndDevelopmentMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse46true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse47false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse14000001.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse48false0us-gaap_RestructuringReserveAccrualAdjustmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse
IsRatio>false-1400000-1.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetary
xbrli:monetaryItemTypemonetaryAmount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse49false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryx
brli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse50false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse12false
falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Selling, general and administrative [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Selling_General_And_Administrative_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSelling, general and administrative [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SellingGeneralAndAdministrativeMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13falsefalseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Selling, general and administrative [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Selling_General_And_Administrative_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSelling, general and administrative [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_SellingGeneralAndAdministrativeMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse51true0us-gaap_RestructuringReserveRollForward
us-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalseActivity related to business restructuring and facility rationalization52false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse8000000.8falsefalsefalsefalsefalse2truefalsefalse8000000.8falsefalsefalsefalsefalseMonetaryxbrli:monet
aryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse53false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse17000001.7falsefalsefalsefalsefalse2truefalsefalse10000001.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse54false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-1500000-1.5falsefalsefalsefalsefalse2truefalsefalse-1000000-1.0falsefalsefalsefalsefalseMo
netaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse55false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse10000001.0falsefalsefalsefalsefalse2truefalsefalse8000000.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse56false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/businessrestructuringchargesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse14false
falseUSDtruefalse{us-gaap_RestructuringReserveByTypeOfRestructuringAxis} : Operating expenses [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Operating_Expenses_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOperating expenses [Member]us-gaap_RestructuringReserveByTypeOfRestructuringAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OperatingExpensesMemberus-gaap_RestructuringReserveByTypeOfRestructuringAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse57true0us-gaap_RestructuringReserveRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse58false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse16000001.6falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse59false0us-gaap_RestructuringReservePeriodExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse1120000011.2falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMone
taryxbrli:monetaryItemTypemonetaryReserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse60false0us-gaap_RestructuringReserveSettledWithCashus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-7300000-7.3falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse61false0us-gaap_RestructuringReserveAccrualAdjustmentus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-1400000-1.4falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
falsefalse62false0us-gaap_RestructuringReserveus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse41000004.1falsetruefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 95-3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4
falsefalse261Business Restructuring Charges (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
71
R1.xml
IDEA: Document and Entity Information
2.2.0.25falsefalse00 - Document - Document and Entity Informationtruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalsefalsefalse1/31/2011
BalanceAsOf_31Feb2011http://www.sec.gov/CIK0000884629instant2011-01-31T00:00:000001-01-01T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli03falsefalseUSDfalsefalse6/30/2010
USD ($)
$BalanceAsOf_30Jun2010http://www.sec.gov/CIK0000884629instant2010-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2true0wpi_DocumentAndEntityInformationAbstractwpifalsenadurationDocument and Entity Information.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringDocument and Entity Information.falsefalse3false0dei_EntityRegistrantNamedeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00WATSON PHARMACEUTICALS INCWATSON PHARMACEUTICALS INCfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
falsefalse4false0dei_EntityCentralIndexKeydeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse0000008846290000884629falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
falsefalse5false0dei_DocumentTypedeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse0010-K10-Kfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:SECReportItemTypenaThe type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type should be limited to the same value as the supporting SEC submission type. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, NCSR, N-Q, and Other.No authoritative reference available.falsefalse6false0dei_DocumentPeriodEndDatedeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse002010-12-312010-12-31falsefalsetruefalsefalse2falsefalsefalse00falsefalsetruefalsefalse3falsefalsefalse00falsefalsetruefalsefalseOtherxbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements this will be the filing date. The format of the date is CCYY-MM-DD.No authoritative reference available.falsefalse7false0dei_AmendmentFlagdeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:booleanItemTypenaIf the value is true, then the document as an amendment to previously-filed/accepted document.No authoritative reference available.falsefalse8false0dei_DocumentFiscalYearFocusdeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse0020102010falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No authoritative reference available.falsefalse9false0dei_DocumentFiscalPeriodFocusdeifalsenadurationNo definition available.falsefalsef
alsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00FYFYfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:fiscalPeriodItem
TypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No authoritative reference available.falsefalse10false0dei_CurrentFiscalYearEndDatedeifalsenadurationNo definition available.falsefalsefalsefal
sefalsefalsefalsefalsefalsefalse1falsefalsefalse00--12-31--12-31falsefalsefalsefalsefalse2falsefalsefalse
00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No authoritative reference available.falsefalse11false0dei_EntityWellKnownSeasonedIssuerdeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00YesYesfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.No authoritative reference available.falsefalse12false0dei_EntityVoluntaryFilersdeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NoNofalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.No authoritative reference available.falsefalse13false0dei_EntityCurrentReportingStatusdeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00YesY
esfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:yesNoItemTypenaIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.No authoritative reference available.falsefalse14false0dei_EntityFilerCategorydeifalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse0
0Large Accelerated FilerLarge Accelerated Filerfalsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherus-types:filerCategoryItemTypenaIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.<
ElementReferences>No authoritative reference available.falsefalse15false0dei_EntityPublicFloatdeifalsecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalse
IsRatio>false00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse50650210005065021000falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryState aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants fo
rm 10K.No authoritative reference available.falsefalse16false0dei_EntityCommonStockSharesOutstandingdeifalsenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse125827379125827379falsefalsefalsefalsefalse3
falsefalsefalse00falsefalsefalsefalsefalseSharesxbrli:sharesItemTypesharesIndicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, InstrumentNo authoritative reference available.falsefalse315Document and Entity Information (USD $)NoRoundingNoRoundingUnKnownUnKnownfalsetrueXML
72
R2.xml
IDEA: Consolidated Balance Sheets
2.2.0.25falsefalse0110 - Statement - Consolidated Balance SheetstruefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4true0us-gaap_AssetsCurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse5false0us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse282800000282.8falsetruefalsefalsefalse2truefalsefalse201400000201.4falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryIncludes currenc
y on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equi
valent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5
falsefalse6false0us-gaap_MarketableSecuritiesCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1110000011.1falsefalsefalsefalsefalse2truefalsefalse1360000013.6falsefalsefalsefalsefalseMonet
aryxbrli:monetaryItemTypemonetaryTotal debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2
-Article 5
falsefalse7false0us-gaap_AccountsReceivableNetCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse<
DisplayZeroAsNone>false560900000560.9falsefalsefalsefalsefalse2truefalsefalse517400000517.4falsefalsefalsefalsefalseMone
taryxbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5
falsefalse8false0us-gaap_InventoryNetus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1
truefalsefalse631000000631.0falsefalsefalsefalsefalse2truefalsefalse692300000692.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).No authoritative reference available.falsefalse9false0wpi_PrepaidExpensesAndOtherCurrentAssetswpifalsedebitinstantPrepaid expenses and other current assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse134200000134.2falsefalsefalsefalsefalse2truefalsefalse213900000213.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryPrepaid expenses and other current assets.No authoritative reference available.falsefalse10false0us-gaap_DeferredTaxAssetsNetCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse179400000179.4false
falsefalsefalsefalse2truefalsefalse130900000130.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary
differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward should be presented as a reduction of the related deferred tax asset.Reference 1: http://www.xbrl.or
g/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42, 43
truefalse11false0us-gaap_AssetsCurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse17994000001799.4falsefalsefalsefalsefalse2truefalsefalse17695000001769.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 9
-Article 5
falsefalse12false0us-gaap_PropertyPlantAndEquipmentNetus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse<
DisplayZeroAsNone>false642300000642.3falsefalsefalsefalsefalse2truefalsefalse694200000694.2falsefalsefalsefalsefalseMone
taryxbrli:monetaryItemTypemonetaryTangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 12
-Paragraph 5
-Subparagraph b, c
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 8
-Article 7
falsefalse13false0wpi_InvestmentsAndOtherAssetswpifalsedebitinstantInvestments and other assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse8450000084.5falsefalsefalsefalsefalse2truefalsefalse114500000114.5falsefalsefalsefalsefalseMone
taryxbrli:monetaryItemTypemonetaryInvestments and other assets.No authoritative reference available.falsefalse14false0us-gaap_DeferredTaxAssetsNetNoncurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalse<
/IsBeginningBalance>falsefalseverboselabel1truefalsefalse141000000141.0falsefalsefalsefalsefalse2truefalsefalse110800000110.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that
is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42, 43
falsefalse15false0us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse16320000001632.0falsefalsefalsefalsefalse2truefalsefalse17135000001713.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 45
falsefalse16false0us-gaap_Goodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse15281000001528.1falsefalsefalsefalsefalse2truefalsefalse15010000001501.0falsefalsefalsefalsefalseM
onetaryxbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
truefalse17false0us-gaap_Assetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse58273000005827.3falsefalsefalsefalsefalse2truefalsefalse59035000005903.5falsefalsefalsefalsefalseMonetaryxbrli
:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Concepts (CON)
-Number 6
-Paragraph 25
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 18
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 12
-Article 7
truefalse19true0us-gaap_LiabilitiesCurrentAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:strin
gItemTypestringNo definition available.falsefalse20false0us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseve
rboselabel1truefalsefalse741100000741.1falsefalsefalsefalsefalse2truefalsefalse614300000614.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAccounts Payable and Accrued Liabilities, CurrentReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 20
-Article 5
falsefalse21false0us-gaap_AccruedIncomeTaxesCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truef
alsefalse3990000039.9falsefalsefalsefalsefalse2truefalsefalse7840000078.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 15
-Subparagraph b(1)
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 15
-Article 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 21
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Section Appendix E
-Paragraph 289
falsefalse22false0us-gaap_DebtCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse307600000307.6falsefalsefalsefalsefalseMonetary
xbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of the sum of short-term debt and current maturities of long-term debt and capital lease obligations, which are due within one year (or one business cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19
-Article 5
falsefalse23false0us-gaap_DeferredTaxLiabilitiesCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1true
IsNumeric>falsefalse2080000020.8falsefalsefalsefalsefalse2truefalsefalse3130000031.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryRepresents the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or lia
bility for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42, 43
falsefalse24false0us-gaap_DeferredRevenueCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse1890000018.9falsefalsefalsefalsefalse2truefalsefalse1630000016.3falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 7, 8
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A
truefalse25false0us-gaap_LiabilitiesCurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse820700000820.7falsefalsefalsefalsefalse2truefalsefalse10479000001047.9falsefalsefalsefalsefalseMonetary<
ElementDataType>xbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 21
-Article 5
falsefalse26false0us-gaap_LongTermDebtNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalse<
DisplayZeroAsNone>false10161000001016.1falsefalsefalsefalsefalse2truefalsefalse11502000001150.2falsefalsefalsefalsefalse
Monetaryxbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
falsefalse27false0us-gaap_DeferredRevenueNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1820000018.2falsefalsefalsefalsefalse2truefalsefalse3190000031.9falsefalsefalsefalsefalseMonetary<
ElementDataType>xbrli:monetaryItemTypemonetaryThe noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 7, 8
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 48
-Paragraph 6
falsefalse28false0us-gaap_OtherLiabilitiesNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse183100000183.1falsefalsefalsefalsefalse2truefalsefalse118700000118.7falsefalsefalsefalsefalseMonetary<
/Unit>xbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet due to materiality considerations. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5
falsefalse29false0us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1true
IsNumeric>falsefalse6510000065.1falsefalsefalsefalsefalse2truefalsefalse7600000076.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 15
-Subparagraph 5
-Article 9
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 15
-Subparagraph a
-Article 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 10
-Section A
-Paragraph 16
falsefalse30false0us-gaap_DeferredTaxLiabilitiesNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse441500000441.5falsefalsefalsefalsefalse2truefalsefalse455700000455.7falsefalsefalsefalsefalseMo
netaryxbrli:monetaryItemTypemonetaryRepresents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial
reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42
truefalse31false0us-gaap_Liabilitiesus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse25447000002544.7falsefalsefalsefalsefalse2truefalsefalse28804000002880.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.No authoritative reference available.truefalse32false0us-gaap_CommitmentsAndContingencies2009us-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00 falsefalsefalsefalsefalse2falsefals
efalse00 falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's res
ources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. This caption alerts the reader that one or more notes to the financial statements disclose pertinent information about the entity's commitments and contingencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 7
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 8, 9
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 25
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 17
-Article 9
falsefalse33true0us-gaap_StockholdersEquityAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse34false0us-gaap_PreferredStockValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDollar value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
falsefalse35false0us-gaap_CommonStockValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse4000000.4falsefalsefalsefalsefalse2truefalsefalse4000000.4falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDollar value of issued common stock whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
falsefalse36false0us-gaap_AdditionalPaidInCapitalCommonStockus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse17718000001771.8falsefalsefalsefalsefalse2truefalsefalse16869000001686.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5
falsefalse37false0us-gaap_RetainedEarningsAccumulatedDeficitus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefal
sefalse18245000001824.5falsefalsefalsefalsefalse2truefalsefalse16401000001640.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
falsefalse38false0us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-2500000-2.5falsefalsefalsefalsefalse2truefalsefalse19000001.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at fiscal year-end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, and unrealized gains and losses on certain investments in debt and equity securities as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5
falsefalse39false0us-gaap_TreasuryStockValueus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefa
lsefalse-312500000-312.5falsefalsefalsefalsefalse2truefalsefalse-306200000-306.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryValue of common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. Treasury stock is issued but is not outstanding. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Note: number of treasury shares concept is in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Technical Bulletin (FTB)
-Number 85-6
-Paragraph 3
truefalse40false0us-gaap_StockholdersEquityus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse32817000003281.7falsefalsefalsefalsefalse2truefalsefalse30231000003023.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
falsefalse41false0us-gaap_MinorityInterestus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse9000000.9falsefalsefalsefalsefalse2truefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 27
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 26
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
truefalse42false0us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse32826000003282.6falsefalsefalsefalsefalse2truefalsefalse30231000003023.1falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 25
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 26
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A
truefalse43false0us-gaap_LiabilitiesAndStockholdersEquityus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse58273000005827.3falsetruefalsefalsefalse2truefalsefalse59035000005903.5falsetruefalsefalsefalseMonetary
xbrli:monetaryItemTypemonetaryTotal of all Liabilities and Stockholders' Equity items.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 32
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 25
-Article 7
truefalse239Consolidated Balance Sheets (USD $)HundredThousandsUnKnownUnKnownUnKnownfalsetrueXML
73
R37.xml
IDEA: Fair Value Measurement (Tables)
2.2.0.25falsefalse0515 - Disclosure - Fair Value Measurement (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_FairValueMeasurementTablesAbstract<
ElementPrefix>wpifalsenadurationFair Value Measurement.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringFair Value Measurement.falsefalse3false0wpi_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTextBlockwpifalsenadurationFair value assets and liabilities measured on recurring basis.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note15_table1 - wpi:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Financial assets and liabilities measured at fair value or
disclosed at fair value on a recurring basis as at
December 31, 2010 and 2009 consisted of the following (in
millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2010
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
23.1
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="69%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="2%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="2%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="2%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="2%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="2%" align="left"> </td><!-- colindex=05 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Fair Value Measurements as at December 31, 2009
Using:</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Total</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 1</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 2</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Assets:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Marketable securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13.6
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Investments
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringFair value assets and liabilities measured on recurring basis.No authoritative reference available.falsefalse4false0us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: wpi-20101231_note15_table2 - us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-->
<div align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times">
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
The tables below provide a summary of the changes in fair value,
including net transfers in
<font style="white-space: nowrap">and/or</font> out,
of all financial assets and liabilities measured at fair value
on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December 31, 2010
and 2009 (in millions):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2010</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
64.8
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
22.7
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
198.5
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="31%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=02 type=body -->
<td width="4%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="4%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=03 type=body -->
<td width="4%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="5%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=04 type=body -->
<td width="5%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=05 type=body -->
<td width="6%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="6%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="1%" align="right"> </td><!-- colindex=06 type=body -->
<td width="6%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Balance at<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Net Transfers<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Purchases, Sales,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Total Realized and<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Ending Balance at<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>in to (Out of)<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Settlements,<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>Unrealized Gains<br />
</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom">
<b>December 31,<br />
</b>
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2008</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Level 3</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>Issuances, Net</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>(Losses)</b>
</td>
<td>
 
</td>
<td colspan="3" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
<b>2009</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Liabilities:</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
Contingent consideration obligations
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
110.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
111.0
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
</div>
<!-- XBRL Pagebreak Begin -->
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 18pt; font-size: 1pt"> 
</div>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element represents, for the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in
the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph c
falsefalse13Fair Value Measurement (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrueXML
74
R63.xml
IDEA: Reportable Segments (Therapeutic Categories) (Details 2)
2.2.0.25truefalse06132 - Disclosure - Reportable Segments (Therapeutic Categories) (Details 2)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_NetProductSalesInTherapeuticCategoriesAbstrac
twpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse3false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse34159000003415.9falsetruefalsefalsefalse2truefalsefalse<
NumericAmount>26993000002699.3falsetruefalsefalsefalse3truefalsefalse24072000002407.2falsetruefalsefalsefalseMonetaryxbrli:monetary
ItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse4true0wpi_ReportableSegmentsTextualsAbstractwpifalsenadurationReportable Segments Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringReportable Segments Textuals Abstract.falsefalse5false0wpi_NumberOfReportableSegmentswpifalsenadurationNumber of Reportable Segments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse33falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalse
falsefalsefalseOtherxbrli:integerItemTypeintegerNumber of Reportable Segments.No authoritative reference available.falsefalse6false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Central nervous system [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Central_Nervous_System_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseCentral nervous system [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CentralNervousSystemMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso
4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Central nervous system [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Central_Nervous_System_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseCentral nervous system [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CentralNervousSystemMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso
4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Central nervous system [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Central_Nervous_System_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseCentral nervous system [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CentralNervousSystemMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso
4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse7true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurati
onNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse8false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse907600000907.6falsefalsefalsefalsefalse2truefalsefalse836700000836.7<
FootnoteIndexer />falsefalsefalsefalsefalse3truefalsefalse795700000795.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse10false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hormones and synthetic substitutes [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Hormones_And_Synthetic_Substitutes_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseHormones and synthetic substitutes [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_HormonesAndSyntheticSubstitutesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hormones and synthetic substitutes [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Hormones_And_Synthetic_Substitutes_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseHormones and synthetic substitutes [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_HormonesAndSyntheticSubstitutesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hormones and synthetic substitutes [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Hormones_And_Synthetic_Substitutes_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseHormones and synthetic substitutes [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_HormonesAndSyntheticSubstitutesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse11true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse12false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse682300000682.3falsefalsefalsefalsefalse2truefalsefalse609800000609.8falsefalsefalsefalsefalse3truefalsefalse525700000525.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse10falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Cardiovascular [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Cardiovascular_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseCardiovascular [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CardiovascularMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Cardiovascular [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Cardiovascular_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseCardiovascular [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CardiovascularMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Cardiovascular [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Cardiovascular_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseCardiovascular [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CardiovascularMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse15true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet p
roduct sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse16false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalse<
/IsEquityAdjustmentRow>falsefalsefalsetotallabel1truefalsefalse594600000594.6falsefalsefalsefalsefalse2truefalsefalse269400000269.4falsefalsefalsefalsefalse3truefalsefalse245500000245.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Referen
ce 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse18false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse13falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Anti-infective agents [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Anti_Infective_Agents_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAnti-infective agents [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AntiInfectiveAgentsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso421
7USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Anti-infective agents [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Anti_Infective_Agents_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAnti-infective agents [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AntiInfectiveAgentsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso421
7USDiso42170USDUSD$15falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Anti-infective agents [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Anti_Infective_Agents_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAnti-infective agents [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AntiInfectiveAgentsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso421
7USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse19true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenaduration
PeriodType>Net product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse20false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse161500000161.5falsefalsefalsefalsefalse2truefalsefalse133700000133.7falsefalsefalsefalsefalse3truefalsefalse116800000116.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse22false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse16falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Urology [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Urology_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseUrology [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UrologyMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Urology [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Urology_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseUrology [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UrologyMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Urology [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Urology_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseUrology [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UrologyMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse23true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic cat
egories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse<
/Cell>Otherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse24false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse127300000127.3falsefalsefalsefalsefalse2truefalsefalse111400000111.4falsefalsefalsefalsefalse3truefalsefalse8870000088.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/p
resentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse26false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse19falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Others [Member]
1/1/2010 - 12/31/2010
USD ($)
$TwelveMonthsEnded_31Dec2010_Others_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OthersMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Others [Member]
1/1/2009 - 12/31/2009
USD ($)
$TwelveMonthsEnded_31Dec2009_Others_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OthersMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Others [Member]
1/1/2008 - 12/31/2008
USD ($)
$TwelveMonthsEnded_31Dec2008_Others_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OthersMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse27true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categori
es.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse<
/Cell>2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalse28false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse942600000942.6falsetruefalsefalsefalse2truefalsefalse738300000738.3fa
lsetruefalsefalsefalse3truefalsefalse634800000634.8falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/present
ationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 32
-Subparagraph a
truefalse322Reportable Segments (Therapeutic Categories) (Details 2) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruetrueXML
75
R56.xml
IDEA: Income Taxes (Details 1)
2.2.0.25falsefalse06111 - Disclosure - Income Taxes (Details 1)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3true0us-gaap_EffectiveIncomeTaxRateContinuingOperation
sTaxRateReconciliationAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse4false0us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.3500.350falsefalsefalsefalsefalse2truetruefalse0.350.35falsefalsefalsefalsefalse3truetruefalse0.350.35falsefalsefalsefalsefalse
Otherus-types:percentItemTypepureThe domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate shall be the regular tax rate if there are alternative tax systems.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 47
falsefalse5false0us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.0160.016falsefalsefalsefalsefalse2truetruefalse0.0290.029falsefalsefalsefalsefalse3truetruefalse0.0260.026falsefalsefalsefalsefalseOtherus-types:percentItemTypepureThe portion of the difference between the effective income tax rate and domestic federal statutory income tax rate that can be explained by the state and local income tax expense (benefit), net of the federal tax benefit (expense) thereon, recorded during the period.No authoritative reference available.falsefalse6false0us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferentialus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse-0.008-0.008falsefalsefalsefalsefalse2truetruefalse-0.001-0.001falsefalsefalsefalsefalse3truetruefalse00falsefalsefalsefalsefalseOtherus-types:percentItemTypepureThe portion of the difference between the effective income tax rate and domestic federal statutory income tax rate that can be explained by the difference between statutory income tax rates in foreign jurisdictions and the domestic federal statutory income tax rate recorded during the period.No authoritati
ve reference available.falsefalse7false0us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel
1truetruefalse0.0570.057falsefalsefalsefalsefalse2truetruefalse0.0080.008falsefalsefalsefalsefalse3truetruefalse0.0030.003falsefalsefalsefalsefalseOtherus-types:percentItemTypepureThe portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to nondeductible expenses under enacted tax laws, or differences in the methodologies used to determine expense amounts for financial statements prepared in accordance with generally accepted accounting princi
ples, not otherwise listed in the existing taxonomy.No authoritative reference available.falsefalse8false0wpi_EffectiveIncomeTaxRateReconciliationReasearchAndDevelopementCreditAndUsManufacturingDeductionwpifalsenadurationEffective Income Tax Rate Reconciliation Reasearch and developement credit And Us Manufacturing Deduction.falsefalsefalsefalsefalsefalsefalse<
IsBeginningBalance>falsefalsefalseverboselabel1truetruefalse-0.037-0.037falsefalsefalsefalsefalse2truetruefalse-0.017-0.017falsefalsefalsefalsefalse3truetruefalse-0.01-0.01falsefalsefalsefalsefalseOtherus-types:percentItemTypepureEffective Income Tax Rate Reconciliation Reasearch and developement credit And Us Manufacturing Deduction.No authoritative reference available.falsefalse9false0us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCharitableContributionsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse-0.010-0.010falsefalsefalsefalsefalse2truetruefalse-0.001-0.001falsefalsefalsefalsefalse3truetruefalse-0.005-0.005falsefalsefalsefalsefalseOtherus-types:percentItemTypepureThe portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to nondeductible charitable contributions under enacted tax laws.No authoritative referenc
e available.falsefalse10false0us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1true<
/IsNumeric>truefalse-0.078-0.078falsefalsefalsefalsefalse2truetruefalse00falsefalsefalsefalsefalse3true
truefalse-0.016-0.016falsefalsefalsefalsefalseOtherus-types:percentItemTypepureThe sum of the differences between the effective income tax rate and domestic federal statutory income tax rate attributable to all income tax settlements during the period.No authoritative reference available.falsefalse11false0us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse-0.014-0.014falsefalsefalsefalsefalse2truetruefalse-0.005-0.005falsefalsefalsefalsefalse3truetruefalse-0.007-0.007falsefalsefalsefalsefalseOtherus-types:percentItemTypepureThe portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in the valuation allowance for deferred tax assets.No authoritative reference available.falsefalse12false0wpi_EffectiveIncomeTaxRateReconciliationTransactionCostswpifalsenadurationEffective income tax rate reconciliation transaction costs.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.0000.000falsefalsefalsefalsefalse2truetruefalse0.0160.016falsefalsefalsefalsefalse3truetruefalse00falsefalsefalsefalsefalseOtherus-types:percentItemTypepureEffective income tax rate reconciliation transaction costs.No authoritative reference available.falsefalse13false0wpi_EffectiveIncomeTaxRateReconciliationSaleOfSubsidiarywpifalsenadurat
ionEffective Income Tax Rate Reconciliation Sale of Subsidiary.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse-0.021-0.021falsefalsefalsefalsefalse2truetruefalse00falsefalsefalsefalsefalse3truetruefalse-0.011-0.011falsefalsefalsefalsefalseOtherus-types:percentItemTypepureEffective Income Tax Rate Reconciliation Sale of Subsidiary.No authoritative reference available.falsefalse14false0us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustmentsus-gaaptruenadurationNo definition available.falsefalsefalsefal
sefalsefalsefalsefalsefalsefalsetotallabel1truetruefalse0.0140.014falsefalsefalsefalsefalse2truetruefalse0.0090.009falsefalsefalsefalsefalse3truetruefalse0.0050.005falsefalsefalsefalsefalseOtherus-types:percentItemTypepu
reThe portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to all other items not otherwise listed in the existing taxonomy.No authoritative reference available.truefalse15false0us-gaap_EffectiveIncomeTaxRateContinuingOperationsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truetruefalse0.2690.269falsefalsefalsefalsefalse2truetruefalse0.3880.388<
CurrencySymbol />falsefalsefalsefalsefalse3truetruefalse0.3350.335falsefalsefalsefalsefalseOtherus-types:percentItemTypepureA ratio calculated by dividing the reported amount of income tax expense attributable to conti
nuing operations for the period by GAAP-basis pretax income from continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 47
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Subparagraph 2
-Article 4
truefalse16true0us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse17false0us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse9420000094.2falsetruefalsefalsefalse2truefalsefalse8690000086.9falsetruefalsefalsefalse3falsefalsefalse00falsefalse<
/ShowCurrencySymbol>falsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe sum of the tax effects as of the balance sheet date of the amount of excesses of tax deductions over gross income in a year which cannot be used on the tax returns in the current year but can be carried forward to reduce taxable income or income taxes payable in a future year, for which there must be sufficient tax-basis income to utilize a portion or all of the carryforward amount to realize the deferred tax asset.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 289
falsefalse18true0wpi_DifferencesInFinancialStatementAndTaxAccountingForAbstractwpifalsenadurationDifferences in financial statement and tax accounting for:falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse
3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringDifferences in financial statement and tax accounting for:falsefalse19false0wpi_DeferredTa
xAssetsInventoriesReceivablesAndAccrualswpifalsedebitinstantDeferred Tax Assets Inventories, receivables and accruals.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse145600000145.6falsefalsefalsefalsefalse2truefalsefalse101600000101.6falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDeferred Tax Assets Inventories, receivables and accruals.No authoritative reference available.falsefalse20false0wpi_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssetswpifalsedebitin
stantDeferred Tax Liabilities Property Plant And Equipment And Intangible Assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-305700000-305.7falsefalsefalsefalsefalse2truefalsefalse-366100000-366.1falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDeferred Tax Liabilities Property Plant And Equipment And Intangible Assets.No authoritative reference available.falsefalse21false0us-gaap_DeferredTaxLiabilitiesTaxDeferredIncomeus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse1290000012.9falsefalsefalsefalsefalse2truefalsefalse1210000012.1falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount as of the balance sheet date of the estimated future tax effects arising from revenue or other income not otherwise listed in the existing taxonomy that is included in accounting income in conformity with generally accepted accounting principles but excluded from tax-basis income, which will increase future taxable income when such income is recognized for tax purposes.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 11
-Subparagraph a
falsefalse22false0wpi_DeferredTaxLiabilitiesTaxDeferredInterestExpensewpifalsecreditinstantDeferred Tax Liabilities Tax Deferred Interest Expense.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1true
IsNumeric>falsefalse-76300000-76.3falsefalsefalsefalsefalse2truefalsefalse-76300000-76.3falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDeferred Tax Liabilities Tax Deferred Interest Expense.No authoritative reference available.falsefalse23false0us-ga
ap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCostus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse1280000012.8falsefalsefalsefalsefalse2truefalsefalse1050000010.5falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from share-based compensation costs, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 11
-Subparagraph b
falsefalse24false0us-gaap_DeferredTaxLiabilitiesOtherus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse43000004.3falsefalsefalsefalsefalse2truefalsefalse1440000014.4falsefalsefalsefalsefalse3falsef
alsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe cumulative amount of the estimated future tax effects attributable to other temporary differences not otherwise specified in this taxonomy that were expensed for tax purposes but capitalized in conformity with generally accepted accounting principles, or which were recognized as revenue under GAAP but not for tax purposes, which will reverse in future periods.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 11
-Subparagraph a, d, e
truefalse25false0wpi_DeferredTaxAssetsLiabilitiesGrosswpifalsedebitinstantDeferred Tax Assets Liabilities Gross.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-112200000-112.2falsefalsefalsefalsefalse2truefalsefalse-216900000-216.9falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDeferred Tax Assets Liabilities Gross.No authoritative reference available.falsefalse26false0us-gaap_ValuationAllowanceAmount<
ElementPrefix>us-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegatedtotal1truefalsefalse-29700000-29.7falsefalsefalsefalsefalse2truefalsefalse-28400000-28.4falsefalsefalsefalsefalse3falsefalsefalse00fal
sefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of the valuation allowance recorded as of the balance sheet date pertaining to the specified deferred tax asset for which an assessment was made that it is more likely than not that all or a portion of such deferred tax asset will not be realized through related deductions on future tax returns.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43
-Subparagraph c
truefalse27false0us-gaap_DeferredTaxAssetsLiabilitiesNetus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse-141900000-141.9falsefalsefalsefalsefalse2truefalsefalse-245300000-245.3falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryFor entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of
an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 42, 43
truefalse28true0us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.falsefalse29false0us-
gaap_UnrecognizedTaxBenefitsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsetruefalsefalseperiodstartlabel1truefalsefalse7220000072.2falsefalsefalsefalsefalse2truefalsefalse6130000061.3falsefalsefalsefalsefalse3truefalsefalse7120000071.2falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of unrecognized tax benefits (tax reductions recognized in financial reports but excluded from tax returns) pertaining to uncertain tax positions taken in tax returns as of the beginning balance sheet date, excluding amounts pertaining to examined tax returns.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a
falsefalse30false0us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositionsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse59000005.9falsefalsefalsefalsefalse2truefalsefalse69000006.9falsefalsefalsefalsefalse3truefalsefalse50000005.0falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of increases in unrecognized tax benefits resulting from tax positions that have been or will be taken in the tax return for the current period, excluding amounts pertaining to examined tax returns.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a(2)
falsefalse31false0us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositionsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2010000020.1falsefalsefalsefalsefalse2truefalsefalse1270000012.7falsefalsefalsefalsefalse3truefalsefalse78000007.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of increases in unrecognized tax benefits resulting from tax positions taken in prior period tax returns, excluding amounts pertaining to examined tax returns.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a(1)
falsefalse32false0us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositionsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-27500000-27.5falsefalsefalsefalsefalse2truefalsefalse-3900000-3.9falsefalsefalsefalsefalse3truefalsefalse-11900000-11.9falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of decreases in unrecognized tax benefits resulting from tax positions taken in prior period tax returns, excluding amounts pertaining to examined tax returns.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a(1)
falsefalse33false0us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthoritiesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1truefalsefalse-2300000-2.3falsefalsefalsefalsefalse2truefalsefalse-4400000-4.4falsefalsefalsefalsefalse3truefalsefalse-10800000-10.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of decreases in unrecognized tax benefits resulting from settlements with taxing authorities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a(3)
falsefalse34false0us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitationsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsetruenegated1
truefalsefalse-400000-0.4falsefalsefalsefalsefalse2truefalsefalse-400000-0.4falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of decreases in unrecognized tax benefits resulting from lapses of the applicable statutes of limitations.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a(4)
falsefalse35false0us-gaap_UnrecognizedTaxBenefitsus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsetruefalseperiodendlabel1truefalsefalse6800000068.0falsetruefalsefalsefalse2truefalsefalse7220000072.2falsetruefalsefalsefalse3truefalsefalse6130000061.3falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe gross amount of unrecognized tax benefits (tax reductions recognized in financial reports but excluded from tax returns) pertaining to uncertain tax positions taken in tax returns as of the beginning balance sheet date, excluding amounts pertaining to examined tax returns.Reference 1: http://www.xbrl.org/2003/role/present
ationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a
falsefalse333Income Taxes (Details 1) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruetrueXML
76
FilingSummary.xml
IDEA: XBRL DOCUMENT
2.2.0.25trueSheet00 - Document - Document and Entity InformationDocument and Entity Informationhttp://watson.com/role/DocumentAndEntityInformationfalseR1.xmlfalseSheet0110 - Statement - Consolidated Balance SheetsConsolidated Balance Sheetshttp://watson.com/role/BalanceSheetsfalseR2.xmlfalseSheet0111 - Statement - Consolidated Balance Sheets (Parenthetical)Consolidated Balance Sheets (Parenthetical)http://watson.com/role/BalanceSheetsParentheticalfalseR3.xmlfalseSheet0120 - Statement - Consolidated Statements of OperationsConsolidated Statements of Operationshttp://watson.com/role/StatementsOfOperationsfalseR4.xmlfalseSheet0130 - Statement - Consolidated Statements of Cash FlowsConsolidated Statements of Cash Flowshttp://watson.com/role/StatementsOfCashFlowsfalseR5.xmlfalseSheet0140 - Statement - Consolidated Statements of Stockholders' Equity and Comprehensive IncomeConsolidated Statements of Stockholders' Equity and Comprehensive Incomehttp://watson.com/role/StatementOfStockholdersEquityfalseR6.xmlfalseSheet0201 - Disclosure - Description of BusinessDescription of Businesshttp://watson.com/role/DescriptionOfBusinessfalseR7.xmlfalseSheet0202 - Disclosure - Summary of Significant Accounting PoliciesSummary of Significant Accounting Policieshttp://watson.com/role/SummaryOfSignificantAccountingPoliciesfalseR8.xmlfalseSheet0203 - Disclosure - Share Based CompensationShare Based Compensationhttp://watson.com/role/ShareBasedCompensationfalseR9.xmlfalseSheet0204 - Disclosure - Acquisitions and DivestituresAcquisitions and Divestitureshttp://watson.com/role/AcquisitionsAndDivestituresfalseR10.xmlfalseSheet0205 - Disclosure - Other IncomeOther Incomehttp://watson.com/role/OtherIncomefalseR11.xmlfalseSheet0206 - Disclosure - Balance Sheet ComponentsBalance Sheet Componentshttp://watson.com/role/BalanceSheetComponentsfalseR12.xmlfalseSheet0207 - Disclosure - Investments in Marketable Securities and Other InvestmentsInvestments in Marketable Securities and Other Investmentshttp://watson.com/role/InvestmentsInMarketableSecuritiesAndOtherInvestmentsfalseR13.xmlfalseSheet0208 - Disclosure - Goodwill, Product Rights and Other IntangiblesGoodwill, Product Rights and Other Intangibleshttp://watson.com/role/GoodwillProductRightsAndOtherIntangiblesfalseR14.xmlfalseSheet0209 - Disclosure - Long Term DebtLong Term Debthttp://watson.com/role/LongTermDebtfalseR15.xmlfalseSheet0210 - Disclosure - Other Long-Term LiabilitiesOther Long-Term Liabilitieshttp://watson.com/role/OtherLongTermLiabilitiesfalseR16.xmlfalseSheet0211 - Disclosure - Income TaxesIncome Taxeshttp://watson.com/role/IncomeTaxesfalseR17.xmlfalseSheet0212 - Disclosure - Stockholders' EquityStockholders' Equityhttp://watson.com/role/StockholdersEquityfalseR18.xmlfalseSheet0213 - Disclosure - Reportable SegmentsReportable Segmentshttp://watson.com/role/ReportableSegmentsfalseR19.xmlfalseSheet0214 - Disclosure - Business Restructuring ChargesBusiness Restructuring Chargeshttp://watson.com/role/BusinessRestructuringChargesfalseR20.xmlfalseSheet0215 - Disclosure - Fair Value MeasurementFair Value Measurementhttp://watson.com/role/FairValueMeasurementfalseR21.xmlfalseSheet0216 - Disclosure - Commitments and ContingenciesCommitments and Contingencieshttp://watson.com/role/CommitmentsAndContingenciesfalseR22.xmlfalseSheet0301 - Schedule - Valuation and Qualifying AccountsValuation and Qualifying Accountshttp://watson.com/role/ValuationAndQualifyingAccountsfalseR23.xmlfalseSheet0402 - Disclosure - Summary of Significant Accounting Policies (Policies)Summary of Significant Accounting Policies (Policies)http://watson.com/role/SummaryOfSignificantAccountingPoliciesPoliciesfalseR24.xmlfalseSheet0502 - Disclosure - Summary of Significant Accounting Policies (Tables)Summary of Significant Accounting Policies (Tables)http://watson.com/role/SummaryOfSignificantAccountingPoliciesTablesfalseR25.xmlfalseSheet0504 - Disclosure - Acquisitions and Divestitures (Tables)Acquisitions and Divestitures (Tables)http://watson.com/role/AcquisitionsAndDivestituresTablesfalseR26.xmlfalseSheet0505 - Disclosure - Other Income (Tables)Other Income (Tables)http://watson.com/role/OtherIncomeTablesfalseR27.xmlfalseSheet0506 - Disclosure - Balance Sheet Components (Tables)Balance Sheet Components (Tables)http://watson.com/role/BalanceSheetComponentsTablesfalseR28.xmlfalseSheet0507 - Disclosure - Investments in Marketable Securities and Other Investments (Tables)Investments in Marketable Securities and Other Investments (Tables)http://watson.com/role/InvestmentsInMarketableSecuritiesAndOtherInvestmentsTablesfalseR29.xmlfalseSheet0508 - Disclosure - Goodwill Product Rights and Other Intangibles (Tables)Goodwill Product Rights and Other Intangibles (Tables)http://watson.com/role/GoodwillProductRightsAndOtherIntangiblesTablesfalseR30.xmlfalseSheet0509 - Disclosure - Long Term Debt (Tables)Long Term Debt (Tables)http://watson.com/role/LongTermDebtTablesfalseR31.xmlfalseSheet0510 - Disclosure - Other Long-Term Liabilities (Tables)Other Long-Term Liabilities (Tables)http://watson.com/role/OtherLongTermLiabilitiesTablesfalseR32.xmlfalseSheet0511 - Disclosure - Income Taxes (Tables)Income Taxes (Tables)http://watson.com/role/IncomeTaxesTablesfalseR33.xmlfalseSheet0512 - Disclosure - Stockholders' Equity (Tables)Stockholders' Equity (Tables)http://watson.com/role/StockholdersEquityTablesfalseR34.xmlfalseSheet0513 - Disclosure - Reportable Segments (Tables)Reportable Segments (Tables)http://watson.com/role/ReportableSegmentsTablesfalseR35.xmlfalseSheet0514 - Disclosure - Business Restructuring Charges (Tables)Business Restructuring Charges (Tables)http://watson.com/role/BusinessRestructuringChargesTablesfalseR36.xmlfalseSheet0515 - Disclosure - Fair Value Measurement (Tables)Fair Value Measurement (Tables)http://watson.com/role/FairValueMeasurementTablesfalseR37.xmlfalseSheet0601 - Disclosure - Description of Business (Details)Description of Business (Details)http://watson.com/role/DescriptionOfBusinessDetailsfalseR38.xmlfalseSheet0602 - Disclosure - Summary of Significant Accounting Policies (Details)Summary of Significant Accounting Policies (Details)http://watson.com/role/SummaryOfSignificantAccountingPoliciesDetailsfalseR39.xmlfalseSheet06021 - Disclosure - Summary of Significant Accounting Policies (Details 1)Summary of Significant Accounting Policies (Details 1)http://watson.com/role/SummaryOfSignificantAccountingPoliciesDetails2falseR40.xmlfalseSheet06022 - Disclosure - Summary of Significant Accounting Policies (Details 2)Summary of Significant Accounting Policies (Details 2)http://watson.com/role/SummaryOfSignificantAccountingPoliciesDetailfalseR41.xmlfalseSheet06023 - Disclosure - Summary of Significant Accounting Policies (Details Textual)Summary of Significant Accounting Policies (Details Textual)http://watson.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextualfalseR42.xmlfalseSheet0603 - Disclosure - Share-Based Compensation (Details)Share-Based Compensation (Details)http://watson.com/role/ShareBasedCompensationDetailsfalseR43.xmlfalseSheet0604 - Disclosure - Acquisitions and Divestitures (Details)Acquisitions and Divestitures (Details)http://watson.com/role/AcquisitionsAndDivestituresDetailsfalseR44.xmlfalseSheet06041 - Disclosure - Acquisitions and Divestitures (Details) (Textual)Acquisitions and Divestitures (Details) (Textual)http://watson.com/role/AcquisitionsAndDivestituresDetailsTextualfalseR45.xmlfalseSheet0605 - Disclosure - Other Income (Details)Other Income (Details)http://watson.com/role/OtherIncomeDetailsfalseR46.xmlfalseSheet0606 - Disclosure - Balance Sheet Components (Details)Balance Sheet Components (Details)http://watson.com/role/BalanceSheetComponentsDetailsfalseR47.xmlfalseSheet0607 - Disclosure - Investments in Marketable Securities and Other Investments (Details)Investments in Marketable Securities and Other Investments (Details)http://watson.com/role/InvestmentsInMarketableSecuritiesAndOtherInvestmentsDetailsfalseR48.xmlfalseSheet0608 - Disclosure - Goodwill, Product Rights and Other Intangibles (Details)Goodwill, Product Rights and Other Intangibles (Details)http://watson.com/role/GoodwillProductRightsAndOtherIntangiblesDetailsfalseR49.xmlfalseSheet06081 - Disclosure - Goodwill Product Rights and Other Intangibles (Details 1)Goodwill Product Rights and Other Intangibles (Details 1)http://watson.com/role/GoodwillProductRightsAndOtherIntangiblesDetails1falseR50.xmlfalseSheet06082 - Disclosure - Goodwill Product Rights and Other Intangibles (Details 2)Goodwill Product Rights and Other Intangibles (Details 2)http://watson.com/role/GoodwillProductRightsAndOtherIntangiblesDetails2falseR51.xmlfalseSheet0609 - Disclosure - Long-Term Debt (Details)Long-Term Debt (Details)http://watson.com/role/LongTermDebtDetailsfalseR52.xmlfalseSheet06091 - Disclosure - Long-Term Debt (Details Textual)Long-Term Debt (Details Textual)http://watson.com/role/LongTermDebtDetailsTextualfalseR53.xmlfalseSheet0610 - Disclosure - Other Long-Term Liabilities (Details)Other Long-Term Liabilities (Details)http://watson.com/role/OtherLongTermLiabilitiesDetailsfalseR54.xmlfalseSheet0611 - Disclosure - Income Taxes (Details)Income Taxes (Details)http://watson.com/role/IncomeTaxesDetailsfalseR55.xmlfalseSheet06111 - Disclosure - Income Taxes (Details 1)Income Taxes (Details 1)http://watson.com/role/IncomeTaxesDetails1falseR56.xmlfalseSheet06112 - Disclosure - Income Taxes (Details Textual)Income Taxes (Details Textual)http://watson.com/role/IncomeTaxesDetailsTextualfalseR57.xmlfalseSheet0612 - Disclosure - Stockholders' Equity (Details)Stockholders' Equity (Details)http://watson.com/role/StockholdersEquityDetailsfalseR58.xmlfalseSheet06121 - Disclosure - Stockholders' Equity (Details 1)Stockholders' Equity (Details 1)http://watson.com/role/StockholdersEquityDetails1falseR59.xmlfalseSheet06122 - Disclosure - Stockholders' Equity (Details Textual)Stockholders' Equity (Details Textual)http://watson.com/role/StockholdersEquityDetailsTextualfalseR60.xmlfalseSheet0613 - Disclosure - Reportable Segments (Details)Reportable Segments (Details)http://watson.com/role/ReportableSegmentsDetailsfalseR61.xmlfalseSheet06131 - Disclosure - Reportable Segments (Geographic Area) (Details 1)Reportable Segments (Geographic Area) (Details 1)http://watson.com/role/ReportableSegmentsDetails1falseR62.xmlfalseSheet06132 - Disclosure - Reportable Segments (Therapeutic Categories) (Details 2)Reportable Segments (Therapeutic Categories) (Details 2)http://watson.com/role/ReportableSegmentsDetails2falseR63.xmlfalseSheet0614 - Disclosure - Business Restructuring Charges (Details)Business Restructuring Charges (Details)http://watson.com/role/BusinessRestructuringChargesDetailsfalseR64.xmlfalseSheet0615 - Disclosure - Fair Value Measurement (Details)Fair Value Measurement (Details)http://watson.com/role/FairValueMeasurementDetailsfalseR65.xmlfalseSheet06151 - Disclosure - Fair Value Measurement (Details 1)Fair Value Measurement (Details 1)http://watson.com/role/FairValueMeasurementDetails1falseR66.xmlfalseSheet0616 - Disclosure - Commitments and Contingencies (Details)Commitments and Contingencies (Details)http://watson.com/role/CommitmentsAndContingenciesDetailsfalseR67.xmlfalseSheet0701 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)Schedule II Valuation and Qualifying Accounts (Details)http://watson.com/role/ValuationAndQualifyingAccountsDetailsfalseR68.xmlfalseBookAll ReportsAll Reportsfalse12607704491falsefalseTwelveMonthsEnded_31Dec2010_Accumulated_Other_Comprehensive_Income_Member2TwelveMonthsEnded_31Dec2008_Urology_Member1BalanceAsOf_02Dec200925BalanceAsOf_31Dec2009_Columbia_Contingent_Consideration_Liability_Member1BalanceAsOf_31Dec2010_Core_Technology_Member1TwelveMonthsEnded_31Dec2010_Rebates_Member2OneMonthEnded_31Jul2010_Term_Facility_Member1TwelveMonthsEnded_31Dec2009_Accumulated_Other_Comprehensive_Income_Member2TwelveMonthsEnded_31Dec2010_Urology_Member1TwelveMonthsEnded_31Dec2010_Vena_Care_Member1ThreeMonthsEnded_31Dec2010_Arrow_Business_Acquisition_Member1BalanceAsOf_31Dec2009_Additional_Paid_In_Capital_Member1TwelveMonthsEnded_31Dec2008_Chargebacks_Member2BalanceAsOf_31Dec2010_Allowance_For_Doubtful_Accounts_Member1TwelveMonthsEnded_31Dec2010_Restricted_Stock_Member8BalanceAsOf_31Dec2009_Notes_Payable_Other_Payables_Member1BalanceAsOf_31Dec2010_Inventory_Valuation_Reserve_Member1TwelveMonthsEnded_31Dec2009_Common_Stock_Member2TwelveMonthsEnded_31Dec2010_Product_Rights_And_Other_Related_Intangibles_Member5BalanceAsOf_31Dec2009_I_P_R_And_D_Member1BalanceAsOf_31Dec2010_Fair_Value_Inputs_Level1_Member2BalanceAsOf_31Dec2010_Retained_Earnings_Member1TwelveMonthsEnded_31Dec2008_Rebates_Member2TwelveMonthsEnded_31Dec2010_I_P_R_And_D_Member2TwelveMonthsEnded_31Dec2008_Anti_Infective_Agents_Member1BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level3_Member2BalanceAsOf_31Dec2009_Restricted_Stock_Member4TwelveMonthsEnded_31Dec2008_Cardiovascular_Member1BalanceAsOf_31Dec2007_Common_Stock_Member2BalanceAsOf_31Dec2010_Global_Generics_Segment_Member1TwelveMonthsEnded_31Dec2010_Notes5_Percent_Due_August142014_Member1BalanceAsOf_31Dec2009_Mandatorily_Redeemable_Preferred_Stock_Member2TwelveMonthsEnded_31Dec2008_Distribution_Segment_Member6BalanceAsOf_31Dec2010_Valuation_Allowance_Of_Deferred_Tax_Assets_Member1BalanceAsOf_31Dec2010_Selling_General_And_Administrative_Member1BalanceAsOf_31Dec2010_Atorvastatin_Contingent_Consideration_Liability_Member1BalanceAsOf_31Dec2008_Contingent_Consideration_Obligation_Member1BalanceAsOf_02Dec2012_Mandatorily_Redeemable_Preferred_Stock_Member1TwelveMonthsEnded_31Dec2010_Global_Brands_Contribution_Member8BalanceAsOf_31Dec2009_Rebates_Member1BalanceAsOf_15Feb2010_Senior_Notes_Due_Two_Thousand_Fourteen_Member1TwelveMonthsEnded_31Dec2008_Returns_And_Other_Allowances_Member2TwelveMonthsEnded_31Dec2009_Treasury_Stock_Member2BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level2_Member_21BalanceAsOf_31Dec2008_Valuation_Allowance_Of_Deferred_Tax_Assets_Member1BalanceAsOf_31Dec2009_Core_Technology_Member1BalanceAsOf_31Dec2010_Chargebacks_Member1BalanceAsOf_31Dec2010_Returns_And_Other_Allowances_Member1BalanceAsOf_31Dec2010_Accumulated_Other_Comprehensive_Income_Member1BalanceAsOf_31Dec2010_Revolving_Credit_Facility_Member1TwelveMonthsEnded_31Dec2009_Inventory_Valuation_Reserve_Member3BalanceAsOf_31Dec2010_Arrow_Business_Acquisition_Member2TwelveMonthsEnded_31Dec2010_Treasury_Stock_Member2TwelveMonthsEnded_31Dec2009_Allowance_For_Doubtful_Accounts_Member3TwelveMonthsEnded_31Dec2010_Cost_Of_Sales_Member3Jan-01-2010_Dec-31-2010234BalanceAsOf_25Nov2009_Lombard_Loan_Member1TwelveMonthsEnded_31Dec2009_Cost_Of_Sales_Member3BalanceAsOf_31Dec2010_Lombard_Loan_Member1BalanceAsOf_02Dec2009_Mandatorily_Redeemable_Preferred_Stock_Member3TwelveMonthsEnded_31Dec2009_Reserve_For_Cash_Discount_Member3BalanceAsOf_31Dec2008_Cost_Of_Sales_Member1BalanceAsOf_31Dec2009_Facility_Closing_Member1TwelveMonthsEnded_31Dec2008_Central_Nervous_System_Member1BalanceAsOf_31Dec2008_Accumulated_Other_Comprehensive_Income_Member1BalanceAsOf_02Jul2010_I_P_R_And_D_Member1BalanceAsOf_02Jul2010_Columbia_Laboratories_Member4BalanceAsOf_31Dec2008_Treasury_Stock_Member2BalanceAsOf_31Dec2009_Inventory_Valuation_Reserve_Member1TwelveMonthsEnded_31Dec2010_Furniture_And_Fixtures_Member2TwelveMonthsEnded_31Dec2010_Returns_And_Other_Allowances_Member2TwelveMonthsEnded_31Dec2008_Common_Stock_Member1TwelveMonthsEnded_31Dec2010_Central_Nervous_System_Member1BalanceAsOf_31Dec2009_Accumulated_Other_Comprehensive_Income_Member1BalanceAsOf_31Dec2009_Reserve_For_Cash_Discount_Member1TwelveMonthsEnded_31Dec2010_Reserve_For_Cash_Discount_Member2BalanceAsOf_31Dec2010_Senior_Notes_Due_Two_Thousand_Fourteen_Member1OneMonthEnded_31Jul2010_Arrow_Business_Acquisition_Member1BalanceAsOf_31Dec2010_Product_Rights_And_Other_Related_Intangibles_Member2BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level1_Member_22BalanceAsOf_31Dec2008_Additional_Paid_In_Capital_Member1TwelveMonthsEnded_31Dec2009_Rebates_Member3BalanceAsOf_31Dec2007_Chargebacks_Member1TwelveMonthsEnded_31Dec2010_Accelerated_Depreciation_Member2TwelveMonthsEnded_31Dec2010_Research_And_Laboratory_Equipment_Member2TwelveMonthsEnded_31Dec2010_Notes6_Point125_Percent_Due_August142019_Member1BalanceAsOf_31Dec2007_Inventory_Valuation_Reserve_Member1BalanceAsOf_31Dec2008_Retained_Earnings_Member1BalanceAsOf_31Dec2009_Chargebacks_Member1ThreeMonthsEnded_31Mar20101BalanceAsOf_31Dec2009_Trade_Names_Member1TwelveMonthsEnded_31Dec2010_Cardiovascular_Member1BalanceAsOf_31Dec2010_Accelerated_Depreciation_Member1BalanceAsOf_31Dec2008_Chargebacks_Member1BalanceAsOf_31Dec2008_Reserve_For_Cash_Discount_Member1BalanceAsOf_31Dec2009121BalanceAsOf_31Dec2009_Retained_Earnings_Member1BalanceAsOf_31Dec2009_Valuation_Allowance_Of_Deferred_Tax_Assets_Member1TwelveMonthsEnded_31Dec2010_Retained_Earnings_Member1TwelveMonthsEnded_31Dec2010_Product_Transfer_Costs_Member2BalanceAsOf_02Dec2009_Eden_Biopharm_Group_Limited_Member1BalanceAsOf_31Dec2009_Arrow_Business_Acquisition_Member1BalanceAsOf_31Dec2009_Allowance_For_Doubtful_Accounts_Member1TwelveMonthsEnded_31Dec2010_Distribution_Segment_Member8TwelveMonthsEnded_31Dec2009_Lombard_Loan_Member1BalanceAsOf_31Dec2010_Contingent_Consideration_Obligation_Member1BalanceAsOf_31Dec2009_Product_Transfer_Costs_Member1BalanceAsOf_31Dec2010_Research_And_Development_Arrangement_Member1TwelveMonthsEnded_31Dec2010_Inventory_Valuation_Reserve_Member2BalanceAsOf_31Dec20074BalanceAsOf_31Dec2008_Selling_General_And_Administrative_Member1TwelveMonthsEnded_31Dec2010_Anti_Infective_Agents_Member1BalanceAsOf_31Dec2010_Line_Of_Credit_Member_21BalanceAsOf_30Jun20101TwelveMonthsEnded_31Dec2010_Operating_Expenses_Member3TwelveMonthsEnded_31Dec2010_Selling_General_And_Administrative_Member2BalanceAsOf_31Dec2010_Line_Of_Credit_Member1BalanceAsOf_31Dec2010_Fair_Value_Inputs_Level3_Member_22TwelveMonthsEnded_31Dec2010_Common_Stock_Member1BalanceAsOf_02Dec20121TwelveMonthsEnded_31Dec2009_Mandatorily_Redeemable_Preferred_Stock_Member1TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member3BalanceAsOf_31Dec2010_Distribution_Segment_Member1BalanceAsOf_31Dec2009_Global_Generics_Segment_Member1TwelveMonthsEnded_31Dec2008_Retained_Earnings_Member1TwelveMonthsEnded_31Dec2008_Accumulated_Other_Comprehensive_Income_Member3BalanceAsOf_31Dec2010_Reserve_For_Cash_Discount_Member1BalanceAsOf_31Dec2010_Fair_Value_Inputs_Level1_Member_21BalanceAsOf_31Feb20111BalanceAsOf_31Dec2010_Notes5_Percent_Due_August142014_Member2TwelveMonthsEnded_31Dec2008_Inventory_Valuation_Reserve_Member2TwelveMonthsEnded_31Dec2008_Global_Generics_Segment_Member8TwelveMonthsEnded_31Dec2008_Allowance_For_Doubtful_Accounts_Member2TwelveMonthsEnded_31Dec2010_Valuation_Allowance_Of_Deferred_Tax_Assets_Member2TwelveMonthsEnded_31Dec2010_Term_Facility_Member2TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member3TwelveMonthsEnded_31Dec2008_Hormones_And_Synthetic_Substitutes_Member1OneMonthEnded_31Jan2010_Eden_Biopharm_Group_Limited_Member1BalanceAsOf_31Dec2010_Senior_Notes_Member4BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level3_Member_21TwelveMonthsEnded_31Dec2008_Global_Brands_Contribution_Member8TwelveMonthsEnded_31Dec2009_Returns_And_Other_Allowances_Member3TwelveMonthsEnded_31Dec2009_Cardiovascular_Member1BalanceAsOf_31Dec2009_Contingent_Consideration_Obligation_Member1BalanceAsOf_31Dec2010_Cost_Of_Sales_Member1TwelveMonthsEnded_31Dec2010_Lombard_Loan_Member1TwelveMonthsEnded_31Dec2009_Contingent_Consideration_Obligation_Member3BalanceAsOf_31Dec2008_Common_Stock_Member2BalanceAsOf_31Dec2010_Foreign_Country_Member_21BalanceAsOf_31Dec2009_Selling_General_And_Administrative_Member1BalanceAsOf_31Dec2008_Allowance_For_Doubtful_Accounts_Member1BalanceAsOf_31Dec2010_Operating_Expenses_Member1BalanceAsOf_31Dec2009_Atorvastatin_Contingent_Consideration_Liability_Member1TwelveMonthsEnded_31Dec2010_Allowance_For_Doubtful_Accounts_Member2BalanceAsOf_31Dec2010_Trade_Names_Member1BalanceAsOf_31Dec2010_Columbia_Contingent_Consideration_Liability_Member3TwelveMonthsEnded_31Dec2008_Others_Member1BalanceAsOf_31Dec2007_Valuation_Allowance_Of_Deferred_Tax_Assets_Member1BalanceAsOf_31Dec2007_Returns_And_Other_Allowances_Member1BalanceAsOf_31Dec2010_Additional_Paid_In_Capital_Member1BalanceAsOf_31Dec2010_Mandatorily_Redeemable_Preferred_Stock_Member2BalanceAsOf_02Jul20107TwelveMonthsEnded_31Dec2008_Reserve_For_Cash_Discount_Member2BalanceAsOf_31Dec2007_Rebates_Member1ThreeMonthsEnded_31Mar2010_Scinopharm_Member2TwelveMonthsEnded_31Dec2009_Hormones_And_Synthetic_Substitutes_Member1BalanceAsOf_31Dec2009_Research_And_Development_Arrangement_Member1TwelveMonthsEnded_31Dec2010_Computer_Equipment_Member2TwelveMonthsEnded_31Dec2010_Chargebacks_Member2BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level2_Member2BalanceAsOf_31Dec2009_Senior_Notes_Member3BalanceAsOf_31Dec2010_Treasury_Stock_Member2TwelveMonthsEnded_31Dec2010_Severance_And_Retention_Member2BalanceAsOf_31Dec2008_Research_And_Development_Arrangement_Member1TwelveMonthsEnded_31Dec2010_Land_Buildings_And_Improvements_Member2BalanceAsOf_31Dec2007_Accumulated_Other_Comprehensive_Income_Member1TwelveMonthsEnded_31Dec2010_Machinery_And_Equipment_Member2TwelveMonthsEnded_31Dec2009_Valuation_Allowance_Of_Deferred_Tax_Assets_Member2TwelveMonthsEnded_31Dec2009_Others_Member1TwelveMonthsEnded_31Dec2008112TwelveMonthsEnded_31Dec2009_Chargebacks_Member3BalanceAsOf_31Dec2009_Senior_Notes_Due_Two_Thousand_Nineteen_Member1BalanceAsOf_31Dec2010_State_And_Local_Jurisdiction_Member1BalanceAsOf_31Dec2010_Notes_Payable_Other_Payables_Member1BalanceAsOf_31Dec2009_U_S_Treasury_And_Agency_Securities_Maturing_Within_One_Year_Member1BalanceAsOf_31Dec2010_Accelerated_Depreciation_Research_And_Development_Member1TwelveMonthsEnded_31Dec2008_Valuation_Allowance_Of_Deferred_Tax_Assets_Member2TwelveMonthsEnded_31Dec2010_Facility_Closing_Member2BalanceAsOf_31Dec2007_Retained_Earnings_Member1BalanceAsOf_31Dec2010_Notes6_Point125_Percent_Due_August142019_Member2TwelveMonthsEnded_31Dec2009_Distribution_Segment_Member6BalanceAsOf_31Dec2009_Cost_Of_Sales_Member1BalanceAsOf_31Dec19921BalanceAsOf_31Dec2009_Distribution_Segment_Member1BalanceAsOf_31Dec2009_Fair_Value_Inputs_Level1_Member1BalanceAsOf_31Dec2009_U_S_Treasury_And_Agency_Securities_Maturing_Within_Two_Years_Member1BalanceAsOf_31Dec2007_Treasury_Stock_Member2TwelveMonthsEnded_31Dec2009_Global_Brands_Contribution_Member8BalanceAsOf_31Dec2009_Common_Stock_Member2BalanceAsOf_31Dec2009_Product_Rights_And_Other_Related_Intangibles_Member1BalanceAsOf_31Dec2010_Fair_Value_Inputs_Level2_Member1TwelveMonthsEnded_31Dec2010_Others_Member1BalanceAsOf_31Dec2007_Reserve_For_Cash_Discount_Member1BalanceAsOf_31Dec2010_Fair_Value_Inputs_Level2_Member_22BalanceAsOf_31Dec2010_Facility_Closing_Member1BalanceAsOf_15Aug2010_Senior_Notes_Due_Two_Thousand_Nineteen_Member1TwelveMonthsEnded_31Dec2009_Anti_Infective_Agents_Member1TwelveMonthsEnded_31Dec2010_Employees_Member1TwelveMonthsEnded_31Dec2010_Hormones_And_Synthetic_Substitutes_Member1BalanceAsOf_31Dec2009_Global_Brands_Contribution_Member1BalanceAsOf_31Dec2007_Allowance_For_Doubtful_Accounts_Member1TwelveMonthsEnded_31Dec2009_Selling_General_And_Administrative_Member2BalanceAsOf_31Dec2010_I_P_R_And_D_Member1BalanceAsOf_31Dec2010_Global_Brands_Contribution_Member1TwelveMonthsEnded_31Dec2010_Director_Member1TwelveMonthsEnded_31Dec2008_Treasury_Stock_Member1BalanceAsOf_31Dec2010_Customer_Relationships_Member1BalanceAsOf_31Dec2010_Term_Facility_Member1TwelveMonthsEnded_31Dec2010_Accelerated_Depreciation_Research_And_Development_Member2BalanceAsOf_31Dec2009_Operating_Expenses_Member1BalanceAsOf_31Dec20087BalanceAsOf_31Dec2010_I_P_R_And_D_Member_21BalanceAsOf_31Dec2009_Treasury_Stock_Member2BalanceAsOf_31Dec2010_Vena_Care_Member1BalanceAsOf_31Dec2010_Severance_And_Retention_Member1BalanceAsOf_31Dec2008_Returns_And_Other_Allowances_Member1BalanceAsOf_31Dec2007_Additional_Paid_In_Capital_Member1BalanceAsOf_31Dec2010_U_S_Treasury_And_Agency_Securities_Maturing_Within_Two_Years_Member1BalanceAsOf_31Dec2010_Rebates_Member1BalanceAsOf_31Dec2008_Inventory_Valuation_Reserve_Member1TwelveMonthsEnded_31Dec2009127TwelveMonthsEnded_31Dec2010_Contingent_Consideration_Obligation_Member3TwelveMonthsEnded_31Dec2009_Research_And_Development_Arrangement_Member3TwelveMonthsEnded_31Dec2009_Retained_Earnings_Member1TwelveMonthsEnded_31Dec2010_United_States_Rights_Columbia_Products_Member1BalanceAsOf_31Dec2010_Senior_Notes_Due_Two_Thousand_Nineteen_Member1TwelveMonthsEnded_31Dec2009_Urology_Member1TwelveMonthsEnded_31Dec2009_Global_Generics_Segment_Member8BalanceAsOf_02Jul2010_Product_Rights_And_Other_Related_Intangibles_Member1BalanceAsOf_31Dec2009_Line_Of_Credit_Member1BalanceAsOf_31Dec2009_Senior_Notes_Due_Two_Thousand_Fourteen_Member1TwelveMonthsEnded_31Dec2010_Moksha_Eight_Member1BalanceAsOf_31Dec2010_Restricted_Stock_Member7BalanceAsOf_31Dec2010_Fair_Value_Inputs_Level3_Member1TwelveMonthsEnded_31Dec2010_Research_And_Development_Arrangement_Member2TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member4BalanceAsOf_31Dec2009_Returns_And_Other_Allowances_Member1BalanceAsOf_02Jul2010_United_States_Rights_Columbia_Products_Member2BalanceAsOf_31Dec2010_Product_Transfer_Costs_Member1BalanceAsOf_31Dec2008_Rebates_Member1BalanceAsOf_31Dec2009_Customer_Relationships_Member1BalanceAsOf_31Dec2010_U_S_Treasury_And_Agency_Securities_Maturing_Within_One_Year_Member1BalanceAsOf_31Dec2009_Severance_And_Retention_Member1BalanceAsOf_31Dec2010_Foreign_Country_Member1TwelveMonthsEnded_31Dec2010_Global_Generics_Segment_Member8BalanceAsOf_31Dec2009_Lombard_Loan_Member1BalanceAsOf_04Oct2010_Moksha_Eight_Member4TwelveMonthsEnded_31Dec2009_Central_Nervous_System_Member1BalanceAsOf_31Dec2010_Common_Stock_Member2BalanceAsOf_31Dec2010152truetrueZIP
77
0000950123-11-015948-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0000950123-11-015948-xbrl.zip
M4$L#!!0````(`"8Q5CYJ"^8A90`"`%)J'0`0`!P`=W!I+3(P,3`Q,C,Q+GAM
M;%54"0`#6)EC35B98TUU>`L``00E#@``!#D!``#L76USVSB2_GY5]Q^XWMO=
MV2K+>G$2O\29+4EV9CQGQR[+F9G[Q()(2,*%`G0@:5O[ZZ\;X)ML2W$24R(H
MS(>,3((@GG[0Z$83:)S\ZV$:.'=4ADSP#SOMO=:.0[DG?,;''W;BL$%"C[&=
M?_W\G_]Q\I=&P_FS=W/A_$(YE22BOG//HHFZ=DGD%Z;]_?W
M>WAY3\AQL]-J[3<9#R/"/;JC2QX'C']941QO#^%]:?&')^7O]U7I]M'145/=
M38O>SUA>D$2AX'N>F$*U[5:CW6GLM]."+!1O.NV#58W6)=('0*YC0F;9`ZIP
M'#:3Z_C,4:/5+KP"2[!OD`K>]=GB"Y+"[YKZ9E8T9,_)`TJVFW]>7@R\"9V2
MQN,7^)0]:3Y<*S8=*'6<$Y3H<:@JN:$C1TGX.)K/Z(>=D$UG`=:HKDTD'7W8
M`:$W4,+MSGY[[R'T=YRFK@<[3E_PB#Y$SH!Z$?17W6W@GI=<9_Z'G=M[&MS1
M2[@R"<^X3WUWOWU*/:S3_9URXO:)I.XEG0ZIU$V$"BB/6#1/_H*_F8]71HQ*
M1S6=+D@HI-[>6-PU^^?_O?-S"_X[/'SSKG-TTLP?RZL*Z7@*5[,+<$G+_Y@^
MS`+FL4BWQ?$9E--J"((\OJ!C$IRI=G4?6+CS,TCF&`%@^_4C)\UG:\K?W5Q\
M^4ES`>?)C$HF_$)3(R*C4U#LGU4?!Q9;;:@CNYH5I-S/BRE5P*K]0J&39J'R
MDV9"T+>Q=0:]0\PI#2O.5J*UQZ=T1*6D?E],9W"/8!?M2DGXF&*=?\!8>"="6=,.KD=OJ:-8[[B7A/@&8+)B[-]2G8#&&`76O92)>=Q`)[XLA?>)"
M\'%$Y?24#J-;L':+C!:@YD@SH`IG.61K,QXAAQWDL-4Y::;7OI_#7'/10H/K
M"(W`GR%(52IU<*^&`1OKGV80^)$P^3L)8GK!R)`%+&(X^)(P!H*N^`WU8BD!
M*6@R"S]S,0RIO$,6S_DLCN"VX!X\I1#WYFD=\[PKX*B>2VM!6+FL2N\$F2*_
M6B=H'=E.8%8G`(?]U3O!H>T$AG6"P]?K!)E)+YW9]9F[6YB>/O)6+XG$$73C
M(+_/@6OME^2\WU!4`.I^!/^]3\()>/.A)V(8!\Q0=U1U[<('@;C'3AUVN9^@
M"I_Z]BB94NKG,:L8V#M()7+BOP.9/;`79
M&5REV:,[+9\5`]`IYA3R5M!^0X=08=WHU>JLD&T%BYE<
M"FH,GEH:N7)OR8/;#4-:6SU^6OYJE*('\!K[5G2%_H3(,71][TO=N%83J1S=
M5K!YSN^@O4+."RJ>>N#U8CYU\ZT_97^4[#Z"]/M_6
M<%?#<%>@*UA/O`XL6O>K3FS:"-BZ(F`5(-M&P-8?`:L`[?:#QGH^:&RW=<;JQ*:USQNPSYNGW=KG-=GG*E!M0R#FLVACFA6):6Z^
M*]CXR=KB)^LA^_EM`5;C-Z?QI:[VM^O"UN9UE\VC]:TJ28L-452:'NO`E.G`
ME,V>C?>6'.\M7_UL[*>LV$_9VT3MT+F>H;.,_9UV-5)%:;$6;6T6K1P"K;]?
M:7JLP[$.AZ,<[FP4L@I1R'*XM5'(=4TTO38B=_Z)GZE$&AG%FN9693$G0V&59`6.RE8^Z2@!!X/[-"XGJ'QH`SN
MK`ZN70=+X=%.[2HQM2N%6SMW6-_E;,S=/DY?@MJ5Z5W%=`K3MQJJG$:V+QZ7CR-`Z@NG2RB3"2=H.3NJ'O./3$U)5SV0G8+F!7D!<0:<-5-
MY=)=>X1Q8/*,2,[XV)3I_@MY2^&EZ,PDJ>N#`P?P2>!>$^:#AKE],F,1_%TK
MMG*<"/.<)R`-)`W7X5K23%MT>V2'0Q-(L@[(1AR0RFLYE23&I5\*Y+,PVB04?3`N_TXH%>C
MP81(VB,A]9$C**?7[DM)^%@1V)OG1:[)'"]U<>VB^D!H7X6P'@]!:
M20+W$\A"Q"&,O"'X[N8SJ6$EJ#2H^O.)R[+L^&K8^OY5;-JIAWF<$.H5.LQ@,M8,CY.$C+VYKB$XVJT<"_G.`.L
M4C@F<.L?1$^.\272FRBF3T$,@9@A&K>P-*:>O!=3OJ,$0``%_`7X6]$/DO'/
MO078X4AM]PN-F=!\A\8G>%.X"NU6$/V1>"R`YKK]0(0@DGI2G&473-`F8+>"
MX0$-`B3V%\HIAIQP9._Z4\89B(FH<$4M.=>&7&%/H`/R1>#UY[]U9/G?)/^;
M#C7K?'DT`/BX6/N4SB3U6'ZPQ+.^7FV[0T$414D\[_+5?W!8U3FVK0]L!=M7
M,P2.QN#L`3<]&!/'_@Z>,ZPIU*U@&"!K4@`1U)3??1!5&5R,%M/[4JBW8
MEMHZNFAZ.YV-NFTZZK;1I-9VDK;F25KYB:VM2F]$I3
M#]-:RW58RW*XL];2.,IL-&WCT;1RB+71M/*C:>4P9Z?XQE%F(VBF<'5HN3(F
MC_2A]4XJX)V40JR=MF]NVOZ#A*Y:)'DJ'DAX%2:L.=SZ9?B2S@A[AD;3TSI
MOOGY1/K\J$L:381_SN]@BHZ5/KU*:7X`$?9K#5IAKDTGON*:X93@WPA7!)^!
M]-T>$[,)D5/W%RGBF7O!I@R7U)C!=R\.P9<(PZX'Q(;J&.2<2H27HE/@$FQ5
MXA6*O?9.F"Z,Q'<$7APQ#CX'QX_7:(#@9PCREWJ5U`4C0_WYJ09,%R'GB!<`
M9WC-7/]D2=THJ65]3@SBZ9"1+2$TA6LZF5])!Q%/XT"M2E4I*M6L3]()2NJ.
MNN?<$U-3/GH,7G889P&S@KR`6`.NDLDM[_PK*[
M+MFE)21E8W3(8A[)U$B[Y0<(?I#@;%'KA0C#/I%R/A(2S^4->_-;\M"-87XL
MH>&/HO,:;0+60#\:-VEAU]9!.N&1P/TMEBSTF6?0VO/O(T\!QV`=PBZBKCJ/
MJZ.N$0%_TW?/B.3J@Z@9%+YP@$WAI>BVPHNRG-;/.[*$^_@-FP5S,%<^I5-%W+6D(RIA5("9@_"^U(*Y`M0<:094
MX3200US9^IQA,INK=9JE_-+\K]"]@,2ACFGY]X\DN?D-H^N$\#3GD*@496_LEQ8G3--\WF)A"YWW3
MRS!NJ-YTED]G30F=?/S6N7@B`RT"D(`20(*_`+]*_:&$J5\_#B,Q39D'B883
M-JLEYUE&J03Q`F`#75:5`DQ2]Y9Z$RX",3;E@\\W:RK"S%$:2)5*SF"IJIP/
MM(0J.R2N8T@L]P`3Z]ELR+-93V*4I2ENKH8!&YMTC/!'PN3O)(AIFK"&(3,D
MC"7UK_@-]6*)B>![)&3A9RZ&F"L>UQ*?\UD\+DF1
MD\NJ-D[NJJW`ML\8UF?6M-5XV9')3+I*R*X26^A>X$D:'6.6YF2=1)N*9?WC
ME(5>(/#6>42GCQR#K`XM`BT!`QWPY7SN;SV?^[7BLVW:$/[*;+8-9%.=7K=2
M.[>5S=)ULZRS"%?JYO:.M:5KYUKY[&RY=I;N";TFFZTW5UYD$[&7EHA]T4+"
M;/=-.2G*<&F`%QFVT3WG;S`ADH*Z41_3'T$Y-93T+ARJIV13XM[XRGRXLSUAPSUA/3D)52J!=^ZU8#QJ=]ZZUU1Z
M&,$Z!5OGLOW-N)B$,\@_$3XQ1\%E,"
MT,O3:VB8"B6`!(PIQ!3A&@9CS%/X]C5\YO;;CW3X`O8^BEC6F[T4X3K8Z[P2
M>W90+6M074NV0^OTE.?TE$-@Y^TG<6V"8[&E;C@\021NQH6"OV[&A8%?9611WM?EI3@XVK
M6+4[VNM.K=U974N"[=;Y>JPL?P'!=G"N'[76FZH?JX>656//G5O%JAV&ZTZM
M=:%,)OBYF--AZ<1]0U3F\/5C:@=5PG=0QA<4\]+]KDP;:V!"\U8G/?;!VK&I:TAV:=
M\8(,A53::HP_]^-[K5/T1?`F]=,7)X&J.I7?DB>L>MD/-I(':JLI-3055#;:
M+LWPE^6X,X3EE4Y!"G=)AKX,JYEDV@/&S.&J/GF>RAA-C4K%EOFN%?+-2_#I
MOIYJ;LL[;;TRSAF8K=5(5WTC:02WFE)#,PE:[\X0KC#,Z@[<6ZDZ[%Q]J>S"
M7,.;NP/LN:HWNY\6I^S^42$/(S$-=W3O"`@RD?Q1R0`*:
M8U1?,#$*#\+!@#P(0D?`\B*%>.T@%1@4T^(JUJ2%I64%HD))F>0C_E#7P%V!
M"-B\,.CZ^P;(2HG*P,X!8[SM'+7H'.4X`-:HU,"HE+D5N>O[RF@#C`PBI9I*)(5WS8P$9YUNK@98=E'Y24:\$N-RM[N5F5W!.[
M(\98ZBJPL'##:V2S/KQQ090<9*H0OE>-D[1^BWGU^&N]:^RW7H<_G5"]725\
MJ*,_P-]OA&,%.H\:]:"F1B487-/(_)=&`]T&9T`]-#N-AKXS*W5\\^K:D\I
M%U/&EU6,=I`=AWC$3+BLYJ=5G#0+"'2A1X"OH9H,[N++9O!S\57/UJ".O0F7
MU/%<@Y^M!03VI(JEPBS6`(PZ9X&:^J:L.BFM>*]'QXP[O4!X7YQ;,AY3W\&T
MB%F9U"FYDF/"V;_5HD1